DOCUMENT RESUME

ED 473 747 CG 032 201

TITLE Emergency Department Trends from the Drug Abuse Warning

Network, Preliminary Estimates January-June 2002. Drug Abuse

Warning Network Series.

INSTITUTION Substance Abuse and Mental Health Services Administration

(DHHS/PHS), Rockville, MD. Office of Applied Studies.

REPORT NO D-22

PUB DATE 2002-12-00

NOTE 563p.

CONTRACT 283-98-9010;283-02-9025;282-98-0003

AVAILABLE FROM National Clearinghouse for Alcohol and Drug Information, P.O.

Box 2345, Rockville, MD 20847-2345; Tel: 301-468-2600; Tel: 800-729-6686 (Toll Free); Tel: 800-487-4889 (TDD) (Toll

Free). For full text: http://www.samhsa.gov/oas/

dawn/TrndED/2001/Text/TrndEDtxt.PDF.

PUB TYPE Numerical/Quantitative Data (110) -- Reports - Research (143)

EDRS PRICE EDRS Price MF02/PC23 Plus Postage.

DESCRIPTORS Data Collection; \*Drug Abuse; \*Hospitals; Incidence;

Probability; \*Trend Analysis

IDENTIFIERS \*Emergency Medical Services

#### **ABSTRACT**

This publication presents estimates of drug-related emergency department (ED) episodes from the Drug Abuse Warning Network (DAWN) from 1994 through the first half of 2001. DAWN is an ongoing, national data system that collects information on drug-related visits to EDs from a national probability sample of hospitals. This publication marks a major change in the presentation of DAWN findings from ED data. The new title introduces a new design with major changes in format and content. These changes were designed to provide more detailed information, information about a larger number of drugs (both illicit and licit), more consistent information, and more information pertaining to the 21 metropolitan areas oversampled in DAWN. This publication has dual purposes: first, to release preliminary estimates for the first half of 2001, and second, to present revised full-year trends from 1994 to 2000 using the new format for the first time. This publication contains the following estimates of drug-related ED episodes and specific drug mentions: preliminary estimates for January-June 2001, with revised half-year estimates from July 1996 through December 2000 for comparison; and final, revised estimates for the full years 1994 through 2000. (Contains 306 tables.) (GCP)



# Emergency Department Trends From the Drug Abuse Warning Network, Preliminary Estimates January–June 2002

U.S. DEPARTMENT OF EDUCATION Office of Educational Research and Improvement EDUCATIONAL RESOURCES INFORMATION CENTER (ERIC)

- ☐ This document has been reproduced as received from the person or organization originating it.
- Minor changes have been made to improve reproduction quality.
- Points of view or opinions stated in this document do not necessarily represent official OERI position or policy.



DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Office of Applied Studies www.SAMHSA.gov

BEST COPY AVAILABLE

#### TABLES IN ED TRENDS FROM DAWN

Tables in *ED Trends from DAWN* follow a 3-part numbering scheme, with each of the 3 terms separated by periods (e.g., Table 2.2.0). The first (beginning) and third (ending) terms have specific meaning.

#### ■ Table numbers beginning with:

- 1. contain information about the ED sample and the precision of the estimates.
- 2. through 5. contain estimates of ED episodes and ED drug mentions.
- 12. through 14. contain corresponding rates per 100,000 population.

Each table of estimates has a corresponding table of rates per 100,000 population, designated by a 1 prefix added to the table number. For example, Table 2.3.0 contains estimates of ED mentions for major substances of abuse; Table 12.3.0 contains population-based rates of ED mentions for the same major substances of abuse.

#### Table numbers ending with:

- .0 contain estimates for the coterminous U.S.
- .1 through .21 contain estimates for the 21 metropolitan areas oversampled in DAWN, where .1 is Atlanta, .2 is Baltimore, ... .21 is Washington, DC (see reverse).

**No third term** (e.g., 3.1, 3.2, 13.1, 13.2, etc.): These tables contain summaries for all the metropolitan areas in DAWN. For example, Table 3.1 summarizes total ED episodes across the 21 metropolitan areas.

- RSE tables follow the same numbering scheme, with a prefix of RSE attached to the companion table number. For example, Table RSE-2.2.0 contains the RSEs for the estimates published in Table 2.2.0.
- Tables 2.3.x through 2.12.x enumerate the specific substances in 5 categories:
  - **2.3.x** and **2.4.x** Major substances of abuse (half year and full year estimates, respectively; e.g., for cocaine, heroin, marijuana, "club drugs")
  - 2.5.x and 2.6.x Psychotherapeutic agents (e.g., benzodiazepines)
  - 2.7.x and 2.8.x Central nervous system (CNS) agents (e.g., narcotic analgesics)
  - 2.9.x and 2.10.x Respiratory agents (e.g., antihistamines)
  - 2.11.x and 2.12.x Cardiovascular agents (e.g., beta-adrenergic blocking agents)

Corresponding population-based rates are found in Tables 12.3.x through 12.12.x.

- Tables 3.x (13.x) summarize ED estimates (rates) across the 21 metropolitan areas.
- Tables 4.1.x (14.1.x) through 4.34.x (14.34.x) summarize DAWN ED cases by patient demographics.
- Tables **5.1.x** through **5.34.x** summarize DAWN ED cases by episode characteristics. No population-based rates are produced for episode characteristics.



# TABLES IN ED TRENDS FROM DAWN

Table numbers ending with	Contain estimates for
.0	coterminous U.S.
.1	Atlanta
.2	Baltimore
.3	Boston
.4	Buffalo
.5	Chicago
.6	Dallas
.7	Denver
.8	Detroit
.9	Los Angeles
.10	Miami
.11	Minneapolis
.12	New Orleans
.13	New York
.14	Newark
.15	Philadelphia
.16	Phoenix
.17	St. Louis
.18	San Diego
.19	San Francisco
.20	Seattle
<b>.21</b>	Washington, DC



# Emergency Department Trends From the Drug Abuse Warning Network, Preliminary Estimates January–June 2002

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Office of Applied Studies

#### **ACKNOWLEDGMENTS**

The findings in this publication are based on data developed for the Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies (OAS), by Johnson, Bassin, and Shaw, Inc. (JBS) under Contract No. 283-98-9010 and by Westat under Contracts No. 283-02-9025 and 282-98-0003. Dr. Judy Ball (SAMHSA/OAS Project Director) and Tracy Garfield (Westat) wrote the publication. Other significant contributors at Westat include Dr. Wendy Kissin (Project Director), Jim Green, Nita Lemanski, Diane Steele, Pat Stouffer, and Lois White.

#### **PUBLIC DOMAIN NOTICE**

All material appearing in this publication is in the public domain and may be reproduced or copied without permission from the Substance Abuse and Mental Health Services Administration (SAMHSA). However, this publication may *not* be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA. Citation of the source is appreciated. Suggested citation:

Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Emergency Department Trends From the Drug Abuse Warning Network, Preliminary Estimates January–June 2002, DAWN Series: D-22, DHHS Publication No. (SMA) 03-3779, Rockville, MD, 2002.

#### **OBTAINING ADDITIONAL COPIES OF PUBLICATION**

Copies may be obtained, free of charge, from the National Clearinghouse for Alcohol and Drug Information (NCADI). NCADI is a service of the Substance Abuse and Mental Health Services Administration (SAMHSA). Write or call NCADI at:

National Clearinghouse for Alcohol and Drug Information (NCADI) P.O. Box 2345, Rockville, MD 20847-2345 301-468-2600 800-729-6686 TDD 800-487-4889

#### **ELECTRONIC ACCESS TO PUBLICATION**

This publication can be accessed electronically through Internet World Wide Web connections:

http://www.samhsa.gov http://www.drugabusestatistics.samhsa.gov http://www.DAWNinfo.net

#### ORIGINATING OFFICE

SAMHSA, Office of Applied Studies 5600 Fishers Lane, Room 16-105 Rockville, MD 20857

December 2002



Section		Page
	ACKNOWLEDGMENTS	2
	HIGHLIGHTS	23
	INTRODUCTION	29
	Other DAWN publications	30
	Overview of DAWN ED component	30
	Data collection methodology	31
	Considerations when interpreting DAWN data	32
	Interpretation of statistical significance	33
	Other considerations when reading DAWN tables	34
	How to use this publication	35
	Organization of tables	36
	Additional content available on the Internet	42
	TRENDS IN ED DRUG EPISODES AND MAJOR SUBSTANCES OF	
	ABUSE	45
	TRENDS IN OTHER SUBSTANCES OF ABUSE	53
	SELECTED TRENDS IN 21 METROPOLITAN AREAS	57
	DISCUSSION OF RESULTS	61



# LIST OF APPENDIXES

Appendix		Page
Α	RACE AND ETHNICITY DATA IN DAWN	63
В	DETAILED DESCRIPTION OF DAWN	65
	Sample design	65
	Sampling weights	67
	Precision of the estimates and standards for publication	67
	Preliminary versus final estimates	69
	Estimates of rates per 100,000 population	70
	Revision of estimation system	71
С	SOURCES OF ERROR IN DAWN ESTIMATES	73
	Changes in sample composition and reporting of episodes	73
	Noteworthy sources of error: Atlanta data for 2001	74
D	GLOSSARY OF TERMS	75
	Definitions of terms common to DAWN's ED and mortality	
	components	75
	Definitions of terms for the DAWN ED component	80
E	MULTUM LICENSE AGREEMENT	87
F	DAWN EMEDGENCY DEPARTMENT DEPORT FORM	04



# **LIST OF TABLES**

Table		Page
	SAMPLING & PRECISION INFORMATION ON THE SAMPLE	
1.1	ED sample information and response rates by metropolitan area, 2001	T-3
1.2	Counties and cities that constitute DAWN ED metropolitan areas, 2001	T-4
1.3	ED visits, drug episodes, and drug mentions: Unweighted sample data and weighted estimates by metropolitan area, 2001	T-5
1.4	ED visits: Estimates by metropolitan area by year	T-6
1.5	ED visits: Estimated rates per 100,000 population by metropolitan area by year	T-7
	MEASURES OF PRECISION	
1.6	ED drug episodes, standard errors, relative standard errors, and confidence intervals: Estimates by metropolitan area, 2001	T-8
1.7	ED drug episodes, relative standard errors, and mentions for major drugs of abuse: Estimates by metropolitan area, 2001	T-9
1.8	ED drug episodes, standard errors, relative standard errors, and confidence intervals: Estimates by drug category, 2001	T-10
1.9	Population by age and gender by metropolitan area	T-12
1.10	ED drug episodes by detailed race and ethnicity: Estimates for the coterminous U.S., 2001	T-15



#### **LIST OF TABLES**

Table		Page
	ESTIMATES <sup>1</sup>	
	SELECTED DRUG CATEGORIES FOR U.S. & 21 METROPOLITAN AREAS  ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates	
2.1.0	Selected drug categories for the coterminous U.S. by half year	T-16
2.2.0	Selected drug categories for the coterminous U.S. by year	<b>~</b> :40
2.2.1	Atlanta	T-18
2.2.2	Baltimore	T-20
2.2.3	Boston	T-22
2.2.4	Buffalo	T-24
2.2.5	Chicago	T-26
2.2.6	Dallas	T-28
2.2.7	Denver	T-30
2.2.8	Detroit	T-32
2.2.9	Los Angeles	T-34
2.2.10	Miami	T-36
2.2.11	Minneapolis	T-38
2.2.12	New Orleans	T-40
2.2.13	New York	T-42
2.2.14	Newark	T-44 T-46
2.2.15	Philadelphia	1-46 T-48
2.2.16	Phoenix	T-50
2.2.17	St. Louis	
2.2.18	San Diego	T-52
2.2.19	San Francisco	T-54
2.2.20	Seattle	T-56
2.2.21	Washington, DC	T-58
	<b>U</b>	T-60

<sup>\*</sup> These tables are published only on the Internet at http://www.samhsa.gov/oas/dawn.htm and http://www.DAWNinfo.net.



Relative standard error (RSE) tables corresponding to all estimate tables are published on the Internet using the same table numbers and beginning with the prefix, "RSE."

Γable		Page
	<b>DETAIL OF DRUGS CONTAINED IN SELECTED DRUG CATEGORIES</b> ED mentions by drug category: Estimates for the coterminous U.S.	
2.3.0	Selected major substances of abuse by half year*2.3.1 – 2.3.21 Selected major substances of abuse for each metropolitan area by half year	T-62
2.4.0	Selected major substances of abuse by year*2.4.1 – 2.4.21 Selected major substances of abuse for each metropolitan area by year	T-72
2.5.0	Psychotherapeutic agents by half year*2.5.1 – 2.5.21 Psychotherapeutic agents for each metropolitan area by half year	T-82
2.6.0	Psychotherapeutic agents by year*2.6.1 – 2.6.21 Psychotherapeutic agents for each metropolitan area by year	T-86
2.7.0	Central nervous system agents by half year*2.7.1 – 2.7.21 Central nervous system agents for each metropolitan area by half year	T-90
2.8.0	Central nervous system agents by year*2.8.1 – 2.8.21 Central nervous system agents for each metropolitan area by year	T-97
2.9.0	Respiratory agents by half year*2.9.1 – 2.9.21 Respiratory agents for each metropolitan area by half year	T-104
2.10.0	Respiratory agents by year*2.10.1 – 2.10.21 Respiratory agents for each metropolitan area by year	T-110
2.11.0	Cardiovascular agents by half year*  *2.11.1 – 2.11.21 Cardiovascular agents for each metropolitan area by half year	T-116
2.12.0	Cardiovascular agents by year*2.12.1 – 2.12.21 Cardiovascular agents for each metropolitan area by year	T-121



Table		Page
	ESTIMATES FOR THE COTERMINOUS U.S. & 21 METROPOLITAN AR ED drug episodes/mentions: Estimates by metropolitan area	EAS
3.1	Episodes by half year	T-126
3.2	Episodes by year	T-127
3.3	Mentions by half year	T-128
3.4	Mentions by year	T-129
3.5	Alcohol-in-combination mentions by half year	T-130
3.6	Alcohol-in-combination mentions by year	T-131
3.7	Cocaine mentions by half year	T-131
3.8	Cocaine mentions by year	T-132
3.9	Heroin mentions by half year	T-134
3.10	Heroin mentions by year	T-134
3.11	Marijuana mentions by half year	T-136
3.12	Marijuana mentions by year	T-137
3.13	Amphetamines mentions by half year	T-137
3.14	Amphetamines mentions by year	T-139
3.15	Methamphetamine mentions by half year	T-140
3.16	Methamphetamine mentions by year	T-141
3.17	MDMA (Ecstasy) mentions by half year	T-142
3.18	MDMA (Ecstasy) mentions by year.	T-143
3.19	Ketamine mentions by half year	T-144
3.20	Ketamine mentions by year	T-145
3.21	LSD mentions by half year	T-146
3.22	LSD mentions by year	T-147
3.23	PCP mentions by half year	T-148
3.24	PCP mentions by year	T-149
3.25	Miscellaneous hallucinogens mentions by half year	T-150
3.26	Miscellaneous hallucinogens mentions by year	T-151
3.27	Flunitrazepam (Rohypnol) mentions by half year	T-152
3.28	Flunitrazepam (Rohypnol) mentions by year	T-153
3.29	GHB mentions by half year	T-154
3.30	GHB mentions by year	T-155
3.31	Inhalants mentions by half year	T-156
3.32	Inhalants mentions by year	T-157
3.33	Combinations NTA by half year	T-157
3.34	Combinations NTA by year	T 450



Γable		Page
	DEMOGRAPHIC CHARACTERISTICS FOR THE COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR ED drug episodes/mentions by patient demographic characteristics: Estim	ates
		T-160
4.1.0	Episodes for the coterminous U.S. by half year*  *4.1.1 – 4.1.21 Episodes for each metropolitan area by half year	1-100
4.2.0	Episodes for the coterminous U.S. by year	T-161
4.2.1	Atlanta	T-162
4.2.1	Baltimore	T-163
4.2.2	Boston	T-164
4.2.3	Buffalo	T-165
4.2.5	Chicago	T-166
4.2.6	Dallas	T-167
4.2.7	Denver	T-168
4.2.7	Detroit	T-169
4.2.9	Los Angeles	T-170
4.2.10	Miami	T-171
4.2.10	Minneapolis	T-172
4.2.11	New Orleans	T-173
4.2.12	New York	T-174
4.2.13	Newark	T-175
4.2.15	Philadelphia	T-176
4.2.16	Phoenix	T-177
4.2.17	St. Louis	T-178
4.2.17	San Diego	T-179
4.2.19	San Francisco	T-180
4.2.19	Seattle	T-181
4.2.20	Washington, DC	T-182
4.3.0	Mentions for the coterminous U.S. by half year	T-184
	*4.3.1 – 4.3.21 Mentions for each metropolitan area by half year	
4.4.0	Mentions for the coterminous U.S. by year	T-185
	*4.4.1 – 4.4.21 Mentions for each metropolitan area by year	
4.5.0	Alcohol-in-combination mentions for the coterminous U.S. by half year	T-186
	*4.5.1 – 4.5.21 Alcohol-in-combination mentions for each metropolitan area by half year	
4.6.0	Alcohol-in-combination mentions for the coterminous U.S. by year *4.6.1 – 4.6.21 Alcohol-in-combination mentions for each metropolitan	T-187
	area by vear	



# **LIST OF TABLES (continued)**

Гable		Page
4.7.0	Cocaine mentions for the coterminous U.S. by half year*4.7.1 – 4.7.21 Cocaine mentions for each metropolitan area by half year	T-188
4.8.0	Cocaine mentions for the coterminous U.S. by year* *4.8.1 – 4.8.21 Cocaine mentions for each metropolitan area by year	T-189
4.9.0	Heroin mentions for the coterminous U.S. by half year*4.9.1 – 4.9.21 Heroin mentions for each metropolitan area by half year	T-190
4.10.0	Heroin mentions for the coterminous U.S. by year*  *4.10.1 – 4.10.21 Heroin mentions for each metropolitan area by year	T-191
4.11.0	Marijuana mentions for the coterminous U.S. by half year*  *4.11.1 – 4.11.21 Marijuana mentions for each metropolitan area by half year	T-192
4.12.0	Marijuana mentions for the coterminous U.S. by year*4.12.1 – 4.12.21 Marijuana mentions for each metropolitan area by year	T-193
4.13.0	Amphetamines mentions for the coterminous U.S. by half year*4.13.1 – 4.13.21 Amphetamines mentions for each metropolitan area by half year	T-194
4.14.0	Amphetamines mentions for the coterminous U.S. by year*4.14.1 – 4.14.21 Amphetamines mentions for each metropolitan area by year	T-195
4.15.0	Methamphetamine mentions for the coterminous U.S. by half year *4.15.1 – 4.15.21 Methamphetamine mentions for each metropolitan area by half year	T-196
4.16.0	Methamphetamine mentions for the coterminous U.S. by year*4.16.1 – 4.16.21 Methamphetamine mentions for each metropolitan area by year	T-197
4.17.0	MDMA (Ecstasy) mentions for the coterminous U.S. by half year*  *4.17.1 – 4.17.21 MDMA (Ecstasy) mentions for each metropolitan area by half year	T-198
4.18.0	MDMA (Ecstasy) mentions for the coterminous U.S. by year*4.18.1 – 4.18.21 MDMA (Ecstasy) mentions for each metropolitan area by year	T-199



Table		Page
4.19.0	Ketamine mentions for the coterminous U.S. by half year*  *4.19.1 – 4.19.21 Ketamine mentions for each metropolitan area by half year	T-200
4.20.0	Ketamine mentions for the coterminous U.S. by year*4.20.1 – 4.20.21 Ketamine mentions for each metropolitan area by year	T-201
4.21.0	LSD mentions for the coterminous U.S. by half year*  *4.21.1 – 4.21.21 LSD mentions for each metropolitan area by half year	T-202
4.22.0	LSD mentions for the coterminous U.S. by year*  *4.22.1 – 4.22.21 LSD mentions for each metropolitan area by year	T-203
4.23.0	PCP mentions for the coterminous U.S. by half year*  *4.23.1 – 4.23.21 PCP mentions for each metropolitan area by half year	T-204
4.24.0	PCP mentions for the coterminous U.S. by year*4.24.1 – 4.24.21 PCP mentions for each metropolitan area by year	T-205
4.25.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by half year*  *4.25.1 – 4.25.21 Miscellaneous hallucinogens mentions for each metropolitan area by half year	T-206
4.26.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by year *4.26.1 – 4.26.21 Miscellaneous hallucinogens mentions for each metropolitan area by year	T-207
4.27.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by half year*  *4.27.1 – 4.27.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by half year	T-208
4.28.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by year *4.28.1 – 4.28.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by year	T-209
4.29.0	GHB mentions for the coterminous U.S. by half year*4.29.1 – 4.29.21 GHB mentions for each metropolitan area by half year	T-210
4.30.0	GHB mentions for the coterminous U.S. by year*  *4.30.1 – 4.30.21 GHB mentions for each metropolitan area by year	T-211



	LIST OF TABLES (continued)	
Table	(	Page
4.31.0	Inhalants mentions for the coterminous U.S. by half year*4.31.1 – 4.31.21 Inhalants mentions for each metropolitan area by half year	T-212
4.32.0	Inhalants mentions for the coterminous U.S. by year*4.32.1 – 4.32.21 Inhalants mentions for each metropolitan area by year	T-213
4.33.0	Cominations NTA mentions for the coterminous U.S. by half year	T-214
4.34.0	Combinations NTA mentions for the coterminous U.S. by year*4.34.1 – 4.34.21 Combinations NTA mentions for each metropolitan area by year	T-215
	EPISODE CHARACTERISTICS FOR THE COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR ED drug episodes/mentions by episode characteristics: Estimates	
5.1.0	Episodes for the coterminous U.S. by half year* *5.1.1 – 5.1.21 Episodes for each metropolitan area by half year	T-216
5.2.0	Episodes for the coterminous U.S. by year	T-217
5.2.1	Atlanta	T-218
5.2.2	Baltimore	T-219
5.2.3	Boston	T-220
5.2.4	Buffalo	T-221
5.2.5	Chicago	T-222
5.2.6	Dallas	T-223
5.2.7	Denver	T-224
5.2.8	Detroit	T-225
5.2.9	Los Angeles	T-226
5.2.10	Miami	T-227
5.2.11	Minneapolis	T-228
5.2.12	New Orleans	T-229
5.2.13	New York	T-230
5.2.14	Newark	T-231
5.2.15	Philadelphia	T-232
5.2.16	Phoenix	T-233
5.2.17	St. Louis	T-234
5.2.18	San Diego	T-235
5.2.19	San Francisco	T-236
5.2.20	Seattle	T-237
5.2.21	Washington, DC	T-238



LIST	OF TA	ARLES	(continue	ď
LIUI	VI 17	VDLLU	<i><b>COHLING</b></i>	u,

I	able		Page
	5.3.0	Mentions for the coterminous U.S. by half year*5.3.1 – 5.3.21 Mentions for each metropolitan area by half year	T-240
	5.4.0	Mentions for the coterminous U.S. by year*5.4.1 – 5.4.21 Mentions for each metropolitan area by year	T-241
	5.5.0	Alcohol-in-combination mentions for the coterminous U.S. by half year *5.5.1 – 5.5.21 Alcohol-in-combination mentions for each metropolitan area by half year	T-242
	5.6.0	Alcohol-in-combination mentions for the coterminous U.S. by year *5.6.1 – 5.6.21 Alcohol-in-combination mentions for each metropolitan area by year	T-243
	5.7.0	Cocaine mentions for the coterminous U.S. by half year*5.7.1 – 5.7.21 Cocaine mentions for each metropolitan area by half year	T-244
	5.8.0	Cocaine mentions for the coterminous U.S. by year*5.8.1 – 5.8.21 Cocaine mentions for each metropolitan area by year	T-245
	5.9.0	Heroin mentions for the coterminous U.S. by half year*5.9.1 – 5.9.21 Heroin mentions for each metropolitan area by half year	T-246
	5.10.0	Heroin mentions for the coterminous U.S. by year*5.10.1 – 5.10.21 Heroin mentions for each metropolitan area by year	T-247
	5.11.0	Marijuana mentions for the coterminous U.S. by half year* *5.11.1 – 5.11.21 Marijuana mentions for each metropolitan area by half year	T-248
	5.12.0	Marijuana mentions for the coterminous U.S. by year*5.12.1 – 5.12.21 Marijuana mentions for each metropolitan area by year	T-249
	5.13.0	Amphetamines mentions for the coterminous U.S. by half year*5.13.1 – 5.13.21 Amphetamines mentions for each metropolitan area by half year	T-250
	5.14.0	Amphetamines mentions for the coterminous U.S. by year*5.14.1 – 5.14.21 Amphetamines mentions for each metropolitan area by year	T-251
	5.15.0	Methamphetamine mentions for the coterminous U.S. by half year*5.15.1 – 5.15.21 Methamphetamine mentions for each metropolitan area by half year	T-252



	LIST OF TABLES (continued)	
Table		Page
5.16.0	Methamphetamine mentions for the coterminous U.S. by year*5.16.1 – 5.16.21 Methamphetamine mentions for each metropolitan area by year	T-253
5.17.0	MDMA (Ecstasy) mentions for the coterminous U.S. by half year*5.17.1 – 5.17.21 MDMA (Ecstasy) mentions for each metropolitan area by half year	T-254
5.18.0	MDMA (Ecstasy) mentions for the coterminous U.S. by year*5.18.1 – 5.18.21 MDMA (Ecstasy) mentions for each metropolitan area by year	T-255
5.19.0	Ketamine mentions for the coterminous U.S. by half year*5.19.1 – 5.19.21 Ketamine mentions for each metropolitan area by half year	T-256
5.20.0	Ketamine mentions for the coterminous U.S. by year*5.20.1 – 5.20.21 Ketamine mentions for each metropolitan area by year	T-257
5.21.0	LSD mentions for the coterminous U.S. by half year*5.21.1 – 5.21.21 LSD mentions for each metropolitan area by half year	T-258
5.22.0	LSD mentions for the coterminous U.S. by year*  *5.22.1 – 5.22.21 LSD mentions for each metropolitan area by year	T-259
5.23.0	PCP mentions for the coterminous U.S. by half year*5.23.1 – 5.23.21 PCP mentions for each metropolitan area by half year	T-260
5.24.0	PCP mentions for the coterminous U.S. by year*  *5.24.1 – 5.24.21 PCP mentions for each metropolitan area by year	T-261
5.25.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by half year*  *5.25.1 – 5.25.21 Miscellaneous hallucinogens mentions for each metropolitan area by half year	T-262
5.26.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by year *5.26.1 – 5.26.21 Miscellaneous hallucinogens mentions for each metropolitan area by year	T-263
5.27.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by half year *5.27.1 – 5.27.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by half year	T-264



Γable		Page
5.28.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by year *5.28.1 – 5.28.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by year	T-265
5.29.0	GHB mentions for the coterminous U.S. by half year* *5.29.1 – 5.29.21 GHB mentions for each metropolitan area by half year	T-266
5.30.0	GHB mentions for the coterminous U.S. by year* *5.30.1 – 5.30.21 GHB mentions for each metropolitan area by year	T-267
5.31.0	Inhalants mentions for the coterminous U.S. by half year*5.31.1 – 5.31.21 Inhalants mentions for each metropolitan area by half year	T-268
5.32.0	Inhalants mentions for the coterminous U.S. by year*5.32.1 – 5.32.21 Inhalants mentions for each metropolitan area by year	T-269
5.33.0	Cominations NTA mentions for the coterminous U.S. by half year *5.33.1 – 5.33.21 Combinations NTA mentions for each metropolitan area by half year	T-270
5.34.0	Combinations NTA mentions for the coterminous U.S. by year* *5.34.1 – 5.34.21 Combinations NTA mentions for each metropolitan area by year	T-271
	[Table numbers 6 through 11 have been reserved for future expansion.]	



# **LIST OF TABLES (continued)**

Table		Page
	RATES PER 100,000 POPULATION <sup>2</sup>	
	SELECTED DRUG CATEGORY RATES FOR COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population	
12.1.0	Selected drug categories for the coterminous U.S. by half year*  *12.1.1 – 12.1.21 Selected drug categories for each metropolitan area by half year	T-272
12.2.0	Selected drug categories for the coterminous U.S. by year	T-274
12.2.1	Atlanta	T-276
12.2.2	Baltimore	T-278
12.2.3	Boston	T-280
12.2.4	Buffalo	T-282
12.2.5	Chicago	T-284
12.2.6	Dallas	T-286
12.2.7	Denver	T-288
12.2.8	Detroit	T-290
12.2.9	Los Angeles	T-292
12.2.10	Miami	T-294
12.2.11	Minneapolis	T-296
12.2.12	New Orleans	T-298
12.2.13	New York	T-300
12.2.14	Newark	T-302
12.2.15	Philadelphia	T-304
12.2.16	Phoenix	T-306
12.2.17	St. Louis	T-308
12.2.18	San Diego	T-310
12.2.19	San Francisco	T-312
12.2.20	Seattle	T-314
12.2.21	Washington, DC	T-316

<sup>&</sup>lt;sup>2</sup> Relative standard errors (RSEs) are identical for estimates and rates. RSE tables corresponding to all rates tables are found on the Internet using the same table numbers, without the preceding number "1," and beginning with the prefix, "RSE."



Гable		Page
	<b>DETAIL OF DRUGS CONTAINED IN SELECTED DRUG CATEGORIES</b> ED mentions by drug category: Estimated rates per 100,000 population	
12.3.0	Selected major substances of abuse by half year* *12.3.1 — 12.3.21 Selected major substances of abuse for each metropolitan area by half year	T-318
12.4.0	Selected major substances of abuse by year* *12.4.1 – 12.4.21 Selected major substances of abuse for each metropolitan area by year	T-328
12.5.0	Psychotherapeutic agents by half year* *12.5.1 – 12.5.21 Psychotherapeutic agents for each metropolitan area by half year	T-338
12.6.0	Psychotherapeutic agents by year* *12.6.1 – 12.6.21 Psychotherapeutic agents for each metropolitan area by year	T-342
12.7.0	Central nervous system agents by half year* *12.7.1 – 12.7.21 Central nervous system agents for each metropolitan area by half year	T-346
12.8.0	Central nervous system agents by year* *12.8.1 – 12.8.21 Central nervous system agents for each metropolitan area by year	T-353
12.9.0	Respiratory agents by half year* *12.9.1 – 12.9.21 Respiratory agents for each metropolitan area by half year	T-360
12.10.0	Respiratory agents by year* *12.10.1 – 12.10.21 Respiratory agents for each metropolitan area by year	T-366
12.11.0	Cardiovascular agents by half year* *12.11.1 – 12.11.21 Cardiovascular agents for each metropolitan area by half year	T-372
12.12.0	Cardiovascular agents by year* *12.12.1 – 12.12.21 Cardiovascular agents for each metropolitan area by year	T-377



	Page
RATES OF MENTIONS FOR THE COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR	
ED drug episodes/mentions: Estimated rates per 100,000 population by metropolitan area	
Episodes by half year	T-382
Episodes by year	T-383
	T-384
	T-385
Alcohol-in-combination mentions by half year	T-386
	T-387
	T-388
Cocaine mentions by year	T-389
Heroin mentions by half year	T-390
Heroin mentions by year	T-391
Marijuana mentions by half year	T-392
	T-393
	T-394
	T-395
	T-396
	T-397
	T-398
	T-399
	T-400
	T-401
LSD mentions by half year	T-402
LSD mentions by year	T-403
	T-404
PCP mentions by year	T-405
Miscellaneous hallucinogens mentions by half year	T-406
Miscellaneous hallucinogens mentions by year	T-407
Flunitrazepam (Rohypnol) mentions by half year	T-408
Flunitrazepam (Rohypnol) mentions by year	T-409
GHB mentions by half year	T-410
GHB mentions by year	T-411
Inhalants mentions by half year	T-412
Inhalants mentions by year	T-413
Combinations NTA by half year	T-414
Combinations NTA by year	T-415
	METROPOLITAN AREAS BY YEAR ED drug episodes/mentions: Estimated rates per 100,000 population by metropolitan area  Episodes by half year



Table		Page
	RATES FOR DEMOGRAPHIC CHARACTERISTICS FOR THE COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR ED drug episodes/mentions by age and gender: Estimated rates per 100,000 population	
14.1.0	Episodes for the coterminous U.S. by half year* *14.1.1 – 14.1.21 Episodes for each metropolitan area by half year	T-416
14.2.0	Episodes for the coterminous U.S. by year	T-417
14.2.1	Atlanta	T-418
14.2.2	Baltimore	T-419
14.2.3	Boston	T-420
14.2.4	Buffalo	T-421
14.2.5	Chicago	T-422
14.2.6	Dallas	T-423
14.2.7	Denver	T-424
14.2.8	Detroit	T-425
14.2.9	Los Angeles	T-426
14.2.10	Miami	T-427
14.2.11	Minneapolis	T-428
14.2.12	New Orleans	T-429
14.2.13	New York	T-430
14.2.14	Newark	T-431
14.2.15	Philadelphia	T-432
14.2.16	Phoenix	T-433
14.2.17	St. Louis	T-434
14.2.18	San Diego	T-435
14.2.19	San Francisco	T-436
14.2.20	Seattle	T-437
14.2.21	Washington, DC	T-438
14.3.0	Mentions for the coterminous U.S. by half year*  *14.3.1 – 14.3.21 Mentions for each metropolitan area by half year	T-440
14.4.0	Mentions for the coterminous U.S. by year*  *14.4.1 – 14.4.21 Mentions for each metropolitan area by year	T-441
14.5.0	Alcohol-in-combination mentions for the coterminous U.S. by half year *14.5.1 – 14.5.21 Alcohol-in-combination mentions for each metropolitan area by half year	T-442
14.6.0	Alcohol-in-combination mentions for the coterminous U.S. by year *14.6.1 – 14.6.21 Alcohol-in-combination mentions for each metropolitan area by year	T-443



1	Table		Page
	14.7.0	Cocaine mentions for the coterminous U.S. by half year*14.7.1 – 14.7.21 Cocaine mentions for each metropolitan area by half year	T-444
	14.8.0	Cocaine mentions for the coterminous U.S. by year* *14.8.1 – 14.8.21 Cocaine mentions for each metropolitan area by year	T-445
	14.9.0	Heroin mentions for the coterminous U.S. by half year* *14.9.1 – 14.9.21 Heroin mentions for each metropolitan area by half year	T-446
	14.10.0	Heroin mentions for the coterminous U.S. by year*14.10.1 – 14.10.21 Heroin mentions for each metropolitan area by year	T-447
	14.11.0	Marijuana mentions for the coterminous U.S. by half year* *14.11.1 – 14.11.21 Marijuana mentions for each metropolitan area by half year	T-448
	14.12.0	Marijuana mentions for the coterminous U.S. by year* *14.12.1 – 14.12.21 Marijuana mentions for each metropolitan area by year	T-449
	14.13.0	Amphetamines mentions for the coterminous U.S. by half year* *14.13.1 – 14.13.21 Amphetamines mentions for each metropolitan area by half year	T-450
	14.14.0	Amphetamines mentions for the coterminous U.S. by year* *14.14.1 – 14.14.21 Amphetamines mentions for each metropolitan area by year	T-451
	14.15.0	Methamphetamine mentions for the coterminous U.S. by half year *14.15.1 – 14.15.21 Methamphetamine mentions for each metropolitan area by half year	T-452
	14.16.0	Methamphetamine mentions for the coterminous U.S. by year*14.16.1 – 14.16.21 Methamphetamine mentions for each metropolitan area by year	T-453
	14.17.0	MDMA (Ecstasy) mentions for the coterminous U.S. by half year	T-454
	14.18.0	MDMA (Ecstasy) mentions for the coterminous U.S. by year	T-455



ED Trends From DAWN

lable -		Page
14.19.0	Ketamine mentions for the coterminous U.S. by half year	T-456
14.20.0	Ketamine mentions for the coterminous U.S. by year* *14.20.1 – 14.20.21 Ketamine mentions for each metropolitan area by year	T-457
14.21.0	LSD mentions for the coterminous U.S. by half year* *14.21.1 – 14.21.21 LSD mentions for each metropolitan area by half year	T-458
14.22.0	LSD mentions for the coterminous U.S. by year* *14.22.1 – 14.22.21 LSD mentions for each metropolitan area by year	T-459
14.23.0	PCP mentions for the coterminous U.S. by half year* *14.23.1 – 14.23.21 PCP mentions for each metropolitan area by half year	T-460
14.24.0	PCP mentions for the coterminous U.S. by year*14.24.1 – 14.24.21 PCP mentions for each metropolitan area by year	T-461
14.25.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by half year*  *14.25.1 – 14.25.21 Miscellaneous hallucinogens mentions for each metropolitan area by half year	T-462
14.26.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by year *14.26.1 – 14.26.21 Miscellaneous hallucinogens mentions for each metropolitan area by year	T-463
14.27.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by half year *14.27.1 – 14.27.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by half year	T-464
14.28.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by year *14.28.1 – 14.28.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by year	T-465
14.29.0	GHB mentions for the coterminous U.S. by half year* *14.29.1 – 14.29.21 GHB mentions for each metropolitan area by half year	T-466



Table		Page
14.30.0	GHB mentions for the coterminous U.S. by year* *14.30.1 – 14.30.21 GHB mentions for each metropolitan area by year	T-467
14.31.0	Inhalants mentions for the coterminous U.S. by half year*  *14.31.1 – 14.31.21 Inhalants mentions for each metropolitan area by half year	T-468
14.32.0	Inhalants mentions for the coterminous U.S. by year* *14.32.1 – 14.32.21 Inhalants mentions for each metropolitan area by year	T-469
14.33.0	Cominations NTA mentions for the coterminous U.S. by half year*14.33.1 – 14.33.21 Combinations NTA mentions for each metropolitan area by half year	T-470
14.34.0	Combinations NTA mentions for the coterminous U.S. by year* *14.34.1 – 14.34.21 Combinations NTA mentions for each metropolitan area by year	T-471
	LIST OF FIGURES	
Figure		Page
1	Relative standard errors (RSEs) for drug-related episodes by metropolitan area: January-June 2002	43
2	Tables in ED Trends From DAWN	43
3	ED drug-related episodes and alcohol-in-combination, cocaine, heroin, and marijuana mentions: July-December 1997 through January-June 2002	51
4	Relative standard errors (RSEs) for major substances of abuse: January-June 2002	51
5	ED mentions of selected narcotic analgesics: July-December 1997 through January-June 2002	56



# **HIGHLIGHTS**

his issue of *Emergency Department Trends From DAWN* presents for the first time preliminary estimates for January to June of 2002, with comparisons to the same months of 2001.

The Drug Abuse Warning Network (DAWN) relies on a sample of hospitals operating 24-hour emergency departments (EDs) to capture data on ED visits induced by or related to substance abuse. DAWN data do not measure prevalence of drug use in the population, but the probability sample of hospitals is designed to produce representative estimates of ED drug episodes and drug mentions for the coterminous United States and for 21 metropolitan areas. The Substance Abuse and Mental Health Services Administration (SAMHSA), the agency responsible for DAWN, is required under Section 505 of the Public Health Service Act to collect such data.

#### Drug Episodes vs. Drug Mentions

Drug Episode: A drug-related ED episode is an ED visit that was induced by or related to the use of an illegal drug(s) or the nonmedical use of a legal drug for patients age 6 to 97 years.

Drug Mention: A drug mention refers to a substance that was recorded ("mentioned") during a drug-related ED episode. Because up to 4 drugs (and alcohol) can be reported for each drug abuse episode, there are more mentions than episodes cited in this report.

Findings are statistically significant unless stated otherwise. Estimates for the first half of 2002 are preliminary, so there is no guarantee that statistically significant differences will remain once the data are complete and estimates for the full year are produced. Final estimates from 1994 to 2001 are provided for reference.

This publication (text and tables), additional tables grouped by metropolitan area, and tables of relative standard errors are available online at http://www.samhsa.gov/oas/dawn.htm and http://www.DAWNinfo.net.

#### **TOTAL DRUG-RELATED ED EPISODES**

- From January through June 2002, DAWN estimates that there were 308,558 drug abuse-related ED episodes in the coterminous U.S. with 564,196 drug mentions (on average, 1.8 drugs per episode) (Table 2.1.0). There was no statistically significant difference between the first half of 2001 and the first half of 2002 in total drug-related ED episodes or ED drug mentions (Table 2.1.0).
- From the first half of 2001 to the first half of 2002, none of the 21 metropolitan areas oversampled in DAWN had increases in drug abuse episodes, but there were significant decreases in drug episodes in 4 metropolitan areas (Table 3.1): Seattle (-54%, from 5,720 to 2,656 episodes), Dallas (-22%, from 3,369 to 2,638), Chicago (-16%, from 16,526 to 13,937), and San Diego (-12%, from 3,615 to 3,194).

BEST COPY AVAILABLE



#### **MAJOR SUBSTANCES OF ABUSE**

- For illicit drugs, a comparison of the first half of 2001 and the first half of 2002 revealed that (Table 2.1.0):
  - There were no significant changes in ED mentions of cocaine, heroin, marijuana, amphetamines, methamphetamine, MDMA (Ecstasy), Ketamine, PCP, GHB, or inhalants.
  - LSD mentions decreased 78 percent (from 1,882 mentions in the first half of 2001 to 407 mentions in the first half of 2002).

#### **Patient Demographics**

- Total drug-related ED episodes and mentions of alcohol-in-combination, cocaine, marijuana, amphetamines, methamphetamine, MDMA (Ecstasy), Ketamine, PCP, and GHB were stable across demographic categories from the first half of 2001 to the first half of 2002 (Tables 4.1.0 through 4.33.0).
- Mentions of heroin declined 18 percent (from 14,924 in the first half of 2001 to 12,260 in the first half of 2002) among patients who were black (Table 4.9.0), and mentions of LSD declined across most demographic subgroups: both genders, white and black patients, and patients age 20 and over (Table 4.21.0).

#### **Characteristics of ED Episodes**

- Characteristics of drug-related ED episodes overall were unchanged from the first half of 2001 to the first half of 2002 (Table 5.1.0). During the first half of 2002:
  - More than half (55%) of drug-related ED episodes involved multiple drugs.
  - The motive for drug abuse was cited as dependence in more than one-third (37%), suicide in another 29 percent, and psychic effects in 20 percent of episodes. Motive was unrecorded in 13 percent of episodes.
  - The reason for the ED visit was overdose in 40 percent, unexpected reaction in 18 percent, and seeking detoxification in 17 percent of drug-related episodes.
     Reason for contact was unrecorded in 5 percent of episodes.
  - Patients were admitted to the hospital (49%) and treated and released (48%) in nearly equal proportions.



#### **ALCOHOL-IN-COMBINATION**

Alcohol is reportable to DAWN only when present in combination with another reportable drug.

- In the first half of 2002, alcohol-in-combination was mentioned in 32 percent of ED drug episodes (97,527 mentions). Overall, mentions of alcohol-in-combination were statistically unchanged from the first half of 2001 to the first half of 2002 (Table 2.1.0).
- Mentions of alcohol-in-combination increased 56 percent (from 804 to 1,252) in Buffalo from the first half of 2001 to the first half of 2002. Significant decreases during this time period were found in Seattle (-46%, from 1,469 to 800 mentions), San Francisco (-29%, from 1,010 to 717), Dallas (-28%, from 934 to 670), and Phoenix (-23%, from 1,296 to 1,004) (Table 3.5).

#### COCAINE

- Nationwide, there were 91,687 ED mentions of cocaine in the first half of 2002 (Table 2.1.0). Cocaine mentions remained stable from the first half of 2001 to the first half of 2002.
- From the first half of 2001 to the first half of 2002, significant increases in cocaine mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.7): Minneapolis (47%, from 462 to 681 mentions) and Denver (47%, from 631 to 926). Significant decreases in cocaine mentions were found in 7 metropolitan areas: Seattle (-67%, from 1,660 to 551), Dallas (-32%, from 964 to 654), Detroit (-32%, from 4,160 to 2,820), Washington, DC (-28%, from 1,440 to 1,032), San Francisco (-21%, from 1,220 to 964), Chicago (-20%, from 8,269 to 6,614), and San Diego (-11%, from 439 to 389).

#### **HEROIN**

- There were 42,571 ED mentions of heroin in the first half of 2002 (Table 2.1.0). Nationwide, mentions of heroin were statistically unchanged from the first half of 2001.
- From the first half of 2001 to the first half of 2002, significant increases in heroin mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.9): Buffalo (71%, from 283 to 484 mentions) and Denver (37%, from 380 to 519). Significant decreases in heroin mentions were found in 7 metropolitan areas: Seattle (-47%, from 903 to 475 mentions), Washington, DC (-42%, from 1,024 to 591), Dallas (-41%, from 251 to 147), Detroit (-32%, from 2,102 to 1,440), Baltimore (-24%, from 2,593 to 1,977), San Diego (-21%, from 401 to 316), and Phoenix (-20%, from 372 to 298).



#### **MARIJUANA**

- There were 55,727 ED mentions of marijuana in the first half of 2002 (Table 2.1.0). Nationwide, marijuana mentions remained statistically unchanged from the first half of 2001 to the first half of 2002.
- From the first half of 2001 to the first half of 2002, significant increases in marijuana mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.11): Miami (30%, from 920 to 1,195 mentions) and San Diego (20%, from 521 to 625). Significant decreases in marijuana mentions were found in 4 metropolitan areas oversampled in DAWN (Table 3.11): Seattle (-65%, from 858 to 298), Buffalo (-49%, from 374 to 192), San Francisco (-44%, from 387 to 217), and Dallas (-36%, from 570 to 364).

#### **AMPHETAMINES AND METHAMPHETAMINE**

- In the first half of 2002, DAWN estimates 10,079 ED mentions of amphetamines and 6,136 ED mentions of methamphetamine in the coterminous U.S. (Tables 2.1.0 and 12.1.0). From the first half of 2001 to the first half of 2002, no significant change was evident for ED mentions of amphetamines or methamphetamine.
- From to the first half of 2001 to the first half of 2002 (Tables 3.13 and 3.15):
  - Significant increases in mentions of amphetamines were found in 2 metropolitan areas: Denver (57%, from 163 to 256 mentions) and San Diego (31%, from 432 to 566).
  - Mentions of amphetamines decreased in 4 metropolitan areas: Seattle (-70%, from 345 to 104), Philadelphia (-45%, from 228 to 126), San Francisco (-26%, from 376 to 279), and Dallas (-24%, from 187 to 143).
  - Of the metropolitan areas with at least 100 mentions of methamphetamine, there were significant decreases in Seattle (-31%, from 166 to 115 mentions) and San Diego (-25%, from 344 to 257), and there were no significant increases.

#### **OTHER SUBSTANCES OF ABUSE**

Not all cases involving prescription or over-the-counter (OTC) drugs are reportable to DAWN. However, DAWN receives reports of ED episodes involving the nonmedical use of legal drugs. These can involve deliberate abuse of prescribed or legally obtained OTC medications or of pharmaceuticals diverted for abuse. Accidental overdoses or ingestions with no intent of abuse, or adverse reactions to OTC or prescription drugs taken as directed are not reportable to DAWN unless they were present in combination with an illicit drug. Only generic drug names are presented in DAWN publications. DAWN estimates should not be attributed to drugs marketed under particular brand (trade) names.

■ DAWN estimates that other substances of abuse (251,015 mentions) accounted for 44 percent of total ED drug mentions in the first half of 2002 (Table 2.1.0). Although the vast majority of these other substances are marketed legally by prescription or over the



counter, it is impossible to know from DAWN the number of ED visits related to the abuse of prescription drugs by the person for whom the drug was prescribed for a therapeutic purpose.

- ED mentions of other substances of abuse in the first half of 2002 were most concentrated among psychotherapeutic agents (104,687 mentions) and central nervous system (CNS) agents (108,081) in nearly equal proportions (19% of total ED mentions each) (Table 2.1.0).
- From the first half of 2001 to the first half of 2002, mentions of psychotherapeutic agents overall were stable, as were mentions for the subcategories of psychotherapeutic agents (antidepressants; antipsychotics; anxiolytics, sedatives, and hypnotics; and CNS stimulants).
- ED mentions of CNS agents overall were stable from the first half of 2001 to the first half of 2002. However, among the subcategories of CNS agents:
  - Mentions of narcotic analgesics/combinations increased 16 percent (from 47,683 to 55,311 mentions),
  - Mentions of miscellaneous analgesics/combinations decreased 17 percent (from 21,447 to 17,849 mentions), and
  - Mentions of anorexiants increased 171 percent (from 383 to 1,038).
- Among the most frequently mentioned narcotic analgesics/combinations (Table 2.7.0):
  - Estimates for codeine/combinations (2,317 mentions in the first half of 2002), hydrocodone/combinations (12,033 mentions), morphine/combinations (1,122 mentions), and propoxyphene/combinations (2,486 mentions) were stable from the first half of 2001 to the first half of 2002, as were mentions of unnamed narcotic analgesics (NOS, 18,970 mentions) and of methadone (5,190 mentions).
  - ED mentions for the category of oxycodone/combinations were not statistically changed from the first half of 2001 to the first half of 2002. However, mentions of oxycodone specifically rose significantly from the first half of 2001 to the first half of 2002 (a 59% increase, from 4,940 to 7,828 mentions).



# INTRODUCTION

his publication presents estimates of drug-related emergency department (ED) visits from the Drug Abuse Warning Network (DAWN) from 1994 through the first half of 2002. Special attention is given to the preliminary estimates for the first half of 2002, which are being released for the first time. DAWN is an ongoing, national data system that collects information on drug-related visits to EDs from a national probability sample of hospitals. The Office of Applied Studies (OAS) of the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services has been responsible for DAWN operations since 1992.

ED Trends From DAWN is published twice each year. Once each year, ED Trends publishes a limited set of preliminary estimates developed from the first half-year of data (i.e., January through June). Each year, a second issue of ED Trends presents final estimates for the most recent full year and comparisons to previous years. The revised estimates in the ED Trends From DAWN series replace those DAWN estimates published previously for 1994 through 2000.

This publication contains the following estimates of drug-related ED episodes and specific drug mentions:

- Preliminary estimates for January

  June 2002, with half-year estimates from July 1997 through December 2001 for comparison.
  - Estimates for January–June 2002 are considered preliminary because some hospitals can be expected to report late and the sampling weights used to derive national and metropolitan area estimates for this period are not final (see Appendix B).
- Final estimates for the full years 1994 through 2001, which were published previously and are provided here for reference.

DAWN relies on a detailed "drug vocabulary" to categorize the thousands of substances that are reported each year. The drug vocabulary is, literally, the language—the codes and terminology—that DAWN uses to record and classify drugs and other substances collected from EDs. In 2001, it was necessary to implement substantial changes to the existing vocabulary to ensure that reported substances are accurately and consistently classified. The overhaul and replacement of the DAWN drug vocabulary as well as the first publication of the revised trends are described in detail in *Emergency Department Trends From the Drug Abuse Warning Network Preliminary Estimates, January—June 2001 with Revised Estimates 1994—2000.* In addition, a separate publication focusing exclusively on the drug vocabulary is forthcoming.

<sup>&</sup>lt;sup>4</sup> The classification of drugs currently in use by DAWN is derived from the Multum Lexicon, Copyright © 2001, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2001). The Multum Licensing Agreement governing use of the Lexicon is provided in Appendix E to this report and can be found on the Internet at http://www.multum.com/.



<sup>&</sup>lt;sup>3</sup> The publication series entitled *ED Trends From DAWN* replaced 2 semi-annual publications—*Mid-year Preliminary Emergency Department Data from DAWN*. It also replaced the trend tables (chapter 4) from the annual *Detailed ED Tables* prior to 2001, which are published exclusively on the Internet. (Prior to 1998, *Detailed ED Tables* were published under the title *DAWN Annual Emergency Department Data*.)

In the next section, we describe the sources and methods used to collect data for DAWN, and then highlight certain limitations of the data. Finally, we provide an overview of the layout of this publication, including a detailed description of each table and its proper interpretation.

#### OTHER DAWN PUBLICATIONS

The DAWN system also collects data on drug-related deaths from a nonrandom set of death investigation jurisdictions. Findings from DAWN mortality data are published annually in a separate publication series entitled *Mortality Data From the Drug Abuse Warning Network.*<sup>5</sup>

A relatively new series called *The DAWN Report* focuses on topics of special interest in a brief publication format.<sup>6</sup> The inaugural issue of *The DAWN Report* (12/2000) focused on club drugs, a topic chosen because of the large volume of requests for information on this emerging drug problem. This issue was recently updated with estimates through 2001 (10/2002). The second issue of *The DAWN Report* featured major drugs of abuse in ED visits, which displayed the geographic distribution of cocaine, heroin, marijuana, and methamphetamine mentions on a U.S. map (7/2001). This was recently updated with estimates from 2001 as well (10/2002). Several new issues of *The DAWN Report* are scheduled for release in the near future.

OAS receives many requests for specific information from potential and actual consumers of information from DAWN. We view these requests as expressions of the need to improve the content of DAWN publications. Topics for *The DAWN Report* and modifications to other DAWN publications are often the result of consumer input.

#### **OVERVIEW OF DAWN ED COMPONENT**

The DAWN system provides information on some of the health consequences of drug abuse in the United States as manifested by drug-related visits to hospital EDs. Hospitals eligible for DAWN are non-Federal, short-stay, general medical and surgical hospitals that operate 24-hour, 7-day EDs. Since 1988, DAWN ED data have been collected from a representative sample of eligible hospitals located throughout the coterminous U.S., with oversampling in 21 metropolitan areas and a National Panel of hospitals sampled from locations outside these areas.

In 2001, the DAWN sample consisted of 564 eligible hospitals.<sup>7</sup> Of these, 458 (81%) participated in DAWN. Response rates in the 21 metropolitan areas ranged from 58 percent to 100 percent, with only 2 metropolitan areas having response rates below 75 percent (Table 1.1). The 2001 sample of hospitals submitted data on 196,268 drug abuse episodes with an average of 1.8 drug mentions per episode (Table 1.3).

In the first half of 2002, 14 metropolitan areas had response rates lower than 70 percent, with the lowest at 49 percent. One of the reasons that estimates from the first half of 2002 are considered preliminary is that additional data from this period are expected and will be

<sup>&</sup>lt;sup>7</sup> The DAWN sample is updated annually, so 2001 is the last full year for which the sample was drawn. The sample for 2002 will be updated at the close of the 2002 data year.



<sup>&</sup>lt;sup>5</sup> For mortality data prior to 2000, the publication series was titled Drug Abuse Warning Network Annual Medical Examiner Data.

<sup>&</sup>lt;sup>6</sup> Issues of The DAWN Report are available on-line at http://www.samhsa.gov/oas/dawn.htm and http://www.DAWNinfo.net.

incorporated before 2002 estimates are finalized. Estimates for the first half (January–June) of 2002 will be updated upon the close of the 2002 data year.

For this publication, sampling weights have been applied to data from the sample to produce estimates representing all ED drug episodes and drug mentions in the total coterminous U.S.<sup>8</sup> and in the 21 metropolitan areas (see Appendix B). The National Panel represents hospitals outside of the 21 metropolitan areas. Estimates for the 21 metropolitan areas are pooled with estimates from the National Panel to produce the national estimates. To account for differences in population and to facilitate comparisons across metropolitan areas, estimated rates of ED drug episodes and mentions per 100,000 population also are presented (see Appendix B). Population estimates used to derive the estimated rates for 2001 are presented in Table 1.9 for each DAWN metropolitan area.

#### DATA COLLECTION METHODOLOGY

Within each hospital that participates in DAWN, a designated DAWN reporter, who is usually a member of the ED or medical records staff, is responsible for reviewing medical charts to identify ED visits that are eligible for submission to DAWN. DAWN reporters rely on information from medical charts that originates with hospital staff who treated the patient. Ultimately, the accuracy and completeness of the data submitted to DAWN depend on the careful recording of information by the medical staff and on the accuracy and completeness of the information provided to the medical staff by the patient.

The DAWN reporter submits an episode report to the DAWN system for each patient who visits a DAWN ED and meets certain criteria. To be included in DAWN, the patient presenting to the ED must meet all of the following criteria:

- The patient was age 6 to 97;
- The patient was treated in the hospital's ED;
- The patient's presenting problem(s) (i.e., the reason for the ED visit) was induced by or related to drug use, regardless of when the drug use occurred;
- The episode involved the use of an illegal drug or the use of a legal drug or other chemical substance for nonmedical purposes; and
- The patient's reason for using the substance(s) was dependence, suicide attempt or gesture, and/or psychic effects.

In addition to drug overdoses, reportable ED episodes may result from the chronic effects of habitual drug use or from unexpected reactions. Unexpected reactions reflect cases where the drug's effect was different than anticipated (e.g., caused hallucinations). DAWN cases do **not** include accidental ingestion or inhalation of a substance with no intent of abuse, or adverse reactions to prescription or over-the-counter medications taken as prescribed.

A single drug abuse episode may have multiple drug mentions. Up to 4 different substances can be recorded for each ED episode. Therefore, not every reported substance is,

<sup>&</sup>lt;sup>8</sup> The total coterminous U.S. consists of the 48 contiguous states and the District of Columbia. Alaska and Hawaii are excluded.



\_\_\_34

by itself, necessarily a cause of the medical emergency. On the other hand, substances that contributed to a drug abuse episode may occasionally go unreported or undetected. Even when only one substance is reported for an episode, an allowance should be made for reportable drugs not mentioned or for other contributory factors.

Alcohol use is reported to DAWN **only** when alcohol is present in combination with a reportable substance.

In addition, each report of a drug-related ED episode includes demographic information about the patient and information about the circumstances of the episode (e.g., the date and time of the ED visit, the reason the patient came to the ED). Only one reason for the ED contact and one reason for taking substances are recorded, regardless of the number of substances involved.<sup>9</sup>

#### CONSIDERATIONS WHEN INTERPRETING DAWN DATA

When interpreting findings from this publication, the reader needs to recognize what DAWN can and cannot measure. DAWN does not measure the frequency or prevalence of drug use in the population, but rather the health consequences of drug use that are reflected in visits to hospital EDs. Moreover, estimates of drug episodes and mentions may increase or decrease for reasons unrelated to the size or characteristics of the drug-using population. The reader should consider the following when interpreting estimates from DAWN:

- The number of ED episodes reported to DAWN is not equivalent to the number of individual patients, because one person may make repeated visits to an ED. DAWN data contain no individual identifiers, which would be required to estimate repeat visits. Therefore, the estimates presented in this publication pertain to total ED episodes or drug mentions, not to the number of different patients involved. In this context, rates should be regarded not as prevalence rates for the population using EDs, but as indicators of the number of ED drug abuse episodes or mentions per 100,000 population.
- DAWN data may be affected by data collection procedures and thereby reflect changes in hospital services or operations. A hospital in one city may open a new detoxification unit that diverts drug-related episodes away from the ED. Conversely, in another city, people may go to the ED to seek care for detoxification because they are unable to gain admission to a drug treatment facility or because they need medical certification before entering treatment. These factors may vary over time and place.
- Estimates of drug-related ED episodes or mentions may be affected by reporting patterns. For example, a change to computer-based recordkeeping systems in a hospital ED could increase or decrease the number of ED visits identified as drug related.
- Greater awareness and knowledge of drug-related problems may result in a greater propensity for ED staff to record drug use in the ED record. Alternatively, the

<sup>&</sup>lt;sup>9</sup> For each drug mentioned, the DAWN reporting form also includes the form in which the drug was acquired (e.g., liquid, pieces), its source (e.g., street buy, patient's own legal prescription), and its route of administration (e.g., oral, injection). However, these data items frequently are unavailable from source records.



- sensitivity of drug-related problems may reduce patients' willingness to disclose drug use and providers' willingness to record it in the permanent medical record.
- Estimates of drug-related ED episodes or mentions can be affected if the weights applied to the data change in an irregular way. We use a set of quality control procedures to identify and investigate unusual weights and data, and our review of the weights and data used in this publication did not reveal any factors that are unduly responsible for the trends reported.
- Trends may be affected by unusual changes in the sample composition. See Appendix B for more information regarding sampling.
- Graphs illustrating trends in drug mentions often use different scales for the vertical axis.
- The DAWN estimates beginning with 2001 utilize population data from the 2000 decennial Census. The U.S. Bureau of the Census is the source for all the population data used to produce the estimated rates (see Appendix B). It is important to note that the population denominator used to calculate rates per 100,000 population is considerably larger for 2001 due to the availability of 2000 decennial Census data. (Estimates for periods prior to 2001 used estimated yearly adjustments from the 1990 Census.) Many large decreases in 2001 population-based rates are attributable to the larger denominator. Therefore, it is important to verify reductions in rates against total estimates for the same measures. It is possible, for example, to have an estimate (in mentions or episodes) increase from 2000 to 2001 and to have the corresponding rate decrease because of changes in the population denominator. To assist the reader, the percent change columns in the rate tables are calculated based on the rates in this issue of *ED Trends*.<sup>10</sup>

#### INTERPRETATION OF STATISTICAL SIGNIFICANCE

The estimates of episodes and mentions displayed in tables in this publication are accompanied by columns indicating the percent change from one period to another. The percent change is indicated only for statistically significant differences and only when both estimates in the comparison are greater than zero. Although estimates in the tables are presented rounded to the nearest whole number, the percent change is calculated based on the actual, non-rounded number. In describing statistically significant differences between DAWN estimates, the traditional level of statistical significance (p less than 0.05) is used.

In tables presenting full years, the estimates for the latest year (2001) are compared to the earliest year presented in the trend (1994 in this publication), and then to the 2 previous years (1999 and 2000).

In tables presenting estimates for half years, the first half of 2002 is compared to the second half of 2001, then the first halves of 2002 and 2001 are compared. Comparisons between the second half of one year and the first half of another may be problematic because of the potential for seasonal distortions. Discussions of half-year findings in this publication will be

<sup>&</sup>lt;sup>10</sup> Previously (in ED Trends From the Drug Abuse Warning Network, Preliminary Estimates January—June 2001 with Revised Estimates 1994–2000), the percent change columns presented in the rate tables reflected the changes for the underlying estimates (mentions or episodes).



limited because the estimates for 2002 are preliminary and will focus on comparisons between the first halves of 2001 and 2002.

Each table of estimates has a corresponding table containing relative standard errors (RSEs) for each estimate, and all the *p*-values, including those that are 0.05 or greater, for the comparisons described above. If a *p*-value has a negative sign in front of it, this means that there was a decrease in the estimate between the periods noted. The RSE tables are published on the Internet. The RSE values for total estimates and rates per 100,000 population are similar, so a single RSE table is provided for each pair of estimate tables. For example, Table RSE-2.2.0 presents RSEs applicable to the estimates in Table 2.2.0 and to the estimated rates in Table 12.2.0. The statistical tests used to determine the significance levels are t-tests (with infinite degrees of freedom). That is, the change score, or the difference between the 2 estimates, is divided by the standard error of the estimate. A value of zero is expected under the null hypothesis.

Although tests for statistical significance are important tools in interpreting results, significance does not always imply that the difference is large or important. Small changes that are statistically significant may occur frequently at the metropolitan area level in DAWN due to the selection of all eligible hospitals (which constitutes a census) in Baltimore, Buffalo, Denver, San Diego, and San Francisco, along with sampling many other metropolitan areas at a high frequency (Table 1.1). The closer the sample is to a census, the higher is the likelihood that a change will be statistically significant, no matter how small it may be. While technically there is no sampling variability in the 5 areas noted, some variability is due to the hospitals' nonresponse, which is treated as sampling error in the variance calculations.

RSEs for the coterminous U.S. and for each metropolitan area are summarized in Figure 1. The RSE for total drug-related ED episodes for the coterminous U.S. is 8 percent. Across the 21 metropolitan areas oversampled in DAWN, RSEs range from a low of 3 percent in San Diego to a high of 23 percent in Los Angeles and Newark. RSEs for particular drugs are often much higher.

Nonsampling errors such as nonresponse and reporting errors may affect the outcome of significance tests. While *p* less than 0.05 significance level is used to determine statistical significance in DAWN ED tabulations, large differences associated with slightly higher *p*-values (specifically those between 0.05 and 0.10) may be of interest also. On the other hand, statistically significant differences are not always meaningful, because the size of the difference is small or because the significance may have occurred simply by chance. In a series of 20 independent tests, it is to be expected that one test will indicate a significant difference merely by chance even if there is no real difference in the populations compared. The text often discusses more than one comparison within a given table (e.g., comparing percentages for different drugs or subgroups). We have made no attempt to adjust the level of significance to account for these multiple comparisons. Therefore, the probability of falsely rejecting the null hypothesis at least once in a family of comparisons is higher than the significance level given for individual comparisons (in this publication, 0.05).

### OTHER CONSIDERATIONS WHEN READING DAWN TABLES

Estimates with RSEs of 50 percent or higher are regarded as too imprecise for publication. In the tables, the symbol "..." (3 dots) has been substituted for estimates that did not meet this



standard of precision. With an RSE of 50 percent, the 95 percent confidence interval for an estimate ranges from 2 to 198 percent of the estimate's value (see Appendix B).

Similarly, some 2001 estimates for the Atlanta metropolitan area are suppressed (indicated by the symbol "---") because they are based on insufficient data (see Appendix C).

Beginning with the 1999 ED data, estimates smaller than 10 were no longer suppressed in DAWN ED publications. Many estimates as small as this are suppressed by virtue of having RSEs greater than 50 percent. For those that are shown in the tables, we note for the reader that small numbers and their associated RSEs should be interpreted with caution.

As described in Appendix B, the DAWN ED data for 1995 through 1997 were reweighted and reprogrammed, and the presentation of findings was improved during 1998. Improvements in the DAWN drug vocabulary resulted in revisions to estimates for 1994 through 2000. The charts, tables, and graphs in this publication present only revised estimates.

### **HOW TO USE THIS PUBLICATION**

This issue of *ED Trends From DAWN* examines the nature of trends in drug-related ED episodes and focuses almost exclusively on the preliminary estimates for the first half of 2002 with statistical comparisons to the first half of 2001. Tables showing the 8 full years 1994 to 2001 have been discussed and published previously, but are reproduced here for ease of reference. In the full-year tables, statistical tests are used to compare full year 2001 estimates with those for 2000, 1999, and 1994. For half years, estimates for the latest half-year period are compared with those for the previous 2 half years. Each table displays the percent change for statistically significant differences. Actual *p*-values are still available in the companion tables of RSEs, which are published on the Internet.

The presentation of ED findings in this publication is divided into the following sections, which mirror the order of the tables in this publication:

- Trends in major substances of abuse, such as cocaine, heroin, and "club drugs;"
- Trends in other substances of abuse, such as prescription and over-the-counter (OTC) drugs;
- Trends for the 21 metropolitan areas oversampled in DAWN; and
- Discussion of results.

Population-based rates are discussed within these sections by topic, because the rates are best used to supplement the other estimates of episodes and mentions. By considering the estimates of drug mentions and episodes relative to the size of the population at risk, the rates yield standardized measures that can be compared across selected drugs, metropolitan areas, and gender and age groups.

<sup>11</sup> A thorough description of the revisions to the DAWN drug vocabulary and the impact of those revisions on published estimates can be found in Appendixes A and B of the ED Trends From DAWN, Preliminary Estimates January—June 2001 with Revised Estimates 1994—2000.



### ORGANIZATION OF TABLES

In this section, we explain the organization of the tables in *ED Trends* and explain the classification of drugs in the context of these tables.

The table numbering scheme is described in a separate exhibit on the inside of the front cover of this publication. Table numbers in this publication are identical to those in the last issue of the *ED Trends From DAWN*.

The tables in this publication are designed to array information from the very general to the very specific. This design responds directly to requests we receive for information at these different levels of detail. Figure 2 illustrates the general to specific organization of the tables.

### **Major Drug Categories**

At the most general level (the left half of Figure 2), estimates are reported for major drug categories. Table 2.2.0 illustrates the standard layout of substances by drug categories. This table and others like it are divided into 2 panels with:

- "Major substances of abuse" (e.g., cocaine, heroin, and "club drugs") in the top panel, and
- "Other substances of abuse" in the lower panel.

Specific content for each of these panels is described later in this section.

National estimates are provided for the major drug categories in one table. The same estimates are provided in separate tables for each of the 21 metropolitan areas oversampled by DAWN. For example, Table 2.2.0 contains national estimates, and Tables 2.2.1 through 2.2.21 contain estimates for each of the 21 DAWN metropolitan areas.

The third term in the table number always indicates the geographic area:

- .0 for national estimates, and
- .1 .21 for the 21 metropolitan areas, where .1 is always Atlanta, .2 is always Baltimore, and so forth. The complete list of the metropolitan areas and their corresponding numbers is provided on the inside of the front cover.

### **Component Drugs**

At a more specific level (the right half of Figure 2), a second set of tables lists the component drugs classified under the 5 largest categories: major substances of abuse, psychotherapeutic agents, CNS agents, respiratory agents, and cardiovascular agents.

National estimates are provided for each of the component drugs; these are followed by estimates for component drugs for each of the 21 metropolitan areas.



This is more detailed drug information than is available from any other substance abuse data system. In response to requests, both high and low frequency terms are displayed, as follows:

 Table 2.4.0 (estimates) and 12.4.0 (rates): full-year estimates for component drugs of the major substances of abuse. Corresponding half-year estimates are published in Tables 2.3.0 and 12.3.0, respectively.

These tables include all the terms, including street names, reported to DAWN for the major substances of abuse. For example, users will consult this table to find estimates for "crack," which is subsumed under the major substance "cocaine" in Tables 2.1.0 and 2.2.0, and to see the relative frequency of particular terms.

- Table 2.6.0 (and 12.6.0): full-year estimates for component drugs of psychotherapeutic agents. Corresponding half-year estimates are published in Tables 2.5.0 and 12.5.0, respectively.
- Table 2.8.0 (and 12.8.0): full-year estimates for component drugs of CNS agents. Corresponding half-year estimates are published in Tables 2.7.0 and 12.7.0, respectively.
- Table 2.10.0 (and 12.10.0): full-year estimates for component drugs of respiratory agents. Corresponding half-year estimates are published in Tables 2.9.0 and 12.9.0, respectively.
- Table 2.12.0 (and 12.12.0): full-year estimates for component drugs of cardiovascular agents. Corresponding half-year estimates are published in Tables 2.11.0 and 12.11.0, respectively.

Except for the major substances of abuse, component drugs are always expressed at the generic substance level (e.g., fluoxetine). No published estimates are provided by brand (trade) name. Tabulations of component drugs will include all substances in the category, regardless of the frequency with which they were reported to DAWN. For example, users interested in the trends in ED visits involving particular narcotic analgesics will consult Table 2.8.0.

### **Major Substances of Abuse**

The major substances of abuse include the most common illicit drugs and drug categories reported to DAWN, alcohol reported in combination with any other substance reported to DAWN, and lower frequency drugs of particular policy interest (e.g., club drugs such as Ecstasy and GHB).

The 15 categories in the major substances of abuse are grouped in a panel at the top of summary tables (e.g., Table 2.2.0) for ease of reference. For each of the major substances, component drugs—that is, the specific terms, including street names as they were reported to DAWN—are enumerated in Table 2.4.0 (and Table 2.3.0 for half years). The 15 major substances of abuse are:

**Alcohol-in-combination.** This is the most frequent drug reported to DAWN, even though it is reported only when present in combination with another reportable drug.



**Cocaine.** This category includes both powder and crack cocaine. Estimates for these and other specific terms are available in the component drug tables.

**Heroin.** ED estimates for heroin and morphine are tabulated separately (with ED morphine estimates presented under narcotic analgesics, below).<sup>12</sup>

Marijuana. This category includes both marijuana and hashish.

Amphetamines. This class of substances has been extracted from the category of CNS stimulants because of its importance as a major substance of abuse. For purposes of classification, "amphetamines" (plural) includes a class of compounds derived from or related to the drug amphetamine. Although some "designer" drugs fall into the class of amphetamines, we choose to report some of them (e.g., methamphetamine) individually as major substances of abuse. This category does not include other CNS stimulants, such as caffeine or methylphenidate.

Methamphetamine. This category includes methamphetamine and the term "speed."

MDMA (methylenedioxymethamphetamine, Ecstasy). This is the "designer" or "club" drug commonly known as Ecstasy. It is classified separately as a major substance of abuse because of widespread interest.

**Ketamine.** This is a veterinary anesthetic classified separately as a major substance of abuse because of widespread interest. It is another of the "designer" or "club" drugs.

- LSD. LSD is listed separately from other hallucinogens because of widespread interest.
- PCP. PCP is listed separately from other hallucinogens because of widespread interest.

**Miscellaneous hallucinogens.** This category includes hallucinogens other than LSD and PCP.

**Flunitrazepam (Rohypnol).** Flunitrazepam is a benzodiazepine that is not legal for marketing in the United States. It is reported under major substances because of increased interest in its use as a "designer" or "club" drug. It is excluded from the list of benzodiazepines described below.

**Gamma hydroxy butyrate (GHB).** This category includes GHB and its precursor gamma butyrolactone (GBL). It is another of the "designer" or "club" drugs.

**Inhalants.** Inhalants include anesthetic gases and certain nonpharmaceuticals for which the documented route of administration was inhalation.

To be classified as inhalants, anesthetic gases are extracted from the category CNS agents, general anesthetics. These substances have the physical property at room temperature

<sup>&</sup>lt;sup>12</sup> In contrast, heroin and morphine are combined in tabulations of DAWN mortality data. It is often impossible to distinguish heroin from morphine during death investigations because the toxicology tests used to identify a drug involved in a drug-related death rely on a metabolite common to both drugs. This is the only such difference in drug classification between DAWN ED and mortality data.



of being a gas or are delivered as a gas and therefore are presumed to have been inhaled. The anesthetic gases include nitrous oxide, ether, and chloroform.

To be classified as an inhalant, a nonpharmaceutical substance must have a psychoactive effect when inhaled and falls into one of 3 subcategories: volatile solvents, nitrites, or chlorofluorohydrocarbons (see Appendix D).

Illicit combinations. This category includes compounds composed of 2 or more major substances of abuse that are mixed and taken together. For example, "speedball," which usually refers to the combination of heroin and cocaine taken at once, would be classified as an illicit combination, whereas separate mentions of heroin and cocaine would be classified separately in the categories heroin and cocaine. Compounds consisting of a major substance of abuse and another substance are classified in the category of the major substance (e.g., heroin with scopolamine is classified as heroin).

### Other Substances of Abuse

Other substances of abuse are summarized by pharmaceutical category (e.g., Table 2.2.0) using the categories and category assignments that are an integral part of the Multum *Lexicon* (the basis for DAWN's drug vocabulary), with a few exceptions noted here. Many of these substances are marketed legally as prescription and OTC medications. Readers should note that the purpose for which these substances are intended may be quite different from the effect for which these substances are abused. Since it is impossible to know patients' actual intentions when abusing a substance, we have chosen to classify these substances by their therapeutic uses. Some drugs may have more than one therapeutic use and could be assigned to multiple categories. To avoid duplication, each drug is assigned to a single therapeutic category and is tabulated only once.

Four of the categories under other substances of abuse are divided into finer subcategories, and the component drugs for these 4 categories are displayed in subsequent tables (e.g., Tables 2.6.0, 2.8.0, 2.10.0, and 2.12.0).

### Psychotherapeutic agents are divided into the following categories:

- Antidepressants
  - MAO inhibitors
  - SSRI antidepressants
  - Tricyclic antidepressants
  - Miscellaneous antidepressants
- Antipsychotics
  - Phenothiazine antipsychotics
  - Psychotherapeutic combinations
  - Thioxanthenes
  - Miscellaneous antipsychotic agents
- Anxiolytics, sedatives, and hypnotics
  - Barbiturates
  - Benzodiazepines This category excludes the benzodiazepine flunitrazepam (Rohypnol), which was assigned to major substances of abuse.
  - Miscellaneous anxiolytics, sedatives, and hypnotics



 CNS stimulants. This category excludes the CNS stimulants that were assigned to major substances of abuse: amphetamines, methamphetamine, and MDMA (Ecstasy).

### Central nervous system (CNS) agents are divided into the following categories:

- Analgesics
  - Antimigraine agents
  - Cox-2 inhibitors
  - Narcotic analgesics and narcotic analgesic combinations This category excludes heroin, which is classified as a major substance of abuse.
  - Nonsteroidal anti-inflammatory agents
  - Salicylates and salicylate combinations
  - Miscellaneous analgesics and miscellaneous analgesic combinations
  - Analgesic combinations NTA
- Anorexiants
- Anticonvulsants
- Antiemetic/antivertigo agents
- Antiparkinson agents
- General anesthetics This category excludes the anesthetic gases that were assigned to major substances of abuse as inhalants.
- Muscle relaxants
- Miscellaneous CNS agents

### Respiratory agents are divided into the following categories:

- Antihistamines
- Bronchodilators
- Decongestants
- Expectorants
- Upper respiratory combinations
- Respiratory agents not tabulated above (NTA) This category captures respiratory agents that did not fit into the 5 other categories of respiratory agents.

# Cardiovascular agents are divided into the following categories:

- Antiandrenergic agents, centrally acting
- Beta-andrenergic blocking agents
- Calcium channel blocking agents
- Diuretics
- Cardiovascular agents NTA This category has been added to capture cardiovascular agents that did not fit into the 4 other categories of cardiovascular agents.

As noted earlier, the general categories used in Table 2.2.0 are expanded in Tables 2.4.0 through 2.12.0 to enumerate the component drugs for the 4 major categories: psychotherapeutic agents, CNS agents, respiratory agents, and cardiovascular agents and their associated subcategories. For example, Table 2.2.0 presents mentions of narcotic analgesics under CNS agents; mentions of particular narcotic analgesics—morphine, codeine, and others—are displayed in Table 2.8.0.



In the tables enumerating component drugs, only generic names are used. Brand (trade) names are not used because estimates for particular brands are considered to be unreliable. Therefore, for example, mentions of the miscellaneous analgesic acetaminophen are tabulated as "acetaminophen," not Tylenol.

Users of DAWN estimates have told us that it is not useful to report only the most frequently occurring substances. Therefore, in Tables 2.4.0 through 2.12.0, substances are enumerated in their relevant category, regardless of the numbers of mentions estimated from DAWN.

The following 6 categories from the Multum *Lexicon* are presented without subdivisions due to the low number of mentions:

- Alternative medicines
- Anti-infectives
- Gastrointestinal agents
- Hormones
- Nutritional products
- Topical agents

Finally, 2 additional categories, "drug unknown" and "all other substances NTA" do not appear in the Multum *Lexicon* but are needed to complete the classification of substances for DAWN.

**Drug unknown.** This includes 2 types of cases: those in which the drug was reported to DAWN as "unknown" and those in which drugs were reported to DAWN as "polysubstances." For the purposes of DAWN, polysubstance refers to the abuse of more than one substance when the individual substances were not identified by the source record. Because DAWN cases are identified through retrospective medical chart review, there will always be cases in which the drug abuse was known but the particular substance was unknown or unknowable. Since 1995, reporting of unknown substances seems to have stabilized at about 2 to 3 percent of drug mentions.

All other substances NTA. This category contains any substance reported to DAWN that could not be classified in the categories noted above and has too few mentions to warrant its own entry in DAWN tables. This category currently includes: antihyperlipidemic agents, antineoplastics, biologicals, coagulation modifiers, immunologic agents, miscellaneous agents, and plasma expanders. Miscellaneous agents include: antidotes, antigout agents, antipsoriatics, antirheumatics, chelating agents, cholinergic muscle stimulants, genitourinary tract agents, impotence agents, local injectable anesthetics, miscellaneous uncategorized agents, psoralens, radiocontrast agents, and viscosupplementation agents.

This category also includes certain legacy terms that could not be assigned reliably to any category. These include ambiguous, nonspecific terms that could fall into any of several categories (e.g., "AIDS medicine" could be an anti-infective, an anticonvulsant, or any number of other drugs); undocumented, nonspecific terms (e.g., "thought organizer"); and street terms for illicit substances that could not be linked reliably to a particular illicit substance (e.g., "T," "butterflies").

<sup>&</sup>lt;sup>13</sup> This issue has been discussed in greater detail in previous issues of ED Trends From DAWN.



We will monitor the content of this category to avoid its uncontrolled expansion in the future. Should a substance or class of substances begin to show significant growth, we intend to add such information to the published categories rather than allow this "all other" category to degrade over time. In addition, regular updates of the Multum *Lexicon* will introduce new prescription and OTC substances as they are approved for marketing and before they begin to appear in DAWN.

### ADDITIONAL CONTENT AVAILABLE ON THE INTERNET

Although this publication includes a large number of tables, even more detail is available through tables that are published only on the Internet. These additional tables can be accessed online at http://www.samhsa.gov/oas/dawn.htm and http://www.DAWNinfo.net. Tables published exclusively on the Internet are:

- Additional tables of estimates by metropolitan area. For ease of reference, these are listed in the table of contents of *ED Trends* and their location noted.
- Relative standard errors (RSEs) for estimates provided in this publication, in a corresponding tabular format. The RSEs used for population-based rates are the same as those used for other DAWN estimates. Although there may be slight differences in the RSEs calculated for the DAWN estimates and the RSEs that would be appropriate for the population-based rates (due to sampling error in the current population estimates), they are sufficiently close for the purpose of this publication.
- Updated indexes listing generic and brand names for prescription and OTC substances. No published estimates are provided by brand (trade) name. The index is provided as an aid for readers who may be unfamiliar with the generic names used in this publication. The updated index is not printed in each issue of ED Trends due to size.<sup>14</sup>

<sup>&</sup>lt;sup>14</sup> An earlier version of this index was printed as Appendix I in Emergency Department Trends From the Drug Abuse Waming Network Preliminary Estimates January—June 2001 with Revised Estimates 1994—2000. The index is updated periodically.



ED Trends From DAWN

Figure 1
Relative standard errors (RSEs) for drug-related episodes by metropolitan area:
January–June 2002





Figure 2
Tables in *ED Trends From DAWN* 



BEST COPY AVAILABLE



# TRENDS IN ED DRUG EPISODES AND MAJOR SUBSTANCES OF ABUSE

his section presents semi-annual estimates from DAWN for total drug-related ED episodes and mentions of major substances of abuse.

"Major substances of abuse" include the most common illicit drugs reported to DAWN, alcohol reported in combination with any other substance reported to DAWN, and lower frequency drugs of particular policy interest (e.g., club drugs such as Ecstasy and GHB). The specific terms (including street names) reported to DAWN for each drug category are listed, with corresponding mentions from July–December 1997 through January–June 2002, in Table 2.3.0 and Table 12.3.0 (corresponding rates per 100,000 population). Corresponding full-year tables for 1994 through 2001 (Tables 2.4.0 and 12.4.0) are also available.

One ED episode can include mentions of one drug alone or mentions of multiple drugs. Therefore, the number of drug mentions exceeds the number of episodes. Major substances of abuse, such as cocaine, heroin, and marijuana, are often reported in combination with other drugs. Alcohol-in-combination is reportable to DAWN only when present in combination with another reportable drug.

The following discussion focuses primarily on comparisons of preliminary estimates for the first half of 2002 versus the first half of 2001. The potential for seasonal variations makes comparisons of the second half of 2001 with the first half of 2002 less reliable.

DAWN estimates for 2001 are based on data from a nationally representative sample of 458 hospitals (Table 1.1).

### **TOTAL DRUG-RELATED ED EPISODES**

- From January through June 2002, DAWN estimates that there were 308,558 drug abuse-related ED episodes in the coterminous U.S. with 564,196 drug mentions (on average, 1.8 drugs per episode) (Table 2.1.0).
- There was no statistically significant difference between the first half of 2001 and the first half of 2002 in total drug-related ED episodes or ED drug mentions (Table 2.1.0). Total ED visits (that is, ED visits for any reason) increased 0.1 percent during this period.
- In the first half of 2002, drug abuse-related ED visits occurred at the rate of 121 ED episodes per 100,000 population in the coterminous U.S. (Table 12.1.0).
- From the first half of 2001 to the first half of 2002, none of the 21 metropolitan areas oversampled in DAWN had increases in drug abuse episodes, but there were significant decreases in drug episodes in 4 metropolitan areas (Table 3.1):
  - Seattle (-54%, from 5,720 to 2,656 episodes),
  - Dallas (-22%, from 3,369 to 2,638),



- Chicago (-16%, from 16,526 to 13,937), and
- San Diego (-12%, from 3,615 to 3,194).

### **MAJOR SUBSTANCES OF ABUSE**

■ From the first half of 2001 to the first half of 2002, the only major substance of abuse that changed significantly was LSD, with mentions decreasing 78 percent (from 1,882 mentions in the first half of 2001 to 407 mentions in the first half of 2002) (Table 2.1.0).

### **ALCOHOL-IN-COMBINATION**

- Alcohol-in-combination was mentioned in 32 percent of ED drug episodes in the first half of 2002 (97,527 mentions) and remains the most common substance reported in drug-related ED visits (Table 2.1.0 and Figure 3). Alcohol is reported to DAWN only when present in combination with another reportable drug, so the actual number of alcohol-related ED visits is higher than the DAWN estimate for alcohol-in-combination.
- Mentions of alcohol-in-combination were statistically unchanged from the first half of 2001 to the first half of 2002 (Table 2.1.0 and Figure 3).
- From the first half of 2001 to the first half of 2002, only Buffalo had a significant increase in mentions of alcohol-in-combination (56%, from 804 to 1,252) (Table 3.5). Significant decreases in mentions of alcohol-in-combination were found in 4 metropolitan areas oversampled in DAWN:
  - Seattle (-46%, from 1,469 to 800 mentions),
  - San Francisco (-29%, from 1,010 to 717),
  - Dallas (-28%, from 934 to 670), and
  - Phoenix (-23%, from 1,296 to 1,004).

### COCAINE, HEROIN, MARIJUANA

- Cocaine continues to be the most frequently mentioned illicit substance, present in 30 percent of ED episodes (91,687 mentions) in the first half of 2002. Cocaine was followed in frequency by marijuana (18%, 55,727 mentions) and heroin (14%, 42,571 mentions) (Table 2.1.0 and Figure 3).
- Mentions of cocaine, heroin, and marijuana remained statistically stable from the first half of 2001 to the first half of 2002. (Table 2.1.0).
- Almost a quarter of the cocaine mentions in the first half of 2002 (23%, 20,694 mentions) were attributed specifically to "crack" (Table 2.3.0). Most cocaine mentions (76%, 70,106) were reported to DAWN simply as "cocaine," and it is not possible to determine what proportion of these might be crack.





- From the first half of 2001 to the first half of 2002, significant increases in cocaine mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.7):
  - Minneapolis (47%, from 462 to 681 mentions) and
  - Denver (47%, from 631 to 926).
- From the first half of 2001 to the first half of 2002, significant decreases in cocaine mentions were found in 7 metropolitan areas (Table 3.7):
  - Seattle (-67%, from 1,660 to 551 mentions),
  - Dallas (-32%, from 964 to 654),
  - Detroit (-32%, from 4,160 to 2,820),
  - Washington, DC (-28%, from 1,440 to 1,032),
  - San Francisco (-21%, from 1,220 to 964),
  - Chicago (-20%, from 8,269 to 6,614), and
  - San Diego (-11%, from 439 to 389).
- From the first half of 2001 to the first half of 2002, significant increases in heroin mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.9):
  - Buffalo (71%, from 283 to 484 mentions), and
  - Denver (37%, from 380 to 519).
- From the first half of 2001 to the first half of 2002, significant decreases in heroin mentions were found in 7 metropolitan areas (Table 3.9):
  - Seattle (-47%, from 903 to 475 mentions),
  - Washington, DC (-42%, from 1,024 to 591),
  - Dallas (-41%, from 251 to 147),
  - Detroit (-32%, from 2,102 to 1,440),
  - Baltimore (-24%, from 2,593 to 1,977),
  - San Diego (-21%, from 401 to 316), and
  - Phoenix (-20%, from 372 to 298).



- From the first half of 2001 to the first half of 2002, significant increases in marijuana mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.11):
  - Miami (30%, from 920 to 1,195 mentions) and
  - San Diego (20%, from 521 to 625).
- From the first half of 2001 to the first half of 2002, significant decreases in marijuana mentions were found in 4 metropolitan areas oversampled in DAWN (Table 3.11):
  - Seattle (-65%, from 858 to 298),
  - Buffalo (-49%, from 374 to 192),
  - San Francisco (-44%, from 387 to 217), and
  - Dallas (-36%, from 570 to 364).

#### **AMPHETAMINES AND METHAMPHETAMINE**

- In the first half of 2002, amphetamines were mentioned in 3 percent of DAWN ED episodes (10,079 mentions, or 4 mentions per 100,000 population) (Tables 2.1.0 and 12.1.0). From the first half of 2001 to the first half of 2002, no significant change was evident.
- There were 6,136 methamphetamine mentions (2 per 100,000 population) in the first half of 2002 (Tables 2.1.0 and 12.1.0). These estimates were not statistically changed from the first half of 2001.
- Most mentions of amphetamines are attributed simply to "amphetamine," while most mentions of methamphetamine are attributed simply to "methamphetamine" or "speed" (Tables 2.3.0 and 2.4.0). It is impossible to know the accuracy of distinctions between amphetamine and methamphetamine. Together they accounted for 16,215 mentions in the first half of 2002.
- From to the first half of 2001 to the first half of 2002 (Tables 3.13 and 3.15):
  - Significant increases in mentions of amphetamines were found in 2 metropolitan areas: Denver (57%, from 163 to 256 mentions) and San Diego (31%, from 432 to 566).
  - Mentions of amphetamines decreased in 4 metropolitan areas: Seattle (-70%, from 345 to 104), Philadelphia (-45%, from 228 to 126), San Francisco (-26%, from 376 to 279), and Dallas (-24%, from 187 to 143).
  - Of the metropolitan areas with at least 100 mentions of methamphetamine, there were significant decreases in 2 metropolitan areas: Seattle (-31%, from 166 to 115) and San Diego (-25%, from 344 to 257). There were no significant increases.



### **CLUB DRUGS**

- No significant changes from the first half of 2001 to the first half of 2002 were evident for the club drugs MDMA (Ecstasy) (2,303 mentions in the first half of 2002), GHB (2,024), or Ketamine (152) (Table 2.1.0).
- None of the 21 metropolitan areas oversampled in DAWN had more than 100 mentions of the club drugs in the first half of 2002 (Tables 3.17, 3.19, 3.27, and 3.29).

### **OTHER TRENDS**

- For the coterminous U.S., LSD mentions decreased 78 percent (from 1,882 to 407) from the first half of 2001 to the first half of 2002 (Table 2.1.0).
- For the coterminous U.S., no significant changes from the first half of 2001 to the first half of 2002 were evident for (Table 2.1.0):
  - PCP (3,257 mentions in the first half of 2002),
  - Miscellaneous hallucinogens (620),
  - Inhalants (559), or
  - Illicit combinations (118).

#### **DEMOGRAPHIC CHARACTERISTICS OF PATIENTS**

- Total drug-related ED episodes were unchanged across demographic subgroups from the first half of 2001 to the first half of 2002 (Table 4.1.0). Similarly, mentions of alcohol-in-combination, cocaine, marijuana, amphetamines, methamphetamine, MDMA (Ecstasy), Ketamine, PCP, and GHB were stable across demographic subgroups (Tables 4.1.0 through 4.33.0).
- Comparing the first halves of 2001 and 2002:
  - Mentions of heroin declined 18 percent (from 14,924 to 12,260) among patients who were black (Table 4.9.0).
  - Mentions of LSD declined across most demographic subgroups: both genders, white and black patients, as well as patients age 20 and over (Table 4.21.0).



### **EPISODE CHARACTERISTICS**

- Characteristics of drug-related ED episodes overall were unchanged from the first half of 2001 to the first half of 2002 (Table 5.1.0).
  - More than half (55%) of drug-related ED episodes involved multiple drugs during the first half of 2002.
  - The motive for drug use was cited as dependence in more than one-third (37%), suicide in another 29 percent, and psychic effects in 20 percent of episodes during the first half of 2002. Motive was unrecorded in 13 percent of cases.
  - The reason for the ED visit was overdose in 40 percent, unexpected reaction in 18 percent, and seeking detoxification in 17 percent. Reason for contact was unrecorded in 5 percent of cases.
  - Patients were admitted to the hospital (49%) and treated and released (48%) in nearly equal proportions.



Figure 3
ED drug-related episodes and alcohol-in-combination, cocaine, heroin, and marijuana mentions: July-December 1997 through January-June 2002





Figure 4
Relative standard errors (RSEs) for major substances of abuse: January–June 2002





# TRENDS IN OTHER SUBSTANCES OF ABUSE

AWN also receives reports of ED episodes involving the nonmedical use of legal drugs. These can involve deliberate abuse of prescribed or legally obtained over-the-counter (OTC) medications or of pharmaceuticals diverted for abuse. Accidental overdoses or adverse reactions to OTC or prescription drugs taken as directed are not reportable to DAWN unless the drugs were present in combination with an illicit drug.

These "other substances of abuse" are tabulated first by categories composed of similar substances (Tables 2.1.0 and 12.1.0 for half year estimates and rates, respectively) and then by generic drug name for the component drugs in each of the largest categories: psychotherapeutic agents (Tables 2.5.0 and 12.5.0), CNS agents (Table 2.7.0 and 12.7.0), respiratory agents (Tables 2.9.0 and 12.9.0), and cardiovascular agents (Tables 2.11.0 and 12.11.0). Corresponding full year tables (Tables 2.6.0, 2.8.0, 2.10.0, and 2.12.0 for estimates and Tables 12.6.0, 12.8.0, 12.10.0, and 12.12.0 for rates) are also available.

By design, all drug mentions in DAWN are tabulated as either major substances of abuse or other substances of abuse. There is no double counting, and the deliberate assignment of drugs into major substances is the result of specific interest in such substances.

Only generic drug names are presented in DAWN publications. DAWN estimates should not be attributed to drugs marketed under particular brand (trade) names. DAWN data are extracted from medical records produced in the course of health care delivery (no patient is ever interviewed), so DAWN case reports contain information about particular substances as that information was documented in the ED medical record. Any prescription or OTC drug may be reported to DAWN by its brand (trade) name, generic name, or chemical name, depending on what was documented in the source record. There is no way to discern whether the brand names in the medical record are always accurate or how frequently brands might have been recorded in generic terms. Therefore, we do not publish estimates for particular brands because we consider them to be unreliable. An index linking brand to generic names is available online at http://www.samhsa.gov/oas/dawn.htm and http://www.DAWNinfo.net. The index is provided solely as an aid to readers who may be unfamiliar with generic names.

In addition, many drug mentions are reported to DAWN by drug type without the drug being named specifically. For publication, these are referred to by the drug type-NOS (not otherwise specified). For example, reports of "benzodiazepine" or "benzos" that do not name a specific benzodiazepine are tabulated as "benzodiazepines-NOS."

This discussion focuses mainly on comparisons of estimates from the first half of 2001 to the first half of 2002.



### OTHER SUBSTANCES OF ABUSE

- DAWN estimates that other substances of abuse (251,015 mentions) comprised 44 percent of total ED drug mentions in the first half of 2002 (Table 2.1.0). Although the vast majority of these other substances are marketed legally by prescription or OTC, it is impossible to know from DAWN the number of ED visits related to the abuse of prescription drugs by patients with legitimate prescriptions.
- ED mentions of other substances of abuse in the first half of 2002 were most concentrated in 2 categories—psychotherapeutic agents (104,687 mentions) and central nervous system (CNS) agents (108,081)—in nearly equal proportions (19% of total ED mentions each) (Table 2.1.0). From the first half of 2001 to the first half of 2002:
  - Mentions of psychotherapeutic agents overall were stable, as were mentions for the subcategories of psychotherapeutic agents (antidepressants; antipsychotics; anxiolytics, sedatives, and hypnotics; and CNS stimulants).
  - Mentions of CNS agents overall were stable. However, among the subcategories of CNS agents, mentions of narcotic analgesics/combinations increased 16 percent (from 47,683 to 55,311 mentions), mentions of miscellaneous analgesics/combinations decreased 17 percent (from 21,447 to 17,849), and mentions of anorexiants increased 171 percent (from 383 to 1,038).

### **Narcotic Analgesics**

- When considered together, narcotic analgesics/combinations comprised 55,311 mentions or 10 percent of ED mentions estimated for the coterminous U.S. in the first half of 2002 (Table 2.1.0).
- From the first half of 2001 to the first half of 2002, mentions of narcotic analgesics/combinations rose 16 percent (Table 2.1.0 and Figure 5).
- Among the most frequently mentioned narcotic analgesics/combinations (Table 2.7.0):
  - Estimates for codeine/combinations (2,317 mentions in the first half of 2002), hydrocodone/combinations (12,033 mentions), morphine/combinations (1,122 mentions), and propoxyphene/combinations (2,486 mentions) were stable from the first half of 2001 to the first half of 2002, as were mentions of unnamed narcotic analgesics (NOS, 18,970 mentions) and of methadone (5,190 mentions).
  - ED mentions for the category of oxycodone/combinations were not statistically changed from the first half of 2001 to the first half of 2002. However, mentions of oxycodone specifically rose significantly from the first half of 2001 to the first half of 2002 (a 59% increase, from 4,940 to 7,828 mentions).




### **Other Substances**

- Respiratory agents comprised 1 percent (6,596) of total ED drug mentions in the first half of 2002 (Table 2.1.0). Mentions of respiratory agents overall and its major subcategories were unchanged from the first half of 2001 to the first half of 2002.
- Cardiovascular agents comprised 1 percent (6,569) of total ED drug mentions in the first half of 2002 (Table 2.1.0). Mentions of cardiovascular agents rose 53 percent (from 4,285) from the first half of 2001 to the first half of 2002.
- None of the smaller categories of other substances experienced a significant change from the first half of 2001 to the first half of 2002 (Table 2.1.0).
- The particular drugs involved in ED visits are sometimes unknown or unknowable. In the first half of 2002, there were 15,311 such mentions (3% of total mentions) (Table 2.1.0).



Figure 5
ED mentions of selected narcotic analgesics:
July-December 1997 through January-June 2002



# SELECTED TRENDS IN 21 METROPOLITAN AREAS

his section presents findings for the 21 metropolitan areas oversampled in DAWN, with particular attention to the major substances of abuse. As noted previously, "major substances of abuse" include the most common illicit drugs reported to DAWN, alcohol present in combination with any other substance reported to DAWN, and lower frequency drugs of particular policy interest (e.g., club drugs such as Ecstasy and GHB).

This section of *ED Trends* focuses primarily on Tables 3.1 to 3.33 (ED episodes and mentions) and 13.1 to 13.33 (rates of ED episodes and mentions per 100,000 population). These tables summarize for <u>all</u> the 21 metropolitan areas the estimates for: total episodes, total mentions, and the 15 major substances of abuse. Those interested in making comparisons across metropolitan areas should rely on the rates per 100,000 population because these account for differences in population across the metropolitan areas.

These are the same estimates presented separately for each metropolitan area in Tables 2.2.1 to 2.2.21 (episodes and mentions) and 12.2.1 to 12.2.21 (rates). As noted in the introduction, 3-part table numbers ending in ".1" to ".21" contain estimates for the 21 metropolitan areas. Some readers will be interested in findings only for a particular area. For these readers, we also provide 21 complete sets of tables, one for each metropolitan area, online at http://www.samhsa.gov/oas/dawn.htm and http://www.DAWNinfo.net.

Readers should note that very small changes in the estimates for some metropolitan areas may result in statistically significant differences. This occurs when all or nearly all eligible hospitals are included in the sample for those cities.

### TOTAL DRUG-RELATED EPISODES

- Nationwide, total ED drug episodes remained statistically unchanged from the first half of 2001 to the first half of 2002 (Table 3.1). However, from the first half of 2001 to the first half of 2002, significant decreases in drug episodes were found in 4 metropolitan areas oversampled in DAWN:
  - Seattle (-54%, from 5,720 to 2,656 episodes),
  - Dallas (-22%, from 3,369 to 2,638),
  - Chicago (-16%, from 16,526 to 13,937), and
  - San Diego (-12%, from 3,615 to 3,194).

<sup>&</sup>lt;sup>15</sup> In addition, demographic characteristics of patients are presented in Tables 4.2.1 to 4.2.21 (episodes and mentions) and 14.2.1 to 14.2.21 (rates). Estimates of episode characteristics are presented in Tables 5.2.1 to 5.2.21 (there are no rates calculated for episode characteristics). Because of the detail involved, this publication focuses little on these estimates by metropolitan area.



### **ALCOHOL-IN-COMBINATION**

Mentions of alcohol-in-combination were stable for the coterminous U.S. from the first half of 2001 to the first half of 2002 (Table 3.5). In the metropolitan areas oversampled in DAWN, only Buffalo had a significant increase in mentions of alcohol-in-combination (56%, from 804 to 1,252 mentions) and 4 other metropolitan areas had significant decreases: Seattle (-46%, from 1,469 to 800), San Francisco (-29%, from 1,010 to 717), Dallas (-28%, from 934 to 670), and Phoenix (-23%, from 1,296 to 1,004).

### COCAINE

■ Nationwide, cocaine mentions remained statistically stable from the first half of 2001 to the first half of 2002 (Table 3.7). Significant increases in cocaine mentions were found in 2 metropolitan areas oversampled in DAWN: Minneapolis (47%, from 462 to 681 mentions) and Denver (47%, from 631 to 926). Significant decreases were found in 7 metropolitan areas: Seattle (-67%, from 1,660 to 551), Dallas (-32%, from 964 to 654), Detroit (-32%, from 4,160 to 2,820), Washington, DC (-28%, from 1,440 to 1,032), San Francisco (-21%, from 1,220 to 964), Chicago (-20%, from 8,269 to 6,614), and San Diego (-11%, from 439 to 389).

### **HEROIN**

Nationwide, ED mentions of heroin remained stable in the coterminous U.S. from the first half of 2001 to the first half of 2002 (Table 3.9). From the first half of 2001 to the first half of 2002, significant increases in heroin mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.9): Buffalo (71%, from 283 to 484 mentions) and Denver (37%, from 380 to 519). Significant decreases were found in 7 metropolitan areas: Seattle (-47%, from 903 to 475 mentions), Washington, DC (-42%, from 1,024 to 591), Dallas (-41%, from 251 to 147), Detroit (-32%, from 2,102 to 1,440), Baltimore (-24%, from 2,593 to 1,977), San Diego (-21%, from 401 to 316), and Phoenix (-20%, from 372 to 298).

### **MARIJUANA**

Nationwide, mentions of marijuana remained statistically stable from the first half of 2001 to the first half of 2002 (Table 3.11). Significant increases in marijuana mentions were found in 2 metropolitan areas oversampled in DAWN: Miami (30%, from 920 to 1,195 mentions) and San Diego (20%, from 521 to 625). Significant decreases were found in 4 metropolitan areas: Seattle (-65%, from 858 to 298), Buffalo (-49%, from 374 to 192), San Francisco (-44%, from 387 to 217), and Dallas (-36%, from 570 to 364).



### **AMPHETAMINES AND METHAMPHETAMINE**

- Nationwide, mentions of amphetamines and methamphetamine remained stable from the first half of 2001 to the first half of 2002 (Tables 3.13 and 3.15).
- From to the first half of 2001 to the first half of 2002:
  - Increases in mentions of amphetamines were found in 2 metropolitan areas (Table 3.13): Denver (57%, from 163 to 256 mentions) and San Diego (31%, from 432 to 566).
  - Decreases in mentions of amphetamines were found in 4 metropolitan areas (Table 3.13): Seattle (-70%, from 345 to 104), Philadelphia (-45%, from 228 to 126), San Francisco (-26%, from 376 to 279), and Dallas (-24%, from 187 to 143).
  - There were no significant increases in mentions of methamphetamine in any of the metropolitan areas with at least 100 mentions (Table 3.15), but decreases were found in 2: Seattle (-31%, from 166 to 115) and San Diego (-25%, from 344 to 257).

#### **CLUB DRUGS**

■ None of the metropolitan areas oversampled in DAWN had more than 100 mentions of the club drugs in the first half of 2002 (Tables 3.17, 3.19, 3.27, and 3.29).

### NARCOTIC ANALGESICS AND NARCOTIC ANALGESIC COMBINATIONS

- Nationwide, ED mentions of narcotic analgesics/combinations rose 16 percent (from 47,683) from the first half of 2001 to the first half of 2002 (Table 2.1.0).
- From the first half of 2001 to the first half of 2002, significant increases in mentions of narcotic analgesics/combinations were found in 2 of the 21 metropolitan areas oversampled in DAWN (Tables 2.1.1 through 2.1.21):
  - Baltimore (69%, from 1,140 to 1,929 mentions) and
  - Buffalo (42%, from 406 to 577).
- From the first half of 2001 to the first half of 2002, significant decreases in mentions of narcotic analgesics/combinations were found in 2 of the 21 DAWN metropolitan areas (Tables 2.1.1 through 2.1.21):
  - Seattle (-44%, from 1,179 to 655 mentions) and
  - San Francisco (-25%, from 403 to 304).



# DISCUSSION OF RESULTS

his publication presents preliminary estimates from the DAWN emergency department (ED) component for the period from January to June 2002. Final estimates for the full years 1994 through 2001, which have been published previously, are also provided here for reference.

By definition, preliminary estimates are not final, and any conclusions from them are subject to change when the year's data submissions become complete and final estimates are produced. In addition to incomplete data, half-year preliminary estimates may reflect seasonal and other anomalies that will not persist in final estimates. Therefore, this discussion is relatively short, and we urge readers to consider the preliminary nature of the estimates in interpreting their meaning and the relationship to trends reported previously.

### **OVERVIEW OF FINDINGS**

DAWN preliminary estimates presented for the first time in this publication show that total drug-related ED episodes and drug mentions were stable from the first half of 2001 to the first half of 2002. ED mentions of most of the major substances of abuse were unchanged from the first half of 2001 to the first half of 2002. LSD—with a 78 percent decrease in ED mentions—was the only major substance of abuse with a significant change at the national level from the first half of 2001 to the first half of 2002. Similarly, there were few changes in drug abuse episodes for any of the demographic subgroups. Mentions of heroin declined among patients who were black, and the decline in LSD mentions was evident across age, race, and age subgroups.

These preliminary estimates show no increases in total drug abuse episodes in the 21 metropolitan areas oversampled in DAWN from the first half of 2001 to the first half of 2002. However, decreases were evident in Seattle, Dallas, Chicago, and San Diego.

A similar pattern—increases in few metropolitan areas, decreases in more—was evident for most of the major substances of abuse. Only 1 metropolitan area (Buffalo) had an increase in mentions of alcohol-in-combination from the first half of 2001 to the first half of 2002, but decreases were evident in 4 (Seattle, San Francisco, Dallas, and Phoenix). Mentions of cocaine increased in 2 metropolitan areas (Minneapolis and Denver) but decreased in 7 (Seattle, Dallas, Detroit, Washington, DC, San Francisco, Chicago, and San Diego). Heroin mentions increased in 2 metropolitan areas (Buffalo and Denver) and decreased in 7 (Seattle, Washington, DC, Dallas, Detroit, Baltimore, San Diego, and Phoenix). Marijuana mentions increased in 2 metropolitan areas (Miami and San Diego) and decreased in 4 (Seattle, Buffalo, San Francisco, and Dallas). Mentions of amphetamines increased in 2 metropolitan areas (Denver and San Diego) and decreased in 4 (Seattle, Philadelphia, San Francisco, and Dallas). Mentions of methamphetamine declined in Seattle and San Diego.

Among the frequently mentioned prescription and over-the-counter medications, ED mentions of narcotic analgesics/combinations increased 16 percent from the first half of 2001 to the first half of 2002. Among the narcotic analgesics, the increase in mentions of oxycodone products (a subset of the category oxycodone/combinations) stood out, while mentions of most of the narcotic analgesics—the unnamed narcotic analgesics and methadone, as well as



products containing codeine, hydrocodone, morphine, and propoxyphene—were statistically unchanged.

### **LIMITATIONS**

It is important to recognize that findings from DAWN alone cannot define an emerging drug abuse problem or quantify precisely the abuse potential of prescription drug products. Instead, DAWN identifies sentinel events—<u>indicators</u> of a <u>potential</u> drug abuse problem—which DAWN can then monitor over time. This information can be put together with information from other sources (other indicators) to determine whether a new drug abuse problem is emerging. Relying on information from DAWN alone would likely result in false positives—identification of problem substances when no problem exists—but this is a hazard when trying to track any problem in its early stages and it is not a hazard particular to DAWN.

DAWN stands virtually alone in publishing preliminary estimates for a portion of a year. We do so because of the intense interest in monitoring on-going trends, especially for illicit drugs, but we caution readers that preliminary estimates may yield premature conclusions. We urge caution especially in consideration of estimates that are small and/or unstable on an annual basis, because these estimates are even smaller and often more unstable when examined for a 6-month period. Because of the potential for seasonal distortions, we focus our attention primarily on comparisons of preliminary estimates for January—June 2002 with estimates for the same period in 2001. Finally, we emphasize that there is no guarantee that the statistically significant differences or the non-significant ones will hold up once data for 2002 are complete.

DAWN data show only one dimension of the total consequences of drug abuse, specifically the impact of drug use that manifests in visits to hospital EDs. DAWN does not measure the prevalence of drug use in the population, the untreated health consequences of drug use, or the impact of drug use on health care settings other than hospital EDs. For measures of prevalence, we refer readers to the National Household Survey on Drug Abuse (NHSDA), a national survey of households that explores drug abuse in the population.

Many factors can influence the estimates of ED visits, including trends in ED usage in general. Comparing the first half of 2002 to the first half of 2001, the number of drug-related ED visits was unchanged while ED visits for any reason increased a modest but statistically significant 0.1 percent. Drug users may visit EDs for a variety of reasons, only some of which may be life threatening. Some seek care in EDs for entry into detoxification and substance abuse treatment. These reasons almost certainly vary across the different substances reported to DAWN. Otherwise, changes in the number of drug-related emergencies may be due to changes in the use of particular drugs in combination; varying patterns of drug use, such as alterations in routes of administration; the amount of drug administered, its purity or price. Finally, estimates of drug-related ED episodes may increase or decrease over time for reasons unrelated to the size of the drug using population. Changes in access to certain health care settings or other factors may also influence findings from DAWN that focus only on ED visits.



61 A

# APPENDIX A: RACE AND ETHNICITY DATA IN DAWN

eginning in January 2000, the race and ethnicity categories on DAWN data collection forms changed to match a revised standard protocol. The new protocol permits separate reporting of race and Hispanic ethnicity, and it incorporates the ability to capture more than one race for an individual, a few modifications in nomenclature (e.g., "Black" was changed to "Black or African American"); division of certain categories ("Asian or Pacific Islander" was split into 2 categories, "Asian" and "Native Hawaiian or Other Pacific Islander"); and elimination of the "Other" category. The complete DAWN report form is reproduced in Appendix F.

Despite the increased detail allowed by the new categories, the actual race and ethnicity data extracted from source records and submitted to DAWN changed very little. This is because the source documents—ED medical records from which DAWN data are abstracted—rarely contain such detailed information on race and ethnicity of patients.

For reference, estimates of race and ethnicity in drug-related ED visits are presented in Table 1.10.<sup>17</sup> This analysis, which is based on the most detailed coding of race and ethnicity in DAWN case reports, reveals that estimates for the following categories are too small to be meaningful:

- Two or more races (that is, 2 or more races were documented in the source record for the same individual),
- Hispanic or Latino ethnicity with any specific race indicated,
- American Indian or Alaska Native,
- Asian, and
- Native Hawaiian or Other Pacific Islander.

Therefore, in the tables of estimates in this and other DAWN publications we have retained the categories used previously to tabulate DAWN data, with one exception. A new category called "Race/ethnicity not tabulated above (NTA)" is used to tabulate those categories that are too small to report independently.<sup>18</sup> All cases reported to DAWN as Hispanic or Latino ethnicity are tabulated as Hispanic race/ethnicity, regardless of race.

This lack of detailed race and ethnicity data in DAWN case reports also prevents us from generating rates per 100,000 population for race and ethnicity categories. Data from the 2000 decennial Census were collected and are being tabulated according to the revised race and ethnicity protocol and are therefore incompatible with DAWN estimates.

<sup>18</sup> One exception is that if 2 races are reported and the second is reported as unknown, the episode is coded for the known race.



<sup>&</sup>lt;sup>16</sup> See Office of Management and Budget, Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity, Federal Register, 62 FR 58782, October 30, 1997.

<sup>&</sup>lt;sup>17</sup> These detailed estimates conform to the OMB guidance on tabulation of race and ethnicity data in Office of Management and Budget, *Draft Provisional Guidance on the Implementation of the 1997 Standards for the Collection of Federal Data on Race and Ethnicity*, February 17, 1999.

# APPENDIX B: DETAILED DESCRIPTION OF DAWN

his section gives a detailed description of the methods and some of the history behind DAWN analysis. The section begins with a description of the sample design, followed by weighting, precision of the estimates, preliminary versus final estimates, rates per 100,000 population, and revision of the estimation system.

### SAMPLE DESIGN

The Drug Abuse Warning Network (DAWN) is a voluntary, national data collection system that gathers information on substance abuse that manifests in visits to hospital emergency departments (EDs) in the coterminous U.S. Currently, DAWN provides semi-annual and annual estimates of the number of drug-related visits to hospital EDs from a nationally representative sample of hospitals located throughout the coterminous U.S. The DAWN system is managed by the Office of Applied Studies (OAS), a component of the Substance Abuse and Mental Health Services Administration (SAMHSA) of the U.S. Department of Health and Human Services (DHHS).

Several changes have been made to the sample design since DAWN began in 1972 under the Drug Enforcement Administration (DEA). In the early 1970s, the DAWN sample consisted of a random sample of hospital EDs. Over time, however, a number of facilities were lost from the original sample because of closures, mergers, attrition, or voluntary termination. New hospitals were recruited to participate, but no sample maintenance plan was devised for selecting new hospitals to sustain the randomness of the sample. As a result, attrition and nonrandom replacement led to a sample that was no longer representative of all hospital EDs in the coterminous U.S.

When the National Institute on Drug Abuse (NIDA) assumed responsibility for DAWN in 1980, one of the agency's goals was to implement a new sample that could be used to produce estimates for the Nation as a whole and for the separate DAWN metropolitan areas. Once a design was determined and the units were selected, the sample required the recruitment of 300 new hospitals. The cost of the project delayed its initiation until early 1986.

Hospitals eligible for DAWN are non-Federal, short-stay general surgical and medical hospitals in the coterminous U.S. that have a 24-hour ED. The American Hospital Association's (AHA) 1984 and 1985 Annual Surveys of Hospitals were used to obtain a sampling frame. (For a definition of sampling frame and other technical terms used in this publication, see the Glossary of Terms in Appendix D.)

Hospitals in the sampling frame were stratified according to several characteristics. First, the sampling frame was divided into the 21 DAWN metropolitan areas and the remainder of the country (called the National Panel). Hospitals having 80,000 or more annual ED visits were assigned to a single stratum for selection with certainty. Then, the remaining hospitals in the 21 metropolitan areas were classified by location (inside or outside the central city) and by whether the hospital had an organized outpatient department and/or a chemical/alcohol inpatient unit



(that is, whether it had zero, one, or both types of units). Similarly, hospitals in the National Panel were classified by the presence/absence of such units.

The 21 metropolitan area boundaries correspond to the Office of Management and Budget (OMB) 1983 definitions of Metropolitan Statistical Areas (MSAs) and Primary Metropolitan Statistical Areas (PMSAs) with a few exceptions. In the case of the Boston metropolitan area, the OMB definition was replaced by the definition for the New England County Metropolitan Area (NECMA). In several metropolitan areas, use of the PMSAs excluded some counties covered by DAWN prior to 1988, such as Nassau and Suffolk Counties in New York, certain counties in the Chicago area, and Niagara County in the Buffalo area. In other areas, such as Atlanta, counties not previously covered in DAWN were included. In addition to geographic coverage, the central cities in the new statistical areas differ from those in the old MSAs used previously in DAWN. For example, Hialeah joined Miami as a central city in the new Miami-Hialeah area, and Long Beach joined the Los Angeles-Long Beach area. In some instances in this publication, only the first city name is cited, but it always refers to the complete metropolitan area.

Sample sizes for the metropolitan areas and the National Panel were determined for each stratum so as to achieve specified levels of precision in the estimates. In this context, precision refers to the amount of sampling fluctuation inherent in the estimate; the less the fluctuation, the greater the precision. Target precision levels were expressed as relative standard errors (RSEs), defined as the ratio of the standard error (SE) of an estimate to the value of the estimate, expressed as a percentage. Lower RSE values are associated with higher levels of precision and, other things being equal, increases in sample size serve to reduce the RSE and thus increase the level of precision of the estimates. Estimates are considered unreliable and are suppressed in DAWN if their RSEs exceed 50 percent. Target RSEs for total episodes were 6 percent for the national estimates; 6 percent for the Chicago, Los Angeles, and New York metropolitan areas; and 8 percent forall other metropolitan areas. In 5 of the metropolitan areas (Baltimore, Buffalo, Denver, San Diego, and San Francisco), such a large proportion of facilities in each area would have been required to reduce the RSE to 8 percent that the decision was made simply to select all eligible hospitals. Figure 1 shows RSEs for total drug-related episodes by metropolitan area.

Once the sample size for each metropolitan area and the National Panel was determined, the number of sample units was allocated to the various strata based on the theory of optimal allocation. With this approach, strata with greater variability in drug-related episodes (from hospital to hospital) receive a proportionally larger number of sample units. Optimal allocation serves to reduce the RSE of the estimates for a given overall sample size or to enable a specified RSE to be achieved with a smaller sample, relative to proportional or random allocation to strata.

A total of 685 hospitals was selected for the new sample. Many of the facilities selected, particularly the larger ones, were already participating in DAWN. As noted earlier, 300 new hospitals had to be recruited. Recruitment started in April 1986 and proceeded in phases. By 1988, recruitment of the selected facilities was sufficiently complete to produce estimates based on the new sample.

Some facilities already participating in DAWN were not selected for the new sample. These facilities were retained in the system for sufficient time to obtain overlapping data for calibrating the estimates and developing estimation procedures for prior years. The period of overlap differed by metropolitan area but generally included the last quarter of 1988 and the first half of



1989. Most terminations of nonselected facilities were made in the second half of 1989 or in 1990.

The total number of eligible sample facilities has not remained at the original 685 because some hospitals have closed or become ineligible since the sample was selected while others have been added as part of sample maintenance. To preserve the integrity of the sample and ensure that the DAWN estimates will continue to be representative, sample maintenance is performed annually. Maintaining the sample involves updating the sampling frame with the most recent available information on the population of eligible hospitals. One purpose for updating the sampling frame is to identify newly eligible hospitals, or hospitals that are eligible and previously did not have a chance of selection, so that they can be sampled. A second purpose, which focuses on the estimation process, is to determine the population of eligible hospitals to which the estimates must apply, as well as the total number of ED visits among this population, which is used in the calculation of the analytical weights.

### SAMPLING WEIGHTS

By 1988, hospital recruitment had progressed to a point where national estimates and estimates for each of the 21 metropolitan areas could be made with reasonable precision. National estimates are obtained by adding the estimates from the 21 metropolitan areas and the estimate from the National Panel for each estimation category.

The development of estimates from the sample data involves the application of analytical weights calculated on the basis of data from the sampling frame and from DAWN reporting records. Weights are calculated for each quarter of data using a 3-component model that considers:

- The base sampling weight calculated as the reciprocal of the sampling probability;
- An adjustment for nonresponse based either on complete nonparticipation or failure to provide data on all the reporting days in a given time period; and
- A correction (benchmark) factor, applied within metropolitan areas, that adjusts the total number of ED visits among participating sample hospitals to the total for the population of hospitals as determined from the sampling frame.

The estimation procedure was modified in 1989 to include the adjustments for 2 types of nonresponse and the ratio or benchmark adjustment based on ancillary data from AHA.

## PRECISION OF THE ESTIMATES AND STANDARDS FOR PUBLICATION

Each estimate from the DAWN ED sample data is subject to sampling variability, which is the variation in the estimate that would be observed if different samples were drawn from the same population using the same procedures. The sampling variability of an estimate is measured by its standard error (SE) and relative standard error (RSE), which is defined as the SE expressed as a percentage of the value of the estimate. The precision of an estimate is inversely related to the degree of sampling variability as measured by the RSE; the greater the RSE value, the lower the precision.



If there are 10,000 estimated mentions of a given drug and this estimate has an SE of 500, then the RSE value is 5 percent. Therefore,

Confidence intervals (CIs) for estimates can be calculated using the corresponding RSE values published in these tables. If the sampling distribution for the estimate is normal, then the 95-percent CIs would be calculated as

$$CI = Estimate \pm 1.96 \times RSE \times Estimate$$

where 1.96 comes from the table of normal distribution z-values. Ninety-five percent of the normal distribution lies between the z-values of  $\pm$  1.96.

Applying the formula in our example, the confidence limits would be as follows:

 $10,000 \pm 1.96 \times 0.05 \times 10,000 = 10,000 \pm 980.0$ Lower limit: 10,000 - 980 = 9,020Upper limit: 10,000 + 980 = 10,980Confidence interval: 9,020 to 10,980

This means that if new samples were drawn from the same population of hospitals using the same sampling and data collection procedures, then the estimated total mentions of the drug in question would lie between 9,020 and 10,980 in 95 percent of the sample hospitals.

One simple rule is that in 68 percent of the episodes, estimates derived from repeated sampling would be expected to differ from the observed estimate by a percentage no more than the RSE value in either direction.

It is important to recognize when this CI formula should and should not be used. This formula can be used to calculate CIs around individual estimates, but some statistical comparisons between estimates (e.g., tests for differences across time) should not be made using this formula. For example, a reader might want to calculate CIs around 2 estimates and use those CIs to make a statistical comparison for which we did not publish a statistical test. (We publish only a fraction of the statistical tests that might be of interest.) However, the CI formula above may yield overlapping CIs even though the difference between the 2 estimates is statistically significant. This is because a comparison of 2 estimates must take into account not only the variance (var) of each estimate but also the covariance (cov) between the estimates as follows:

$$var(x - y) = var(x) + var(y) - 2cov(x,y)$$

Therefore, the above method for calculating CIs can be used only to compare independent estimates (i.e., where the covariance is zero). Whenever 2 estimates are not independent, as with ED episodes from 2 different years, their covariance must be taken into account.

The tests of statistical significance published in *ED Trends* account for the covariance between estimates from different years. From this, we know that the covariance between DAWN estimates is often sizable. Given the tremendous number of possible comparisons



between DAWN estimates, it is not possible to publish comprehensive covariance matrices at this time.

Examples of estimates, SEs, RSEs, and CIs are shown in Tables 1.6 and 1.8. RSE values for total episodes vary according to metropolitan area, not only because of differences in the target precision levels in the sample design, but also because of nonresponse. Table 1.8 shows data for estimates of mentions of the selected drug groups in the total coterminous U.S. As illustrated in this table, larger estimates tend to have lower RSE values, at least in the national estimates.

DAWN estimates with an RSE value of 50 percent or higher are regarded as too imprecise and are not published. With an RSE of 50 percent, the 95-percent CI for an estimate ranges from 2 percent to 198 percent of the estimate's value. In the tables, the symbol "..." is substituted for estimates that have an RSE of 50 percent or higher. The 3-dot symbol identifies cells in which the estimates do not meet the standard of precision required for publication.

Historically, estimates of less than 10 were not shown in the tables because we deemed them and their associated RSEs to be unreliable. Percentages corresponding to these numbers were shown or suppressed according to the same rules.

Beginning with the 1999 ED data, estimates of less than 10 are no longer suppressed in DAWN Detailed ED Tables or other ED publications. Many estimates as small as this will be suppressed by virtue of having RSEs greater than 50 percent. For those that are shown in the tables, we note for the reader that small numbers and their associated RSEs should be interpreted with caution.

Beginning with the 1999 ED and 1997 mortality data, we began suppressing small cells in selected tables to protect the confidentiality of individuals who are the subjects of these data. We will continue this practice for tables that involve detailed cross tabulations of patient and geographic characteristics.

### PRELIMINARY VERSUS FINAL ESTIMATES

Final estimates are produced annually when all hospitals participating in DAWN have submitted their data for that year and when ancillary data used in estimation have become available. In recent years, the final publication has included separate final estimates for the first half and the second half of the year (quarterly estimates were produced in earlier years). In addition to the final estimates, preliminary estimates are also produced semi-annually based on responding hospitals. Data are weighted to produce national and metropolitan area estimates of ED drug-related mentions. The following factors clarify differences between preliminary and final estimates:

- Preliminary estimates may be based on less complete data than final estimates. Data from a small number of late-reporting hospitals are used in the production of final estimates. Data are continuously updated for a fixed time period. As such, final estimates usually have higher response rates.
- The DAWN sample is updated once annually, before the production of final estimates. Additional hospitals are added to the sample and incorporated into the final estimates for a given year (not the preliminary estimates for that same year). Most of these



hospitals are "newly eligible" because they became DAWN eligible sometime after the original sample was selected. The final DAWN estimates are produced after we receive the most current AHA Annual Survey of Hospitals file. This file is used initially to establish a sampling frame for DAWN. The most current AHA file is used once a year to maintain representativeness of the sample. Between the releases of the preliminary and final estimates, the use of the newer AHA survey can result in hospitals being added to the sample and incorporated into the final estimates.

Data from the most current AHA file also are used to produce the final benchmarkadjusted weights.

### **ESTIMATES OF RATES PER 100,000 POPULATION**

Rates of ED episodes or mentions per 100,000 population are generated using population data from the U.S. Bureau of the Census. The Office of Management and Budget (OMB) defines Metropolitan Area as the city core and its immediately adjacent geographic areas that are highly integrated economically and socially with the city core. Estimates of incidence rates are obtained by taking the estimates of total episodes and mentions for a given demographic category, dividing by the population estimate for that demographic category, and dividing by 100,000. These standardized measures provide the means for comparing drug abuse episodes and mentions across cities and over time. Semi-annual estimates are based on preliminary data from the first half of the year and are not comparable to annual estimates, which are based on 12 months of data.

Population estimates are derived from the following U.S. Census Bureau files:

- Civilian Noninstitutional Population of the United States by Age, Sex, and Race, which provides monthly population estimates by age, gender, race, and Hispanic origin for the total United States;
- Decennial Census Counts by Age, Sex, and Race, which provides population estimates by state and county, broken out by combinations of age, gender, race, and Hispanic origin; and
- County-Level Population Estimates, which provides estimates of annual total population by county as of July 1 of each year.

Population estimates<sup>19</sup> are obtained by:

- Adjusting the annual County-Level Population Estimates to the Census Counts by Age. Sex, and Race to produce annual county demographic counts:
- Adjusting the annual county demographic counts to the Civilian Noninstitutional Population data to produce monthly county demographic counts; and
- Summing the monthly county demographic counts across all counties in the metropolitan area and across all months in the quarter (half year or year), to produce semi-annual or annual demographic counts for each DAWN area.

<sup>&</sup>lt;sup>19</sup> Table 1.9 shows population estimates by age and gender by metropolitan area.



Population estimates for 1994 through 2000 rely on 1990 Census data, and those beginning with 2001 use data from the 2000 Census. Inevitably, the accuracy of population estimates deteriorates over time relative to actual census counts. Population estimates for 2001, which are based on the 2000 Census, are considerably higher than population estimates generated for recent years. As a result, the incidence rates for 2001 may appear to have decreased significantly (or not to have increased as much as expected), but this may be an artifact of the increase in the population denominators for these rates. Changes in rate estimates between 2001 and prior years should be verified by comparing changes in the corresponding episode or mention estimates and their significance levels. If a statistically significant change in episode or mention estimates did not occur, it is likely that the statistically significant change in the rate was due to the changes in population.

### **REVISION OF ESTIMATION SYSTEM**

In 1997 and 1998, a thorough review of the DAWN estimation system was undertaken by Westat. As a result of this review, the computer programs that compute the weighted estimates were rewritten to make them more accurate and efficient. While the methodology for computing weights did not change, errors were discovered in the prior programs that affected the estimates for 1995 and 1997. Final estimates for these 2 years were presented for the first time in *Midyear 1998 Preliminary ED Data from DAWN*. The 1995 estimate of total drug-related episodes decreased by less than 1 percent (from 517,800 to 513,600) while the 1997 estimate increased by 5.5 percent (from 487,600 to 514,300). These changes had varying effects on the metropolitan area estimates.

The following changes had the greatest effect on the estimates:

- A change was made in the method for assigning eligibility status to a hospital. The current system tracks partial year eligibility, which improves the sensitivity of the DAWN nonresponse adjustment. Formerly, there was no recognition that a hospital could change its eligibility status during the year.
- A concerted effort was made to ascertain the current eligibility status of all nonparticipating DAWN sampled hospitals. Changes in status from eligible nonrespondent to ineligible (or vice versa) also affected the nonresponse adjustment.



# APPENDIX C: SOURCES OF ERROR IN DAWN ESTIMATES

hen producing estimates from any sample survey, 2 types of errors are possible—sampling and nonsampling errors. The sampling error of an estimate is the error caused by the selection of a sample instead of a census of hospitals. Sampling error is reduced by selecting a large sample or by using efficient sample design and estimation strategies such as stratification, optimal allocation, and ratio estimation. Nonsampling errors include nonresponse, difficulties in the interpretation of the collection form, coding errors, computer processing errors, errors in the sampling frame, and reporting errors.

Many procedures, such as data auditing and periodic retraining of data collectors, are used in DAWN data collection to minimize nonsampling errors. Moreover, nonrespondent hospitals are identified for additional recruitment. Late reporters are assigned for priority data collection and respondents with changes in reporting are designated for followup. Since data are abstracted from medical records completed by hospital staff who treated the patients, the accuracy of these reports depends on their careful recording of these conditions.

It is also important to recognize that DAWN does not provide a complete picture of problems associated with drug use, but rather focuses on the impact that these problems have on hospital EDs in the United States. If a patient is admitted to another part of the hospital for treatment, or treated in a physician's office or at a drug treatment center, the episode would not be included in DAWN.

## CHANGES IN SAMPLE COMPOSITION AND REPORTING OF EPISODES

Periodic minor modifications are made to the sample to keep it current. Adjustments are made in the weights to account for lapses in reporting by the sampled hospitals. It is unlikely that modifications to the sample will affect estimates of the total drug, cocaine, and heroin mentions over time. Analyses of the previous changes in the sample composition have found them to have little impact on trends across several years.

It is important to consider the potential impact on DAWN trends from changes in the sample composition or reporting anomalies in key sample hospitals, particularly for metropolitan area data. Historically, DAWN analysts and field staff have attempted to identify and document such situations in the period before data release, and events that may have had a significant impact on the estimates were published in this section.

However, choosing the particular situations to highlight often involves more art than science, given that the actual impact on the estimates rarely has been known at the time of publication. This practice led us to question whether the situations that were being highlighted actually had the anticipated impact on DAWN estimates.

We analyzed some specific situations highlighted in recent DAWN publications to determine if those situations had the anticipated effect on DAWN estimates. These analyses have shown that generally, the types of situations published previously as limitations did not have the anticipated effects. Changes in small hospitals do not have a large impact on the estimates, and the DAWN estimation system already corrects for many nonsampling errors. Extensive



quality control measures have been implemented to investigate and address irregularities in the data prior to publication.

As a result of this analysis, we have concluded that listing inconsequential, nonsampling errors discredits the DAWN system unnecessarily and possibly contributes to misinterpretation of DAWN data. Therefore, we have decided to discontinue reporting data limitations unless the impact on the estimates is clear.

### NOTEWORTHY SOURCES OF ERROR: ATLANTA DATA FOR 2001

We experienced significant missing data in Atlanta for 2001. Reliable Atlanta estimates could not be produced for January–June of 2001 because insufficient data were submitted by participating facilities for this period. The column of estimates for January–June 2001 have been suppressed and are indicated by "---" in tables for Atlanta in this publication and in tables published online. More Atlanta data were available for the second half of 2001, although missing data were still a concern.

The missing data from Atlanta also affects DAWN's national estimates, which depend on estimates from the 21 metropolitan areas. The national estimate is equal to the sum of the metropolitan area estimates and the National Panel estimate. Therefore, we adopted an imputation approach to preserve the integrity of the national estimates. Imputation refers to the assignment of values to replace missing data and typically involves standard statistical methods and practices. In this case, the imputation used statistical models to determine what characteristics (e.g., drug mentions and patient demographics) the imputed episode records should contain. The statistical models used data submitted by all Atlanta hospitals prior to 2001 along with the available Atlanta data for 2001. As a conservative measure, we have also suppressed any Atlanta estimates for the second half July—December 2001 that were derived from more than 25 percent imputed data (also indicated by "---"). This suppression rule affected only a few Atlanta estimates for the second half of 2001 and none of the national estimates.

# APPENDIX D: GLOSSARY OF TERMS

his glossary defines terms used by the Drug Abuse Warning Network (DAWN) in data collection activities, analyses, and publications. DAWN collects data and publishes findings separately for emergency departments (EDs) and death investigation jurisdictions. As a result, there are a number of terms that are unique to each component of DAWN.

This appendix is divided into 3 sections. The first section contains terms common to both the ED component and the mortality data component of DAWN. The second section focuses on terms specific to the DAWN ED system, while the third section focuses on terms specific to the mortality data system.

# **DEFINITIONS OF TERMS COMMON TO DAWN'S ED AND MORTALITY COMPONENTS**

**Drug abuse:** The nonmedical use of a substance for any of the following reasons: psychic effect, dependence, or suicide attempt/gesture. In DAWN, nonmedical use means:

- The use of prescription drugs in a manner inconsistent with accepted medical practice;
- The use of over-the-counter drugs contrary to approved labeling; or
- The use of any substance (e.g., heroin, marijuana, peyote, glue, aerosols) for psychic effect, dependence, or suicide.

Drug category: A generic grouping of substances reported to DAWN, based on the classification of generic drugs by Multum Information Services. Multum Information Services is a subsidiary of the Cerner Corporation and a developer of clinical drug information systems and a drug knowledge base. More information is available at http://www.multum.com. The DAWN system has accumulated a vocabulary of thousands of substance names that have been mentioned in incidents of abuse. This vocabulary is updated monthly by the inclusion of new abuse substances and, through receipt of identifying information, the reclassification of drugs. Occasionally, this reclassification may result in a drug being shifted to a different drug grouping. The DAWN drug groupings are periodically reviewed in order to reflect the most recent changes in pharmaceutical classifications and drug legislation. Occasional changes in drug classification should be taken into consideration when comparing drug data from this publication with other DAWN publications. These classifications may involve street names and brand names, which are sometimes used to identify a substance and its generic drug group. Individual drugs comprising the most commonly reported drug categories can be found in Tables 2.3 to 2.7 of Emergency Department Trends From DAWN.

Additional clarification is provided for the following drug categories:

 Alcohol-in-combination – DAWN does not gather data on alcohol used alone, only alcohol used concomitantly with another abused substance. Therefore, all alcohol mentions are combination mentions.



- All other substances not tabulated above (NTA) This category contains any substance reported to DAWN that could not be classified in other categories and has too few mentions to warrant being reported independently in DAWN tables. This category also includes certain terms that cannot be assigned reliably to any new category such as: (1) ambiguous, nonspecific terms that could fall into any of several categories (e.g., "AIDS medicine" could be an anti-infective, an anticonvulsant, or any number of other drugs); (2) undocumented, nonspecific terms (e.g., "thought organizer"); and (3) street terms for illicit substances that could not be linked reliably to a particular illicit substance (e.g., "T," "butterflies").
- Amphetamines This class of substances has been extracted from the category of central nervous system (CNS) stimulants because of its importance as a major substance of abuse. For purposes of classification, "amphetamines" (plural) includes a class of compounds derived from or related to the drug amphetamine. Although some "designer" drugs fall into the class of amphetamines, we choose to report some of them individually as major substances of abuse (e.g., methamphetamine). This category does not include other CNS stimulants, such as caffeine or methylphenidate.
- Club drugs During the 1990s, use of certain illicit drugs was linked to "raves" and dance clubs. These substances are commonly referred to as "club drugs." When used in DAWN, the term club drugs includes Ketamine, flunitrazepam (Rohypnol), gammahydroxy butyrate (GHB, or its precursor, gamma butyrolactone [GBL]), and methylenedioxymethamphetamine (MDMA or Ecstasy). Although commonly used in the rave scene, methamphetamine and hallucinogens are classified separately from club drugs in DAWN.
- Drug unknown "Drug unknown" may be recorded when drug abuse was known or suspected to have been involved, but the specific substance could not be determined. This includes 2 types of cases: those in which the drug was reported to DAWN as "unknown" and those in which drugs were reported to DAWN as "polysubstances." For the purposes of DAWN, polysubstance refers to the abuse of more than one substance when the individual substances were not identified by the source record. Because DAWN cases are identified through retrospective medical chart review, there will always be cases in which the drug abuse was known but the particular substance was unknown or unknowable.
- Heroin and Heroin/morphine This is the only drug classified differently in the ED and mortality components of DAWN. In the ED publications, heroin is classified as a major substance of abuse, separate from morphine, which is classified as a narcotic analgesic under CNS agents. In the mortality data publications, heroin and morphine are classified together in a single category. When heroin is ingested, it is metabolized to morphine, so that the toxicology testing commonly used in death investigations often does not distinguish between the 2. Therefore, a mention of either substance is recorded as heroin/morphine. A case mentioning both heroin and morphine will be "de-duplicated" and counted as a single heroin/morphine mention.
- Illicit combinations This category includes compounds composed of 2 or more major substances of abuse that are mixed and taken together. For example, "speedball," which usually refers to the combination of heroin and cocaine taken at once, would be classified as an illicit combination, whereas separate mentions of heroin and cocaine would be classified separately in the categories heroin and cocaine. Compounds

- consisting of a major substance of abuse and another substance are classified in the category of the major substance (e.g., heroin with scopolamine is classified as heroin).
- Inhalants This category includes anesthetic gases and psychoactive nonpharmaceutical substances for which the documented route of administration was inhaled, sniffed, or snorted. Psychoactive nonpharmaceuticals fall into one of the following 3 categories: (1) volatile solvents—adhesives (model airplane glue, rubber cement, household glue), aerosols (spray paint, hairspray, air freshener, deodorant, fabric protector), solvents and gases (nail polish remover, paint thinner, correction fluid and thinner, toxic markers, pure toluene, cigar lighter fluid, gasoline, carburetor cleaner, octane booster), cleaning agents (dry cleaning fluid, spot remover, degreaser), food products (vegetable cooking spray, dessert topping spray such as whipped cream, whippets), and gases (butane, propane, helium); (2) nitrites—amyl nitrites ("poppers," "snappers") and butyl nitrites ("rush," "locker room," "bolt," "climax," "video head cleaner"); or (3) chlorofluorohydrocarbons (freons). Anesthetic gases (e.g., nitrous oxide, ether, chloroform) are presumed to have been inhaled.
- Major Substances of Abuse We use this term to refer to the most commonly abused drugs (e.g., alcohol-in-combination and cocaine) and those drugs that are typically referred to as "illicit."
- Other Substances of Abuse We use this term to refer to pharmaceutical agents not included in the Major Substances of Abuse.
- Drug mention This refers to a substance that was recorded ("mentioned") in a DAWN case report. In addition to alcohol-in-combination, up to 4 substances ("mentions") can be reported for each ED episode, and up to 6 substances can be reported for each drug abuse death. Therefore, the total number of drug mentions exceeds the total number of ED visits or deaths. Even when only one drug is mentioned, it should not be assumed that the substance was the sole and direct cause of the episode or death; allowances should be made for reportable drugs not mentioned or other contributory factors. (See also Single-drug episode/death.)
- Metropolitan area: An area comprising a relatively large core city or cities and the adjacent geographic areas. Conceptually, these areas are integrated economic and social units with a large population nucleus. The current DAWN ED sample, which was redesigned in the 1980s, is based on the definitions of Metropolitan Statistical Areas (MSAs) and Primary Metropolitan Statistical Area (PMSAs) issued by the Office of Management and Budget (OMB) in 1983, with a few exceptions. Metropolitan areas represented in the DAWN mortality data system are consistent with those represented in the DAWN ED system, also with a few exceptions. Users of DAWN should note that the ED component provides estimates for each of the 21 metropolitan areas. However, in the mortality data component, only raw counts are provided, and in many instances less than 100 percent of the MSA is represented in those counts.
- Not otherwise specified (NOS): Catch-all category for substances that are not specifically named in the listing. Terms are classified into an NOS category only when assignment to a more specific category is not possible based on information in the source documentation (ED patient charts and death investigation case files).



Not tabulated above (NTA): Designation used when categories are not presented in complete detail; smaller units are combined in the NTA category.

Race/ethnicity: Beginning in January 2000, the race and ethnicity categories collected on DAWN case report forms changed to match a change in the standard protocol issued by the OMB in 1997.<sup>20</sup> The new protocol permits separate reporting of race and Hispanic ethnicity; the ability to capture more than one race for an individual; modifications in nomenclature (e.g., "Black" was changed to "Black or African American"); division of certain categories ("Asian or Pacific Islander" was split into 2 categories, "Asian" and "Native Hawaiian or Other Pacific Islander"); and elimination of the "Other" category.

The race/ethnicity categories on the DAWN data collection forms are as follows:

## Race

- White A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.
- Black or African American A person having origins in any of the black racial groups of Africa.
- American Indian or Alaska Native A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment.
- Asian A person having origins in any of the original peoples of the Far East,
   Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China,
   India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.
- Native Hawaiian or Other Pacific Islander A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.
- Unknown Used when documentation of race is not available from source records.

# **Ethnicity**

- Hispanic or Latino A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.
- Not Hispanic or Latino Ethnicity does not meet the definition of Hispanic or Latino.
- Unknown Used when documentation of ethnicity is not available from source records.

Despite the increased detail allowed by the new categories, the actual race/ethnicity data reported to DAWN changed very little because race and ethnicity are often not documented with this level of specificity in patient/decedent records. As a result, we have retained the classification used previously to tabulate DAWN data. The one exception is that we now collapse the less commonly used categories into a category termed "Not tabulated above

See Office of Management and Budget, Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity, Federal Register, 62 FR 58782, October 30, 1997.



(NTA)" instead of "Other." Categories used to tabulate race and ethnicity data in the ED publications are:

- White Anyone meeting the definition of white (above). Those who are identified as white and Hispanic are classified as Hispanic.
- Black Anyone meeting the definition of black or African American (above). Those
  who are identified as black or African American and Hispanic are classified as
  Hispanic.
- Hispanic Anyone whose ethnicity is Hispanic or Latino is placed in the category Hispanic, regardless of race.
- Race/ethnicity NTA This includes those categories that are too small to report independently including: 2 or more races, American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander.
- Unknown Race and ethnicity are unknown. Those who are identified only as Hispanic are classified as Hispanic.

In Mortality Data from DAWN, race/ethnicity data are tabulated as White, Black, Hispanic, and All others, where "All others" includes other reported races and ethnicities as well as unknown or missing data.

**Route of drug administration:** DAWN reporters are asked to record the method by which the substance was taken into the drug abuser's body according to the following categories:

- Oral Substance was ingested through the mouth (swallowed).
- Injection Substance entered the body through a vein (intravenously), into the muscle (intramuscularly), or under the skin (subcutaneously).
- Inhaled Gases or fumes of a substance were taken into the body by inhaling through the nose or mouth into the lungs (e.g., inhaling the fumes of glue, aerosols, paints, gasoline).
- Smoked (includes freebase) Substance was consumed by smoking a cigarette, pipe, or similar device.
- Sniffed/snorted Substance, acquired in a powder or crystalline form, was forcefully inhaled through the nose.
- Other This category is used when the route of administration of the substance cannot logically be included as any of the above.

Readers should note that this information is often not documented in patient/decedent files and is therefore missing in DAWN tabulations. Caution should therefore be exercised in interpreting this information.

**Single-drug episode/death:** A single-drug episode or death is that in which only one drug was involved. Because multiple substances may be recorded for each DAWN case (see **Drug** 



mention), readers should exercise caution in interpreting the relationship between a given drug and the number of associated ED visits or deaths. For example, if records for a given patient "mentioned" marijuana, this does not mean that marijuana was the only drug involved in the ED visit or that the marijuana caused the ED visit. One should always consider whether and how many other drugs were used in combination, but even then attributing a causal relationship between the visit and a particular drug may not be possible. Additionally, because alcohol is only documented if used in combination with another drug, DAWN cannot provide single-drug episode/death totals for alcohol.

# DEFINITIONS OF TERMS FOR THE DAWN ED COMPONENT

Coterminous U.S.: The contiguous 48 States and Washington, DC; excludes Alaska and Hawaii. National estimates from DAWN refer only to the coterminous U.S.

**Disposition of ED patient:** Suggestions or recommendations made or actions taken by the hospital as they relate to the patient's presenting problem:

- Treated and released or referred The patient was given appropriate ED treatment and was released or, after appropriate ED treatment, the hospital referred the patient to another agency or to a private physician for additional services.
- Admitted to hospital The patient was admitted as an inpatient to a hospital.
- Left against medical advice The patient left the treatment setting without a physician's approval.
- *Died* The patient expired.

**Drug abuse episode:** A reported ED visit that involved drug abuse. Episodes involving patients under the age of 6 or over the age of 97 are not reported to the DAWN system. The number of ED patients in DAWN is not synonymous with the number of patients involved. One patient may make repeated visits to an ED or to several EDs, thus producing a number of episodes. It is impossible to determine the number of unique patients involved in the reported ED episodes because no patient identifiers are collected.

**Drug concomitance:** This term refers to whether a drug abuse episode involved a single drug (one mention) or multiple drugs (multiple mentions).

**Drug use motive:** DAWN classifies ED drug abuse episodes according to one or more of the following reasons for taking a substance(s):

- Psychic effects A conscious action to use drugs to improve or enhance any physical, emotional, or social situation or condition. Two categories of psychic effect are:
  - Use of drugs for experimentation or to enhance a social situation (e.g., curiosity, peer pressure, "just wanted to know what it felt like," "wanted to have fun," "to get high," "for kicks," "to party"); and



- Use of drugs to improve or enhance any mental, emotional, or physical state (e.g., depression, anxiety, to relieve headache, reduce pain, stay awake, lose weight, relax, help study, get to sleep). Referred to in DAWN as "other psychic effects."
- Dependence A physiological or psychological condition characterized by a compulsion to take the drug on a continuous or periodic basis in order to experience its effects or to avoid the discomfort of its absence (e.g., had to take, had to have, needed a fix).
- Suicide attempt or gesture Successful or unsuccessful action(s) taken for the purpose of self destruction or to gain attention.
- Other reason Used when the reason for taking the substance cannot be classified into the categories above.

Estimate: A statistical estimate is the value of a parameter (such as the number of drug-related ED episodes) for the universe that is derived by applying sampling weights to data from a sample. DAWN produces representative statistical estimates for 21 metropolitan areas based on data from a sample of EDs in each of the 21 areas. An estimate for the coterminous U.S. is produced by summing estimates for the 21 metropolitan areas and an estimate for the National Panel.

Form in which drug was acquired: The form in which the substance was received by the user/abuser, not the form in which the substance was consumed. Categories are: tablet/capsule/pill, aerosol, liquid, powder/crystal, paper, pieces/chunks, injectable liquid, cigarette, plant material, unknown, and other. Readers should note that this information is often not documented in ED records and is therefore missing in DAWN tabulations. Caution should therefore be exercised in interpreting this information.

Hospital emergency department (ED): Only hospitals that meet eligibility criteria for DAWN are recruited to participate. To be eligible, hospitals must be non-Federal, short-stay, general medical and surgical facilities with EDs that are open 24 hours a day, 7 days a week, and located in the coterminous U.S. Specialty hospitals; hospital units of institutions; long-term care facilities; pediatric hospitals; hospitals operating part-time EDs; hospitals in Alaska and Hawaii; and hospitals operated by the Veterans Health Administration and the Indian Health Service are excluded.

National Panel: This term is used to denote 2 concepts relative to DAWN ED data: (1) The universe of eligible hospitals outside the 21 DAWN metropolitan areas but within the coterminous U.S. and (2) the sample of hospitals in DAWN that were selected from this universe. The National Panel sample is weighted to produce estimates for the National Panel universe. (See also Metropolitan area.)

*p-value:* The probability value is the actual probability associated with a statistical estimate; this is then compared with the significance level to determine whether that value is statistically significant. For a statistically significant result, the *p*-value must be less than or equal to the significance level. The traditional significance levels are *p* less than 0.001, 0.01, 0.05, and 0.10. A result with a *p*-value less than 0.05 is considered statistically significant in DAWN ED publications.

Population: See Universe.



**Precision:** The extent to which an estimate agrees with its mean value in repeated sampling. The precision of an estimate is measured inversely by its standard error (SE) or relative standard error (RSE). In DAWN publications, estimates with RSEs of 50 percent or higher are regarded as too imprecise to be published. ED table cells where such estimates would have appeared contain the symbol "..." (3 dots). (See also **Relative standard error**.)

Rank: A rank indicates the relative frequency of a measure, such as mentions for a particular drug category. For example, a drug category ranked second indicates that it accounted for the second highest number of mentions among all drug categories. When 2 or more drugs receive equal numbers of mentions, they are assigned the same rank. A difference in rank should be considered only as indicative of a difference in frequency among drugs reported to DAWN, regardless of the size of the difference. Such differences are not necessarily meaningful or statistically significant.

**Reason for present ED contact:** The reason for the patient's visit to the ED, based on documentation provided in the medical record. Categories are:

- Overdose/toxic ingestion Either intentional or accidental (e.g., effects of suicide attempt, coma). Anyone whose reason for contact is overdose is placed in this category, regardless of other reasons.
- Unexpected reaction The drug's effect was different than anticipated, thus causing concern (e.g., bad trip, panic, hallucinations).
- Withdrawal Symptoms which occur when a patient stops taking a substance upon
  which he or she is physiologically dependent and suffers physical symptoms, including
  abdominal pain, cold sweat, hyperactivity, and tremors that require treatment.
- Chronic effects Secondary conditions resulting from habitual use or dependence, including malnutrition, tetanus, blood poisoning, and so forth.
- Seeking detoxification Patients with identified problems with chronic substance abuse who seek admission to a detoxification program and receive treatment from ED staff. This category was added to the data collection form in 1987. Some hospitals require patients to be processed in the ED prior to admission for detoxification. Caution should therefore be exercised in interpretation of this category and the remaining information.
- Accident/injury Injuries resulting from accidents that were caused by or related to drug abuse. This category was added to the data collection form in 1987.
- Other Reasons which cannot be classified into one of the aforementioned categories.

Reason for taking substance: See Drug use motive.

Relative standard error (RSE): A measure of the sampling variability or precision of an estimate defined as the estimate's SE expressed as a percentage of the estimate's value. For example, an estimate of 2,000 cocaine mentions with an SE of 200 mentions has an RSE of 10 percent. (See also *Precision* and *Standard error*.)



- Sampling: Sampling is the process of selecting a proper subset of elements from the full population so that the subset can be used to make inference to the population as a whole. A probability sample is one in which each element has a known and positive chance (probability) of selection. A simple random sample is one in which each member has the same chance of selection. In DAWN, a sample of hospitals is selected in order to make inference to all hospitals; DAWN uses simple random sampling within strata.
- Sampling frame: A list of units from which the ED sample is drawn. All members of the sampling frame have a probability of being selected. A sampling frame is constructed such that there is no duplication and each unit is identifiable. Ideally, the sampling frame and the universe are the same. The sampling frame for the DAWN hospital ED sample is derived from the American Hospital Association (AHA) Annual Survey of Hospitals.
- **Sampling unit:** A member of a sample selected from a sampling frame. For the DAWN sample, the units are hospitals, and data are collected for all drug-related ED episodes at the responding hospitals selected for the sample.

Sampling weights: Numeric coefficients used to derive population estimates from a sample.

**Source of substance:** The immediate source of the substance that the patient abused is coded as follows:

- Patient's own legal prescription This is coded only when the abuser was legally prescribed the drug of abuse. If one patient obtains a drug by legal prescription and sells it to another who abuses it, the source to the abuser is marked "street buy." If the patient for whom the prescription was issued gives the drug to another patient who abuses it, the source to the abuse is "other unauthorized procurement."
- Street buy The drug abuser purchased a drug and/or prescription from a source other than legitimate channels.
- Other unauthorized procurement The drug was acquired in a manner not consistent with accepted medical care but was not bought on the street. This category includes drugs purchased using forged prescriptions, stolen, or received as a gift.
- Other -- Used when the source of the substance cannot logically be included as any of the above. This category includes all over-the-counter medications.
- Unknown Reported when information on source was unavailable.

Readers should note that this information is often not documented in ED records and is therefore missing in DAWN tabulations. Caution should therefore be exercised in interpreting this information.

- **Standard error (SE):** A measure of the sampling variability or precision of an estimate. The SE of an estimate is expressed in the same units as the estimate itself. For example, an estimate of 10,000 cocaine mentions with an SE of 500 indicates that the SE is 500 mentions.
- Strata (plural), stratum (singular): Subgroups of a population within which separate ED samples are drawn. Stratification is used to increase the precision of estimates for a given



sample size, or, conversely, to reduce the sample size required to achieve the desired level of precision. The DAWN ED sample is stratified into 21 metropolitan area cells plus an additional cell for the National Panel. Then, within these cells strata are defined according to the annual number of ED visits, whether the hospital is located inside or outside the central city of the metropolitan area, and by the presence or absence of an organized outpatient department, alcohol/chemical dependence inpatient unit, or both. The strata are as follows:

Stratum	Annual ED visits	Location within metropolitan area	Outpatient department or alcohol/chemical dependence inpatient unit
In the 21 [	DAWN metropolita	an areas:	
0	≥80,000	Not applicable	Not applicable
1	<80,000	Central city	Both
2	<80,000	Central city	One only
3	<80,000	Central city	Neither
4	<80,000	Outside Central city	Both
5	<80,000	Outside Central city	One only
6	<80,000	Outside Central city	Neither
In the Nat	ional Panel:		
0	<u>≥</u> 80,000	Not applicable	Not applicable
7	<80,000	Not applicable	Both
8	<80,000	Not applicable	One only
9	<80,000	Not applicable	Neither

Note: Stratum "0" is defined for each of the 21 metropolitan areas and the National Panel cells. See Drug Abuse Warning Network Sample Design and Estimation Procedures: Technical Report, November 1997.

**Statistically significant:** A difference between 2 estimates is said to be statistically significant if the value of the statistic used to test the difference is larger or smaller than would be expected by chance alone. For DAWN ED estimates, a difference is considered statistically significant if the *p*-value is less than 0.05. (See also *p-value*.)

Universe: The entire set of units for which generalizations are drawn. The universe for the DAWN ED sample is all non-Federal, short-stay, general medical and surgical hospitals in the coterminous U.S. with EDs open 24 hours a day, 7 days a week. (See also Coterminous U.S.).

# **DEFINITIONS OF TERMS FOR THE DAWN MORTALITY COMPONENT**

Cause of death: Cases are reportable to DAWN if the death investigation concludes that the death was either directly or indirectly caused by drug abuse. If a death was directly caused by drug abuse (e.g., a drug overdose), DAWN refers to the death as drug-induced. If drug abuse was a contributing factor in the death, but not the immediate or sole cause, then DAWN refers to the death as drug-related. It is important to note that DAWN data include both types of deaths. It is also important to note that a drug-induced death may involve more than a single drug. (See Single-drug episode.)



- **Certified death:** Any case accepted and reviewed by a medical examiner or coroner, who uses information from the death investigation to complete the death certificate.
- Consistent panel: DAWN does not impute missing data for jurisdictions that have not reported for all or part of a given year. Therefore, tables and charts showing trends in deaths over time are based on a consistent panel of reporting jurisdictions. A consistent panel includes those jurisdictions that have reported data for at least 10 months of each year reflected in the trend table/chart. The reason for a consistent panel is to ensure that apparent changes over time are not a result of gaps in reporting. Because participating jurisdictions may change from year to year, consistent panels used in published reports will also change from year to year. This means that trends published in one annual publication are not necessarily comparable to trends published in subsequent annual publications.
- Coroner: Death investigation jurisdictions typically use either a medical examiner system or a coroner system. Unlike medical examiners, coroners need not be physicians; usually the only prerequisite for serving as a coroner is that the individual be more than 18 years of age and a resident of the county or district to be served. Coroners are typically elected rather than appointed. They may have jurisdiction over counties or districts within states. (See also Jurisdiction and Medical examiner.)
- **Drug combinations:** Published tables from the DAWN mortality data refer to "drug combinations" rather than "drug concomitance" (the term used in the ED component). This term refers to multiple drug mentions for a single death, and tables show particular combinations of substances reported for deaths. Readers should note that DAWN cannot differentiate between drugs actually *used* in combination (simultaneously) and drugs used sequentially.
- **Drug-induced death:** A death directly resulting from drug abuse or other substance abuse, such as drug overdoses or the interactive effects of drug combinations. When more than one drug is mentioned, it cannot be determined which or whether one drug was the sole and direct cause of the episode or death.
- Drug-related death: A death in which the abuse of a drug is a contributing factor, but is not the sole cause of death. Such cases include drug abuse that exacerbates a pre-existing physiological condition; drug abuse in combination with an external physical event (e.g., a fall or automobile accident); or a medical disorder that was itself caused by drug abuse (e.g., hepatitis contracted through injection drug use). Drug-related deaths are classified into 2 types, confirmed and presumed. The drug-relatedness is "confirmed" if documentation in the decedent's file substantiates that conclusion. The drug-relatedness is "presumed" if the investigation suggests drug involvement, but the medical examiner/coroner has insufficient evidence to list drug abuse as a contributing cause on the death certificate. Both confirmed and presumed deaths are included in the published mortality data tables.
- Jurisdiction: DAWN uses the term "jurisdiction" to mean the geographic area for which a medical examiner/coroner's office is responsible. In many states, there is a 1:1 correspondence between jurisdictions and counties. In some states, there are multiple medical examiner/coroner offices within a given county, or there may be multiple counties covered by a "district" that includes one or more medical examiners/coroners. A few states are organized as a single statewide jurisdiction.



Understanding jurisdictions is important because this assists readers in interpreting aggregated data. Published DAWN mortality data are aggregated into metropolitan areas, which often comprise multiple jurisdictions. In some states, there are different death investigation procedures for different jurisdictions (most notably, some jurisdictions have medical examiner systems, while others have coroner systems). There are nearly always some differences in death investigation procedures across states (and notably, some metropolitan areas include jurisdictions in multiple states). Readers should be mindful of these variations when interpreting or comparing data.

Information on death investigation practices and an updated list of jurisdictions throughout the U.S. and Canada are available from the Centers for Disease Control and Prevention, Epidemiological Program Office at www.cdc.gov/epo/dphsi/mecisp/death\_investigation.htm.

**Manner of death:** This variable is used to describe how the decedent died. It is applicable to both drug-induced and drug-related deaths. On the DAWN data collection form, manner of death is coded into the following categories:

- Accidental/Unexpected Although the drug abuse was deliberate, the resulting death was unintended.
- Suicide Death in which there is evidence that the decedent deliberately used drugs to bring about his or her demise.
- Homicide Death in which the decedent's life was taken by another individual by means of drugs. These cases, which do not involve the intentional abuse of drugs by the decedent, are <u>not</u> currently included in published tabulations of DAWN mortality data.
- Natural Death was due to natural causes such as a medical disorder or disease process, if drug abuse caused or worsened the decedent's condition.
- Undetermined The manner of death cannot be determined from all available evidence.

In Mortality Data from DAWN, manner of death is collapsed into 3 categories: suicide, accidental/unexpected, and "all others." The "all others" category includes cases for which manner of death was recorded as natural, unknown, or undetermined, and cases for which manner of death was missing.

**Medical Examiner (ME):** Death investigation jurisdictions typically use either a medical examiner system or a coroner system. Most medical examiners are licensed physicians or forensic pathologists, and are generally appointed (rather than elected). They may have jurisdiction over a county, district, or entire state. (See also **Coroner** and **Jurisdiction**.)



# APPENDIX E: MULTUM LICENSE AGREEMENT

# **LEXICON LICENSE**

Multum Lexicon<sup>1</sup>

**End-User License Agreement** 

# 1. INTRODUCTION

- A. This License Agreement (the "License") applies to the Multum Lexicon database (the "Database"). This License does not apply to any other products or services of Cerner Multum, Inc. ("Multum"). A "work based on the Database" means either the Database or any derivative work under copyright law; i.e., a work containing the Database or a substantial portion of it, either verbatim or with modifications. A translation of the Database is included without limitation in the term "modification." Each enduser/licensee is addressed herein as "you".
- B. Your use of the Database acknowledges acceptance of these restrictions, disclaimers, and limitations. You expressly acknowledge and agree that Multum is not responsible for the results of your decisions resulting from the use of the Database, including, but not limited to, your choosing to seek or not to seek professional medical care, or from choosing or not choosing specific treatment based on the Database.
- **C.** Every effort has been made to ensure that the information provided in the Database is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive.
- **D.** Multum does not assume any responsibility for any aspect of healthcare administered or not administered with the aid of information the Database provides.

# 2. TERMS AND CONDITIONS FOR COPYING, DISTRIBUTION AND MODIFICATION

- A. You may copy and distribute verbatim copies of the Database as you receive it, in any medium, provided that you conspicuously and appropriately publish on each copy an appropriate copyright notice and disclaimer of warranty; keep intact all the notices that refer to this License and to the absence of any warranty; and give any other recipients of the Database a copy of this License (the readme.txt file) along with the Database and anything else that is part of the package, which should be identified.
- **B.** You may modify your copy or copies of the Database or any portion of it to form a derivative work, and copy and distribute such modifications or work under the terms of Section 2.A. above, provided that you also meet all of these conditions:

<sup>&</sup>lt;sup>1</sup> The Multum License Agreement can be found on the Internet at http://www.multum.com.



- i) You must cause the modified files to carry prominent notices stating that they are derived from the Multum Lexicon database from Cerner Multum, Inc. and that you changed the files and the date of any change(s).
- ii) If you incorporate modified files into a computer program, you must cause it, when started running for interactive use in the most ordinary way, to print or display an announcement including an appropriate copyright notice, a notice that you have modified the Multum Lexicon database from Cerner Multum, Inc., and a notice that there is no warranty (or that you provide the warranty) and telling the user how to view a copy of this License.
- C. It is not the intent of this section to claim rights or contest your rights to work written entirely by you; rather, the intent is to exercise the right to control the distribution of derivative or collective works based on the Database.
- **D.** You may copy and distribute the Database (or a work based on it, under Section 2.B.) in an encoded form under the terms of Sections 2.A. and 2.B. above provided that you also do one of the following:
  - i) Accompany it with the complete corresponding machine-readable plain text, which must be distributed under the terms of Sections 2.A and 2.B. above on a medium customarily used for software interchange; or,
  - ii) Accompany it with a written offer to give any third party, for no charge, a complete machine-readable copy of the Database (and the entirety of your derivative work based on it, under Section 2.B.), to be distributed under the terms of Sections 2.A. and 2.B. above on a medium customarily used for software interchange.
- E. You may not copy, modify, sublicense, or distribute the Database except as expressly provided under this License. Any attempt otherwise to copy, modify, sublicense or distribute the Database will automatically terminate your rights under this License. However, parties who have received copies, or rights, from you under this License will not have their licenses terminated so long as such parties remain in full compliance.
- F. You are not required to accept this License. However, nothing else grants you permission to copy, modify or distribute the Database or its derivative works. These actions are prohibited by law if you do not accept this License. Therefore, by copying, modifying or distributing the Database (or any work based on the Database), you indicate your acceptance of this License to do so, and all its terms and conditions for copying, distributing or modifying the Database or works based on it.
- **G.** Each time you redistribute the Database (or any work based on the Database), the recipient automatically receives a license from Multum to copy, distribute or modify the Database subject to these terms and conditions. You may not impose any further restrictions on the recipients' exercise of the rights granted herein. You are not responsible for enforcing compliance by third parties to this License.



# 3. DISCLAIMER OF WARRANTIES; LIMITATION OF DAMAGES

- A. Because the database is licensed free of charge, there is no warranty for the program or data, to the extent permitted by applicable law. Except when otherwise stated in writing. Multum and/or other parties provide the database "as is" without warranty of any kind, either expressed, statutory or implied, including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the quality and performance of the database is with you. Should the database prove defective, incomplete, or inaccurate, you assume the responsibility and cost of all necessary servicing, repair or correction.
- **B.** In no event (unless required by applicable law or agreed to in writing) will Multum, or any other party who may modify and/or redistribute the database as permitted above, be liable for any special, incidental, consequential, or indirect damages, including damages for loss of profits, loss of business, or down time, even if Multum or any other party has been advised of the possibility of such damages.
- C. In addition, without limiting the foregoing, the database has been designed for use in the United States only and covers the drug products used in practice in the United States. Multum provides no clinical information or checks for drugs not available for sale in the United States and clinical practice patterns outside the United States may differ substantially from information supplied by the database. Multum does not warrant that uses outside the United States are appropriate.
- D. You acknowledge that updates to the database are at the sole discretion of Multum. Multum makes no representations or warranties whatsoever, express or implied, with respect to the compatibility of the database, or future releases thereof, with any computer hardware or software, nor does Multum represent or warrant the continuity of the features or the facilities provided by or through the database as between various releases thereof.
- E. Any warranties expressly provided herein do not apply if: (i) the end-user alters, mishandles or improperly uses, stores or installs all, or any part, of the database, (ii) the end-user uses, stores or installs the database on a computer system which fails to meet the specifications provided by Multum, or (iii) the breach of warranty arises out of or in connection with acts or omissions of persons other than Multum.

# 4. ASSUMPTION OF RISK, DISCLAIMER OF LIABILITY, INDEMNITY

- **A.** The end-user assumes all risk for selection and use of the database and content provided thereon. Multum shall not be responsible for any errors, misstatements, inaccuracies or omissions regarding content delivered through the database or any delays in or interruptions of such delivery.
- B. The end-user acknowledges that Multum: (a) has no control of or responsibility for the end-user's use of the database or content provided thereon, (b) has no knowledge of the specific or unique circumstances under which the database or content provided thereon may be used by the end-user, (c) undertakes no obligation to supplement or update content of the database, and (d) has no liability to any person for any data or information input on the database by persons other than Multum.



C. Multum shall not be liable to any person (including but not limited to the end-user and persons treated by or on behalf of the end-user) for, and the end-user agrees to indemnify and hold Multum harmless from any claims, lawsuits, proceedings, costs, attorneys' fees, damages or other losses (collectively, "losses") arising out of or relating to (a) the end-user's use of the database or content provided thereon or any equipment furnished in connection therewith and (b) any data or information input on the database by end-user, in all cases including but not limited to losses for tort, personal injury, medical malpractice or product liability.

# 5. MISCELLANEOUS

- **A.** You warrant that you have authority within the organization you identified during registration for the Database to enter into license agreements with other organizations including Multum.
- B. You agree that Multum may identify you and/or your organization by name as a "licensee", "licensed user", or "licensing organization" of the Database or a "client" of Multum in Multum's external market communications. You also agree that Multum may issue, if it desires, a press release stating that you and/or your organization have licensed the Database
- C. If conditions are imposed on you (whether by court order, agreement or otherwise) that contradict the conditions of this License, they do not excuse you from the conditions of this License. If you cannot distribute so as to satisfy simultaneously your obligations under this License and any other obligations, then as a consequence you may not distribute the Database at all.
- **D.** If any portion of this License is held invalid or unenforceable under any particular circumstance, the balance of this License is intended to apply and the License as a whole is intended to apply in other circumstances.
- E. If the distribution and/or use of the Database is or becomes restricted in certain countries either by patents or by copyrighted interfaces, Multum may add an explicit geographical distribution limitation excluding those countries, so that distribution is permitted only in or among countries not thus excluded. In such case, this License incorporates the limitation as if written in the body of this License.

Multum Lexicon Copyright (c) 1997, 1998, 1999, 2000, 2001 Cerner Multum, Inc. 3200 Cherry Creek South Drive, Suite 300 Denver, Colorado 80209

document revised November 30, 2000

Lexicon
Copyright © 2001 Multum Information Services, Inc.
3200 Cherry Creek South Drive, Suite 300
Denver CO 80209



# APPENDIX F: DAWN EMERGENCY DEPARTMENT REPORT FORM

FORM NUMBER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

**XXXXXXX** 

SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION

FORM APPROVED: OMB NO. 0930-0076 Expires: 11/30/2002

DRUG AB (Sample Form Only) EMERG	USE WARNING NETWORK (DAWN) GENCY DEPARTMENT REPORT	(Sample	e Form Only)
1. PROVIDER NUMBER	2. CROSS REFERENCE (Facility Use Only)	:	
PATIENT INFORMATION	DRUG/SUBSTANCE INFORMAT	rion.	
3. DATE OF Month Day Year	12. ALCOHOL INVOLVED (Mark [X] one response)		
VISIT	1 ☐ Yes	2 □ No 3	3 🗆 Unknown
4. TIME OF VISIT Hours Minutes (Mark (X))  1. □ am  2. □ pm  3. □ mllitary  5. AGE (Must be 06-97 yrs.)	13. LIST EACH DRUG/SUBSTANCE SEPARATELY (Generic, Tra IN ONE OF THE SPACES BELOW (Do NOT list alcohol)  SAMHSA USE ONLY  1 2	de, or Street i	Name) Mark [x] if confirmed to toxicology tests
6. SEX  1	For each non-alcohol substance listed above, mark [X] one respo	nse in each d	ata item below.
2 Not Hispanic or American	14. FORM IN WHICH DRUG WAS ACQUIRED		SUBSTANCES
Latino ☐ American Indian or Alaska Native	<del></del>	1	2 3 4
☐ Native Hawaiian or	Tablet/Capsule/Pill	01	+ + + -
Other Pacific Islander Unknown	Aerosol	02	+++-
8. PATIENT'S HOME ZIP CODE	Liquid (oral)	03	
	Powder/Crystal	04	
	Paper (e.g., LSD/Acid)	05	+
(Otherwise mark [X] one response)	Pieces/Chunks (e.g., Crack)	06	
1 Unknown 2 No Fixed Address	Injectable Liquid	07	
(See reverse side)	Cigarette	08	
9. REASON FOR TAKING SUBSTANCE(S)	Plant Material	09	
(Mark [X] one response)  1 Dependence	Unknown	10	
2 Suicide Attempt or Gesture	Other	11	
3 Psychic Effects: "Recreational Use"	15. ROUTE OF ADMINISTRATION		SUBSTANCES
(e.g., to get high, kicks)  4  Other Psychic Effects (See reverse side)	<del>-</del>	1	2 3 4
5 ☐ Unknown 6 ☐ Other (Specify)	Oral	1	<del>                                     </del>
6 Guier (Specify)	Injection	2	
10. REASON FOR PRESENT CONTACT	Inhaled (e.g., fumes)	3	
A. Was This an Overdose/Toxic Ingestion?	Smoked (Includes Freebase)	4	
1 Yes No	Sniffed, Snorted	5	
B. If "No," mark one response	Unknown	6	
2 Unexpected Reaction	Other	7	
Chronic Effects (See reverse side)      Withdrawal	16. SOURCE OF SUBSTANCE		SUBSTANCES
5 Seeking Detoxification	Patlent's Own Legal Rx	1 1	2 3 4
6 Accident/Injury		1 -	<del>                                     </del>
7 Unknown 8 Non-toxic Inspetion/Other	Street Buy	2	+ $+$ $-$
8 Non-toxic Ingestion/Other (Specify)	Other Unauthorized Procurement (e.g., stolen, gift, etc.)	3	<del>                                     </del>
(See reverse side)	Unknown	4	+
11. DISPOSITION FROM EMERGENCY DEPARTMENT	Other (Includes Over-The-Counter [OTC])	5	
Treated and Released or Referred  Market as inpatient to This or Any Hospital  Left Against Medical Advice	17. CODED REMARKS (If case involves an IV drug user with HIV+/AIDS, ptease write "HIV+" or ")	AIDS* in the firs	t four spaces below.)
4 Died			



# SELECTED REPORTING GUIDELINES AND INSTRUCTIONS DRUG ABUSE WARNING NETWORK (DAWN) EMERGENCY DEPARTMENT REPORT

### I. General

The following abbreviated guidelines and instructions highlight critical reporting items. Please refer to the detailed instructions found in the Instruction Manual for Emergency Departments for further information.

### II. Reporting Guidelines

Report data on all patients seen in the emergency department for problems induced by or related to drug abuse. For DAWN, drug abuse is defined as the use of any illegal drug or the nonmediacal use of a legal drug where the reason for taking the substance was for: psychic effects, dependence, or suicide attempt or gesture.

Detailed discussion of the "nonmedical" use definition and other case selection criteria can be found in Chapter II, Case Identification Guidelines, of the Instruction Manual for Emergency Departments.

### III. Abbreviated Instructions for Completing Selected Items

Data Item #8 - Patient's Home Zip Code

Use "no fixed address" for the homeless (even if staying at a shelter) and for prisoners brought into the hospital.

Data Item #9 - Reason for Taking Substance(s)

The response categories are: Dependence, Suicide Attempt or Gesture, Psychic Effects: "Recreational Use," Other Psychic Effects, Unknown, and Other (Specify). The definitions are as follows:

- Dependence A physiological or psychological condition characterized by a compulsion to take the drug on a
  continuous or periodic basis in order to experience its effects or to avoid the discomfort of its absence (i.e., to avoid
  withdrawal).
- 2. Suicide Attempt or Gesture Successful or unsuccessful action(s) taken for the purpose of self-destruction or to gain attention.
- Psychic Effects: "Recreational Use" Use of drug(s) for experimentation or to enhance social situations or conditions.

  Examples of common patient responses are: "just wanted to know what it felt like," "wanted to have fun," or "to get high."
- 4. Other Psychic Effects Use of drug(s) to improve or enhance, any mental, emotional, or physical state. Examples of common patient responses concerning this self-applied medication are: "needed to relax," "wasn't feeling well," "to stay awake," "depression," "anxiety," "lose weight," "fight with a boyfriend/mate."
- 5. Unknown Should be used only if information is unobtainable or unavailable.
- Other (Specify) Should be used only when the Reason for Taking the Substance cannot be classified into the categories above. Write the appropriate reason in the space provided.

## Data Item #10 - Reason for Present Contact

This data item has two parts, A and B. Part A requires a selection of "YES" or "NO" to indicate whether the case is an Overdose / Toxic Ingestion. If the response to part A is "NO," part B requires a response.

- 3. Chronic Effects Includes Hepatitis, Abscess, Cellulitis, Tremors, and AIDS contracted by IV drug abuse (see manual for additional examples).
- 8. Non-Toxic Ingestion / Other (Specify) Should be used only when Reason for Present Contact cannot be classified into the categories above. (For example, police bring patient in for toxicological testing related to commission of a crime or parents force a child to come in to be checked because of strange behavior.) If Other, write reason in space provided.

# Data Item #17 - Coded Remarks

Please be certain to write "HIV+" or "AIDS" in the first four blocks if the patient is a confirmed IV drug user.

SMA 100-1 (BACK) REV. 11/99



გმ

# **Detailed Tables**

Additional tables can be found on the Internet (http://www.samhsa.gov/oas/dawn.htm and http://www.DAWNinfo.net) for each of the 21 metropolitan areas sampled by DAWN.



# Table 1.1 - ED sample information and response rates by metropolitan area, 2001

Metropolitan area¹	Responding sample hospitals	Eligible hospitals in the sample	Response rate, sample hospitals	Total eligible hospitals²	Response rate for visits (unweighted) <sup>2</sup>
TOTAL COTERMINOUS U.S	458	564	81	4,683	85
Atlanta Baltimore	16	19	<u>\$</u> 8	33	6 K
Boston	23	24	96	4	2 96 8 6
Buffalo	8 10	10	8 1	9	49
Dallas	11	00°	. 85 28 38	9 6	88 52
Denver	6	14	28	4-	8 8
Detroit	17	20	88	42	8
Los Angeles	33	43	12	82	83
Miami	132	17	88	22	92
Minneapolis	12	18	29	58	80
New Orleans	12	16	75	: 23	06
New York	32	32	6 6	78	96
Philadelphia	26	34	\$ 2	2.59	88
Phoenix	15	18	8	24	93
St. Louis	20	26	77	35	92
San Diego	16	18	88	18	91
San Francisco	16	19	\$	9	8
Seattle	15	15	100	20	100
Washington, DC	16	18	68	31	95

<sup>&#</sup>x27; See Table 1.2 for a list of counties and independent cities constituting the metropolitan areas in this table.

BEST COPY AVAILABLE



<sup>&</sup>lt;sup>2</sup> Based on annual emergency department visits to eligible and responding hospitals in the sample as reported in the previous year's American Hospital Association (AHA) Annual Survey.

ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 1.2 - Counties and cities that constitute DAWN ED metropolitan areas, 2001

St. Louis (MSA)  Clinton County, IL (17-027) Franklin County, MO (29-071) Jefferson County, MO (29-071) Jersey County, IL (17-183) Madison County, IL (17-183) St. Charles County, MO (29-183) St. Charles County, MO (29-183) St. Louis City, MO (29-510) St. Louis County, MO (29-189) San Diego (MSA) Marin County, CA (6-073) San Francisco County, CA (6-075) San Francisco County, CA (6-081) San Mateo County, CA (6-081) Seattle (PMSA) Marin County, WA (53-061) Mashington, DC (MSA) Alexandria City, VA (51-510) Arlington County, MD (24-017) District of Columbia (11-001) Fairfax County, MD (24-017) District of Columbia (11-001) Fairfax County, WA (51-059) Fairfax County, WA (51-059) Frederick County, WA (51-610) Frederick County, WA (51-610) Frederick County, WA (51-683) Manaesase City, VA (51-683)	Manassas Park Ciry, VA (51-685) Montgomery County, MD (24-031) Prince George's County, MD (24-033) Prince William County, VA (51-153) Stafford County, VA (51-179)
New Orleans (MSA) Jefferson Parish, LA (22-051) Orleans Parish, LA (22-071) St. Bernard Parish, LA (22-087) St. Charles Parish, LA (22-089) St. John the Baptist Parish, LA (22-095) St. Tammany Parish, LA (22-03) New York County, NY (36-047) New York County, NY (36-047) New York County, NY (36-047) Richmond County, NY (36-081) Richmond County, NY (36-081) Reckland County, NJ (34-027) Sussex County, NJ (34-027) Sussex County, NJ (34-027) Union County, NJ (34-037) Union County, NJ (34-037) Union County, NJ (34-005) Bucks County, PA (42-017) Burlington County, NJ (34-005) Chester County, NJ (34-005) Chester County, PA (42-045) Gloucester County, PA (42-045) Gloucester County, PA (42-045) Philadelphia County, PA (42-011) Phoenix (MSA) Maricopa County, AZ (4-013)	
Dalias (PMSA)  Collin County, TX (48-085) Dalias County, TX (48-13) Denton County, TX (48-13) Ellis County, TX (48-139) Kaufman County, TX (48-397) Rockwall County, TX (48-397) Berver (PMSA) Adams County, CO (8-031) Denver County, CO (8-031) Denver County, CO (8-031) Denver County, CO (8-035) Jefferson County, CO (8-035) Jefferson County, MI (26-095) Macomb County, MI (26-093) Marcomb County, MI (26-093) Marcomb County, MI (26-155) Cakland County, MI (26-155) St. Clair County, MI (26-147) Wayne County, MI (26-163) Los Angeles-Long Beach (MSA) Los Angeles County, CA (6-037) Miami-Hialeah (MSA) Dade County, MN (27-003) Carver County, MN (27-003) Carver County, MN (27-025) Dakota County, MN (27-025) Deaced County, MN (27-053) Isanti County, MN (27-053) Isanti County, MN (27-053) Isanti County, MN (27-053)	Kamsey County, MN (27-123) Scott County, MN (27-139) St. Croix County, WI (55-109) Washington County, MN (27-163) Wright County, MN (27-171)
Atlanta (MSA)  Barrow County, GA (13-013)  Butts County, GA (13-057)  Cherokee County, GA (13-057)  Clayton County, GA (13-067)  Cobb County, GA (13-067)  Cobb County, GA (13-067)  Cobb County, GA (13-087)  Eayette County, GA (13-114)  Fayette County, GA (13-117)  Fulton County, GA (13-121)  Gwinnett County, GA (13-121)  Gwinnett County, GA (13-121)  Henry County, GA (13-121)  Rockdale County, GA (13-227)  Paulding County, GA (13-223)  Rockdale County, GA (13-255)  Walton County, GA (13-255)  Walton County, GA (13-255)  Baltimore (MSA)  Anne Arundel County, MD (24-005)  Carroll County, MD (24-013)  Harford County, MD (24-027)  Queen Anne's County, MD (24-027)  Queen Anne's County, MA (25-017)  Norfolk County, MA (25-017)  Norfolk County, MA (25-017)  Norfolk County, MA (25-017)  Plymouth County, MA (25-021)  Plymouth County, MA (25-021)  Plymouth County, MA (25-023)	Buffalo (PMISA) Buffalo (PMISA) Ene County, NY (36-029) Cook County, IL (17-031) Du Page County, IL (17-043) McHenry County, IL (17-111)

Two exceptions are the Boston New England county metropolitan area and the St. Louis metropolitan statistical area, which correspond to 1990 definitions. Parentheses contain Federal NOTE: Metropolitan areas are defined according to the Office of Management and Budget's 1983 definitions of metropolitan statistical areas and primary metropolitan statistical areas. In subsequent tables and in the text, compound names (e.g., Los Angeles-Long Beach) are abbreviated (e.g., Los Angeles) for ease of reference.

Information Processing Standard (FIPS) State-County codes.
ED = emergency department, MSA = metropolitan statistical area, NECMA = New England county metropolitan area, PMSA = primary metropolitan statistical area.



# Table 1.3 - ED visits, drug episodes, and drug mentions: Unweighted sample data and weighted estimates by metropolitan area, 2001

Metronolitan araa	Un	Unweighted sample data	ata	N	Weighted estimates	S
	ED visits	Drug episodes	Drug mentions	ED visits	Drug episodes	Drug mentions
TOTAL COTERMINOUS U.S.	16,406,562	196,268	349,916	100,517,664	638.484	1.165.367
Atlanta	712,429	11,474	21,462	1,248,776	14,456	27.254
Baltimore	986,696	11,283	20,187	1,023,651	11,625	20.777
Boston	868,287	10,233	18,294	1,616,628	16,853	29.795
Buffalo	185,602	2,236	3,853	277,666	3,356	5,935
Chicago	927,681	15,552	27,337	2,305,890	32,647	57,817
Dallas	608,726	3,965	7,468	1,051,155	6,500	12,114
Denver	388,556	3,933	6,673	592,182	5,468	9,412
Detroit	641,217	12,590	24,516	1,583,300	19,265	37,164
Los Angeles	1,197,880	14,530	27,097	2,435,376	24,669	44.670
Miaml	490,635	8,103	14,606	765,070	8,886	15,919
Minneapolis	454,084	4,098	7,672	797,477	6,521	12,300
New Orleans	414,460	2,857	5,239	587,566	3,729	7,037
New York	1,754,552		28,155	3,748,794	32,307	52,055
Newark	502,892		699'6	770,151	7,217	12,589
Philadelphia	900'968		31,847	1,769,335	25,790	48,222
Phoenix	616,199	6,833	11,979	936,633	10,084	17,805
St. Louis	586,612	4,774	8,991	902,774	8,216	15,963
San Diego	577,860	6,476	10,973	624,031	6,962	11,779
San Francisco	427,957	7,111	11,342	544,753	8,575	13,743
Seattle	517,038	9,104	15,553	700,646	11,495	19,818
Washington, DC	747,707	6,858	11,115	1,260,749	10,566	17,480

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



Table 1.4 - ED visits (in 1,000s): Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
TOTAL COTERMINOUS U.S	769'68	88,548	91,189	89,720	89,683	91,100	96,163	-	12.1	10.3	4.5
utanta	1,140	1,129	1,125	1,041	1,032	1,026	965			21.7	29.3
Baltimore	825	838	865	873	931	970	978		24.0	5.5	4.6
Boston	1,679	1,601	1,714	1,568	1,556	1,518	1,584	1,617		6.5	
Buffalo	325	300	294	268	272	288	264		•	-3.5	5.2
Chicago	2,145	2,216	2,204	2,197	2,141	2,204	2,257		7.5	4.6	2.2
Dallas	826	843	835	886	914	904	1,015			16.2	3.5
Denver	424	464	446	439	426	521	527			13.6	12.3
Detroit	1,436	1,513	1,537	1,449	1,461	1,481	1,474			6.9	7.4
os Angeles	2,375	2,237	2,335	2,233	2,142	2,307	2,599			5.6	6.3
Miami	627	622	632	899	200	200	740			8.4	3.4
Minneapolis	642	683	169	683	9	703	741			13.5	9.2
New Orleans	565	275	603	216	263	585	209			0.4	-3.2
New York	3,345	3,196	3,624	3,432	3,472	3,426	3,685			9.4	1.7
Newark	629	702	681	649	269	720	765			7.0	9.0
Philadelphia	1,620	1,657	1,657	1,638	1,691	1,711	1,739			3.4	1.8
Phoenix	639	701	732	069	717	765	828			22.4	9.5
St. Louis	917	869	880	841	819	876	918			3.0	-1.6
San Diego	519	204	575	586	611	657	639				-2.4
San Francisco	222	481	495	479	513	228	503			-2.3	8.3
Seattle	200	220	299	582	220	264	621		0.2	24.2	12.8
Washington, DC	1,195	1,176	1,090	1,077	1,112	1,129	1,201			11.7	5.0

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate 1 DAWN estimates of emergency department visits (in 1,000s) should be close to but will not necessarily equal totals from previous year's American Hospital Association (AHA) Annual Survey. <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

with an RSE greater than 50% has been suppressed.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 1.5 - ED visits (in 1,000s): Estimated rates per 100,000 population by metropolitan area by year<sup>1</sup>

ge <sup>2</sup> % change <sup>2</sup> % change <sup>2</sup> . 1999, 2000, . 2001
% change, 1994, 2001
Total 2001
Total 2000
Total 1999
Total 1998
Totai 1997
Total 1996
Total 1995
Total 1994
Metropolitan area

DAWN estimates of emergency department visits (in 1,000s) should be close to but will not necessarily equal totals from previous year's American Hospital Association (AHA) Annual Survey.

2 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</p>
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coteminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 1.6 - ED drug episodes, standard errors, relative standard errors, and confidence intervals: Estimates by metropolitan area, 2001

Metropolitan area	Estimated episodes	Standard error	Relative standard error	95% Confidence interval	l
TOTAL COTERMINOUS U.S.	638,484	44,694			8
AtlantaAtlanta	14,456	1,301		11,906 - 17,00	900
Baltimore	11,625	267			148
Boston	16,853	2,477	14.7	11,998 - 21,708	802
Buffalo	3,356	537			409
Chicago	32,647	3,591		25,609 - 39,68	385
Dallas	6,500	475			131
Denver	5,468	476			401
Detroit	19,265	2,716			588
Los Angeles	24,669	3,651			325
Miami	8,886	453			774
Minneapolis	6,521	554		5,435 - 7,60	307
New Orleans	3,729	496			701
New York	32,307	4,652			125
Newark	7,217	1,386			334
Philadelphia	25,790	3,353			362
Phoenix	10,084	746			346
St. Louis	8,216	1,742			330
San Diego.	6,962	181			317
San Francisco	8,575	386			332
Seattle	11,495	471	4.1		118
Washington, DC	10,566	1,786	16.9		29(
					I

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

∫ fable 1.7 - ED drug episodes, relative standard errors, and mentions for major drugs of abuse: Estimates by metropolitan area, 2001

Metropolitan area	Total drug episodes	episodes	Total drug mentions	mentions	Cocaine mentions	nentions	Heroin mentions	nentions	Marijuana mentions	mentions
	Est.	RSE	Est.	RSE	Est.	RSE	Est.	RSE	Est.	RSE
TOTAL COTERMINOUS U.S.	638.484	0.7	1,165,367	7.3	193,034	10.7	93,064		110,512	14.9
Atlanta	14.456	0.6	27,254	9.6	8,891	9.4	848		3,486	12.9
Ralfimore	11.625	2.3	20,777	2.4	4,930	2.2	4,481		1,786	6.1
Roston	16,853	14.7	29,795	14.7	4,933	19.3	4,358	9.7	3,423	35.7
Briffelo	3,356	16.0	5,935	18.7	1,220	25.9	209		561	21.7
Chicado	32.647	11.0	57,817	11.6	16,202	14.3	11,902		5,186	11.9
Dallac	6,500	7.3	12,114	7.1	1,770	12.1	443		1,049	15.3
Denver	5,468	8.7	9,412	9.2	1,343	11.8	769		979	23.6
Definit	19,265	14.1	37,164	13.7	7,730	13.3	3,870		5,017	17.4
Loc Angelos	24.669	14.8	44.670	18.8	6666	23.9	2,878		5,729	37.4
Mismi	8.886	5.1	15,919	5.4	4,641	7.2	1,666		1,932	6.4
Minneanolis	6.521	8.5	12,300	8.2	1,105	14.1	338		1,200	13.0
New Orleans	3,729	13.3	7,037	15.5	1,422	14.2	530		814	21.3
New York	32,307	14.4	52,055	15.9	13,898	21.0	10,644		3,501	14.4
Newsork	7.217	19.2	12,589	19.7	2,631	25.4	3,718		647	24.8
Dhiladeinhia	25.790	13.0	48,222	13.6	11,358	18.1	5,362		5,496	16.8
Dhoeniy	10.084	7.4	17,805	8.1	1,752	12.6	777		1,284	13.2
Of Lottis	8.216	21.2	15,963	24.7	3,080	36.6	1,309		2,311	35.2
Can Diago	6.962	2.6	11,779	3.0	812	5.8	733		1,107	9.9
Nan Francisco	8.575	4.5	13,743	4.6	2,482	4.1	2,790		704	9.8
Coll I coll College	11 495	4.1	19,818	3.9	3,409	9.6	1,927		1,596	9.2
Washington, DC.	10,566	16.9	17,480	18.9	2,894	14.4	1,888		2,135	26.4

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, Est. = estimate, RSE = relative standard error.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 1.8 - ED drug episodes, standard errors, relative standard errors, and confidence intervals: Estimates by drug category, 2001

Drug category¹	Estimated episodes	Standard error	Relative standard error	95% Confidence interval	e interval
MAJOR SUBSTANCES OF ABUSE.  Alcohol-in-combination Cocaine. Heroin. Marijuana. Amphetamines. Methamphetamine. MoDMA (Ecstasy). Ketamine. LSD PCP. Miscellaneous hallucinogens. Flunitrazepam (Rohypnol) GHB. Inhalants.	669,559 218,005 193,034 93,064 110,512 18,555 14,923 5,542 6,102 1,788 1,788 3,340 676 2,821 6,102 1,788	60,260 20,928 20,655 11,819 11,867 4,372 881 314 494 702 672 882 883 104	9.0 10.7 17.7 10.6 10.6 10.6 10.6 10.6 10.6 10.6 10.6	551,449 - 176,986 - 152,550 - 69,899 - 78,239 - 14,700 - 6,354 - 6,354 - 4,726 - 4,726 - 4,726 - 4,726 - 4,726 - 276 - 94 - 94 - 94 - 94	787,669 259,024 233,518 116,229 142,785 22,410 23,492 7,269 1,294 3,789 7,478 3,105 1,076 1,076 1,076
PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Miscellaneous antidepressants. Thioxanthenes. Miscellaneous antipsychotics. Phenothiazine antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Benzodiazepines. Misc. anxiolytics, sedatives, and hypnotics. CNS stimulants. Analgesics. Analgesics. Analgesics. Norcotic analgesics/combinations. Nonsteroidal anti-inflammatory agents. Salicylates/combinations. Nonsteroidal anti-inflammatory agents. Salicylates/combinations.	495,808 220,289 61,012 26,972 12,445 20,182 1,3594 9,506 103,972 22,472 3,146 210,685 1,314 99,317 22,663 8,499	34,707 16,962 5,430 1,180 1,180 2,425 2,425 11,148 1,148 1,223 13,960 11,421 1,421 2,157 2,157 3,616	0.7.7.8.6.4.1.1.1.2.1.2.1.2.1.2.1.2.1.2.1.2.1.2.1	427,782 - 187,043 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 50,369 - 5	253,834 253,835 71,655 71,655 31,888 15,936 24,968 1,859 11,909 122,110 26,700 4,059 1,22,482 201,862 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639 1,639
Analgesic combinations NTA		2 ::	64.9	• 10g/40	49,131 

Table 1.8 - ED drug episodes, standard errors, relative standard errors, and confidence intervals: Estimates by drug category, 2001 (continued)

Drug category¹	Estimated episodes	Standard error	Relative standard error	95% Confidence interval	interval
Anorexiants	953 14,642 526 985 985 10,001	231 1,816 163 252 252 4 2,413	24.2 12.4 30.9 37.8 37.8 12.7	500 - 11,083 - 207 - 491 - 2 - 14,272	1,406 18,201 845 1,479 18 23,730
RESPIRATORY AGENTS. Antihistamines. Bronchodilators. Decongestants. Expectorants. Upper respiratory combinations. Respiratory agents NTA.	12,238 4,112 422 859 859 5,697 672	1,469 580 133 192 131 131 200	12.0 14.1 31.5 22.3 27.6 16.7	9,359 - 2,975 - 161 - 483 - 219 - 3,833 - 280 -	15,117 5,249 683 1,235 7,561 1,064
CARDIOVASCULAR AGENTS	9,984 1,852 2,382 1,386 821 3,543	1,428 419 598 327 237 556	14.3 22.6 25.1 23.6 23.6 15.7	7,185 - 1,031 - 1,210 - 745 - 356 - 2,453 -	12,783 2,673 3,554 2,027 1,286 4,633
OTHER SUBSTANCES Alternative medicines. Anti-infectives. Gastrointestinal agents Hormones Nutritional products Topical agents Drug unknown	42,611 662 5,282 2,792 4,032 1,449 2,600 23,923 1,871	3,579 167 729 385 637 637 283 471 223	25.3 13.8 13.8 15.8 15.8 19.5 19.5 19.5	35,596 - 335 - 3,853 - 2,037 - 2,783 - 19,468 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 - 793 -	49,626 989 6,711 3,547 5,281 2,004 3,523 28,378 2,949
TOTAL DRUG ABUSE EPISODESTOTAL DRUG ABUSE MENTIONSTOTAL ED VISITS (in 1,000s)	638,484 1,165,367 100,518	44,694 85,072 402,071	7.0 7.3 0.4	550,884 - 998,626 - 99,730 -	726,084 1,332,108 101,306

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous <sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warming Network, 2002 (09/2002 update).

ERIC

Full Text Provided by ERIC

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed

Table 1.9 - Population by age and gender by metropolitan area, 2001

Gender and age	Coterminous U.S.	Atlanta	Baltimore	Boston	Buffalo	Chicago	Dallas	Denver
TOTAL	253,560,271	3.643.568	2.300.858	3 568 848	NOV NA	5 950 420	3000	1000
6-17 years		719 017	445 420	622 640	159 607	3,030,120	3,039,190	458,549,1
6-11 years.	25 231 287	377 013	220 028	324 612	100,037	1,130,300	936,122	3/0,426
12-17 vears	24 257 510	342,008	245,402	20,470	200,440	292,919	332,202	190,291
18-25 veare	22 52 546	247,740	20,430	230,330	167,87	242,001	305,860	180,136
18_10 waste	00,000,040	01,,10	204,310	440,040	662'96	838,308	481,568	269,716
10-13 yadıs	C/C'//6'0	97,143	25,521	76,213	20,556	159,142	92.126	50.789
20-23 years	26,558,971	420,575	208,795	363,827	75,844	679,167	389.443	218 927
26-34 years	30,433,965	555,477	276,697	478,911	91.154	783.107	465 917	274 274
26-29 years	10,146,439	190,022	88 044	155 931	29.045	260,10	464 660	417,412
30-34 years.	20,287,527	365 455	188 653	222 080	62,013	200,011	800'101	82,023
35 years and older.	140 101 046	1 851 356	1 314 425	2 026,300	407.05	0.67,410	304,247	1/9,220
35-44 vears.	44 811 003	721,000	1,41,423	7,020,347	CCB, /B4	3,090,124	1,513,589	1,029,417
45-54 vears	37.673.046	246,000	455,214	705,800	146,384	1,032,350	600,554	375,046
55 years and older	27,043,010	240,021	367,242	240,668	127,567	831,984	431,952	306,060
So years and older	07,047,027	282,549	519,970	816,912	224,004	1,225,790	481,084	348,311
MALES	123,216,620	1 786 230	1 002 605	4 740 452	000 000	000		
6-17 vears	25 340 854	007'00 ''.	200,000	200	900,004	7,0,070,7	1,540,887	367,780
6-11 vagre	10,010,01	400,000	617,122	319,220	155,18	282,095	326,634	189,809
12.17 years	12,310,300	132,400	450,711	156,335	41,357	303,020	169,462	97,209
10-11 years	12,422,047	1/6,183	109,685	152,885	39,995	279,075	157,172	92,600
10-20 years	15,842,932	263,822	126,881	217,576	47,838	422,914	248,773	138,823
10-13 years	3,586,663	51,291	27,806	39,919	10,588	82,818	49,054	26.701
20-22 years	13,256,270	212,531	99,074	177,658	37,250	340,096	199.719	112 122
20-34 years	15,060,540	276,647	131,557	233,914	43,882	390,548	236.426	141.428
Z0-Z9 years	2,009,880	94,628	41,754	75,937	13,835	133,582	81.176	49 275
30-34 years	10,050,661	182,019	89,803	157,977	30,047	256,966	155,250	92 152
35 years and older	65,972,293	877,098	607,949	939,742	227,317	1.433,115	729 054	497 720
35-44 years.	21,991,008	354,639	207,188	326,566	70.382	506 248	302 423	188 212
45-54 years	18,347,079	262,663	172,770	259,613	61.395	399 403	211 418	154 780
55 years and older	25,634,206	259,796	227,990	353,564	95.540	527 465	215,710	157,791
	470 040 004				1		2	131,161
. LIISELS	150,545,051	1,857,338	1,207,253	1,858,396	443,816	3,021,448	1,558,310	976.054
6 44	24,147,859	350,354	218,201	303,729	77,345	556,486	311,489	180,617
45 47	12,313,032	184,533	112,391	158,279	39,089	289,900	162,802	93.082
12-17 years	11,834,827	165,821	105,810	145,451	38,257	266,585	148.687	87.535
18-25 years	16,693,614	253,896	137,435	222,464	48.561	415.395	232 795	130,000
18-19 years	3,390,912	45,852	27,714	36,295	2966	76.324	43 072	24.088
20-25 years	13,302,702	208,044	109,721	186,169	38 594	339.074	180 723	200,24
26-34 years	15,373,425	278.830	145.140	244 998	47 272	302,558	20,00	100,003
26-29 years	5,136,559	95,394	46.290	700 02	15,12	436,000	164,627	740,251
30-34 years.	10,236,866	183 436	98.850	165,003	32,50	133,229	564,00	45,779
35 years and older.	74 128 753	074 258	706,000	100,000	260,25	625,762	148,998	87,067
35-44 vears	22 810 005	367.7AB	200,477	242, 203	270,638	1,657,009	784,535	531,697
45-54 vears	10 205 027	20,740	020,022	342,801	/6,003	526,102	298,131	186,834
55 years and older	22,533,337	70±, 20	100,471	CCU, L82	66,1/2	432,581	220,534	154,280
		- X X X X						

			•	•			-	
Gender and age	Detroit	Los Angeles	Miami	Minneapolis	New Orleans	New York	Newark	Philadelphia
	4 450 490	9 554 663	2 064 841	2 599 055	1 152 254	8.357.548	1.729.081	4,503,442
TOTAL	4, 139,409	0,00,000	200,000	522,000	235,088	1 503 538	328 629	879.743
6-17 years	830,202	2,783,073	200,000	262,033	448,550	787 961	173 605	450 609
6-11 years	436,010	957,476	196,455	267,731		106,301	200,444	420,004
12-17 years	394,194	825,597	191,626	771,967		0/0'01/	133,023	21,021
18-25 vears	504,760	1,313,139	274,584	341,888	_	1,198,093	199,941	550,056
40-40 years	107 811	258,533	57,085	67,695		221,509	40,649	110,857
10-10 years	306 040	1 054 607	217 499	274,193	•	976.584	159,291	419,201
Z0-Z5 years	000,000	24,04,0	258 770	346 745	132 821	1 161 681	215,301	527.850
26-34 years	040,226	224,012,1	20,00	7,0,1	44.040	204 220	86.608	170 575
26-29 years	176,034	408,/42	671,08	113,730	0 0 0	021,470	2000	350,536
30-34 vears	346,006	801,680	172,645	232,947	88,503	710,412	140,000	12,100
35 years and older	2.302.486	4.248.030	1,143,376	1,386,568	625,510	4,494,236	012,089	7,505,791
20 July 20 20 20 20 20 20 20 20 20 20 20 20 20	755 464	1 513 276	360.379	512.413	201,580	1,458,724	326,729	816,276
50-44 years	1000	4 4 4 7 200	282 776	394 770	177 201	1 182 360	265.463	676.308
45-54 years	020,20	100,001	202,70	100.021		4 853 152	303 018	1 073 207
55 years and older	911,785	1,586,965	222,000	4/9,362	•	201,000,1	0 0,000	10.0
•		117,00,	000 000	207 070 4	245 080	2 020 751	826 718	2 140 073
MALES	LZ/'0L0'Z	4,201,173	300,000	007,077,1	70000	101,000,0	169 162	449 674
6-17 vears	425,083	911,989	197,780	202,802	CRO'RLL	800', 707	201,001	0,000
6-11 vears	223.383	489,162	100,216	137,108		402,345	88,944	230,465
7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	201 600	422 827	97.565	131,158		365.245	79,217	219,208
12-17 years	201,033	667,027	125,55	171 840		583 350	907.99	259,640
18-25 years	111'1.07	200,100	000	000,10	10,1	442 475	24 447	FG 624
18-19 years	55,922	133,508	78,740	33,200		100	77,17	
20.25 vears	195.190	533,495	106,910	136,575		469,8/5	(8,559	203,010
24 :00 25	256 324	613 538	127,504	173.062	62,914	260,587	103,466	253,063
20-24 yddis	06 420	206 55R	42 411	56 697		188.089	32.046	81.726
Z6-Z9 years	00,130	200,000	600 40	146 366		372 408	71 420	171 338
30-34 years	1/0,183	400,900	500,00	200,000		2000	455 29A	1 177 696
35 years and older	1,078,205	2,008,645	222,686	010,000	200,002	4,019,224	2000	, i
35-44 vears	369,889	753,677	174,864	226,072		T80,TU/	138,180	392,700
45.54 years	309 384	552,505	133,381	194,814		247,991	126,220	322,699
יייייייייייייייייייייייייייייייייייייי	208 033	702 463	217 441	214,732	•	769,603	170,968	462,228
33 years and older	000,000		· ·	-		•	•	
	2 148 768	4 353 489	1.078.185	1.320.269	607.194	4,426,797	902,364	2,363,369
remarks and a second se	405 440	871 084	100 301	255 588		735.949	160.467	430,069
6-1/ years	+03,13		0000	200,004		205 615	84 662	220 144
6-11 years	212,625		90,240	130,024		0,000	100,11	1000
12-17 vears	192,494	402,771	94,061			350,333	CD8,C/	276,607
40 25 300 30	253 649	646 137	138.928	170.048	83,349	614,743	100,235	270,418
10-£3 years	1000		28 330			108.034	19.503	54,233
18-19 years	00,100		44,000	•		506 709	80 732	216,185
20-25 years	201,760		696,011			000,100	444 000	707 770
26-34 vears	265,719		131,266			460,109	000,111	1,412
26.20 vears	89.896	202.184	43,714	57,101		203,181	34,650	88,850
70.04	175 822		87,552	116 582		397.913	77.185	185,937
30-34 years	620,671	•	200,100	,		2 475 011	520 R26	1 388 096
35 years and older	1,224,281	Ņ	089,710		10000	10,011	020,020	2,000,1
35-44 vears	385,575	159,599	185,515		_	560,757	168,533	423,506
45.54 years	325,853	595,284	149,395	199,957		634,370	139,243	353,608
	010 011	CO3 100	200 704	264 652	140 040	1 083 549	222 050	610.9

Gender and age	Phoenix	St. Louis	San Diego	San Francisco	Seattle	Washington, DC
TOTAL	2,847,270	2.294.731	2.520.050	1 571 529	2 137 012	4 470 020
6-17 years.	556.580	461 474	488 804	213 744	210,101,2	704.01.4
6-11 vears.	293 2 15	231 988	258 328	410042	37.9,07.7	545,107
12-17 vears	263,266	220,300	220,320	20,017	193,8/3	410,987
18.25 ware	777	104,622	500,000	102,932	185,805	
10-23 years	436,/12	284,302	378,025	202,289	281,969	
10-19 years	87,905	62,808	70,171	30,886	53,747	
Z0-Z5 years	348,808	221,493	307,855	171,402	228,222	4
26-34 years	379,337	261,646	331,542	245,662	298,400	587 683
26-29 years	131,912	86.913	111,202	83.376	08 R21	402 624
30-34 years	247.425	174,733	220 340	162.286	100,021	10,261
	1 474 641	1 287 300	1 224 580	002,200	130,079	00,4,000
35-44 vears.	487 871	410 462	1,521,505	909,000	1,175,900	7
	277 478	24.575	10,00	000,182	410,399	
55 years and older	10000	343,320	700,400	249,128	345,300	670,544
	167'600	324,320	099,116	369,126	413,267	782,273
MALES	1416.178	1 096 901	1 243 427	100 007	4 000 034	2000
6-17 vears	285 456	235,440	721,012,1	100,001	1,000,031	2,010,434
6-11 years	100,430	770,440	700,700	8/0'801	194,085	399,417
45-47 years	0/0,001	118,400	132,608	26,750	99,534	209,976
10 JE 100 JE 100 JE	132,382	040,71	118,1//	22,930	95,151	
10-23 years	228,482	138,910	193,226	103,783	142,379	259,361
16-19 years	46,221	32,358	35,641	16,466	27,558	
Z0-Z5 years	182,261	106,553	157,585	87,316	114,820	210 622
26-34 years	196,740	126,565	168,246	128,160	152 674	285 496
26-29 years	68,263	41,950	56.085	43,039	50.410	03 015
30-34 years	128,477	84.614	112,161	85 120	102 265	10,00
35 years and older	705,500	595,986	631.170	439.183	570 203	1 071 160
35-44 years	246,529	203,598	228,604	150 701	211 203	400 545
45-54 years	183,832	165,165	173 322	123 478	170 678	340,010
55 years and older	275,139	227 224	229 245	165,003	188 411	354,040
C L				2000	<u>-</u>	20,100
TEWALES	1,431,092	1,197,830	1,276,622	790,724	1,076,981	2.155.494
b-1/ years	271,125	226,035	238,108	104,065	184,992	381 925
6-11 years	143,144	113,589	125,720	54.062	94 339	201 015
12-17 years	127,980	112,445	112,388	50,002	90,654	180 910
18-25 years	208,230	145,391	184.799	98 506	139 590	264 886
18-19 years	41,683	30,450	34,530	14 420	26,188	717 77
20-25 years	166,547	114.941	150,269	84 086	113,403	727 000
26-34 years	182,597	135.081	163 296	117 503	145 725	200,403
26-29 years	63,650	44 963	55 117	40 337	48,44	202,107
30-34 vears.	118 947	00,118	108 170	10,00	40,4	50,00
35 years and older	769 140	601,203	00,10	770 654	418,78	203,224
35-44 vears	244 242	24.02.	1000	100,074	900,074	1,205,495
45-54 vears	240,142	73,000	896,927	140,880	207,196	424,323
55 woons and older	193,040	178,330	181,036	125.649	174 622	350 918
		(4, 100	1			

¹ Average 2001 civilian noninstitutional population estimated using data from 3 Census Bureau data files: The Civilian Noninstitutional Population of the U.S. by Age, Race, and Sex (CNP Tables); 2000 Census Counts by Age, Sex, and Race (ASR files); and County-Level Population Estimates (CPOP file).

Table 1.10 - ED drug episodes by detailed race and ethnicity: Estimates for the coterminous U.S.<sup>1</sup>, 2001

		Ethnicity		
Race	Hispanic	Not Hispanic	Ethnicity unknown	Total
SINGLE RACE	24 47	243 288		392,700
White	10,4,14		58 740	139 794
Black/African American	435 ac	980,00		3.678
Asian	2 6			1.024
American Indian/Alaska Native	27		255	474
Native Hawaiian/Other Pacific Islander	10		ú.	100.649
Race unknown	110,75			
TWO RACES	•	ď	<u></u>	4-
White + Black/African American	J	<u> </u>		9
White + Asian.	r	2		2
White + American Indian/Alaska Native	7	~		167
White + Native Hawaiian/Other Pacific Islander	÷	ο αC	13	32
White + Unknown	_	<del>, -</del>		-
Black/African American + Asian		•	2	2
Black/African American + American Indian/Alaska Native	α	7		23
Black/African America + Unknown				2
Asian + American Indian/Alaska Native		1 (5		26
Asian + Native Hawaiian/Other Pacific Islander		7	•	7
Asian + Unknown	•		101	15
Native Hawaiian/Other Pacific Islander + Unknown	+		2	•
THDEE DACES			•	•
a Nativ				_
		224 222	227 625	638 484
TOTAL DRUG ABUSE EPISODES	. (9,517)	351,352		. 21 (222

ethnicity are collected as separate data elements, and one or more races for an individual can be collected, when available. This level of detail is not shown in most tables because of the need to report consistently from the data collected using old and new categories. Further, at this level of detail, small sample sizes produce some estimates that are unreliable and could pose a threat to <sup>†</sup> This detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in accordance with the Draft Provisional Guidance on the Implementation of the 1997 Standards for the Collection of Federal Data on Race and Ethnicity (Office of Management and Budget, 10/2000). During 2000, DAWN began to implement the revised Federal standards whereby race and NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. patient confidentiality. Up to 5 race categories can be indicated for each patient, but only those categories that had at least 1 entry are reported here.

ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

**ED Trends From DAWN** 

T-15

Table 2.1.0 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for the coterminous U.S. by half year

% change <sup>2</sup> H1 2001,			16.0
% change <sup>2</sup> H2 2001, H1 2002	-8.5 -14.1 -13.0	-9.1 -12.9 -16.4	-13.3
Jan-Jun * 2002	313,181 97,527 91,687 42,571 55,771 10,079 6,136 2,303 1,257 3,257 3,257 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024 1,0024	251,015 104,687 30,554 13,554 5,802 11,196 9,215 747 23 63,031 47,884 108,081 108,081 89,905	801 55,311 11,289 4,453 17,849
Jul-Dec 2001	342,327 113,472 96,282 48,926 55,347 9,506 8,137 3,115 3,028 1,070 1,661 338	256,934 115,170 30,695 30,695 10,394 10,365 616  9,560 72,355 5,105 54,797 12,454 1,754 107,416 88,971	809 51,634 11,492 4,036 20,597
Jan-Jun 2001	327,232 104,533 96,4533 96,752 44,138 55,164 9,049 6,786 6,786 6,786 1,882 3,074 7,18 7,18 7,18 7,18 7,18 7,18 7,18 7,18	238.874 105,119 30,316 6,040 11,065 9,817 743  21 8,982 63,594 4,011 49,175 103,269 85,529 85,529	504 47,683 11,170 4,463 21,447
Jul-Dec 2000	314,910 104,176 90,1764 47,169 8,638 6,182 2,385 1,859 1,859 1,058 1,058 1,058 59	231,094 97,592 28,259 2,507 10,113 9,748 913,659 10,959 11,517 99,606 81,350	607 41,394 12,013 6,617 20,461
Jan-Jun 2000	309,480 100,347 84,704 47,635 49,028 8,497 7,323 2,125 2,157 2,167 791 2,865 946 68	243,822 106,935 32,317 14,078 6,331 11,848 1,194  8,921 62,451 3,651 11,381 11,381 11,381 103,966 85,843	395 40,979 12,780 7,166 24,207
Jul-Dec 1999	294,956 94,134 89,176 44,786 43,974 6,575 5,717 1,903 2,057 960 1,987 627 627	209,839 94,142 27,762 7,040 9,645 9,545 9,944 1,775 84,873 69,554 1,775	36,128 9,977 5,408 17,523
Jan-Jun 1999	280,762 102,088 79,575 37,406 43,094 5,921 4,730 209 2,427 1,607 573 1,192 573 47	228,686 102,156 31,202 10,896 10,896 1,123 6,940 60,817 1,869 10,207 1,869 86,335 69,182	32,883 11,654 5,969 18,403
Jul-Dec 1998	277,570 93,927 86,254 37,829 38,979 6,706 4,952 792 3,215 1,711 986 895 931	212,785 93,960 25,529 11,754 5,971 7,791 8,206 1,951  5,971 58,426 4,53 44,398 9,475 1,799 86,951 70,496	30,575 12,343 7,724 19,657
Jan-Jun 1998	271,490 91,064 85,757 37,859 37,863 5,547 6,534 51 1,767 1,725 863 387 1,725 1,725	219,919 29,136 28,853 28,853 14 13,015 7,160 8,664 8,064 2,360 4,207 44,410 11,309 2,292 87,169	28,371 13,352 7,382 21,944
Jul-Dec 1997	258,833 86,744 82,359 35,899 32,331 5,946 8,936 1,542 1,542 1,760 845 1,214 1,214 1,214	21,253 91,572 25,361 11,507 7,186 6,527 7,718 2,224  416 5,007 55,455 3,310 40,686 11,460 3,038 85,889 70,852	28,528 13,153 7,477 21,360
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-In-combination Cocaine Heroin Marijuana Amphetamines Methamphetamine MDMA (Ecstasy) LSD LSD LSD PCP Miscellaneous hallucinogens Flunitrazepam (Rohypnol) GHB Inhalants	Antidepressants.  Antidepressants.  Antidepressants.  MAO inhibitors.  SSRI antidepressants.  Tricyclic antidepressants.  Miscellaneous antidepressants.  Phenothiazine antipsychotics.  Phychotherapeutic combinations.  Thioxanthenes.  Miscellaneous antipsychotic agents.  Anxiolytics, sedatives, and hypnotics.  Barbiturates.  Barbiturates.  Barzodiazepines.  CNS stimulants.  CNS stimulants.  CNS stimulants.  Analgesics  Analgesics	Narcotic analgesics/combinations Nonsteroidal anti-inflammatory agents Salicylates/combinations Miscellaneous analgesics/combinations Analgesic combinations NTA

Table 2.1.0 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for the coterminous U.S. by half year (continued)

Drug category <sup>1</sup>	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
Anorexiants	952	981	571	708	727	795	745	383	569	1,038		171.0
Anticonvulsants	5,973	6,407	643	6, - 13 598	405	515	624	396	131	517	294.7	
Antiparkinson agents	1,090	968	666	899	595	448	306	442	544	520		
General anesthetics	0 0	30	6 6 5 5	4	 6 7 16	7 867	 8.047	8 973	10 028	8.187		
Muscle relaxants	0,/40	608,0	, ,	9,	<u> </u>	) '-	7,0,0	) :	:	3		
Miscellaneous CNS agents	•	<del>-</del>	)	:	:	:	•					
RESPIRATORY AGENTS	5,549	969'9	4,559	4,885	3,863	5,578	5,943	5,729	6,510	6,596		
Antihistamines	1,446	1,239	1,231	1,768	1,279	1,761	1,503	7,917	2,195	328,1		
Bronchodilators	651	4/3	370	264	4 - 6	100	909	503	350	333		
Decongestants	331	644	372	283	261	488	287	260	216	473		
Expectorants	2 2 18	3 056	2.007	1.987	1.411	2,483	3,193	2,432	3,265	3,367	_	
Opper respiratory agents NTA.	59	:	:	51		214	123	429	242	242		
CABBIONASCIII AB ACENTS	4 482	4.174		4.722	4.826	4,826	4,522	4,285	5,699	6,569		53.3
Antiadrenemic agents centrally acting	8	356		738	999	750	406	484	1,368	1,196		147.1
Reta-adreneralc blocking agents	1,149	1,081	1,174	066	1,345	1,006	920	1,161	1,221	1,175		
Palcium channel blocking agents	879	722		009	730	629	998	647	739	995		
Olivetics	439	300		447	340	542	202	438	383	584		
Cardiovascular agents NTA	1,174	1,716		1,947	1,749	1,869	1,794	1,555	1,988	2,619		68.4
OTHER SUBSTANCES	23.761	22,742			22,134	22,517	8	20,472	22,139	25,083		
Alternative medicines	83	391				802		453	209			
Anti-infectives	4,655		4,024		3,037	2,640	2,801	2,366	2,916	2,040		
Gastrointestinal agents.	1,679					1,791		1,443	1,349			
Hormonee	1,677					1,908			2,237			
Nutritional products	855	1,088				1,193		610	839			
Conical agents	233	222				380					_	
Daid Inknown	13.025				12,777	11,780	13,918	12,073				
All other substances NTA	1,553	1,621	1,527			2,023	1,621		1,042	1,385		
TOTAL DRIG ABLISE EPISODES	261.719	271.862	270,570	278,243	276,524		298,890		326,699		-	
TOTAL DRUG ABUSE MENTIONS	470,085	491,409		4,	504,795	۳,		4,	599,261	<b>"</b> /		
TOTAL ED VISITS (in 1,000s)	45,378	44,309		45,389		47,747	48,416	49,962		50,017	-1.1	r.o.

1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002) Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, LSD = lysergic acid diethylamide, for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (\*--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

エセシ

Table 2.2.0 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for the coterminous U.S. by year

T-18

iable 2.2.0 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for the coterminous U.S. by year (continued)

2000, 2000, 2001		60.2	10.7 322.8 -48.7 15.1 6.1 14.9 6.0	
% change <sup>2</sup> 1999, 2001	38.5	67.7 244.6	რ 	
% change <sup>2</sup> 1994, 2001	595.5 56.5 58.4 -72.0 400.0 55.5 55.5 -85.0			
Total 2001	953 14,642 526 985 10,01 12,238 4,112 852		42,011 662 5,282 2,732 4,032 1,449 2,600 23,923 1,871 638,484	·
Total 2000	1,540 16,849 1,139 755 759 15,914 11,521 11,521 11,521 1,049	5,675 5,676 337 3,148 1,156 1,956 1,049 3,662	45,746 999 999 5,441 3,514 2,120 615 25,698 3,644 1,099,306	
Total 1999	1,436 1,003 1,003 1,264 13,717 .:: 8,749 3,047 955	3,398 195 195 1,401 1,330 1,330 1,630 1,530 1,530 1,530 1,530 1,530	52,721 6,129 3,230 4,436 1,878 1,878 633 32,804 2,934 554,767	
Total 1998	1,552 13,990 1,134 1,895 10 13,612 0 11,258 2,470 4,54	5,064 5,064 1,003 1,003 1,406 668 3,141	45,758 8,493 8,497 4,072 3,487 1,787 430 23,704 3,148 3,148	89,683
Total 1997	2,349 12,193 786 2,564 12,318 11,593 2,770 1,084	5,117 1,173 1,603 1,511 1,511 2,182	49,214 312 9,743 3,334 2,305 2,869 2,869 526,818	
Total 1996	2,655 11,496 865 3,039 13,520 12,856 2,222 1,536	634 634 6745 10,242 1,931 1,035 3,525	45,156 661 10,142 3,997 2,405 20,271 3,469 513,933	91,189
Total 1995	10,455 10,455 10,455 3,463 3,463 13,733 13,915 2,739 2,739 2,063	2,000 6,232 478 12,016 1,291 2,598 3,095 1,209 1,209	57,781 13,575 5,418 4,060 3,032 797 27,412 3,376 513,519	88,548
Total 1994	2,354 9,358 1,263 3,519 12,223 15,747 15,747 2,805	2, 150 6, 849 12, 939 1,293 1,293 2,827 2,658 1,105 5,090	64,825 12,982 5,816 4,080 3,171 897 3,200 518,880	
Drug category¹	Anorexiants	Decongestants	Alternative medicines	TOTAL DRUG ABUSE MENTIONS

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

ERIO Provided by

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 2.2.1 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Atlanta by year

% change <sup>2</sup> 2000, 2001		57.8 157.4	-34.9	24.5	30.1				900.0
% change <sup>2</sup> 1999, 2001		107.2 182.3 -69.2	-60.0				-100.0	-23.4	17.1
% change <sup>2</sup> 1994, 2001			8,300.0		84.0	171.4	-100.0 116.9 52.2	63.3 51.4 52.3	112.7
Total 2001	21,072 6,878 8,891 848 3,486	175 175 80 80 35	1 2 8 2 :	6,183 2,527 626	298 138	190 197 20	167 1,668	2,632 2,186	10 1,108 328 93 640
Total 2000	16,364 6,436 6,229 485 2,431	109 68 70	129	5,575 2,542 503	229 113	161	136	1,257 277 48 2,453 2,094	1,034 326 151 151
Total 1999	13,836 4,952 5,236 2,515	83 13 28 28 28 28 3	142 142 18	5,644 2,777 647	263	219 165 31	1 1,919	1,392 285 47 2,228 1,845	0 1,018 280 96 443
Total 1998	14,509 4,660 5,980 473 2,633	162 33 108 108	22 88: 72	5,658 2,766 592	236	169 162 : 40	4 113 1,970	1,374 300 43 2,304 1,931	 0 966 315 103 533
Total 1997	11,638 4,714 4,244 384 1,577	21 0 0 1 2 2 8 2	3 :12 : :	4,544 2,002 527	174	128 124 ::	1,309	917 275 42 1,819 1,496	635 274 274 87 493
Total 1996	13,984 6,140 5,434 388 1,547	135	4 O & & O	5,098 2,218 580 0	198	95 0	1,418 1,418	959 311 60 1,948 1,568	632 289 175 468 0
Total 1995	16,868 7,825 6,515 404 1,671	.:. 0 162 142	10 17	5,430 2,012 511	199	33	1,301	832 326 56 1,952 1,603	 638 305 110 542 0
Total 1994	15,606 6,971 6,190 443 1,544	95  217 35	25 3	5,241 1,779 460 	162 224	178 89 ::	1,096 96	717 283 45 1,739 1,435	521 286 157 457
Drug category¹	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin. Marijuana Amphetamines	Methamphetamine MDMA (Ecstasy) Ketamine LSD PCP Miscellaneous hallucinooens.	Fluntrazepam (Rohypnol). GHB	OTHER SUBSTANCES OF ABUSE	SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants	Antipsychotics. Phenothiazine antipsychotics. Psychotherapeutic combinations.	Intoxanthenes.  Miscellaneous antipsychotic agents.  Anxiolytics, sedatives, and hypnotics.  Barbiturates.	Benzodiazepines Misc. anxiolytics, sedatives, and hypnotics CNS stimulants CNS AGENTS Analgesics Antimicraine anents	Cox-2 inhibitors.  Narcotic analgesics/combinations.  Nonsteroidal anti-inflammatory agents.  Salicylates/combinations.  Miscellaneous analgesics/combinations.  Analgesic combinations NTA

able 2.2.1 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Atlanta by year (continued)

% change <sup>2</sup> 2000, 2001		59.6 102.9		86.0	825.0	30.1
% change <sup>2</sup> 1999, 2001	65.3	64.1 72.5 119.2	31.8	64.3	-63.2	41.9 39.9 21.7
% change <sup>2</sup> 1994, 2001	166.7			-52.8	126.1 1,133.3	35.6 30.7
Total 2001	31 200 .:: 20 20 176 0	233 69 120 201 141 141	<u></u>	677 12 84		14,456 27,254 1,249
Total 2000	159 159 6 18 0 0 0	44 222 222 34 34 34 34 34 34 34 34 34 34 34 34 34	70 15 3	364 12 74 16	33 23 171 31	11,112 21,939 965
Total 1999	121 151 15 233	24 10 10 10 10 10 10 10 10 10 10 10 10 10	85 11 12 10 23	412 4 75 28	22 207:	10,189 19,480 1,026
Total 1998	2 2 29 206 206 0	25. 85 :: 84 :: 25. 85 :: 84 ::	£ :4 6 :8	401 97 97	22 8 8 8 8 8 8 8	10,717 20,167 1,032
Total 1997	26 :: : 205	45. 9 9 9 8. 	86 13 24 4 37	504 .:: 97 47	38 29 265 17	8,003 16,182 1,041
Total 1996	103 15 15 0 0	235 79 7 43 93	120 32 25 25 47	578 2 123	33 4 10 33 4 8	9,400 19,083 1,125
Total 1995	30 68 20 21 21 209 0	25 84 85 85 85 85 85 85 85 85 85 85 85 85 85	95 27 16 16 38	<del>-</del>	35 18 35 35 38 38	11,063 22,298 1,129
Total 1994	75 75 29 0 173	175 48 29 3 83	113 22 16 16	1,435	23 33 1,158 47	10,660 20,847 1,140
Drug category <sup>1</sup>	Anorexiants	RESPIRATORY AGENTS	CARDIOVASCULAR AGENTS	OTHER SUBSTANCES	Gastronnesuna agents  Hormones  Nutritional products  Topical agents  Drug and and agents  All other substances NTA	TOTAL DRUG ABUSE EPISODES

This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements 2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

ERIC Full Text Provided by ERIC

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

Table 2.2.2 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Baltimore by year

% change <sup>2</sup> 2000,				10.2	49.7			40.8	-37.5	•	133.3	700.0	26.8	24.3	5.4				26.1	-14.3		30.6	28.6	76.9	26.4	-18.0	29.4	25.3	27.1	300.0	37.2	702	-21.8
% change <sup>2</sup> 1999, 2001		-18.4 -28.8			40.0	114.3	500.0	45.3	-54.5	-100.0	-66.7	700.0	17.5	12.8		100	2	20.0	14.5	40.0	0.001-	24.6	15.3	31.3	15.3	-15.3		23.8	25.5		39.4	42.0	-22.4 -100.0
% change <sup>2</sup> 1994, 2001		-37.3		131.9					-73.7		-66.7		33.3	46.3			-356	74.2	47.3	89.5	-100.0	2	79.0	243.8	88.1	0.14	1.47-	8 6 8 6	102.5		216.9	-56.4	-32.2
Total 2001	14,586	2,911	4,481	1,786	9	75	9	23	O GO	10	9	· 60	6,191	2,225	350	156	87	108	87	<u> Ф</u> С	50	81	1,765	306	435,	<u> </u>	7	3,206	3,032	8	2,624	51	208
Total 2000	14,992	2,628	5,405	1,620	9	49	4 (	449	200	0 6	s 5	<del>-</del>	4,882	1,790	332	166	63	102	69	~ ~	0	62	1,372	173	۲,0,۲	17	- 1	2,558	2,300	7	138	99	266
Total 1999	19,505	3,566 6,921	666'9	1,679	<u></u>	35	6	25 45	=	0 6	- 81	<del>-</del>	5,268	1,973	34.	175	92	06	9 9	2 -	- 0	65	1,531	233	471,1	25.	0	2,389	2,4	0 0	1,882	88	268
Total 1998	18,403	5,079	6,711	1,495	9	9	<del>ہ د</del>	S 23	9	5 6	24.0	4	5,138	1,819	346	146	98	111	9	20	2	83	1,346	162	77.	29	2 573	2,3,7	4	0,7	174	106	¥ 6 0
Total 1997	17,150	6,253	5,863	89	7	0.0	7 7	87	ro c	5 6	<u> </u>	4	4,906	1,908	350	163	06	£ 8	2 6	7	<del>-</del>	•	<del>-</del> -	84.7		52		1 748	2	7,40	185	106	304
Total 1996	22,442	8,515	8,093	200	9	7	2 0	2 86	40	5 6	<u>æ</u>	7	4,640	1,50,1	ر دري دري	170	80	8 5	82	90	က	62	1,131	102	<u> </u>	35	1 481	1 299	4	737	176	62	303
Total 1995	22,937	8,603	8,207	35	4	<b>∞</b> c	- 13. c	222	90	5 6	17	9	4,180	- 54,	<del>7</del> 6	162	127	2 20	47	<del>۳</del>	9	8 2	924	, a	182	33	1 598	1,400	က	94 0	23.	133	4 4
Total 1994	22,247	8,882	7,471	55	4	0	: &	900	<b>60</b> C	50	8	,	4,645	170,1	ţ :	142	135	62	22	5 <sup>©</sup>	က	9 9	988	720	178	29	1,740	1,497	<u>.</u>	828	240	117	) O
Drug category¹	MAJOR SUBSTANCES OF ABUSEAlcohol-in-combination.	Cocaine	Marijuana	Amphetamines	Methamphetamine	MUMA (Ecsiasy) Ketamine	LSD	PCP	Miscellaneous hallucinogens Flunitrazeoam (Rohvonol)	GHB.	Inhalants	Computations N.A.	OTHER SUBSTANCES OF ABUSEPSYCHOTHERAPEITIC AGENTS	Antidepressants	MAO inhibitors.	( SSRI antidepressants	Miscellonome artificial and a Miscel	Antipsychotics.	- > Phenothiazine antipsychotics.	Psychotherapeutic combinations	Thioxanthenes	Miscellarieous anapsychotic agents	Barbiturates	Benzodiazepines	Misc. anxiolytics, sedatives, and hypnotics	CNS stimulants	CNS AGENTS	Analgesics	Antimigraine agents	Narcotic analgesics/combinations.	Nonsteroidal anti-inflammatory agents	Miscellaneous analoesics/combinations	Analgesic combinations NTA.

—© ¬ able 2.2.2 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Baltimore by year (continued)

% change <sup>2</sup> 2000, 2001	-37.5 -11.2 33.3	26.8	-18.5	-33.3 -25.0	-70.0	20.0	16.7	83.6 8	i	-50.0 87.5	54.6	44.4 4.4	-36.8		62.5	80.1	-56.0	,	4. 3.	4.6
% change <sup>2</sup> 1999, 2001	44.4 -10.3 100.0 20.0	16.4		-50.0	50.0	20.0	-36.4	-50.0	0.09	40.0	15.6	-33.3	45.5	-18.2	14.3	25.3	42.1	-18.0	-16.1	5.5
% change <sup>2</sup> 1994, 2001	-78.3 -20.0 -79.3	-28.3	-59.2 -40.0	-90.0 -90.0	-50.0	-20.0	-46.2	-69.6	-57.1	-83.3 -51.6	43.3	177.	-50.0	41.9	116.7	40.9	-35.3	-26.7	-22.7	24.0
Total 2001	87.4	0 7.0	12	N 6	33	i en	56	7	9	15.2	651	24.5	12	<u>æ</u> .	<u> </u>	560	-	11,625	20,777	1,024
Total 2000	8888	26.0	65 15	<del>ന മ</del> േ	10	2	48	- 8	9	4 00	421	21	19	<u>0</u>	ກ «ດ	311	25	11,505	19,874	9/8
Total 1999	97 2 5	610	₹ 5	4 1	2 2 2	7	88	4.	15	25	563	36	22	2 '	~ 6	447	19	14,171	24,772	9/6
Total 1998	116 0 17	<u> </u>	16	4 0	3 2 5	87	69	ဂ္ဂ ဖ	15	4 4	612	52	31	52	77	475	12	13,736	23,541	931
Total 1997	13 92 12	28.0	93	7 -	. <del>0</del> 4	, ro	79	7 4	9	<u>4 4</u>	905	- 89	22	<u>⊕</u> (	жо ил	754	27	12,755	22,055	8/3
Total 1996	24 82 6	0 25 0	19	<u> </u>	- W	4	87	4 4	12	11 26	1,364	<u> </u>	20	24	4 4	1,190	35	15,994	27,082	865
Total 1995	16 93 4 19	900	98	9 =	. ro 4	. r.	8 4	<u>6 2 </u>	52	<del>7</del> <del>7</del>	959	: 6	37	33	9 -	764	=	15,966	27,117	838
Total 1994	23 86 5 29	- 6 0	130	20	9 6	9	104	23.4	4	3 12	1,149	105	24	31	<del>6</del> a	948	17	15,863	26,892	825
Drug category <sup>1</sup>	Anorexiants	Muscle relaxants	RESPIRATORY AGENTSAntihistamines	Bronchodilators	Expectorants  Expectorants  Inner receiptory combinations	Respiratory agents NTA	CARDIOVASCULAR AGENTS	Antiadrenergic agents, centrally acung Beta-adrenergic blocking agents	Calcium channel blocking agents	Diuretics	OTHER SUBSTANCES	Alternative medicines	Gastrointestinal agents.	Hormones	Nutritional productsTonical agents	Drug unknown.	All other substances NTA	TOTAL DRUG ABUSE EPISODES	TOTAL DRUG ABUSE MENTIONS	TOTAL ED VISITS (In 1,000s)

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

111

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

Table 2.2.3 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Boston by year

% change <sup>2</sup> 2000, 2001	16.1 16.9 20.3 12.7 109.1	13.5	-50.0	-100.0 16.2 16.0	20.6 27.0 44.3 46.5
% change <sup>2</sup> 1999, 2001	228.6 60.9	33.2	-62.9	26.4 58.6 25.4	63.6 9.0 9.0 9.0
% change <sup>2</sup> 1994, 2001	70.0 250.0 2,700.0  -69.4 -53.1	4	-31.0 -75.6 -63.2 -92.4	-54.8 -68.1	146.3 -53.7 -84.4 -33.8
Total 2001	19,207 5,818 4,933 3,423 3,423 140 140 10 331 28 31 31 31	10,587	380 170 170 247 23	223 4,181 536 3,388 257	4,101 3,772 13 2,902 203 585 0
Total 2000	16,539 4,976 4,999 3,867 2,945 369 125 2,945 125 20 111 113 20 20 20 20 20 20 20 20 20 20 20 20 20	9,324	369 469 161 349 307 49	255 3,599 2,920 235 52	3,401 2,971  2,011 233 127 591
Total 1999	13,272 4,439 3,560 1,960 12 12 12 14 14 14 14 15 16 17 18 17 18 17 18 18 18 18 18 18 18 18 18 18 18 18 18	7,947	380 380 309 62	245 3,308 338 2,701 269	2,674 2,305 1,488 257 78 481
Total 1998	15,648 2,738 2,907 180 180 181 181 181 181 181 181 181 181	9,229 5,353	3 411 187 358 238 86 86	152 4,090 347 3,454 288 66	3,050 2,631  0 1,611 241 156 618
Total 1997	12,775 4,890 3,332 2,500 1,768 13 14 4 4 31 0 0	9,617	563 320 438 294 115	1 178 3,977 3,264 3,264 3,89	2,871 2,461 3 0 1,109 397 302 650
Total 1996	14,619 5,351 7,27 2,729 116 3 3 1 18 28 28 118 118 118	10,294 5,942	572 477 477 433 416 222	10 184 3,929 317 3,072 540 102	3,151 2,592 .:. 0 1,082 395 272 832
Total 1995	17.487 6,297 5,267 2,956 2,401 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	12,550 6,995 1,641	540 693 693 693 760 760 760	252 4,693 3,827 504	3,645 3,041 0 1,375 448 303
Total 1994	15,485 5,932 4,810 2,563 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859 1,859	12,946 7,374 1,930	806 697 411 672 301	332 4,659 288 3,803 568 113	3,688 2,937 2 1,178 438 435 884
Drug category¹	MAJOR SUBSTANCES OF ABUSE.  Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines. Methamphetamine Moth (Estasy). Ketamine. LSD. P.CP. Miscellaneous haltucinogens. Fluritrazepam (Rohypnol). GHB. Inhalants.	OTHER SUBSTANCES OF ABUSEPSYCHOTHERAPEUTIC AGENTSAntidepressants	MAO inhibitors	Thioxanthenes	Analgesics

-© Table 2.2.3 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Boston by year (continued)

Drug category¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
AnorexiantsAnticonvulsants	45 360	33	18 339	282	17 275	15	10	17	-62.2		-23.2
Antiemetic/antivertigo agentsAntiparkinson agents	44 88	: 4	10	: :	14 15	: <del>4</del>	<del>6</del> <del>6</del>	: :	:		
General anesthetics	233	2,0	137	<del>- 8</del>	- 85	0 83	170	0 8	-64.4	_	
Miscellaneous CNS agents	30	0	0	0	90	0	0	0			
RESPIRATORY AGENTS	211	245	201	122	127	94	137	124	-41.2	85.7	
Bronchodilators	28	98	1 00 8	16	: 9	; ;	123		-89.7		
Decongestants	: 48	31	ਲ :	40	19 25	0 0	16.				
Upper respiratory combinationsRespiratory agents NTA	: 82	106	<b>%</b> :	59 12	040	.: 42	4 t	43 0	-54.7		
CARDIOVASCULAR AGENTSAntiadranernic anents centrally action	239	252	195 55	199	103	133	122	121	-49.4		
Beta-adrenergic blocking agents.	72	<u> </u>	52	68	38	29	33	29	-59.7		
Diuretics. Cardiovascular agents NTA.	14	3 : 2	3 12	3 : <b>8</b>	17	36	: : 88	<u> 4</u>		-85.7	
OTHER SUBSTANCES	1,433	1,413	806	765	595	443	725	831			
Altemative medicines	148	144	132	107	: 22	38	35	10	-65.5		900.0 45.7
Gastrointestinal agentsHormones	90	98	22 33	71	41	32	14 4 1 4 4	37			
Nutritional products	46	29	8	13	31	<u></u> 6	12	23		155.6	91.7
Topical agents	12	8 66	14 507	7	376	288	: :		241./	:	፥
All other substances NTA	<u>e</u>	55	37	4	42	33	49	10	-87.7	-69.7	-79.6
TOTAL DRUG ABUSE EPISODES	15,374	16,067	13,537	12,224	13,657	11,669	14,902	16,853		4.4.4	13.1
TOTAL DRUG ABUSE MENTIONS	1,679	30,037	1,714	1,568	1,556	1,518	1,584	29,795 1,617		6.5	15.2

1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. (2002). The Multun Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

Table 2.2.4 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Buffalo by year

% change <sup>2</sup> 2000, 2001	-32.0	-70.0 -100.0 -83.3 -100.0	-56.4	52.2 63.6 59.5 59.1	-100.0	-70.0	-32.6 -67.5 25.0
% change <sup>2</sup> 1999, 2001	.39.3 .50.0 .51.5	200.0 -100.0	31.5	-37.1 -76.5 -58.3	50.0	21.1 62.5 32.3 37.3	65.5 -52.3 -66.7
% change <sup>2</sup> 1994, 2001		-50.0 -100.0 -100.0	-36.2 -75.1	-76.3 -81.0 -82.4	-100.0 -100.0 -57.1 -45.7	-32.4 -78.6 45.0 67.4	345.4 -75.4 -86.6 -41.0
Total 2001	3,981 1,548 1,220 607 77 77 4 8 8 8	w00+00	1,955 423 44	, <u> </u>	36.7	92 92 3 1,076 1,023	864 31 115 0
Total 2000	3,717 1,393 1,018 681 553 255 25 18	<u>0</u> - 0 0 4 0	1,657 477 101	23 33 46 2	345 26 26 37 38 38 38 38 38 38 38 38 38 38 38 38 38	914 865	685 46 40 92 0
Total 1999	3,441 1,222 1,119 2,222 493 28 7 7 7 16	- 400-0	1,487 437 109	25.57	310 229 29	813 813 745	522 65 39 119
Total 1998	3,57 1,22 1,22 1,1 1,1 1,22 1,2 1,2 1,2 1,2	040000	1,358 392 87	22 22 15 24	285 1585 1585	65 953 566	300 79 37 150
Total 1997	3,980 1,448 1,526 468 472 9 9 0 0	0001-	1,305 468 116	2828.	0 0 4 9 E C	291 591 512	24 1 139 0 0
Total 1996	5,061 1,835 2,203 2,203 512 20 9 0		1,621 561 117	1 2 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	38 8 32 32 36 36 36 36 36 36 36 36 36 36 36 36 36	85 18 770 675	310 99 75 190
Total 1995	3,218 1,140 1,333 379 295 22 6 0 0	0 0 0 1 1 2 0 0	1,654 591 153 0	38 3 6 6 7	35.5 23 23 23 23	103 26 703 620	205 127 83 198
Total 1994	2,831 1,136 11,136 100 100 101	9 - 0 0 2 5	1,948 663 177	93 21 51	22 1 2 1 1 2 2 1 1 2 4 9 2 4 9	136 742 611	194 126 97 195 0
Drug category¹	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin Marijuana Amphetamine MOMA (Ecstasy). Ketamine	Miscellaneous hallucinogens Funitrazepam (Rohypnol) GHB Inhalants Combinations NTA	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS Antidepressants MAO inhibitors.	SSRI antidepressants	Psychotherapeutic combinations Thioxanthenes Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates Benzodiazepines	Misc. anxiolytics, sedatives, and hypnotics	Narcotic analgesics/combinations. Nonsteroidal anti-inflammatory agents. Salicylates/combinations. Miscellaneous analgesics/combinations. Analgesic combinations NTA

Table 2.2.4 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Buffalo by year (continued)

% change <sup>2</sup> 2000, 2001	-100.0	-100.0 -100.0 300.0 -100.0	-100.0	85.3	-70.0 -83.3	94.2	5.2
% change <sup>2</sup> 1999, 2001	-50.0	-75.0 -100.0 100.0 100.0	-50.0 -100.0 -50.0 -75.0	117.3	-70.0	80.0 -80.0 250.0 139.3	-3.5
% change <sup>2</sup> 1994, 2001	-50.0 -55.0 -100.0 -100.0	-76.2 -83.3 -100.0 -100.0 -66.7 -42.9	-68.4 -100.0 -50.0 -92.9 -65.7 -54.5		-96.1 -94.7	-42.9 -83.3 27.6 -72.7	-14.4
Total 2001	<u> </u>	<u> </u>	<u> </u>	428	<u>ი</u> ← 0	407 1 1	3,356 5,935 278
Total 2000	9200027	<u> </u>	20 3 4 4 9 9 9	231	500	207	2,899 5,374 264
Total 1999	24 0 0 36 0	<u> </u>	44046	197	544	168	2,711 4,927 288
Total 1998	22 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	<u> </u>	£ w w + 0 w	289	18	215	2,683 4,934 272
Total 1997	26 0 0 0 0 0 0	£ 0 0 € 0 € 2	20 - 7 3 6	190	25 6 4	<u> </u>	2,812 5,285 268
Total 1996	22 2 10 0 52 0	94 01 10 10 10 10 10 10 10 10 10 10 10 10	13 0 2 2 0 7	231	6 <del>4</del> 51 c	7 7 149	3,587 6,682 294
Total 1995	20 20 11 47	<u> </u>	20 4 9 8 9	299	4 6	222 3	2,714 4,871 300
Total 1994	40 40 5 16 0 67	82 <u>+5</u> 22	38 1 9 7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	442	19	3.00 tt	2,745 4,779 325
Drug category¹	Anorexiants	RESPIRATORY AGENTS	CARDIOVASCULAR AGENTS	OTHER SUBSTANCESAlternative medicines	Anti-infectives. Gastrointestinal agents.	Nutritional products Topical agents Drug unknown All other substances NTA	TOTAL DRUG ABUSE EPISODES

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.



NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 2.2.5 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Chicago by year

Drug category¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000,
MAJOR SUBSTANCES OF ABUSEAlcohol-in-combination	26,334	27,655	31,552	38,752	38,138 9,318	38,128 9,228	44,908 10,236	45,283 10,307	72.0 39.2	18.8	
Heroin Heroin Marijuana.	4,737 2,226	10,702 4,702 2,922	12,688 6,268 3,531	14,373 8,602 4,424	13,642 9,316 5,002	13,399 9,629 4,555	12,454	16,202 11,902 5,186	151.3	20.9	
Amphetamines	72	<u>4</u> 8	194 28	23	181	204 22	386	, 409 604 604	468.1	100.5	:
MDMA (Ecstasy) Ketamine	50	<b>®</b> O	1 22	33	.: 55	103	215	121	1,110.0		43.7
PCP Micelland	780	278 873	129 537	468 468	120 352	138 631	115	69 874	-72.9	-50.0 38.5	40.0
Miscellareous naturangens	40	<u></u>	ස <u>ි</u> 4	: 45	53	33	\$ <del>0</del>	200	-20.0		-51.1
GHB. Inhalants. Combinations NTA.	0 9 6	တ ဆွ ဝ	8 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	27 0	69 4 5 	135	139 27 	<b>2</b> 00 ::	-56.5	-53.5	-25.2
OTHER SUBSTANCES OF ABUSE	10,908	10,752	10,861	11,727	10,206	9,740	10,541	12,534		28.7	18.9
Antidepressants	18	20 0	803	80 8	825	798	813 0	879	-100.0		
Trockle antidepressants	290	312	319	312	212	412 178	425 124	455 157	47.5		
Miscellations andoepressants	387	335	383	239	221	300	264 216	306	138.4	(	41.7
Psychotherapeutic combinations. Thioxanthenes.	23.0	8 8	2 =	5	00	ÿ <u>:</u> 0	300	Q : :	7:L <b>0</b> -	4. 0.	
miscallamedus antipsychouc agents	230 2,679 344 1,821	2,820 410 1,959	3,357 524 524	3,250 3,250 525 2,264	173 2,695 377	2,662 330	3,365 404	3,691	37.8	38.7	43.5
Misc. anxiolytics, sedatives, and hypnotics	513	451	455 78	111	417	421	397	530 89 89	e e	9	33.5
CNS AGENTS	4,570 4,148 21 0	4,496 4,101 16	4,761 4,316 5 0	5,348 4,857 10	4,775 4,286 14 0	4,646 4,183	4,579 4,118 10	6,099 5,629 0	33.5 35.7 -100.0	34.8	33.2 36.7 -100.0
Narcotic analgesics/combinations	1,751 649 440	1,780 581 458	1,966 547 488	2,582 674 395	2,292 551 383	2,574 420 342	2,368 484 325	3,775 521 300	115.6 -19.7 -31.8	46.7 24.0	59.4
Miscellaneous analgesics/combinations	1,280	1,266	1,305	1,193	1,047	840 0	910	1,011	-21.0	20.4	

#### Table 2.2.5 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Chicago by year (continued)

% change <sup>2</sup> 2000, 2001	-39.0	29.5	86.7	-7.8 683.3	-23.0
% change <sup>2</sup> 1999, 2001		166.7	43.3 125.0 65.6	11.6 683.3 -39.1	24.8 20.8 4.6
% change <sup>2</sup> 1994, 2001	-65.2	-70.4	-38.9 45.1 -49.1 -83.7	41.3 1,075.0 -56.7 -48.0 -59.2	-50.9 -50.9 102.3 52.0 55.3 7.5
Total 2001	255 256 13 16 0 0 158 ::	268 56 24 24 16 16 16	192 27 28 27 7	1,011 474 877 833 244	502 89 32,647 57,817 2,306
Total 2000	41 269 29 8 8 0 110	207 50 9 22 14 103	167 26 15 30 19	0,096 158 158 64 64 65 65	652 79 30,327 55,449 2,257
Total 1999	268 36 25 0 0 0	220 56 27 17 107	134 28 24 12 9	906 127 55 87 32	510 80 26,154 47,867 2,204
Total 1998	50 249 37 29 0	253 39 24 22 13 150	174 33 45 27 12 58	1,193 6 185 40 49 61	808 38 26,206 48,344
Total 1997	243 243 29 44 0	174 30 27 29 13 70	199 4 4 1 1 4 4 1	1,503 12 221 87 87 58 59	995 61 26,875 50,479 2,197
Total 1996	32 260 10 38 	187 35 38 32 12 66	158 19 41 68 68 23	1,134 13 187 75 75 70	600 77 23,522 42,412 2,204
Total 1995	32 198 255 51 0 0	325 42 81 21 137	158 24 57 50 50	1,754 236 66 77 63	1,210 80 21,883 38,407 2,216
Total 1994	23 202 17 46 0	35 8 8 8 8 1 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	314 26 51 51 43	1,723 4 337 106 102 103	1,022 44 21,484 37,241 2,145
Drug category¹	Anorexiants	RESPIRATORY AGENTS	CARDIOVASCULAR AGENTS	OTHER SUBSTANCES Alternative medicines Anti-infectives Gastrointestinal agents Hormones Nutritional products Topical agents.	Drug unknown. All other substances NTA

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an



ONS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. estimate with an RSE greater than 50% has been suppressed.

Table 2.2.6 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Dallas by year

Drug category¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% cnange- 1994, 2001	% cnange 1999, 2001	% change 2000, 2001
MAJOR SUBSTANCES OF ABUSE	4,004	4,330	4,189	5,515		6,248	6,750				-11.7
Ocaine	1,442	1,457	1,393	1,778	2,586	2,106	2,180	1,770	22.7	-16.0	-18.8
Heroin	242 470	264 549	33.1 553	505 946		428 1.172	478 1.225				
Amphetamines.	92	133	120	263		307	35.			23.1	
Methamphetamine	152	203	115	159		100	135				
MDMA (Ecstasy)	21	27	2 2	4		24	7 5				
Ketamine	107	133	4 4	<u>۲</u> ۳		105	0 29			266.7	
PCP	27	65	78	3 %		95	2 2				
Miscellaneous hallucinogens	Ω.	7	19	72		11	12				
Flunitrazepam (Rohypnol)	<del>- ,</del>	4 5	: 8	<del>2</del> 5		υ,	4 (	•			
Unbalants.	- 99	36	57	2 2		<u> </u>	169	128	1,063.6		
Combinations NTA	7	· ·	^	:		6	? ;				
OTHER SUBSTANCES OF ABUSE	5,307	5,310	4,983	5,913	5,866	5,197	5,726	6,156			7.5
PSYCHOTHERAPEUTIC AGENTS	2,110	2,318	2,191	2,554	2,669	2,322	2,494	2,866	35.8	23.4	14.9
Antidepressants	633	92	728	801	774	8	830	832	31.4		
MAO Inhibitors	0 50	22	0 00	4 6	0	0	0	1			
SSKI anudepressants	4 7 6	265	200	302	306	286	276	292	ì		
Miscellaneous antidenressants	127	187	302	762	253	27.0	208	2 2	-31./ 170 E		
Antipsychotics	245	223	182	191	192	172	158	215	-	25.0	36.1
Phenothiazine antipsychotics	106	22	2	29	69	79	23	23	-78.3		·
Psychotherapeutic combinations	<del></del> 0	:	က	: 3	<del> ,</del>	<del></del> (	0	<del></del> (			
Miscellaneous antipsychotic agents	130	: <del>I</del>	: 5	108	121	143	135	183	40.8		35.6
Anxiolytics, sedatives, and hypnotics	1,183	1,322	1,212	1,487	1,654	1,322	1,453	1,780	50.5	34.6	22.5
Barbiturates	787	87.	259	114	112	123	114	110	7,		7
Misc. anxiolytics, sedatives, and hypnotics.	321	368	382	337	342	223	311	323	2	37.3 44.8	
CNS stimulants	49	78	89	9/	49	26	53	39			
CNS AGENTS	2,258	2,156	2,057	2,468	2,358	2,116	2,383	2,514		18.8	
Analgesics	1,807	1,779	1,673	1,989	1,990	1,729	1,966	2,011			
Antimigraine agents	<u></u>	<u> </u>	m c	~ 0	= -	<u>1</u>	<u>თ წ</u>	æ u			
Narcotic analgesics/combinations.	547	467	524	730	780	717	775	925	69 1	29.0	10.4
Nonsteroidal anti-inflammatory agents.	410	469	387	416	390	8	382	326	-20.5	0.53	-14.7
Salicylates/combinations.	242	22.	162	190	143	113	155	8	-61.2		-39.4
Miscellaneous analgesics/combinations	297	615	989	444	999	537	627	93 <del>4</del>	7		
Alagasic Collibriations INTO	-	:	:	5	5	:	:	5	-100.0		

# Table 2.2.6 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates

% change <sup>2</sup> 2000, 2001			-100.0	t o			100.0 -52.0	-81.8																	3.5
% change <sup>2</sup> 1999, 2001		÷	48 9	2		45.1		-85.7												153.8					16.2
% change <sup>2</sup> 1994, 2001	-64.0 41.3	-63.5	33.0	S		Ö	-69.2		٠	.54.7		-75.0	-63.6	-45.9		:	-70.1	43.3	-42.2		84.7		26.4	30.1	27.3
Total 2001	18 178	14	274	i	239	74	<u> </u>	7	135	2	4	œ	<u>φ</u> 1	33	459	16	6	\$ C	26	33	218	25	6,500	12,114	1,051
Total 2000	25 191	7 1	4 4 173	0	244	99	25	Ξ	133	: 42	- α	16	: '	27	518	18	₩ 2	9 4	42	25	222	35	6,796	12,476	1,015
Total 1999	28 153	: 6	0 48	0	192	51	<u>. t</u>	4 6	105	:	4	18	<u>e</u> .	27	490	18	87	4 K	3 8	13	229	29	6,245	11,445	908 408
Total 1998	45 147	<u>- 4</u>	161	0	247	99	:- 19	80 (	133	: 3	13	16	=	: 4	498	<b>6</b>	124	43	8	13	204	45	7,198	13,405	918
Total 1997	67 170	.:. 26	206	0	222	<del>8</del> 6	22 =	15	<u>s</u> 6	26	9	13	<u>0</u> 5	40	571	15	171	5.0	49	:	181	40	6,194	11,428	88
Total 1996	56 107	32	177	0	233	59	2 <u>9</u>	6	411	: 76	:	16	<u></u>	43.0	408	7	₹ 2	47	8	:	82	21	4,975	9,171	833
Total 1995	37 108	35	187	0	257	77	9 9	: 5	711	112	16	20	7 5	42.4	468	: ;	194	4.4	48	15	68	31	5,230	9,640	240 24
Total 1994	50 126	18	206	0	247	61	4 4	: 7	) «	172	20	35	44	61	519	: 8	204	44	45	15	118	7.7	5,141	9,310	070
Drug category <sup>1</sup>	AnorexiantsAnticonvulsants	Antiemetic/antivertigo agents	General anesthetics	Miscellaneous CNS agents	RESPIRATORY AGENTS	Antihistamines	Decongestants.	Expectorants	Upper respiratory combinations Respiratory agents NTA	CARDIOVASCULAR AGENTS.	Antiadrenergic agents, centrally acting	Beta-adrenergic blocking agents	Calcium channel blocking agents	Cardiovascular agents NTA	OTHER SUBSTANCES	Alternative medicines	Anti-Infectives	Hormones	Nutritional products	Topical agents	Drug unknown.	All other substances NIA	TOTAL DRUG ABUSE EPISODES	TOTAL DRUG ABUSE MENTIONS	101ALED VISITS (III 1,000S)

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multun Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.</p> estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

Table 2.2.7 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Denver by year

% change <sup>2</sup> 2000, 2001	15.5	-26.3 -32.8	113.3	:	13.8 17.3 28.0	24.1	35.2 28.2 -80.0	38.7 13.9	13.4 22.6 45.5	12.7	31.3
% change <sup>2</sup> 1999, 2001	22.3 44.6 72.8	180.0 1,000.0 -50.6	 3.77-	:	15.1	0	-20.7	-100.0	41.5	29.2 29.1	52.7
% <b>c</b> hange² 1994, 2001	62.9 147.8 114.8	2,000.0		:		200	-32.4 102.9 -26.7 -97.6	-100.0	82.5 -64.0		112.0 -24.7 -39.5
Total 2001	2.4.	98 4 1 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	32 - 19 35 - 19	ח	3,746 1,492 425	165	132 <u>145</u> <u>8</u>	0 129 917	73 644 201 18	1,899 1,606 8	797 220 144 432 0
Total 2000	5,268 1,758 1,342 666 817 334	57 12 64	20 0 <del>1</del> 4 <u>4</u> 4	:	3,293 1,272 332	3.0	<u> </u>	0 0 93 805	568 164 33	1,685 1,400 9	607 224 151 409
Total 1999	4,973 1,710 1,382 629 677 235	15	27	:	3,254 1,403 412	145	109	93 845	635 142 38	1,470 1,244 8	522 174 141 397
Total 1998	4,146 1,542 1,1542 492 114	_	0 t t c	7	3,024 1,235 352	45 5	20 4 4 4 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	91	53 173 39	1,407	420 224 129 360
Total 1997	4,283 1,524 1,072 465 505 216	292 11 83 14	480 - 02	<b>†</b>	3,236 1,323 435	185	8 2 2 8	0 4 86 736	200 31	1,490	376 255 142 399
Total 1996	2,942 1,190 811 336 288 95	0 0 65	- <u>8</u> 0 0 9 4		2,966 1,164 372	154	8 <u>42</u> 8	0 6 82 613	396 193 54	1,317 1,072 14	273 231 161 393
Total 1995	4,423 1,635 1,144 463 497 280	0 136 0 8 6	0 C C C 4	•	3,794 1,458 432	148	152 47		58 573 197 46	1,673	342 304 209 517
Total 1994	4,308 1,633 1,273 472 395	25 0 95 0	38 0 0 61		3,993 1,473 428	182	180 83	988 846	588 187 50	1,628	376 292 238 410
Drug category¹	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines.	Metrampretamine MDMA (Ecstasy) Ketamine LSD	Miscellaneous hallucinogens. Flunitrazepam (Rohypnol) GHB Inhalants		OTHER SUBSTANCES OF ABUSE	WAC Iffiliations	Miscellaneous antidepressants Antipsychotics. Phenothiazine antipsychotics.	Psychotherapeutic combinations Thioxanthenes	Benzodiazepines.  Misc. anxiolytics, sedatives, and hypnotics	CNS AGENTS	Cox-z innibitors.  Narcotic analgesics/combinations

## Table 2.2.7 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Denver by year (continued)

% change <sup>2</sup> 2000, 2001	:	-57.1 85.7 -70.0 51.5 -100.0	10.0 100.0 -38.5	-68.2 5.55	28.6 28.6 66.7	10.6 9.9 12.3
% change <sup>2</sup> 1999, 2001	<b>68</b> .	41.0 88.9 -70.0 -72.4		-23.2 300.0 -63.2	200.0 -63.6	13.6 14.4 13.6
% change <sup>2</sup> 1994, 2001	-77.8	-29.5 -66.7 -50.0	-50.0	-71.8 -61.6 -72.0	-66.7 125.0	39.7
Total 2001	138 138 128 128 128	8 7 7 8 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	77 12 18 13 8 13 26	192 12 7 7	2 0 4 C	5,468 9,412 592
Total 2000	112 13 7 7 111 0	86 24 7 7 7 10 33 5	70 6 13 13 22	181 39 222	19 7 15 15	4,944 8,561 527
Total 1999	126 6 8 8 0 7 0	60 4 8 0 1 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	69 12 10 10 24 24	250 3 43 19	121 3 26	4,815 8,226 521
Total 1998	150 6 6 103 103	15 12 12 9 25 0	77 19 8 8	242 2 48 15	107	4,087 7,170 426
Total 1997	164 164 10 109	72 7 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	86 44 48 4 48	260 3 65 24	21 87 31	4,332 7,519 439
Total 1996	138 7 7 111 0 82	134 134 134 134 134 134 134 134 134 134	113 17 20 23 12 43	286 1 4 30 38	19 186 17	3,416 5,908 446
Total 1995	139 20 20 15 105 0	33 8 34 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	0.4774 0.00 0.00 0.00 0.00 0.00 0.00 0.0	444 161 161 27	32 152 20	4,606 8,217 464
Total 1994	124 124 36 10 113	22 2 8 8 2 8 8	88 4 1 1 0 4 4 7	681 0 125 25 39	27 4 :: 4	4,951 8,300 424
Drug category¹	Anorexiants	RESPIRATORY AGENTS. Antihistamines. Bronchodilators. Decongestants. Expectorants. Upper respiratory combinations. Respiratory agents NTA.	CARDIOVASCULAR AGENTS Antiadrenergic agents, centrally acting Beta-adrenergic blocking agents. Calcium channel blocking agents. Diuretics. Cardiovascular agents NTA.	OTHER SUBSTANCES	Nutritional products.  Topical agents.  Drug unknown.  All other substances NTA.	TOTAL DRUG ABUSE EPISODESTOTAL DRUG ABUSE MENTIONS

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 2.2.8 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Detroit by year

% change <sup>2</sup> 2000, 2001	16.3	 -57.1		30.6 38.9 42.3	36.5 34.2 79.3 84.4	94.4 34.7 19.3 38.3 44.2	26.1 24.3 15.2 38.5 77.2
% change <sup>2</sup> 1999, 2001	19.5 26.5 45.9	177.5	-78.4		53.1	82.1 74.3	34.8 45.6
% change <sup>2</sup> 1994, 2001	79.2	84.8	-64.5	136.3	93.4 153.4 -78.5 -100.0	111.4	
Total 2001	26,397 9,109 7,730 3,870 5,017 437	11.7.2.2.2.38.6	0.5.0	10,766 5,168 1,413	294 294 343 283 0	315 3,364 656 2,381 326 48	4,738 3,995 3,995 2,852 367 152 597
Total 2000	24,498 8,447 7,870 3,328 4,344	335	22 17 0	8,242 3,722 993	323 506 164 186 122	162 2,498 550 1,721 226 45	3,758 3,214  2,476 265 117
Total 1999	22,083 7,199 7,699 2,653 4,100	63 24 63	51 51 0	8,123 3,574 939	297 442 196 224 39	2,345 2,345 380 1,777 187 66	3,514 3,030 0 2,160 252 175 438
Total 1998	24,296 7,992 8,617 2,879 4,335	27 20 20	11 58	8,286 3,917 935	310 428 197 226 52	166 2,707 2,707 496 1,991 220	3,468 2,899 .:. 1,962 326 145 466
Total 1997	23,299 7,894 8,093 3,028 3,742 3,742	74 19	0 : : :	9,189 4,255 991	317 513 157 317 82	201 2,894 4,84 2,103 307	3,780 3,219 19 2,070 415 199 513
Total 1996	27,546 9,085 10,435 3,188 4,210	22 0 0 21 24	20 : 95	11,405 4,958 1,203	398 620 185 350 120	30 197 3,306 595 2,367 344	5,031 4,323 0 2,759 480 306 766
Total 1995	23,960 8,378 8,763 2,390 3,875	14.0 56.0 56.0	3006 :	10,192 4,226 822	343 376 100 351 122	25 193 2,969 2,108 291 84	4,403 3,852  2,409 455 290 691
Total 1994	21,362 7,484 8,268 2,160 2,955 305	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	. <del>2</del> :	10,301 4,053 598	228 252 116 335 130	40 149 3,014 604 2,112 298 106	3,681 3,231 0 1,892 387 275 667
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines	Methamphetamine MDMA (Ecstasy) Ketamine LSD PCP	Inscending and (Rohypnol)	OTHER SUBSTANCES OF ABUSE	WACO Initiotics.  SSRI antidepressants.  Tricyclic antidepressants.  Miscellaneous antidepressants.  Antipsychotics.  Phenothiazine antipsychotics.  Psychotherapeutic combinations.	Thioxanthenes Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics Barbiturates Benzodiazepines Misc. anxiolytics, sedatives, and hypnotics CNS stimulants	Analgesics

## Table 2.2.8 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Detroit by year (continued)

% change <sup>2</sup> 2000, 2001	128.6	i		126.5	425.0	 130.0	95.8	211.1		-24.8		33.3	43.6	7.4
% change <sup>2</sup> 1999, 2001	8.69	:		141.5		452.0	93.8		1,133.3	-50.1	48.2		266.7 -66.2	6.9
% change <sup>2</sup> 1994, 2001	196.9	-75.4			-65.6	:				-80.4	-79.6	-64.3	-87.6	10.2
Total 2001	32 377	16	298 0	256	21	138 138	188	23 23	37	416	2 4 c	2 38	203	19,265 37,164 1,583
Total 2000	14 279	: 7	232	113	4	: : 6 °	98	12 <sup>o</sup>	<del>4</del> 8	553	35	15	360 360	17,042 32,740 1,474
Total 1999	14 222	.:.	213	106 36	100	2222	97	23	27	833	83 84 84	15	60 3 30	16,125 30,207 1,481
Total 1998	20 255	29	257 0	106	24	. 45 °	150	23 38	: 22	644	119	37	349	17,477 32,582 1,461
Total 1997	20 247	50	237 0	119	23	.: 44	228	22 22 22 23	21 67	807	125	97	63 63 63	17,604 32,487 1,449
Total 1996	25 326	90	279 0	192	27	2 2 2 :	214	38 44	10	1,010	16. 27.	. 29 29	621 48	20,796 38,952 1,537
Total 1995	24 202	46	274	158	28	827	224	31 59	16 96	1,181	. <u>1</u>	44 42	764 49	18,626 34,152 1,513
Total 1994	57 127		199	239	61	114	209	41 46	17 80	2,119	211	63 56	1,638	17,653 31,663 1,436
Drug category¹	Anorexiants	Antiparkinson agents	General allesurencs	RESPIRATORY AGENTSAuthistamines	Bronchodilators	Expectorants Upper respiratory combinations Respiratory agents NTA	CARDIOVASCULAR AGENTSAntiadrenergic agents, centrally acting	Beta-adrenergic blocking agents	Diuretics	OTHER SUBSTANCESAlternative medicines	Anti-infectives. Gastrointestinal agents.	Hormones Nutritional products.	I opical agents	TOTAL DRUG ABUSE EPISODES

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 2 This column denotes statistically significant (ho<0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values. (2002). The Multurn Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multurn.com.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. estimate with an RSE greater than 50% has been suppressed.

Table 2.2.9 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Los Angeles by year T-36

% change <sup>2</sup> 2000, 2001	40-	10.3	-19.4 -44.3 	-17.2 -19.9 -50.5	-27.7 -47.1	33.9
% change <sup>2</sup> 1999, 2001	47.7	45.6 66.7 173.1	250.0	40.1	-52.6 -100.0	22.0
% change <sup>2</sup> 1994, 2001	81.0	246.0 129.3 914.3	1,300.0 186.7 207.4	7:69-	-100.0	-39.6 -61.0
Total 2001	33,802 10,907 9,999	5,729 1,261 1,517	41 175 86 88  83 7	10,867 3,694 808 388 388	267 287 37 0 0 2,554 1,823 406	4,562 3,990 .:. 14 2,135 451 295 1,090
Total 2000	33,073 10,993 9,094 3,177	5,846 1,072 1,375	217 217 823 88 149 149 35	11,942 4,460 1,009 369 311	330 397 70 70 70 71 71 74 74 848 548	4,860 4,237 11 1,978 546 446 1,253
Total 1999	26,368 8,195 6,768	5,472 866 910 52	229 731 42 42 130 36	10,578 4,084 873 0 356 257	259 331 78 12 23 2,833 2,014 2,014 555	4,291 3,676  1,750 373 412 1,137
Total 1998	20,174 6,129 5,779 2,601	3,422 541 786 30		9,631 3,672 838  350 253	233 305 87 16 16 2,479 1,858 436 50	3,923 3,299  1,432 445 308 1,103
Total 1997	16,983 4,650 4,703	2,084 728 1,229	286 696 59 79 79 79 79 79	12,701 5,276 1,061 10 451 407	980 980 315 12 3,132 3,132 3,72 2,199 627 93	4,994 3,821  1,412 519 507 1,382
Total 1996	19,820 5,648 5,708	2,132 627 1,268 46	216 709 709 709 709 709 709 709 709 709 709	15,398 5,976 1,201 0 485	219 1,323 411 18 13,354 2,382 2,382 716	6,279 4,936 10 0 1,793 672 853 1,608
Total 1995	18,882 5,594 4,980	1,706 596 1,276 37	260 1,266 26 26 26 27 24 8	14,506 5,525 956  358 439	156 395 47 35 35 3273 307 2,254 711	5,998 4,748 14 0 1,470 672 1,027 1,566
Total 1994	18,675 5,649 5,069	1,656 1,656 1,399 4,	208 1,098 30 30 27 23	14,520 5,533 1,021  353 508	153 424 59 76 3,192 2,256 653 75	5,790 4,709 16 0 1,628 747 757 1,560
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABUSE	Marijuana	Ketamine	OTHER SUBSTANCES OF ABUSE	Miscellaneous antidepressants Antipsychotics Phenothiazine antipsychotics Psychotherapeutic combinations Thioxanthenes Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics Barbiturates Benzodiazepines Misc. anxiolytics, sedatives, and hypnotics CNS stimulants	Analgesics



ED Trends From DAWN

194

# Table 2.2.9 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates

Drug category¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change 1994, 2001	% change 1999, 2001	% criange 2000, 2001
Anorexiants	99	88	87	126	35	28	29	22	-66.7	-62.1	
Anticonvulsants.	409	436	461	401	297	259	263	208			
Antiemetic/antivertigo agents	15	4	20	31	24	:	:	æ			
Antiparkinson agents	÷	:	:	:	<u>5</u>	35	22	20			
General anesthetics	<del>-</del>	0	:	0	0	<del>-</del>	<del>-</del>	0	1		
Muscle relaxants	174	245	248	223	242	257	301	313	79.9		
Miscellaneous CNS agents	0	0	0	0	0	0	0	0			
BESDIPATORY AGENTS	439	347	325	284	192	161	<u> 25</u>	148	-66.3		
Milietamines	2	8	53	22	5.0	25	52	37			
Prophodilatore	3 5	8 8	78	7.4	8 8	7 2	12	;			
Decondestants	22	4	3	30	37	7	13	80	-88.6		
Expectorants	11	12	:	80	7	13	0	17			
Upper respiratory combinations	208	11	115	98	99	72	9	83	-60.1		
Respiratory agents NTA	:	:	5	14	:	:	:	:			
CARDIOVASCULAR AGENTS	327	332	286	312	121	145	136	83		42.8	-39.0
Antiadrenergic agents, centrally acting	48	28	39	ষ্ঠ	22	22	22	12			
Beta-adrenergic blocking agents	53	51	48	43	78	23	25	24	-54.7		
Calcium channel blocking agents	73	109	69	71	19	17	9	:		:	:
Diuretics	27	43	20	56	19	22	1	_	-74.1	-68.2	
Cardiovascular agents NTA	127	<u></u>	Ξ	138	32	22	47	<del>8</del>	-73.2		
OTHER SUBSTANCES	2,431	2,304	2,532	1,835	1,724	1,896	2,333	2,381			
Alternative medicines	0	=	80	80	Ξ	27	:	:			
Anti-infectives	393	408	453	353	202	126	139	109	-72.3		
Gastrointestinal agents	<u>4</u>	135	119	114	46	48	25	52			
Hormones	154	170	153	136	62	26	89	94		67.9	
Nutritional products	138	165	150	26	28	40	45	19	-86.2	-52.5	
Topical agents	क्ष	:	12	8	:	:	0	26			
Drug unknown	1,486	1,343	1,574	1,089	1,302	1,557	1,967	2,024		-	
All other substances NTA	81	29	83	72	41	<u>용</u>	84	37	-54.3		
TOTAL DRUG ABUSE EPISODES	19,250	19,258	20,275	17,187	17,103	20,677	25,286	24,669		19.3	
TOTAL DRUG ABUSE MENTIONS	33,195	33,389	35,218	29,684	29,805	36,945	45,015	44,670	34.6	20.9	
TOTAL ED VISITS (In 1.000s)	2375	2 237	2 335	2 233	2 142	2 207	2 500	2 135		4	6

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

Table 2.2.10 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Miami by year

% change <sup>2</sup> 2000, 2001	16.1	80.0	75.2 100.0		-28.3 -73.3 -50.0				9	21.3					40.0		0 000	0.006,1	380	-100.0
% change <sup>2</sup> 1999, 2001	35.0 39.1	50.6	211.9		-82.6 50.0	18.7	29.7	34.7	-32.4	40.2		40.8	32.9	43.3		23.1	?	59.5	28.6	
% change <sup>2</sup> 1994, 2001	128.0 141.6 68.9 545.7	171.0	9,100.0	7.62-	-81.8 -50.0	-11.4	12.3	-100.0 45.9	6 8 6 6 7	-33.5	-82.9	39.0	8.72	53.6 40.5	-62.5					-33.6
Total 2001	-	1,932 64 27		တ က တ	o € 4 €	3,606	1,695 265	159	20	129	<u> </u>	107	92,	1,075	9	1,059	: 4	437	<u>4</u> 8	267
Total 2000	11,131 3,168 4,383 1,452				0 <del>0 1</del> 0	3,752	1,603	145	63	132	200	110	74	963	9	1,070	0 +	370	135	333
Total 1999	9,121 2,645 4,018 917	1,283 53 9	5 10 10 10	9 0 0 1	23 2 2 3 2 3	3,037	1,307	118	74	85	000	76	C ::	148	Ω.	860 734	NC	274	112	247
Total 1998	7,774 2,132 3,553 767				<u> </u>	2,981	201	119	47	8 6 6	400	75.0	92.	142	80	842	: 0	274	127	269
Total 1997	7,010 1,948 3,254 591	1,024 28 10	8 8 8	<u> 4 6</u>	3004	3,238	1,359 253	133 0	76	145	o ro	78	25	185	Ω.	925 813	m С	213	166	321
Total 1996	6,386 1,688 3,104 388	1,011	o 0 ₹	4 6	10	3,516	1,435 235	116	88	135	3 0 0	77 77 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	44 6	242	9	1,055	4 0	202	146 208	335
Total 1995	6,225 1,682 3,078 333	966	40 8	<u> </u>	3 O & R	3,847	23.4	<del>-</del> 8	122	45.	3 w	52	63	240	16	1,133	; 0	199	20e 163	425
Total 1994	5,400 1,523 2,748 258	713	202	<b>1</b> 0 7	7020	4,071	286	109	161	40.5	3 : 4	7 2	4 6	264	16	1,134	0.0	172	163	402
Drug category¹	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin	Marijuana Amphetamines. Methamphetamine.	MDMA (Ecstasy) Ketamine	PCP Miscellaneous hallucinogens Fluntrazanam (Rohumol)	Combinations NTA.	OTHER SUBSTANCES OF ABUSE	Antidensiants	WAO inhibitors	Tricyclic antidepressants	Antipsychotics.	Psychotherapeutic combinations.	Miscellandous antipsychotic agents	Barbitrates Barrodiates	Misc. anxiolytics, sedatives, and hypnotics	CNS stimulants	CNS AGEN I SAnalgesics	Antimigraine agents	Narcotic analgesics/combinations.	Nonsteroldal anti-Imiammatory agents	Miscellaneous analgesics/combinations Analgesic combinations NTA

Table 2.2.10 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Miami by year (continued)

% change² 2000, 2001		67.7	300.0	90.0	40.7	-100.0	-22.8	116.7 127.3 -28.3 -62.1	3.4
% change <sup>2</sup> 1999, 2001	-66.7	92.6			-66.7	-52.9 -100.0	-33.3	:	24.7 30.9 8.4
% change <sup>2</sup> 1994, 2001	-55.6 25.5 -87.5 -70.0	-31.6	-85.2 -80.0	-32.1	-44.4 -57.1	-68.0 -100.0	-55.7	212.5 -42.2 -62.1	50.4 68.1 22.0
Total 2001	<u>∞4-ño₩o</u>	52	<u>∶4 0 −</u>	19	3000	<u> </u>	764 4 15 35	26 25 25 293 11	8,886 15,919 765
Total 2000	29000	31	0 + 0	: 6 :		23 + 28	330	12 11 827 29	8,560 14,883 740
Total 1999	70 70 13 13 0	27	0 10 00	· 6 :	52	12 81	790 6 41 25	20 658 24	7,128 12,158 706
Total 1998	44 0 0 8 1 8 0	33	<u>0004</u>	40	65	28 27	753 4 4 59 14	613 8 8 8 8 8	6,426 10,755 700
Total 1997	22 0 0 0 0 0 0	46	- 804	. 22.	4 0	16 21 21	867 7 68 36	20  687 27	6,283 10,248 668
Total 1996	16 70 41 90	46	. 8 :	:: <del>1</del>	49 5 4	6 4 6	930	202	6,283 9,902 632
Total 1995	22 4 8 0 0 0 0	68	<u>ນ 10 o n</u>	<u>, ∳ ∨</u>	8 6 5	<u> </u>	113	33	6,417 10,072 622
Total 1994	85 8 0 0 0 0	92	100	782	63	23.25	1,287 0 115 39	32 8 1,026	5,908 9,471 627
Drug category¹	Anorexiants	RESPIRATORY AGENTS	Anthistamines Bronchodilators Decorgestants	Expectorants	CARDIOVASCULAR AGENTSAntiadrenergic agents, centrally acting	Beta-adrehergic blocking agents	OTHER SUBSTANCESAlternative medicines	Notificial products.  Topical agents.  Drug unknown.  All other substances NTA.	TOTAL DRUG ABUSE EPISODES

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 2.2.11 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Minneapolis by year

% change <sup>2</sup> % change <sup>2</sup> 1999, 2000, 2001	54.1 32.6 33.4 25.7 35.7 31.4 85.7 48.2 92.0 49.4 123.8 109.8 381.3 200.0 -70.3 -67.2	25.7 14.0 36.8 22.4 30.1 17.6 40.9 -62.9 40.0 30.6 45.1 30.6 45.1 30.6 55.6 20.6 20.8 9.6 17.7 -54.5 62.1 43.5	16.3
% change <sup>2</sup> % ch 1994, 19 2001 2	111.0 57.3 96.6 420.0 192.0 584.8 463.2 3,750.0 -78.7 200.0	141.8 -100.0 -100.0 96.3 96.3 164.3 46.0	·
Total 2001	5,702 2,238 1,105 338 1,200 321 77 77 77 77 77 77 77 77 77 77 19 19 19 19 19 19 19 19 19 19 19 19 19	2,794 1,227 1,227 1,227 205 505 515 728 1,232 1,232 1,232 1,07 107 107 107 107 107 107 107 107 107	928
Total 2000	4,301 1,780 803 165 165 173 173 173 173 173 173 173 173 173 173	5,789 1,043 1,043 464 134 135 0 0 183 943 183 943 183 22 2,396 22 2,396 664 664	897
Total 1999	3,699 1,678 1844 1844 101 101 101 101 101 101 101 101 101 1	5,250 2,043 943 359 137 172 21 150 849 38 455 356 79 2,423 2,155 11 15 15 15 15 15 15 15 15 15 15 15	798
Total 1998	3,184 1,491 7,75 145 490 2 0 0 51 7 7 7 7 0 8 8 8 9 9	4,913 1,960 1,960 135 135 135 101 101 101 103 103 103 103 103 103 103	685
Total 1997	3,629 1,676 736 138 604 70 217 .:: 79 16 16 16 16 16 16 16 16 16 16 16 16 16	5,711 1,083 1,083 1,083 1,083 1,083 1,09 1,09 1,09 1,09 1,09 1,09 1,09 1,09	842
Total 1996	3,229 1,596 674 105 543 46 108 2 2 2 62 8 8 8 8 8 31	5,897 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200	865
Total 1995	2,725 1,418 465 83 469 35 35 116 	5,599 1,028 1,028 1,028 1,028 1,028 1,02 1,17 1,17 1,17 1,19 1,19 1,19 1,19 1,19	718
Total 1994	2,702 1,423 562 65 411 33 57 57 57 69 89 89 83 31	2,298 982 982 322 241 115 107 966 2,500 2,182 9 0 0 0 496 453 453 453 465 467 496 439	830
Drug category¹	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines Methamphetamine MDMA (Ecstasy) Ketamine LSD LSD PCP ILSD PCP Miscellaneous hallucinogens Flunitrazepam (Rohypnol). GHB Inhalants	PSYCHOTHERAPEUTIC AGENTS.  Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Phenothiazine antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotic agents. Miscellaneous antipsychotic agents. CNS stimulants.  CNS stimulants.  Antimigraine agents. Cox 2 inhibitors. Norocic analgesics/combinations. Nonsteroidal anti-inflammatory agents. Salicylates/combinations.	Miscellaneous analgesics/combinations Analgesic combinations NTA.

### fable 2.2.11 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Minneapolis by year (continued)

% change² 2000, 2001		88.7	43.2 207.7		i		40.0	25.5 21.9 7.6
% change <sup>2</sup> 1999, 2001	33.6	59.1	57.8 110.5	60.9			i	40.4 37.4 13.5
% change <sup>2</sup> 1994, 2001	47.6	98.9	158.1	200.0		•	-36.4 1,233.3	49.4 46.2 24.2
Total 2001	171	0 183	262 80 2			0.4 1.5 88 1.5 1.5 1.5	25 25 25 25 25 25	6,521 12,300 797
Total 2000	12 156 	97	183 26 2	39 10 10 10	177 25 30 22 15 86	21 89 52	20 18 172 172	5,197 10,090 741
Total 1999	11 128 3 9	115	166	69 69	4 + + + + + + + + + + + + + + + + + + +	100 100 53	25 : <u>\$</u>	4,643 8,949 703
Total 1998	30 116 8		170	35 18 81 9	4 0 0 0 0 0 0 0 0 0 0 0 0	393 15 96 24	24 24 58	4,328 8,097 661
Total 1997	40 127 18 18	: 86 0	212	55 24 04	217 18 46 30 10	423 7 142 61	31 87 87 87	4,957 9,340 683
Total 1996	148	020	39	917	211 42 23 8	511 169 53	75 10 12 184	4,828 9,126 691
Total 1995	123 :: 19	<u> </u>	221	56 10 10	190 15 37 18 8	201 45	68 68 68	4,325 8,324 683
Total 1994	 127 21	920	31	9339	205  41 24 7	490 1 196 32	44 6 27 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	4,364 8,413 642
Drug category¹	Anorexiants	General anesthetics	RESPIRATORY AGENTSAntihistamines	Bronchodiators	CARDIOVASCULAR AGENTS	OTHER SUBSTANCESAlternative medicinesAnti-infectives	Hormones  Nutritional products  Topical agents  Drug unknown  All other substances NTA	TOTAL DRUG ABUSE EPISODES

1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum information Services, inc. The classification has been modified to meet DAWN's unique requirements <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, estimate with an RSE greater than 50% has been suppressed.

Table 2.2.12 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for New Orleans by year

% change <sup>2</sup> 2000, 2001	-33.1 -39.4 -28.8 -46.0 -23.8	-50.0 48.6	-100.0		42.4 110.9 -32.1	-59.4 -57.1	-57.1	-36.2 ::	-61.7 -47.9
% change <sup>2</sup> 1999, 2001		-33.3 -77.8 -76.3 -50.0	-100.0		44.6	-50.9	-50.0	i	-76.3
% change <sup>2</sup> 1994, 2001	j		-100.0	-33.3	4.7.	-90.5 -94.5 -100.0	62.9		112.7 -70.5 -74.2 -51.7
Total 2001	4,215 1,181 1,422 530 814	:¥ v \$ \$ 4 0 V c	0	2,822 1,241 204 0	116 36	<u> </u>	1,008 1,008 170	67 1,310 1,041	857 23 23 0
Total 2000	6,301 1,948 1,998 1,068 1,068	74 4 8 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	· -	2,871 1,204 200 0	52 52	<u>4</u> 4 ±	49 881 117 659	105 58 1,220 993	675 60 60 60 188
Total 1999	6,058 1,916 2,139 649 1,044	23 6 6 9 51 78 0 11	2	2,848 1,112 215 0	67.73	<u>% ⊕ :</u>	818 100 642	76 26 1,164 935	589 75 97 174
Total 1998	6,285 1,919 2,395 510 1,196	224 24 27 24 0 88	4	3,364 1,316 246 0	<del>8</del> <del>2</del> 2 8	28 0 +	933 115 705	113 67 1,293 1,043	569 107 124 243
Total 1997	6,301 1,970 2,363 422 1,345	2,2 2,2 1,3 2,2 1,3 1,3 1,3 1,3 1,3 1,3 1,3 1,3 1,3 1,3	-	3,419 1,355 0	20.00	8 0 F	58 992 134 694	164 52 1,323 1,107	528 148 127 303
Total 1996	6,532 2,457 2,380 303 1,247	22 0 8 0 4 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0	-	4,501 1,667 295 0	115	000	1,086 1,086 157 705	76 76 1,631 1,214	557 186 129 337
Total 1995	6,292 2,807 2,018 263 1,025	0 0 0 0 0 0 0 0 0 1 1	2	4,836 1,698 398	166	100	149 104 104 658	1,603 1,107	473 189 127 315
Total 1994	5,746 2,626 1,883 191 884	75084	-	3,704	168 46 775	9 6 8	149 892 103 569	221 27 1,316 873	403 176 89 203 0
Drug category¹	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin. Manjuana. Amphetamines Methamohetamine	MDMA (Ecstasy). Ketamine. LSD LSD PCP Miscellaneous hallucinogens. GHB.	Combinations NTA	OTHER SUBSTANCES OF ABUSE. PSYCHOTHERAPEUTIC AGENTS. Antidepressants. MAO inhibitors. SSRI antidepressants	Tricyclic antidepressants.  Miscellaneous antidepressants.  Antipsychotics.	Phenothiazine antipsychotics Psychotherapeutic combinations. Thioxanthenes.	Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics Barbiturates Benzodiazepines	CNS stimulants	Cox-2 inhibitors.  Narcotic analgesics/combinations.  Nonsteroidal anti-inflammatory agents

### Fable 2.2.12 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for New Orleans by year (continued)

					}			f	,	2	2, 1, 1, 2, 2
Drug category¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change* 1994, 2001	% change <sup>-</sup> 1999, 2001	% change 2000, 2001
Anorexiants	8	12 245	190	:: 22	50 4	10 4	6	13.2	-75.0 -94.6	-80.0 -69.0	-66.7 -72.3
Anticonyusarits	7	: :	0	0 7	0 4	00	← 0	<u> </u>	-60.3		200.0
Antiparkinson agents	200	<u> 2</u>	<del>0</del> 0	. o	<u>0</u> 0	<del>л О</del>	00	0	-36.3		
General anesthetics	110	176	179	136	18.	167	164	243			000
Miscellaneous CNS agents	0	0	0	0	0	0	_	0		-	-100.0
RESPIRATORY AGENTS	118	128	88	48	29	65	45	19	-83.9	-70.8	-57.8
Antihistamines	34	26	27	<del>5</del> 6	<u>6</u> 4	<del>1</del> 6	<del>-</del> -	: -		-66 7	
Bronchodilators	ee °	7.52	<u>0</u> 4	n	0 ~	<del>-</del>	- :	- 0	-100.0	-100.0	
Decongestants	0 4	- 12	r 00	<del>-</del>	4	· <b>6</b> 0	7	0	-100.0	-100.0	-100.0
Upper respiratory combinations	. S.	72	29	23	<u>۾</u>	37	16	50	-66.7	-73.0	-100.0
Respiratory agents NTA	ה 	÷	:	5	N	-	,				
CARDIOVASCULAR AGENTS	206	266	199	48	32	99	24	:	:	•	:
Antiadrenergic agents, centrally acting	29	35	ဓ္	12	_ ;	: 5	9 -	:	:		
Beta-adrenergic blocking agents	ခင်	45	17	Ω,	<u></u>	2 0	4 4	:	:	:	
Calcium channel blocking agents	\$ 5	70	2 %	4 ru	0 0	0 4	<del>0 4</del>	: 0	-100.0	-100.0	-100.0
Uluretics	22.7	7.5	88	12	9	35	9	:	:	•	
OTHER SIIBSTANCES	564	1,141	915	645	654	448	378	239	-57.6	46.7	-36.8
Alternative medicines	0	0		Ω. S	0 9	es f	4 +	77	-88.2		
Anti-infectives	119	110	\$ 6	4 4	<del>2</del> <del>C</del>	12.5	2	7	-96.0	-83.3	
Gastrointestinal agents	52	89		17	12	13	7	9	-94.7		
Normones	33	27		13	6	7	8	S.	-84.8		
Topical agents	0	4		0	- !	: 6	200	2 000		0.44	35 F
Drug unknown		730	636	512	55/	909 4	320	000	-88.	Ŧ	-75.0
All other substances NTA	42	82	‡	<u>•</u>	2	2	3				
TOTAL DRUG ABUSE EPISODES		_		5,209	5,088	4,459	4,664	3,729	-21.3		-20.0
TOTAL DRUG ABUSE MENTIONS	9,449	77,17 575	603	576	563	585	607	588		0.4	

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 2 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. estimate with an RSE greater than 50% has been suppressed.

Table 2.2.13 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for New York by year

1,1,2,5	47,323         47,996         52,887         48,809         47,150           12,323         13,534         16,033         14,689         47,150           20,145         19,715         21,592         20,202         19,494           20,145         19,715         21,592         20,202         19,494           2,678         2,974         3,571         3,839         3,682           11,129         10,706         11,132         9,481         9,218           2,178         2,974         3,571         3,839         3,682           2,150         11,132         2,481         3,682         52           1,100         1,132         2,481         3,682         52           1,100         1,132         2,481         3,682         58           1,100         1,132         2,481         3,682         58           1,100         1,132         2,481         3,682         58           1,100         1,132         2,481         3,582         2,88           1,100         1,132         1,424         4,144         1,441         1,441           1,100         1,144         1,144         1,444         1,444         1	Drug category¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994,	% change <sup>2</sup> 1999,	% change <sup>2</sup> 2000,
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0	47,323         47,3896         52,887         48,809         47,150           12,323         13,534         16,033         14,689         14,159           20,145         19,746         21,532         20,205         19,489           20,145         19,746         21,532         20,205         19,489           11,129         10,706         11,132         9,481         9,218           21         23         24         41         36           21         23         24         41         36           21         36         697         229         261         268           21         36         697         229         261         266           41         22         22         13         8         261         266           41         22         22         13         8         261         267         266           40         2,692         31,22         31         11         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210 <t< td=""><td>Collect Alloge Of Aprilon</td><td></td><td>T</td><td></td><td></td><td></td><td></td><td></td><td></td><td>2001</td><td>2001</td><td>2001</td></t<>	Collect Alloge Of Aprilon		T							2001	2001	2001
1,1,2,2,3,1,3,5,4,1,4,5,4,5,5,5,5,5,5,5,5,5,5,5,5,5,5	13,534   16,033   14,689   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   14,194   1	obolin-combination	47,323	47,996	52,887	48,809	47,150	40,513	41,905	40 417			
1,129   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,145   1,14	1,129   19,745   19,745   19,549   19,549   19,549   19,549   19,148   19,148   19,148   19,148   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19,218   19	Caine	12,323	13,534	16,033	14,689	14,194	12,333	12.450	11,821			
1,122   10,729   10,729   11,122   10,729   11,122   10,729   11,122   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10,729   10	1,129		20,145	19,715	21,592	20,202	19,549	14,799	14.250	13 898			
2.578         2.974         3.571         3.682         3.467         3.544         3.541         3.682         3.449         3.541         3.682         3.449         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541         3.541 <th< td=""><td>7.578         2.974         3.571         3.839         3.682           21         53         24         41         31           150         188         142         139         75           852         697         229         281         28           852         697         229         281         28           7         18         142         139         75           852         697         229         281         28           7         18         18         14         11           7         18         18         23         11           7         18         12,726         11,441         11,210           18         18         12,726         14,441         11,210           18         18         12,726         14,441         11,210           18         18         12,726         14,441         11,210           18         18         12,726         14,441         11,210           18         18         12,441         14,40         14,40           18         18         16         18         16           18</td><td></td><td>11,129</td><td>10,706</td><td>11,132</td><td>9,481</td><td>9,218</td><td>9,302</td><td>11 009</td><td>10.644</td><td></td><td></td><td></td></th<>	7.578         2.974         3.571         3.839         3.682           21         53         24         41         31           150         188         142         139         75           852         697         229         281         28           852         697         229         281         28           7         18         142         139         75           852         697         229         281         28           7         18         18         14         11           7         18         18         23         11           7         18         12,726         11,441         11,210           18         18         12,726         14,441         11,210           18         18         12,726         14,441         11,210           18         18         12,726         14,441         11,210           18         18         12,726         14,441         11,210           18         18         12,441         14,40         14,40           18         18         16         18         16           18		11,129	10,706	11,132	9,481	9,218	9,302	11 009	10.644			
1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5   1.5	T.         21         53         34         59         52           T.         21         23         24         41         31           150         188         142         139         75           852         697         229         221         38         75           150         188         142         139         75         36           16         22         22         13         28         28         13         75         36           16         25         22         13         8         75         11         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1	Judalia	2,578	2,974	3,571	3,839	3.682	3.491	3.544	2 504			
150   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180	150   188   142   139   148   142   139   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148   148	pneramines	21	53	8	29	52	48	,,	0,0			
150   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180   180	150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150	mamphetamine	21	23	21	32	38	7	3 6	ō.			
150   180   140   120   256   276   276   277   263   768   756   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266   266	150   188   142   139   75   15   15   15   15   15   15   15	IMA (Ecstasy)	7	:	24	4	3	136	500	: 1	,		
150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150   150	150   188   142   139   75   188   142   139   75   188   142   139   75   188   142   139   75   188   142   139   75   148   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144   144	amine	:	6	16	23	ά	3 5	7	7/1	7,357.1		
10	852         697         229         261         256           1         2         22         13         8           1         1         1         1         1           1         1         1         1         1           1         1         1         1         1           1         1         1         1         1         1           1         1         1         1         1         1         1           1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         <		150	188	142	139	75	72	73	4 6	: !		
1	TS		852	269	229	261	256	278	237	7 6	-58.7		
1	TS	cellaneous nallucinogens	4	22	22	13	00	i	<u>}</u>	307	-/6.2		
16,654   14,456   12,726   11,441   11,210   10,088   10,731   11,637   -30.1   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -100.0   -1	TS   16   16   17   18   18   19   19   19   19   19   19	nuazepam (Konypnol)	_	0	-	_	<del>-</del>	•	2 0	0 0	4.05		
1.55   1.65   1.44   1.65   1.44   1.12   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15   1.15	16,654   14,458   12,726   11,441   11,210   11,210   11,210   12,529   64.9   3,276   2,902   2,902   3,004   2,692   3,123   3,276   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902   2,902	Stante	<del>-</del>	0	:	9	S	16	3.	<u> </u>	0.001		
15   15   15   15   15   15   15   15	TS         16,654         14,458         12,726         11,414         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210         11,210	nbinations NTA	~ =	<del>8</del>	<u>∞</u> (	- 1	:	-	; ;	0	-100.0	-100.0	
16,654   14,458   12,726   11,441   11,210   10,088   10,731   11,637   13,04   13,04   12,32   13,27   13,04   13,04   13,04   13,04   13,04   13,04   13,04   13,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,04   14,0	TS         16,654         14,458         12,726         11,441         11,210         1           TS         3,004         2,692         3,123         3,276         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,902         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102         2,102 <td></td> <td>,</td> <td>:</td> <td>4</td> <td>23</td> <td>=</td> <td>m</td> <td>Ω</td> <td>_</td> <td></td> <td></td> <td>-80.0</td>		,	:	4	23	=	m	Ω	_			-80.0
TS.         3,004         2,186         1,172         10,088         10,731         11,637         -30.1           737         559         649         794         658         560         886         360         367         2,886         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         30.1         40.8         30.1         40.8         30.1         40.8         30.1         40.8         30.1         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         40.8         4	TS	SUBSTANCES OF ABUSE	16 654	44 450	40 706	777 77				Ī			
737         559         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,123         5,1	737         559         5123         5120         2102           283         219         281         386         359           408         287         330         350         237           408         287         330         350         237           41         49         36         57         62           450         352         356         297         262           23          3         3         3           246         184         230         204         215           1,792         1,741         2,101         2,157         1,960           1,792         1,741         2,101         2,157         1,960           1,592         1,741         2,101         2,157         1,960           1,592         1,741         2,101         2,157         1,960           1,592         1,741         2,101         2,157         1,960           1,591         1,249         1,614         1,440           379         4,249         4,424         4,070         4,135           3,815         2,424         4,424         4,070         4,135	CHOTHERAPEUTIC AGENTS	200	1,00	2,720	1,441	11,210	10,088	10,731	11,637	-30.1		
283         219         794         658         560         586         597           408         287         281         386         359         303         37         349         657         408         586         597         408         408         408         408         408         408         408         408         408         408         408         408         408         409         408         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         409         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400         400	283 219 281 386 359 408 287 330 350 237 41 49 36 287 330 350 237 450 352 356 297 262 245 177 154 2,101 2,157 1,960 1,792 1,741 2,101 2,157 1,960 253 3,915 4,249 4,424 4,070 4,135 279 3,915 3,906 4,140 3,824 3,828 219 278 2,620 2,502 2,534 279 659 886 737 771	depressants	2,004	2,032	3,123	3,276	2,902	2,946	3,160	3,286			
283         219         281         386         359         303         317         349         -65.7           408         287         330         350         237         167         143         140         -65.7           408         287         330         237         167         143         140         -65.7           450         356         356         237         262         294         193         182         -59.6           24         124         124         90         43         24         13         -100.0           246         184         230         204         215         246         13         148.8           1,792         1,741         2,101         2,157         1,360         2,080         2,364         2,501           1,792         1,741         2,101         2,157         1,360         2,080         2,364         2,501           1,792         1,749         1,614         1,440         1,540         1,753         1,918         52.1           26         40         16         2,824         3,824         3,828         3,501         4,244           4,775         3,945<	283         210         281         386         359           408         287         330         350         237           41         49         36         57         62           450         352         356         297         262           177         154         124         90         43           246         184         230         204         215           1,792         1,741         2,101         2,157         1,960           1,792         1,741         2,101         2,157         1,960           1,792         1,741         2,101         2,157         1,440           379         342         421         391         383           26         40         4,24         4,070         4,135           3,915         4,249         4,424         4,070         4,135           3,915         4,249         4,140         3,824         3,828           3,915         4,249         4,140         3,824         3,828           3,915         4,140         3,824         3,828         3,828           3,916         2,746         2,620         2,502         2,534	MO inhibitors.	<u> </u>	RCC C	949	<del>2</del> 6,	658	260	586	297			
408         213         360         359         303         317         349         -65.7         -65.7         -65.7         -45.8         36         359         303         317         349         -65.7         -65.7         -65.7         -45.9         -65.7         -45.9         -65.7         -45.9         -45.9         -45.0         -65.7         -45.9         -45.0         -45.0         -45.0         -45.0         -45.0         -45.0         -45.0         -45.0         -45.0         -45.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0 <t< td=""><td>4.00         2.13         386         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         439         439         443         443         359         204         215         150         21         350         204         215         150         21         350         204         215         150         21         350         204         215         150         21         350         204         215         1440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440</td><td>SRI antidepressants.</td><td>283</td><td>: 6</td><td>: 2</td><td>- 655</td><td>0</td><td>_</td><td>0</td><td>9</td><td></td><td></td><td></td></t<>	4.00         2.13         386         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         359         439         439         443         443         359         204         215         150         21         350         204         215         150         21         350         204         215         150         21         350         204         215         150         21         350         204         215         1440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440         11,440	SRI antidepressants.	283	: 6	: 2	- 655	0	_	0	9			
450         450         330         350         237         167         143         140         -65.7           450         352         356         297         262         294         193         182         -59.6         -38.1           450         352         356         297         262         294         193         182         -59.6         -38.1           23          3         3         3         3         3         3         38.1         -52.7         -72.9           1,792         1,741         2,101         2,157         1,960         2,080         2,364         2,501         -100.0         -100.0           1,792         1,741         2,161         2,157         1,360         2,080         2,364         2,501         -100.0         -100.0           1,792         1,741         1,440         1,540         1,540         1,753         1,918         52.1         -72.9           1,281         1,614         1,440         1,540         1,753         1,753         1,918         52.1           2,61         1,222         1,444         4,070         4,135         3,824         4,211         5,148	41         49         350         350         237           450         352         356         297         262           177         154         124         90         43           23          3         3         204         215           1,792         1,741         2,101         2,157         1,960         2,151           1,261         1,222         1,498         1,614         1,440         1,175           1,261         1,222         1,498         1,614         1,440         1,175           1,261         1,222         1,498         1,614         1,440         1,175           3,915         4,249         4,424         4,070         4,135         3,828         3,828           3,915         4,249         4,140         3,824         3,828         3,828         3,828           1         0         0         0         0         0         0         0           2,088         2,746         2,620         2,534         2,534         2,534         2,534         2,534         2,534         2,74           2,19         4,140         3,824         3,16         2,534	ricyclic antidepressants	207	200	182	988	329	303	317	349	_		
450         35         36         37         56         90         126         102         148.8           177         154         124         90         43         48         24         13         -59.6         -38.1           246         177         154         124         90         48         24         13         -59.6         -59.6         -38.1           246         184         230         204         215         240         165         168         -100.0         -100.0           1,792         1,741         2,101         2,157         1,540         1,540         1,753         1,918         -100.0         -100.0           1,261         1,614         1,440         1,540         1,753         1,918         52.1         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0	450         352         356         297         262           177         154         124         90         43           23         1,741         2,101         2,157         1,960         2,15           1,522         1,741         2,101         2,157         1,960         2,15           1,261         1,222         1,498         1,614         1,440         1,15           1,261         1,222         1,498         1,614         1,440         1,15           3,915         4,249         4,424         4,070         4,135         3,83           3,475         3,906         4,140         3,824         3,828         3,828           3,745         3,906         4,140         3,824         3,828         3,828           1         0         0         0         0         0           2,088         2,746         2,620         2,502         2,534         2,534           2,19         182         241         207         771           1         0         0         0         0         0	liscellaneous antidepressants	5 4	707	080	<u>g</u> !	237	167	143	140	-65.7		
23         0         29         43         48         294         193         182         -59.6         -38.1           23         0         0         0         0         0         0         -100.0         -72.9           246         1.74         2.30         204         2.15         1.960         2.080         2.364         2.501         -72.9           1,792         1,741         2.101         2.157         1.960         2.080         2.364         2.501         -100.0           1,792         1,771         182         1.57         1.960         2.080         2.364         2.501         -100.0           1,781         2,722         1,498         1,614         1,440         1,540         1,753         1,918         52.1           26         40         16         28         24         1,753         1,918         52.1           26         40         16         28         2,413         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         3,824         <	177         154         124         90         43           23          3         3         3          43           246         184         230         204         215          245          215          200         0         0         0         0         0         0         0         0         0         0         0         0         0         204         215         1,240         1,741         1,440         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,540         1,54	psychotics	450	25.2	02.0	200	95	06	126	102	148.8	_	19.0
23            43         48         24         13         -92.7         -72.9           246         1.84         2.30         2.04         2.15         2.06         2.080         2.364         2.501         -100.0           1,792         1,741         2.101         2.157         1,960         2.080         2.364         2.501         -100.0           1,792         1,741         2.101         2.157         1,960         2.080         2.364         2.501         -100.0           1,761         1,722         1,498         1,614         1,440         1,540         1,753         1,918         52.1           26         40         16         28         21          1,753         1,918         52.1           26         40         16         28         21          1,7         7         -73.1           3,915         4,424         4,070         4,135         3,821         4,211         5,148         36.7           3,475         3,906         4,140         3,824         3,824         2,365         3,981         4,837         39.2           1         0         <	246 184 230 204 215 1,792 1,741 2,101 2,157 1,960 2, 152 137 1,222 1,498 1,614 1,440 1, 2, 2, 2, 3, 3, 3, 475 3,906 4,140 3,824 3,828 3,475 3,906 4,140 3,824 3,828 3,69 2,182 2,19 2,19 2,19 2,19 2,19 2,19 2,19 2,1	henothiazine antipsychotics	177	15.4	220	) 67	762	294	193	182	-59.6	-38.1	2
23          3           0         0         -100.0           246         184         230         204         215         240         165         168         -100.0           1,792         1,741         2,101         2,157         1,960         2,080         2,364         2,501         -100.0           152         1,77         182         1,514         1,440         1,540         1,753         1,918         52.1           26         40         161         1,440         1,540         1,753         1,918         52.1           3,915         4,249         4,424         4,070         4,135         3,821         4,211         5,148         52.1           3,475         3,906         4,140         3,824         3,505         3,981         4,837         39.2         34.7           1         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	246 184 230 204 215 1,792 1,741 2,101 2,157 1,960 2, 152 137 1,960 2, 137 1,222 1,498 1,614 1,440 1, 26 1,222 1,498 1,614 1,440 1, 381 3,915 3,915 3,906 4,140 3,824 3,828 3, 3,16 2,188 2,746 2,620 2,534 2, 27 1,960 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	sychotherapeutic combinations	· 67	5 -	<u>†</u> C	<u> </u>	£4 20	48	24	<del>1</del>	-92.7	-72.9	45.8
246         184         230         204         215         240         165         168         -100.0           1,792         1,741         2,101         2,157         1,960         2,080         2,364         2,501           1,561         1,722         1,498         1,614         1,440         1,540         1,753         1,918         52.1           379         342         421         391         383         383         433         402         -73.1           3,915         4,249         4,424         4,070         4,135         3,821         4,211         5,148         52.1           3,475         3,906         4,140         3,824         3,828         3,505         3,981         4,837         39.2         38.0           1         0         0         1         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0 <td< td=""><td>246 184 230 204 215 1,792 1,741 2,101 2,157 1,960 2, 137 1,222 1,498 1,614 1,440 1, 261 1,222 1,498 1,614 1,440 1, 381 3,915 3,906 4,140 3,824 3,828 3, 3,475 3,906 4,140 3,824 3,828 3, 3,16 2,08 2,746 2,620 2,534 2, 377 1,97 659 886 737 7771</td><td>hioxanthenes</td><td>23.0</td><td><del>-</del></td><td><u> </u></td><td><del>-</del> •</td><td>5</td><td>0</td><td><del>-</del></td><td>0</td><td>-100.0</td><td></td><td></td></td<>	246 184 230 204 215 1,792 1,741 2,101 2,157 1,960 2, 137 1,222 1,498 1,614 1,440 1, 261 1,222 1,498 1,614 1,440 1, 381 3,915 3,906 4,140 3,824 3,828 3, 3,475 3,906 4,140 3,824 3,828 3, 3,16 2,08 2,746 2,620 2,534 2, 377 1,97 659 886 737 7771	hioxanthenes	23.0	<del>-</del>	<u> </u>	<del>-</del> •	5	0	<del>-</del>	0	-100.0		
1,792         1,741         2,101         2,157         1,960         2,364         2,501         1,68           1,521         1,771         182         1,67         1,440         1,540         1,753         1,918         52.1           379         342         421         391         383         383         433         402         -73.1           3,915         4,249         4,424         4,070         4,135         3,821         4,211         5,148         52.1           3,475         3,906         4,140         3,824         3,828         3,505         3,981         4,837         39.2         38.0           0         0         0         0         0         0         0         0         0         0           2,088         2,746         2,620         2,534         2,362         2,573         3,444         64.9         45.8           370         319         382         2,562         2,573         3,444         64.9         45.8         1           797         659         886         737         771         716         843         807	1,792 1,741 2,101 2,157 1,960 2, 17, 1,222 1,498 1,614 1,440 1, 1,222 1,498 1,614 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1,140 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1, 1,440 1,140 1, 1,440 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,140 1,	iscellaneous antipsychotic agents	246	: 26	230	204		: 6	: (	o į	-100.0	-	
152         177         182         2,184         2,564         2,501           1,261         1,222         1,498         1,614         1,440         1,540         1,733         1,918         52.1           379         342         421         391         383         383         433         402           3,915         4,249         4,424         4,070         4,135         3,821         4,211         5,148         52.1           3,475         3,906         4,140         3,824         3,828         3,505         3,981         4,837         39.2         38.0           0         0         1         0         0         0         0         0         0         10         2.8           2,088         2,746         2,620         2,522         2,534         2,362         2,573         3,444         64.9         45.8           370         370         319         369         351         2,362         2,573         3,444         64.9         45.8           797         659         886         737         771         716         843         807	152     177     182     1,500       1,261     1,222     1,498     1,614     1440       379     342     421     391     383       3,915     4,249     4,424     4,070     4,135     3,824       3,475     3,906     4,140     3,824     3,828     3,828       0     0     0     0     0       0     0     0     0     0       0     0     0     0     0       0     0     0     0     0       182     2,620     2,502     2,534     2,534       219     182     241     214     207       797     659     886     737     777       0     0     0     0     0	olytics, sedatives, and hypnotics	1.792	1741	2 101	2 157	7 7 7	240	165	168			
1,261         1,222         1,498         1,514         1,440         1,540         1,753         1,918         52.1           26         40         16         28         21          7         -73.1           3,915         4,249         4,424         4,070         4,135         3,821         4,211         5,148         34.7           3,475         3,906         4,140         3,824         3,828         3,505         3,981         4,837         39.2         38.0           0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0 <td>1,261     1,222     1,498     1,614     1,440       379     342     421     391     383       26     40     16     28     21       3,915     4,249     4,424     4,070     4,135     3       3,475     3,906     4,140     3,824     3,828     3,828       0     0     0     0     0       0     0     0     0     0       0     0     0     0     0       0     0     0     0     0       182     241     241     214     207       182     241     214     207       183     333     369     316       184     265     886     737     777       185     286     737     777</td> <td>arbiturates.</td> <td>152</td> <td>177</td> <td>182</td> <td>153</td> <td>1,900</td> <td>2,080</td> <td>2,364</td> <td>2,501</td> <td></td> <td></td> <td></td>	1,261     1,222     1,498     1,614     1,440       379     342     421     391     383       26     40     16     28     21       3,915     4,249     4,424     4,070     4,135     3       3,475     3,906     4,140     3,824     3,828     3,828       0     0     0     0     0       0     0     0     0     0       0     0     0     0     0       0     0     0     0     0       182     241     241     214     207       182     241     214     207       183     333     369     316       184     265     886     737     777       185     286     737     777	arbiturates.	152	177	182	153	1,900	2,080	2,364	2,501			
379         342         4,249         4,424         4,070         4,135         1,918         52.1           26         40         16         28         21          7         -73.1           3,915         4,249         4,424         4,070         4,135         3,821         4,211         5,148         34.7           3,475         3,906         4,140         3,824         3,828         3,505         3,981         4,837         39.2         38.0           1         0         0         0         0         0         0         0         39.2         38.0           1         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	3,915 4,249 4,424 4,070 4,135 3,383 1,15 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1,745 1	enzodiazepines	1.261	1.222	1 498	18.4	2 7	2 7	9/1	081	_		
26 40 16 28 21 363 433 402 77.73.1 3.847 3.858 433 402 34.7 77.1 3.915 3.809 43.8 4.24 4.070 4.135 3.821 4.211 5.148 3.9.2 38.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	26 40 16 28 21 3,915 4,249 4,424 4,070 4,135 3,324 2,135 3,328 3,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	isc. anxiolytics, sedatives, and hypnotics	379	342	421	2,0	2 6 6	, 0, 0, 0, 0,	1,753	1,918	52.1	_	
3,915 4,249 4,424 4,070 4,135 3,821 4,211 5,148 34.7 39.2 38.7 37.1 37.1 37.1 37.1 37.1 37.1 37.1 37	3,915 4,249 4,424 4,070 4,135 3,475 3,906 4,140 3,824 3,828 3,828 3,508 2,746 2,620 2,502 2,534 3,797 659 886 737 777	stimulants	26	40	146	- 00	<u>ရှိ</u>	283	433	402			
3,915 4,249 4,424 4,070 4,135 3,821 4,211 5,148 34.7 39.2 34.7 34.7 3,906 4,140 3,824 3,828 3,505 3,981 4,837 39.2 38.0 38.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3,915 4,249 4,424 4,070 4,135 3,475 3,906 4,140 3,824 3,828 1 0 0 1 0 0 2,088 2,746 2,620 2,502 2,534 370 319 393 369 316 797 659 886 737 771	STREET	<u> </u>	?	2	07	1.7	:	14	_	-73.1		-58.8
3,475 3,906 4,140 3,824 3,828 3,505 3,981 4,837 39.2 34.7 39.2 3.6.0 3.6.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3,475 3,906 4,140 3,824 3,828 2,088 2,746 2,620 2,502 2,534 370 319 393 369 316 2797 659 886 737 771	AGEN I S	3,915	4,249	4,424	4,070	4.135	3 821	4 211	2 4 40		,	
2,088         2,746         2,620         2,523         2,524         38.0           370         319         393         369         316         296         351         362         45.8         1           797         659         886         737         71         716         843         807         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         907         90	2,088 2,746 2,620 2,502 2,534 370 319 393 369 316 797 659 886 737 771	gesics	3,475	3,906	4,140	3,824	3.828	3.505	3 0 %	2,140	- 0	¥. 8	22.3
2,088 2,746 2,620 2,502 2,534 2,362 2,573 3,444 64.9 45.8 219 182 241 207 132 203 182	2,088 2,746 2,620 2,502 2,534 370 319 393 369 316 219 182 241 214 207 0 0 0 0 0	innigrante agents	_	0	0	_	0	0	2	, ,	29.5	38.0	21.5
2,088         2,746         2,620         2,502         2,534         2,362         2,362         2,553         3,444         64.9         45.8           370         319         393         369         316         296         351         362         45.8           219         182         241         214         207         132         203         182           797         659         886         737         771         716         843         807           0         0         0         0         0         0         0         0	. 2,088 2,746 2,620 2,502 2,534 370 319 393 369 316 219 182 241 214 207 659 886 737 771	and the months of the second o	0	<del>-</del>	<del>-</del>	0	0	0	<del>-</del>	: č			,
370 319 393 369 316 296 351 362 45.8 219 182 241 214 207 132 203 182 0 0 0 0 0 0 0 0 0 0 0	370 319 393 369 316 219 182 241 214 207 797 659 886 737 771 0 0 0 0	protocoldal pati inflammations.	2,088	2,746	2,620	2,502	2,534	2.362	2.573	3 444	0.79	4	180.0
minations     219     182     241     214     207     132     203       pinations     797     659     886     737     771     716     843       minations     0     0     0     0     0     0	Junations	alicylates/combinations	370	319	393	369	316	296	351	362	ņ.	40.8	33.9
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Scellaneous analogoico/combineticas	219	182	241	214	207	132	203	182			
	0 0 0	Schools combined by ATA	797	629	988	737	771	716	843		_		
		laigesic combinations NIA	0	0	0	0	0		3	3 6			

able 2.2.13 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates

% change <sup>2</sup> 2000, 2001	39.5					-83.3	:										:			1.7
		_						_							_		400.0			9.4
% change <sup>2</sup> 1999, 2001												_					_			
% change <sup>2</sup> 1994, 2001	258.3	:		7 00	-26-	69- 89.3	787	200			-60.0		-67.8	-68.2			2,900.0		-24.8	12.1
Total 2001	43	: :	: 🛪 🖰	5 L	33	<u> </u>	3 4	<u> </u>	125	2 <del>2</del>	12	38	2,994	88	37	16	30	45	32,307	
Total 2000		: 27	<u> </u>	5 ,	36	<del>ਨ</del> ਦ	: :6	<u>.</u>	105	3 2	18	38	3,145		23	2 2	 0.048	49	31,882	3,685
Total 1999	20 245	; o	၁ စ္က ၆	o (	16	: ^	11.	<del>-</del> -	135	35	<u>. 6</u>	0 00	3,103		32		6 2774	53	30,662	3,426
Total 1998	45 195	27	<u> </u>	0	17	85	2 - 3	<del>,</del> 0	401	52	" :	: 6	3,988			88		2,000 41	36,141	3,472
Total 1997	17 156	34:	<u> </u>		142	38	:0 (	9 4	148	47	7 7 7 8	13	3,806	124	88	27	0	5,505 49	37,111	3,432
Total 1996	20 173	37	<u>o 4</u>	0	190	32	3 = 8	0 0	159	23	37	16	4,830	169	5.	46	: 0	36	40,468	3,624
Total 1995	19	32	50 o	0	157	3 22	70;		130	29	24	25	7,230	189	25	66 46	16	6,807	40,792	3,196
Total 1994	15 ::	: 88	28 0	0	203	28 8	<b>9</b> :	<u> </u>	241	37	9 6	69	9,290	0 000	25	<u>5</u> 2	-	8,755	42,980	3,345
Drug category <sup>1</sup>	AnorexiantsAnticonvulsants	Antiemetic/antivertigo agents. Antiparkinson agents.	General anesthetics	Miscellaneous CNS agents	RESPIRATORY AGENTS	Anunsianines.  Bronchodilators.	Decongestants Expectorants	Upper respiratory combinationsRespiratory agents NTA		Antiadrenergic agents, centrally acting	Beta-adrenergic biocking agents	Diaretics County of Continue County of County o	OTHER SUBSTANCES	Alternative medicines	GastroIntestinal agents	Hormones	Topical agents	Drug unknownAll other substances NTA	TOTAL DRUG ABUSE EPISODES	TOTAL DRUG ABUSE MENTIONS

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake Inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 2.2.14 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Newark by year

% change <sup>2</sup> 2000,	-7.2 -15.5	-100.0 133.3		78.8 -23.6	20.8	-75.0	<b>48</b>
% change <sup>2</sup> 1999,	-15.4 -15.8 -15.8 -15.8 -21.4	133.3		92.4	31.2	-80.0	41.8 -36.6 -50.9
% change <sup>2</sup> 1994,		-68.8 105.9 		-82.4	54.5 6.45.45.65.65.65.65.65.65.65.65.65.65.65.65.65	3	71.5 -48.1 -74.3 -27.9
Total 2001	9,230 2,015 2,631 3,718 647	0 4 1 1 2 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3,359 1,536 348 0	129 139 149 151 151 151 151 151 151 151 151 151 15	1,066 83 849 134	1,228	739 97 28 227
Total 2000	9,943 2,123 2,726 4,399 539	: 0 10 0 0 10 0 0 1	3,129 1,324 311	137 85 89 96 14	908 05 14 1 5 5 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	12 1,071 971	582 115 54 217
Total 1999	10,912 2,377 3,124 4,733 533	38: 38: 30: 40: 50: 50: 50: 50: 50: 50: 50: 50: 50: 5	3,067 1,267 298 0	142 79 78 100 16	854 54 647	15 1,079 965 0	521 153 57 235
Total 1998	12,252 2,830 3,743 5,072 532		2,928 1,169 247 0	123 7 7 7 39 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	822 29 620 172	1,055	463 154 164 262 
Total 1997	11,473 2,967 3,571 4,364 500	: 10 2 t : 0000	3,565 1,142 252 0	118 73 109 10 10	59 762 41 499 222	992	368 177 177 60 275 0
Total 1996	14,469 3,947 4,436 5,386 627	1224: 12700 :	3,542 1,341 322 0	68 133 133 8 : 63	862 36 618 208	1,103 984	332 215 88 349 0
Total 1995	15,258 4,040 4,658 5,681 742	: : o & 4 @ o o o o u	4,033 1,322 309	25 25 25 26 26 27 27 27	831 35 605 190	37 1,262 1,123	438 251 111 323 0
Total 1994	12,667 3,209 4,228 4,493 628 18	5 : 00 37 300 : 0	3,855 1,251 263	115 174 174 12 12 11	804 51 202	1,156	431 187 109 315 0
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines	Methamphetamine. MDMA (Ecstasy). Ketamine. LSD. PCP. Miscellaneous hallucinogens. Flunitrazepam (Rohypnol). GHB Inhalants.	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS. Antidepressants. ANTION OF THE PROPERTY OF	Tricyclic antidepressants.  Tricyclic antidepressants.  Miscallaneous antidepressants.  Antipsychotics.  Phenothiazine antipsychotics.  Psychotherapeutic combinations.	Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates Benzodiazepines Misc. anxiolytics, sedatives, and hypnotics	CNS AGENTS	Narcotic analgesics/combinations. Nonsteroidal anti-inflammatory agents. Salicy/ates/combinations. Miscellaneous analgesics/combinations. Analgesic combinations NTA.

\_able 2.2.14 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates

for Newark by year (continued)

% change <sup>2</sup> 2000, 2001		70.6	40.5	-39.1			-18.0	-66.7 228.6 225.0	-26.3 -75.0	9.0
% change <sup>2</sup> 1999, 2001		45.0	:		112.5	250.0	-21.7 -100.0	-57.9 283.3 225.0	-32.2 -66.7	-13.1
% change <sup>2</sup> 1994, 2001	120.6		49.0	:				-76.5	-66.5 -80.0	13.5
Total 2001	15 7 7 7 7	0 00	12	. 58 0	131	: 4	495	23.8	379 379 5	7,217 12,589 770
Total 2000	0 4 4	0.7	<u>8 to 0 4</u>	17 46 ::	94 91 9	15	604	22 - 4	514 20	7,747 13,072 765
Total 1999	11 69 5	0 00 0	65 14 14	: 46 :	10 :: 7	⊃ <del>4</del>	632	0 4 6	559	8,301 13,979 720
Total 1998		0 50 0	31	3:: 0	4 <del>4</del> <del>0</del> 9	; ∞	585	2 2 2 8	507	8,944 15,180 697
Total 1997	67	<u> </u>	48 4 0	34: 0	24 11:	16	1,306	<u> </u>	1,187	8,893 15,038 649
Total 1996	41 55 1	0 80	87 18 12	:::4 0	14 17	20 e	944	23	774	9,909 18,011 681
Total 1995	62 	37	1 2 3 6 7 7	05 :	32 11 34 4	21	1,257	41	1,080	10,870 19,291 702
Total 1994	27 8 0 22	040	98 19		44 :12	0 4	1,306	23 24 28 20 0	1,130	9,394 16,522 679
Drug category¹	Anorexiants	General anesthetics	RESPIRATORY AGENTSAuthistamines	Decongestants	CARDIOVASCULAR AGENTS	Diuretics	OTHER SUBSTANCESAlternative medicines	Anti-infectives	Topical agents	TOTAL DRUG ABUSE EPISODES

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

Table 2.2.15 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Philadelphia by year

% change 2 % change 2 2000, 2001 2001		66.0	); ()	12.4 B	124.0	105.0	7.67		128.1 44.0			82.1 35.3 30.0	49.1		_			110.0	110.0	110.0		110.0											7		23.5	-35.2	-35.2	-35.2	-1-	1-35.2	. 35.2	-35.2	-35.2	1-35.2	-35.2	-35.2	-35.2	-35.2	.35.2
Total % Chi 2001 196 200		33,163	11 258	7,362	5,002	0,00	90	09	203	:	74	785	27	6	06		42	24.2	21	21 21 25059	21 21 15,059 7.759	21 21 15,059 7,759	42 21 15,059 1,759 1,884	21 21 7,759 1,884	21, 21, 21, 25,059 1,884 0,074	42 21 15,059 7,759 1,074 176	42 21 5,059 7,759 1,884 1,074 634	7,759 1,074 1,074 1,66 634	7,759 1,074 1,684 5,04 1,074 1,634 5,04	42 21 21 27,759 1,884 1,074 176 634 571																			
Total T		30,005			800 4	1,920	5 0 1	/9	141	73	104	604	38	0	19	32		<del>1</del>	10	14,379	14,379	14,379 7,263 1,604	10 14,379 7,263 1,604	10 14,379 7,263 1,604	10 14,379 7,263 1,604 0 855	10 14,379 7,263 1,604 0 855 206	10 14,379 7,263 1,604 0 855 206 544	10 1,379 1,604 0 855 206 544 434	10 1,379 1,604 0 855 206 544 434	14,379 7,263 1,604 0 855 206 544 434	10 7,263 7,263 1,604 0 855 206 544 434 434	10 7,263 7,263 1,604 0 855 206 544 434 61	14,379 7,263 1,604 0 855 206 206 244 51 51 51	14,379 7,263 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,379 1,158 1,158	10 7,263 1,604 0 855 206 544 434 51 6 378 5,158 491	10 7,263 7,263 1,604 0 855 206 544 434 434 51 5158 5,158 491	10 1,379 1,604 1,604 1,604 206 206 206 244 51 378 2,158 491 491 4,491	14,379 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604 1,604	10 1,379 1,604 1,604 1,604 1,604 1,404 1,404 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,112 1,1		· ·			<u> </u>			· ·		
Total 1999			12.434				T	7 6		3	121	280	23	0	23	8	:			13,372	13,372	13,372 7,016 1,332	13,372 7,016 1,332	13,372 7,016 1,332 0	13,372 7,016 1,332 0	13,372 7,016 1,332 0 733 205	13,372 7,016 1,332 0 733 205 394	13,372 7,016 1,332 0 733 205 394	13,372 7,016 1,332 0 733 205 394 547	13,372 7,016 1,332 733 205 394 547	13,372 7,016 1,332 0 733 205 394 547 89	13,372 7,016 1,332 0 733 205 394 547 89	13,372 7,016 1,332 0 733 205 394 547 89 0	13,372 7,016 1,332 0 733 205 394 547 89 0	13,372 7,016 1,332 0 733 205 394 547 89 0 0 0 0 7,016 623	13,372 7,016 1,332 0 733 205 394 547 89 0 0 0 1,332 1,332 1,432 5,086 6,23 3,916	13,372 7,016 1,332 0 733 205 394 547 89 623 3,916	13,372 7,016 1,332 205 394 547 89 0 0 623 3,916 526 536 546	13,372 7,016 1,332 205 394 547 89 0 0 1,332 0 0 0 1,332 0 0 0 1,332 0 0 0 1,332 0 0 1,332 0 1,332 0 1,332 0 1,332 0 1,332 0 1,332 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,044 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,047 0 1,047 0 1,046 0 1,046 0 1,046 0 1,046 0 1,047 0 1,046 0 1,046 0 1,047 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,047 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 1,046 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	13,372 7,016 1,332 0 733 205 394 547 89 0 0 0 0 1,332 1,432 623 3,916 623 3,916 623 3,916 623 4,587	13,372 7,016 1,332 205 394 547 89 0 0 4,77 5,086 623 3,916 548 546 546 548 548 548 548	13,372 7,016 1,332 205 394 547 89 0 0 623 3,916 5,086 623 3,916 5,487 3,887 10	13,372 7,016 1,332 205 394 547 89 623 3,916 623 3,916 546 547 5,086 623 3,916 5,086 623 3,916 5,086	13,372 7,016 1,332 205 394 547 89 0 0 0 0 1,332 1,016 623 3,916 623 3,916 546 547 3,883 10	13,372 7,016 1,332 205 394 547 89 0 0 4,47 5,086 6,23 3,916 51 4,587 10 10	13,372 7,016 1,332 205 394 547 89 0 0 1,386 623 3,916 623 3,916 546 547 5,086 623 3,916 548 547 546 547 546 547 547 548 623 3,916 547 547 547 547 547 547 547 547 547 548 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 3,916 623 623 623 623 623 623 623 623 623 62	13,372 7,016 1,332 0 733 205 394 547 89 0 0 0 0 0 1,332 1,016 523 3,916 523 3,916 546 546 546 546 546 546 547 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 7,016 10 10 10 10 10 10 10 10 10 10 10 10 10	13,372 7,016 1,332 203 394 547 89 623 3,916 528 3,916 546 51 4,587 3,883 10 2,270 2,270 2,270 2,318 3,918	13,372 7,016 1,332 205 394 547 89 0 0 6,086 6,086 6,086 6,086 6,086 6,086 7,47 5,086 6,187 10 10 10 10 10 10 10 10 10 10 10 10 10
Total 1998		31,330										573		0	;	27	22			-			-	-	_	-	-	-	-	-	-	-	-	-	-	•	•	•	•		-						•		
Total 1997		7 496										481		0			21					_	, 14, 7, 1,																										
Total 1996	25 444	6.825				j	34					367		0		33				13,338	13,338	13,338 6,763 1,251		•	1	•	•	•																					
Total 1995	24 524											286				4					-	-	12,	12,	12.0	21.00.11	51.00.1	51.0, 4.	21.0.0.1.	-	27.00.4	21 20 1.	21 0 1 1	21 4,4	21 6 6 4 4	21 6 7 8 8	21 20 4, 8,	21 20 4 & &	21 6 4 6,	21 20 4, 8, 4,	20 + 4 ° 6 + 6 ° 6	21 4 & 4 & 4 & 4 & 4 & 4 & 4 & 4 & 4 & 4	21 4 & 4. & 4. & 4. & 4. & 4. & 4. & 4. &	50 E 4 E 4 E 5	500± 4 6 4.6 ±,	50 4 6 4 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	50± 4 € 4 € ±	50 £ 4 € £ £ £ £ £ £ £ £ £ £ £ £ £ £ £ £ £	
Total 1994	10 077	_		_	2,086	_			: `	•			7.	0	0	22			,,,,,,	11,744	11,744 5,437	11,744 5,437 1,011	11,744 5,437 1,011	5,437 1,011 508	11,744 5,437 1,011 508 556	11,744 5,437 1,011 508 355	5,437 5,437 1,011 508 355	11,744 5,437 1,011 508 355 141 679	11,744 5,437 1,011 508 358 141 679 246	11,744 5,437 1,011 508 355 141 679 246	11,744 5,437 1,011 508 355 141 679 246 10	11,744 5,437 1,011 508 355 141 679 246 10	11,744 5,437 1,011 358 355 141 679 10 53	11,744 5,437 1,011 508 355 141 679 246 13 370 3,668	11,744 5,437 1,011 508 355 141 679 246 10 378 376	11,744 5,437 1,011 508 355 141 679 246 10 53 3,668 3,668 3,668	11,744 5,437 1,011 355 141 679 246 10 53 3,668 3,668 3,668 2,629 664	11,744 5,437 1,011 508 355 141 679 246 13 370 3,668 3,668 3,668 3,668 3,668 3,668	11,744 5,437 1,011 508 355 141 679 246 10 3,668 3,668 2,629 664 79	11,744 5,437 1,011 508 355 141 679 3,668 3,668 2,629 664 79	11,744 5,437 1,011 358 358 141 679 10 53 3,668 2,629 664 79 3,967	11,744 5,437 1,011 508 355 141 679 246 3,68 3,68 3,967 3,301 3,301	11,744 5,437 1,011 508 355 141 679 246 3,668 3,668 3,967 3,967 3,967	11,744 5,437 1,011 5,08 3,55 141 679 3,668 3,668 3,967 3,301 1,230	1,744 5,437 1,011 355 355 141 679 2,629 3,967 3,306 3,306 3,306 3,306 3,306 3,306 3,306 3,306 3,306 3,306 3,306 3,306 3,306	11,744 5,437 1,011 5,63 3,55 141 679 2,46 3,668 3,668 3,668 3,967 3,301 1,230 1,230	11,744 5,437 1,011 5,68 3,55 141 679 246 13 3,68 3,967 3,301 1,230 627 627 629 644 79	11,744 5,437 1,011 358 358 141 679 3,668 3,668 3,668 3,967 3,301 1,230 627 1,230 627 1,230 627 1,230 627	1,744 5,437 1,011 508 355 141 679 246 3,668 3,668 3,967 3,967 3,967 3,967 3,967 1,230 664 1,230 1,230 1,022
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABIISE	Alcohol-in-combination	Cocaine	Heroin	Marijuana	Amphetamines	Methamphetamine	MDMA (Ecstasy)	Ketamine	ISD		Missallonoons hollinghama	Elimited of Albertain (Option)	riuniu azepam (Konypnoi)	2	Inhalants	Combinations NTA		OTUED SIDSTANCES OF ABILE	OTHER SUBSTANCES OF ABUSE	OTHER SUBSTANCES OF ABUSE	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS Antidepressants	OTHER SUBSTANCES OF ABUSE	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS  Antidepressants  SSRI antidepressants  Tricyclic antidepressants	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS  Antidepressants  MAO inhibitors  SSRI antidepressants.  Tricyclic antidepressants  Miscelling antidepressants	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS Antidepressants MAO inhibitors SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS. Antidepressants. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antipsychotics.	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS Antidepressants NAVO inhibitors SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants Antipsychotics Phenothiazine antipsychotics	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS Antidepressants MAO inhibitors SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants Antipsychotics Phenothiazine antipsychotics Psychotherapeutic combinations.	OTHER SUBSTANCES OF ABUSE. PSYCHOTHERAPEUTIC AGENTS Antidepressants MAO inhibitors SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants. Antipsychotics Phenothiazine antipsychotics Psychotherapeutic combinations Thioxanthenes.	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  SSRI antidepressants. Tricyclic antidepressants.  Antipsychotics. Phenothiazine antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Thioxanthenes.	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  SSRI antidepressants.  Tricyclic antidepressants.  Miscellaneous antidepressants.  Antipsychotics.  Phenothiazine antipsychotics.  Psychotherapeutic combinations.  Thioxanthenes.  Miscellaneous antipsychotic agents.  Miscellaneous antipsychotic agents.	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Phenothiazine antipsychotics. Phenothiazine antipsychotics. Phychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics.	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS Antidepressants MAO inhibitors SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants Antipsychotics Phenothiazine antipsychotics Psychotherapeutic combinations Thioxanthenes Miscellaneous antipsychotic agents Miscellaneous antipsychotic agents Barbiturates	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  MAO inhibitors.  SSRI antidepressants.  Tricyclic antidepressants.  Miscellaneous antidepressants.  Phenothiazine antipsychotics.  Phenothiazine antipsychotic agents.  Thioxanthenes  Miscellaneous antipsychotic agents.  Miscellaneous antipsychotic agents.  Barbiturates  Benzodiazepines.	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  SSRI antidepressants. Tricyclic antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antisychotics. Phenothiazine antipsychotics. Psychotherapeutic combinations. Thioxanthenes Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates Benzodiazepines. Benzodiazepines.	PSYCHOTHERAPEUTIC AGENTS. Antidepressants. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants Antipsychotics. Phenothiazine antipsychotics. Phychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. CNS stimulants.	PSYCHOTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  NAO inhibitors. SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants Antipsychotics. Phenothiazine antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates. Benzodiazepines. Misc. anxiolytics, sedatives, and hypnotics. CNS stimulants.	PSYCHOTHERAPEUTIC AGENTS. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Miscellaneous antipsychotics. Phenothiazine antipsychotics. Phychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Benzodiazapines. Misc. anxiolytics, sedatives, and hypnotics. CNS stimulants.	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS. Antidepressants. SSRI antidepressants Tricyclic antidepressants Tricyclic antidepressants Miscellaneous antidepressants Antipsychotics. Phenothiazine antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates. Benzodiazepines. GNS stimulants. CNS stimulants. CNS stimulants. CNS stimulants.	PESYCHOTHERAPEUTIC AGENTS. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antisychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Benzodiazepines. Benzodiazepines. CNS stimulants. CNS stimulants. Analgesics. Antimigraine agents.	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  MAO inhibitors. SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants Psychotherapeutic combinations Thioxanthenes. Psychotherapeutic combinations Thioxanthenes. Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. CNS stimulants. CNS stimulants. Analgesics. Analgesics. Antimigraine agents Cox-2 inhibitors.	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  MAO inhibitors.  SSRI antidepressants  Tricyclic antidepressants  Miscellaneous antidepressants  Phenothiazine antipsychotics  Phenothiazine antipsychotics  Phenothiazine antipsychotics  Phenothiazine antipsychotics  Psychotherapeutic combinations.  Thioxanthenes.  Miscellaneous antipsychotic agents  Anxiolytics, sedatives, and hypnotics.  Barbiturates.  Benzodiazapines.  Benzodiazapines.  CNS stimulants.  CNS stimulants.  CNS stimulants.  Analgesics.  Antimigraine agents.  Cox-2 inhibitors.  Narcotic analdesics/combinations.	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  MAO inhibitors.  SSRI antidepressants.  Tricyclic antidepressants.  Tricyclic antidepressants.  Antipsychotics.  Phenothiazine antipsychotics.  Phenothiazine antipsychotics.  Physicyclotics agents.  Miscellaneous antipsychotic agents.  Miscellaneous antipsychotic agents.  Anxiolytics, sedatives, and hypnotics.  Benzodiazapines.  Benzodiazapines.  CNS stimulants.  CNS stimulants.  CNS stimulants.  CNS dents.  Antimigraine agents.  Cox-2 inhibitors.  Narrotic analgesics/combinations.  Narrotic analgesics/combinations.  Narrotic analgesics/combinations.	PESYCHOTHERAPEUTIC AGENTS. Antidepressants. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Phenothiazine antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotics. Phyloxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. CNS stimulants. CNS stimulants. Analgesics. Antimigraine agents. Cox-2 inhibitors. Narcotic analgesics/combinations. Nonsteroidal anti-inflammatory agents.	PSYCHOTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  MAO inhibitors.  SSRI antidepressants  Tricyclic antidepressants  Miscellaneous antidepressants  Psychotherapeutic combinations.  Thioxanthenes.  Miscellaneous antipsychotic agents  Anxiolytics, sedatives, and hypnotics.  Barbiturates.  Benzodiazepines.  Benzodiazepines.  CNS stimulants.  CNS AGENTS.  Antingraine agents.  Cox-2 inhibitors.  Narcotic analgesics/combinations.  Nonsteroidal anti-inflammatory agents.	PESYCHOTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS. Antidepressants. SSRI antidepressants Tricyclic antidepressants Tricyclic antidepressants Tricyclic antidepressants Miscellaneous antidepressants Antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates. Benzodiazepines. Benzodiazepines. CNS stimulants. CNS stimulants. CNS stimulants. Cox-2 inhibitors. Narcotic analgesics/combinations. Narcotic analgesics/combinations. Narcotic analgesics/combinations. Narcotic analgesics/combinations.	PESYCHOTHERAPEUTIC AGENTS. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Tricyclic antidepressants. Tricyclic antidepressants. Tricyclic antidepressants. Tricyclic antidepressants. Antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Benzodiazepines. Benzodiazepines. Benzodiazepines. CNS stimulants. CNS stimulants. Cox-2 inhibitors. Analgesics. Antimigraine agents. Cox-2 inhibitors. Narcotic analgesics/combinations. Narcotic analgesics/combinations. Narcotic analgesics/combinations. Miscellaneous analgesics/combinations. Miscellaneous analgesics/combinations.

-© Table 2.2.15 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Philadelphia by year (continued)

% change <sup>2</sup> 2000, 2001	31.3	2.79	: 1	. 8.
% change <sup>2</sup> 1999, 2001			528.6	3.4
% change <sup>2</sup> 1994, 2001	-64.3 -84.9 -58.8		-68.4 193.3	45.5 52.0 9.2
Total 2001	22 22 23 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	109 109 127 157	2.22 8.88 8.88 7.35 7.35 8.80 8.80 8.80 8.80 8.80 8.80 8.80 8.8	25,790 48,222 1,769
Total 2000	243 27 27 27 28 27 27 27 27 27 28 23 33 33 33 33	35  65 1,382	139 141 102 141 887 85	23,431 44,385 1,739
Total 1999	355 435 60 181 0 216 84 84 9 9 172 172	28 13 73 1,381	133 133 14 14 15 16 16 16 17 18 18 18 18 18 18 18 18 18 18 18 18 18	24,413 45,659 1,711
Total 1998	222 222 63 63 87 87 87	92 92 172,1	15.1 104 107 18 18 758 758	24,924 45,593 1,691
Total 1997	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	23 59 1,345	25.7 76 92 40 13 742 123	23,225 42,818 1,638
Total 1996	382 125 125 174 174 188 33 33 137 137 245 245	56 13 96	258 101 100 43 776	21,628 38,752 1,657
Total 1995	53 68 68 0 239 312 37 37 14 167 17	27 105 1,644	300 122 86 66 63 958	20,501 36,947 1,657
Total 1994	279 15 16 98 77 171 171 171	78 18 79 79	29.1 148 106 58 30 932 68	17,731 31,721 1,620
Drug category <sup>1</sup>	Anorexiants	Detar-aurening of blocking agents	Arter flatters Anti-infectives. Gastrointestinal agents. Hormonel products. Topical agents. Drug unknown. All other substances NTA.	TOTAL DRUG ABUSE EPISODES

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the penods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDIMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 2.2.16 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Phoenix by year

Drug category¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000,
MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination  Cocaine	5,277 2,000 1,057	6,218 2,756 1,165	6,380 2,595 1,382	6,800 2,528	6,233 2,168	6,847 1,915	7,609	8,212 2,627			14.1
Heroin Marijuana	472		632	827	873 727	1,028	1,073	1,284			
Ampnetamines	802	777	304 725	800	362 446	34.1	661 600 76	888 604		77.1	34.3
KetamineLSD	0 4 4	. o 12 (	. 0 4	7: 7:	7 :65	4 6	135	0 4 <u>2</u>		380.0	-71.4 -54.1
Miscellaneous hallucinogens. Flunitrazepam (Rohypnol)	<u> </u>	<u> </u>	200	<u>6 8 ⊆</u>	<u>&amp;</u> € €	7 39	47 53	25	281.3 212.5	56.4 -64.8	-52.8
GHB	21	14	30		N & O	14	16	:: 19 4 V	-81.0		
OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTSAntidepressants	6,164 2,628 686	6,968 3,180 905	6,138 3,044 826	5,854 2,789 916	6,052 2,702 758	7,197 2,881 904	7,818	9,593 3,738	55.6 42.2 73.9	33.3	22.7
MAO inhibitors	0 197 337	243 499	257 421	322	272	323	365	511	159.4	58.2	40.0
Miscellaneous antidepressants	151 325 91	162 378 62 4	148 404 72	193 332 62	207 325 70	342 275 52	289 43 0	4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	176.8 176.8 29.8 -50.5	53.5	46.0
Thioxanthenes	16 218 1,547	305 1,831	321 1,665 132	264 1,450	244 1,571	217 1,661	244 1,667	374	71.6	72.4	53.3 24.6
Benzodiazepines	1,031	1,307 404 65	1,192 341 148	280	1,140 291 48	1,265 291 40	1,219 324 54	1,488 432 46	46.3	48.5 48.5	22.1 33.3
CNS AGENTSAnalgesicsAntimigraine agents	2,451 1,919 9	2,502	2,247	2,210	2,442	3,121	3,429	3,303	68.5	32.3	20.4
Cox-2 inhibitors	492 342 385 691	0 483 330 247 652	515 251 222	645 289 183	841 287 201	1,429 284 213	1,321 383 334	1,820 512 145	269.9 49.7 -62.3	400.0 27.4 80.3 -31.9	-50.0 275.0 37.8 33.7 -56.6
Analgesic combinations NTA	0		0	0	3 1	0	30	3		4.00	

Table 2.2.16 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Phoenix by year (continued)

% change <sup>2</sup> 2000, 2001	31.9	35.3	97.2 231.7 150.0	133.3	49.7 72.2	62.9	43.2 67.4 108.3	5,100.0	15.4 9.2
% change <sup>2</sup> 1999, 2001	36.3	57.1	148.6 369.0	105.4 425.0	60.9	124.4	87.5	940.0	21.6 26.8 22.4
% change <sup>2</sup> 1994, 2001	41.4 267.4 40.0		145.1 423.1 -35.5	181.5 133.3	167.0 106.7 100.0	339.1	425.0		48.1 55.6 46.6
Total 2001	17 327 9	33 0 437 	353 136 20	21 22 21	259 31 58	101	1,114 21 126 72 72 150	57 52 612 84	10,084 17,805 937
Total 2000	16 248 3	323	179 41	111	173 18 56	13 62	1,005 14 88 43 72	255 1 715 48	9,072 15,428 858
Total 1999	240 12	284 284 :	24 2 4 5	<u>8</u> € 4 4	161 28 39	¥ 8 4	892 14 97 67	542 67	8,291 14,044 765
Total 1998	20 210 9	41 0 276 0	20 t	50 80	118 18 37	3 13	650 105 34 45	21 392 28	7,058 12,285 717
Total 1997	67 180 4	62 0 271 0	121 10 10 10	38 16	\$= ¥8	2 4 5 2 4 6	630 11 35	371	7,327 12,654 690
Total 1996	44 153 5	119 342 0	109	24 4 6	35 4 8	38	645 11 76 36	25 4 4 21	7,431 12,517 732
Total 1995	27 138 7	135 0 473 0	151 35 25	61 61 83	121	44 10 44	1,014	35 718 29	7,910 13,187 701
Total 1994	29 89 15	46 0 353 0	144 26 31	20 20 6	97 15	73 e 73	844 4 171 57	40 0 499 30	6,808 11,441 639
Drug category¹	Anorexiants	Antiparkinson agents	RESPIRATORY AGENTSAntihistamines. Bronchodilators	Decongestants	CARDIOVASCULAR AGENTS	Calcium channel blocking agents	OTHER SUBSTANCES	Nutritional products. Topical agents. Drug unknown.	TOTAL DRUG ABUSE EPISODES

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

<sup>&</sup>lt;sup>2</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

Table 2.2.17 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for St. Louis by year

	1		
% change <sup>2</sup> 2000, 2001	;		34. 34. 5. 5.
% change <sup>2</sup> 1999, 2001	323.1	27.1 22.1 22.1 31.8 85.9 85.9 38.5 38.5	67.1 23.8
% change <sup>2</sup> 1994, 2001	233.9 157.6 351.4 125.5	-55.8 196.2 -83.2 126.1 -52.0 -52.0	168.9 -58.4
Total 2001	10,382 3,080 1,309 1,309 167 167 167 100 100 100 100 100 100 100 100 100 10	2,580 2,734 813 365 134 311 279 19 1,619 1,269 2,286 1,954 1,954	1,108 281 102 438 0
Total 2000	8,259 2,490 2,490 1,084 1,763 126 126 74 74 77 77 77	5,059 2,506 7,516 334 117 300 250 30 1,473 1,123 2,019 1,726 1,726 1,726	824 268 155 447 0
Total 1999	7,298 2,323 2,323 1,639 1,639 104 104 105 10 10 10 10 10 10 10 10 10 10 10 10 10	2,239 664 140 2,86 140 236 170 0 1,355 1,355 1,355 1,439 1,651	663 227 103 438 0
Total 1998	6,380 2,092 2,072 622 1,338 0 0 0 35 11 11	2,262 723 723 176 176 214 180 1,306 1,306 1,316 1,513 1,513	230 116 421
Total 1997	5,179 1,898 1,494 447 1,109 88 67 2 2 2 0 0 0 0 0 0 0 0 7 7	5,130 836 836 836 191 213 193 105 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,139 1,	301 159 135
Total 1996	5,521 1,892 489 924 76 0 0 0 0 0 0 27 2	5,499 968 968 3 2,799 1,486 1,500 1,500 1,664 1,148 2,66 2,66 2,66 2,66 2,66 2,66 2,66 2,6	212 394 611 .:
Total 1995	5,409 2,006 1,841 369 369 74 76 70 70 70 70	2,498 848 848 848 1,342 1,342 1,342 1,689 1,441 1,689	369 197 470
Total 1994	6,055 2,1329 392 897 87 51 77 77 77 15 0 0	4,951 762 762 350 350 303 105 111 111 1005 325 325 100 111 111 1005 325 1005 111 111 1005 1005 1005 1005 1005	365 245 490 .:
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Cocaine Marijuana Marijuana Amphetamine Methamphetamine Michamphetamine MDMA (Ecstasy) Ketamine LSD RCP  I SD  Miscellaneous hallucinogens Fiuritrazepam (Rohypnol). GHB Inhalants	PSYCHOTHERAPEUTIC AGENTS. Antidepressants MAO inhibitors. SSRI antidepressants. Iricyclic antidepressants. Miscellaneous antidepressants. Antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. CNS stimulants. CNS stimulants. Antimigraine agents.	Nonstrong and anti-inflammatory agents

The solutions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates

% change <sup>2</sup> 2000, 2001	46.7		93.3	22.9	190.9	-1.6
% change <sup>2</sup> 1999, 2001	32.2	-64.7	-57.9		540.0	3.0
% change <sup>2</sup> 1994, 2001	-76.7 97.5	-75.0	107.1		700.0	-1.5
Total 2001	7 156 12 154 0	255 6 6 6 6 7 1 7 7 1 7 1 7 1 7 1 7 1 1 1 1	20 : 22 82 0 4	33 26 33 38 38 38 38 38 38 38 38 38 38 38 38	2 2 4 5 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	8,216 15,963 903
Total 2000	153 153 13 10 105	163 127 13 100 100 100	95 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	275 6 41 32 19	108 39	6,908 13,317 918
Total 1999	118 118 7 7 0	115 22 27 7 7 7 3 ::	92 0 19 37 37	292 7 84 34 37	30 30	6,336 11,687 876
Total 1998	21 11 5 0 64	102 31 8 13 13 145	82 0 1 0 0 1 2 4 6	361 101 55	84 84	5,719 10,704 819
Total 1997	31 106 7 21 0 88	120 211 41 + 44 68 68	126 17 15 36 11	398 11 124 32	31 137 35	5,664 10,310 841
Total 1996	25 92 14 24 103 0	130 19 10 14 14 18 58	166 20 26 48 21 52	482 140 73 57	138 31	6,179 11,020 880
Total 1995	120 120 29 0 74	167 28 13 18 18 90 90	141 144 32 32 	452 .:: 128 61	147 147	5,657 10,346 869
Total 1994	30 79 8 26 0 121	252 222 222 222 222 222 222 222 222 222	116 18 14 7 7	450 .:. 151 78 35	30 4 22 30 4 20 8	6,038 11,006 917
Drug category¹	Anorexiants	RESPIRATORY AGENTS	CARDIOVASCULAR AGENTS	OTHER SUBSTANCES	Nutritional products	TOTAL DRUG ABUSE EPISODES

This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

AVAILABLE

COPY

BEST

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

Table 2.2.18 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for San Diego by year

% change <sup>2</sup> 2000, 2001	-5.8	-19.0	-28.9	15.9				-16.7	7.40	0.89	-37.5	9	-50.0	28.6	007	0.01	 	- 5	-100.0	20.0	4.00				200.0		10.6	Ċ	9.0 25.1	40.0	11.	5 - 5	-58.3	100.0	28.7	-12.2	-32.7	
% change <sup>2</sup> 1999, 2001	-7.3	-23.6	-31.0	19.9		15.2	108.0	-23.1	7.00-	7 47	?	-26.0	-75.0									-29.3	-38.4			-27.4		14.0		-46.4	14.4	15.4	4.44		29.0		-23.1	
% change <sup>2</sup> 1994, 2001	30.8			116.2	147.2	ľ	/99/	000	7.66-	-615	2	1,800.0	-80.0	200.0	74.6	0.14	45.4	100.4	26.3	?	85.0	-23.2	-72.4	-85.7	-82.4	82.0	71.0	116.2	S. S.	48.3	649	6 02	-50.0		227.6	19.1	7	
Total 2001	6,133			1,107								. 57	က	o o	5 645	5 0	2,333 605	9	250	223	222	212	45	_	က	162	1,678	147	212	15	2.545	2,123	O.	4	1,304	237	2 2	00
Total 2000	6,508											9	9	7	5 131	0,101	623	300	230	160	231	212	47	0	_	164	1,517	145	175	25	2.280	1,913	12	7	1,013	270	133	0
Total 1999	6,619	1,063	1,063	923	916	98 46 46	720	2 4	3 6	22	5	77	12	13	5 421	2,42	672	10	245	193	235	300	73	-	က	223	1,600	25.0	222	78	2.224	1.839	6	0	1,01	727	462	0
Total 1998	6,668	971	984	1,128	7 2	12/	<u> </u>	1 K	22.65	3 45	80	34	4	7	5.517	2,0,0	733	3 -	292	204	237	268	112	2	9	148	1,614	5 5	262	32	2,204	1,783	15	0	882	729	464	0
Total 1997	6,578	844	91	970	7/0	0 a	0	: 6	3 25	14	7	34	4	9	5 272	2,2,0	709	3	264	278	164	226	105	0	9	115	1,525	3 5	258	36	2,054	1,688	12	0	206	324 178	464	1
Total 1996	5,646									53			: '		4 538	2,000	622	er.	208	238	172	263	133	9	9	114	1,2/3	02.6	231	30	1,779	1,452	80	0	612	170	425	0
Total 1995	4,494	644	675	450	624	900	o c	. <u>1</u>	28	23	0	22	<del>0</del>	<b>60</b>	3 681	1,660	453	0	124	180	149	211	112	က	<del>-</del>	86	9/6	999	231	72	1,512	1,247	17	0	464	163	387	0
Total 1994	4,689	299	687	212	2 6	- <b>"</b>	o c	47	: 12	26	;	က	15	m	3.987	1 788	503	, es	160	220	120	276	163	7	17	88	981	671	241	29	1,543	1,242	<del>0</del>	0	398	197	438	0
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABUSEAloohol-in-combination	Cocaine	Heroin	Manjuana Amphetamines	Methamphatamina	MDMA (Festasy)	Ketamine	LSD	PCP	Miscellaneous hallucinogens	Flunitrazepam (Rohypnol)	GHB	inhalants	Combinations N i A	OTHER SUBSTANCES OF ABUSE	PSYCHOTHERAPEUTIC AGENTS.	Antidepressants	MAO inhibitors.	SSRI antidepressants.	Tricyclic antidepressants	Miscellaneous antidepressants	Antipsychotics	Phenothiazine antipsychotics	Psychotherapeutic combinations	Hioxanthenes	Miscellaneous andpsychotic agents	Rarbiturates	Benzodiazepines.	Misc. anxiolytics, sedatives, and hypnotics	CNS stimulants	CNS AGENTS	Analgesics	Antimigraine agents	Cox-2 inhibitors.	Narcouc analgesics/combinations Nonsteroidal anti-inflammaton, agents	Salicylates/combinations	Miscellaneous analgesics/combinations.	Analgesic combinations NTA

Table 2.2.18 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for San Diego by year (continued)

% change <sup>2</sup> 2000, 2001	-33.3		78.3 88.9 375.0 95.0	-8.6 -66.7 -37.3 -17.4 500.0	-1.9
% change <sup>2</sup> 1999, 2001	-37.5 -45.5 -55.2 25.4	26.5 -66.7	24.4 -34.8 850.0 56.0	28.4 -83.3 -47.9 -53.7 -54.5 1,100.0 -21.7 -48.0	
% change <sup>2</sup> 1994, 2001	-54.5 49.5 -64.7 -74.0	-78.9	66.7 -43.3 111.1	-35.9 -64.4 -57.8 200.0	38.1 35.8 20.2
Total 2001	160 160 13 13 232 0	907 4 E 4 29	107 15 17 17 19	288 37 - 37 - 19 - 19 - 10 - 10 - 10 - 10 - 10 - 10	6,962 11,779 624
Total 2000	151 7 15 15 0 187	00 00 00 00 00 00 00 00 00 00 00 00 00	09 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	315 23 23 36 19 14 2	7,094 11,639 639
Total 1999	16 144 11 29 0 0	30 30 30 30 4 4 4 4 6	86 23 20 20 25 25	402 427 427 40 40 11 18 18 25	7,036 12,040 657
Total 1998	36 151 26 4 199 0	126 16 25 4 4 6 4	110 15 35 35 24 24	429 95 427 477 4 7 4 178	6,982 12,184 611
Total 1997	37 113 12 40 0 164	127 11 27 27 3	107 16 30 23 18	488 134 52 39 19 200 23	6,747 11,851 586
Total 1996	29 111 8 32 0 147	22 24 25 25 26 27	73 27 11 22	377 113 37 25 23 23 143	5,806 10,184 575
Total 1995	19 82 82 34 34 124	47 47 61 61 62 7 7	80 18 27 17 16	314 38 38 36 4 4 123 4 16	4,660 8,175 504
Total 1994	22 107 17 50 50 0 105	117 119 119 119 120	91 30 21 21	449 104 104 45 23 23 24 213 213	5,043 8,676 519
Drug category¹	Anorexiants	RESPIRATORY AGENTS  Antihistamines Bronchodilators Decongestants Expectorants Upper respiratory combinations. Respiratory agents NTA.	CARDIOVASCULAR AGENTS Antiadrenergic agents, centrally acting Beta-adrenergic blocking agents Calcium channel blocking agents Diuretics Cardiovascular agents NTA	OTHER SUBSTANCES Alternative medicines Anti-infectives Gastrointestinal agents Hormones Nutritional products Topical agents Drug unknown	TOTAL DRUG ABUSE EPISODES

This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

Table 2.2.19 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for San Francisco by year

Drug category <sup>1</sup>	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
	12,458	10,512	9,649	8,697	7,263	8,309	8,675	10,033	-19.5	20.7	15.7
	3,227	2,560	2,310	1,979	1,843	1,935	2,054	2,482	-23.1	28.3	20.8 20.8
	3,654	3,113	3,132	2,719	2,360	3,050	2,756	2,790	-23.6		
	200	206	424	388	391	469	627	704	40.8	50.1	12.3
	5 63	328	235	273	1/2	254	371	186	81.5	209.4	111.9
	1,301	1,106	934	1,012	616	554	591	611	-53.0		
	7 7	87	32	cg.	38	47	107	152	375.0	223.4	42.1
	- a	2 4	4 5	- 64	7 5	4 /	<del>4</del> 5	<u></u> ;	1,000.0	175.0	•
·	2 5	2 0	7 2 4	<u> </u>	5 0	သို့	79	9 1	68.9	-16.4	-31.3
	2 K	50	0 2 4	7 6	200	92	2 6	<u> </u>	42.0	22.6	
	20	-	3~	<u>+</u> +	3.0	<u> </u>	<u>, c</u>	24 0	133.3	180.0	
	7	. 4	7 2	- 8	10.0	3,0	15.4	2 0 4	1 226 1	4	
	. ~	<u> </u>	4	3 5	70.	2	<u> </u>	0 4	4.000.4	C.4.	
	28	4	<b>8</b>	36	- 7-	17	25	17	-70.7		-32.0
5,6	5,689	5,014	4,564	4.794	5.263	4.393	3.496	3 7 10	-34 8	145	4
2.056	26	1,818	1,608	1 481	1 236	1366	1,304	7,7,7	2 6	2 4	
4	418	382	355	320	289	358	786	800	21.2	13.7	4.1.4
	<del>-</del>	က	3	0	} :	7	5	250	1001-	1000	13.3
Ť	142	147	125	127	106	145	102	124		- 100.0	216
×	205	144	108	87	94	86	52	55	7 67-	420	0.14
_	2	87	119	106	82	114	130	149	112.9	30.7	14.6
311	<del>-</del>	273	190	163	123	142	117	145	-53.4	3	23.0
150	0	120	107	73	45	45	25	23	-84.7	-45.2	2
,	0	2	:	0	0	0	0	0			
	9 1	23	10	12	2	:	က	-	-96.2		-66.7
<del>-</del> ;	135	124	7.1	77	73	97	88	121		24.7	36.0
1,300	9 2	1,146	1,041	980	817	847	882	1,096	-15.7	29.4	23.8
- (	<u>¥</u> į	75	99	4	51	48	78	115		139.6	47.4
Ö	32/	08/	98	727	619	665	664	825		24.1	24.2
m	349	291	245	188	147	134	143	157	-55.0	17.2	
	72	- 1/	55	-19	_	19	4	9	-63.0	47.4	
1,477	1	1,330	1,361	1,184	1,151	1.207	1.389	1.589		31.6	14.4
1,2	8	1,077	1,082	964	964	286	1,194	1,353		37.5	7 -
	ω ,	<del></del>	<b>80</b>	7	က	~	<u></u> 8	~	-75.0	100.0	?
	0	0	<del>-</del>	<del>-</del>	<del>-</del>	<del>-</del>	<del>-</del>	4			
-,	545	227	515	529	541	009	969	839	53.9	39.8	20.5
•	88 ;	173	161	127	119	131	130	155	-17.6	18.3	19.2
	145	97	117	89	75	64	103	65	-55.2		-36.9
,	200	7/7	187	60X	77	191	263	288		20.8	9.5
	,	,	,	5	5	5	n i	5			

# Table 2.2.19 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for San Francisco by year (continued)

% change <sup>2</sup> 2000, 2001	-30.0	-37.5	78.7	20.6 107.7	80.0	-18.9	65.1	90.9	50.0	166.7 150.0		100.0	92.9		325.0	-55.5 -29.4	9.1 8.3 8.3
% change <sup>2</sup> 1999, 2001		-61.5		86.4 125.0	80.0	7.007	31.5			300.0 212.5	-77.5	300.0	575.0	133.3	1,600.0	-83.7 -36.8	-2.3
% change <sup>2</sup> 1994, 2001	-36.4 27.3	-92.5		-24.8	-36.4 -59.1	-31.8 -66.7		75.0	-60.0	-38.5	-80.3	-80 o	!	-17.6	240.0	-84.8 -52.0	-29.2 -24.3 -5.6
Total 2001	112	יט כ	109	82	<u> </u>	30,	71	121	9	25	387	4 C	27	20 4 4	17	267 12	8,575 13,743 545
Total 2000	111	າ ∞ ⊂	<u>. 6</u> 0	68	യ വ	37	43	<del>1</del> <del>1</del>	4	<del>د 5</del>	692	2 1	4.6	2 4 4	4	17	7,857 12,171 503
Total 1999	103	<u>, ω</u> c	93	44		25.0	22	23	80	0 80	1,723	2 م	4	9 9	_	1,636	8,928 12,702 558
Total 1998	6 77	25.	0 0	58 13	ოთი	3.50	28	23	4	8 L	2,759	4 %	9 6	9 2	4	6 6 9 9 9 9	9,068 12,525 513
Total 1997	18 95 4	7,00	40	58 9	270	32.2	72	20	<b>o</b>	19	1,999	9 <del>1</del>	.t.	c7	Ω.	1,881	9,424 13,491 479
Total 1996	112	38	117	90	23 2	4.20	81	25	=	ა ნ	1,422	5. 5.	22	15.0	4	1,281	9,533 14,213 495
Total 1995	£ 48 €	46.	116	106	25 4	56	105	35	15	11 28	1,655	£ 69	78	2 8	4	1,497	10,161 15,527 481
Total 1994	11 88 4	67	50	109 24	25 1	4 m	62	12 42	15	13 22	1,967	101	<u>ج</u> ج	1 20	5	1,738	12,115 18,147 577
Drug category¹	AndrexiantsAnticonvulsantsAntiemetic/antivariiton agents	Antiparkinson ageing ageing Antiparkinson ageing ageing	Muscle relaxants	RESPIRATORY AGENTS	Bronchodilators	Upper respiratory combinations	CARDIOVASCULAR AGENTS	Antiadrenergic agents, centrally acting	Calcium channel blocking agents	Diuretics	OTHER SUBSTANCES	Autemative medicines	Gastrointestinal agents	Nutritional products	Topical agents	Drug unknown	TOTAL DRUG ABUSE EPISODES

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

: .\* \*

<sup>&</sup>lt;sup>2</sup> This column denotes statistically significant ( $\rho < 0.05$ ) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for  $\rho$ -values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

Table 2.2.20 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Seattle by year

Drug category¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
MAJOR SUBSTANCES OF ABUSE	9,787	8,286	8,303	11,653	8,768	9,033	12,078	11,614		28.6	
Cocaine	3,029	2,272	2,149	2,988		2,228	3,338	3,145		41.2 35.3	
Heroin	2,137	2,023	2,418	2,894	(2)	2,470	2,490	1,927		-22.0	-22.6
Marijuana	910	993	899	1,663		808	1,414	1,596	75.4	97.5	
Amphetamines	186	233	178	462		345	640	669		102.6	
Methamphetamine	309	258	195	479		353	540	395			
MDMA (Ecstasy)	7	10	12	20		32	128	115	5,650.0	259.4	-10.2
Ketamine	0	0 !	0	7		က	4	1			-75.0
LSD	212	245	182	163	<u>8</u> :	121	107	79,	-70.8		42.1
Miscellandous hallucinosans	7.20	3 6	000	9 r	4 4	7 6	116	128	540.0	172.3	3
Flinitrazenam (Rohymon)	-	<del>-</del> C	3 -	3 0	?	<del>-</del>	<u> </u>	पट		20.0	o.
GHB	<u> </u>	0 0	<u>е</u>	5		- 72	57	9		-100.0	-21 E
Inhalants	4	<u> </u>	<u> </u>	:5	- 4	16	5 5	1,00	275.0		25.0
Combinations NTA	9	:	12	<u></u> 60	· m	<b>.</b> 00	21	12	100.0	50.0	42.9
OTUED SUBSTANCES OF ABUSE	4 000	£ 702	7 455	0	977	, 60	38.0	1000		1	
OTHER SUBSTANCES OF ABUSE	026,7	20,70	0,420	0,000	0,140	4,821	0,840	8,204		70.2	19.0
POTCHOINERAPEUTIC AGENTS	3,436	2,518	7,387	2,720	2,122	1,839	2,630	2,883		56.8	9.6
Andepressants	0¢r,r	718	<del>2</del> (	839	646	287	96/	798		35.9	
MAC Inhibitors	7	m (	D ;	:	- !	0	0	0	-100.0		
SSKI antidepressants	287	293	284	257	199	186	317	308		65.6	
Tricyclic antidepressants	613	333	272	366	529	191	229	233	-62.0	22.0	
Miscellaneous antidepressants	248	188	224	210	218	210	250	257		22.4	
Antipsychotics	328	219	192	203	155	121	181	195		61.2	
Phenothiazine antipsychotics	113	87	65	47	35	23	20	17	-85.0	-26.1	-15.0
Psychotherapeutic combinations	7	က	0	7	0	0	0	0	-100.0		
Thioxanthenes	23	16	S.	18	သ	0	0	0	-100.0		
Miscellaneous antipsychotic agents	185	112	122	137	116	86	160	178		81.6	11.3
Anxiolytics, sedatives, and hypnotics	1,912	1,421	1,360	1,634	1,275	1,092	1,611	1,845		0.69	14.5
Baroiturates	\$ 5	130	60	153	108	106	130	191	127.4	80.2	46.9
Benzodiazepines	1,207	887	947	1,104	925	785	1,220	1,354		72.5	11.0
Misc. anxiolytics, sedatives, and hypnotics	620	404	319	377	243	202	261	300	-51.6	48.5	14.9
CIND Sumulants	40	20	ß	44	<del>2</del>	33	42	4		12.8	
CNS AGENTS	3,394	2,459	2,311	2,903	2,222	2,201	3,040	3,991		81.3	31.3
Analgesics	2,798	2,073	1,936	2,504	1,904	1,947	2,666	3,505		80.0	31.5
Antimigraine agents	4	9	က	1	7	5	80	:			
Cox-2 inhibitors	0	0	0	0	0	0	5	80			
Narcotic analgesics/combinations	1,215	954	943	1,422	4,1	1,237	1,699	2,560	110.7	107.0	20.7
Nonsteroidal anti-inflammatory agents	426	284	277	276	276	203	242	250	4. 6.	23.2	
Microllegone graftagio/combinetica	393	700	730	247	¥ 6	147	178	143	-63.6	4	-19.7
Analogic combinations NTA	ē C	200	<del>1</del> c	Š,	202	d d	48.0	n n n		52.3	
	,	, T	,	,	,	,	7	5			

# Table 2.2.20 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Seattle by year (continued)

% change <sup>2</sup> 2000, 2001	-10.0	100.0	51.7 -100.0		-50.0	30.4 -33.3	27.3 -54.5	85.7 500.0 29.6	6.3	125.0	7.8	12.8
% change <sup>2</sup> 1999, 2001	125.0 90.0	166.7	82.4	103.3		136.8	50.8	125.0 52.2	67.5	-30.0	79.0	36.5 43.0 24.2
% change <sup>2</sup> 1994, 2001	43.8	-37.5 -83.7		-29.7	-95.0 -45.2		-41.7 -76.2	-52.6	59.3 450.0 -74.3	47.8	234.0 -55.8	0.2
Total 2001	18 228	<u>v</u> & c	217	187	23 2	- 06 8	98	13	1,045 11 45	27 23	845 23	11,495 19,818 701
Total 2000	20 199	<u> 4 c</u>	143	167	4 8 a	12	77	27	983 11 63	12 7	784	11,115 18,974 621
Total 1999	120	<u>ი ო c</u>	0 10	92	<u>ο 5</u> α	ာ ထွ က	15	23	624 10 32 35	2000	472	8,424 13,854 564
Total 1998	23 151	200	107	23	23	27.4	18	30 6 7	619 65 32	17 ::	413 34	8,327 13,914 550
Total 1997	25 178	25	159	0£ 8			130	32 24	667 19 106 32	96 12 6	384	10,587 18,203 582
Total 1996	14 163	- <del>1</del> 8 -	152	113	2 <u>5 6</u>	. <u>6</u>	113 27 36	21 18	501 13 125 45	37 20	244 16	8,471 13,728 599
Total 1995	138	380	17,	<u>8</u> 4	39	12.5	140 29	13	481 3 129 39	30	210	8,505 14,068 570
Total 1994	32 222	47 49	270	266	4 4 2 7	97	168 21	22 8	656 2 175 56	67 34 15	253 52	10,363 17,707 700
Drug category¹	Anticorvulsants	Antiemeticzaniwerugo agents	Muscle relaxants	RESPIRATORY AGENTS	Bronchodilators	Upper respiratory combinations Respiratory agents NTA	CARDIOVASCULAR AGENTSAntiadrenergic agents, centrally acting	Calcium channel blocking agents	OTHER SUBSTANCESAltemative medicinesAnti-infectives	Hormones. Nutritional products. Topical agents.	Drug unknownAll other substances NTA	TOTAL DRUG ABUSE EPISODES

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 2.2.21 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Washington, DC by year

% change <sup>2</sup> 2000, 2001	20.6	ŧ	4.4.4 65.6		63.6	
% change <sup>2</sup> 1999, 2001		į	-71.3 198.3		44.8	
% change <sup>2</sup> 1994, 2001	43.7 40.3 50.6	:	-85.1 -59.6	i	  -100.0	
Total 2001	10,612 2,774 2,894 1,888 2,135	24 110	25 525 	:	6,868 2,452 7,33 37.5 80 80 27,5 263 2,583 2,596 2,596 1,098 1,098 1,098 1,098 1,098	
Total 2000	10,302 2,300 2,830 1,946 2,510	 62 78 7	317 317 0 24	:	5,927 2,177 610 610 315 722 220 220 220 1,303 1112 839 839 351 44 2,427 2,094 2,094 672 395 672 883 883 883 883 883 883 883 883 883 88	0
Total 1999	10,695 2,745 3,150 1,771 2,516	: ee : e	87 176 12 13	7	2,342 6,747 6,70 6,70 1,406 1,406 1,406 1,406 1,406 1,406 1,406 1,406 1,406 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,506 1,	0
Total 1998	11,876 3,270 3,718 2,097 2,360	. 10 4 4	152 152 0 0 4 15	:	2,705 805 805 805 354 229 229 235 49  1,581 1,063 352 83 352 83 3,011 2,559  0 740 740 964	:
Total 1997	11,083 3,216 3,223 1,689 2,394	: : :2	2007 212 1007 1007	0	2,876 3,204 910 3,990 2,843 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,107 1,10 1,10	0
Total 1996	11,842 3,605 3,881 1,527 2,167	: <b>:</b> : 6	132 347 	0	3,305 893 893 893 199 199 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,970 1,97	0
Total 1995	11,474 3,407 3,542 1,295 2,035	<u> </u>	176 868  0	7	3,380 945 0 481 248 1,903 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,205 1,20	0
Total 1994	15,419 4,926 4,849 1,254 2,712	: <b>8</b> : :	168 1,301 0	9	9,768 3,788 1,003 1,003 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438 1,438	:
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin Marijuana	Amphetamines	LSD. PCP. Miscellaneous hallucinogens. Flunitrazepam (Rohypnol). GHB.	Combinations NTA	OTHER SUBSTANCES OF ABUSE  PSYCHOTHERAPEUTIC AGENTS. Antidepressants. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Phenothiazine antipsychotics. Phenothiazine antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. CNS stimulants. Anxiolytics, sedatives, and hypnotics. CNS stimulants. Analgesics. Antimigraine agents. Analgesics. Analgesics. Antimigraine agents. Cox-2 inhibitors. Analgesics. Antimigraine agents. Cox-2 inhibitors. Analgesics. Antimigraine agents. Salicytates/combinations. Nonsteroidal anti-inflammatory agents. Salicytates/combinations.	Analgesic combinations NTA

# Table 2.2.21 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates for Washington, DC by year (continued)

% change <sup>2</sup> 2000, 2001	200.0	59.2	72.3					666.7	5.0
% change <sup>2</sup> 1999, 2001	212.5		65.6	58.5	55.0	47.8		ī	11.7
% change <sup>2</sup> 1994, 2001	61.1			-82.6		-57.1	-32.6	-31.7	5.5
Total 2001	207 25 25	121	100	130	98 31	20 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	1,038  77 46 71	47 46 714 31	10,566 17,480 1,261
Total 2000	18 227 	0 0 0	173 51	: :6 :	98 29	18 7 7 8 7	1,053  53 46 57	33 6 817 35	10,303 16,229 1,201
Total 1999	13 233 8 22	020	180 54 9	82 ::	117 20 20	38 0 23	1,046 10 84 47	29 .:. 780 26	10,282 16,936 1,129
Total 1998	26 297 	0 00 0	217 51 12	32 15 104	140 31	47	1,105 19 106 44 51	37 808 40	11,596 19,054 1,112
Total 1997	305	127	279 62 20	8 1 1 1 1 1 1 1 1	129 28 27	8 2 2 3	947 .:: 182 29 36	55 1 581 50	11,193 18,959 1,077
Total 1996	38 208  58	145	303 57 18	50 17 156	152 46	34 18	993 195 55 48	39 599 52	11,720 19,801 1,090
Total 1995	20 207 18 55	151	318 72 25	45 6 1 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	141 37	32 33	1,278 .:: 210 95 76	62 762 42	11,830 19,876 1,176
Total 1994	26 220 10	040	358 83 26	46 164	154 25	28 28 40 40	1,539 0 264 71	1,045 42	14,152 25,187 1,195
Drug category <sup>1</sup>	Anorexiants	General anesthetics.  Muscle relaxants	RESPIRATORY AGENTSAntihistaminesBronchodilators.	Decongestants	CARDIOVASCULAR AGENTSAntiadrenergic agents, centrally acting	Calcium channel blocking agents Diuretics Cardiovascular agents NTA	OTHER SUBSTANCES	Nutritional products	TOTAL DRUG ABUSE EPISODES

333

149 **ED Trends From DAWN** 

T-61

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimate with an RSE greater than 50% has been suppressed.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 2.3.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half year

Alcohol in Combination	1997	1998	1998	1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% cnange H2 2001, H1 2002	% change- H1 2001, H1 2002
8-Ball Cocaine	86,744 82,359	91,064 85,757 3	93,927 86,254 0	102,088 79,575 0	94,134 89,176 2	100,347 84,704 0	104,164 90,178 0	104,533 96,752 0	113,472 96,282 2	97,527 91,687 	<u> </u>	
Basuco	0 8	04	0 +	0 +	<del>- 0 -</del>	0 +	00	00	00	00	-100 0	
Benzoylecgonine	<u>6</u> 0	;°	150	: :	148	152	' ; <sup>c</sup>	200	ī <u>;</u> c	) ¦c	2	7
Candy	00	00	200	00	00	0.00	00 ;	100	000	; <del>o</del>		-100.0
Cinnamoylcocaine	62,044	64,248	64,916	59,837	68,420	64,822	69,835	72,721	72,439	70,106		
Cocaine Metabolite Coke	247	4 60	0 :: 6	4 4	⊃ : ç		0 0 1	100	1170	123		i i
Crack.	19,949	20,873	20,854	19,220	20,348	19,356	19,911	23,466	23,497	20,694	_	9.6/-
Crystal Cocaine.	0	0	00	0	00	;0	<del>-</del>	<del>-</del>	; <b>r</b> o	150	•	:
Dust. Ecgonine Methylester	;°	:0	4 0	<u> </u>	<del>- 0</del>	; 0	<del>т 0</del>	: :	4+	w c	-100	
Eight Ball Ethyleαonine	00	<del>-</del> c		00	:	; c	: 6	-	· ; c	00	2	-100.0
Flake	000	000	- 0 -	10	. 0	0 0	0	:0	00	;°		
Love Drug	5	5	<del>-</del>	0	0	0	0	0	_	_		
Methylecgonine	:	0	~	0	0	:	0	_	0	0	-	-100.0
Norcocaethylene.	00	00	- 0	0 0	0 0	00	0 (	0	0	0		
P-Blow	00	00	<b>?</b> ;	٧ :	<del>5</del> :	00	0	:°	<del></del>	00		
Ready RockRock Cocaine.	<del>-</del>	<u>- 7</u>	<u>2 t</u>	<del>- u</del>	7	0 0	40	:	01	77		
<del></del>	35,899	37,859	37,829	37,406	44,786	47,635	47,169	44,138	48,926	42,571	-13.0	
Beast.	00	0	0 1	0 (	0 (	0	0	0	0	0		
Blue Diamond Heroin.	n	:	o ·	2	2	7	:	4	m	:		
Brown Heroin	0	0	0	-	0	c		_		_		
Brown Mexican Heroin	00	00	00	00	00	000	000	0	0 ;	: :6		
China Cat Heroin	•	•	>	5	5	5	5	:	F	22		:
China White Heroin	; c	:	00	0 0	00	0	0	0	: '	0		
Dead President.	00	:0	0	<del>-</del>	<del>5 0</del>	<del></del>	<del>-</del>	<del>-</del>	0 0	00		
Diacetylmorphine	0	0	0	0	0	0	· :	· :	0	00		
Heroin	35,873	37,843	37,771	37,387	44,715	47,556	47,044	44,120	48,897	42,494	-13.1	

Table 2.3.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half jear (continued)

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
Heroin Dope Heroin with Dormin	0	; C	00	00	00	00	00	0	40	25	525.0	
Heroin with Scopolamine.	. •	Ö		0	0	0	0	00	00	00		
Horse	•	•	_				c	-	-	-		
Mexican Heroin.	- 0	- 0	00	:0	: <sup>©</sup>	:0	0	00	0	0		
Mexican Mud	•	•	•	(		•	•	•				
Mixed Jive Heroin	>	<b>&gt;</b>	<b>&gt;</b>	5	5	5	0	0	0	21		
Mixed Junk Heroin	0	0	0	0	0	÷		:	0	0		
Monoacetylmorphine	0	0	0	:	_	0	i	က	0	0		-100.0
P-Dope	:	9	0	-0	0	0	0	0	_	Ċ	-100 0	
Pakistani Heroin	0	0	0	0	0	0	0	0	0	<del>, -</del>		
Persian Heroin	00	00	00	0 0	0,	0	0	0	0	0;		
Polo	5 6	0	<del>-</del>	0		<b>5</b> C	5 0	<b>5</b> C	<del>7</del> <del>-</del>	4 0	1000	
	<b>'</b> :	0	' :	2	0	· :	0	0	- 0	0	2.00	
Stuff.	0	0	0	0	0	0	0	0	0	0		
Super Buick	8	0	- 1	7	:	0	: '	0	0	0		
I ootsie Koll Heroin	<del>5 c</del>	O +	0 0	0 0	<del> c</del>	00	00	0 0	; °	: 6		
Marijiana	32 331	37.863	38 97	43 094	43 074	40.028	47 308	55 164	0 247	0 23		
11-Hvdroxv-THC	. 00,20	200		† ? ?	t none	020,64	060,74	5	140,00	/7/cc		
11-Nor-Delta-9-THC												
51'S	0	0	0	0	0	0	0	0	_	0	-100.0	
Ash	0	_	0	0	<del>-</del>	0	0	0	0	0		
Bad Grass	0 0	0 0	0	0 0	0	:	0	0 (	0	0		
Dad Weed	- E	<del>-</del> ;	: ,	V (	:	:	: 6	o ;	0	0		
Bullitan Dot	07	6	1	10	:	:	24	24	22	=		
	0	C	C	C	c	_		_		ć		
Cannabinoids.	4,020	6,328	4,412	4,978	5,433	5,803	5,744	6,917	6.974	7.690		
Cannabinol	5	0	:	0	0	0	:	:	10	:		
Cannabis Sativa	836	1,392	1,068	1,056	1,193	1,173	1,145	1,467	1,127	1,054		
Camabis rea	<del>-</del> -	<del>-</del>	<b>5</b> C	5 6	5 6	<b>5</b> C	0 0	0 0	00	: `		
Cheba	0	0	•	<del>-</del>	0	0 0	o c	o c	o c	5 6		
	<b>'</b> :	0	0	0	<del>, -</del>	0	0	0	0	5 6		
Clickers Pot with Formaldehyde	4	က	0	0	0	:	0	0	0	0		
Columbian Grass	,	1	,									
Crazy Eddie	0 0	0 +	0 0	0 0	<del></del>	0 6	0 0	: `	0	0		
Delta-9-THC	4	42	<b>&gt;</b>	>	0 0	ر د و	5	- 6	⊃ ເ	: °	7	•
Double Barrell THC.	. •	10	; O	<u>:</u> °	50	2 :	0	<u>, 0</u>	7 :	<del>5 0</del>	-100.0	- 100.0
Flowers	(				1					I -		
Grass	0 0	: °	: `	0 0	7	7 0	<del>- (</del>	<del>- (</del>	0	: ·		
нарру Сідагеце	7	2	, ו	5	2	2	ַ ק	2	7	15		

Table 2.3.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half year (continued)

<sup>2</sup> % change <sup>2</sup> H1 2001, H1 2002	-75.0 -100.0
% change <sup>2</sup> H2 2001, H1 2002	
Jan-Jun * 2002	26,128 2,1499 2,1499 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,2151 3,
Jul-Dec 2001	28,736 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Jan-Jun 2001	8 27,827 27,827 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Jul-Dec 2000	22, 26, 27, 20, 10, 10, 10, 10, 10, 10, 10, 10, 10, 1
Jan-Jun 2000	23, 44, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114, 1000 114
Jul-Dec 1999	22,189 000000000000000000000000000000000000
Jan-Jun 1999	26,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6,167 6
Jul-Dec 1998	22,790 1 1 1 2 2 2 3 3 3 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Jan-Jun 1998	20,393 20,000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,1000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,00
Jul-Dec 1997	71 18,908 16,000 17 17 18,908 18 18 18 18 18 18 18 18 18 1
Drug name¹	Haxh

The continued selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half year (continued)

\$
6,575 8,497
8,05
000
0 ;
00
00
00
000
0
- 0
00

Table 2.3.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half year (continued)

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
Yellow Mollies	8,936	6,534	4,952	4,730	5,717	7,323	6,182	98/9	8,137	6,136		
30-30'S. Bathtub Speed	00	00		0 0	00	;0	00	00	00	00		
Blue Speed	0	0	0	0	0	0	0	0	0	0		
Criss Cross Speed	:	:	÷	:	:	:	:	:	:	:		
Crystal	315	253	<u>6</u>	26	168	226	£,	241	270	288	,	0
Crystal Methedrine	12	÷	4	5	<b>5</b>	5	4	<u>.</u>	9	393	417.1	0.026,2
Easter Eggs Speed												
Humcane	•	•	•	•	(	(	•	Ş	ć	6		
Moth Cristale	4 ⊂		4 6		N C	<b>∞</b> ⊂		20.0	202	9. 0.		
Meth Tabs.	0	00	0	0	0	0	0	0	i "	: o	800.0	
Methampex			1	1	ı	1	•		1			
Methamphet Crystalline	7 27	3 470	2 556	0 086	3 7 3 0	7 60	3 824	V	59	552		
Methamphetamine/ohenobarbital/ohenvtoin	<u>;</u>		2,30	2,000	r'o	ř	170,0	2 1	<u>-</u>	2		
Monster	0	0	0	0	0	0	0	0	:	0		
Mr Pep	0	0	0	0	0	0	0	0	0	0		
Pink Ladies Speed			1	,	(	1	•		•			
PTA-Speed	: '	<del></del>	0	0	0.0	0 0	0 0	; °	0	; 6		
Red Devils Speed	5	<del>-</del> c	5	: <sup>c</sup>	5 0	5 0	>	5 6	; •	5 6		
Rock Speed	: 0	- v	: :	9	0	<del>ი</del>	: :	<u> </u>	<b>4</b>	27	575.0	107.7
Rock Crystal.	0	0	:	0	0	0	:	0	0	0		
Speed	1,211	1,162	593	762	832	943	820	1,293	1,096	:		
Speed Crystal	0	:	5	0	5	0	0	:	-	:		
Splash	0	0	0	0	0	0	0	0	0	:		
White Cloud Speed			1									
Zoom Speed	0	0	0	0	0	7	0	0 !	0 !	0		
(MDMA) Ecstasy	363	351	797	7 20	1,903	2,125	2,385	2,427	3,115	2,303		
MDM	200	7	5 0		30	, . ,	6,7	202,	50,5	0,4,4		
MDMA	0	0	0	0	0	0	0		- 85	15		-53.1
Methylenedioxymethamphetamine	i	2	5	က	19	=	39		0	0		-100.0
Ketamine	:	57	:	209	: ;	107	156	451	:	152		
Ketamine	:	32	:	19/	113	 	12/		:	129		
Norketamine	0	0	0	0	0	0	0	0	0	:		
Special K.	:	18	7	13	:	24	29	:	:	22		
LSD	1,542	1,767	3,215	2,427	2,699	2,157	1,859	1,882	939	407	-56.7	-78.4
Acid Blotter	174	200	, . O	20	10	- 70	30	5	30	<u>:</u> 6		
Acid Blue	. 0	0	0	0	0	0	0	0	0	0		
Acid Purple	0	0	0	0		7		0	7	0		

able 2.3.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half sear (continued)

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
Beauty Acid	000	: :°	000	000	000	000	000	00	000	666		
Blue HazeBlue Heaven			•	•	<del>-</del>	<del>-</del>	•	:	<b>5</b>	<del>)</del>		
Felix the Cat									_			
Hallucinogenic AcidHits	0 0	00	0 0	₩ 0	; °	00	77 0	; •	00	00		
Kool Aid LSD	0	0	· :	00	0	0	0	0	<del></del>	<del>5 0</del>		
LSD with Streethine	1,1	1,114	1,921	1,641	2,098	1,336	1,318	1,301	830	219	-73.6	-83.2
Mickey Mouse	>	<b>5</b>	÷	>	>	5	5	5	0	6		
Micro Dots	0	_	0	0	0	0	0	0	0	0		
Orange Barrel Sunshine	0	0	0	0	0	0	0	:	0	0		
Paper Acid.	C	Ċ			c		c	Č	c			
Pink Hearts LSD.	0	0	<u>:                                    </u>	- 0	0	0	0	<del>-</del>	<b>5</b> C	<b>)</b> C		
Pink Micro Dot LSD.						•	•	•	•	<del>-</del>		
Pink Sunshine Add	C		•	•	•	(						
Purple Balter I SD	N C	; C	5 6	D	<del></del>	0 0	0 0	00	0 (	0		
Purple Haze	0	<del>-</del>	0 0	: -	<b>&gt;</b> C	5 6	5 6	<b>5</b> C	5 7	5 0	7	
Snoopy	0	0	0	• •	0	0	0 0	<b>O</b> C	- c	<del></del>	-100.0	
Sugar	0	0	0	0	0	0	0	00	0	<del>5</del> 6		
White Lightning Acid	0	0 !	0	0	0	0	0	2	2	-	-50.0	-20.0
Andel Dist	7,760	1,725	1,711	1,607	2,057	2,607	2,798	3,074	3,028	3,257		
Animal Tranquilizer	3 -	3 ~	<u> </u>	74	2	9	<u> </u>	2 2	232	4.0		
Black Dust	0	<del>1 ←</del>	- 0	<del>.</del> 0	: °	0	5 6	<del>-</del> -	5 6	<del>5</del> C		
Buzz	2	0	0	0	0	0	0	0	0	0		
Cools PCP	-	•	•	1								
Crystal PCP.  Dummy Dust	5	5	<del>-</del>	0	0	<del>-</del>	0	0	2	0	-100.0	
Energizer	0	•		o	_	-	c		c	-		
Fireball	0	0	0	2	0	· :	0	<u>:</u> 4	0	0		-100 0
Green	<del>-</del>	0	:	0	:	:	_	0	0	0		
Tog	C			(	•	•	•	•	,			
Love Boat	5 6	•	: <	۳ כ	5 6	<del>-</del>	5 7	<del>5                                    </del>	<del></del>	<del>5 1</del>		
Lovely	)	:	•	<del>,</del>	•	•	+	4	5	n		
Mad Dog	0	o	0	0	0	0	0	0	-	0		
MILE LOST	•	•	(	,								
Night I rain.	1 457	4 00	7,00	0 0	: 63	0 8	0	0	0	0		
Phencyclidine.	244	123	200	1,430	769'1	2,389	2,394	2,698	2,483	2,991		
Phencyclohexyl Ethyl	0	:	0	0	0	90	<del>: °</del>	90	0	<u>y</u> =		
Semyl	0	<del>- (</del>	0 (	0	0	0	0	0	0	0		
Sullalling	5	5	٦	5	5	5	5	Б	0	6		

Table 2.3.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half year (continued)

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
Super KoolsTAC	00	0	0	00	; C	٧ ٥	00	00	- 0	n	-	
Tea PCPTiC		3 O C	; ; <b>c</b>	000	000	000	000	, 0	00 ;	: o ō		
Wack		N	00	<del></del>	) O (	<del>&gt; ← </del> ₹	00 6	0 -	00	; C		-100.0
Whack		00	10	10	000	107	0 0 0	0 0	000	000		
Miscellaneous hallucinogens	22	883	986	573	960		1,058	<u> </u>	0,0°F	0 0 0 0 0 0		-100.0
Crystal Mescaline	o ;	<del>- 0</del>	00	00	o :	00	0 0	00	; 0	: :		
Hallucinogen Miscellaneous	80	· ; ·	16	32	: "	: `	36	51	:	ਰ ਹ		-82.4
Jimson Weed Jimson Weed Tea	: :	<b>80</b> O	;0	0 0	00	4 0	0	:°	; °	:0		
Liberty Cups Mushrooms	0.0	00	; C	0	00	00	00	00	00	<del>6 6</del>		
Madic Mushrooms	•	· :	· :	<u>:</u> ന	· :	00	<b>'</b> :	<b>'</b> :	' :	· ;		
Mescaline	:	i	i	39	:	25	9	12	i	12		
Mescaline Chocolates												
Microdot Mescaline	:	0	0	0	0	0	0	0	0	0		
Morning Glory Seeds	0	: ;	က	7	- 6	0	0 8	: 6	:	: 1		
Mushrooms	. 521	465	365	409	656	930	6/3 8/3	223	: 5	452	.50.0	
Needle Point Mescaline		<b>&gt;</b> :	5 6	- 0	0	00	00	· :	0	10	3	
Peyote	2	0	:			_	က	:	0	:	•	
Psilocybin	:	_	က	7	:	:	0	0	2	0	-100.0	
Psilocyn		*	_			13	c	Υ-	0	0		-100.0
Shums		0	0	. 0		: :	-	0	0	-		
Toad Stools.	<del>-</del>	00	i	00	00	00	0.0	00	00	00		
Wild Mushrooms	<b>5</b>	<b>5</b>	:	•		5	7	> ;	• i	<u>. 6</u>		
Flunitrazepam (* Congress)		: :	0	0	0	0	0	0	0	:		
Rochas	<u>-</u>	00	00	00	<del></del>	<del>-</del> c	<del>- 0</del>	7 7	<del>-</del> c	:		
Roche Poblogial	:	>	5	7	-	>	-	- ;	7	: <sup>on</sup>		
Roofles	: 4	; <b>0</b>	<u>:</u> ₹	: :	: :	. ₹	. ~	. ~	: :	8		
Ruffles	· m	S.	0	2	; 6	77	: `		4 0	<del>- </del>	-75.0	
Rufinal	459	387	895	1 192	1.987	2.865	- ;	1.679	1.661	2.024		0.001-
Gamma Hydroxy Butyrate	. :	387	895	1,051	1,922	2,754	: :	1,679	1,660	2,021		
GBL	-	00	<del>-</del>	0	0	0	0	00	<del>-</del> -			
Renewthent. Inhalants (volatile agent).	1,124	1,053	818	451	555	856	550	· :	329	485		
Acetone		2 0	4 0	<del>-</del> -	; 6	; <b>c</b>	; •	; c	00	; C		
ACIVIICS	3	7			7	,	-	-				



able 2.3.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half | year (continued)

H	Drug name¹	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun *	% change <sup>2</sup> H2 2001.	% change <sup>2</sup> H1 2001.
		/881	0881	1990	666	666	2000	2000	רטטצ	2007	2002	H1 2002	H1 2002
	shener	0 (	0	0,	0	0 (	-	0	0	0	: '		
		<del>-</del>	:	-	÷α	∞ ≺	: •	5	: •	; <b>c</b>	N হ		7
		0	0	. 0	0	0	. 0	<u>:</u> •	- 0	0	0		200
		:	12	i	က	_	:	:	0	0	0		
		0	0	0	:	:	_	0	_	0	0		-100.0
		: "	0.0	: `	: '	m	0	: '	7	7	:		
		5 0	5 6	- (	5 6	:	0 0	<del>-</del>	<del>- (</del>	<del>-</del>	0 0		
	HOTIOG	5	<del>-</del>	>	>	: 5	<b>.</b>	5	<b>5</b> (	5 7	0 0	000	
	g ruelg	; <b>c</b>	<u>;</u> c	; C	; <b>c</b>	<u> </u>	n c	; C	n c		<del>უ (</del>	200.0	
		5 0	0	•	о er	7	•	<del>-</del>	<del>-</del>	<del>-</del>	<del>-</del>		
		o c	1_	:	•	- ~	; C	7	0 0	5	<del>5</del>		
	emover	0	<u>:</u> •	<u>:</u> C	<u>:</u> C	<del>-</del> -	) C		<del>, c</del>	<u>;</u>	<u>;</u> c		
		· c	· c	7	) C	<del>,</del>	, c	· c	0 0	<del>-</del>	5 6		
		<b>O</b> C	5 0	- (	•	<del>-</del>	<b>-</b>	5 0	<del>-</del>	5 6	5 6		
	376	5 (	5 (	<del>5 ·</del>	: '	5 (	<b>5</b>	5	0	5	5		
		0	0	-	0	0	_	<del>-</del>	0	0	0		
		:	:	<del>-</del>	0	0	0	_	0	0	0		
		•	C	_	C	-	_	· c	)	· C	)		
	loadi			· c	·	- c	, ,		: °	· ·	: 6		
		<b>-</b>	<del>-</del>	<b>5</b> 4	n (	<del>-</del> (	) I	7	וכ	<b>5</b> (	5		
		2	7	n	٥	=		=	_	7	:		
		0	0	<del>-</del>	0	0	0	0	0	0	0		
	***************************************	:	_	0	0	:	_	:	0	_	0	-100.0	
	Į,	0	ις.	:	0		•	C	<u> </u>	· c			
	ant	•	· c	: -	•	<u>:</u> C		· c	<del>,</del>	o c	: °		
	401	- 6	- C	0	•	9 6	<del>-</del>	5 0	<del>-</del> •	5 6	5 (		
		5 6	5 (	5	: '	5 (	5 (	5	<b>5</b>	5	5		
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		5	5	:	0	5	<del>-</del>	0	0	0	0		
1	sh Aerosol	0	:	:	:	5	0	7	0	0	0		
17		9	:	6	:	0	:	0	0	•	0		
17		•	:	-	9	;		7	I	er.			
		17	22	23	28	6	25	100	-	σ	Ţ		
	inent		j	7	ì	α	7	?	: <	· c			
		:	:	•	: •	•	•	<u>: °</u>	>	0	: '		
	***************************************	: '	: °	: '	- (	: `	፥	,	:	<del></del>	57		
		<b>5</b> (	>	1 C	<b>5</b> (	- (	:	- ;	: :	<b>5</b>	N		
	***************************************	n ·	: '		<u>D</u>	12	:	4	<u></u>	∞	_		
		0	0	_	0	0	<del>-</del>	<del>-</del>	0	0	0		
		c	:	<del>-</del>	0	0	_	m	:	<del>-</del>	0		
	***************************************	0	0	<del>-</del>	0	0	0	0	0	0	•		
	er.	0	0	0	-	0	0	•	0	C	-		
		_	•			_	_	•	· C	· c	•		
					•	,	•	•	9 (	•	: <b>°</b>		000
		7 (	- (	: '	: (	: '	5 (	5 (	ο ·	5	5		D.001-
		5 (	<b>5</b> (	<b>5</b> (	<b>&gt;</b> •	7	5	5	-	0	5		-100.0
- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		<del>-</del>	2	0	0	0	_	:	0	0	:		
0000		0	9	_	2	:	0	_	•	C)	0	-100.0	
0000		0	0	0	0	0	0	- C		· c	· c		
000	<b>E</b>	· C	· C	· C	· C	· C	· c	<del>,</del>	<del>, c</del>	о <b>с</b>	o c		
	oride	0	0	· c	· C	7	· C	<del>-</del>	<del>-</del>	0 0	<u> </u>		
		· C	· C	· C	5		<del>-</del>	<del>-</del>	o c	- C	0		

Table 2.3.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half year (continued)

% change <sup>2</sup> H1 2001, H1 2002	-100.0
% change <sup>2</sup> H2 2001, H1 2002	
Jan-Jun * 2002	0 100 \$ 000 1 1 1 - 100000000 1 1000000000 1 00 10 100 10
Jul-Dec 2001	
Jan-Jun 2001	1 1 00 2 100000 00000 10000 100000 10000 00 1000
Jul-Dec 2000	0 100 10 10 00000 100000 10000040000 +0 WN 10000 1
Jan-Jun 2000	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Jul-Dec 1999	4   0 0 4 @ 0 0 0 w   0
Jan-Jun 1999	046   0000   0
Jul-Dec 1998	0     1   1 0 0 0 0   1 0 0 0 0 0 0 0 0
Jan-Jun 1998	04-0800000 000-00 10-00 1000000 10 1 1- 00 100000
Jul-Dec 1997	0   0   18   0   0   0   0   0   0   0   0   0
Drug name <sup>1</sup>	Motor Oil  Nail Polish Remover.  Natural Gas. Octane Booster. Paint Thinner. Paint Winwown composition. Pesticideuknrown composition. Pesticideum Distiliate. Propane Gas. Roach Poison. Rubber Cement. Silicone Shoe Saver. Solvents. Tolucio. Tol

able 2.3.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by half year (continued)

% change <sup>2</sup> H1 2001, H1 2002	
% change <sup>2</sup> H2 2001, H1 2002	
Jan-Jun * 2002	0 : 00 0 - 0 : # : : n : : 0 n - 5 - 5 4 : - 0 % - :
Jul-Dec 2001	04 00 04 00 10 10 10 00 1 0 1000 104 1 10
Jan-Jun 2001	0; 000; 00°C
Jul-Dec 2000	<u>οδ</u> <u>ου οδ</u> ουθουο <sup>†</sup> ο <u>νο ο του - 4</u> οο
Jan-Jun 2000	oō oc i+∞000 io oc oco i ioo∞oc
Jul-Dec 1999	00 00
Jan-Jun 1999	08 0+ 00 0040+0 :0 004 0+000 <u>000</u> 400
Jul-Dec 1998	0 1 00 0 1 00 10 00 1 1 0 0 0 0 0 0 0 0
Jan-Jun 1998	:: 00 0 : 0000-0 :0 -0± 0 000000 \$000
Jul-Dec 1997	14 00 10 1 10 0 1 10 0 0 0 0 0 0 0 0 0 0
Drug name¹	Trichlorotrifluoroethane Inhalants (general anesthetics) Destlurane Enflurane Fluoromar Halothane Soflurane Nitrogen Hypoxide Combinations NTA Acid with PCP LSD with PCP LSD with PCP LSD with PCP LSD with PCP Marijuana with Angel Dust Marijuana with Horin Marijuana with Horin Marijuana with Horin Marijuana with PCP Narijuana with PCP Speedball Pot with Cocaine PCP with Cocaine PCF w

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). above, PCP = phencyclidine.

<del>159</del>

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with ED = emergency department, GHB = gamma hydroxy butyrate, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, MDMA = methylenedioxymethamphetamine, NTA = not tabulated for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.</p> Drugs are classified to the degree of specificity recorded in the DAWN case reports.

Table 2.4.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S.

by year

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
Alcohol in Combination	160,798 143,337	166,907 135,711	166,172 152,420 	171,963 161,083 5	184,991 172,011 3	196,222 168,751 2	204,510 174,881 0	218,005 193,034 2	35.6 34.7	14.4	10.4
Anhydroecgonine Methylester Basuco	0	-	0	0	0	0	6	0			
Bazooka	- F	<del>5</del> %	_	ß	, ,	76.7	1	7			
Blow	0	<u>, o</u>	: ₹	:°	† •	9	000	: Ñ			
Candy	m	2	0	0	LC.	o		C	-100 0		
Cinnamoylcocaine	)		•	•	•	•	•	•			
Cocaine	107,773	101,043	118,371	121,928	129,165	128,257	134,658	145,160	34.7		
Cocaine Metabolite	o 5	113	142	<u> </u>	-	5	164	226			
Coke	511	458	354	629	495	275	379	386			
Crack	34,728	33,789	33,373	38,243	41,727	39,568	39,266	46,964	35.2		19.6
Crack Joint	<del>0 +</del>	: <	<del>0 +</del>	00	00	00	: *	:			
Dust.	- 54	28	- :	<u> </u>	- ∞	<u>. 6</u>	- 4	: =			
Ecgonine Methylester	0	0	: :	:	0	0	0	<u>က</u>			
Eight Ball	4	~	14	က	80	:	:	i			
Ethylecgonine	0 0	<del>- (</del>	<del>o (</del>	<del>-</del>	<del>- (</del>	: '	0	: '			
Frake Base Cocaine	<del>5</del> ₹	5 0	5 6	<i>?</i> 7 ⊂	<b>5</b> C	<del>5</del>	; <b>c</b>	<del>-</del>	75.0		
Love Drug	۲	•	•	•	<del>-</del>	<del>,</del>	•	•	2.5		
Methylecgonine	:	:	:	:	-	0	:	-			
Moon Dust	<del>-</del>	0	<del>-</del>	0	0	0	0	0	-100.0		
Norcocaethylene	0	0 0	0 0	0 0	<del>- c</del>	00	00	0			
Norcocaine P-Ricw	<u>э</u> ч	<del>-</del>	<b>5</b> ¥	<del>5</del> C	5	7 0	5 6	; °	000	700	
Ready Rock	0	: 0	0	<del></del>	: °	<del>о</del> го	<b>7</b>	>	2.00	0.00.	
Rock Cocaine	· :	:	25	:	8	· :	56	: :			
Heroin	63,158	69,556	72,980	70,712	75,688	82,192	94,804	93,064	47.4		
Acetylcodeine	_	*		c	•	_	•	-			
Black Tar Heroin	<u>. 6</u>	- დ	45	<u> 1</u>	<u> </u>	22	•	<b>0</b>		-63.6	
Blue Diamond Heroin		•		!	,						
Blue Ring	•	•	•	•	•	-	•	•			
Brown Heroin	<del>-</del>	<del></del>	<del></del>	<del>o c</del>	<del>o c</del>	<del>- c</del>	00	<del>- c</del>			
Carachi	0	40	00	5 0	0	0	<del></del>	<u> </u>			
China Cat Heroin.	· :	0	0	0	0	0	0	0			
China White Heroin	5	∞ ·	7	7	i	0	0	:	i		
D-Funk	0 0	<del>- 0</del>	0	<del>-</del>	: '	<del>o</del> ,	0	0			
Discet/decryline	5 6	5 6	<del></del>	<del>-</del>	5 6		<del>5</del>	5		-100.0	
Floaters	· :	0	10	-0	0	0	<u>;</u> 0	<u>;</u> 0			
Heroin.	62,987	69,487	72,904	70,657	75,614	82,102	94,600	93,017	47.7		

Drug name <sup>1</sup>		Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994,	% change <sup>2</sup> 1999,	% change <sup>2</sup> 2000,
Heroin Dope Heroin with Dornin		00	00	00	0 :	;0	00	00	40	1007	000	1007
Heroin with Scopolamine		0	<del></del>	0	: :			0	0			
Horse		<del>-</del>	0	0	0			0	0	-100.0		
Iranian Heroin		0	0	0	7			: '			-100.0	
Mexican Heroin		0	<del>-</del>	0	0			0			-100.0	
Mixed Done				0		0	0	0	Ö			
Mixed Dobe		•	:	>	:	•	•	•	· ·			
Mixed Junk Heroin		:	0	0	0	0	0	:	:			
Monoacetylmorphine		:	:	:	0	0	က	:	n			
Mxd Siu Whpd Cracker		- ;	3		(	(		•	•	8		
P-Dope		9	<del>ا</del> ن	÷	٥	٥	5	>		-95.0		
Pakistani Heroin			c	c			_		Č			
Persian nerom		<del>-</del>	>	>	: <sup>C</sup>	0 0	<del>, -</del>	0	5 K			
Polo	***************************************	<u>:                                    </u>	<u></u>	<u> </u>	0	0	0	0	-			
Smack		0	. 2	-	· :	· :	7	:	0		-100.0	
Stuff		0	0	0	:	0	0	0	0			
Super Buick		<del>-</del>	0	0	2	_	:	: '	0			
Tootsie Roll Heroin		<del>-</del> •	0 (	0 (	0 (	<del>o ,</del>	=7	0 (	: 6			
White Fox Heroin		0 70	0 20	0 22	0 27 730	76 842	0 78	06 426	110 512	176.0		44.6
Marijuana 44 Usdanss FLD		40,04	45,23	077,80	04,40	70,042	900, 70		410,011			e E
11-Nor-Delta-9-THC												
51'S.		:	0	:		0	0	0	_			
Ash		0	<b>~</b>	0		-	0	0	ō			
Bad Grass		<del>5</del> 6	<del>-</del>	: `	5 6	>	<del>5</del> ~	:	<del>-</del>		1000	
Blint		2 5	22	43.4	98	: %	,	:	43	95.5		
Bolivian Pot.		1	i	!	}	}			!			
Buda		0		-	0	0	0		0			
Cannabinoids		3,537	4,420	5,878	8,395	10,739	10,411	11,547	13,892	292.8		
Cannabinol		0 0	::07		1 070	: 47	0 20 0		CL 2	254 6		
Cannable Sativa		် ်	1,121	)  -  -	5/0,1	7,400	2,230	2,310				
Cannable 1 ea	***************************************		-	_		_	_	C	_			
Chebe		<del>-</del>	<del>, c</del>	0	<u>:</u> °	· ;	<del>, -</del>	0	0		-100.0	
Chronic		0	0	0		0	-	0	0		-100.0	
Clickers Pot with Formaldehyde		46	23	4	4	က	0	:	0	-100.0		
Columbian Grass				-		c	-	c				
Delta-9-carboxy-THC		: m	0	0	0	<del>-</del>	50	<u> </u>	: -			1.99-
Delta-9-THC		2,5	55	72	22	134	219	22	124	490.5		43.6
Double Barrell THC		<del></del>	0	<del></del>	0	0	0	•	:	,		
Flowers		7	5	>	5	<del>-</del>		>		2.001-		
	_	-	ā	۵						7 10	_	-66 7

그 나 by year (continued)

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
Hash	24	19	35	29	22	12	o.				
Hawaiian Marijuana	0		00	0	: '	: '	0	0			
Herbs	: :	- თ	<b>5</b> :	: -	<del>-</del>	<b>o</b> :	0	<del>-</del>			
Joint	35	4	:	:	4	9	: :	: <del>1</del>	-60.0		
Joystick Marijuana	0 0		0.0	0.0	0	0	: '	0			
Госомеед	<b>O</b> C		5 6	<b>5</b> C	<del>ه</del> د	0 0	0	: `			
Love Leaf.	0	0	200	0	? C	o c	<u>:</u> c	<b>&gt;</b> C			
Marijuana	29,265	32,39	35,088	37,173	43,183	48.291	46.355	56.563	93.3		000
Marijuana Cookies	0		0			7	0	3			7.77
Marijuana Distillate	0		<del>-</del>	0	0	0	:	0			
Marijuana Dizza	0 0	0	<del>-</del>	0	0 (	0	0	0			
Marijuana Tea	5 6	: *	: 5	; °	0 0	<del></del>	0	0 0			
Marijuana with Formatdehyde.	0 0	- vc	Э e	) (d	> €	5 7	<del>5</del> 6	0 6			,
Marijuana with THC.	0	2	<del>-</del>	5 0	7 -	† C	D.	7 C			-66.7
Mary Anna	က	· •	0	0	- 2	0	: -	0 0	-1000		
Mary Jane	-	0	0	0	•	<u> </u>	0.0	· -	2		
Mexican Gold Marijuana	:	2	က	-	: :	:	ı <del>←</del>	<u>:</u> °			-1000
Mixed Jive.											
MJT	2,157	1,663	1,755	1,635	1,558	276	2,197	2,797		186.3	27.3
Pot Dot	7 7 7	17	m	7	2	_	7	-	-50.0		-85.7
Pot Brownies	, 0	7,004 0,004	; °	: °	5,679	: '	: '	:			
Primo	<del>,</del>	7	<u>→</u>	<u>σ</u>	5	5 4	7) ¥	5			-100.0
Ragweed Marijuana	0	10	0	0	:	† C	<del>-</del> c	: -			
Red Bud	-	0	0	0	0	0	0 6	0	-100 0		
Reefer	09	32	38	56	26	22	· ;	,	2		
Roaches	0	0	0	:	:	:	9	:			
Seeds	0	0	0	2	0	0	0	0			
Shermans	01	0 (	<del>.</del>	:	0	0	0	0			
Sinsemilla Mariuana	_	6	4	:	7	m	6	21	200.0	0.009	133.3
Smoke	6	7			c		-				
Теа	0	•	0	0 0	o c	:	>	5 6			
Tetrahydrocannabinol	131	264	· :	• :	<del>-</del>	: :	298	120			
Thai Stick.	က	4	:	<del>-</del>	0	0	0	0	-100.0		
THC	1,968	2,824	5,718	8,137	12,295	16,581	<u>:</u>	:			
THC Metabolite	4				•		-	_			
Trip Weed.	<del>,</del>	:	0	5	5	:	0	:			
Tung Shueh	;	0	0	6	0	- <del>c</del>		C			
Turbo	7	:	0	· :	0	0	00	•			
Weed	96	170	161	225	128	190	386	392	106.3	106.3	
Witch	<u>n</u> c	<b>n</b> c	<del>~</del>	:	4 (	0	7	:	:		
	•	5	•	:	>	_	:	0		-100.0	
								=			

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
Amphetamines	10,118	9,581	9,772	10,496	12,183	12,496	17,134	18,555	83.4	48.5	
Amobarbital/dextroamphetamine/thyroid	-					c	0	67			
Amphetamine	9,392	9,341	9,129	10,085	11,616	11,842	16,169	17,200	83.1	45.2	
Amphetamine-dextroamphetamine	<del></del>	<del></del>	0	<del>о</del> с	: `	261	635			188.9	
Bam	5 6	N C	:	5 6	5 6	5 6	0	40			
Beans	0	<b>'</b> :	: 0	0	0	0	0	0			
Bennies	က	0	0	: '	: `	0	0	:	:		
Benzphetamine	:	:	0	7	0	0	:	:			
Risck Besuty		10		v.	-01	~	C				
	: :	<u>-</u>	: :	<del>-</del>	<del>-</del>	<del></del>	<b>'</b> :	:0		-100.0	
	÷	0	0	0	0	0	<del>-</del>	0			
			,		,						
Brown and Clears	0 0	0 0	<del>-</del>	0 0	0 0	: °	00	0			
Cal.	<del>-</del>	5 6	-	<del>-</del>	- c	<del>5 +</del>		; •		11000	4000
_	: °	0	: 0	: 0	70	- 0		<del>-</del>		2.20	<u> </u>
_	2	0	7	:	0	0		0	-100.0		
	0	0	0	0	0	0		0			-100.0
_	: 4	<del>-</del>	<del>-</del> 7	0 6	- 55	0 2	0 6	0 4			
	<del>0</del>	:	<u>*</u>	3	20	707	707	404	0.000		
	•	c		2	-	C	C	•			
Footballs	- =	<del>- 4</del>	<del>-</del>	<del></del>	' :	0	0	0	-100.0		
Green and Clear Amphetamine	•	•		•		1	1				
Hearts	0	:	0	<u> </u>	0	0	0	:			
Khat	0	0 1	0	0	0	<del>-</del>	0	0		-100.0	
MDA	<del></del>	~	<del></del>	7 (	: `	E .	: '		/33.3		
Methylcrystalline	:	5	5	5	-	<b>5</b>	<b>5</b>				
Wollies	•	•	C	•	C	c	•				
Nexus	>	<b>-</b>	>	<del>о</del> с	<del>-</del>	7	<del>-</del> ۲	:			
Disk Hoods Amsketsmine	:	; c	; <b>c</b>	v C	<b>o</b> c	- c	o C	; <b>c</b>			
Purole Heart Amphetamine	<u>:</u> C	•	0 0	, c	0 0	0.0	00	C			
Red Hearts	-	:	•	)	)	•	)	)			
Rockets	0	0	0	0	0	0	0	:			
STP	2	0	0	:	_	0	0	0	-100.0		
Sweethearts	0	0 9	0	:	0 ;	-		0		-100.0	
Uppers	1/	<u>n</u> c	; C	: "	2 2	: <sup>c</sup>		: 0	:		
West Coast Tumarounds.	:	•	•	•	•	•		_			
	0	0	0	:	:	0	0	0			
White Crosses Amphetamine	:	:	:	:	:	0	_	0			-100.0

Table 2.4.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by year (continued)

3.9 -100.0 -100.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0 1,000.0	Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,000   1,00	Yellow Mollies	17,5	15,933	11,002	17,154	11,486	10,447	13,505	14,923			
1,096   7,50   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096   1,096	Bathub Speed	000	00	o ; ·	00	00	00	00	00		-100.0	-100.0
1,036   729   746   353   265   307   511   90.7   92.8   99.9   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0	Grank	7,604	: :	<del>-</del>	<del>o</del> ;	o ;	<del>•</del> :	<del>•</del> :	1,988		_	
1,094   623   15   15   15   15   15   15   15   1	Crystal Communication	1,036	799	493	746	353	265	307	511	-50.7	92.8	66.4
1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1000.0   1	Crystal Methedrine	1,094	623	15	42	i	0	4	9	-91.7		2,175.0
1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,000.0   1,00	Easter Eggs Speed Hurricane			_	_	_		-	-			
Trystalline		30	20	:	i	4	က	15	33		1.000.0	120.0
1		: =	<u>~ c</u>	<del>o c</del>	00	<del>ო c</del>	00	00	26	:		
Operation         Operation <t< td=""><td>Methampex</td><td>· :</td><td>0</td><td><del></del></td><td><del>5</del></td><td><b>5</b> C</td><td>5 6</td><td>5 6</td><td></td><td></td><td></td><td></td></t<>	Methampex	· :	0	<del></del>	<del>5</del>	<b>5</b> C	5 6	5 6				
1	Methamphet Crystalline	0	-	~	0	• :	<del></del>	50	<b>&gt;</b>			
1	Methamphetamine/obenchartital/obenchartital	4,850	5,618	5,127	8,247	6,035	5,508	8,424	9,693	6.66	76.0	
1	Monster	•	C				-	•				
bed         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	Mr Pep.	0	0	• :	0	0	50	<del>5                                    </del>	<u>;</u> c	_		
98d.         1         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	Pink Ladies Speed		-			ı	)	•	5			
2,902 2,905 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005 2,005	PIA-Speed	<u>o</u> ,	0	0	:	0	0	0	:			
13	Reds Speed.		<del>7 −</del>	<del>-</del>	:	_	: •	0	; •			
2,902 2,965 2,030 2,265 1,754 1,629 1,762 2,389	Rock	<u>. 6</u>	4	12	:	: ^	5	: ₹	0 [			
2.902 2,965 2,030 2,265 1,754 1,629 1,762 2,389	Rock Crystal	0	0	. 0	<u>.</u> 0	•	<u>;</u> c	=	_			
3ed         1         0         0         0         0         0         0         100         0         100         0         100         0         100         0         100         0         100         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	Speed	2,902	2,965	2,030	2,265	1,754	1.629	1.762	2389			:
300         0         0         0         0         0         -100.0           30edd.         253         421         319         637         1,143         2,850         4,511         5,542         2,090.5         94.5           253         421         319         637         1,143         2,850         4,551         5,478         2,091.2         93.7           7         250         413         312         626         1,135         2,828         4,455         5,478         2,091.2         93.7           7         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	Speed Crystal	0	0	0	0	:	0	0	) i			
253         421         319         637         1,143         2,850         4,511         5,542         2,090.5         94.5           250         413         312         626         1,135         2,826         4,455         5,478         2,090.5         94.5           methamphetamine         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0<	Speeders Speed	<del>-</del>	0	0	0	0	0	0	0	-100.0		
253         421         319         637         1,143         2,850         4,511         5,542         2,090.5         94.5           250         413         312         626         1,135         2,828         4,455         5,478         2,091.2         93.7           methamphetamine         0         0         0         0         0         0         0         0         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5         94.5	White Cloud Speed					_			_			
253     421     319     637     1,143     2,850     4,511     5,542     2,090.5     94.5       7     250     413     312     626     1,135     2,828     4,455     5,478     2,090.5     94.5       7     0     0     0     0     0     0     0     0     93.7       7     22     50     14     22     50     14     20     3,473.7       8      54     242     180     309     210     423     5,187.5       9     27      29      53     4,669     5,219     4,982     5,126     4,016     2,821     45.0       1,189     1,523     1,022     1,476     1,787     1,331     1,359     623     47.6     -53.2       1     0     0     0     0     0     0     0     0       1     0     0     0     0     0     0     0     0       1     0     0     0     0     0     0     0     0       1     0     0     0     0     0     0     0     0       1     0     0     0     0     <	Zoom Speed.	0	0	0	-	-		-	-			0007
250         413         312         626         1,135         2,828         4,455         5,478         2,0912         93.7           methamphetamine         0         0         0         0         0         0         50         50         50         93.7           methamphetamine         0         0         0         0         0         0         0         50         14         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	(MDMA) Ecstasy	253	421	319	637	1.143	2.850	4.511	5.542	2 090 5	7 70	0.001-
//methamphetamine.         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	:	250	413	312	929	1,135	2,828	4,455	5,478	2,091.2	93.7	
//methamphetamine         0         8          1         2         50         14         473.7           19          8          209         396         263         679         3,473.7           8          54         242         180         309         210         423         5,187.5           9          29          29          53          45.187.5           11         9         27          29          53          45.0           11,189         1,523         1,022         1,476         1,787         1,331         1,359         623         47.6         -53.2           9	MOMA	; •	<del>- •</del>	<del>-</del>	<del></del>	0 (	0	9	0			-100.0
19     3473.7       8     3473.7       8     3473.7       9     242     180     396     263     679     3473.7       11     9     27     29     0     0     0       5,158     5,682     4,569     5,219     4,982     5,126     4,016     2,821     45.0       1,189     1,523     1,022     1,476     1,787     1,331     1,359     623     47.6     -53.2       0     0     0     0     0     0     0     0	Methylenedioxymethamphetamine	<del>-</del>	- α	5	5	0 1	<del>- 2</del>	0 6	20	_		
6      54     242     180     309     210     423     5,187.5       11     9     27      29      53      45.0       5,158     5,682     4,569     5,219     4,982     5,126     4,016     2,821     45.0       1,189     1,523     1,022     1,476     1,787     1,331     1,359     623     47.6     -53.2       0     0     0     0     0     0     0     0     -100.0	Ketamine	0 6	•	: &	:	200	306	000	47.9	770	-	-72.0
0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0 <td>Ketamine</td> <td>80</td> <td>: :</td> <td><u>x</u></td> <td>242</td> <td>180</td> <td>308</td> <td>2402</td> <td>423</td> <td>5,4/3./</td> <td></td> <td></td>	Ketamine	80	: :	<u>x</u>	242	180	308	2402	423	5,4/3./		
11     9     27     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0     0<	Norketamine						;	<u> </u>	?	5		
5,158 5,682 4,569 5,219 4,982 5,126 4,016 2,821 45.3 45.0 1,122 1,476 1,787 1,331 1,359 623 47.6 -53.2 1 1,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Special K	<del>-</del>	: 0	<u> </u>	0	<del>-</del>	0	0	0			
1,189 1,523 1,022 1,476 1,787 1,331 1,359 623 47.6 -53.2 1,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	LSD.	5.158	5.682	4.569	5 2 19	4 98 29	t	23	: 6		į	
3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Acid	1,189	1,523	1,022	1,476	1,787	1,331	1,359	623	45.5	45.0 5.5.0	-542
	Acid Blue	er c	<del></del>	; •	:	0	0		O	-100.0	!	1
	Acid Purple	50	_	50	o -	00	0 7	0	8		-	

Beauty Acid.  But Hotal  But Hota	Total         Total         Total         Total           1995         1996         1997         1998	al Total	Total Total 2000	% change*   %   1994,   2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
28 34 41 3,626 3,436 3,663 5,404 12	000			-100.0		
28 31 1 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0	_	: D	•		
Hallucinogenic Acid Acid Acid Acid Acid LSD  I cold yield LSD  I c	- 6		_	-100.0		
Kool Aid LSD.   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989   1989	<u> </u>	•	•			
3,936 4,118 3,524 3,726 3,035 3,739 2,654    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	50				_	
292 299 5,963 3,444 1 3,65	3,524 3,726 0 0		2,654 2,131 0	45.9	43.0	
5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,899 5,963 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,404 5,	• •			- (		
5,899 5,963 3,441 3,626 3,436 3,663 5,404	0 0		: <del></del>	<del>-</del> -		
5,899 5,963 3,441 3,626 3,436 3,663 5,404 11 214 11 214 11			•	(		
5,899 5,963 3,441 3,626 3,436 3,663 5,404 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 111 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144 11 2,144	0 C	•	0 0	5 0		
5,899 5,896 3,441 3,626 3,436 3,463 5,404 111 2,92 4,29 4,29 4,29 4,29 4,29 4,29 4,29	00		0	0		
5,899 5,963 3,441 3,626 3,436 5,404    2,992 4,299 1,22 118 1,56 1,111 2,14    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		•	c			
5,899 5,963 3,441 3,626 3,436 3,640 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	; c		5 0	50		
292 429 122 118 156 111 214 1	0		0	<del>-</del>		
5,899 5,963 3,441 3,626 3,436 111 214 214 111 214 111 214 111 214 111 214 111 214 111 214 111 214 111 214 111 214 111 214 111 214 111 214 111 214 111 214 111 214 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			0 0			
5,899 5,963 3,441 3,626 292 429 122 148 156 111 214 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	) <del>-</del>			4		
	3,441 3,526		5,404 6,102 214 8,300	<u> </u>	99.0	
	<u>1</u> m			0		-100.0
	0 (		00	0		
	<del>-</del> -		<del>-</del> -	-100.0		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0		0			
	C		C			
19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	<del>-</del>			<u>.</u> 4		
19 7 5 4 3	0 01	•	: :	. 6		
19 7 5 4 3	_				-	
	0 4		<u>o r</u>	78.0		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	•		·	2		
0 0 0 0	0		0			
	c					
PCP	2,975 3,092	2,870 3,127	ý.	31	65.7	
313 496 324 405 324 391	324 405	66 	374 521	24		
Semular Semula	0	1	0	_		

Table 2.4.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by year (continued)

% change <sup>2</sup> % change <sup>2</sup> 1999, 2000, 2001	2001 2001	-	-85.7			-100.0		_			_			_		_		-64.3				_	_	9000	) ) )				-94.4	1		-1000	2.00		0 000	0000	200.0			-66.7				
% change <sup>2</sup> % 1994, 2001	2001			-100.0		-100.0	-66.7									-100.0		-88.3									-77.8	?						-1000	?		_			<u>.</u>	5,864,3		5,862.5	5,862.5
Total 2001		•		0	i	0	<del>-                                    </del>	1 789	- α	•	C	56		0	0	0	:	15			0		1 287	_			7	C	<del></del>	0	0	0		0	· e	· cr	,	¥.	יט נט	7	3,340	0000	3,339	2,339
Total 2000		٦		0	0	<del>- 1</del>	_ 0	1 840	5,4	- 0	' :	145	1	0	0	0	:	42			0	0	1.502		0	4	:	0	13	2	0	2	· ;	0	-	-			4	· 60	4,969	7 052	20.1	70°
Total 1999			: =	0	0	<del>- c</del>	<b>э</b>	1 533		0	•	133	80	0	0	:	4	111			0	က	1.065	_	0	:	:	0	- 82	0	0	0	:	0	_	4	· ;	:	9	9	3,178	2 073	2.0.4	0,5,4
Total 1998	1	-	•	: :	0	7	4 C	1 849	2	-	0	:	:	0	:	0	:	:			0	5	830	0	:	:	4	0	_	0	:	:	-	:	0	0	:	4	. C	:	1,282	1 282	1	
Total 1997	$\dagger$	_	- 0	0	0	<del>-</del>	- c	1,629	:	0	:	8	:	:	0	<del>0</del> ;	11				:	0	957	0	0	6	19	0	:	:	0	0	i	<del>-</del>	2	:	:	6	2	17	762	762	ļ.	0
Total 1996		-	<u>:</u> 0	:	00		:	1.600	2	0	_	7	:	0	0	<del>-</del> 6	3 5	119			0	<del>-</del>	1,165	0	•	:	4	0	4	0	0	0	:	4	0	2	-:	0	32	32	638	638 638		00
Total 1995			0	:	0 0	<del>77 (</del>	, c	1.463		0	0	:	:	<del>-</del>	0	5	: 5	54			ō	0	945	<del>-</del>	:	:	:	0	9	:	:	_	:	:	:	0	21	0	19	6	145	145	•	00
Total 1994	$\uparrow$	Ŧ	0	က	<del></del>	<del></del>	<del>, c</del>	1.577	-	0	0	0	:	: '	<del></del>	N 6	۳ <u>د</u>	128		1	0	:	789	0	<del>-</del>	7	6	:	4	:	0	0	<del></del>	4	0	<del>0</del>	:	0	:	0	26	26		00
Drug name¹	Cunar Knole	TAC	Tea PCP	TIC	VBT.	Whack	Zombie	Miscellaneous hallucinogens	Angels Trumpet	Crystal Mescaline	Datura Stramonium	Hallucinogen Miscellaneous	Jimson weed	Jimson Weed Tea	Mose Mushrooms	Maric Mushmoms	Mecceline	Mosolisa Observator	Wescaline Chocolates	Mescaline Synthetic	Microdot Mescaline.	Morning Glory Seeds	Mushrooms	Needle Point Mescaline	Nutmeg	Peyote	Psilocybin	Psilocyn	Psychedelics	Shrums	Toad Stools.	Wild Mushrooms	Flunitrazepam (Rohypnol)	Fluntrazepam	Rochas	Roche	Rohypnol	Roofies	Ruffies	Rufinal	GHB	Gamma Hydroxy Butyrate		GBL Renewitient

									% change	% change	% change
Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	2001	2001	2000, 2000, 2001
Aerosol air freshener	:	0	0	:	0	0	-	0			-100.0
Aerosol Spray	:	:	16	00	:	<u>6</u> C	:	•		7.16-	
Airplane Glue	: :	: :	: °	0	<u>:</u> 0	0				•	
Alpha terpineol	2	: '	=	17	15	4		0	-100.0	-100.0	
Brake Fluid	:	0 0	:	4		: °					
Butane	<u>;</u> C	ο c	: `	: `		ю					
Carbon tetrachloride	0	0	0	0		: :	0				
Carburetor Cleaning Fuel	· :	· :	5	· :					:		
Chlorothene	0	-	0	0	0						
Cleaner Solvent	0	:'	00	<del>- (</del>						-100.0	
Cleaning Fluid	n (		N C	5 0					፥		
Collee Stain Remover	<b>o</b> c	۰ : ۳	5 6	5 6							
Contact Cement	7	) C	o c	- C							
Correction Fluid	- ო	0	<del></del>	<del>-</del>		-		0	-100.0		-100
Cresol	0	0	0	:							-100.0
	_	0	:	0							
Deodorant Aerosol.	7	0	<del>ന (</del>	0,		n (			-100.0	-100.0	ì
Embaiming Fluid	n (	0 0	7 +	4 0							0.00-
Epoxy Glue	>	⊃ e.	- c	>							
Ethylene Givcol	: -	· :	<b>'</b> :	: :	· თ		7	0	-100.0		-100.0
Facial Astringent.	0	0	0	-		_				-100.0	
Fingernail Polish	0	0	0	0							
Fluorine	0 (	0 (	0 0	0		0 (				0007	Š
Furniture Polish Aerosol	<b>&gt;</b> 4	<u>&gt; </u>	7	: 6	: 5	71				-100.0	-100.0
Gasoline	•	1	:	3		:					
Glie	: :	: :	22	: :	45	47	35	9		-59.6	-45.7
Hair Sprav Aerosol	: :	: :	<del> </del>	: :		16				-100.0	(
Helium	•	0	0		:	8					
Hydrocarbon	:	:	:	0		_		:			
Inhalants	15	4	7	0		22					
lnk	0	0	0	0	_	0	0				
Kerosene Oil	:	0	: '	S.	•	0					
Lacquer	: '	0	0	0	0	0					
Lacquer Thinner	0 (	0 (	<del></del>	<del>-</del>		- (				-100.0	
Leather Cleaner	5	5	5	5 7	:	5	0				
Malathion	<u>:</u> c	: <	:	r	•	: `					
Methane	2	· :	: e	0	2	10		- 0	-100.0		
Methanol	:	4	12	:	7	:					
Methylbenzene	0	:	0	0	0	0		8			
Methylchloroform	<del>-</del>	0	0	:	0	<del>-</del>	0				
Mathylana Chlorida										2	

Table 2.4.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S. by year (continued)

nge <sup>2</sup>		-100.0	-100.0		-100.0	0.09-	-100.0
% change <sup>2</sup> 2000, 2001		7 T	7		7	Ψ	÷
% change <sup>2</sup> 1999, 2001	-100.0	-100.0	-100.0	-100.0	-100.0		
% change <sup>2</sup> 1994, 2001		-100.0	-100.0	100.00			-100.0
Total 2001		00000		· :00000±000	000   000	00 N :00	00
Total 2000	382	: : 	•		0004000 ;	10 mm 10	. 0 - 0
Total 1999	. &	.00%	•	, ,		•	00 ; ;
Total 1998	. 50	000 : 000			00000 10 1	1- 1 1000	
Total 1997	685		• • •		000 10 104	-0 0,	-00 ;
Total 1996	: :16		44000		•	00 -01	.00
Total 1995	0 4 : 9 5 5 6					<u> </u>	0000
Total 1994	170 0 170 170 160		; ; <sup>, , 0</sup> 0 0	00 1000 10++	NOO   OO	00 0 1 100	0 <del>-</del> 10
Drug name¹	Motor Oil	Pesticide/unknown composition. Petroleum Distillate. Petroleum hydrocarbons. Phenolic disinfectants. Polish Remover.	Propane Gas. Roach Poison. Rubber Cement. Shoe Polish.	Solvents. Spot Remover. Starting Fluid. Tape Recorder Cleaner. Tolluene Glue. Toluch. Transmission Go.	Trichloroethane/trichloroethylene Tulilo Tuleao Turpenfine Vaporizers Volatile/unknown components Xylene Inhalants (nitrites)	Isobuty Nurite Locker Room. Poppers. Rush. Inhalants (chloro-fluoro-hydrocarbons). Chlorinetted Hydrocarbons.	Freon propellant. Silicone Spray. Trichloroffuromethane.

To able 2.4.0 - ED mentions for selected major substances of abuse by drug category: Estimates for the coterminous U.S.

by year (continued)

% change² 2000, 2001								
% change <sup>2</sup> 1999, 2001	_	-100.0				0.009		
% change <sup>2</sup> 1994, 2001	-							-83.3
Total 2001	0 :	00	° ;	298	<b>α</b> π ; φ		;° ; ;	159
Total 2000	32	00	28	127	0400	707	000 ;	101
Total 1999	29	0+	25	: 0 A	-080	000	000	0 0 0
Total 1998	1 1	00	о <sub>:</sub>	125	+0 ;0	4 i	000-	0 88 0
Total 1997	30	00	.: 52	20.1	00 <u>;</u> 0	; O O O	0 00	100
Total 1996	20	; O	04	383	-000	0010	0000	287 287 0 0
Total 1995	i i	; <b>o</b>	° :	163	:000	<u>0</u> +0	0000	143
Total 1994	25	00	22 0	495	00 ;0	00 : 06	00 :00	264
Drug name¹	Trichlorotrifluoroethane	Fluoromar Halothane Isoflurane	Methoxynurane. Nitrogen Hypoxide Nitrous Oxide	Trichloroethylene. Whippets. Combination NTA.	Acid with PCF. Cocale with Speed. Crystal Crank with THC. LSD with PCP.	LSD with Speed	Manjuana with Speed Manjuana with Speed PCP with Cocaine PCP with THC Pot with Cocaine	Pot with PCP

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique

ED = emergency department, GHB = gamma hydroxy butyrate, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. from January-June 2000. Drugs are classified to the degree of specificity recorded in the DAWN case reports.

Table 2.5.0 - ED mentions for psychotherapeutic agents by drug category: Estimates for the coterminous U.S. by half year

% change <sup>4</sup> H1 2001, H1 2002	7007																											-100.0																
% change <sup>4</sup> H2 2001, H1 2002	7007																			-100.0												_			-100.0	-57.7							_	
Jan-Jun * 2002	30 554		0	: °	<del>5 +</del>	13,554		2,7	22	98,4	24,0	2 802	2,002	: ;	0	1	451		258	0		2.781	11,196	2,133	0	1,323	524	5 1	00°, c	2,430	0 215	747	488	30	Ö	-	:	::	27	; c	5	3:	1	19
Jul-Dec 2001	30.695	_	0	: `	<b>-</b>		2,499	3,332	: 0	4,039	0 (2,5)	6 407	2.346	0	:	:	463	:	334	2	:	2,947	10,394	1,783	0	1,005	621	7,70	4,712	2,003	10.365	616	368	20	2	56	: '	0	: 1		5	: :	.0	-
Jan-Jun 2001	30.316		0	:	: :	13,086	1,975	3,031	146	4,324	,,,	6.040	2,328	7	:	:	309	297	325	0	:	2,568	11,065	2,361	0	893	7,8	1 637	+, t.	311	9.817	743	269	27	:	:	; °	0	;	; =	2	<u>y</u> :	<del>-</del>	4
Jul-Dec 2000	28.259				- 0			<u>ო</u>		3.242		5.507	2,907	:	:	:	554	278	359	0	0	1,197	10,113	1,630	0	993	0.0	7 233	1 948	434	9.748	913	:	32	2	28	204	::0	200	3 0	2	! :	: :	-:
Jan-Jun 2000	32.317	_	<u> </u>		- 0			3,994		3.458		6.331		:	:		269			<del>-</del>	_	1,426	11,840	2,179	0 0,	1,423	200	5 465	1,774	166	10,348	1,194	335	:	7	:	: 5	740	27	7, ;	: :	:	:	-:
Jul-Dec 1999	27,762	_				_		3,881		2,788			3,240	:	13	፧	719	256	426	0		_	9,645	1,853	: 1	7 0 -	2	4 429	1.308	104	6,955	965	290	:	:	:	; °	176	2 80	90	19	:	_	:
Jan-Jun 1999	31,202		о <del>б</del> 			13		nne'e	4 192			6,486		:	:	:	833	491	462	0	:	1,999	10,896	2,006	::0	905	3	5.424	1.901	240	8,268	1,123	276	147	10	:	: `	303	3	<u>.                                    </u>	:	6	ल	:
Jul-Dec 1998	25,529	_	0 ~			11,754		D++'+		3,091		5,971		:	:		623			:	:	1,084	7,791	1,499	240	745		4.517	678	:	8,206	1,951	386	253	10	333	: <	494	252	0	:	:	:	•
Jan-Jun 1998	28,		12	_		13,015				3,796		7,160		9	:	: ;	914	505	252	: `	<u> </u>	1,343	8,554		35.5	808	0	5,158	950	:	8,064	2,360	484	171	: 0	258	3	733	3 :	0	6	:	:	-:
Jul-Dec 1997	25,361	; °	• :	_	0	11,507	7 116		3.614	2,605	_	7,186	4,059	:	: 6	202	600	750	345	;`	L ,	1,192	0,527		•	296	0	4,545	691	279	7,718	2,224	280	193	0.45	214		905	129	0	:	:	: ;	13
Drug name <sup>1,2,3</sup>	Antidepressants	isocarboxazid	phenelzine	tranylcypromine	monoamine oxidase inhibitors-NOS	ooki anudepressants	fluoxetine	fluvoxamine	paroxetine	sertraline	SSRI antidepressants-NOS	I ricyclic antidepressants.	amimplyline	clominsmine	desinamine	dovonin	iminamine	portionalise		triminamina	travelic softenesses and a sof	Miscellaneous antidoppessons	binopion	maprotiline	mirtazapine	nefazodone	nomifensine maleate	trazodone	venlafaxine.	antidepressants-NOS	Antipsychotics.	chlomiazine antipsychotics	Anothorogical	mesoridazine	perphenazine	prochlorperazine	promazine	thioridazine	trifluoperazine	triflupromazine	phenothiazine antipsychotics-NOS.	Psychotherapeutic combinations	amitriotyline-chombons-rino	מווות ולא ייווס באוזם ומרום ואלו אווים לאווות לאווות לאווות לאווות

able 2.5.0 - ED mentions for psychotherapeutic agents by drug category: Estimates for the coterminous U.S. by half year continued)

•	1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	2001		H2 2001, H1 2002	H1 2001, H1 2002
psychotherapeutic combinations-NOS	0	0	0	0	0	0	0	: 6	3	: 4	:	
Thioxanthenes	416	:	i	:	:	:	3 2	2 2	: :	<u> </u>		
Miscellaneous antipsychotic agents	5,007	5,431	5,971	6,940	5,830	8,921	8,740	8,982	9,560	8,433		
butaperazine		-	c		c	C	c		C			
chlorpromixene	: 8	<del>-</del>	>	ο <u>σ</u>	5	) 	•	•	•	5 :		
GIOZZIDITIE	1 150	951	1.179	929	507	374	793	658	357	528		
	2,083	1,84	1,64	2,422	1,444	1,640	2,081	1,646	1,764	1,088		
loxapine	:	:	: '	42	17	:	57	17	:	; °		700
molindone	<b>8</b>	: ;	9	4 (	9 7,		2 446	5 575		1 0 1		-100.0
olanzapine	699	7,1,7	1,605	Z18,L	4/4,	2,979	2,473	C'C'7	7,042	0,		
pimozide	4 C		351	409	487	1.529	1.480	1.917	2,429	2,735		
queuabille nspendone	960	1.129	1.025	1,543	1,809	2,069	1,830	2,015	2,030	1,863		
ziprasidone	0	0		0	0	0	0	÷	:	i		
antipsychotics-NOS	_		i		-	7	:	: (	1		,	
Anxiolytics, sedatives, and hypnotics	55,455	59,926	58,426	ш	57,650	62,451	58,068	63,594	72,355	9	-12.9	
Barbiturates	3,310	4	4,553	4,395	3,382	3,651	3,450	L04,4	cur,c	4,737		
acetylcarbromal/pentobarbital	5 0	5 0	; c	<del>-</del>	<del>-</del>	<del>-</del>	: 0	-	-	: 6		-100.0
allobaroital	5	•	>	•	•	•	•	•		)		
amidopynne/butalbitai/caneine	•	c	c				•	0	0	0		
amobarbital	0	2	<u>~</u>	· i		0	•	0	0	•		
aprobarbita/butabarbital/ohenobarbital		1			l							
barbital	0	0	0	0	0	0	2	:	0	0		
barbital/butabarbital/dihydroergotamine/												
phenobarbital/scopolamine									,			
barbituric acid	0	:	0	0	0	0	0	0	0	:		_
belladonna/phenobarbital		ı	•		Ų	c		7	0			
butabarbital	:		/1	:	•	7	:	0		:		
butabarbital/chlorpheniramine-	_		•	•	•	•	c	•	c	Ċ		
phenylpropanolamine/theophylline	0	:	<b>o</b>	<b>5</b>	5	5	>	5	•			
butabarbital/pentobarbital/phenobarbital/	•	C	· c	•	c		_	c				
secobarbital	>	<b>O</b>	<b>.</b>		0 0	:		9 65		· «		
	; c		0	: °	· c	: <sup>C</sup>	: C					
Cyclobal Dilat	٧		•		•	•						
orbedine/henthbarbital												
enhedrine/ohenobarbital	0	0	1	0	0	0	0	0	•	0		
ephedrine/secobarbital												
heptabarbital												
hexobarbital						•	•					
hexobarbitone	-		0		0	0	0				-100.0	
homatropine/phenobarbital	_	o (	2	5 0	5 0	0	0	5 0	- C	_		
mephobarbital	0 (		: °		<b>.</b>	<b>5</b>						
mephobarbital/phenytoin	_		<u> </u>			:	:	•				

Particular control of the control	RIC 4	(continued)												
periodacidal periodacida perioda periodacida perioda periodacida perioda periodacida perioda periodacida perioda periodacida perioda perio	<u></u>	Drug name <sup>1,2,3</sup>	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>4</sup> H2 2001, H1 2002	% change <sup>4</sup> H1 2001,
pentobachbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-broadbillation-br		methylphenobarbital. pavatrine/phenobarbital.	00	40	00	00	00	+ 0	- 0	0	0	0	2002	7007 11
pumodazilaticial         831         1,220         1,326         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926         1,926		pentobarbital	:0	; m	24	<u>+-</u> c	:	P :	<del>-</del> :	1 1	o ::	о <u> </u>	_	
specialization and control and		phenobarbitalphenobarbital/phenytoin	831	1,220	1,326	908	693	1,012	786	506	611	367		
2.381         2.870         3.16         3.6         15         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16		phenyltoloxamine/secobarbitalsecobarbital	4	, <u>i</u>	, ;	•	•	· _	)	_	:	8		-100.0
Bentzodaranelos Secretarios de la contractación de la contracta		talbutal	0	30	<u>v</u> 0	:0	; 0	: =	<del>τ</del> .	8 +	4 0	; 6		: 5
uppersonant         8,726         9,446         1,726         1,721         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726         1,726		barbiturates-NOS	2,351	2,870	3,161	3,281	2,472	2,433	2,415	3,361	3,848	3,930		-100.0
colorazoparoide         374         662         854         837         221         728         678         727         400         678         727         400         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         678         774         600         678         678         678         678         778         678         678         778         678         678         778         678         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778         778		alprazolam hromazonam	8,782	9,049	8,783	10,023	10,461	10,731	43,659 11,375	49,175 12,035	54,797 13,609	47,884 13,154	-12.6	
clorazeptan         7.23         8.83         8.54         8.44         8.52         1.06         7.78         228.3         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         1.78         2.28         2.28         1.78         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28         2.28	ED	chlordiazepoxide	374	662	:: 8	893	6 291	758	627	9	: 85	102	2 6	: 6
clorazepate         558         623         384         200         777         478         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283         283 <th< td=""><td>Tre</td><td>clobazam clonazepam</td><td>7,233</td><td>0 8.863</td><td>8.587</td><td>8 831</td><td>7 754</td><td></td><td>0 5</td><td></td><td></td><td>0</td><td>0</td><td>7.1.7-</td></th<>	Tre	clobazam clonazepam	7,233	0 8.863	8.587	8 831	7 754		0 5			0	0	7.1.7-
edizzepalm	en:	clorazepate	556	623	388	2007	5 :	† 0 0	176,0	8,250	10,861	7,786	-28.3	
Indicatepant         Page of the control of the c	ds	diazepamestazolam	6,536	5,846	6,912	5,155	6,251	6,603	5,487	4,971	6,476	5,286		
Nationary parameter   1,222   1,224   1,237   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225   1,225	Fro	flurazepam	292	412	16 472	331	207	244		: 67	ω <u>(</u>	:		
United separation   1	om	halazepam	0 0	0	0	0	0	:	2 2	9 0	C04	:		
Imidazepam   Imi	DA	lometazepam	5,5,5 0	0,630 0	4,836	5,965	4,726	5,999	4,672	5,626	6,276	5,198		
Proceedings	w	midazolam	-	0	· :	0	00	0	0	<del>-</del>	>	: =		1000
1,222         1,767         1,337         1,672         1,726         1,016         1,237         1,400         890           1,222         1,767         1,337         1,672         1,022         1,726         1,016         1,237         1,400         890           1,222         1,767         1,357         1,672         1,726         1,726         1,016         1,237         1,400         890           1,1,460         11,745         12,462         13,058         11,389         10,987         14,516         14,771           1,1,460         11,309         9,475         10,207         9,44         11,389         10,098         16,787         14,516         14,771           1,1,460         11,309         9,475         10,207         9,44         11,389         10,098         10,018         12,454         10,411           1,1,460         11,309         9,475         10,207         9,44         11,389         10,098         10,411         10,411           1,1,460         11,309         11,309         11,309         11,309         10,411         10,411         10,411           1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,	N	охазерат	272	7 2	33	0 2	: 8	:	-	0	0	N		0.00
1,222         1,767         1,337         1,672         1,022         1,726         1,016         1,237         1,400         890           1,222         1,767         1,337         1,672         1,022         1,726         1,016         1,237         1,400         890           1,222         1,763         1,1745         12,462         13,058         11,389         10,987         15,787         14,516         14,711           1,1460         11,309         9,475         10,207         9,944         11,381         10,987         15,787         14,516         14,711           0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	1	prazepam	1 :	00	<del>-</del> -	\$ 7	ઝ	<del>;                                    </del>	214	: 0	241	•	-	
1,222     1,726     1,016     1,237     1,400     890       1,422     1,763     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1460     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,1471     1,14	7	quazepam	- 200	9 1	: }	8	<u> </u>	• ;	۳.	0	: <b>-</b>	:0	-100.0	
9,887 10,763 11,745 12,462 13,058 11,389 10,987 15,787 14,516 14,711 11,460 11,309 9,475 10,207 9,944 11,381 10,959 10,018 12,454 10,411 1	2	triazolam	142	350	1,337	1,672	1,022	1,726	1,016	1,237	1,400	890		
11,460		benzodiazepines-NOS.	9,887	10,763	11,745	12,462	13,058	11,389	10,987	15,787	14.516	14.711		
576       573       617       961       1,125       1,204       1,095       422       858         0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0		acepromazine	11,460	908,11	9,475	10,207	9,944	11,381	10,959	10,018	12,454	10,411	-16.4	
576       578       573       617       961       1,125       1,204       1,095       422       858         0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0 <t< td=""><td></td><td>acetophenazine maleate</td><td>0</td><td>0</td><td>0</td><td>. O</td><td>- 0</td><td>0</td><td>4 0</td><td>-0</td><td>- 0</td><td>; c</td><td></td><td></td></t<>		acetophenazine maleate	0	0	0	. O	- 0	0	4 0	-0	- 0	; c		
576       573       617       961       1,125       1,204       1,095       422       858         0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0		acetylical bullar				-		•			)	<del>-</del>		
576     573     617     961     1,125     1,204     1,095     422     858       0     0     0     0     0     0     0     0     0     0       50     29     16       14     23         20     8     1     3     5     1     0     0     0       4     9     0     0     0     0     0     0     0       4     4     6     0     0     0     0     0     0	_	bromisovalum	0	0	0	0	50	5 0	5 6	0 0	0 0	8 6		
20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		buspironecarbamate	576	573	617	961	1,125	1,204	1,095	422	828	718		
20 8 1 3 5 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		chloral betaine.	0	00	0	0	50	0 0	0 0	<del>o c</del>	0 0	; 6		
20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		chlorat nydrate	20	59	91	:	:	14	23	•	:	· :	_	
20 8 1 3 5 1 0 0 0 2 2 3 3 5 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		chlormezanone.	0	0	0	0	0	-	C					
4 966 4 4 508		demoxepamdexmedetomidine	20	<b>6</b> 0	-	က	Ω	-	0	00	7	: :		
4 966 4 508 3 540 3 3 540 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	_	dextromethorphan/doxylamine	0	0	0	0	0	0	0		0	c	-	
		diohenhydramine	4 966	4 508	2 640	0 0	0 6	0	0	0	0	00		

# able 2.5.0 - ED mentions for psychotherapeutic agents by drug category: Estimates for the coterminous U.S. by half year (continued)

% change <sup>4</sup> H1 2001, H1 2002		-100.0													
% change <sup>4</sup> H2 2001, H1 2002												-100.0	-100.0		
Jan-Jun *	773	: 0 9	3 :	es .	000	6	000	00	268 4,075	995 1,887	1,155	:00	0 0	716	
Jul-Dec 2001	713	0 0 %	15	£ '	000	0	:00	00	4,684	840	978	0-0	0 -	752	10
Jan-Jun 2001	597	0 0 7	<b>5</b> :	₽ '	500	0	000	00	3,605	845 1.392		000	0 0	527	9
Jul-Dec 2000	723	009	8 :	G '	000	0	-00	00	3,662	969	635	000	0 0	746	42
Jan-Jun 2000	710	0 0 2	16	: '	000	0	: :°	00	3,149	1,117	1,039	000	0 -	742	29
Jul-Dec 1999		0 0 4	25.	81	:00	0	;00	:0	2,406	0 771 1,775	1,147	000	<del>-</del>	554 0	14
Jan-Jun 1999	r.		2 : -	:	000	•	0 0 0	· · ·	2,862	816 1.869	923	000	0 0	924	15
Jul-Dec 1998	725	000	2 :	ω	000	0	° ; °	0 -	0 2,664	920		000	; 0	757	20
Jan-Jun 1998	710	008	? :	ŧ	000	0	;00	0 :	2,973	1,405	1,161	000	ო 0	970	35
Jul-Dec 1997	533	0 ::0	30	:	000	0	000	000	2,914	1,404	1,501	000	: 0	1,235	219 26
Drug name <sup>1,2,3</sup>	doxylamine doxylamine/pyridoxine ethchlorvynol	ethinamateglutethimide	nydroxyzine meprobamate meprobamate/pentaerythritolchloral	methaqualonemethylpentynol	methyprylonparaidehyde	nphenprobamatephenprobamatine	pyriamine salicylamide/scopolamine sulfordazine	tricloryltybamate	zaleplon	zopictone	caffeine	caffeine/ephedrinecaffeine/multivitamin/phenylpropanolamine	caffeine/phenylpropanolaminedexmethylphenidate	methylphenidatemodafinil	pemoline CNS stimulants-NOS

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors.

CNS = central nervous system, ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, MAO = monoamine oxidase, NOS = not otherwise specified,

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ABLE

ITAWA

The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com

Flunitrazepam (Rohypnol) is classified under Major Substances of Abuse.

Amphetamines are classified under Major Substances of Abuse.

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were Imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates Drugs are classified to the degree of specificity recorded in the DAWN case reports.

NTA = not tabulated above, SSRI = selective serotonin reuptake inhibitor.

Authorogramm         Drug name v.s.         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         1764         176												
54,422         53,784         55,886         54,188         54,382         58,984         60,576         61,012         2001           289	Drug name <sup>1,2,3</sup>	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>4</sup> 1994,	% change <sup>4</sup> 1999,	% change <sup>4</sup> 2000,
4442         56,764         56,886         54,138         54,382         54,984         60,576         61,012           20         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0										1002	1002	7007
299         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700         700 <td>Antidepressants</td> <td>54,442</td> <td>53,764</td> <td>55,886</td> <td>54,138</td> <td>54,382</td> <td>58,964</td> <td>925'09</td> <td>61,012</td> <td></td> <td></td> <td></td>	Antidepressants	54,442	53,764	55,886	54,138	54,382	58,964	925'09	61,012			
299         299         279         11         279         11         279         279         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270         270	isocarboxazid	001	3	:	-67 -0	87 0	4 0	; C	; c	:		
20,402         21,565         23,651         24,374         24,768         24,882         26,775         26,977         32.2           9,110         9,566         9,598         10,562         9,813         24,882         26,775         26,977         32.2           3,914         5,666         5,998         10,562         9,813         3,488         3,474         30.2           3,914         5,666         5,990         7,472         5,997         6,897         6,706         6,922         30.2           7,377         6,150         7,472         5,997         6,897         6,870         6,932         12.80           1,266         8,897         8,874         8,445         6,710         5,776         6,444         4,673         -88.5           1,277         2,482         2,244         1,301         1,377         1,528         1,133         1,247         -88.5           1,277         2,482         2,091         1,378         1,528         1,133         1,134         1,144         4,673         -88.5           1,277         2,482         2,091         1,378         1,489         6,210         6,372         9,44         4,673         -88.5	phenetzine	299	· i	: :	278	9	, <del>[</del>	)	5			
20,402         21,585         23,651         24,317         24,682         26,717         32,27           20,402         21,585         23,651         24,317         24,683         34,68         4,474         32,2           3,110         9,506         9,586         10,586         1,583         34,88         4,474         30,2           7,377         6,606         9,586         10,586         5,997         6,887         6,210         6,570         6,582         128,0           1,246         7,256         8,897         18,982         16,229         13,38         12,447         4,95         12,88           1,246         7,256         8,897         18,382         13,383         13,38         12,447         14,47         14,58         12,447         14,58         12,447         14,47         14,58         12,447         14,58         14,47         14,58         14,47         14,58         14,47         14,58         14,47         14,58         14,47         14,58         14,47         14,58         14,58         14,47         14,58         14,58         14,47         14,58         14,59         14,58         14,59         14,59         14,59         14,59         14,59	tranylcypromine	:	:	23	-	00	: ;	: ^	:	:		
20,402         21,566         23,651         24,17         24,768         24,882         26,715         26,972         32,2           9,110         9,506         9,586         10,502         9,813         9,181         7,486         26,775         26,972         3,27           3,914         5,686         5,990         10,502         9,813         9,386         10,272         3,914         2,472         3,927           2,4625         19,429         18,962         16,223         13,130         13,526         1,183         12,447         4,955           1,1240         1,1266         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,897         8,898         8,897         8,898         8,897         8,898         8,897         8,898         8,897         8,898         8,897         8,898         8,898         8,898         8,898         8,899         8,899         8,899         8,899	monoamine oxidase inhibitors-NOS	0	0	0	2	_	0	0				
9,110         9,506         9,508         9,110         9,506         4,474         4,474         1,509         9,110         9,506         4,474         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509         1,509 <td< td=""><td>SSRI antidepressants</td><td>20,402</td><td>21,585</td><td>23,651</td><td>24,317</td><td>24,768</td><td>24,882</td><td>26,715</td><td>.,</td><td>32.2</td><td></td><td></td></td<>	SSRI antidepressants	20,402	21,585	23,651	24,317	24,768	24,882	26,715	.,	32.2		
9,110         9,566         9,598         10,502         9,813         9,381         7,939         6,382         -30,2           3,914         5,656         5,990         7,180         7,472         6,887         6,210         6,670         6,982         -30,2           1,246         6,897         8,874         8,445         6,710         5,716         6,444         4,673         -5,85           1,246         8,897         8,874         8,445         6,710         5,716         6,444         4,673         -5,85           1,240         735         755         401         238         22,91         1,247         5,716         6,444         4,673         -5,85           1,240         735         755         401         238         20         1,237         1,525         1,123         172         -81,9           2,757         2,726         2,244         1,301         1,275         888         683         688         75,5           1,001         1,244         1,301         1,275         888         683         688         75,7           1,001         1,244         1,301         1,275         888         683         688         75	citalopram	0	0	0	0	0	1,563	3,458	4,474		186.2	
3,944         5,954         6,38         4,21         4,71         6,29         7,256         8,020         8,227         128.0           7,377         6,150         7,472         5,997         6,887         6,210         6,670         6,922         128.0           11,286         8,897         8,874         8,445         6,710         5,716         6,444         4,673         -8.85           11,286         8,897         8,874         8,445         6,710         5,716         6,444         4,673         -8.85           11,286         8,897         8,874         8,445         6,710         5,716         6,444         4,673         -8.85           2,727         2,726         2,401         1,238         2,19         1,231         1,231         1,231         1,231         1,232         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810         -810	fluoxetine	9,110	9,506	9,598	10,502	9,813	9,381	7,939	6,362	-30.2		
3.974         5.656         5.990         7.180         7.266         8.020         8.923         128.0           2.4625         1.960         6.150         6.150         6.150         6.932         128.0           2.4625         1.970         6.170         6.710         6.710         6.710         6.714         4.953           1.266         8.897         8.874         8.72         1.3130         1.356         1.188         1.247         -8.85           1.240         735         755         401         238         2.9         1.244         4.573         -8.85           2.777         2.726         2.240         2.091         1.537         1.522         1.123         772         -819           2.777         2.748         2.742         2.091         1.537         1.529         2.623         -819         -819           2.777         2.748         2.747         4.289         6.63         6.89         -819         -819           1.301         1.819         2.224         2.326         2.427         4.289         2.623         2.631         -819         -819         -819         -819         -819         -819         -819         -819	fluvoxamine	0	271	591	638	421	471	629	227			
7.377         6,150         7,472         5,997         6,887         6,210         6,670         6,932           2,4,625         19,425         18,962         16,223         13,130         13,526         11,838         12,447         -49,53           1,1266         8,897         8,874         8,710         5,716         6,444         4,673         -58,53           1,1266         8,897         8,874         8,445         6,710         5,716         6,444         4,673         -58,53           1,1266         8,897         8,874         8,710         5,716         6,444         4,673         -58,53           1,1240         735         7,25         401         238         219         1,247         -58,53         24,17         -51,123         77,27         -51,23         1,247         -58,53         1,475         -51,23         1,475         -51,23         1,476         -51,23         1,476         -51,23         1,476         -51,23         1,476         -51,23         1,476         -51,23         -51,123         1,476         -51,23         -51,24         -75,77         -74,53         -75,77         -74,59         -75,77         -74,59         -75,77         -74,59         -75,77 <td>paroxetine</td> <td>3,914</td> <td>5,656</td> <td>5,990</td> <td>7,180</td> <td>7,646</td> <td>7,256</td> <td>8,020</td> <td>8,923</td> <td>128.0</td> <td></td> <td></td>	paroxetine	3,914	5,656	5,990	7,180	7,646	7,256	8,020	8,923	128.0		
24825         19,429         18,982         16,223         13,130         13,526         17,447         4,673         -88.5           11,266         8,887         8,842         6,710         5,716         6,444         4,673         -88.5           11,266         8,887         8,842         8,442         6,710         5,716         6,444         4,673         -88.5           11,267         330         386         202           19.3         772         -81.9           2,777         2,402         2,081         1,537         1,582         1,123         772         -81.9           2,707         2,350         2,244         1,301         1,275         886         66.3         65.8         -75.7           1,301         1,819         2,224         1,301         1,275         886         66.3         65.8         -75.7           1,301         1,819         1,2447         1,315         1,425         1,425         1,447         4,476           1,301         1,131         1,447         1,444         1,465         1,426         1,464         4,476         1,895           1,301         1,484         1,301         1,	sertraline	7,377	6,150	7,472	2,997	6,887	6,210	6,670	6,932			
24,625         19,429         18,962         16,223         13,130         13,526         11,838         12,447         -49.5           11,266         8,897         8,874         8,445         6,710         5,716         6,444         4,673         -58.5           11,266         8,897         36,874         8,445         6,710         5,716         6,444         4,673         -58.5           1,240         736         2,625         2,401         238         1,537         1,552         1,123         772         -81.9           2,777         2,483         1,383         1,78         748         563         563         -85.9           2,777         2,483         1,383         1,78         748         563         5515         323.9           1,301         1819         2,224         1,301         16,485         2,623         5,515         323.9           9,011         12,447         13,155         13,307         16,485         2,623         3,693         4,445         447.6           0         0         0         0         0         0         0         0         1,475         1,475         1,475         1,475         1,475 <t< td=""><td>SSRI antidepressants-NOS</td><td>0</td><td>:</td><td>0</td><td>0</td><td>:</td><td>_</td><td>0</td><td></td><td></td><td></td><td></td></t<>	SSRI antidepressants-NOS	0	:	0	0	:	_	0				
11,266         8,897         8,874         8,445         6,710         5,716         6,444         4,673         -58.5           1,240         735         330         368         202          19.          4,123          4,123          49.           19. </td <td>Tricyclic antidepressants</td> <td>24,625</td> <td>19,429</td> <td>18,962</td> <td>16,223</td> <td>13,130</td> <td>13,526</td> <td>11,838</td> <td>12,447</td> <td>-49.5</td> <td></td> <td></td>	Tricyclic antidepressants	24,625	19,429	18,962	16,223	13,130	13,526	11,838	12,447	-49.5		
797         330         368         202          191          -81.0           1,240         735         755         401         238         219          191          -81.0           2,767         2,726         2,402         2,091         1,537         1,552         1,123         772         -81.9           2,767         2,380         2,244         1,383         718         748         663         658         -75.7           1,301         1,819         2,224         1,307         1,278         888         663         658         -75.7           1,301         1,819         2,224         2,326         2,427         4,259         2,623         5,515         323.9         -85.9           1,301         1,819         2,224         1,307         16,455         20,522         2,623         3,699         4,776         4,776           1,301         1,247         1,315         1,307         16,455         20,542         2,462         1,499         -75.7           1,01         0         0         0         0         0         0         1,440         4,476         1,476         4,476<	amitriptyline	11,266	8,897	8,874	8,445	6,710	5,716	6,444	4,673	-58.5		-27.5
797         330         366         202          1740         330         366         202          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410          410 <td>amoxapine</td> <td>÷</td> <td>:</td> <td>:</td> <td><del>00</del></td> <td>:</td> <td>:</td> <td>:</td> <td>2</td> <td></td> <td></td> <td></td>	amoxapine	÷	:	:	<del>00</del>	:	:	:	2			
1,240         775         2,402         2,031         2,13         7,25         -81.0           2,757         2,483         1,884         1,837         1,552         1,123         772         -81.9           2,757         2,483         1,884         1,884         1,884         1,87         1,552         1,123         772         -81.9           2,707         2,380         2,244         1,301         1,275         888         663         658         -75.7           1,301         1,819         2,224         2,326         2,427         4,259         2,623         5,515         323.9         -85.9           1,301         1,819         2,224         2,326         2,427         4,259         2,623         2,515         33.9         -85.9         1,557         1,459         4,145         4,765         1,559         2,623         2,623         2,515         33.3         1,476         4,765         1,455         1,455         1,455         1,455         1,455         1,455         1,455         1,455         1,455         1,455         1,456         1,476         1,476         1,476         1,476         1,476         1,476         1,476         1,476         1,476	clomipramine	197	330	368	202	:	;	191	:	;		
4,272         2,775         2,483         1,833         1,537         1,552         1,123         772         -81.9           2,757         2,483         1,888         1,883         1,718         748         563         658         -75.7           2,757         2,350         2,244         1,301         1,245         1,365         2,427         4,259         2,623         5,515         323.9           9,011         12,447         13,155         13,307         16,455         2,0542         2,1953         21,459         133.9           0         0         0         0         0         0         0         4,145         447.6         47.6           0         0         0         0         0         0         0         4,145         447.6         133.9           0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	desipramine	1,240	735	755	401	238	219	:	236	-810		
2,757         2,483         1,838         1,383         718         748         563         390         -85.9           2,707         2,350         2,244         1,301         1,275         888         663         658         -75.7           1,301         1,819         2,224         1,307         1,429         2,427         4,289         2,623         5,515         323.9           9,011         12,447         13,155         13,307         16,455         2,642         2,1459         4,145         447.6           0         0         0         0         0         0         0         4,145         447.6           0         0         0         0         0         0         1,608         1,429         447.6           0         0         0         0         0         0         0         1,476         1,898           0         0         0         0         0         0         0         1,476         447.6           0         0         0         0         0         0         0         0         1,476         1,698         1,769         447.6           0         0         0	doxepin	4,272	2,726	2,402	2,091	1,537	1,552	1.123	772	6 6		
2,707         2,350         2,244         1,301         1,275         888         663         658         -757           1,301         1,819         2,224         2,326         2,427         4,259         2,623         5,515         323.9           1,301         1,819         2,224         2,326         2,427         4,259         2,633         2,1459         138.1           9,011         12,447         13,155         13,307         16,455         20,542         2,1459         138.1           0         0         0         0         0         0         0         447.6           0         0         0         0         0         0         0         447.6           0         0         0         0         0         0         0         0         0           0         0         0         0         0         0         0         0         0         0           0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	imipramine	2,757	2,483	1,838	1,383	718	748	563	300	9.58-		
1,301         1,819         2,224         2,326         2,427         4,259         2,623         5,515         323.9           9,011         1,2447         13,152         2,427         4,259         2,623         5,515         323.9           9,011         1,2447         13,152         2,681         3,859         2,1459         138.1           0,011         1,2447         13,152         2,681         3,859         2,145         447.6           0         234         1,103         673         1,652         1,890         4,145         447.6           0         234         1,103         673         1,652         1,890         2,416         1,494           1         2,265         9,210         8733         9,674         9,853         9,347         1,071.3           1         2,265         9,216         1,632         1,627         1,698         1,713           2,5012         2,192         1,897         1,632         1,632         1,671.3           2,5012         2,192         1,893         1,6270         1,522         2,416         1,071.3           2,5012         2,192         1,894         5,732         4,310         2	nortriptyline	2,707	2,350	2,244	1.301	1.275	888	663	658	-757		
1,301         1,819         2,224         2,326         2,427         4,259         2,623         2,615         323.9           9,011         12,447         13,155         13,307         16,455         20,542         21,653         21,459         138.1           7,57         1,249         15,155         13,307         16,455         20,542         21,459         4,145         447.6           1,00         0         0         0         0         0         1,499         4,145         447.6           1,00         0         0         0         0         0         1,494         447.6         1,898         1,494         447.6           1,00         0         0         0         0         0         1,494         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         447.6         44	protriptyline	:	4			į	0	}	3	5		
1,301         1,819         2,224         2,326         2,427         4,259         2,623         5,515         323.9           9,011         12,447         13,155         13,307         16,455         20,542         21,953         21,459         138.1           0         0         0         0         0         0         0         4,145         447.6           0         0         0         0         0         0         0         4,145         447.6         447.6           0         0         0         0         0         0         0         4,145         447.6         447.6           1         0         234         1,103         673         1,522         1,800         1,498         447.6         447.6           1         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0 </td <td>trimipramine</td> <td></td> <td>7</td> <td></td> <td>^</td> <td>:</td> <td>•</td> <td>7</td> <td>1</td> <td></td> <td></td> <td></td>	trimipramine		7		^	:	•	7	1			
9,011         12,447         13,155         13,307         16,455         20,452         21,953         21,459         138.1           757         1,249         964         1,529         2,681         3,859         3,809         4,145         447.6           0         234         1,103         673         1,522         1,800         1,608         1,494           7,285         9,455         9,210         8,733         9,674         9,853         9,798         9,347           7,285         9,455         9,210         8,733         9,674         9,853         9,798         9,347           7,285         9,455         9,210         8,733         9,674         9,853         9,798         9,347           1,489         9,125         7,743         1,629         3,209         3,722         3,994         1,071.3           2,507         2,102         1,897         1,632         1,629         3,209         3,722         3,994         1,071.3           2,501         2,132         1,632         1,629         3,209         3,722         3,994         1,071.3           2,507         2,202         2,143         1,529         4,310         2,088	tricyclic antideoressants-NOS.	1301	1819	2 224	2 326	2 427	4 250	2623	v	3330		
757         1,249         964         1,529         2,681         3,859         2,145         447.6                                                                                                  <	Miscellaneous antidepressants.	9.011	12,447	13 155	13,307	16.455	20.542	21,023	2,2,5	120.4		5.0 5.0
<td>bupropion</td> <td>757</td> <td>1.249</td> <td>964</td> <td>1,529</td> <td>2,681</td> <td>3,859</td> <td>200, 5</td> <td>4 145</td> <td>130.1</td> <td></td> <td></td>	bupropion	757	1.249	964	1,529	2,681	3,859	200, 5	4 145	130.1		
0         0         0         0         0         0         1,420         2,416         1,898           0         234         1,103         673         1,552         1,800         1,608         1,494           1         0         0         0         0         0         0         1           1         0         0         0         0         0         0         0           1         0         0         0         0         0         0         0           1         1,285         9,455         9,210         1,629         3,209         3,722         3,944         1,071.3           25,012         21,902         1,688         1,629         3,209         3,722         3,944         1,071.3           25,012         21,902         1,688         1,627         15,223         20,097         20,182         -19.8           2,607         2,202         2,154         1,198         870         424         207         88         47         -96.8           1,475         786         1,484         501         424         207         88         47         -96.8           1,475         78	maprotiline		1	3	2		2	9	ŕ	) }		
0         234         1,103         673         1,552         1,800         1,608         1,494           0         0         1         0         0         1         0         0         1         0         0         1         0         0         1         0         0         0         1         0         0         1         0         0         0         1         1         0         0         0         0         0         1         1         0         0         0         0         0         1         1         0         0         0         0         0         1         1         0         0         0         0         1         1         0         0         0         0         0         1         0         0         0         0         1         0         0         0         0         0         1         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0 <td>mirtazapine</td> <td>0</td> <td>0</td> <td>0</td> <td>:</td> <td>909</td> <td>1 420</td> <td>2 416</td> <td>1 808</td> <td></td> <td></td> <td></td>	mirtazapine	0	0	0	:	909	1 420	2 416	1 808			
7,285         9,455         9,210         8,733         9,674         9,853         9,798         9,347         1,071.3           341         1,235         1,606         1,632         1,629         3,209         3,722         3,994         1,071.3           25,012         21,902         18,947         16,983         1,6270         15,223         20,097         20,182         -19.3           11,896         21,67         16,983         16,270         15,223         20,097         20,182         -19.3           25,012         21,902         18,947         16,983         16,270         15,223         20,097         20,182         -19.3           11,896         2,167         1,988         2,107         1,359         -88.6         -75.6           2,212         1,896         1,452         764         813          9         9           2,212         1,896         1,452         764         813          9         9           3,189         2,566         2,243         1,725         1227         478         782         201         -93.7           249         131         135         231          0	nefazodone	_	234	1 103	673	1 552	2,0	4,4	, 636			
7,285         9,455         9,210         8,733         9,674         9,853         9,798         9,347         1,071.3           341         1,235         1,606         1,632         1,629         3209         3,722         3,994         1,071.3           25,012         21,902         18,947         16,983         16,270         15,223         20,097         20,182         -19.3           11,899         9,125         7,743         5,332         4,310         2,088         2,107         1,359         -88.6           2,607         2,202         2,154         1,198         870         567         613         636         -75.6           1,475         2,202         2,154         1,198         870         89         47         -96.8           1,475         782         307         284         400         272         31         26.8           302         555         307         284         400         272         31         20           3189         2,566         2,243         1,725         1,227         478         782         201         -93.7           249         131         135         231 <t< td=""><td>nomifensine maleate.</td><td><del>)</del> C</td><td>-</td><td></td><td>5</td><td>200.</td><td>000,</td><td>000,</td><td>40.4. 40.4.</td><td></td><td></td><td></td></t<>	nomifensine maleate.	<del>)</del> C	-		5	200.	000,	000,	40.4. 40.4.			
341         1,235         1,606         1,629         3,209         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         3,790         4,790         88.6         2,700         4,700         2,750         88.6         2,750         88.6         2,750         4,750         4,750         4,700         2,72         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700         3,700	trazodone	7 285	9 455	0 210	8 733	0 674		0 700	- K 7 C O			
516         144         268         7,22         261         342         5,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         3,122         4,136         870         567         613         636         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6         -88.6         -75.6	venlafaxine.	341	1 235	1,506	1,632	1 620	0000	3,733	7000	4 074 9		
25,012         21,902         18,947         16,983         16,270         15,223         20,097         20,097         -19.3           11,899         9,125         7,743         5,332         4,310         2,088         2,107         1,359         -88.6           2,607         2,202         2,154         1,198         870         567         613         636         -75.6           1,475         792         884         501         424         207         89         47         -96.8           1,475         782         844         501         813          168          -96.8           1,475         1,496         1,452         764         813          168          -96.8           1,301         2,243         1,725         784         400         272         311         207             1,391         736         2,243         1,725         1,227         478         782         201            2,49         131         135         231                2,49         131         1	antidepressants-NOS	516	144	268	225,	26.	343	500	5,334	5.		
11,899         9,125         7,743         5,332         4,310         2,088         2,107         1,359         -886           2,607         2,202         2,154         1,198         870         567         613         636         -75.6           1,475         792         884         501         424         207         89         47         -96.8           2,212         1,896         1,452         764         813          168          9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9 <t< td=""><td>Antipsychotics.</td><td>25.012</td><td>21.902</td><td>18.947</td><td>16 983</td><td>16 270</td><td>15 223</td><td>20 00</td><td>20 182</td><td>10.2</td><td>9 00</td><td></td></t<>	Antipsychotics.	25.012	21.902	18.947	16 983	16 270	15 223	20 00	20 182	10.2	9 00	
2,607         2,202         2,154         1,198         870         567         613         636         -75.6           1,475         792         884         501         424         207         89         47         -96.8           2,212         1,896         1,452         764         813          168          9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9         9	Phenothiazine antipsychotics	11,899	9.125	7.743	5,332	4.310	2.088	2 107	1 350	2,00	32.0	
1,475     792     884     501     424     207     89     47       2,212     1,896     1,452     764     813      9     9       3,189     2,212     307     284     400     272     311     207       3,189     2,566     2,243     1,725     1,227     478     782     201       1,391     736     397     454     370     119     49        2     0      0     0      0       617     522     369     283       4        472     374     177	chlorpromazine	2.607	2,202	2.154	1.198	870	567	613	989	7.5.6	5	
2,212     1,896     1,452     764     813      9     9       302     555     307     284     400     272     311     207       3,189     2,566     2,243     1,725     1,227     478     782     201       1,391     736     397     454     370     119     49        2,49     131     135     231           617     522     369     283           472     374     177	fluphenazine	1,475	792	88	501	424	202	8	47	2 0		
2,212     1,896     1,452     764     813      168        302     555     307     284     400     272     311     207        3,189     2,566     2,243     1,725     1,227     478     782     201        1,391     736     397     454     370     119     49         249     131     135     231       15                                                                                         .	mesoridazine		248	167		į	<u> </u>	3 0	•	2		
3,189 2,566 2,243 1,725 1,227 478 782 201 1,391 736 397 454 370 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	perphenazine	2.212	1.896	1.452	764		:	168	•			
3,189 2,566 2,243 1,725 1,227 478 782 201 1,391 736 397 454 370 119 49 249 131 135 231 472 283 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472 374 177 472	prochlorperazine	302	555	307	284	400	27.0	317	207	:		
3,189     2,566     2,243     1,725     1,227     478     782     201       1,391     736     397     454     370     119     49        2     0      0     0      0       249     131     135     231      15       617     522     369     283       4       472     374     177	promazine		0	r	; ;	0	i	;	2			
1,391     736     397     454     370     119     49       2,49     131     135     231       15       617     522     369     283       44     5       7     374     177       4     5	thioridazine	3,189	2.566	2.243	1.725	1227	478	782	201	-03 7		77.3
249 131 135 231 15 15	trifluoperazine	1,391	736	397	454	370	119	49		;		?
249     131     135     231      15       617     522     369     283	triflupromazine	7	0	:	0	0	0	? ;	0	-100.0		
617 522 369 283 44 5 472 374 177	phenothiazine antipsychotics-NOS	249	131	135	231	:	i	:	15	9		
472 374	Psychotherapeutic combinations	617	225	369	283	:	:	:	:	:		
472 374	amitriplyline-chlordiazepoxide	:	•	:	:	:	4	2	:			
	aminipryline-perprenazine	472	374	177			:	:	:	:		

Drug name (x2)         Total Total Total         Total Total Total Total         Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total Total T												
1,781	Drug name <sup>1,2,3</sup>	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>4</sup> 1994, 2001	% change <sup>4</sup> 1999, 2001	% change <sup>4</sup> 2000, 2001
1,781   1,775   551   828   299	psychotherapeutic combinations-NOS	0	0	0	0	0	0	0	5			
1,74   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75   1,75	thenes	1,781	1,176	23.	828	299	:	:	:	:		
418         214         331         2306         213         146         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683         -683	lixene	10,715	11,079	10.304	10.540	11 402	12.771	17.661	18 542	73.0	45.2	
10   10   10   10   10   10   10   10	erazine		)	2	2		Î		<u> </u>	2	1	
3,044         2,714         3,144         2,718         1,187         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167         1,167 <td< td=""><td>prothixene</td><td>0</td><td>0</td><td>0</td><td>:</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td></td></td<>	prothixene	0	0	0	:	0	0	0	0			
5.104 6.707 8.537 7.206 2.739 1.183 1.167 1.016 -456.3  5.104 6.707 8.537 7.206 2.739 1.183 1.167 1.016 -456.3  5.104 6.707 8.331 2.206 2.759 3.286 5.444 5.217 7.102 1.006.4  5.105 7.108 881 112.847 114.228 118.325 3.899 4.046 5.217 14.18 1.100.0  5.105 7.108 881 112.847 114.228 118.325 3.899 4.046 5.15 1.100.0  5.105 7.108 881 112.847 114.228 118.325 3.899 4.046 5.15 1.100.0  5.105 7.108 881 112.847 114.228 118.325 3.899 4.046 5.15 1.100.0  5.105 7.109 7.109 7.109 7.100 7.100 7.100.0  5.105 7.109 7.109 7.109 7.100 7.100 7.100.0  5.105 7.109 7.109 7.109 7.100 7.100.0  5.105 7.109 7.100 7.100 7.100.0  5.105 7.109 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100.0  5.105 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.100 7.1000 7.100 7.100 7.1000 7.1000 7.1000 7.1	pine	418	214	\$ 3	83	: (	: :	191	214			
106   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107   107	endol	3,014	2,718	3,311	2,306	2,130	1,183	1,167	1,016			
100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100	II.	0,00 0,00 0,00	937	4,078	4,804	3,480	3,867	3,720	3,410			
106.421   108.881   1,024   1,449   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,544   1,444   1,444   1,444   1,444   1,444   1,444   1,444   1,444   1,444   1,444   1,444	dona	<u> </u>	t ?	222	::2	:		: «	; <sup>(</sup>			
588 1,024 1,846 1,616 2,434 3865 3,009 4,346 588.1 385.0    106,421 108,881 1,12,847 114,228 118,352 118,467 120,519 135,949 27.7 14.8    5,887 6,793 7,129 7,039 8,760 7,777 7,102 9,506 61.5    10	apine	2 0	<u>;</u>	3 0	1 449	2 759	3 285	5 454	F 217		a a	
106.421	ide	>	m	•	4	, , , ,	2	;	7170		0.00	
5 88 1 1024 1 1948 1 516 2 154 3 352 3 899 4 646 5 88 1 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 12 84 1 1 12 84 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	apine	0	0	0	0	484	896	3,009	4 346		385.0	
106.421 108.881 112.847 114.228 118.322 118.467 120.519 135.949 27.7 14.8 118.322 118.467 120.519 135.949 27.7 7 7.02 9,506 61.5 14.8 118.322 118.467 120.519 135.949 27.7 7 7.02 9,506 61.5 14.8 118.322 118.467 120.519 135.949 27.7 7 7.02 9,506 61.5 14.8 118.322 118.467 120.519 135.949 27.7 7 7.02 9,506 61.5 14.8 118.322 118.467 120.519 135.949 27.7 7 7.02 9,506 61.5 14.8 118.322 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.467 120.519 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325 118.325	idone	588	1.024	1.848	1.616	2.154	3.352	3,899	4 046	588.1	9	
106,421         108,881         112,847         114,228         118,352         118,467         120,519         135,949         27.7         14.8           5,887         6,793         7,129         7,039         8,706         118,467         7,777         7,102         9,506         61.5         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8         14.8	sidone	0	0	0	0	o î	0	0	?			
106,421         102,887         112,287         114,228         114,228         118,467         120,519         27.7         14.8           5,887         6,793         7,129         7,039         8,760         7,777         7,102         9,506         61.5         14.8           10         20         0         0         0         0         0         0         10         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	sychotics-NOS	12	2	4	:	4	Ω.	9	8			
fpentobarbital         5,887         6,783         7,129         7,039         8,760         7,777         7,102         9,506         61.5           albital/caffeine         0         0         0         0         0         0         1         1         0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -100.0         -	s, sedatives, and hypnotics	106,421	108,881	112,847	114,228	118,352	118,467	120,519	135,949		14.8	12.8
100	rates	5,887	6,793	7,129	7,039	8,760	7.77.7	7,102	9,506		•	33.8
10	/Icarbromal/pentobarbital	0	: '	0	0	:	0	i	0			
10	arbital	0	0	0	0	0	0	0	-			
100	opyrine/butalbital/caffeine											
10.000	arbital	: :	14	9	0	0	:	•	0			-100.0
1   2   0   0   0   0   0   0   0   0   0	arbital-secobarbital	10	- 50	:	<del>∞</del>	2	9	:	0	-100.0	-100.0	
	oarbital/butabarbital/phenobarbital	ı		•	(	(	(	(				
8 12 22 5 33 312.5 12 22 5 33 312.5 14 8 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		n	:	<u></u>	7	0	0	7	:	:		
1   1   1   1   1   1   1   1   1   1	tal/butabarbital/dihydroergotamine/											
	obarbital/scopolamine											
8 12 22 14 0 0 15 33 312.5 16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	lunc acid	0	0	0	0	:	0	0	0			
1   1   2   1   1   2   1   1   2   1   1	donna/phenobarbital			_								
	arbital	∞	:	:	12	22	:	Ω.	33	312.5		260.0
	arbital/chlorpheniramine-											
	/Ipropanolamine/theophylline	i	0	0	0	:	0	0	0			
	arbital/pentobarbital/phenobarbital/											
14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	)arbital	0	<del>-</del>	<del>-</del>	0	<del>-</del>	0	፥	<del>-</del>			
ital 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	bital	:	: '	14	<del>20</del>	<u>-</u>	:	:	Ω.			
ital 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	barbital	0	0	0	7	0	0	0	i			
	/lbarbituric acid					•						
	drine/pentobarbital	:	0	0	0	0	0	0	0			
	Jrine/phenobarbital	:	5 0	0 (	0 0	<del>- (</del>	0	0 (	0			
1 0 0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0	JIII TE/SECODAL DITAL	÷	5	>	5	5	<del>-</del>	5	5			
1 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0	Darbital											
1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Jai Dital			-	٣	c	c	C	٧			
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	tronica/obencharbital	<del>-</del>	5 0	<del>-</del>	- c	0 0	o c	<b>5</b> C	- c			
phenytoin	obarbital	<del>, -</del>	<del>,</del> е	<del>, -</del>	0	7	o c	0 0	о <b>с</b>	1000		
	obarbital/phenytoin	<u></u>	0	0	0	C	•	0	•	2		

Table 2.6.0 - ED mentions for psychotherapeutic agents by drug category: Estimates for the coterminous U.S. by year (continued)

% change <sup>4</sup> 2000, 2001	-100.0				48.7	14.2	16.0										-100.0					35.4	-80.0	?			74.3	<del>}</del>				100.0			
% change <sup>4</sup> 1999, 2001						14.8	25.2																				386	9				-75.0			
% change <sup>4</sup> 1994, 2001		-54.9		-89.6	152.8	39.3	49.4	-62.8	57.1	5		-96.6	7.60-						:		-76.3	231.6								:	-100.0	-90.0			45.0
Total 2001	0 :	1,117		22	7,209	5,	25,644	953	19 117		11,447	6	200	11,902		tD (	2,0	702	-	2,637	235	30,302	24,412	0	-	5 0	1 280	0	0	:	0	2	:	0	7,670
Total 2000	0 0	253 1,798		23		0, (	22,105	1,384	18,005		12,090			10,671	0	0	307			2,742	363	22,376	10	0	(	5 6	2 299	0	0	37	0	-	0	0	7,440
Total 1999	00;	1,6		•		0, (		1,184	16 584		11,406			10,69		0	347		:	2,694	560	25,520		0	•	<b>5</b> C	2.08		0	:	0	•	0	0	6,771
Total 1998	40	2,546	0	37		ω ,		1,5	17 450		12,7	27	50	10,47	0	; '	670		1	3,104		20,507		0	•	o c	1.19	•	0	45	0	6	0	0	8,058
Total 1997	202	<del>-</del> -	0	45			17,458	1,155	0 14.597		13,366	720	33	10,81	0	<del>-</del> (	395	2	10	2,731	322	24.569	2	0		; =	1.510	0	0	152	0	43	0	: 6	11,122
Total 1996	0 0 254	7,	0	200	4,220	78,640	cca'al 8	2,074	13.375	1,342	13,601	354	0	10,035	0		697	0	210	2,699	727	27,078	i	0		:	1.316	0	0	475	0	4	0	0	13,008
Total 1995	0 0 4	2,8	0	; -			9	2,66	12.802		4	1 407	•	11,256	: '	-	342			2,888	776	25.541	:	÷	c	<del>-</del>	1.682	:	: (	381	0	\$	:	0 0	11,953
Total 1994	°° :	2,479	0	212	2,852	74,637	17,168	2,563	12.165	725	13,560	267	; :	12,226	0	0	475	13	ï	3,739	991	25.898	:	0	C	0	1,358	0	0 !	4//	-	20	0	0	13,938
Drug name <sup>1,2,3</sup>	methylphenobarbitalpavatrine/phenobarbitalpentobarbital	pentobarbital/phenobarbitalphenobarbital	phenobarbital/phenytoin phenyttoloxamine/secobarbital	secobarbitaltalbural	barbiturates-NOS	Benzodiazepines	bromazepam	chlordiazepoxide	clobazam clonazepam	clorazepate	diazepam.	flurazenam	halazepam	lorazepam	lormetazepam		T oxazebam		_	temazepam	triazolam	Misc. anxlolytics, sedatives and hypnotics	acepromazine	acetophenazine maleate	henachzine	bromisovalum	buspirone	carbamate	chloral betaine	chlorat nydratechlormethazanone	chiormezanone	demoxepam	dextromethorphan/doxylamine	dichloralphenazone	dipnennydramine

#### able 2.6.0 - ED mentions for psychotherapeutic agents by drug category: Estimates for the coterminous U.S. by year continued)

% change <sup>4</sup> 2000, 2001																-100 0														1	0.c./-
% change <sup>4</sup> 1999, 2001													0	-100.0				57.4					_							_	
% change <sup>4</sup> 1994, 2001		-100.0		-53.7	:						-100.0		7	-100.0				487.9		40.0	-31.5	-42.3									
Total 2001	1,310	00	2	1,458	:		:	0	0	0	0		; °	<del></del>	o	0	410	8,289	:	1,685	3,146	4,00,1	-	0	0		-	1,279	12	<u> </u>	5
Total 2000	1,433	7	0	1,921	ŧ		:	0			0			: -	0	2	0	6,810	0	2,086	3,336	4,0,1	0	0	0		Ψ-	1,487	0	3:	7
Total 1999	1,230	1	0	2,525	:		:	:	0	0	÷	_	: °	n C	9	:	0	5,267	0	1,587	0,040 0,040	2,070	0	0	0		_	1,478	5	: 8	7.0
Total 1998	1,435	· i	0	1,713	206		:	0	0	0	0		:	: C	0	:	0	5,637	0	2,326	190,4 10,4	2,120	0	0	:		0	1,728	<b>5</b>	: ٤	200
Total 1997	1,269	30	:	2,168	126		:	0	0	0	0	-	m c	•	0	2	0	5,624	0	2,433	0,102	;	0	0	:		:	2,474	) C	787	2
Total 1996	2,034	52	7	2,776	66	:	:	0	0	•	0	•	4 C	0	' :	0	0	5,250	:!	716,1	2,009	<u>.</u>	0	0	i		0	- 96,	000	145	
Total 1995	1,933	:	0	2,680	178	173	•	0	-	0	:		; ⊂	· :	: :	0	0	4,037	0 !	2,153	3,562	700,0	:	-	4	•	7	1,860	171	=	
Total 1994	2,024	86	0	3,150	435		-	0	0	0	Ψ-		. 67	0	0	:	0	1,410	0 0	2,808	4,032	) )	0	:	:		က	1,190	5	4	!
Drug name <sup>1,2,3</sup>	doxylaminedoxylamine/byridoxine	ethchlorynol.	glutethimide	hydroxyzine	meprobamate	methaqualone	methylpentynol	methyprylon	paraldehyde	penflundol	phenprobamate	proporties	Pylliamitesalicylamide/scopolamine	suffordazine	tricloryl.	tybamate	zaleplon	zolpidem	Zopicione	Anxiolytics, sedantes and hypnotics-NOS	Caffeine	caffeine-sodium benzoate.	caffeine/ephedrine	caffeine/multivitamin/phenytpropanolamine	caffeine/phenylpropanolamine	dexmethy/phenidate	doxapram	metnylphenidate	Demoline	CNS stimulants-NOS	

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. ¹ This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique Plunitrazepam (Rohypnol) is classified under Major Substances of Abuse.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

<sup>&</sup>lt;sup>3</sup> Amphetamines are classified under Major Substances of Abuse.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data CNS = central nervous system, ED = emergency department, MAO = monoamine oxidase, NOS = not otherwise specified, NTA = not tabulated above, SSRI = selective serotonin reuptake estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to \* This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. from January-June 2000. Drugs are classified to the degree of specificity recorded in the DAWN case reports.

0		-	ľ										0, 04, 11, 14	0/ -44
reagents	Drug name <sup>1,2,3</sup>	ਤ`	Il-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% cnange H2 2001, H1 2002	% change H1 2001, H1 2002
March of the control for the	Analgesics		70,852	71,433	70,496	69,182	69,554	85,843	81,350	85,529	88,971	89,905		
A PA Publication of processors in the control c	Anumigraine agentsalmotriotan		607	0	:	107	0.4	743	/07	RC7	402	:		
Particular definition of the confinition of the con	APAP/dichloralphenazone/isomethepten	<u>е</u>	÷	347	:	:	388	228	:	43	310	:		
## Provide analysis of the first confinement o	belladonna/caffeine/ergotamine/													
Constitution	pentobarbital	-	-	C		•	•			•		•		
Control March   Control Marc	dibydroemotamine	-	n	o c	; °		- 0	: 5		N C	: `			-100.0
International part of the following sequence of the following sequen	ergotamine		:	0	•	: `	0	- ~		5 6	<del>-</del>		-100 0	
Strong the place and experimentations   Continued to the place and place a	frovatriptan			)			)	I		)	•			
methypergide miletale         0         2         1         3         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	isometheptene mucate		0	0	0	0	0	0	0	:	0	0		
Controller   Control French   Control	methysergide maleate	-	0	7	_	ო	0	0	0	0	0	0		
sumaripath	naratriptan					-								
summigration participation of continuidation of continuidatio	nzatriptan			•	1	,								
20x2 Infinition decominations.         4         10         2         7         395         607         564         809         801           Obsection between the condense control registers.         2         4         10         2         7         395         667         564         809         801           Obsection between the control registers and pages is a small registers.         2         2         2         2         2         2         8         9         4         10          395         667         564         809         801          388         801          388         801          388         801          388         801          388         801          388         801          388         801          388         801          388         801          388         801          301          301         301          301          301          301          301          301          301          301          301	sumatriptan		: '	13	7	12	12	7	:	:	:	:		
and migration agents-NOS	zolmitriptan	:	<del>-</del>	0 :	0	<del>-</del>	m	0	တ	4	<del>6</del>	:		
colectoral bring to col	antimigraine agents-NOS	-	4	9	7	:	;	က	:	7	0	i		
Occordion         Occordion <t< td=""><td>Cox-2 inhibitor</td><td></td><td><del>-</del></td><td>0 0</td><td>0 0</td><td><u></u></td><td>:</td><td>395</td><td>607</td><td>504</td><td>808</td><td>801</td><td></td><td></td></t<>	Cox-2 inhibitor		<del>-</del>	0 0	0 0	<u></u>	:	395	607	504	808	801		
The continue contin	celecoxID	-	5	<del>5</del>	0	7	: '	395	209	265	491	388		
Ordecoxib.         0         0         0         0         0         240         313         331           Addecoxib.         Cox-2 Inhibitor-NOS.         28,28         36,128         40,978         41,394         47,683         51,634         55,311           Arrotic analgesic combinations.         14,375         12,861         13,512         13,194         14,141         17,550         16,990         15,70         18,811         17,997           Arrotic analgesic combinations.         14,175         12,861         13,512         13,194         14,141         17,550         16,990         15,700         18,811         17,997           Arrotic analgesic combinations.         14,175         12,861         13,512         13,194         14,141         17,550         16,990         15,700         18,811         17,997           anilerdine.         1         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	meloxicam		0	0	0	0	0	0	0	<del>-</del>	:	÷		
According Stationary Control Englished Control	rofecoxib	:	0	0	0	0	0	0	0	240	313	331		
Secretary   Secr	valdecoxib													
Narcotic analgesic combinations   28,528   28,371   30,575   32,883   36,128   40,979   41,944   31,963   32,823   37,315     Narcotic analgesic combinations   14,175   12,861   13,512   13,194   14,141   17,550   16,990   15,720   18,811   17,997     Narcotic analgesic combinations   14,175   12,861   13,512   13,194   14,141   17,550   16,990   15,720   18,811   17,997     Narcotic analgesic combinations   14,175   12,861   13,512   13,194   14,141   17,550   16,990   15,720   18,811   17,997     Narcotic analgesic combinations   14,175   12,861   13,194   14,141   17,550   16,990   15,720   18,811   17,997     Narcotic analgesic combinations   14,175   12,861   13,194   14,141   17,550   16,990   15,720   18,811   17,997     Narcotic analgesic combinations   14,175   12,861   12,708   13,802   13,993   14,741   14,741   14,741   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,741   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,994   14,	cox-2 inhibitor-NOS	_												
Natrocia rangestics.         14,353         15,510         17,063         19,089         27,429         24,404         31,983         32,833         37,315           Natrocia rangestic combinations.         14,755         12,861         13,194         14,141         17,550         16,990         15,720         18,811         17,997           alfentanii         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	Narcotic analgesics/combinations		28,528	28,371	30,575	32,883	36,128	40,979	41,394	47,683	51,634	55,311		16.0
anilerdation         anilerdation         4         15,712         13,512         13,512         13,512         13,141         17,530         16,990         15,290         15,290         18,811         17,991           anilerdation         anilerdation         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0 <td></td> <td>_</td> <td>14,353</td> <td>15,510</td> <td>17,063</td> <td>19,689</td> <td>21,987</td> <td>23,429</td> <td>24,404</td> <td>31,963</td> <td>32,823</td> <td>37,315</td> <td></td> <td>16.7</td>		_	14,353	15,510	17,063	19,689	21,987	23,429	24,404	31,963	32,823	37,315		16.7
ameliardine aspirin/ethoheptazine	7	_	14,175	12,861	13,512	13,194	14,141	17,550	16,990	15,720	18,811	17,997		
aspirivcariemicophenacetin.  Asybutabilital/caffeine/codeine.  Asybutabilital/caffeine/codeine/phanacetin.  Asy		:	•	(	•	•	•							
autorpharations plazaries         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0 <td></td> <td>:</td> <td>0</td> <td>0</td> <td>0</td> <td>7</td> <td>0</td> <td>: '</td> <td>4</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td></td>		:	0	0	0	7	0	: '	4	0	0	0		
mattons         1         0         0         1         0         0         1         10         7         3         1         -66.7           nations         3.671         3.322         3.298         2.473         2.501         2.578         2.777         460         470         673           nencodeline         490         950         469         447         447         378         777         460         470         673           nencodeline         3.023         2.341         2.708         1,866         1,978         2.108         1,741         1,073         1,526         1,626           nencodeline         3.023         2.341         2.708         1,866         1,978         2.108         1,741         1,073         1,526         1,526           nencodeline         3.14e/caffeine/codeline         3.14e/caffeine/codeline         3.14e/caffeine/codeline         3.14e/caffeine/codeline         3.14e/caffeine/codeline         3.14e/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/caffeine/c		:	<del>-</del>	0	: '	<del>-</del>	0	0	<del>-</del>	0	0	0		
nations         3,671         3,322         3,298         2,473         2,501         2,578         2,717         1,603         2,117         2,33           nations         3,023         2,341         2,708         469         447         378         2,717         1,603         2,117         2,33           ten/caffeine/codeine         3,023         2,341         2,708         1,866         1,978         2,108         1,741         1,073         1,567         1,6           ten/caffeine/codeine	puprenorphine	:	_	0	0 9	: '	:	<del>-</del>	<u></u>	_	m <sup>-</sup>	=	-66.7	-85.7
nations         3,671         3,322         3,2473         2,473         2,578         2,717         1,603         2,117         2,3           nen-codeine         490         950         469         447         447         378         777         460         470         66           nen-codeine         3,023         2,341         2,708         1,866         1,978         2,108         1,741         1,073         1,567         1,6           ten/caffeine/codeine	butorphanol		: [	9	13	<b>o</b> ;	:	:	: :	:	:	:		
metcodeine         490         490         490         490         490         490         490         490         490         490         490         490         470         66         471         471         470         66         470         66         470         66         470         66         470         66         470         66         470         66         470         66         470         66         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         67         470         470         470         470         470         <	codeine/combinations		3,671	3,322	3,298	2,473	2,501	2,578	2,717	1,603	2,117	2,317		
Table-Codeline         3,023         2,341         2,708         1,978         2,108         1,441         1,0/3         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/         1,56/	Codeine	:	5 6	920	9 6	447	447	3/8		460	0/4	6/3		
ten/Carliertes/Codeline         14         10         0         0         9          7           all/Caffeine/Codeline         2          14         10          5         3         1          7           ine/codeline/phenacetin/ ine/codeline/phenacetin/ averine         1          0         0         0         0         0         0         0           ine/codeline/phenacetin/ averine          0         0         0         0         0         0         0         0         0           nacetin	acetaminophen-codeine	i	3,023	7,341	2,708	998,	8/6'.	2,108	1,741	1,0/3	1,56,	1,626		
Inel/codeline/codeline         14         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10<	ADADAntalkin/callellie/Codelile				•	•		•	•			·		
ine-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline-codeline	ASA/hutalhital/caffeine/codeine		:		<u> </u>	<del>-</del>	÷	>	n _	:	; <b>^</b>			
ine/codeine	aspirin-codeine		. ^		2	; <sub>(C</sub>	: "	: *	:	: -	- C			
ine/code/ine/phenacetin/ ine/code/ine/phenacetin/ averine	aspirin/caffeine/codeine	:	•	:	:	•	•	•	:	•	•			
ine/codeine/phenacetin/ averine	aspirin/caffeine/codeine/phenacetin			-	:	0	-	C	_	-	C	-		
averine	aspirin/caffeine/codeine/phenacetin/				1	ı	)	)	)	)	, '	5		
nacetin	codeine/papaverine		:	0	0	~	0	0	0	0	0	0		
2ylates	codeine/phenacetin	-	:	0	0	0	0	0	0	0	0	0		
bination-NOS	codeine/salicy/ates	-									ı			
Modernment         Modernm	codeine combination-NOS	-	0	7	:	0	0	0	0	-	:	ന		
1	dezocine	-	0	0	0	:	0	0	0	0	0	0		
	dihydrocodeine/combinations	-	:	<del></del>	:	:	0	0	n	_	:	4		

	ننontinued)												
	Drug name <sup>12,3</sup>	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	- Jan-Jun *	% change <sup>4</sup> H2 2001, H1 2002	% change <sup>4</sup> H1 2001, H1 2002
-	dihydrocodeineAPAP/caffeine/dihydrocodeine	00 ;	-00	0 :0	::00	000	000	:0+	-00	:00	400		
	dinydromorphinone fentanyl/combinations fentanyl	16	33	254 254	245 245	: :	251 251	325 325	512 512	: :	: :		
	droperidol-fentanyl	6,044 5,48 5,496	6,465 746 5,719	7,145 1,160 5,967	6,806 807 5,980	8,446 1,267 7,063	10,123 1,148 8,793	9,975 1,092 8,745	10,403	11,164 737 10,216	12,033 1,296 10,507		
ED	aspirin-hydrocodone hydrocodone-ibuprofen hydroxy-N-methylmorphinan kaolin-hedin/naraenoic	<u> </u>	510	427 0	0 496 0	° ; ; ° °	0     0 0	933	T   O	: : : - 0	230		-100.0
Trends Fro	levomethadyl acetate	485 411 411	238	491 373 0	337 223 ::	245 289 0	678 678 613	293 8	0 4 4 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	184 108 108	228 218 0	-	-100.0
m DAWN	meperdine-promethazine	1,952 759 757	2,292 695 695 0	2,518 1,261 1,260 1,4	2,826 1,159 1,158	2,600 1,057 1,055 1,055	3,405 1,221 1,218 3	4,415 1,262 1,261	4,874 1,506 1,506 0	5,851 1,897 1,897 0	5,190 1,122 1,122 0		
179	opium/combinations opium belladonna-opium oxycodone/combinations acetaminophen-oxycodone aspirin-oxycodone	24 24 2,711 2,326 130	2,293 2,293 1,655	2, 12 2, 918 600 2, 186 133	3,060 813 2,207	3,369 992 2,296	 0 2,050 3,121 2,050	5,388 1,743 3,516	22 22 22 0 0 3,069 68	 10,332 6,160 6,121 7,121	11,230 7,828 3,221		: 88 3.
	papaveretum. pentazocine/combinations. pentazocine acetaminophen-pentazocine.	0 10 1	00 :0 :8	243	00 ! 10	90	90	;° ; ;°	241	, o o	<u> </u>	:	-100.0
T-9	aspinn-penazocine naloxone-pentazocine phenacetin/combinations APAP/ASA/caffeine/phenacetin aspirin/caffeine/phenacetin/	:000	2000	10	:000	0000	0	:000	237 1 0 0,	::00	0000		-100.0 -100.0
)1 )1	pseudoephedrine	0	0	0	0	0	1	0	0	0	0		

Table 2.7.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by half year (continued)

Drug name <sup>12,3</sup>	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	H2 2001, H1 2002	H1 2001, H1 2002
propoxyphene/combinations	3,637	3,286	2,540	3,253	2,379	2,872	2,613	2,763	2,598	2,486	,	
acetaminophen-propoxyphene	2,829	2,705	2,009	2,622	2,193	2,595	2,296	2,204	2,471	2,192		
remifentanil	•	: `	<del>,</del>	•	<b>5</b> (	: '	<b>&gt;</b> (	5	: '	o ·		
surentanii	8.790	9.057	9.439	11.878	14.068	13.027	12.908	15.880	16.317	18 970		
narcotic analgesic combinations-NOS	0	-	0	-	2	17	0	3 :	80	2 :	•	
Nonsteroidal anti-inflammatory agents	13,153	13,352	12,343	11,654	9,977	12,780	12,013	11,170	11,492	11,289		
bromienacdiclofenac.	386	<u> </u>	4 5	<b>&gt;</b>	<b>&gt;</b>	: 7	5	<u>o ç</u>	<u> </u>	0 7		
diclofenac-misoprostol	0	0	<u> </u>	0	: 0	0	. 0	0	<u>i 6</u>	7		
etodolac	: *	<u>\$</u>	; •	; <b>°</b>	<u>&amp;</u>	; <b>°</b>	: 6	:`	: •	: '		į
flurbiprofen	- m	: <b>c</b>	<del>-</del> с	<u>-</u> М	?	5	5	- c	<b>5</b> <del>-</del>	5 6	0.001	-100.0
ibuprofen	8,900	9,100	8,467	7,701	6,994	9,617	8,721	8,320	8,802	8,272	2	
indomethacin	:	왕 (	:	:	; ;	:	: :	:	:	29		
Katoproten	:	406	:	:	15	:	4	4	:	፥		
mediofenamate	: <b>c</b>	:	:	: c	: C	: "	:	; <b>c</b>	; <b>c</b>	; c		
mefenamic acid	n	<u>:</u> 0	: °	· :	0 0	- 2	:	0 00	۰ ۲-	o C	-100 0	-100 0
nabumetone	:	193	278	437	340	۱ :	: :	<b>'</b> :	· :	· :	2	2
naproxen	2,620	2,842	2,706	2,580	2,031	2,512	2,568	2,175	2,096	2,476		
oxaprozin	216	245	; '	:	: '	: '	: '	:	0	<del></del>	-90.0	
piretiyipudazorie	5	-	ם כ	:	7 7		⊃ <b>«</b>	<del>- «</del>	5	5 ~		-100.0
sulindac	: :	S	0	. O	: :	- ro	9	<del></del>	: :	· ;		
tolmetin	:		:	0	:	0	0	•	0			
nonsteroidal anti-inflammatory agents-NOS	18	:	:	11	:	10	:	0	4	6		
Salicylates/combinations	7,477	7,382	7,724	5,969	5,408	7,166	6,617	4,463	4,036	4,453		
aspinn/combinations	6,7,9	6,716	6,757	5,309	4,979	6,664	6,046	3,986	3,249	3,746		
Al hydroxide/ASA/Ca carbonate/Mo	00,0	5	20,0	- 00, *	±00.	0,000	007'0	0,400	67/7	3,452		
hydroxide	-		٣				_	4				
ASA/citric acid/Na bicarb.	4	: ~	, =	: :	: :	: :	: 2	- <b>ເ</b> ດ	<u>:</u> C	:		
ASA/butalbital/caffeine	1,025	942	573	333	404	980	766	390	9	273		
ASA/caffeine/salicylamide	:	:	:	0	0	; :	-	9	: :	i		
aspinn-butalbital	0	0	0	0	0	0	0	0	0	0		
aspinn-caffeine	:	18	:	4	:	15	7	:	:	8		
aspirin-diphenhydramine	0	0	0	0	0	0	0	:	9	_		
aspirin-phenyltoloxamine	: •	: *	<del>-</del> -	0 (	0	<del>-</del> (	<del>-</del>	0	: '	0		
aspirin/salsalate	<b>5</b> C	5 6	5	5	<del></del>	5 6	5	<del></del>	0	50		
choline salicylate-magnesium salicylate	<u>, c</u>	<b>5</b>	; c	5	<del>-</del>	<del>-</del>	5 6	<del></del>	5 6	5 0		
diflunisal	i 0	: :	) ;	: "	m	9 4	•	<del></del>	<del>-</del>	0.0		
magnesium salicylate	:	12	:	17	· 60	:	6	9	•	· :		
10000									•			



able 2.7.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by half year (continued)

Drug name <sup>1,2,3</sup>	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change H2 2001, H1 2002	% change H1 2001, H1 2002
sodium salicylatesodium triosalicylate	543	595	845	633	413	373	558	470	727	694		
Miscellaneous analgesics/combinations	21,360	21,944	19,657	18,403	17,523	24,207	20,461	21,447	20,597	17,849	-13.3	
acetaminophen/combinations	20,028	20,663	17,985	14,363	15,252	17.545	15,290	15,931	19,234	15,637		-16.5
acetaminophen-butaibital	:	:	9		0	က	7	:	:	0		
acetaminophen-caffeineacetaminophen-diphenhydramine	1.559	1.992	1.353	1.691	1.362	2,442	1,782	1.870	1.643	1.534	-100.0	
acetaminophen-pamabrom.	0	0	0	0	0	i	0	0	:	0		
acetaminophen-phenyltoloxamine	: '	: '	7	: '	: '	ις ·	9	: :	31	: '		,
acetaminophen-salicylamide	<del></del>	<del>5 c</del>	0 0	00	o c	- 0	: <sup>C</sup>	<u>5</u> 0	0 0	5		-100.0
acetaminophen/ascorbic		•	•	)			)		•	•		
acid/chlorpheniramine/phenylephrine												
acetaminophen/aspirin												
acetaminophen/aspinn/pyinamine acetaminophen/atropine/caffeine/		-										
ephedrine	_	C	c	c			c	c	•	_		
APAP/Al hydroxide/ASA/caffeine/Mg	•	•	•		•	•	•	•				
hydroxide	_	0	;	_	•	0	0	0	0	0		
APAP/ASA/caffeine	694	1,110	877	1,154	938	1,851	1,203	1,676	1,158	1,153		
APAP/ASA/caffeine/salicytamide	:	0	0	0	0	0	0	0	0	•		
APAP/butalbital/caffeine	988	530	1,053	528	479	830	807	561	865	368	-57.5	
APAP/catteine/pyrilamine	5	<b>5</b>	5	5	5	5	5	5	)	)		
APAP/pamabrom/pyridoxilleAPAP/pamabrom/pyridomine	;	28	:	32	;			:				
ammonium sulfate	0	} :	<u>:</u> 0	10	; O	<u>.</u> 0	<u>:</u> 0	: °	; 0	0		
benoxaprofen	ı				ı							
benzydamine HCL												
dipyrone	0	0	0	0	0	0	0	0	0	0		
dypyrone	0	0	0	-	:	ဖ	_	0	0	0		
methotrimeorazine												
morazone												
oxyphenbutazone		-										
salicyłamide	0	0	:	0	0	0	0	0	-	_		
suproten	1	3	,	2	000		L	000	,	,		
tramadoli	8 0	200	<u>.</u>	2 0	000	<u>.</u>	C B B	907,1	1,123	), (	1000	
zomepirac	0	· :	0	· :	0	0	0	<del></del>	•	0		-100.0
analgesics-NOS	564	467	508	254	334	340	445	308	: :	131		
Analgesics combinations NTA	:	:	Ē	2	:	:	-	÷	0	0		
dipnennydramine-magnesium salicylate						C					_	
magnesium saiicylate-prienyltotoxamine paraaminobenzoic acid/sodium salicylate	5 6	5 0	0	0	<b>&gt;</b>	<b>5</b> C	o c	; C	<b>o</b> c	<b>5</b> 6		
prednisone/salicv/amide.	1	ı	ı	l			)	)	)			
A Complete Contract Along					•							

181

Table 2.7.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by half year (continued)

Table 2.7.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by half year (continued)

dolasetron. dronabinol. granisetron. isopropamide iodide	1	1998	1998	1999	1999	2000	2000	Jan-Jun 2001	2001	2002	H2 2001, H1 2002	H1 2001, H1 2002
dronabinol	•	•	•	(				1				
isopropamide lodide	4 (	- 0	7 0	<del>∞</del> (	: '	: '	<del>- 0</del>	Ω (	2	N (		
anizinam	<b>-</b> C	<del>5</del> C	5 6	<del>-</del> -	<del></del>		<del>5</del> C	<b>5</b> C	0	N C		
	· :	189	· ;	· ;	•		•	•	:	5		
ondansetron	0	-	-	-	0	7	0	7	: :	: :		
phosphorated carbohydrate solution	0	0	0	_	0	0	0	0	0	0		
scopolamine	0	: '	0	_	:	0	0	:	0	:		
thiethylperazine	0	0	0	0	0	:	0	0	፥	Ö		
trimethobenzamide	22	9	10	:	: '	:	:	13	÷	i		
antiemetic/antivertigo agents-NOS	0	0	0	: {	0	7	က	0	:	ιΩ		
Antiparkinson agents	1,090	968	666	999	595	448	306	442	544	520		
Denziropine	202	ang ang	806	756	499	418	239	274	461	374		
Dipenden	7 7	5	<del>-</del> 5	5 6	o (	0 0	0	01	0	o		
Diolifoci paride	- 6	: °	0 0	n c	2 (	5 6	: '	n	: '	: '		
carpidone longdone	5	<u> </u>	5	<b>&gt;</b> 6	5	5 6	5	:	5	5		
carpidopa-ievouopa	: 5	N C	; °	0 0	: °	2 0	: 0	: '	: 0	:		
loudono.	<del>-</del>	5 6	<del>-</del>	5 6	5 6	5 6	5 0	5				
IEVOUDPA	: '	5 6	- (	5 6	5 (	5 (	<del>- (</del>	: '				
pergolide	5	5 6	5	5 (	5 (	<del>5 (</del>	0 (	0		٠		
pramipexole	5 6	5 6	0	<del>5 ,</del>	<del></del>	0 (	0	0		0	-100.0	
procycliaine	N	5	5	_	5	<b>D</b>	5	0				
Topicing	•	•	•	•		•		,		1		
seteglilne	5	5	<b>D</b>	5	:	5	:	0	0	0		
tolcapone	- 6				7							
trinexyphenidyl	213	: 0	: '	: "	<u>2</u> 7	20	: '	: '	6	17		
anuparkinson agents-INOS	5	5 (	) i	5 (	5	5	<del>-</del>	0	:			
inerai anestnetics	<del>- (</del>	m (		<del>-</del>	: '	;	:	_	;	i		
droperidol	<del>-</del>	က	4	0	0	_	:	0	0	0		
etomidate 3												
methohexital	•	•										
propotol	0	0	:	0	:	:	0	7	÷	:		
thiamytal sodium	•	,	•	•	•	(	1					
unopental	5	5	7	5	5	5	<del>-</del>	0	0	:		
general anesaleucs-IVOS	6 740	9	6 6 6 6	7	27.0	7 067	170	0	70000	i		
acetaminonhon/chlorovozono	,,	6,0	000 0	9,	0,'0	,00,	40,0	5/8,0	10,028	8,18/		
acetalillioplierveliloraxazorie	: 5	<del>-</del>	7 0	5 6	: `	N C	5 6	5 0	5	5 (		
ACA/anthripolombonodrino	5 6	>	5	5		5	5,	5	5 (	<del>5</del> ;		
ASA/sariesprodol/codeine	ח כ	; °	:	; °	: °	: °	- 0	: 0		9		
Service series and conference and co	5	>	:	5 6	<del>-</del>	5 6	5	ccc c	3/2	:		
aspirit-calisopioadol	;	: `	: °	<b>5</b> C	>	5 6	; °	5	5 7	: '	0	
aspirio-methocarbamol	: <	0 0	7	<del>-</del>	; C	5 6	<del>-</del>	: °		5	0.001-	
	•	•	-	•	5	5	5	>		:		
hacken	45							707				
bootoctamine	? -	<u>;</u> c	<u>:</u> c	<u>:</u> c	: °	: `	: `	<u> </u>	: •	: °		
both diagram favia has A	<del>-</del>	<del>-</del>	5 6	<del>-</del>	<b>-</b>	5 6	- (	5	0 0	5		
botalions toxis two B	<del>-</del>	<b>5</b>	>	5	5	>	<b>5</b>	:	5	5		

### Table 2.7.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by half year (continued)

Drug name 12.3	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change* H2 2001, H1 2002	% change, H1 2001, H1 2002
carisoprodol	3,174	4,412	4,042	4,323	4,506	4,916	4,604	5,407	5,833	4,972		
chlorzoxazone		<del></del>	19	5	:	:	:	13	<b>.</b> 6	· :		
cyclobenzaprine.	2,075	1,538	1,429	1,549	1,212	1,909	2,067	2,096	2,095	1,255	40.1	
doxacunum	•	•	<del>-</del>	<del>)</del>	•	•	-	<b>5</b>	<b>)</b>	:		
metaxalone	: (	: !	i	: }	i	221	306	202	707	:		
methocarpamol. methoxyethoxyethylaminomethyl-1-4-	461	485	:	426	294	281	408	208	389	i		
benzodioxan	0	0	i	က	:	0	0	0	0	0		
miyacurium	0	0	0	0	ō	0	0	0	0	:		
orphenadrine	: •	; C	: °		; C	: `	: 6	78	` : <b>°</b>	: i <sup>c</sup>		
pipecuronium	- 0	00	00	00	50	00	50		<del>-</del> :	50		
rapacuroniumrocuronium												
Succinylcholineitsanidine	; c	00	00	0	0	0	0	0	0 7	0		
ubocurarine	· ·	<del>-</del>	5 (	: '	: '	: '	:	:	42	:		
muscle relaxants-NOS	327	5	168	5	2 4	0 6	: 4	0	:	0 6		
Miscellaneous CNS agents.	<del>, -</del>	:0	30	: :	<u> </u>	3 :	7	: :	: :	250		
cevimeline	c	_	5						c			
ergoloid mesylates	<del>, -</del>	0	0	: 0	: 0	<u>; 0</u>	- 0	:0	v 0	; •		
galantamine	C		c					• •	, c			
pilocarpine	•	•	•	:	•	:	<b>&gt;</b>	>	>	<b>5</b>		
nvastigmine	0	0	0	0	0	0	0	0	:	0		

<sup>&</sup>lt;sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

<sup>2</sup> Cocaine (Schedule I substance) / morphine is Brompton's mixture. All other mentions of cocaine are classified under Major Substances of Abuse.

3 Anesthetic gasses are classified under Inhalants.

CNS = central nervous system, ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NOS = not otherwise specified, NTA = not tabulated above SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates 4 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. Drugs are classified to the degree of specificity recorded in the DAWN case reports.

Table 2.8.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by year

% change <sup>4</sup> 2000, 2001				-50.0			-50.0		20.6 35.4		-29.7	-31.4			
% change <sup>4</sup> 1999, 2001	25.8		100.0		-100.0		: :		43.9 55.5 26.3	-100.0	-25.2	-31.3	-100.0	-100.0	<del>-</del> ,
% change <sup>4</sup> 1994, 2001	27.4		-87.1	-85.7		:			123.1 233.7 37.6	400.0	-60.6 60.6	-61.4	-100.0		
Total 2001	174,500 660	353	4.0		:0	: 4	1,314 755	552	99,317 64,786 34,531	000	3,720	2,641	: ;0	0000	mО <u>;</u>
Total 2000	167,194 502	391	; 6	0.0	00	: <sup>©</sup>	1,002	0	82,373 47,833 34,540	:05	5,295	3,849	217	0000	00%
Total 1999	138,736 671	586	2	: -	On	24	; ; 0	0	69,011 41,676 27,335	0 i	4,974	3,845	226	00-0	° ; ;
Total 1998	141,929 507	460	~	P :	<u>0</u> m	27	<u> </u>	0	58,946 32,573 26,373	0 ; 0	6,620 1.420	5,049	. 24	:000	; O ;
Total 1997	140,385 798	564	18	: :	00	;0	4000	0	54,116 26,298 27,819	00 :	7,869	6,598	: in	00 : :	.00
Total 1996	134,638	417	25	വ	o ;	;°	:000	0	46,941 22,525 24,416	700	239 7,594 1,208	5,907	197	100+	: e e
Total 1995	137,231	528	- ; c	<b>'</b> i	: :	60	-000	0	45,254 20,910 24,343	000	8,732	6,838	317	:000	80 :
Total 1994	136,939 549	442	31	~	00	<b>π</b> Ο	:000	0	44,518 19,415 25,102	000	35 9,439 2,142	6,839	264 16	: :00	3 : :
Drug name <sup>1,2,3</sup>	Analgesics Antinigraine agents almotriptan	APAP/dichloralphenazone/isometheptenebelladonna/caffeine/ergotamine/	pentobarbital	ergotamine. frovatriptan.	isometheptene mucate	sumatriptan.	cox-2 inhibitor	rofecoxib valdecoxib cox-2 inhibitor-NOS	Narcotic analgesics/combinations	anijeridine. aspirin/ethoheptazine. buprenorphine.	butorphanol. codeine/combinations. codeine.	acetaminophen-codeineacetaminophen/coffeine/codeine	ASA/butalbital/caffeine/codeineaspirin-codeineaspirin-codeineaspirin/caffeine/codeine.	aspirin/caffeine/codeine/phenacetin aspirin/caffeine/codeine/phenacetin/ codeine/papaverine codeine/phenacetin codeine/salicylates.	codeine combination-NOSdezocinedihydrocodeine/combinations

ERIC

Table 2.8.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by year (continued)

1										2, 4		
_   -	Drug name <sup>1,2,3</sup>	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% cnange 1994, 2001	% change 1999, 2001	% change 2000, 2001
	propoxyphene/combinations	6,731	6,294	5,889	6.502	5.826	5.632	5.485	5.361			
	propoxyphene	1,515	1,068	1,065	1,166	1,109	816	593	684	-54.9		
	acetaminophen-propoxyphene	5,216	5,224	4,822	5,337	4,714	4.816	4.891	4.675			
	ASA/caffeine/propoxyphene	0		7	0	:	0	:	)			
	remifentanil											
	sufentanil	0	:	0	0	4	0	0	*			
	narcotic analgesics-NOS	8,307	9,562	11,855	15,893	18,495	25,946	25.935	32,196	287.6		24.1
	narcotic analgesic combinations-NOS	0	0	0	0	-	ਲ	-	11		266.7	i
	Nonsteroidal anti-Inflammatory agents	28,742	30,401	25,295	26,441	25,695	21,631	24,793	22.663	-21.2		
	bromfenac	0	0	0	0	15	0					
	diclofenac	225	210	456	725	30	310		28	-87.6	-910	
	diclofenac-misoprostol	0	0	0	0	0	0	0	•	?		
	etodolac	802	612	324	489	279	:	· :		;		
	fenoprofen	:	:	0	~	•	· co	0	-	:		
	flurbiprofen	291	469	:	20	m	9	,		7 66-	-83.3	
	ibuprofenibuprofen.	19,588	21,754	17,350	17.647	17.567	14.696	18.338	17.123			
	indomethacin	355	304	153	307		191					
	ketoprofen	395	178	284	306	716		:	:			
	ketorolac	1,485	546	254	287	276	237	:	:	:		
	meclofenamate	12	Ω.	,	0	i	0	•	: C	-1000		
	mefenamic acid	9	<u>е</u>	4	· ;	0	•	· "	,	200		
	nabumetone	434	460	359	490	471	777	240	•			
	naproxen	4,302	5,253	4,546	5.330	5.549	4.610	5.080	4 270			
	oxaprozin	157	243	833	365	377	256	182	i			
	phenylbutazone	:	:	i	:	0	က	m	-		-66.7	
	piroxicam	154	:	:	:	· -	<b>'</b> ;	7	· œ			
	sulindac	18	:	19	•	ις.	: :	- 1-				
1	tolmetin	:	15	10	:	•	: :	0				
C	nonsteroidal anti-inflammatory agents-NOS	214	:	:	:	:	:	· :	4	-93.5		
, ,-	Salicylates/combinations	18,990	17,153	15,717	14,699	15,106	11,376	13.784	8.499	-55.2		-38
7	aspirin/combinations	16,875	15,443	13,382	13,173	13,472	10.288	12.710	7,235	-57.1	262-	4 4
	aspirin	14,586	12,701	11,811	11,231	11,696	9.365	11,096	6.137	-57.9		-44.7
	Al hydroxide/ASA/Ca carbonate/Mg						•			:		
	hydroxide	:	œ	14	15	;						
	ASA/citric acld/Na bicarb	;			23	12	•	:	: <b>'</b>			
	ASA/butalbital/caffeine	1 657	1 813	188	1 736	1 545	727	4 447	7	21.0		ì
	ASA/caffeine/salicylamide	 } -			2	2	<u> </u>	* *	2	5.70-		-51.1
	asolrio-butalbital	:	:	; c	0 0	: °	5 6	0	: "			
	aspirio-caffeina	310	740	- G	947	5	5	⊃ <u>6</u>	5			
	asnirin-dinhanhydramina	5	2	8 0	2	: °	: •	7 '	: 5			
	aspirio-phenytroloxamine	>	•	2	<b>5</b>	5	5 6	5 1	2			
	aspirin/salsalate	: C	<u>;</u> C	1 ~	<u>:</u> C	<u>;</u> c	o c	- 6	: °			
	choline salicylate	0	0	· c	<del>-</del>	>	o c	5 6	5 6			
	choline salicylate-magnesium salicylate	17	9	<b>'</b> :	• 4	: :	· ;	0	0 0	-1000		
	diflunisal	:	:	21	23	:	9	- 00		9	-86.7	
	magnesium salicylate	:	250	371	210		30	1		:	3	
				;	->-	:	107	•	=			

Table 2.8.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by year (continued)

coloring subjective         1,772         1,289         1,721         1,221         1,429         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197         1,197 <th></th> <th>Drug name<sup>1,2,3</sup></th> <th>Total 1994</th> <th>Total 1995</th> <th>Total 1996</th> <th>Total 1997</th> <th>Total 1998</th> <th>Total 1999</th> <th>Total 2000</th> <th>Total 2001</th> <th>% change<sup>4</sup> 1994, 2001</th> <th>% change<sup>4</sup> 1999, 2001</th> <th>% change<sup>4</sup> 2000, 2001</th>		Drug name <sup>1,2,3</sup>	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>4</sup> 1994, 2001	% change <sup>4</sup> 1999, 2001	% change <sup>4</sup> 2000, 2001
accutantiophenication accumulations 4119 (2) 45,49 (4) 6002 (4) 4175 (4) 601 (1) 601 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (2) 69 (		sodium salicylatesodium thiosalicylate	1 772	1 299	1 781	1 221	1.439	1 046	931	1,197			
a colarminophenical problem.  a cola	2	discellaneous analgesics/combinations	44,119	43,499	46,002	44,129	41,601	35,926	44,667	42,044		17.0	
accelarino(pher-Agricular) accelarino(pher-Agric		acetaminophen	37,293	35,371	37,093	34,867	31,424	27,702	32,835	30,888	-17.2	Ì	
acostamicopien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-cipien-c		acetaminophen-butalbital	283	16	: '	186	: `	; °	5 6	<del>-</del> ;	0		
a celaminophen-parametric months of the parameter of the		acetaminophen-caffeineacetaminophen-diphenhydramine	1,513	2,703	3,081	2,891	3,345	3,054	4,224	3,513	-80.0 132.2		
acctaninoptier satisfyanida accessivanida accessivanida accessivanida and accessivanida accessivanida accessivanida accessivanida accessivanida accessivanida accessivanida accessivanti accessivanida accessivania accessivanida accessivanida accessivanida accessivanida accessivanida accessivanida accessivanida accessivanida accessivanida		acetaminophen-pamabrom	0	0	0	0	0		0 ;	:			
acetaminophen/ascorbic acid/chlopphen/ascorbic acetaminophen/ascorbic acetaminophen/ascorbi		acetaminophen-salicylamide	: °	; °	: :	:°	; °		= ;	: <del>.</del> 5		_	
a celaninophen/applinte		acetaminophen-tramadolacetaminophen/ascorbic											
acetaminopheraspin/pyrliantine		acid/chlorpheniramine/phenylephrine											
acetaminophen/atripliene/califeine/ APA/Introxides/Aschaffeine-Mg APA/Introxides/Aschaffeine-Mg		acetaminophen/aspirinacetaminophen/aspirin/pyrilamine											
appropriate         and propriate         and propri		acetaminophen/atropine/caffeine/											
APAP/AI Indicate/ASA/catfielneithig         8         1,321         1,665         1,888         1,987         2,091         3,054         2,834         -100.0           APAP/ASA/caffeine         2,267         1,921         1,665         1,888         1,987         2,091         3,054         2,834           APAP/ASA/caffeine         1,878         1,772         1,773         1,650         1,683         1,007         1,683           APAP/ASA/caffeine         1,878         1,773         1,650         1,683         1,007         1,426           APAP/Carteline(syntamine		ephedrine	0	0	0	_	0	0	0	0			
APAP(ASSA/Caffeine         2.2267         1,921         1,666         1,884         1,987         2,081         3,084         2,1000           APAP(ASSA/Caffeine         1,878         1,724         1,773         1,665         1,883         1,007         1,637         1,426           APAP(ASSA/Caffeine         1,878         1,724         1,773         1,665         1,687         1,426           APAP(ASSA/Caffeine         1,878         1,724         1,773         1,665         1,687         1,426           APAP(ASSA/Caffeine)         1,878         1,724         1,773         1,665         1,683         1,007         1,687         1,426           APAP(ASSA/Caffeine)         1,881         1,774         1,773         1,683         1,007         1,687         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126         1,126<		APAP/Al hydroxide/ASA/caffeine/Mg	·	•		c			•	~	0007		
APAP/ASA/caffeine/salicy/amide		nydroxideAPAP/ASA/caffeine	2.267	1.921	1.665	1.888	1.987	2.091	3.054	2.834	-100.0		
APAP/cycarlein/cyfrainine		APAP/ASA/caffeine/salicy/amide	: :	0	:	:	0	O	0	0			
APAP/parathenopyridamine         183         424         383         174         170         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0		APAP/butalbital/caffeine	1,878	1,724	1,773	1,620	1,583	1,007	1,637	1,426			
Apply plane autoring pyllication by pyllica	1	APAP/caffeine/pyrilamine	:	-	0	0	0	0	0	5			
ammontum sulfate benzydarinte HCC. dipyrone diphyrone dipyrone dipyrone dipyrone dipyrone dipyrone dipyrone diphyrone dipyrone dipyrone diphyrone diphyr	8	APAP/pamabrom/pyrilamine	183	424	383	174	170	:	:				
0          0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	8	ammonium sulfate	0	0	0	0	:	0	0				
0          0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0		benoxaprofen benzvdamine HCL											
0          0          0          0         1418         1,972         1,113         1,810         2,329         109.3           0         645         1,290         1,418         1,972         1,113         1,810         2,329         109.3           2         0         0         0         0         0         1         109.3           478         415         407         1,001         975         588         785         544            20                 20                 20                 20                 20                 20                 20		dipyrone	0	;	0	0	0	0	0	0			
0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		dypyrone	:	:	0	:	0	:	7	0			-100.0
0          0         0          0         0         1,290         1,418         1,972         1,113         1,810         2,329         1,2329         1,418         1,972         1,113         1,810         2,329         1,000         1,000         0         0         0         0         0         1,000         1,000         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         <		methotrimeprazine											
0         645         1,290         1,418         1,972         1,113         1,810         2,329           2         5         8         0         0         0         1           478         415         407         1,001         975         588         785         544           20                  20                  20                  20		morazone											
0         645         1,290         1,418         1,972         1,113         1,810         2,329           1         2         0         0         0         0         1           2         5         8         0         1         1           20                20               20               20               20		oxyprenbulazoresalicylamide.	0	:	0	0	:	0	0	_			
0         645         1,290         1,418         1,972         1,113         1,810         2,329           1         0         0         0         0         0         1           2         5         8         0         0         1           20                20                20                20                 20		suprofen				-							
478     415     407     1,001     975     588     785     544       20             0     0     0     0     0        20           20           20		tramadol	00	045	1,290	1,418	1,972	1,13	1,810	2,329		109.3	
478         415         407         1,001         975         588         785         544           20                 0         0         0         0         0             20		zomepirac	~~	O CO	- ∞	10	<b>'</b> :	<b>•</b> :	0	- :			
20		analgesics-NOS	478	415	407	1,00,1	975	288	785	544			
	⋖	Analgesics combinations NTAdiobenhydramine-magnesium salicylate	S	:	:	:	:	:	:	:	•		
20		magnesium salicylate-phenyltoloxamine	0	0	0	0	0	0	0	: '			
		paraaminobenzoic acid/sodium salicylate	0	0	0	0	0	:	0	0			
		analgesic combinations-NOS	20	:	:			9	:			***	

able 2.8.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by year continued)

Drug name <sup>1,2,3</sup>	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>4</sup> 1994, 2001	% change <sup>4</sup> 1999, 2001	% change⁴ 2000, 2001
Anorexiants	2,354	2,489	2,655	2,349	1,552	1,436	1,540	953	-59.5		
dexfentluramine	0 4	10	000	<del></del>	: :	000	· ·			-100.0	
fenfluramine	? :	: 4	<u>, 6</u>	537	: :	<u>:</u> ھ	3 6	: :			
fenproporex	0	-	0	0	0	0	0				
mazindol	0	; °	00	<u>о</u> г	0	0	0	0			
phenmetrazine HCl.	: -	<del>о С</del>	<b>5</b> C	<u>0 0</u>	: -	; =	; °	<u>ත</u> ද	6	:	:
phentermine	• ;	192	176	505	197	217	<u> </u>	5	-100.0		
phenylpropanolamine	1,487	1,366	1,312	770	545	647	725	129	-91.3	-80.1	-82.2
siburamine. anorexiants-NOS	677	77.4	1 00	200	0 0	0 10	25.7	: 6			
Anticonvulsants	9,358	10,455	11,496	12,193	13.990	14.938	16.849	14 642	5.55		
5-allyl-5-isobutylbarbituric acid	•	•			•				?		
aloxidone	0 0	<del>-</del>	00	00	: 6	0	0	ഗ			
carbamazepine	3.879	3.633	3 743	3 473	3 224	3 4 3 3	0	7	0 0 0		
divalproex sodium	1,762	2,550	4,099	5,155	6,228	5,984	6.235	5.365	204.5		
ethosuximide	S.	9	:	:		:	0	:			
emotolin felhamate		•	•	•	•	_		•			
fosphenytoin	; 0	? C		N C	N C	5	0	00	:		
gabapentin	· :	28	• :	296	1,002	2.395	4,465	3.461	,		
hydantoin	∞ (	0	9	:	0	7	0	(C)	•		
lamoungine	50	0 0	00	; c	: -	; <b>c</b>	: <b>°</b>	323			
Ø mephenytoin.	•	•	•	5	5	5	<del>-</del>	:			
_	:	0	0	0	0	:	0	:			
methsuximide	<del>- c</del>	<del>- c</del>	4 (	0	0	_	:	0	-100.0	-100.0	
Oxcarbazepine	5	5	<b>5</b>	0	6	<del>o</del>	0	:			
phenacemide								-			
phensuximide	_	0	•	0	-	-		_			
phenytoin	3,266	3,573	2,923	2,426	2,974	2,766	2,239	1,795	45.0		
primidone	23	211	23	:	:	19	12	O	6.09-		
topiramate	5 6	<del>5</del> C	0 0	<del>-</del>	0	0	0	: ;			
trimethadione	•	•	<b>5</b>	>	:	:	Ž	621		:	
valproic acid	279	449	298	618	263	357	916	:			
Zonisamide	<del>-</del>	<del></del>	01	0	0	0	<del>-</del>	7			
Antiemetic/antivertigo agents	1.263	849	865	786	1 134	200	1 100	<del>6</del> 9	125.0		
benzocaine-trimethobenzamide		?	}	3	="	2	621.	070	4.00.		
CyGlzine	<u>α</u>	33	- 6	<u>ස (</u>		: !	<b>6</b>	0	-100.0		-100.0
dimenhydrinate/niacin/pentylenetetrazol	o S	) 80	<u>8</u> L0	45/	674	475	849	329			
diphenidol	0	:	0	0	0	0	0	0			

그 Table 2.8.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by year | (continued)

% change <sup>4</sup> 2000, 2001		ŧ		-100.0	19.4	-100.0
% change <sup>4</sup> 1999, 2001	800.0		-100.0		38.5	
% change <sup>4</sup> 1994, 2001	: :	-72.0	-100.0	400.0	-100.0	_
Total 2001	<b>8</b> ; 5 6	20 20 20 38 38 40 10 10	: =0 0	: :00 0	19,001 0 0 7 928 928	306
Total 2000		2 9	0 00 ;	; O ; O ;	15,914 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	; <del>-</del> 0
Total 1999	. 0 : + +	0 1,264 1,036 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 126 1	0 0 = :	; 0 ; 0 ;	13,717	318 0 0
Total 1998	368	 0 16 1,895 1,713 1,713 2 0 0	- 00 0	10 10 10 11 11 11 11 11 11 11 11 11 11	13,612 2 2 2 2 2 3 3 3	319 0 0
Total 1997	:	2, 2, 0, 0,	: ° : :	426 0 6	0 12,318  12 12 4 4 	72 0
Total 1996		2,363 2,363 2,363 2,363	; 00 F	464 0 :: :	13,520	:00
Total 1995	380	15.787 2.7787 0	- 0+ 0	462 0 1	13,733 2 2 22 	00
Total 1994	 1 573 0	2 2 3,519 2,790 	; 00 ;	525	12,223	
Drug name <sup>1,2,3</sup>	dolasetron dronabinol. granisetron. isopropamide iodide. medizine. ondansetron. phosphorated carbohydrate solution	scopolamine	entacapone levodopa pergolide pramipexole C. ropinirole C. selegiline tolcapone	trihexyphenidyl	thiopental thiopental general anesthetics-NOS.  Muscle relaxants	atracurum. baclofen. bencidamine botulinum toxin type A botulinum toxin type B

### Table 2.8.0 - ED mentions for central nervous system agents by drug category: Estimates for the coterminous U.S. by year (continued)

% change <sup>4</sup> 2000, 2001			-100.0								
% change <sup>4</sup> 1999, 2001			51.8		-100.0			:			
% change <sup>4</sup> 1994, 2001	1.17	-95.7	-100.0	-100.0 5,247.1 -47.0	-100.0		-100.0				
Total 2001	11,239	23.0	4,191	0 909 597	0	:0		350		. 0 0	:
Total 2000	9,520	· :	3,975	527 689	0	; O (		358 358	9 ::	: ° :	0
Total 1999	8,829	· :	2,761	359 719	7	178	0		S :	· • ·	0
Total 1998	8,454	27	2,967	0 246 977	:	228			0	0 0	0
Total 1997	6,133	;	3,626 6	0 266 1,054	0	395	9 :	0 0 6	- 0	<del>-</del> 0	0
Total 1996	7,279	512	3,599	235 682	4	301	0 0	0 0	0 0	0 0	0
Total 1995	1	338	2,924	1,053	i	302	0 0	200	,	0 0	0
Total 1994	6,569	535	3,133	1,127	4	57	. e.	0 0 374		0 0	0
Drug name <sup>1,2,3</sup>	carisoprodol	chlorzoxazone	cyclobenzaprine dantrollen	mephenesin	benzodioxan	mivacurium. orphenadrine. pancuronium.	rapacuronium rocuronium succinycholine	tubocurarine  Vecuronium  Welunonium	Miscellaneous CNS agents cevimeline donepezil	ergoloid mesylates galantamine laudanosine	pilocarpine rivastigmine tacrine

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 'This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique <sup>2</sup>Cocaine (Schedule I substance) / morphine is Brompton's mixture. All other mentions of cocaine are classified under Major Substances of Abuse. Anesthetic gasses are classified under Inhalants.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Drugs are classified to the degree of specificity recorded in the DAWN case reports. CNS = central nervous system, ED = emergency department, NOS = not otherwise specified, NTA = not tabulated above.

SOURCE:Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 2.9.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by half year

ge <sup>2</sup> % change <sup>2</sup> 31, H1 2001, 02 H1 2002						-80.3					_			-100.0			_		-100.0										_	-100.0
% change H2 2001, H1 2002																														7
Jan-Jun * 2002	1,852	00	:	o :	32	0 64	ŧ	. 0	:	457	50	c	<del>-</del>	0	00	732	_	:	0	0.0	5	328	221	; C	•	0				0
Jul-Dec 2001	2,195	00	:	226	i	502			347	410	0	c	•	: '	00	324		:	0	0 0	- <del>2</del>	241	:	: <	5	0			•	-
Jan-Jun 2001	1,917	00	0	305	35	o :	: 0	0	201	263	50	c	>	-	0 ;	471		:	<del>-</del> 1	0 0	> ;	182	23	: =	•	:			1	0
Jul-Dec 2000	1,503	00	0	237	32	00	7	0	:	376	0	•	-	: '	0 0	487		:	0	5 6	264	231	; c	<del></del>	•	0				:
Jan-Jun 2000	1,761	00	0	° :	31	: :	: 0	0	:	142	00	c	>	0	50	745		: '	0	5 6	378	188	: `	<del>-</del> -		0				0
Jul-Dec 1999	1,279	00	4	289	25	0 m	:0	0	:	222	00	c	•	0	: °	442		: '	0	; C	•	419	: `	0	1	0			•	5
Jan-Jun 1999	1,768	<del>-</del> :	:	249	:	00	; °	0	36	285	00		:	4	; °	779		: '	0	5 6	149	536	<u></u>	0	ī	0				:
Jul-Dec 1998	1,231	00	:	271	27	0 0	; °	i	:	178	00	_ c	•	7	0	538		7	0	<del>-</del>	8	370	<u> </u>	· :		0				:
Jan-Jun 1998	1,239	; o	:	: :	49	o :	<b>~</b> 0	0	:	334	00		•	0	: °	363		~	<del>-</del>	5	: :	473	: -	0		0			•	5
Jul-Dec 1997	1,446	; 0	6	<del>-</del> ;	: '	<del>о</del> :	; °	7	:	409	- 0	c	•	<del>-</del>	- 0	227		: '	5 0	<b>-</b> C	200	651	: ⊂	· :	•	0	,			:
Drug name¹	Antihistamines	astemizole azatadine.	bromodiphenhydramine brompheniramine.	carbinoxamine. cetirizine	chloropyramine	chlorphentermine	cyproheptadine desloratadine	dexbrompheniramine dexchlorpheniramine	diphenyipyraline HCI	loratadine	methapyrilene HCI	methdilazine neo-anterdan hydroden meleata	phenindamine	pheniramine	phenitalinite/phenylloloxarinite/pyrilaninite	promethazine	pyribenzamine rotoxamine tartrate	terfenadine	umeprazine	triprolidine	antihistamines-NOS	Bronchodilators	albuterol.	aminophylline	bitolterol	dyphylline	isoetharine	isoproterenol-phenylephnne	[evalbuterol	metaproterenol

Table 2.9.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by half year (continued)

1996   1996   1999   1999   1999   2000   2001   2001   2001   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200   11200	l												% change <sup>2</sup>	% change <sup>2</sup>
1, 1, 1, 1, 2, 2, 3, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 3, 4, 4, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4,		Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	H2 2001, H1 2002	H1 2001, H1 2002
4.66         2.77         3.78         3.78         3.78         3.78         3.78         4.79         4.79         4.79         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70         4.70 <td< td=""><td>I</td><td>pirbuterol</td><td>00</td><td>00</td><td>00</td><td>0</td><td>00</td><td>0</td><td>00</td><td>; 0</td><td>° :</td><td><del>-</del> ∞</td><td>_</td><td></td></td<>	I	pirbuterol	00	00	00	0	00	0	00	; 0	° :	<del>-</del> ∞	_	
2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		salmeterol	000	0	. 7 7	:	<u>+</u> «	7 -	:	; 0	: :	<del>с -</del>		:
486         272         213         522         522         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533         533 <td></td> <td>terbutalinetheobromine magnesium oleate</td> <td>• ;</td> <td>; 0</td> <td>0</td> <td>; °</td> <td>0 0</td> <td>. 0</td> <td>0</td> <td>0 0</td> <td>0;</td> <td>0</td> <td></td> <td></td>		terbutalinetheobromine magnesium oleate	• ;	; 0	0	; °	0 0	. 0	0	0 0	0;	0		
1186		theophylline	486	272	213	; <b>L</b> C	322	: :	; °	7 :	= :	; 0		
835 1077 281 244 343 378 300 1 300 1 300 310 310 310 310 310 310	۵	pronchodilators-INOS	843	1,185	370	261	348	443	909	509	350	333		
331 644 372 283 281 488 287 280 216 473  331 643 371 283 281 483 287 280 216 473  332 84 3056 210 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		pseudoephedrine	832	1,071	261	244	343	378	261	000 0000	. <del>1</del> 6	25 20 20 20 20 20 20 20 20 20 20 20 20 20	-100.0	-100.0
25 261	w	decongestants-NOSxpectorants	331	644	372	283	261	488	287	260	216	473		
2218 3,056 2,007 1,987 1,411 2,483 2,877 2,60 2,13 4,73 4,73 2,14 2,14 2,14 2,14 2,14 2,14 2,14 2,14		ambroxol	0	00	<del>-</del> (	0 0	0 0	00	00	00	; -	5 6		
331 643 371 283 261 483 287 260 213 473  2218 3056 2007 1987 1441 2483 3.193 2.442 3.265  25 261 19 21 19 21		anhydrous calcium iodide-isoproterenol	<del></del>	<del>5 -</del>	<del>5</del> C	5 6	<del></del>	5 6	50	56	0	00		
2.218         3.056         2.007         1.987         1.411         2.488         3.193         2.432         3.265         3.387           2.5         2.61          1.94         154         154         154         159         3.987         3.387           2.5         2.61          1.94         154         154         159         2.1                                                                         <		chophenialinie/coeine/prenylephinie	33.1	643	371	283	261	483	287	260	213	473		
2.218     3.066     2.007     1,987     1,411     2,483     3,193     2,432     3,285     3,387       2.5     2.26     2.06     1,987     1,411     2,483     3,193     2,432     3,285     3,387       2.5     2.61      19     21            0     0              0              0              0              0              0               0               0               0               0		potassium iodide												
2,218     3,056     2,007     1,987     1,411     2,483     3,193     2,432     3,265     3,367       25     2,61      19     21             0     0     0      0     0     0          0     0     0     0     0     0           0     0     0     0     0     0           0     0     0     0     0     0           0     0     0     0     0            0     0     0     0     0            0     0     0     0            0     0     0             0     0              0		terpin hydrate	0	0		0	6	:	0	0	0	0		
25 261 19 21		toper respiratory combinations	2,218			1,987	1,411	2,483	3,193	2,432	3,265	3,367		
25 261 19 21	<u>,                                     </u>	acetaminophen-chlorpheniramine	27			152	159	395	722	994	997	836		
25 261 19 21		acetaminophen-dextromethorphan	0	0		0	5	5	5	5	5	-		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		acetaminophen-phenylephrine	25	261		19	21	•	:	:	:	:		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 17 14 17 15 15 20 6 170.0		acetaminophen/dextromethorphan/	3	ì			İ							
		doxylamine/ephedrine					•	•	•		c	-		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1	acrivastine-pseudoephedrine	0	0	i	:	0	<b>5</b>	5	:	5	5		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	$\mathbf{o}$	ammonium chloride/CPM/DM/												
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2_	ephedrine/ipecac/PE												
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		anhydrous calcium iodide-codeine												
		APAP/brompheniramine/phenylpropanolamine	0	0	0	0	00	00	00	00	; c			
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		APAP/brompheniramine/pseudoephedrine	0	0	5	>	5	>	>	>	>			
0 0 0 0 0 0 0 0 7 14 111 111 15 12 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111		APAP/calleine/CPM/hydrocodone/PE												
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		APAP/caffeine/guaifenesin/phenylephrine							_					
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		APAP/catteine/PPA/salicylamide												
0 0 0 0 0 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0		APAP/chloroheniramine/dextromethorohan/PPA	0			0	0	0	0	:	2	•		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		APAP/chlorpheniramine/dextromethorphan/PSE	0			0	0	0	0	7	14	=======================================		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		APAP/chlorpheniramine/guaifenesin/PPA	0			0	0	0	0	0	0	:		
15 16 8 17 15 20 6 -70.0		APAP/chloroheniramine/ohenylephrine/			'									
15 16 8 17 15 20 6 -70.0		dextromethorphan/guaifenesin	0	i	0	0	0		0	0 !	0	0		
12 10 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12		APAP/chlorpheniramine/phenylpropanolamine	:!		o (	7	; °		: 4	17	200	: <sup>4</sup>		
APAP/Cemastraphedrine	_	APAP/chlorpheniramine/pseudoephedrine	15		٥١	•	0		=	2	27	5	_	
		APAP/clemastine/pseudoepnedrine												

Table 2.9.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by half year (continued)

92 % change <sup>2</sup> H1 2001,	+		0.0								0.0	_			_																																
% change <sup>2</sup> H2 2001, H1 2002		ρ̈	-100.0					_			-100.0																																				
Jan-Jun * 2002	•			L4.	0	<b>1</b> :		;	:	,	0	•	5				•	3	: `			:	•	: '	0				o ·	0			•	0			=	0		_		,	6	: '	<del>-</del>	₹	
Jul-Dec 2001	8		- 670	0.0	•	. 0		:	:	•	_		:				•	5 (	50	5		:	- 1	<del>o (</del>	ō			•	0 (	<del>-</del>			•	5			0	0					፧	: '	5	14[	
Jan-Jun 2001	,	•	0	) i c	: 0	0		21	27	•	D	C	5					:	: <b>°</b>	>		; °	n .	-	:			•	<del></del>	5			-	5			:	•			•	c	7	: °	5	:	
Jul-Dec 2000	-	· -	200	70	· :	0		:	22	(	5		:				c	•	: °	5	i		5 6	5	:			•	5 6	5			•	5		•	9	:	_			<u> </u>	<del>-</del>	- 6	5	:	
Jan-Jun 2000	6	•	356	30	•	0		0	12	•	5		•					5	; °	>		: °	5 6	000	697			•	5 0	5			-	5		-	<del></del>	<del>-</del>			_	c	>	: 6	5	:	
Jul-Dec 1999	0	•	417	7	80	0		4	15	•	5		:					<del>, ,</del>	7 6	5		<u>;</u> °	5 6	>	:			•	5	:		_	-	5		•	5	5				_	) r	) C	<del>- (</del>	מ	
Jan-Jun 1999	0		483	30	13	0		ις (	10	•	>		:				C	5 0	<del>-</del>	<del>-</del>	ŭ	0	; °	2 0	97			C	<del>-</del>	7			-	5		•	5	5					; <del>c</del>		>	:	
Jul-Dec 1998	8		288	0	9	0		_	:	-	>	_	•				C	5 0	7	-	o C	07	<u>:</u> c	7	7				:	:			_	-	_		- <	5					•	; ē	2 6	3	
Jan-Jun 1998	0	•	062	0	80	0	(	<del>ი</del> (	81	c	>	_					0	•	<u>:</u> C	•	12	2	: `	•	:				o c	<del>-</del>			_	•		c	7	:		_		0	<del>-</del>	· C	, a	?	
Jul-Dec 1997	0		650	2	n	0		: 8	87	-	•	;					0	•	: °	)		:	: 0	<u> </u>	2	_			<del>-</del>	•				<del>,</del>	_		:	:		_		<del>-</del> 0	· :	C	•	=	
Drug name¹	APAP/CPM/phenylephrine/salicylamide	APAP/dexbrompheniramine/pseudoephedrine	APAP/dextromethorphan/doxylamine/PSE	APAP/dextromethorphan/guaifenesin/PPA	APAP/dextromethorphan/guaifenesin/PSE	APAP/dextromethorphan/phenylpropanolamine	APAP/dextromethomorphismine	APAP/diphophydromipo/psoudocabodaine	APAD/neglidophedrine/pseudoepiledilile	ASA/brompheniramine/dextromethomban/PPA	ASA/chlorpheniramine/dextromethorphan	ASA/chlorpheniramine/dextromethorphan/PPA	ASA/chlorpheniramine/phenylpropanolamine	ASA/diphenhydramine/PPA	aspirin-pseudoephedrine	atropine/CPM/hyoscyamine/PE/PPA/	scopolamine	azatadine-pseudoephedrine	bromodiphenhydramine-codeine	brompheniramine-phenylephrine	brompheniramine-phenylpropanotamine	brompheniramine-pseudoephedrine	brompheniramine/codeine/phenylpropanolamine	brompheniramine/dextromethorphan/PPA	brompheniramine/dextromethornhan/PSF	brompheniramine/DM/quaifenesin/PPA	brompheniramine/guaifenesin/phenylephrine/	PPA.	brompheniramine/phenylephrine/PPA.	caffeine/pheniramine/PE/Na citrate, salicylat.	carbetapentane-chlorpheniramine	carbetapentane/chlorpheniramine/phenylephrine	carbetapentane/CPM/ephedrine/phenylephrine	carbetapentane/quaifenesin/phenylenhripe	carbetanentane/PE/PDA/K onajacolsulfonate	Carbinoxamina-oseudoenhedrine	carbinoxamine/dextromethornhan/PSE	carbinoxamine/hydrocodone/nseudoenhedrine	carbinoxamine/methscopolamine/	pseudoephedrine	cetirizine-pseudoephedrine	chlorpheniramine-dextromethorphan	chlorpheniramine-hydrocodone	chlorpheniramine-phenylephrine	chloroheniramine-phenylpropanolamine		

Table 2.9.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by half year (continued)

% change <sup>2</sup> H1 2001, H1 2002							90	-100.0			-83.3	2			-100.0			:				-100.0	-100.0					
% change <sup>2</sup> H2 2001, H1 2002															-100.0													
Jan-Jun *	; 6	<del>•</del>			:00	0	: '	00	c	7 N	<del></del> ⊂	-	0	00	00	5	6	:	:	:		0	0 2	70	<u></u>		•	
Jul-Dec 2001	; 6	<del></del>			: :	. 0	0	00		: 8	i	: 8	0 0	<b>&gt;</b> :	₩ 0	5	0	; c	>	19		0	:				12	
Jan-Jun 2001	: 0	000		•	- 0 0	0	0	- 0	-	<b>o</b>	9 +	- :	0 0	7	<del>-</del>	:	0	<b>~</b> °	•	20		_	2 5	<u> </u>			:	
Jul-Dec 2000	4 0	<del>-</del>		C	000	00		;°	c	^ 0	:	: :	0	00	0	:	0	: 0	>	9		0	7 5	<del>-</del>	•		i	
Jan-Jun 2000	:	:00		c	0	. 0	0	; °	•	<b>→</b>	က	: -	0	: °	:	:	0	: °	5	:	-	0	: °	<u> </u>	' :		:	
Jul-Dec 1999	4 0	000	_		:00	0	0	0 0		0.0	: °	0	0 0	00	0 0	0	0	: `	> -	c)		4	0 0	5	<u>:                                    </u>		:	
Jan-Jun 1999	: 0	000			00 +	- 0	0	; °		<del>5</del> ;		•	0	5 <u>:</u>	0 1	<u>.</u>	0	: <	5	7		0	0 0	<b>5</b> C	ο &		i	
Jul-Dec 1998	:	-00	_		:°	0	÷	: :		0	i	: 8	0	:°	0	:	0	~ 0	>	7			0		•		:	
Jan-Jun 1998	13	000	_	C	500	0	0	0 O		<del>-</del>	: °	<u>4</u>	0	00	; <b>'</b>		0	: "	•	:		0	0		·		:	
Jul-Dec 1997	15	<del>-</del> ;	_	C	00	0	0	0 0	, (	⊃ :	: *	<b>-</b> :	0	00	0	:	0	: •	<b>o</b>	:		0	2	<b>5</b>	: <sup>(2)</sup>		:	
Drug name¹	chlorpheniramine-pseudoephedrine	chlorpheniramine/codeine/pseudoephedrine chlorpheniramine/dextromethorphan/PPA chlorpheniramine/dextromethorphan/PSE	chlorpheniramine/dihydrocodeine/PE/PPAchlorpheniramine/DM/guaifenesin/phenylephrinechlorpheniramine/DM/guaifenesin/dephrinechlorpheniramine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaifenesin-mine/DM/guaif	chlorpheniramine/gualfenesin/phenylephrine	chlorpheniramine/hydrocodone/phenylephrine	chlorpheniramine/methscopolamine/PPA	chlorpheniramine/methscopolamine/PSEchlorpheniramine/PE/phenyltoloxamine	chlorpheniramine/PE/PPA/phenyltoloxamine	chlorpheniramine/phenylephrine/PPA	chlorpheniramine/phenylephrine/PPA/pyniamine chlorpheniramine/phenylephrine/pyrilamine	clemastine-phenylpropanolamine	codeine-guarrenesin	codeine-pseudoephedrine	codeine/guaifenesin/pheny/propanolaminecodeine/guaifenesin/PSE.	codeine/pheniramine/phenylephrine/Na citrate	codeine/phenylephrine/promethazine	codeine/priefryrephrinis/pylitalinine	dexbrompheniramine-pseudoephedrine	dexchlorpheniramine/gualfenesin/PSEdextromethomban/doxylamine/phenylephrine	dextromethorphan-guaifenesin	dextromethorphan-phenylpropanolamine	dextrometriorphan-potassium gualacoisulloriate dextromethorphan-promethazine	dextromethorphan-pseudoephedrine	dextromethorphan/gualtenesin/phenylephine	dextromethorphan/gualfenesin/pseudoephedrine	dextromethorphan/phenylephrine/pyrilamine	aipnennydramine-pseudoepnedrineephedrine-quaifenesin	ephedrine-potassium lodide

Table 2.9.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by half year (continued)

	Drug name¹	1997	Jan-Jun 1998	1998	1999	1999 1999	2000	2000 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	H2 2001, H1 2002	76 Chiange H1 2001, H1 2002
	Texofenadine-pseudoephedrineguaifenesin-hydrocodone	00	00	00	00	00	00	00	00	° ;	8	:	
	gualfenesin-phenylephrine	0	0	-	0	0	ō	0	- 2	C			-
	gualienesin-pnenyipropanolaminegualfenesin-oseudoephedrine	:	; 4	5 4	:	;	<u>t</u>	; ;	12	<del></del>	• :		-
	guaifenesin/hydrocodon/pheniram/PPA/pyrilamin	:	<del>,</del>	0	:	:		72	∞	:	:		
_	guaifenesin/hydrocodone/pheniramine/PE/PPA	0	0	0	0	0	0	0	-				
	guailenesin/nydrocodone/phenylephrine		-	-	•			,	•	,	:		
_	gualfenesin/phenylephrine/PPA.	: :	· :	5 00	5	: ∓	0	0	0 ;	<del>-</del> ;	0		
_	homatropine-hydrocodone	-	: :	;	; <del>4</del>		: 4	: *	F		<u>=</u> ,		
_	hydrocodone-phenylephrine	•			•	•	•	•	:	7	4		
_	fonste	5	: °	<del>-</del> c	0		•	;	:	_	ัก		
_	hydrocodone-pseudoephedrine.	<del>-</del>	<del>-</del>	5 6	0 0	<del></del>	<del>o</del> (	0	i '	0	0		
Tre	hydrocodone/pheniramine/PE/PPA/pyrilamine	•	5	5	5	5	5	<del>-</del>	<del>-</del>	:			
_	hydrocodone/phenylephnne/pyrilamine							_	_				
_	hydrocodone/potassium guaiacoisulfonate/PSE	_											
_	ibuprofen-pseudoephedrine.	9	:	;	9	0	:	ō	7		*		
_	ioratagine-pseudoephedrine	:	i	80	:	:	:	· :	• ;	:	- 6		
	meurschporamine-pseudoepnednne			•				-	ł		2		
_	napiovari-pseudoepriedrine			_	_								
_	photogramme/PPA/phenytoloxamine/PSZ/pyniamine		•		•					_			
_	pheniramine/PPA/pvrilamine	:	_	:	5	0	7	0	<del>-</del>	0	0		
	phenylephrine-promethazine	0	c	c			-	•					
_	phenylephrine-pyrilamine	•	•	•	•	>	<del>-</del>	5	5	;	N		
	pseudoephedrine-terfenadine											_	
	pseudoephedrine-triprolidine	56	234	;	:	24	30	12	22	7		•	
	upper respiratory combinations-NOS	279	360	165	215	i :	87	117	3 6	-	:		
	Respiratory agents NTA	29	:	:	51	: :	214	123	429	242			
	acetylcysteine	<del>-</del>	0	0	0	0	0	0	10	70	247		
	aipna I-proteinase Innibitor aminophylline-quaifenesin							1	)	•	F	_	
	aminophylline/amobarbital/ephedrine				_		_						
	aminophylline/ephedrine/quaifenesin/PB		c		•	- (	<del>-</del> ,	•					
_	aminophylline/ephedrine/PB/K lodide	0	5	<del>-</del>	- 7	5 6	<del>5</del> 6	<del>-</del> -	<del>-</del>	<del>o</del>	0		
	bedomethasone	0	0	<del>-</del>	<del>-</del>	•	<del>-</del>	<del>5</del> 6	5	:	<del>-</del>		
_	benzonatate	18	10		<del>,</del>	: ₹	5	5 0	:	: '	0		
	beractant	!	?	•	:	-	<u>:</u> ·	ח	:	Φ	:		
	pnqesoniqe	_				_		_					
	calfactant					_	-	-			-		
	caramiphen-phenyipropanolamine	-							_			_	
_	Codeline/terpin nydrate	0	<del>-</del>	0	0	0	0	0	0	:	-		
_				_	_				,	:	<del>-</del>		
	1 4 career			_		_			_	-	=	_	

# Table 2.9.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by half year (continued)

% change <sup>2</sup> H1 2001, H1 2002								
% change <sup>2</sup> H2 2001, H1 2002	_			i			_	
Jan-Jun * 2002	0	:	000	0 ;	6	: :	- o <sub>i</sub>	4 : 0
Jul-Dec 2001	212	0	000	7	0	: =	0 :	00
Jan-Jun 2001	° :	:	0 ;0	00	0	0 ;	0 :	0   0
Jul-Dec 2000	<b>o</b> :	0	000	00	0	- 0	- 0 <sub>:</sub>	0 ; 0
Jan-Jun 2000	о <sub>:</sub>	0	000	; O	0	- 0		00
Jul-Dec 1999	0 ;:	0	000	00	0	0 0	0 0	00 0
Jan-Jun 1999	34	-0	000	00	0	0 0	0	00 0
Jul-Dec 1998	0 ::	0	000	00	:	0 0	0 0	0000
Jan-Jun 1998	0 ;	0	000	00	0	: 0	0 0	0 0 1 0
Jul-Dec 1997	39	0	000	00	0	- 0	0 0	0 0 1
Drug name¹	cyclopentamine/methapyrilene HCI/ pyrrobutamine	domase alfa dyphylline-gualfenesin dyphylline-bhedrine/gualfenesin/PB	ephedrine/flydroxyzine/theophylline ephedrine/PB/K todide/theophylline ephedrine/phenobarbita/theophylline ephedrine/phenobarbita/theophylline/	gualfenesin	guaifenesin-oxtriphylline	homatropine	nedocromil nesiritide inkethamide poractant.	zilantorast. zilantorast. aritasthmatic combinations-NOS antitussives-NOS leukotriene modifiers-NOS lung surfactants-NOS respiratory agents-NOS

This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NOS = not otherwise specified, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). Drugs are classified to the degree of specificity recorded in the DAWN case reports.

ERIC

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) Indicate that an estimate with for Attanta for the period January-June 2001. For the Attanta contribution to the national estimates, data were imputed for Attanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. The Multurn Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multurn.com

Table 2.10.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by year

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994,	% change <sup>2</sup> 1999,	% change <sup>2</sup> 2000,
Antihistaminesacetaminophen/phenylpropanolamine/	3,021	2,739	2,222	2,770	2,470	3,047	3,265	4,112	1007	1002	1007
prienylioloxamine astemizole azatadine.	215	: 0	: 6	:	; c	τ=	00	00	-100.0	-100.0	
bromodiphenhydramine brompheniramine		5 5		: °	⊃ m	:	<b>5</b> C	5 .			
carbinoxamine cetirizine	00	00	000	) <del>-</del>	36:	0 238	0 0 0	7 :: 6			
chloropyramine chlorpheniramine		467	23	234	92	30 :	<u> </u>	20 2			
choprienermine		16.2	16	° :	0 ;	0 0	1	0	2 744 7	22 623 2	
cypronepradine desloratadine.	: :	180	136	:	:	· :	: :	297	7:17:7	62,000.0	:
dexbrompheniramine dexchlorpheniramine diphenylovraline HCI	: :	က	_	n	:	0	0	0			
fexofenadine loratadine	. :	7	0 00	: 1	175	191	265	547			
meclozine HCI.	: :	20	067	<u>c – </u>	512	204 0	518 0	673	:		
methdiazine	:	:	<del>-</del>	0	0	0	0	0			
neo-antergan hydrogen meleate		0	:	0	0	:	-				9
pnenindamine pheniramine	•	00	00	0+	00	0	0	00	-100.0		1.00.0
pheniramine/phenyltoloxamine/pyrilamine	•	•	<del>-</del> :		× :	4 1	:°	:0		-100 0	
promethazine	631	0 886	552	0	0 0	0 0	0 0	: ;		2	
pyribenzamine pyribenzamine tartrate					9	777	767'	<u> </u>			
terfenadine. mimenzarine	<del></del>	411	489	464	0	9	<u></u>		:		
tripelennamine		ວ ຕ	00	0 ;	0 0	0	00	<del>-</del> c			
uprolidine antihistamines-NOS		0 00	0	0 (	<u> </u>	0	0	00		:	
Bronchodilators.	2,805	2,063	1,354	1,084	192 843	281 955	643 419	422	-85.0		
albuterol-ipratropium.	_	88	455	315	172	130	: '	181	-71.4	-	
aminophylline hitotterol		0 0	00	<del>-</del> :	<del>-</del> :	<del>5 0</del>	00	v 0	-100.0		
dyphylline	0	-	0	0	0	-0		_			
iornoterol		<u> </u>		_ c	c		, (	<u> </u>			
isoproterenol-phenylephrine		•	<del>-</del>	•	5	5	5	<del>-</del>	_	_	
metaproterenol	:	;	4	က	·	:	- <u>-</u>	_			
	=	0	0	0	0	0	0	0	-100.0		

lable 2.10.0 - ED memons for respirate	,	مهرست کا مناطع دستوی از	Spin		- 1						•
Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>4</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change* 2000, 2001
pirbuterol	0+	0	00	00	0	0	0	: :			
proxypriyilitiesalmeterol	- 0	: -	0	0	2	: :	· : '	ιά) ·	Ġ		
terbutaline	279	: `	32	7 70	: <	: -	N C	<del>4 C</del>	4.0A-		
theobromine magnesium oleate theophylline	1,662	1,154	853	741	485	629	255	. 4	-97.4	-93.2	
bronchodilators-NOS	2,198	2,000	0 1,629	1,797	1,554	609	1,049	859 859	6.09-		
pseudoephedrine	2,050	1,723	1,279	1,768	1,331	587	938	846	-58.7		
decongestants-NOS Expectorants	456	402	634	658	1,016	544	775	476			
ambroxol	; c	0 0	0	<del></del>	- 0	00	50	; <b>0</b>			
chlorpheniramine/codeine/phenylephrine	00	0 0	0 0	0	7 7	0 2	0 222	0			
guaifenesin	0	404	670	2	2.	5	2	ř			
terpin hydrate	2	0	0	0	0	0	0	0	-100.0		
expectorants-NOS	0 8 9	6 232	 6 742	5 111	5.064	3 398	5.676	0 5.697		67.7	
acetaminophen-chloroheniramine		8	3	42	289	314	1,116	1,991	9,855.0	534.1	
acetaminophen-dextromethorphan								_			
acetaminophen-phenylephrine	623	442	539	65	344	4	:	:	: 		
acetaminophen/dextromethorphan/											
doxylamine/ephedrine	1	•	•	•			C				
acrivastine-pseudoephedrine	0	5	5	5	ì	:	>	:			
ammorium chloride/CPM/DM/											
ephedrine/ipecac/PE											
anhydrous calcium iodide-codeine			Č	-	c		•	<b>-</b>			
APAP/ASA/PPA	: 0	5 6	o	0	0	0	0	•			
APAP/brompheniramine/pseudoephedrine	0	:	0	0	0	0	0	0			
APAP/caffeine/chlorpheniramine/PPA											
APAP/caneine/Crwinydrocodone/PEAPAP/caffeine/ouaifenesin/ohenvleohrine											
APAP/caffeine/PPA/salicylamide											
APAP/chlorpheniramine/codeine/phenylephrine		C	_	_	_	-		ur.			
APAP/chlorpheniramine/dextromethorphan/PPA APAP/chlorpheniramine/dextromethorphan/PSE	_	00	· :	0	· :	0	0	21			
APAP/chlorpheniramine/guaifenesin/PPA											
APAP/chlorpheniramine/phenylephrine											
APAP/cnorpnenirariine/piteriyiepiiiine/ dextromethorohan/quaifenesin	;	-	0	0	:	0	0	0			
APAP/chlorpheniramine/phenylpropanolamine	:	8	18	•	:	17		35		218.2	
APAP/chlorpheniramine/pseudoephedrine	202	180	29	:	፧	÷	:	96 			
APAP/clemastine/pseudoephedrine											
ALAL/OLIMPIENS/SPINING/LL SPINING											

Table 2.10.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by year (continued)

% change <sup>2</sup> 2000, 2001					ŧ		6.88-
% change <sup>2</sup> 1999, 2001		į				-100.0	
% change <sup>2</sup> 1994, 2001				-100.0	:		
Total 2001	12,1,327	11 11	· • · ·	; ; °	10,	00 0	F ;
Total 2000	1,17	o : : : : : : : : : : : :	0 ;	0 :0	333	00 0	o ; o ; o
Total 1999	006	21,0	0 ;	000	: :° ;	0 6	
Total 1998	3 0 1,378	o. <del>‡</del> _ 4 :	0 0	0	41 0 0 169	11 5	500 : 0
Total 1997	0 0 1,386	, t	0 ;	0 : 00	171	04 0	0
Total 1996	1,425	? i i i	0 ;	: o o	289	0 ; 0	0 148
Total 1995	0 008		0	0 8 7	0	<b>~</b> : :	3 2 2 0 
Total 1994	0 0 1,564	9 : 08	0 0	; N	 0 327	0 ; ;	. 33 444 444
Drug name¹	APAP/CPM/phenylephrine/salicylamideAPAP/dexbrompheniramine/pseudoephedrineAPAP/dextromethorphan/diphenhydramine/PSEAPAP/dextromethorphan/doxylamine/PSE APAP/dextromethorphan/doxylamine/PSE APAP/dextromethorphan/doxylamine/PSE	APAP/dextromethorphan/gualfenesin/PSE APAP/dextromethorphan/phenypropanolamine APAP/dextromethorphan/PSE/pyrilamine APAP/dextromethorphan/pseudoephedrine	APAP/pseudoephedrine/triprolidine	scopolamine	brompheniramine-phenylpropanolamine	PPA.  brompheniramine/phenylephrine/PPA.  caffeine/pheniramine/PE/Na citrate, salicylat.  carbetapentane-chlorpheniramine.  carbetapentane/chlorpheniramine/phenylephrine  carbetapentane/CPM/ephedrine/phenylephrine  carbetapentane/CPM/ephedrine/phenylephrine	carbinoxamine-pseudoephedrine

Table 2.10.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by year (continued)

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change* 1994, 2001	% change <sup>4</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
chlorpheniramine-pseudoephedrine	247	228	20	:	15	10	:	:			
chlorpheniramine/codeine/phenylephrine/PPA	•	(		•		(					
chlorpheniramine/codeine/pseudoephedrine	0	0 0	: =	<del>- 0</del>	<del></del>	00	: =	<del>o c</del>			
chlombeniramine/dextromethornhan/PSF	:	> :	•	- ;	0	0	<del></del>	•			
chlorpheniramine/dihydrocodeine/PE/PPA	:	•	<u> </u>	•	)	)	•				
chlorpheniramine/DM/guaifenesin/phenylephrine											
chlorpheniramine/DM/phenylephrine											
chiorpheniramine/ephedrine/guairenesin										_	
chlombariramine/guaireriesin/prentyrephritie chlombariramine/guaifenesin/pseudoephedrine											
chlorpheniramine/hydrocodone/phenylephrine	0	:	<del>-</del>	0	:	:	0	i			
chlorpheniramine/hydrocodone/PSE	0	0	0	0	0	0	0	i			
chlorpheniramine/methscopolamine/PE	က	:	:	6	:	:	:	:			
chlorpheniramine/methscopotamine/PPA	0	:	0	0	0	0	0	0			
chlorpheniramine/methscopolamine/PSE			•	(		(	•	(			
chlorpheniramine/PE/phenyttoloxamine	2	<del>o</del> ;	<del>-</del>	5	: '	5 (	-	5 ,	-100.0		-100.0
chlorpheniramine/PE/PPA/phenyltoloxamine	: '	4	: '	9	xo	<b>20</b> (	: '	- (		-87.5	
chlorpheniramine/phenindamine/PPA	5	0	5	5	:	5	5	3			
chlorpheniramine/phenylephnne/PPA	(	(	•		•	C	•				
chlorpheniramine/phenylephnne/PPA/pynlamine	<b>5</b> (	5 1	5	5	<del>-</del> -	5	5 (	: ;			
chlorpheniramine/phenylephnne/pynlamine	13	c c	:	: [	- 0	:	×	ביי	C		
clemastine-phenylpropanolamine	245	245	:	153	310	:	:	2	92.8		
codeine-gualrenesin	~ 0	: `	: ₹	; °	<u>5 r</u>	: *	; °	: <sup>C</sup>		5000	
Codelle-pionestatine	o c	r	- c	7 0	· c	- c	7 0	o c			
Codelite-pseudoepriedritie	<del>-</del>	: ⊂	o c	<del>-</del>	5	0 0	•	0 0			
codeine/guaifenesin/PSE	0	0	2 0	0	0	· :	0	m		•	
codelne/pheniramine/phenylephrine/Na citrate	0	0	0	0	:	0	<del>-</del>	2			100.0
codeine/phenylephrine/promethazine	:	:	:	:	-	7	:	:		:	
codeine/phenylephrine/pyrilamine			-		_						
codeine/pseudoephedrine/triprolidine	÷	:	0	<del></del>	0	0	0	0			
dexbrompheniramine-pseudoephedrine	:	:	232	53	:	:	:	;			
dexchlorpheniramine/guaitenesin/PSE											
dextromeurorphan/doxylamine/pnenylephrine		ç	35			7		30		0 000	
dexirometromatical about the state of the st	:	3	3	:	:	2	:	n n		200.0	
dexicometromprentificational mile											
devicomento interporassium granacoisumonais	-	_			_	4	c	-			
dextromethorphan-pseudoenhedrine	7	<del>, -</del>	m	•	0	- 0	· ;	•			
dextromethorphan/quaifenesin/phenylephine	0	0	0	0	0	0	0	:			
dextromethorphan/guaifenesin/PPA	-	:	:	:	5	:	က	7			
dextromethorphan/guaifenesin/pseudoephedrine	:	:	:	:	:	19	:	4		-78.9	
dextromethorphan/phenylephrine/pyrilamine											
dipnennydramine-pseudoepnednne		į	9,0	CCC	C						
ephedrine-guarienesin	418	/19	1,048	320	335	:	218	:	:		
ephednine-potassium todide		1	1		1	1					

		agents by urug category:	y arag c	aregory		ites ror	the cote	Lunon	s U.S. by	Estimates for the coterminous U.S. by year (continued)	ntinued)
Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
fexofenadine-pseudoephedrineguaifenesin-hydrocodone	00	0	00	00	00	00	00	5 :			
gualienesin-hydromorphone guaifenesin-phenylephrine		c					•	_			
guaifenesin-phenylpropanolamine	232	• :	367	193	<del>-</del>	>	5	<u> </u>			
guaifenesin-pseudoephedrine	24	212	o	:	=	: :	15	5 5	-58.3		
guafenesin/hydrocodone/pheniramine/PE/PPA guafenesin/hydrocodone/pheniramine/PE/PPA											
guaifenesin/hydrocodone/pseudoephedrine	: 6	0	0	i	0	:	0	0			
guaieriesiir prieriyieprimier P.P.A	C87	219	303	207	:	; <sup>(c</sup>	: <b>"</b>	22	-92.5		
hydrocodone-phenylephrine	-	• •	!	•	:	•	•	:			
hydrocodone-potassium guaiacolsulfonate	<del>-</del> 0	N 0	<del></del>	00	; =	<del></del>	; C	<del>س</del>			
hydrocodone-pseudoephedrine	0	0	0	0	00	00	0	: :			
nydrocodone/pheniramine/PŁ/PPA/pyritamine hydrocodone/phenylephrine/pyritamine			_				-				
hydrocodone/potassium guaiacolsulfonate/PSE								<del></del>			
Ibratedine and a seudoephedrine	: '	13	: '	:	:	:	:	:			
methscopolamine-pseudoephedrine	5	5	0	:	15	÷	:	:	-		
naproxen-pseudoephedrine											
pheniramine/phenyltoloxamine/PSE/pyrilamine											
priemramine/PP/Aprienyttotoxamine/pyniamine	0	0	<del>-</del>	ŧ	-	0	7	0			-100.0
phenylephrine-promethazine	-	0	0	ō	_						
phenylephrine-pyrilamine	:	1	)	•	•	5	5	:			
pseudoephedrine-terfenadine	I										
pseudoepnedrine-inprolidine	507	664	466	4 2	363	: ;	4	发	-93.3		
Respiratory agents NTA	419	478	275	28G 173	252	421 105	205			3	
acetylcysteine			i	) :	<u>.                                    </u>	3	3	7 0		0.44.0	
aminophylline-gualfenesin				-							
aminophylline/amobarbital/ephedrine					-						
aminophylline/ephedrine/gualrenesin/PB	0	<del></del>	<del></del> -	0	0	_	0	0		-100.0	
beclomethasone	<del>-</del>	<b>&gt; «</b>	<u> </u>	<u>о к</u>		<del>-</del>	0 0	: °			
benzonatate	<u> </u>	26	· :	• :	= :	14	5	<del>,</del>		_	
beractant. budesonide	-						İ	<del></del> -	_		
calfactant			-								
caramiphen-phenylpropanolamine								_			
codelne/terpin hydrate	<del>-</del>	0	0	0	0	0	0	:		_	
cromolyn	0	:			-	•	c	-			
				,		,	•	5			

Table 2.10.0 - ED mentions for respiratory agents by drug category: Estimates for the coterminous U.S. by year (continued)

% change² 2000, 2001																									
% change <sup>2</sup> 1999, 2001								-100.0							_		_	_	_		_	_			
% change <sup>2</sup> 1994, 2001					-1000																			:	
Total 2001	0	000	÷	6	<u>;</u> e	T .	•	<del>5                                    </del>			0 (	5		:	:		C	•	i		•			:	
Total 2000	0 0	80	5	0	00	1		:0	Ì		0	<b>5</b>		7	0			:	80		•			:	
Total 1999	0	: '	5	0	00	•	(	0 0	)		0	0	c	•	0		C	)	80		0			0	
Total 1998	0	: '	5	0	00	•	•	00	•		0	:		:	0		C		0		:			<del>-</del>	
Total 1997	0	Ď,	5	0	<del>- 0</del>	•		0 0	)		0	<del>-</del>	T	-	0		_	)	0		7			0	
Total 1996	0 0	081	D .	ო	00	)	1	0 0	)		0 (	0		:	0		~	•	0		•			:	
Total 1995	1	χος Υ <u>ο</u> ς	5	:	0	:		: 0	)		0	0		:	0			,	0		2	ı		:	
Total 1994	0	138	4	i	0 (	5	ı	0 0	)		:'	0	c	5	0		_	,	0		r.	,		က	
Drug name¹	cyclopentamine/methapyrilene HCI/ pyrrobutamine	dextromeunorphan dextromese alfa	dyphylline-guaifenesin	ephedrine/guaifenesin/theophyllineephedne/theophylline	ephedrine/PB/K iodide/theophylline	ephedrine/phenobarbital/theophylline/	guaifenesin	funisolide	fluticasone-salmeterol	guaifenesin-oxtriphylline	guaifenesin-theophylline	hexylresorcinol	nomaropine	ketotifen fumarate	montelukast	nedocromii	nesitude	poractant	zafirlukast	zileuton	antitussives-NOS		lung surfactants-NOS	respiratory agents-NOS	ופאוומוסן וווומומוי אווטטעניא וווומומוי ווווסטין וווומומוי וווומומויי

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multurn Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multurn.com. estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based

ED = emergency department, NOS = not otherwise specified, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

on actual data from January-June 2000. Drugs are classified to the degree of specificity recorded in the DAWN case reports.

ERIC

Full Text Provided by ERIC

Table 2.11.0 - ED mentions for cardiovascular agents by drug category: Estimates for the coterminous U.S. by half year

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001,
Antiadrenergic agents, centrally acting	841	356	878	730	669	,	3				7007 14	7007 11
clonidine	780	29.	89	73.4	700	00.0	904	4 8 4 6	1,368	1,196		147.1
guanabenz		0	30		5	260	<del>-</del>	0,4	1,305	1,121		
guanfacine	•	8	<b>'</b> ;	)	=	•	5	5	5	3		
methyldopa	4	· :	: ;	: ^	•	: °	: °	: 5	: °	; °		
antiadrenergic agents, centrally acting-NOS			ì	ī	:	J	7	5	7	5	-100.0	
Beta-adrenergic blocking agents	1.149	1.081	1 174	000	1 245	4 000	ou o	7077	7			
acebutolol			:	5	5	900,	000	וסו,ר	1,22,1	1,175		
atenolol	391	336	25.0	284	200		7	: 6	: ;	: ;		
betaxolol	}	}	3	7	<u> </u>	co co	4 4 4	233	(02	693		
bisoprotol									_			
carteolol				-								
carvedilol	Ċ	C		-	•	-	_		_			
esmolol.	•	•	5	5	5	5	5	:	7	m		
labetalo	٣	٢	·		•							
metonroloi	7	- 1	2 6	: [	×	<del>-</del>	:	7	:	:		
	:	717	<u>0</u> 287	287	152	:	:	325	:	-		
ovorancial	; '	: '	: '	က	:	9	7	:	2	0	-100.0	
	57	5	0	0	<del>o</del>	0	0	0		6		
	0	<del>-</del>	0	0	0	0	0	-	0	<u> </u>		
pilidolid	m	0	:	:	:	0	0		_	<del>,</del>		
propranolol	480	453	228	411	514	473	264	287	•	:		
sotatol	0	0	0	0	;	! :	, c	1	: 0	: 6		
fimolol	0	0	0	0	-	<u>:</u> C	) C	<del>-</del>	<del>-</del>	5 6		
beta-adrenergic blocking agents-NOS	9	:	æ		5	5	<del>-</del> ~	5	5	5		
Calcium channel blocking agents	879	722	684	009	730	659	866	647	730	: 6		
amlodipine	:	19	30		255	}	287	Ì	200	000		
bepridil			-	•	3	:	707	:	780	R12		
diltiazem	407	46	210		27		207			_		
felodipine			i	: °	5 ^	:	9 5	:	: "	<u>;</u>		
isradipine	0	· c	<del>)</del> C	5		: °	7	: '	χo ·	_		
mibefradil	)	•	<del>-</del>	:	5	5	:	5	=	<del>o</del>	-100.0	
nicardipine	2		c		_	•		•	1	_		
nifedipine	149	226	<del>-</del>	7	77.	7	5	5	<del>-</del>	<del>-</del>		
nimodipine	:	3	<u>:</u> c	ţ ·	<u></u>	: '	: '	:	:	:		
nisoldipine	<del></del>	0 0	o c	5 6	<del>-</del>	57	5 (	:	<del>-</del>	0		
verapamil.	173	427	27.6	•	0 8	5 6	<del>-</del> 5	-	0	0	-	-100.0
calcium channel blocking agents-NOS.	:	7	24	: °	8 4	797	211	: '	172	:		
Diuretics.	439	200	368	7,77	- 070	- 4	0 !	0	0	:		
acetazolamide	3	<u> </u>	<del>-</del>	F	<del>,</del>	242	) 06	438	383	284		
amiloride	<u>.</u> 0	0		- c	<del>-</del>	<del>5</del> c	: 0	<del></del>	: '	:		
bendroflumethiazide	)	•	<del>-</del>	<del>-</del>	:	5	5	5	0	<del>-</del>	_	
benzthiazide	c		_	-	-		•					
bumetanide	,	<del>,</del>	5 6	5	57	<del>- 0</del>	<del>-</del>	12	÷	:		:
chlorothiazide	: ₹	:	<b>5</b> 4	:	- (	2	<del>-</del>	7	0	:	_	
chlorthalidone		: =	n	: <sup>c</sup>	71 0	: '	: '	0	0	0		
dichlorphenamide	•	<del>-</del>	:	5	5	5	5	0	0	0		
ethacrynic acid							_		_	_		
furosemide	172	-	210	255		327		-		-		
				-		153		-				

1 able 2.11.0 - ED mentions for cardiovascular agents by drug category: Estimates for the coterminous U.S. by half year (continued)

-						•					•	,	•
I	Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
1	hydrochlorothiazide	6E :	;00	\$000	;00	:00	;°;	:00	: : :	;° 0	;0;		
	mannitol	:01		000	000	000	001	000	-00	-07	000	-100.0	-100.0
	metolazone	0 0	;0	0 -	<b>9</b> :	P ;	4 0	50	50	- 0	56	0.001	
	polythiazide spironolactone spironolactone torsemide		<u> </u>	10 O E	40 ;	00 <u>:</u>	<b>90</b> :	. O 4	: : :	15	<u> </u>	-55.0	
Ü	urea urea duretro-NOS Cardiovascular agents NTA	13	1,716	1,425	1,947	1,749	1,869	1,794	1,555	1,988	2,619		68.4
,	adenosine			90	-0	000	-01	; 0 '	00	o ; ·	00		
	amiodarone amlodipine-benazepril	000	000	<del>00</del> ;	<del>-</del> - <u>-</u> 60	<del>-</del> -	- 00	- ; <del>-</del>	; <b>^</b> ;	- ; <del>o</del>	<u>- 10 O</u>		:
	arbutamine atenolol-chlorthalidone benazeprii	0 ;	91	1 1	° ;	: :	° ;	о <sub>:</sub>	0 ;	10	: :		
	benazepril-hydrochlorothiazide	0	0	0	0	0	0 (	0	0	-	0 (	-100.0	
20	bisoprolol-hydrochlorothlazide	400	;00	<b>&amp;</b> O O	:00	;00	<u> </u>	; ° °	: :0	<sup>;</sup> 0 4	o o :		
5	candesartan-hydrochlorothlazide Captopril Captopril-hydrochlorothlazide Captopril-hydrochlorothlazide Captopril-hydrochlorothlazide	0 22	:0 0	14	100	0 0	;0 0	40 0	;0 0	- 80 0	;0 0		
	chlortulidade-teserpine chlortualidone-reserpine cilostazol cyclandelate	. 0			0	0	0	0	0	0	:		3 <u>.</u>
	deserpidine deserpidine-hydrochlorothlazide deserpidine-methyclothlazide deserpidine-methyclothlazide	0	0	0	0	6	0	0	6	0	6		
'	digitoxin digoxin diltiazem-enalapril	243	300	:	:	: [	;	:	226	:	241		

ERIC
Full Text Provided by ERIC

Table 2.11.0 - ED mentions for cardiovascular agents by drug catego

Table 2:11.0 - ED mentions for cardiovascular agents by drug category:	giovasci	ılar ageı	nts by dr	ug cate		timates	for the	cotermir	ous U.S	S. by half	Estimates for the coterminous U.S. by half year (continued)	ntinued)
Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001,	% change <sup>2</sup> H1 2001,
disopyramide dobutamine	:	8	i	:	0	:	0	0		0		2002
dofetilide					_							
dopamine doxazosin	0 0	0	<del></del>	0	0	0	2	0	0	0		
edetate disodium (EDTA).	7	o T	4	7	:	:	:	o	i	=		-88.9
enalapril enalapril-felodinine	49	:	:	:	234	:	i	21	:	22		
enalapril-hydrochlorothiazide		0				-		-	•			
ephedrine	239	361	365	329	333	<del>-</del>	466	464	264	0 2		
epineprine	က	80	i	0	_	0	0	-	8	<del>,</del> 6		500.0
erythrityl tetranitrate	0	_	_ c		_	_						2
ethanolamine oleate	<u> </u>	<del>-</del>	•	<b>-</b>	>	_	5	:	0	4		
ethaverine fenoldonam	0	0	0	0	0	0	0	0	-0			
flecainide			•	•					1			
fosinopril	- <del>-</del>		5	<u> </u>	<del>-</del> -	: "	0	: 5	0	:		
fosinopril-hydrochlorothiazide	,	•	:	2	4	<u>n</u>	ົກ	12	7	i	;	i
guanadrei								-				
guanethidine-hydrochlorothio-ido	0	0	0	0	0	0	0	0	0	0	_	
hydralazine	c			•		_	_		1	)		
hydralazine-hydrochlorothiazide	m C	: 0	; 6	4 0	: '	: '	2	က	-	0	-100.0	-100.0
hydralazine/hydrochlorothiazide/reserpine.	0	0	0	<del>-</del> -	<del>5</del> 6	<del></del>	0 0	: 6	<del>ო</del> (	0	-100.0	
hydrochlorothiazide-irbesartan	0	0	0	0	0	0	<del>-</del>	5	5	-		
hydrochlorothiazido locadas	: '	: '	0		က	· ;	<del>-</del>	: ~	; =	:	-	
hydrochlorothiazide-methyldona	00	<del></del>	<del></del>	0	0	0	0	:		<del>-</del>		
hydrochlorothiazide-metoprolof	5	5	<del>5</del>	<del>-</del>	0	0	0	0	0	0		
hydrochlorothiazide-moexipril				_								
hydrochlorothiazide-propranolol	0	0	0	0	-							
hydrochlorothiazide-quinapril	0	0	0	0	<del>-</del>	0	<del>-</del>	0 0	: 0	5		
hydrochlorothiazide-reserpine.	:	0	0	0	0	0	0 0	<del>-</del>	5 6	- 0		
hydrochlorothia-ido folminados	0	0	÷	0	0	0	0	<del>5 =</del>	> -	5		
hydrochlorothiazide-fimolol				-				,		<del>-</del> -		
hydrochlorothiazide-triamterene	90				-				_		_	
hydrochlorothiazide-valsartan.	<del>-</del>	<u>;</u>	; c	; °	; c	; °	4 (	: '	: '	n		
hydroflumethiazide-reserpine	'		•	5	5	5	5	5	7	<del>o</del>	-100.0	
inaminana											_	
irhespran	•	•	_				_		-	-		
isoproterenol	<del>-</del>	5 6	<del>-</del>	<del>-</del>	0	0	0	:	÷	<del>-</del>		
isosorbide dinitrate	1	>	7 0	0	_	0	0	0	_	0	-100.0	
isosorbide mononitrate		. 7	•	<u>;</u> •c	:	: °	: ^	:	: 3	: '	_	
Soxsuprine	0	0	0	· :	.0	10	- 0	<u>;</u> 0	=	₹ 6		
	158	210	189	::	242	227	:	9/	583	293		

|--|

Table 2.11.0 - ED mentions for cardiovascular agents by drug category: Estimates for the coterminous U.S. by half year (continued)

	Jul-Dec	Jan-Jun	Jul-Dec		Jul-Dec	Jan-kın	JeC-lul.	an- ue	1.1.00	* 4.4 0.01	Ľ	_
	1997	1998	1998	1999	1999	2000	2000	2001	2001	2002	_	H1 2001,
veratrum alkaloidsagents for hypertensive emergencies-NOS	0	0	00	00	00	00	00	00	0	0		7007
angiotensin converting enzyme inhibitors-NOS			,			5	•	5	:	5		
antiadrenergic agents, peripherally acting-NOS		-										
antiarrhythmic agents-NOS.						_	-					
antihypertensive combinations-NOScardiovascular agents-NOS.	00	00	0 0	00	00	0	0	2	i	4		
inotropic agents-NOS	•	•	5	<b>&gt;</b>	5	5	6	0	0	i		
peripneral vasodilators-NOS	•		-									
vasopressors-NOS	0	0	0	0	0	0	0		C			

1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. Drugs are classified to the degree of specificity recorded in the DAWN case reports.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NOS = not otherwise specified, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

·able 2.12.0 - ED mentions for cardiovascular agents by drug category: Estimates for the coterminous U.S. by year

		•	•	)	,					1	
Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Totai 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change² 2000, 2001
Antiadrenergic agents, centrally acting	1,259 1,108 0	1,291	1,412	1,603	1,003 859 0	1,401 1,377 0	1,156 1,093 0	1,852 1,781 0			60.2 62.9
guaracie guaracie methydopa	35.	' : :	' : :	: : :	' : :	<u>6</u> 8	: 4	: 8	-94.3		-50.0
antiadrenergic agents, centrally acting-NOS Beta-adrenergic blocking agents.	2,827	2,598	2,339	2,250	2,255	2,334	1,956	2,382			
acebutolol atenolol	825	394	931	702	594	830	858	1,238			
betaxololbisoprolol		_			-	_					
carvedilol	0	0	0	0	0	0	0	4			
esmolol	367	9	4 6	352	10	11	278	538		-63.6	
nadolot	: 6	: '	!	: 6	: 6	: 6	17	80			
oxprenoioi penbutoloi	0	50	00	0	00	00	0	: :			
pindolol	1.424	1,639	1,232	968	1,011	925	737	521	-63.4		
sotatol	0	0	0	00	0	: 6	; 6	0			
timololbeta-adrenergic blocking agents-NOS	0	0 <del>1</del> 0 0	: 8 F	, 1 o	15 0	3: 0	1.525	1386	-47.9		
	21	3 :	246	:	48	350	332	453	2,057.1		
bepridit dittazem	529	917	347	473	256	353	272	216	-59.2		
felodipine isradipine	u 85	; co	D 00	<u>v</u> 0	20	2 ;	: :	<u> </u>	-94.4 -94.4		
mibefradil	60		i	2	0	0	:	0	-100.0		
nifedipine.	1,342	1,149	732	274	388	375	305	378	-71.8		
nisoldipine	0 0		0 2	900	0 0	0 0	0 5				
verapamilcalcium channel blocking agents-NOS	1,55		. :	7/6	707	4 4	<u>5</u> —	350	-100.0	-100.0	-100.0
Diuretics.	1,105	1,209	1,035	878	668	787	1,049	821			
acetazoiamide	• :	10	0	0 0	- 0	<del>-</del> :	; °	:0			
bendroflumethiazidebenzthiazide	0	0	ß	:	0	0	0	19			
bumetanide	11		:	: 5	:	က	N 5	<u> </u>	-81.8	100	1000
chlorthalidone	: -	: 0	: 0	2 :	: :	00	0	00	-100.0		
dichlorphenamideethacrynic acid											
furosemide	486	379	319	280	304	382	539	251			

ERIC

<del>209</del>

, , , ,

Table 2.12.0 - ED mentions for cardiovascular agents by drug category: Estimates for the coterminous U.S. by year (continued)

Total 1994 448		Total 1995 428	Total 1996 341	Total 1997 207	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
, o m	* *	105	0 :	:	:00	000	000	241			
: O T	:07		00	: - 0	00	000	00	00	100.0		
. 4	•		-	- 70	<u>: -</u>	<del>5</del> ;	. 0	4 <del>-</del> 0	-100.0		
33 20	0 0		; 0	:0	50	90	:0	:			
	i		<u>10</u>	:	ŧ	:	:				
15 12 5,090 3,823	3,823		3,525	20,182	3,141	3,696	3,662	3,543	-30.4	_	
0	00		8 0	00	10	m	: 0	0		-100.0	
	· ; c		<u> </u>	000	:00	<del></del>	<del>-</del>	: :			
+ <del>1</del>	<u> </u>		- 6	<u>5</u>	<del>o</del> :	: 4	: 0	9 :			
· · ·	0		:	0	:	:	_ <sub>0</sub>			•	
.:	÷		58	:	:	252	290	1	-		
:	0		0	0	0	0	0	<del>-</del>	_		
•	÷		:	9	12		-	:			
00	<del></del>		00	00	00	0	0				
	5		•	<del>-</del>	5	5	5	4	_		
7 7	, , ,		: :	ဂ္ဂ ဝ	: :	: °	; =	; c	000	_	
-6	-				C	•	5 6	,		_	
	•		<del>-</del>	:	<del>-</del> -	<del>-</del>	5	5		_	
									_		
0	0		0	0	0	0	0	0	-100.0		
0	<del></del>		0	0	0	0	-	0			
521 567	567		323	424	475	i	312	369		<u> </u>	
		١					1	=		-	

Comparation												
disopyramide         disopyramide           dobuldramine         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
dobtainine		:	:	:	:	12	:	:	:			
dotabilities		:	0	0	0	0	0	0	0			
Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Contact   Cont			•	_		•		•				
Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachostic   Octobachosti		:	77	<del>- 1</del>	: ;	0 (	0	2	0			-100.0
Production of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the c	[41	:	ກ	n		10	:	235	:			
enalapril-felodipine enalapril-felodipine enalapril-felodipine enalapril-felodipine enalapril-felodipine enalapril-felodipine epinephrine		460	108	137	140	177	423	102				
enalgorithydrochlorothiazide—  ephedrine—  ephedrine		}	3	5	?	•	77	76	:	;		
ephedrine         1,992         1,265         481         7           ephedrine         0         0         0         0           ephraphine         0         0         0         0           ethanolaphine         0         0         0         0           ethanolapamine oleate         0         0         0         0           feranoldopam         0         0         0         0           feranoldopam         0         0         0         0           fosinopril         0         0         0         0         0           guanatelidine         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	niazide	0	0	_	:	:	0	•	0			
epinophirine         0         0         0           epinosarlan         0         0         0           ephrosarlan         0         0         0           ethanolamine oleate         0         0         0           flacalinide         3         1         0           fosinopril-hydrochlorothlazide         0         0         0           guanethidine-hydrochlorothlazide         0         0         0           hydralazine-hydrochlorothlazide-resempline         0         0         0           hydrochlorothlazide-hydrochlorothlazide-resempline         0         0         0           hydrochlorothlazide-hydrochlorothlazide-methydropa         0         0         0           hydrochlorothlazide-methydropa         0         0         0           hydrochlorothlazide-methydropa         0         0         0           hydrochlorothlazide-resemplace-methydropa         0         0         0           hydrochlorothlazide-resemplace-methydropa         0         0         0           hydrochlorothlazide-resempline         0         0         0           hydrochlorothlazide-resempline         0         0         0           hydrochlorothlazide-resempline         0		1,992	1,265	1,366	481	726	692	749	728	-63.5		
epydrafizardan         0         0           ethanolaridardan         0         0           ethanolaridardandine oleate		:	:	:	:	:	_	0	o		800.0	
Parametrical et al.   Parametrical et al.   Parametrical et al.												
### ethanolarimine oleate #### ethanolarimine oleate ###################################		0	0	0	0	0	0	_	:			
Paraceline		•	•									
Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosinopal   Tosi		0	0	:	0	0	0	0	0			
fosinopril			C	•	•		_	_				
Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazide   Osinopril Hydrochlorothiazid		; °	·	<del>-</del>	5 0	: \$	5;	: 5	: (			
Desirophination of the properties of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product of the product		ח	:	:	ח	<u> </u>	14	13	19			
guanethidine bydrochlorothiazide hydrochlorothiazide hydrochlorothiazide hydrochlorothiazide hydrochlorothiazide hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide hosartan hydrochlorothiazide	mazide											
Superprinted   Mydraelazine   Mydraeliorothiazide   Mydraeliorothiaz		c	-	-		-	C	•	•			
hydraelazine—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlorothiazide—hydrochlor	orothiazide	•	•	•	:	<del>-</del>	>	>	5			
hydralazine-hydrochlorothiazide hydrochlorothiazide-reserpine hydrochlorothiazide-reserpine hydrochlorothiazide-irbesartan hydrochlorothiazide-irbesartan 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		_	12	13		;	LC.		7			
hydrochlorothiazide-irbesartan	rothiazide	0	0	0	0	0	0	; °	٠;			
hydrochlorothiazide-irbesartan	othiazide/reserpine	0	_	0	0	0	0	0	0			
hydrochlorothiazide-lisinopril   1 3 6     hydrochlorothiazide-methylopa	esartan	0	0	0	0	0	0	0	7			
hydrochlorothiazide-metaprolol	inopril	: '	<del>-</del> (	က	9	÷	7	1	က			
hydrochlorothiazide-metrylotopa   hydrochlorothiazide-metrylotopa   hydrochlorothiazide-metrylotopa   hydrochlorothiazide-metrylotopa   hydrochlorothiazide-propranolol   hydrochlorothiazide-telmisartan   hydrochlorothiazide-telmisartan   hydrochlorothiazide-telmisartan   hydrochlorothiazide-telmisartan   hydrochlorothiazide-telmisartan   hydrochlorothiazide-terserpine   hydrochlorothiazide-terserpine   hydrochlorothiazide-terserpine   hydrochlorothiazide-terserpine   hydrochlorothiazide-reserpine   hydr	sartan	<del>-</del> -	0 0	0	0 0	0 (	0	0	7			
hydrochlorothiazide-moexipril	etnyidopa	5	<b>)</b>	:	0	0	0	0	0			
hydrochlorothiazide-propranolol	supriori						•					
hydrochlorothiazide-quihapril.         0         0         3           hydrochlorothiazide-reserpine.          0         0           hydrochlorothiazide-telmisartan.          0         0           hydrochlorothiazide-timolol.         377         230         116           hydrochlorothiazide-timolol.         0         0         0           hydrochlorothiazide-teserpine.         0         0         0           hydrochlorothiazide-reserpine.         0         0         0           ibutilide.         inamrinone.         0         0         0           isoproterenol.         1          0         0           isoproterenol.         0         0         0         0           isoproterenol.         0         0         0         0           isosorbide dinitrate         0         0         0         0           isosorbide mononitrate         0         0         0         0	opranolol	0	0	0	C	C	c					
hydrochlorothiazide-reserpine	inapril	1	Ī	ı	1	)	•	•	:			
hydrochlorothiazide-spironolactone          0         0           hydrochlorothiazide-telmisartan         377         230         116            hydrochlorothiazide-timelenementarian         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	serpine	:	0	0	က	0	0	0	0			
hydrochlorothiazide-telmisartan  hydrochlorothiazide-timolol  hydrochlorothiazide-timolol  hydrochlorothiazide-teserpine  hydrochlorothiazide-reserpine  ibutilide  inamrinone  isoproterenol  isosorbide dinitrate  isosorbide mononitrate	ironolactone	:	:	0	0	:	0	0	:			
hydrochlorothiazide-fimolol.         377         230         116            hydrochlorothiazide-triamterene.         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	misartan											
hydrochlorothiazide-triamferene         377         230         116            hydrochlorothiazide-valsartan         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0	lolor											
hydrochlorothiazide-valsartan	amterene	377	230	116	:	:	:	:	:			
hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine   hydroriumetniazide-reserpine	Isartan	<del>-</del>	0	0	0	0	0	0	2			
Inamirrone	erpine				_							
Integration						-						
isoproterenol		-	c	-	c	•	-	•				
isosorbide dinitrate 42 31 22 25 isosorbide mononitrate 6		<del>-</del>	>	0 0	<del>-</del>	<del>5 c</del>	<del>-</del>	50	: •			
isosorbide mononitrate		45	3.	22	25.	> ;	•	226	=			
-		0	:	:	:	: ;	: :	6	: :			
		0	0	0	0	0	:	0	Ŧ			
269 198 2		289	269	198	239	339	369	475	629			

Table 2.12.0 - ED mentions for cardiovascular agents by drug category: Estimates for the coterminous U.S. by year (continued) T-124

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change* 1994, 2001	% change <sup>2</sup> 1999, 2001	% <del>change<sup>2</sup></del> 2000, 2001
losartan	0	0	0	0	13	16	:				
mecamylamine											
mephentermine	Ŧ	-	•			c	c	•	000		
methoxamine	-	· -		•	•	>	>	<b>5</b>	0.001-		
methyclothlazide-reserpine											
metyrosine											
mexiletine	:	:	7	:	2	-	-	:			
midodnne											
militrone	C	r		•	_	•	•				
moexing	5 6	NC		4 C	5 6	- 0	<b>5</b> C	-			
mordzine	0	0		5 0	- C	<b>O</b> C	<b>5</b> C	:			
morrhuate sodium	•	, =		5	•	•	<del>-</del>	:			
nitroglycerin	152	431	427		340	;	1111				
nitroprusside.					!	•		•			
norepinephrine	0	ō	0	0	0	7	:	0		-100.0	
nylidrin HCI	0	1		0	0	0	0	0			
papaverine	0	2		:	-	0	_	6			-100.0
pargyline	0	ō	:	0	0	0	0	0			
pentaerythritol chloral											
pentaeryunitol tetranitrate											
penndopul	•	-		ļ							
pnenoxybenzamine	0	ō,	o	0	0	0	0	_			
phentolamine	_	<del>-</del> '		0	0	0	0	:			
pnenylepnrne	:	กั	:	0	0	0	_	0			-100.0
polythiazide-plazosmine	_	C	•	•		•	•	(			
polyginaziones eserpine	<u> </u>	>	) F	<b>⊃</b> α	i	5	5	<del>-</del>	S		
proceinamide	7	: -		<del>,</del>	:		:	- c	- 90.0		
propafenone	m	<del>. 0</del>	: :	<del>, -</del>	; °	<del>о</del> м	:	7	200.2	-66 7	
quinapril	•	7		20	' ;		:	401	3	3	
quinidine	:	:		17	12	: :					
ramipril	4	:	12	0		: :		•			
rauwolfia serpentina											
rescinnamine											
reserpine	: '	io i	0	: '	0	0	:	0			
reserpine-urchiormemiazide	5	0	<del>-</del>	0	_	<del>-</del>	0	0			
sodium teuradecyl sullate		C	•	C	C	G		ı			
telmicarian	>	5	-	<del>-</del>	5	5	5	מ			
ferazosin	•				ţ		•	Ç	C C		
tocainide	<del>1</del> C	<u>:</u> C	<u>:</u> C	:	<u> </u>	; •	n c	<u> </u>	0.000		
tolazoline	•	,	•	:	•	>	•	5			
trandolapril	0	0	0	ō	0	0	C	-			
trandolapril-verapamil	0	0	0	0	0	0	0	-			
trimethaphan camsylate											
valsartan	<u>-</u>	0	0	0	0	0	0	26			
											•

تارامها المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المارية المار

Total         Total         Total         Total         Total         Total         Total         % change²         % change² <th< th=""><th>OO OO /th></th<>	OO OO OO OO OO OO OO OO OO OO OO OO OO
Drug name¹	veratrum alkaloids agents for hypertensive emergencies-NOS angiotensin converting enzyme inhibitors-NOS.angiotensin II inhibitors-NOS antiadrenergic agents, peripherally acting-NOS antiadrrhythmic agents-NOS antihypertensive combinations-NOS cardiovascular agents-NOS inotropic agents-NOS inotropic agents-NOS inotropic agents-NOS aperipheral vasodilators-NOS vasodilators-NOS

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to ' This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. from January-June 2000. Drugs are classified to the degree of specificity recorded in the DAWN case reports.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, NOS = not otherwise specified, NTA = not tabulated above.

T-125

## Table 3.1 - ED drug episodes: Estimates by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change¹ H1 2001, H1 2002
TOTAL COTERMINOUS U.S	261,719	271,862	270,570	278,243	276,524	302,673	298,890	311,785	326,699	308,558		
Atlanta	3,979	5,540	5,177	4,891	5,298	5,435	5,677	. 1	6,822	6,537		
Baltimore	6,137	6,440	7,296	7,122	7,049	5,731	5,774	6,110	5,515	5,952		
Boston	5,868	6,739	6,917	5,784	5,885	7,230	7,672	8,163	8,690	8,452		
Buffalo	1,241	1,276	1,407	1,223	1,487	1,416	1,484	1,743	1,614	2,254	39.7	
Chicago	14,037	12,873	13,333	12,482	13,673	14,651	15,676	16,526	16,121	13,937		-15.7
Dallas	3,283	3,632	3,566	3,104	3,141	3,473	3,323	3,369	3,131	2,638	-15.7	-21.7
Denver	2,235	2,030	2,057	2,258	2,557	2,505	2,439	2,692	2,777	3,003		
Detroit	8,241	8,482	8,994	8,183	7,942	8,584	8,458	9,580	9,685	8,482		
Los Angeles	8,378	8,127	8,976	9,938	10,739	12,976	12,310	12,157	12,512	11,266		
Miami	3,045	3,170	3,255	3,402	3,725	4,125	4,435	4,311	4,574	4,720		
Minneapolis	2,402	2,235	2,094	2,414	2,229	2,533	2,664	3,188	3,333	3,358		
New Orleans	2,607	2,762	2,325	2,328	2,131	2,286	2,378	1,862	1,868	2,158		
New York	18,162	18,045	18,096	15,172	15,491	15,635	16,247	16,799	15,508	15,166		
Newark	4,738	4,619	4,326	4,085	4,216	3,970	3,777	3,643	3,574	3,709		
Philadelphia	11,772	12,670	12,254	12,303	12,110	11,545	11,886	12,716	13,074	13,761		
Phoenix	3,581	3,752	3,306	4,067	4,224	4,392	4,680	4,866	5,217	5,055		
St. Louis	2,828	2,861	2,858	3,206	3,129	3,683	3,225	3,897	4,319	4,927		
San Diego.	3,671	3,590	3,391	3,239	3,796	3,660	3,434	3,615	3,347	3,194	4.6	-11.6
San Francisco	4,791	4,596	4,472	4,224	4,704	4,161	3,697	4,171	4,405	3,618	-17.9	
Seattle	5,487	4,620	3,707	3,931	4,492	5,717	5,398	5,720	5,776	2,656	-54.0	-53.6
Washington, DC	5,543	5,973	5,623	5,025	5,258	5,125	5,179	5,357	5,209	4,272	-18.0	

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 3.2 - ED drug episodes: Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
TOTAL COTERMINOUS U.S	518,880	513,519	513,933	526,818	542,432	554,767	601,563	638,484	23.1	15.1	6.1
tlantatlanta	10,660	11,063	9,400	8,003	10,717	10,189	11,112	14,456	35.6	41.9	30.1
3altimore	15,863	15,966	15,994	12,755	13,736	14,171	11,505	11,625	-26.7	-18.0	
3oston	15,374	16,067	13,537	12,224	13,657	11,669	14,902	16,853		44.4	13.1
-	2,745	2,714	3,587	2,812	2,683	2,711	2,899	3,356			
Chicago	21,484	21,883	23,522	26,875	26,206	26,154	30,327	32,647	52.0	24.8	
Jallas	5,141	5,230	4,975	6,194	7,198	6,245	6,796	6,500	26.4		
	4,951	4,606	3,416	4,332	4,087	4,815	4,944	5,468		13.6	10.6
	17,653	18,626	20,796	17,604	17,477	16,125	17,042	19,265			
	19,250	19,258	20,275	17,187	17,103	20,677	25,286	24,669		19.3	
	5,908	6,417	6,283	6,283	6,426	7,128	8,560	8,886	50.4	24.7	
	4,364	4,325	4,828	4,957	4,328	4,643	5,197	6,521	49.4	40.4	25.5
	4,737	5,867	5,844	5,209	5,088	4,459	4,664	3,729	-21.3		-20.0
	42,980	40,792	40,468	37,111	36,141	30,662	31,882	32,307	-24.8		
	9,394	10,870	606'6	8,893	8,944	8,301	7,747	7,217		-13.1	
	17,731	20,501	21,628	23,225	24,924	24,413	23,431	25,790	45.5		
_	6,808	7,910	7,431	7,327	7,058	8,291	9,072	10,084	48.1	21.6	
	6,038	2,657	6,179	5,664	5,719	6,336	6,908	8,216			
	5,043	4,660	5,806	6,747	6,982	7,036	7,094	6,962	38.1		-1.9
San Francisco	12,115	10,161	9,533	9,424	890'6	8,928	7,857	8,575	-29.2		9.1
Seattle	10,363	8,505	8,471	10,587	8,327	8,424	11,115	11,495		36.5	
Nashington, DC	14,152	11,830	11,720	11,193	11,596	10,282	10,303	10,566			
-					_	-					

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department.

NOSOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



#### Table 3.3 - ED drug mentions: Estimates by metropolitan area by half year

546,004 566,106 599,261 (1,232 12,808 10,275 10,804 9,973 2,352 14,154 15,641 28,891 29,184 28,633
11,232 12,808 10,275 10,804 9,973 2,783 14,154 15,641 2,783 3,096 2,840 28,891 29,184 28,633
10,275 10,804 9,973 13,352 14,154 15,641 2,783 3,096 2,840 28,891 29,184 28,633
13,352 14,154 15,641 2,783 3,096 2,840 28,891 29,184 28,633
2,783 3,096 2,840 28,891 29,184 28,633
28,891 29,184 28,633
6,167 6,268 5,846
4,223 4,557 4,855
16,274 18,076 19,088
707 00 07 170
471,62 d4C,12 dc7,12
7,743 7,652 8,267
7,743 7,652 8,267 5,098 5,998 6,303
7,743 7,652 8,267 5,098 5,998 6,303 4,713 3,484 3,552
21,700 21,340 23,124 7,743 7,652 8,267 5,098 6,303 4,713 3,484 3,552 26,583 27,226 24,829
27,743 7,652 8,267 7,743 7,652 8,267 8,267 8,267 8,267 8,267 8,267 8,298 6,303 27,226 24,829 6,312 6,335 6,254
23,124 7,743 7,652 8,267 5,098 5,998 6,303 4,713 3,484 3,552 26,583 27,226 24,829 6,312 6,335 6,254 22,576 23,945 24,276
21,700 21,340 23,124 7,652 8,267 7,743 7,652 8,267 8,303 4,713 3,484 3,552 26,583 27,226 24,829 6,312 6,335 6,254 8,017 8,600 9,205
21,700 21,340 23,124 7,652 8,267 8,267 8,267 8,267 8,267 8,267 8,267 8,267 8,267 8,312 6,312 6,312 6,314 8,600 9,205 6,260 7,470 8,492
25,583 27,226 24,829 6,303 27,726 26,583 27,226 24,829 6,303 22,576 22,576 8,017 8,600 9,205 6,720 6,142 5,637
21,700 21,346 23,124 7,743 7,652 8,267 8,267 8,267 8,267 8,267 8,312 6,335 6,254 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,001 8,0
23,239         21,739         21,240         23,124         20,922           7,140         7,743         7,652         8,267         8,635           4,593         4,713         3,484         3,552         4,080           26,053         26,583         27,226         24,829         23,728           6,759         6,312         6,335         6,254         6,603           7,411         8,017         8,600         9,205         8,609           7,057         6,260         7,470         8,492         9,099           5,919         5,720         6,142         5,637         5,486           9,599         9,375         9,471         10,347         4,718

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 3.4 - ED drug mentions: Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
TOTAL COTERMINOUS U.S.	009'668	900,287	906,366	942,382	981,764	1.014.243	1.099.306	1.165.367	29.5	14.9	90
Atlanta	20,847	22,298	19,083	16,182	20,167	19,480	21,939	27,254	30.7	39.9	}
Baltimore	26,892	27,117	27,082	22,055	23,541	24,772	19,874	20,777	-22.7	-16.1	4.5
Boston	28,431	30,037	24,912	22,392	24,876	21,219	25,863	29,795		40.4	15.2
Buffalo	4,779	4,871	6,682	5,285	4,934	4,927	5,374	5,935			
Chicago	37,241	38,407	42,412	50,479	48,344	47,867	55,449	57,817	55.3	20.8	
Dallas	9,310	9,640	9,171	11,428	13,405	11,445	12,476	12,114	30.1		
Denver	8,300	8,217	5,908	7,519	7,170	8,226	8,561	9,412		14.4	6.6
Detroit	31,663	34,152	38,952	32,487	32,582	30,207	32,740	37,164			
Los Angeles	33,195	33,389	35,218	29,684	29,805	36,945	45,015	44,670	34.6	20.9	
Miami	9,471	10,072	9,902	10,248	10,755	12,158	14,883	15,919	68.1	30.9	
Minneapolis	8,413	8,324	9,126	9,340	8,097	8,949	10,090	12,300	46.2	37.4	21.9
New Orleans	9,449	11,127	11,033	9,721	9,649	8,907	9,172	7,037	-25.5	-21.0	-23.3
New York	63,977	62,454	65,614	60,250	58,360	50,601	52,636	52,055			
Newark	16,522	19,291	18,011	15,038	15,180	13,979	13,072	12,589			
Philadelphia	31,721	36,947	38,752	42,818	45,593	45,659	44,385	48,222	52.0		
Phoenix	11,441	13,187	12,517	12,654	12,285	14,044	15,428	17,805	55.6	26.8	15.4
St. Louis	11,006	10,346	11,020	10,310	10,704	11,687	13,317	15,963			
San Diego	8,676	8,175	10,184	11,851	12,184	12,040	11,639	11,779	35.8		
San Francisco	18,147	15,527	14,213	13,491	12,525	12,702	12,171	13,743	-24.3		12.9
Seattle	17,707	14,068	13,728	18,203	13,914	13,854	18,974	19,818		43.0	
Washington, DC	25,187	19,876	19,801	18,959	19,054	16,936	16,229	17,480			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 3.5 - Alcohol-in-combination: ED mentions: Estimates by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
TOTAL COTERMINOUS U.S	86,744	91,064	93,927	_	٠,	100,347	104,164	_	113,472	97.527	-14.1	
Atlanta	2,266	2,522	2,138			3,076	3,360		3,355	3.192		
Baltimore	1,437		1,779			1,186	1,442		1,386	1,522		
Boston	2,315	.,	2,585			2,361	2,615		3,144	2,616		
Buffalo	615	290	683	267	655	629	764		744	1,252	68.3	22.7
Chicago	5,262	4,533	4,785			4,820	5,416		5,124	4,882		
Dailas	840	978	1,046			917	953		852	029	-21.4	-28.3
Denver	788	733	809			920	838		1,017	991		
Detroit.	3,908	4,042	3,949			4,215	4,232		4,766	3.904		
Los Angeles	2,240	2,646	3,483			5,708	5,286		5,803	5.249		
Miami	945	1,043	1,089			1,508	1,659		1,924	2,009		
Minneapolis	789	775	716			867	913		1,137	1,094		
New Orleans	985	1,043	876			984	964		565	674		
New York	7,459	6,956	7,238			6,152	6,298		5,629	5.060		
Newark	1,546	1,481	1,349			1,080	1,043		984	985		
Philadelphia	3,779	4,226	4,339			4,110	4,221		4,712	4,799		
Phoenix	1,286	1,253	915			1,085	1,219		1,331	1,004	-24.6	-22.5
St. Louis.	1,015	1,050	1,046			1,333	1,157		1,752	1,418		
San Diego	994	985	893			808	813		854	816	4	
San Francisco	1,008	827	759			806	897		1,144	717	-37.3	-29.0
Seattle	1,563	1,242	979			1,526	1,647		1,677	800	-52.3	45.5
Washington, DC	1,629	1,693	1,577			1,127	1,173	1,301	1,473	1,239		!

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 3.6 - Alcohol-in-combination: ED mentions: Estimates by metropolitan area by year

TOTAL COTERMINOUS U.S.         160,798         166,907         166,172         171,963         184,991           Alanda.         Alanda.         4,749         4,714         4,660         4,714         4,660           Baltimore.         6,971         7,825         6,140         4,714         4,660           Baltimore.         6,297         5,351         4,890         5,130           Boston.         1,119         1,140         1,835         1,448         1,273           Buffalo.         1,119         1,140         1,835         1,448         1,273           Chicago.         1,119         1,140         1,835         1,448         1,273           Dallas.         1,140         1,835         1,48         1,542           Dallas.         1,140         1,835         1,48         1,542           Os Angeles.         1,148         1,524 <th>Total Total 1995 1996</th> <th>1997</th> <th>1998 </th> <th>1999 1999</th> <th>Total 2000</th> <th>Total 2001</th> <th>1994, 2001</th> <th>% change 1999, 2001</th> <th>% change 2000, 2001</th>	Total Total 1995 1996	1997	1998 	1999 1999	Total 2000	Total 2001	1994, 2001	% change 1999, 2001	% change 2000, 2001
6,971 7,825 6,140 4,714 4,640 4,749 4,377 3,371 5,932 6,297 5,351 4,890 1,119 1,140 1,835 1,448 7,406 7,911 8,021 10,342 1,533 1,635 1,190 1,584 1,523 1,682 1,190 1,584 1,423 1,682 1,688 1,948 1,232 1,534 16,033 14,689 3,209 4,040 3,947 2,967 6,192 6,887 6,825 7,496 2,000 2,756 2,595 2,528 2,301 2,206 1,391 1,898 1,375 1,405 1,776 1,802 2,900 2,272 2,149 2,988	-	171.963	184.991	196 222	204 510	218 005	35.6		
4,640 4,749 4,377 3,371 5,932 6,297 6,351 4,890 1,119 1,140 1,835 1,448 1,367 1,364 1,384 1,587 1,483 1,190 1,524 1,523 1,682 1,688 1,948 1,523 1,682 1,688 1,948 1,523 1,534 1,596 1,676 2,626 2,807 2,457 1,907 2,576 2,500 2,756 2,595 2,528 2,941 2,578 2,173 1,941 2,971 2,941 2,578 2,941 2,578 2,173 1,941 2,941 2,578 2,149 2,941 2,578 2,143 1,941 2,941 2,578 2,143 1,941 2,578 2,143 2,941 2,578 2,143 1,941 2,941 2,578 2,143 1,941		4.714	4.660	4.952	6.436	6,878	9	380	
5,932 6,297 5,351 4,890 1,119 1,140 1,835 1,448 1,446 1,334 1,533 1,635 1,1490 1,534 1,524 1,523 1,635 1,688 1,948 1,523 1,682 1,596 1,576 2,626 2,807 2,457 1,900 2,756 2,595 2,528 2,941 2,578 2,173 1,940 2,941 2,272 2,149 2,2941 2,272 2,149 2,941 2,272 2,149 1,948 1,948 1,375 1,405 1,776 1,892 2,941 2,272 2,149 2,948 1,246 1,776 1,940 1,941 1,776 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,941 1,94		3,371	3,079	3.566	2,628	2,000	-37.3	184	40.0
1,119 1,140 1,835 1,448 1,57 1,357 1,364 1,384 1,587 1,563 1,190 1,524 1,523 1,635 1,190 1,524 1,524 1,523 1,682 1,682 1,688 1,948 1,532 1,448 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,534 1,536 1,545 1,370 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1,375 1		4.890	5,130	4.439	4.976	5,818	?	31.1	9.0
7,406 7,911 8,021 10,342 1,357 1,364 1,384 1,587 1,635 1,190 1,524 1,587 1,484 8,378 9,085 7,894 5,649 5,649 5,649 1,548 1,948 1,423 1,418 1,596 1,676 2,626 2,807 2,457 1,970 12,323 13,534 16,033 14,689 3,209 4,040 3,947 2,967 6,192 2,131 2,006 1,991 1,898 1,375 1,405 1,776 1,802 2,941 2,277 2,143 2,941		1,448	1,273	1,222	1,393	1.548			2
1,357 1,364 1,384 1,587 1,633 1,635 1,190 1,524 1,524 1,524 2,649 5,649 5,649 1,682 1,688 1,948 1,565 2,626 2,807 2,457 1,970 12,323 13,534 16,033 14,689 3,209 4,040 3,947 2,967 6,192 2,941 2,000 2,756 2,595 2,528 2,941 2,578 2,173 1,941 2,900 2,272 2,149 2,941		10,342	9,318	9,228	10,236	10,307	39.2		
1,633 1,635 1,190 1,524 7,484 8,378 9,085 7,894 5,649 5,594 5,648 4,650 1,523 1,682 1,688 1,948 1,423 1,418 1,596 1,676 2,626 2,807 2,457 1,970 12,323 13,534 16,033 14,689 3,209 4,040 3,947 2,967 6,192 6,887 6,825 7,496 2,000 2,756 2,595 2,528 2,131 2,006 1,776 1,898 1,375 1,405 1,776 1,802 2,901 2,272 2,149 2,988		1,587	2,024	1,673	1.870	1,786	31.6		
7,484 8,378 9,085 7,894 1,523 1,524 5,648 4,650 1,423 1,682 1,688 1,948 1,948 1,2423 13,534 16,033 14,689 3,209 4,040 3,947 2,967 6,192 6,887 6,825 2,528 2,131 2,006 1,776 1,892 2,901 2,277 2,941 2,2901 2,277 2,149 2,988		1,524	1,542	1,710	1,758	1,875			
5,649 5,594 5,648 4,650 1,523 1,682 1,688 1,948 1,423 1,418 1,596 1,676 2,626 2,807 2,457 1,970 12,323 13,534 16,033 14,689 3,209 4,040 3,947 2,967 6,192 6,887 6,825 7,496 2,000 2,756 2,595 2,528 2,131 2,006 1,776 1,898 1,375 1,405 1,776 1,802 2,941 2,578 2,173 1,941 2,900 2,272 2,449		7,894	7,992	7,199	8,447	9,109		26.5	
1,523 1,682 1,688 1,948 1,423 1,418 1,596 1,676 2,626 2,807 2,457 1,970 3,223 13,209 4,040 3,947 2,967 6,192 6,887 6,825 7,496 2,000 2,756 2,595 2,528 2,731 1,375 1,405 1,776 1,802 2,941 2,277 2,149 2,988		4,650	6,129	8,195	10,993	10,907			
1,423 1,418 1,596 1,676 2,626 2,807 2,457 1,970 12,323 13,534 16,033 14,689 3,209 4,040 3,947 2,967 2,000 2,756 2,595 2,528 2,131 2,006 1,991 1,898 1,375 1,405 1,776 1,802 2,900 2,272 2,149 2,988		1,948	2,132	2,645	3,168	3,679	141.6	39.1	16.1
2,626 2,807 2,457 1,970 12,323 13,534 16,033 14,689 3,209 4,040 3,947 2,967 6,192 6,887 6,825 7,496 2,131 2,006 1,991 1,898 1,375 1,405 1,776 1,802 2,900 2,272 2,149 2,988		1,676	1,491	1,678	1,780	2,238	57.3	33.4	25.7
12,323 13,534 16,033 14,689 3,209 4,040 3,947 2,967 6,192 6,887 6,825 7,496 2,000 2,756 2,595 2,528 2,131 2,006 1,991 1,898 1,375 1,405 1,776 1,802 2,900 2,272 2,149 2,988		1,970	1,919	1,916	1,948	1,181	-55.0	-38.4	-39.4
3,209 4,040 3,947 2,967 6,192 6,887 6,825 7,496 2,000 2,756 2,595 2,528 2,131 2,006 1,776 1,898 2,901 2,272 2,149 2,988		14,689	14,194	12,333	12,450	11.821			3
6,192 6,887 6,825 7,496 2,000 2,756 2,595 2,528 2,131 2,006 1,991 1,898 1,375 1,405 1,776 1,802 2,941 2,578 2,173 1,941 2,900 2,272 2,49 2,988		2,967	2,830	2,377	2,123	2,015		-15.2	
2,000 2,756 2,595 2,528 2,131 2,006 1,991 1,898 1,375 1,405 1,776 1,802 2,941 2,578 2,173 1,941 2,900 2,272 2,49 2,988		7,496	8,565	8,815	8,331	9,228	49.0		
2,131 2,006 1,991 1,898 1,375 1,405 1,776 1,802 2,941 2,578 2,173 1,941 2,900 2,272 2,149 2,988		2,528	2,168	1,915	2,303	2,627	31.4	37.2	14.1
1,375 1,405 1,776 1,802 2,941 2,578 2,173 1,941 2,200 2,272 2,149 2,988		1,898	2,096	2,033	2,490	3,157			•
2,941 2,578 2,173 1,941 2,988		1,802	1,878	1,801	1,622	1,660			
2.900 2.272 2.149 2.988		1,94	1,586	1,705	1.804	2.155	-26.7	26.4	19.5
2001		2,988	2,221	2,228	3,173	3,145		41.2	2
4,926 3,407 3,605 3,216		3,216	3,270	2,745	2,300	2,774	43.7		20.6

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 3.7 - Cocaine: ED mentions: Estimates by metropolitan area by half year

	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
82,359	6	85,757	86,254	79,575	89,176	84,704	90,178	96,752	96,282	91,687		
2,016	75	3,127	2,853	2,453	2,783	2,820	3,410	į	4,306	4,036		
3,041	_	3,167	3,704	3,449	3,472	2,353	2,590	2,554	2,376	2,806	18.1	
1,672		2,051	2,475	1,722	1,838	1,883	2,217	2,267	2,666	2,524		
642		610	615	494	624	430	288	619	601	838		
7,273		6,883	6,760	6,150	7,248	7,287	7,592	8,269	7,933	6,614		-20.0
626		1,262	1,324	1,011	1,096	1,105	1,075	964	802	654	-18.8	-32.2
581		205	653	658	724	899	674	631	712	956	30.1	46.8
3,604		4,172	4,445	3,785	3,914	4,028	3,842	4,160	3,570	2,820	-21.0	-32.2
2,408		2,629	3,150	3,183	3,586	4,622	4,472	4,625	5,374	4,652		
1,616		1,768	1,785	1,872	2,146	2,131	2,252	2,192	2,450	2,492		
377		394	381	407	407	397	444	462	643	681		47.4
1,186		1,304	1,091	1,081	1,058	937	1,061	689	734	694		
696'6		686'6	9,560	7,386	7,413	6,883	7,367	7,449	6,450	6,334		
1,944		1,908	1,835	1,553	1,571	1,448	1,278	1,327	1,304	1,654		
5,798		6,623	6,425	6,207	6,227	5,285	5,213	5,686	5,673	6,247		
629		749	737	862	1,015	855	920	848	904	788		
787		1,017	1,055	1,180	1,149	1,255	1,148	1,434	1,645	1,830		
420		462	209	423	640	484	518	439	373	389		-11.4
286		912	930	176	1,159	1,071	982	1,220	1,261	964	-23.6	-21.0
1,583		1,261	1,139	1,089	1,430	1,584	1,754	1,660	1,750	551	-68.5	-66.8
1,619		1,892	1,826	1,472	1,678	1,373	1,458	1,440	1,454	1,032	-29.0	-28.3
	_						-					

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 3.8 - Cocaine: ED mentions: Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change¹ 1999, 2001	% change¹ 2000, 2001
TOTAL COTERMINOUS U.S	143,337	135,711	152,420	161,083	172,011	168,751	174,881	193,034		14.4	10.4
Attanta	6,190	6,515	5,434	4,244	5,980	5,236	6,229	8,891	43.6	8.69	42.7
Baltimore	8,882	8,603	8,515	6,253	6,871	6,921	4,943	4,930	•	-28.8	
Boston	4,810	5,267	4,106	3,332	4,526	3,560	4,099	4,933		38.6	20.3
Buffalo	1,136	1,333	2,203	1,526	1,225	1,119	1,018	1,220			
Chicago	10,733	10,702	12,688	14,373	13,642	13,399	14,879	16,202		20.9	
Dallas	1,442	1,457	1,393	1,778	2,586	2,106	2,180	1,770	22.7	-16.0	-18.8
Denver	1,273	1,144	811	1,072	1.154	1,382	1,342	1,343			
Detroit	8,268	8,763	10,435	8,093	8,617	7,699	7,870	7,730			
Los Angeles	5,069	4,980	5,708	4,703	5,779	6,768	9,094	666'6		47.7	
Miami	2,748	3,078	3,104	3,254	3,553	4,018	4,383	4,641			
Minneapolis.	295	465	674	736	775	814	24	1,105	99.6	35.7	31.4
New Orleans	1,883	2,018	2,380	2,363	2,395	2,139	1,998	1,422		-33.5	-28.8
New York	20,145	19,715	21,592	20,202	19,549	14,799	14,250	13,898			
Newark	4,228	4,658	4,436	3,571	3,743	3,124	2,726	2,631		-15.8	
Philadelphia	8,481	9,502	10,383	11,202	13,048	12,434	10,497	11,358			
Phoenix	1,057	1,165	1,382	1,337	1,486	1,877	1,775	1,752	65.8		
St. Louis	2,329	1,841	1,852	1,494	2,072	2,329	2,403	3,080			
San Diego.	299	44	906	844	971	1,063	1,002	812		-23.6	-19.0
San Francisco.	3,227	2,560	2,310	1,979	1,843	1,935	2,054	2,482	-23.1	28.3	20.8
Seattle	3,029	2,158	2,143	2,850	2,399	2,519	3,338	3,409		35.3	
Washington, DC	4,849	3,542	3,881	3,223	3,718	3,150	2,830	2,894	-40.3		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from <sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



#### Table 3.9 - Heroin: ED mentions: Estimates by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change	% change <sup>1</sup> H1 2001, H1 2002
TOTAL COTERMINOUS U.S	35,899	37,859	37,829		`	47,635	47.169	44.138	48.926	42 571	-13.0	
Atlanta	213	228	245			241	244	1	439	337		
Baltimore	2,832	3,015	3,696	3,502	3,497	2,887	2,518	2,593	1.888	1.977		-23.8
Boston	1,229	1,358	1,380			1,820	2,048	2,022	2,336	2,155		
Buffalo	263	222	316			363	318	283	325	484		710
Chicago	4,651	4,506	4,810			6,109	6,346	6,178	5.724	4.359		?
Dallas	256	261	239			262	215	251	191	147		414
Denver	278	248	244			323	343	380	389	519		36.6
Detroit	1,451	1,426	1,453			1,661	1.667	2.102	1.768	1,440	-186	-31.5
os Angeles	1,147	1,214	1,387			1,791	1.386	1.440	1.437	1 245		2
Viami	314	364	403			681	771	830	837	632		
Minneapolis	8	83	62			96	132	72	18	180		
New Orleans	208	257	253			466	516	262	268	278		
New York	4,581	4,613	4,605			5,378	5,630	5.428	5.216	4.635		
Newark	2,504	2,575	2,497			2,285	2.114	1.849	1.869	1 925		
Philadelphia	2,013	1,600	1,845			2,249	2,411	2.513	2.849	2 441		
Phoenix	414	467	406			424	416	372	405	298	-26 4	-19 9
St. Louis	212	300	322			556	528	561	:	640		2
San Diego	496	477	202			290	442	401	332	316	4	-212
San Francisco	1,318	1,323	1,038			1,490	1,266	1,357	1.433	1.344		!
Seattle	1,496	1,279	1,142			1,403	1,087	903	1.024	475	-53.6	474
Washington, DC	863	1.050	1.048			057	080	1 007	730	Č		

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000 \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors.

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 3.10 - Heroin: ED mentions: Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
TOTAL COTERMINOUS U.S.	63,158	922'69	72,980	70,712	75,688	82,192	94,804	93.064	47.4		
Atlanta	443	404	388	384	473	415	485	848	91.4	104.3	74.8
Baltimore	7,471	8,207	8,093	5,863	6,711	666'9	5,405	4,481	40.0	-36.0	-17.1
Boston	2,563	2,956	2,729	2,500	2,738	2,861	3,867	4.358	70.0	52.3	12.7
Buffalo	314	379	443	468	538	522	681	607			
Chicago	4,737	4,702	6,268	8,602	9,316	9,629	12,454	11,902	151.3	23.6	
Dallas	242	264	331	202	200	428	478	443	83.1		
Denver	472	463	336	465	492	629	999	169	62.9	22.3	15.5
Detroit	2,160	2,390	3,188	3,028	2,879	2,653	3,328	3,870	79.2	45.9	16.3
Los Angeles	2,928	3,060	3,278	2,471	2,601	2,923	3,177	2,878			4.6
Miami	258	333	388	591	191	917	1,452	1,666	545.7	81.7	14.7
Minneapolis	65	83	105	138	145	182	228	338	420.0	85.7	48.2
New Orleans	191	263	303	422	510	649	982	530	177.5	-18.3	46.0
New York	11,129	10,706	11,132	9,481	9,218	9,302	11,009	10,644			
Newark	4,493	5,681	5,386	4,364	5,072	4,733	4,399	3,718		-21.4	-15.5
Philadelphia	2,385	3,839	3,864	3,712	3,445	4,087	4,661	5,362	124.8		
Phoenix	472	485	632	827	873	839	84	777	64.6		
St. Louis	392	369	489	447	622	851	1,084	1,309	233.9		
San Diego	687	675	920	911	984	1,063	1,031	733		-31.0	-28.9
San Francisco	3,654	3,113	3,132	2,719	2,360	3,050	2,756	2,790	-23.6		
Seattle	2,137	2,023	2,418	2,894	2,421	2,470	2,490	1,927		-22.0	-22.6
Washington, DC	1,254	1,295	1,527	1,689	2,097	1,771	1,946	1,888	20.6		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 3.11 - Marijuana: ED mentions: Estimates by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jui-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change H2 2001, H1 2002	% change ' H1 2001, H1 2002
TOTAL COTERMINOUS U.S	32,331	37,863	38,979	43,094	43,974	49.028	47.398	55.164	"	55.727		
Atlanta	807	1,410		1,185	1,331	1,265	1,166	I		1.910		
Baltimore	713	708		801	878	792	854	942		944		
Boston	847	1,484		296	993	1,425	1,520	1.684		1.741		
Buffalo	197	204		225	268	253	300	374		192		-48.7
Chicago	2,364	2,607	2,395	2,273	2,282	2,494	2,905	2,704	2,482	2,238		
Dallas	481	159		614	558	670	555	570		364	-24.0	-36.1
Jenver	290	291		291	387	404	413	461		423	l	
)etroit	1,888	2,049		2,254	1,846	2,125	2,219	2.417		2.695		
os Angeles	1,023	1,343		2,517	2,955	3,219	2,627	2,685		3.037		
Viami	460	261		574	709	855	913	920		1,195		29.9
Minneapolis	296	241		308	317	404	399	582		620		
Vew Orleans	709	714		545	200	519	549	424		444		
New York	1,900	1,986		1,799	1,692	1,856	1,688	1.904		1.624		
Vewark	251	266		313	220	274	265	309		414		
Philadelphia	2,396	2,830		2,841	2,624	2,446	2,482	2,863		3,441		
Phoenix	384	386		548	479	464	609	635		609		
St. Louis	588	693		864	775	696	793	1,112		1.592		
San Diego	514	209		409	513	481	474	521		625	6.8	20.0
San Francisco	194	204		163	306	342	285	387		217	-31.5	43.9
Seattle	888	269		409	398	723	691	828		298	-59.6	-65.3
Washington, DC	1,225	1,121	1,238	1,208	1,308	1,284	1,226	1.087		843		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 3.12 - Marijuana: ED mentions: Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change <sup>1</sup> 2000, 2001
TOTAL COTERMINOUS U.S.	40.034	45,259	53,770	64,720	76,842	87,068	96,426	110,512	176.0		14.6
Atlanta	1,544	1,671	1,547	1,577	2,633	2,515	2,431	3,486		38.6	
Baltimore	770	945	1,194	1,402	1,495	1,679	1,620	1,786			10.2
Boston	1,859	2,401	2,127	1,768	2,907	1,960	2,945	3,423		74.6	
Buffaio	219	295	512	472	451	493	553	561			
Chicago	2,226	2,922	3,531	4,424	5,002	4,555	5,398	5,186			
Dallas	470	549	553	916	1,510	1,172	1,225	1,049			
Denver	395	497	288	505	578	229	817	979		44.6	
Detroit	2,955	3,875	4,210	3,742	4,335	4,100	4,344	5,017			
Los Angeles.	1,656	1,706	2,132	2,084	3,422	5,472	5,846	5,729			
Miami	713	996	1,011	1,024	1,113	1,283	1,768	1,932		9.09	
Minneapolis	411	469	543	604	490	625	803	1,200		92.0	49.4
New Orleans	884	1,025	1,247	1,345	1,196	1,044	1,068	814			-23.8
New York	2,578	2,974	3,571	3,839	3,682	3,491	3,544	3,501			
Newark	628	742	627	200	532	533	539	647		21.4	
Philadelphia.	2,086	3,059	3,432	4,560	5,302	5,465	4,928	5,496			
Phoenix	451	474	610	741	727	1,028	1,073	1,284	184.7	24.9	
St. Louis	897	861	924	1,109	1,338	1,639	1,763	2,311			
San Diego.	512	480	929	970	1,128	923	955	1,107		19.9	15.9
San Francisco.	200	206	424	388	391	469	627	704		50.1	12.3
Seattle	910	993	899	1,663	936	808	1,414	1,596		97.5	12.9
Washington, DC	2,712	2,035	2,167	2,394	2,360	2,516	2,510	2,135			
Wasinigion, DC	2,1,2	2,000	7, ',	2,2,7	2,000	2.2.2	7			- 1	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 3.13 - Amphetamines: ED mentions: Estimates by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change¹ H1 2001, H1 2002
OTAL COTERMINOUS U.S.	5,946	5,476	6,706		ļ			9.049	9.506	10.079	1	
tlanta	:	<u>48</u>	112						151	297		
Baltimore	90	46	29						136	125		
Boston	:	82	95						204	213		
uffalo	4	4	9						4	-	150 0	
hicago	122	73	109			143		223	185	184		
allas	182	163	173						191	143	-25.1	-23.5
Jenver	11	26	88						243	256		57.1
Detroit	170	207	155						270	227		5
os Angeles	391	272	268				240		999	188 188 188 188 188 188 188 188 188 188		
Miami	8	<u> 56</u>	37				39		33	40		
Minneapolis	20	23	21				113		117	200		
New Orleans	18	29	56				9		99	93		
New York	15	25	27				6	7	3	3		
Newark	89	80	12				! ;		:	:		
Philadelphia	201	169	191				240		171	126		7 77
Phoenix	252	218	144				367		499	676		Ī
St. Louis	51	40	25				99		8	)		
San Diego	491	424	329				462		510	566	77	310
San Francisco	133	06	83				201		409	270		5. c.
Seattle	246	199	93	<b>1</b> 54	192	291	348	345	354	104	-20.6	0.02
Washington, DC	:	:	;	29			÷				<u> </u>	2

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 3.14 - Amphetamines: ED mentions: Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 199 <b>4,</b> 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
TOTAL COTERMINOUS U.S	10,118	9,581	9,772		•	12,496	17,134			48.5	] :
Atlanta	67	83	134				:		•		
Baltimore	55	35	20	88	105	150	175	262	376.4	74.7	49.7
Boston	:	:	116				369			81.5	
Buffalo	5	22	20				25			-39.3	-32.0
Chicago	72	1 <del>4</del> 4	194				360			100.5	
Dallas	92	133	120				351			23.1	
Denver	189	280	95				334			72.8	
Detroit	305	292	440				:				
Los Angeles.	220	296	627				1,072		129.3	45.6	
Miami	:	:	:				83				
Minneapolis	33	35	46				189		584.8	123.8	
New Orleans	27	12	56				103				
New York.	21	53	8				39				
Newark	18	19	7				:				
Philadelphia	143	251	256				489				
Phoenix	402	453	304				661			71.1	34.3
St. Louis.	37	74	92				126				
San Diego.	381	425	489				894		147.2		
San Francisco.	433	329	235				371			209.4	111.9
Seattle	186	233	178				640			102.6	
Washington, DC	:	8	:				:				i
			_								

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 3.15 - Methamphetamine: ED mentions: Estimates by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change 1 H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
TOTAL COTERMINOUS U.S	8,936	6,534	4,952			7,323		6.786	8 137		1	7007
Atlanta	129	8	29	31	52	65	4	1	8	,		
Baltimore	က	:				5		4	2			
Boston	:	က				7		4	16			
Buffalo	:	2				10	C	•	?			
Chicago	19	16			12	,		:	. 5.			
Dallas	82	118	9			75	9	: <u>'</u>	3			:
Denver	143	99	53			75	46	2 6	: <del>V</del>	: 8		
Detroit	0	0	0			; =	?	3	ř			
Los Angeles	633	418	368	414	496	682	: 693	711	8	2		
Miami	00	7	O		2	7	3 ~	- 5	5	34		3
Minneapolis.	:	89	41	25	55.	. 04	9.40		7	5	φ 5	٠. ت
New Orleans	17	13	12		14	2	7	- 4	2 7	102		9
New York		•	φ			1 0	2	5	: °	n n	i	483.3
Newark	•	:	2		;	=	: `	: '	7)	:		
iladelnhia	: \$	: 7	: 6	: 1	: 6	:	4 (	<del>o</del> ,	0	0		
Dhobaix	7 8	- 6	5 5	1	3	;	29	<u>.</u>	30	32		
T LOGILA.	333	45.	152	147	194	269	331	264	340	224		
St. Louis	43	စ္တ	37	4	9	106	26	62	53	Q.		
San Diego	558	421	300	260	324	411	336	344	329	257	21.0	25.2
San Francisco	528	385	232	251	303	270	322	274	337	323	6.12	5.02-
Seattle	267	160	106	150	203	305	235	166	228	11.5	406	702
Nashington, DC	:	₽	9	:	29		18	6	15	2 5	9	130.7
								,	?	1		7.77

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

Table 3.16 - Methamphetamine: ED mentions: Estimates by metropolitan area by year

Metropolitan area	1994	1995	1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change 1994, 2001	% cnange 1999, 2001	% change 2000, 2001
TOTAL COTERMINOUS U.S.	17.537	15,933	_	17,154	·		`	14,923			:
λtlanta	95	147	135	214				172	81.1	107.2	57.8
Baltimore	4	4		_				9		40.0	
Boston	4	7		13				4			
3uffalo.	80	9	o	80	6	2	Ω.	4	-50.0	42.9	
Chicago	17	8		29				45			÷
Jallas.	152	203		159			135	111	-27.0		
Jenver	139	175		292				86			
Detroit	17	15						:			
os Angeles.	1,399	1,276	_	1,229	786		•	1,517		66.7	10.3
Miami	8	5		9	16			27	237.5	200.0	80.0
Vinneapolis	25	93		217	109		153	321	463.2	186.6	109.8
New Orleans	12	18		26	25			:			
Vork	21	23		32	36			:			
dewark	:	:		:	7			8			-100.0
hiladelphia	9	91	99	101	48			09			
hoenix	802	717	725	800	446			604		77.1	
St Louis.	51	92	39	29	99			115	125.5		
San Diego	911	989	999	926	721			673		15.2	
San Francisco	_	1,106	934	1,012	616			611	-53.0		
Seattle	309	258	195	479	266			395			-26.9
Washington, DC	33	24	=	i	16			24			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 3.17 - MDMA (Ecstasy): ED mentions: Estimates by metropolitan area by half year

% change <sup>†</sup> H1 2001, H1 2002	-37.0 -41.3 275.0 -57.5 -23.5 -60.3 -60.3 -68.8
% change <sup>1</sup> H2 2001, H1 2002	1
Jan-Jun * 2002	2,303 298 377 117 128 138 147 158 158 158 158 158 158 158 158 158 158
Jul-Dec 2001	2,1,0 2,0 2,0 2,0 3,0 4,0 4,0 4,0 4,0 4,0 4,0 4,0 4,0 4,0 4
Jan-Jun 2001	2,427 
Jul-Dec 2000	2, 2, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4,
Jan-Jun 2000	2125 19 48 43 22 23 44 45 65 65 65 65 65 65 65 65 65 65 65 65 65
Jul-Dec 1999	255 27 27 27 27 27 27 27 27 27 27 27 27 27
Jan-Jun 1999	947 27 27 7 7 7 7 8 16 8 16 67 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
Jul-Dec 1998	22 24 25 25 25 25 25 25 25 25 25 25 25 25 25
Jan-Jun 1998	25.00 10 10 10 10 10 10 10 10 10 10 10 10 1
Jul-Dec 1997	363 0 2 1 1 1 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3
Metropolitan area	Atlanta

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (ho < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, MDMA = methylenedioxymethamphetamine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 3.18 - MDMA (Ecstasy): ED mentions: Estimates by metropolitan area by year

		4	.2			7.7		£.		-19.8	2.2				 3	0.					2.	
% change <sup>1</sup> 2000, 2001		157.4	17			43.7		-26.3		-15	75				133.3					42.1	-10	
% change <sup>1</sup> 1999, 2001	94.5	182.3	114.3	6.09	-50.0		220.8	180.0	177.5	173.1	211.9	381.3	-33.3			128.1	380.0		108.0	223.4	259.4	:
% change¹ 1994, 2001	2,090.5	:		2,700.0		1,110.0	266.7	2,000.0	:	914.3	9,100.0	3,750.0	183.3	2,357.1		:	:		7.997	375.0	5,650.0	:
Total 2001				140																		
Total 2000				125																		
Total 1999				87						52	29	16	51	136	38	88	20	15	25	47	32	:
Total 1998				39						30	12	2		31		27					19	23
Total 1997	637	19	2	16	0	33	17	1	:	24	28	:	13	4	:	19	9	7	8	35	20	:
Total 1996	319		7			22	20	_	0	46	6	4	12	24	:	0	:	:	17	32	12	i
Total 1995	421	:	80	7	0	8	57	က				:		:	:	:	_	_	9	29	10	:
Total 1994	253	:	0	S	<del>-</del>	9	21	2	:	14	2	2	12	7	0	:	:	0	9	32	2	:
Metropolitan area	TOTAL COTERMINOUS U.S.	Atlanta	Baltimore	Boston	Buffalo	Chicado	Dallas	Denver	Detroit	Los Angeles.	Miami	Minneapolis	New Orleans	New York	Newark	Philadelphia	Phoenix	St Louis	San Diego.	San Francisco.	Seattle	Washington, DC

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department, MDMA = methylenedioxymethamphetamine.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 3.19 - Ketamine: ED mentions: Estimates by metropolitan area by half year

% change 1 % change 1 H 2001, H 2001, H 2002	500.0 200.0 -100.0 250.0	-100.0
Jan-Jun * 2002	250 6 4 4 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	00
Jul-Dec 2001	1000 100-01- 10 1 1 104	<del></del>
Jan-Jun 2001	4	o :
Jul-Dec 2000	8 :0 8 0 1 4 0 :8 : 1 : 2 : 2 : 2 : 2	၉ တ
Jan-Jun 2000	504 1000 800 0 10 1 1 1 1 1 1 1 1 1 1 1 1 1	
Jul-Dec 1999	14-10 10- 10 10 1400 1400 1400 1400 1400	N M
Jan-Jun 1999	00 00000000 1 1 1 4 0 W 1 1 1 4 0 W 1 1	-0
Jul-Dec 1998	10-50000 1-0-5 1 1 1044	o N
Jan-Jun 1998	244440 100 10004 to 100 100	0 0
Jul-Dec 1997	140404 10 10404 11 100 140	⊃ ຫ
Metropolitan area	Atlanta Atlanta Baltimore Boston Chicago Dallas Dervoit Los Angeles Miami Minneapolis New York New York Philadeiphia Phoenix St. Louis San Diego	Washington, DC

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 3.20 - Ketamine: ED mentions: Estimates by metropolitan area by year

% change¹ 2000, 2001	50.0  100.0 200.0 -50.0 -71.4 -16.7
% change¹ 1999, 2001	-69.2 500.0 1,000.0 -60.0 200.0 -77.8 175.0 -66.7
% change¹ 1994, 2001	3,473.7
Total 2001	04 0 0 0 4 - 1 - 5 4 4 8 0 2 4 6 1 6 1 - 1
Total 2000	263 23 10 10 10 11 10 10 10 10 10 10 10 10 10
Total 1999	86 65 65 7 7 7 7 7 7 7 7 7 7 8 7 8 8 8 8 8 8 8
Total 1998	800 84 8 50 100 1 1 10 20 85 1 10 4 50 0 4
Total 1997	100400 100 1 10 1 10 1 10 1 10 1 1 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Total 1996	80 ≈ ≈ 0 ± 400 ; 0 100 € € ; 0 0 4 4 0 €
Total 1995	100400+00 1000004000w0+
Total 1994	±000000000000000000000000000000000000
Metropolitan area	TOTAL COTERMINOUS U.S. Atlanta. Battimore. Buston. Chicago. Chicago. Dallas. Denver. Dervoit. Los Angeles. Miami. Minneapolis. New Orleans. New York. New York. Philadelphia. St. Louis. St. Louis. San Diego. San Diego. San Francisco. Seattle.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from <sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (…) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 3.21 - LSD: ED mentions: Estimates by metropolitan area by half year

% change <sup>1</sup> H1 2001,	-78.4 -78.4 -74.1 -89.5 -74.1 -89.5 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4 -51.4
% change <sup>1</sup> H2 2001,	7.2 0.0
Jan-Jun * 2002	704 01 022 020 020 01 020 020 020 020 020 0
Jul-Dec 2001	98 66 67 67 68 68 68 68 68 68 68 68 68 68
Jan-Jun 2001	1,882 1,22 1,88 1,88 1,84 1,12 1,12 1,13 1,13 1,13 1,13 1,13 1,13
Jul-Dec 2000	28. 3.2 2. 2. 3.2 3.2 3.2 3.2 3.2 3.2 2.2 2
Jan-Jun 2000	2,157 36 77 71 100 100 124 225 126 126 127 128 128 128 128 128 128 128 128 128 128
Jul-Dec 1999	2,699 25 25 19 19 117 17 17 17 17 17 17 18 18 18 19 19 19 19 19 19 19 19 19 19 19 19 19
Jan-Jun 1999	24.2 25.2 25.2 24.2 24.2 25.2 24.2 25.2 26.2 26.2 26.2 26.2 26.2 26.2 26
Jul-Dec 1998	3,275 823 823 833 844 852 852 852 852 852 852 852 852 852 852
Jan-Jun 1998	1,767 1,58 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1,767 1
Jul-Dec 1997	1,542 107 115 129 133 133 139 143 144 143 144 144 145 146 147 148 149 149 149 149 149 149 149 149 149 149
Metropolitan area	Atlanta

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates 1 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, LSD = lysergic acid diethylamide. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ERIC

#### Table 3.22 - LSD: ED mentions: Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
TOTAL COTERMINOUS U.S.	5,158				•		•	2,821	-45.3	-45.0	
Atlanta	217										
Baltimore	82									45.3	40.8
Boston	108										
Buffalo	7									-61.5	233.3
Chicago	255								-72.9	-50.0	40.0
Dallas	107									-59.0	
Danver	92									-50.6	-32.8
Detroit	8									-76.2	-57.1
Los Angeles	208	260	216	186	162	229	217				-19.4
Miami	74								-		
Minneapolis	89								-78.7	-70.3	-67.2
New Orleans	26									-76.3	-48.6
New York	150								-58.7		
Newark	32										
Philadelphia.	113										
Phoenix										-60.3	-5 <del>4</del> .1
St Louis											
San Diego	47									-66.2	-54.2
San Francisco.									-68.9	-16.4	-31.3
Seattle										48.8	42.1
Washington, DC										-71.3	-44.4

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, LSD = lysergic acid diethylamide. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ED Trends From DAWN

T-147

#### Table 3.23 - PCP: ED mentions: Estimates by metropolitan area by half year

% change <sup>1</sup> H1 2001, H1 2002			280.0	-53.0 -53.0		-100.0	:					30.5	2		76.5		-63.0	63.3
% change   9 H2 2001, H1 2002		23.5		-31.3		-100.0		-71.4			_	39.8	?		42.9	'	-79.3	
Jan-Jun * 2002	3,257	4	<u></u> 6 c	244	59	0	543	N	36	0 (	200	569	32	46	30	35	17	351
Jul-Dec 2001	3,028	18	8 2	355	20	<u>*</u>	528	7	12	m 6	0 <del>L</del>	407	27	2	21	41	82	311
Jan-Jun 2001	3,074	1 4	<u>.</u> 5	519	46	4 5	462	7	13	2 5	5 4	378	용	39	17	35	46	215
Jul-Dec 2000	2,798	: <del>8</del>	- 1	574	· 62	<u> </u>	367	7	<u>σ</u>	. c	2 8	370	20	39	4	33	22	179
Jan-Jun 2000	2,607	40.		4.		0 1	456					233	27	용	23	37	61	138
Jul-Dec 1999	2,057	- <del>2</del> 2	N 0	330	<u>&amp; &amp; </u>	<u> </u>	376	<u> </u>	2 5	2 €	:	253	21	13	15	37	35	74
Jan-Jun 1999	-	- 2,		301		: <del>E</del>	355	က	9 (	149	9	327	18	4	52	25	12	103
Jul-Dec 1998	1,711	27.	- 0	195	**	: 00	346	: `	4 0	25.0	:	230	19	<u></u>	32	50	6	72
Jan-Jun 1998	1,725	385	<u> </u>	157	77	, <u>C</u>	259	<u> </u>	<u>უ ი</u>	136	:	283	28	10	21	47	28	98
Jul-Dec 1997	1,760	8 6	2 20	242	<u>5</u> 5	2 :	340	- ;	- 7	114	m	247	23	67 7 7	45.5	61	22.5	æ
Metropolitan area	TOTAL COTERMINOUS U.SAtlanta	Baltimore	Buffalo.	Chicago	Derver	Detroit	Los Angeles.	Minneanolie	New Orleans	New York	Newark	Philadelphia	Phoenix	OL COUIS	San Diego	Sall rightisco	Workington DO	Washington, DC

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, PCP = phencyclidine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 3.24 - PCP: ED mentions: Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change¹ 2000, 2001
TOTAL COTERMINOUS U.S.	5,899	5,963	3,441	3,626	3,436	3,663	5,404	6,102		9.99	
Atlanta	35	4	25			28		35			
Baltimore	309	222	98			45		75		66.7	
Boston	49	8	18			7		23	-53.1	228.6	109.1
Buffalo	9	9	2			<del></del>		n		200.0	-70.0
Chicago	780	873	537			631	_	874		38.5	
Dallas	27	65	56			95		96	255.6		
Denver	œ	6	7			÷		7		:	
Detroit	26	20	21			24	21	38			
os Angeles.	1,098	1,266	200		605	731	823	066			
Mami	2	00	15			6	15	o			
Minneapolis	σ0	:	80			18	20	24	•		
New Orleans	74	9	27			16	16	æ		-50.0	
New York	852	697	229			278	237	203			
Newark	17	42	13			15	39	35	105.9	133.3	
Philadelphia.	431	296	367			280	604	785		35.3	30.0
Phoenix	16	23	31			39	47	61		56.4	
St. Louis	92	2	29			26	74	110		323.1	
San Diego.	2	58	ষ্ঠ			37	36	38			
San Francisco.	131	89	158			62	02	92		22.6	
Seattle	20	36	20			47	116	128	540.0	172.3	
_	1,301	868	347			176	317	525		198.3	65.6

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department, PCP = phencyclidine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 3.25 - Miscellaneous hallucinogens: ED mentions: Estimates by metropolitan area by half year

% change <sup>1</sup> H1 2001,	
% change <sup>1</sup> H2 2001, H1 2002	
Jan-Jun * 2002	020 7 88 11 22 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1
Jul-Dec 2001	22 122 18 18 18 18 18 18 18 18 18 18 18 18 18
Jan-Jun 2001	817 13 9 9 9 13 13 13 14 14 14 14 14 14 14 14 14 14 14 14 14
Jul-Dec 2000	800,1 8 0 0,1 8 0,1 1 1 1 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1
Jan-Jun 2000	797 100 100 100 100 100 100 100 100 100 10
Jul-Dec 1999	960 233 161 191 192 193 193 193 193 193 194 195 195 195 195 195 195 195 195 195 195
Jan-Jun 1999	573 8 : 2 1 2 4 2 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Jul-Dec 1998	88 8 8 8 8 8 8 7 7 7 7 8 8 8 8 8 8 8 8 8
Jan-Jun 1998	863 : : 14 14 14 14 14 14 14 14 14 14 14 14 14 1
Jul-Dec 1997	845 29 25 11 11 16 16 17 17 17 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18
Metropolitan area	Atlanta. Atlanta. Bastimore. Boston. Buffalo. Chicago. Dallas. Detroit. Los Angeles. Miami. Minneapolis. New York. New York. Philadelphia. Phoenix. San Diego. San Diego. Santie. Washington, DC.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

ERIC

weropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change 1994, 2001	% cnange 1999, 2001	% cnange 2000, 2001
TOTAL COTERMINOUS U.S.	1,577	1,463	1,600	1,629	1,849	1,533	1,849	1,788			
Atlanta	:	7	4	13		2	7	j		1	I
Baltimore	8	9		S			80	2	-37.5	-54.5	-37.5
Boston	44	27		31		39	25	31			
Buffalo	_	9		S		7	_	0	•	-100.0	-100.0
Chicago	4	38	33	45	29	32	45	22	-50.0		-51.1
Jallas	2	7		21		7	12	፡			
Denver	38	30		18	19	27	15	32			113.3
Detroit	=	80		•		16	2	10			
os Angeles	30	26		59	33	42	88	86	186.7		
Miami	9	S		4	9	9	80	CZ.			
Minneapolis	:	:		39	20	31	46	20	:		
New Orleans	7	:	4	_	4	:	5	4			
New York	4	22	22	13	80	:	10	9	-85.4		
Newark	23	9	:	:	0	10	:	:	:	:	
Philadelphia	12	27	36	36	22	53	38	27		-49.1	
Phoenix	80	7	10	23	က	71	53	25	212.5	-64.8	-52.8
St. Louis	15	:	1	13	:	12	2	:			
	56	23	29	17	34	22	27	10		-54.5	-63.0
San Francisco	18	4	52	24	23	15	33	42	133.3	180.0	
Seattle	74	41	09	53	45	48	37	72		50.0	94.6
Washington, DC		:	:	13	21	12	:	:			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from ¹ This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to

January-June 2000. ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 3.27 - Flunitrazepam (Rohypnol): ED mentions: Estimates by metropolitan area by half year

% change <sup>1</sup> H1 2001, H1 2002	-100.0	-25.0
% change <sup>1</sup> H2 2001, H1 2002	-100.0	200.0
Jan-Jun * 2002		00 0000
Jul-Dec 2001	140000 10004-0000	:0-000
Jan-Jun 2001	110000 1-0 1400000	004000
Jul-Dec 2000	; ;0000000 ;0000	;0-000
Jan-Jun 2000	100000 100 100000	
Jui-Dec 1999	1 1 100 10000000	
Jan-Jun 1999	; ; 000 ; 000 ; 100000	
Jul-Dec 1998	TOOO   OOO   OOO	000000
Jan-Jun 1998	,0000 ,000 00 -00	0040 10
Jul-Dec 1997	;00000000000000000000000000000000000000	000-0;
Metropolitan area	TOTAL COTERMINOUS U.S Atlanta Battimore Boston Chicago Calias Detroit Los Angeles Miami Miami Misami New Orleans New York New York	Probentx St. Louis San Diego San Francisco Seattle Washington, DC

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 3.28 - Flunitrazepam (Rohypnol): ED mentions: Estimates by metropolitan area by year

% change <sup>1</sup> 2000, 2001	-37.5
% change <sup>1</sup> 1999, 2001	-100.0
% change <sup>1</sup> 1994, 2001	50.0
Total 2001	NOOOO   O NOOO   O NOOO
Total 2000	1 10000400 10 10000 100000
Total 1999	0
Total 1998	1 1 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Total 1997	1 1 0 0 0 1 2 3 3 0 0 0 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1
Total 1996	100 104 1004 1000 1000 1000 1000 1000 1
Total 1995	1000004-0 180 1000-00
Total 1994	
Metropolitan area	TOTAL COTERMINOUS U.S

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant ( $\rho < 0.05$ ) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ED Trends From DAWN

#### Table 3.29 - GHB: ED mentions: Estimates by metropolitan area by half year

Jul-Dec Jan-Jun   % change   % change   % change   2001   H1 2001, H1 2002   H1 2002	2,0	43 11 -73.2 -57.7 43 19 -55.8	
Jan-Jun Ju 2001	1,679 6 20 1 52 7 75 10 22 31		8 22
Jul-Dec 2000	 72 2 2 1 1 1 87 87 9 9 16 9 17		
Jan-Jun 2000	2,865 57 20 20 88 88 112 28 128 128 128 128 128		
Jul-Dec 1999	1,987 613 514 32	4 64 : : : : : : : : : : : : : : : : : :	39
Jan-Jun 1999	1,192 11 13 14 16 16 16 16 17 77	19 29 1 1 1 28 28 5	38 70
Jul-Dec 1998	899 460 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ω <u>\$</u> 4000 <sup>†</sup>	23 59
Jan-Jun 1998	387 333 337 00 00 16 16 16 16 16 16 16 16 16 16 16 16 16	. 6 - 0 · 40	11
Jul-Dec 1997	459 23 26 1 1 26 51 51 51 51	0 10 0 0 0	17 40
Metropolitan area	Atlanta. Atlanta. Baltimore. Boston. Chicago. Dallas. Derver. Detroit. Los Angeles.	Minneapolis. New Orleans. New York. Newark. Philadelphia. St. Louis.	San Diego. San Francisco.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department, GHB = gamma hydroxy butyrate, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 3.30 - GHB: ED mentions: Estimates by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change¹ 2000, 2001
TOTAL COTERMINOUS U.S.	56	145			_						
Atlanta	1-	4	38	72	8	142	129	8	8,300.0		-34.9
Baltimore		0									133.3
Boston	0	0									
Buffalo	0	0									-83.3
Chicago	0	9									-25.2
Dallas	7	37							1,063.6		
Denver	0	0								-77.5	-62.8
Detroit	:	0		:	7						
Los Angeles	27	i	108	:	48				207.4		-44.3
Miami.	0	0	:	2	9						-28.3
Minneapolis	_	0	7	1	80				6,700.0	106.1	
New Orleans	0	_	80	27	35						
New York		0	i	9	5						
Newark	0	0	0	0	0						
Philadelphia	0	0	0	:	i						
Phoenix	0	0	0	က	7	17					
St. Louis.	0	-	0	0	:	89			,	•	;
San Diego.	က	22	37	34	34	77		22		-26.0	
San Francisco	Ŧ	16	78	83	102	138		•	1,336.4	14.5	
Seattle	0	0	က	:	17	34					-31.6
Washington, DC.	0	_	0	0	4	13					
						1					

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

January-June 2000. ED = emergency department, GHB = gamma hydroxy butyrate. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 3.31 - Inhalants: ED mentions: Estimates by metropolitan area by half year

% change	-60.09	-92.0			-100.0
% change <sup>†</sup> H2 2001, H1 2002		254.5			-100.0
Jan-Jun * 2002	Ω.	3000	13	- <del>1</del> 9 <del>6</del> 1 8	: n o :
Jul-Dec 2001	338	120 8 0	: : 4 <b>£</b> c	000 10 10	<u> </u>
Jan-Jun 2001	338	25 25 25 25 25 25 25 25 25 25 25 25 25 2	. <u>: o to c</u>		•
Jul-Dec 2000	576	27 22 5	22440	<u>, 00 0 4 i </u>	<u>ა ←</u> ო <sup>;</sup>
Jan-Jun 2000	946	28 <u>4 8</u>	4500	<u>,                                    </u>	0 4 9 0
Jul-Dec 1999	627	79 T S	<u> </u>	1004454	0 6 7 7
Jan-Jun 1999	rc.	25 4 4 2		10 10	
Jul-Dec 1998	931 11 12 0	<u> </u>	7 2 6 2	005000	<u>7</u> 77 ; €
Jan-Jun 1998	1,280	2228	20 2 2 2 2	: : <b>6</b> 2 4 4	ა <b>ი</b> ი 4
Jul-Dec 1997	1,214	. 4 5 32 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	20 - 13	0000 m 4 m	o ≻ 0 4
Metropolitan area	TOTAL COTERMINOUS U.S. Atlanta. Battimore. Boston.	Chicago. Dallas Denver	Los Angeles Miami Minneapolis. New Orleans.	New York. Newark. Philadelphia. Phoenix. St. Louis.	San Francisco

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

BEST COPY AVAILABLE



Table 3.32 - Inhalants: ED mentions: Estimates by metropolitan area by year

% change¹ 2000, 2001	-55.6	-50.0	-100.0					-73.3							0.05.	9	25.0	
% change <sup>1</sup> 1999, 2001		-66.7	-100.0	-53.5		100	-/8.4	-82.6			-100.0				75.0	2		
% change¹ 1994, 2001	-55.3	-66.7	-100.0	-56.5	-31.8	i.	0.40 U	-81.8		-100.0	-100.0		3	0.18-	O Ca	150.0	275.0	
Total 2001	676	900	50	8	4 0	32	=	: ₹	26	0	6	0	24	4 1	- "	יא כ	15	:
Total 2000	1,522	725	<u>5</u> 4	27	49	<del>1</del> 1	77	3 12	23	0	:	0	32	, ,	- 4	2 4	12	:
Total 1999	1,162		; -	43	53	32	ري م	23.82	24	:	_	i	.83	14	0 5	<u> </u>	<u>, 6</u>	i
Total 1998	2,211	. 22.	- 2	45	4	37	28	3 6	39	80	:	i	27	<u></u> σ τ	- 7	<u> </u>	- 49	15
Total 1997	2,225	: 82 (					: 8			:	<del>-</del>	0	47	12	•	<u> </u>	2 8	4
Total 1996	1,313	<u>, ⇔</u>		49	25	56	20	07	31					9 3		: <	r m	:
Total 1995	1,036	17-	2 23	38	39	25	<u>ල</u> ද	† <sup>80</sup>	25	:	18	0	14	4 (	9	2 °	<u> 1</u>	O
Total 1994	1,511	C 25 i	7	46	99	61	31	3 8	31	က	2	:	22	21	17,	<u>υ</u>	7 4	•
Metropolitan area	TOTAL COTERMINOUS U.S	Atlanta	Boston.	Chicago	Dallas	Denver	Detroit	Los Angeles	Minneapolis	New Orleans	New York	Newark	Philadelphia	Phoenix	St. Louis	San Diego	San Francisco	Washington, DC.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.</p>
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 3.33 - Combinations NTA: ED mentions: Estimates by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001,
TOTAL COTERMINOUS U.S	75	0,	55	42	52	89	59	156	-	118	7007 111	7007
Auanta. Baltimore.	: °	- 0	<del>- 4</del>		00		: °	۱۳	0 6	00		1 5
Boston	<del>-</del> 0		00		<del>-</del> -		N C	<del></del>	ō <del>4</del> €	າທິດ		400.0 0.00
ChicagoDallas.	0 +	10	· ; \	0 4	` ; <sup>u</sup>	•	0	• <u>•</u>	÷ ;	<u></u>		
Denver Detroit	•	<u>.</u> ~	r 6 c	F <sub>i</sub> C		:00	: :	٠ <sub>;</sub> د	1 1	: 50	:	
Los Angeles. Miami	<u>: 0 ç</u>	: :	· 6	<u> </u>		<u>ه</u> : د	0 0	0 10	o :	∾ :		
Minneapolis New Orleans	900	70	001	V 0 1	00	ا ا	00	N <del>L</del>	<del>-</del> :	: :		
New York	P   6	: 2 °	(	= ;		00	<del>- Ω</del>	00	<del>- 0</del>	00	-100.0	
Philadelphia.	50	<u>. 6</u>	۱ ; د	: :	Э <sub>:</sub> '	: :	7 0	<u>o ti</u>	0 80	၀ ဇ္တ	275.0	130.8
St. Louis.	00	4 0	<u>, 0</u>	4 :	00	<del>m 0</del>	ო ო	; ;	90	<del>▼</del> C		
San Diego. San Francisco.	<del>22</del> 3	9 6	: 8	<del>6</del> +	<u>. 1</u>	4 0	<u> 6 7</u>	4 0	א מזי	<u> </u>	0.09	-50.0
Seattle	;0	00	ິຕ ;	· 0 0	90	100	4 :	2 - 0	°∓ :	2 : :	0.90	

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with for Attanta for the period January-June 2001. For the Attanta contribution to the national estimates, data were imputed for Attanta nonrespondents based on actual data from January-June 2000. \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 3.34 - Combinations NTA: ED mentions: Estimates by metropolitan area by year

% change <sup>1</sup> 2000, 2001	700.0	
% change <sup>1</sup> 1999, 2001	700.0	-100.0
% change¹ 1994, 2001	100.0	,
Total 2001	25 8 : 8 : 8 : 8 : 8 : 8 : 8 : 8 : 8 : 8 :	
Total 2000	127	. 2287.3376
Total 1999	4 :- RO : 8 :000	1000 ; in the
Total 1998	20 4 10 180 1 1±	:0410800v1w
Total 1997	10 14 10 14 10 14	0 7 2 0 3 7 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1996	388 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 - 8 : 2 2 0 8 2 0
Total 1995	160 160 160 160 160 160 160 160 160 160	<u>  00   10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 </u>
Total 1994	495 7 7 5 9 9 7 7 18 18 18 18 18 18 18 18 18 18 18 18 18	0 - 1 - 2 0 0 4 : 8 8 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Metropolitan area	TOTAL COTERMINOUS U.S	Winneapolis. New Orleans. New York. Newark. Philadelphia. St Louis. San Diego. San Francisco. Seattle. Washington, DC.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 4.1.0 - ED drug episodes by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>†</sup> H2 2001, H1 2002	% change <sup>†</sup> H1 2001, H1 2002
GENDER Male Female Unknown	133,615 125,639 2,464	141,133 127,809 2,920	140,130 128,402 2,038	145,341 130,452 2,450	146,677 127,531 2,317	154,922 143,181 4,569	154,685 138,612 5,593	164,777 142,265 4,743	168,594 154,048 4,058	161,704 143,883 2,972		-37.3
RACE/ETHNICITY² White White Black Hispanic. Race/ethnicity NTA. Unknown.	140,374 66,853 26,247 2,990 25,254	145,619 69,299 30,084 2,809 24,051	149,727 67,175 27,078 2,574 24,017	158,635 64,339 27,635 2,425 25,210	151,329 68,642 29,206 3,160 24,187	170,906 67,275 33,232 2,511 28,749	163,913 66,460 35,049 2,649 30,819	169,037 71,620 37,014 2,570 31,544	182,208 67,755 42,503 2,639 31,594	172,628 66,764 37,197 2,241 29,728		
AGE 6-17 years	29,426 1,117 28,309 51,996 13,994 38,002	32,990 495 32,496 50,790 14,806 35,983	27,046 458 26,589 52,583 15,255 37,328	29,652 634 29,018 54,114 14,978 39,136	24,218 551 23,666 55,464 14,760	34,182 687 33,495 62,069 17,224 44,845	30,286 337 29,948 61,241 17,134 44,106	32,614 435 32,178 60,395 16,928 43,467	30,094 577 29,517 66,780 17,650 49,130	30,659 813 29,846 65,721 18,246 47,475		
26-34 years	69,980 29,082 40,898 109,553	70,476 29,781 40,696 116,813	67,995 27,552 40,443 122,327	65,729 27,880 37,849 128,358	65,525 25,020 40,505 130,898	68,192 27,286 40,906 137,808	67,272 27,865 39,407 139,475	29,631 42,140 146,186	73,637 31,579 42,058 155,606	68,114 27,389 40,724 143,580	-13.3	
45-54 years 55 years and older Unknown	26,470 8,301 765 261,719	28,763 28,763 9,469 793 271,862	31,438 9,447 619 270,570	35,407 11,673 390 278,243	36,292 10,400 418 276,524	37,668 11,450 422 302,673	41,140 11,969 617 298,890	311,785	95,924 46,913 12,769 582 326,699	85,430 43,733 14,417 485 308,558	n:01-	

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ERIC

Table 4.2.0 - ED drug episodes by patient demographic characteristics: Estimates for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male	263 823	256 049	257 490	260 010	281 262	202.040	200 607	000		,	1
Female	250,182	252,343	250,826	252,035	256 211	257 983	281 793	206.313	4.02	14.2	). 
Unknown	4,875	5,333	5,616	4,864	4,958	4,766	10,162	8,800	80.5	84.6	3.6
RACE/ETHNICITY <sup>2</sup>											
White	278,747	277,538	273,690	284,026	295,346	309.964	334.819	351.245	26.0		
Black	141,351	139,388	135,303	134,895	136,474	132,981	133,735	139,375	2		
Hispanic	50,368	47,354	55,026	52,697	57,162	56,840	68,282	79,517		39.9	
Kace/ethnicity N I A	6,038	5,533	6,020	260'9	5,382	5,585	5,160	5,209			
Unknown	42,377	43,705	43,895	49,102	48,068	49,397	59,568	63,138	49.0	27.8	
AGE	_										
6-17 years	61,294	62,219	65,051	63.157	60.037	53 870	64 467	62 ZOB		7 47	
6-11 years	1,00,1	1,503	1,175	1,727	952	1,185	1.024	1013	•	<u>†</u>	
12-17 years	60,293	60,715	63,876	61,429	59,084	52,685	63,443	61,695		17.1	
18-25 years	112,273	103,704	98,614	104,630	103,373	109,579	123,310	127,175		16.1	
18-19 years	27,863	28,543	26,863	29,276	30,062	29,738	34,359	34,578	24.1	16.3	
20-25 years	84,410	75,161	71,751	75,354	73,311	79,841	88,951	92,597		16.0	
26-34 years	151,419	143,930	139,545	138,890	138,471	131,254	135,464	145,408			
Z6-29 years.	61,825	58,796	26,006	57,044	57,332	52,900	55,151	61,210			11.0
30-34 years.	89,594	85,135	83,539	81,846	81,138	78,354	80,314	84,198			
35 years and older	190,446	202,287	209,864	218,422	239,140	259,256	277,283	301,792	58.5	16.4	8.8
35-44 years	132,312	142,339	143,731	147,533	160,025	165,483	175,055	187,213	41.5	13.1	6.9
45-54 years	42,012	44,752	49,379	54,388	60,200	71,699	78,808	88,542	110.8	23.5	12.4
55 years and older	16,121	15,196	16,754	16,502	18,915	22,074	23,420	26,036	61.5		11.2
Unknown	:	1,379	829	1,719	1,412	808	1,038	1,401		73.2	!
TOTAL DRUG ABUSE EPISODES	518,880	513,519	513,933	526,818	542,432	554,767	601,563	638,484	23.1	15.1	6.1

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the penod January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 4.2.1 - ED drug episodes by patient demographic characteristics: Estimates for Atlanta by year

		•						•			
Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER  Male Female Unknown	6,823 3,737 100	6,926 4,059 78	5,626 3,717 57	4,647 3,302 54	6,250 4,420 47	5,822 4,323 44	6,490 4,425 198	8,726 5,571 159	49.1	49.9 28.9 261.4	34.5
RACE/ETHNICITY <sup>2</sup> White	2,585 5,920	2,932 5,989	2,987	3,004 3,516	4,246 5,446	4,275 5,068	4,139 6,086	4,159 8,055	6.09	58.9	32.4
Hispanic	. 20 20 31	103 57 	39 39 39	\$ PC :	100 79 845	130 67 	164 51 672	137 71 2,034	158.5	:	39.2 202.7
AGE 6-17 years	609	636	609	671	760 4 755	602	564	694 ::			
18-25 years. 18-19 years.	1,689	1,809	1,556	1,332	1,720	1,715	1,716	2,211	30.9	28.9	28.8 12.2
20-25 years	1,323 3,848 1,341	1,434 3,792 1,407	1,190 2,921 1,013	954 2,455 947	1,268 3,172	1,264	1,291 2,658	1,733 3,410	31.0	37.1	34.2 28.3
30-34 years	2,507	2,385	1,908	1,508	1,932	1,588	1,639	2,097	81.5	32.1	27.9
35-44 years	3,472 823 142	3,674 896 220	3,208 900 190	2,577 749 191	3,553 1,204 279	3,434 1,329 295	4,076 1,707 359	5,305 2,397 348	52.8 191.3	54.5 80.4	30.2
Unknown	11	35	15	28	30	23	33	06		291.3	172.7
TOTAL DRUG ABUSE EPISODES	10,660	11,063	9,400	8,003	10,717	10,189	11,112	14,456	35.6	41.9	30.1

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



Table 4.2.2 - ED drug episodes by patient demographic characteristics: Estimates for Baltimore by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER	,										
Male	9,728	9,738	9,623	7,506	8,083	8,249	6,710	6,855	-29.5	-16.9	2.2
Female	5,999	6,112	6,280	5,148	5,547	5,825	4,658	4,605	-23.2	-20.9	
Unknown	135	116	91	102	107	6	136	165	22.2	70.1	21.3
RACE/ETHNICITY <sup>2</sup>											
White	3,779	3,774	3,842	4,227	4.811	5.158	4.960	5233	38.5		r.
Black	11,815	11,883	11,641	8,103	8,398	8,397	5,986	5,270	-55.4	-37.2	-12.0
Hispanic	20	52	86	22	49	Ŗ	37	61	22.0	13.0	6,49
Race/ethnicity NTA	တ္တ	24	37	20	43	63	31	25	0.06	-9.5	83.9
Unknown.	189	230	377	320	434	499	491	1,003	430.7	101.0	104.3
AGE						•					
6-17 years.	574	581	540	772	721	738	716	744	29.6		8
6-11 years	13	18	16	12	18	21	16	20	53.8		9
12-17 years	561	563	524	760	703	717	700	724	29.1		3.4
18-25 years	2,284	2,227	2,048	1,785	2,015	2,100	1,913	2,052			7.3
18-19 years	306	343	377	374	476	488	485	540	76.5	10.7	11.3
20-25 years	1,978	1,884	1,671	1,411	1,538	1,612	1,429	1,512	-23.6	-6.2	2.8
26-34 years	5,831	5,839	5,608	3,998	4,134	4,131	3,093	2,956	-49.3	-28.4	4.4
26-29 years	2,193	2,216	2,110	1,526	1,529	1,482	1,084	1,086	-50.5	-26.7	
30-34 years	3,638	3,623	3,498	2,472	2,605	2,649	2,010	1,870	-48.6	-29.4	-7.0
35 years and older	7,147	7,301	7,772	6,175	6,827	7,171	5,761	5,843	-18.2	-18.5	
35-44 years	5,551	5,582	5,803	4,505	4,853	5,043	4,008	3,943	-29.0	-21.8	
45-54 years	1,355	1,466	1,668	1,413	1,696	1,823	1,525	1,590	17.3	-12.8	4.3
55 years and older	241	253	301	257	278	305	228	310	28.6		36.0
Unknown.	27	17	56	22	38	30	21	29			38.1
TOTAL DRUG ABUSE EPISODES	15,863	15,966	15,994	12,755	13,736	14,171	11,505	11,625	-26.7	-18.0	
			1								

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 4.2.3 - ED drug episodes by patient demographic characteristics: Estimates for Boston by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male	8,107	8,548	7,085	6,061	7,395	6,479	8,286	9,742		50.4	17.6
Female	7,052 215	7,198	6,234	5,967	6,140	5,136 54	6,434	6,918 193		34.7 257.4	
RACE/ETHNICITY <sup>2</sup> White	10,416	11,114	9,056	8,304	9,153	7.818	9.514	10.843		38.7	14.0
Black Hispanic	2,038	1,781	1,477	1,129	1,478	1,529	1,823	2,014	58.7	31.7	10.5 35.4
Kaceleunicity N I A	136 1,855	135	2,050	131 2,012	121 2,055	1,411	108 2,368	100			
AGE											
6-17 years	1,217	1,379	1,249	1,163	1,103	800	1,185	1,115			
12-17 years.	1,213	1,354	1,198	1,151	1,09	781	1,163	1,092	7.999		
18-25 years	2,871	2,948	2,556	1,998	2,562	2,240	2,911	3,307		47.6	13.6
20-25 years.	2,232	2,228	1,916	1,510	1,819	1,635	2,181	2,509		53.5	15.0
26-34 years	5,251	5,224	4,148	3,301	3,831	2,964	3,881	4,213		42.1	8.6
30-34 years	3,157	3,226	2,639	2.013	2.463	1.805	2.360	2.499		47.9 38.4	12.7
35 years and older	5,980	6,466	5,557	5,732	6,128	5,623	6,902	8,185		45.6	18.6
35-44 years	4,363	4,686	3,966	3,971	4,272	3,890	4,611	5,276		35.6	14.4
45-54 years	1,182	1,386	1,195	1,378	1,541	1,424	1,856	2,416	104.4	69.7	30.2
Unknown	55.	9	27	3 25	£ 8	42	23	T C C		n. n.	
TOTAL DRUG ABUSE EPISODES	15,374	16,067	13,537	12,224	13,657	11,669	14,902	16,853		4.44	13.1

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>&</sup>lt;sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 4.2.4 - ED drug episodes by patient demographic characteristics: Estimates for Buffalo by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male Female	1,556 1,162 27	1,566 1,128	2,229 1,346 13	1,790 1,015 8	1,584 1,079 20	1,694 994 23	1,772 1,052 75	2,193 1,137 27			64.0
RACE/ETHNICITY² White White Black Hispanic Race/ethnicity NTA.	1,226 1,144 231 23 122	1,200 1,201 181 161	1,373 1,874 165 20 155	1,224 1,360 153 25	1,325 1,118 146 20 75	1,420 860 283 20 127	1,554 808 376 19	1,683 1,135 371 12	60.6	31.1	40.5 -36.8
AGE 6-17 years. 6-11 years. 12-17 years. 18-25 years. 20-25 years. 26-34 years. 26-34 years. 30-34 years.	171 170 170 141 392 970 970 564 696	188 186 527 102 424 910 368 542 1,083	243 240 240 521 113 1,235 444 792 1,585	188 100 1100 317 882 379 503 1322	200 194 107 107 128 128 128 128 128 128	138 138 103 103 794 782 1380	113 110 110 110 110 110 110 110 110 110	125 122 122 122 122 1303 1303 1400 1500 1500 1500 1500 1500 1500 1500	-26.9 -27.1 -13.5 -26.4	-9.4 -10.1 31.7 36.5	10.6 -50.0 12.7 17.3
35-44 years	780 237 52 2 2 2,745	810 220 53 6 2,714	1,179 337 69  3,587	969 291 62 2 2	927 279 82 4 2,683	929 333 118 7 2,711	959 474 112 11 2,899	1,187 132 132 6 3,356	145.1 153.8 200.0	74.5	45.

<sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

Indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studles, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 4.2.5 - ED drug episodes by patient demographic characteristics: Estimates for Chicago by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female	12,803 8,514	12,939	13,373 9,934	15,397	15,202	15,440	17,568	19,032	48.7 57.1	23.3	
Unknown	166	166	215	135	117	187	422	242	45.8		42.7
RACE/ETHNICITY <sup>2</sup> White	6,166	5,761	5,943	5,949	6,842	6,508	6,764	2,066			
Black. Hispanic.	10,989	11,291	12,282 3,550	15,003	13,538	13,228	3.910	14,959	84.5	33.3	
Race/ethnicity NTAUnknown	171	228	171	174	184	175 2,937	141	196 6,018	240.2	104.9	39.0
AGE 27 com	4	7	7	6	7	7	7	-	_		
6-11 years	22	37	3 4	29	36,,	- 62 - 7	22/1	35			
12-17 years	1,493	1,707	1,742	1,844	1,716	1,602	1,708	1,697		0	
18-19 years.	7967	4, 146 872	764	4,100 826	991	918	1,219	1,080	35.7	17.6	-11.4
20-25 years	3,507	3,274	3,262	3,340	3,141	2,869	3,555	3,661		27.6	
26-29 years	3,126	2,849	3,173	3,266	3,131	2,843	2,899	3,047		-	
30-34 years	4,342	4,161	4,382	4,913	4,773	4,395	4,792	5,002		13.8	
35 years and older	8,149 6,196	8,951 6,634	10,077	12,569	12,365	13,460	16,102	18,082	121.9	84 S	12.3 12.4
45-54 years	1,446	1,834	2,115	2,913	2,994	3,689	4,771	5,185	258.6	40.6	į
55 years and older	507 50	88 33 E	555 80	695 88	630 52	757 38	31	1,155	127.8	52.6	30.7
TOTAL DRUG ABUSE EPISODES	21,484	21,883	23,522	26,875	26,206	26,154	30,327	32,647	52.0	24.8	

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

T-166

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

indicate that an estimate with an RSE greater than 50% has been suppressed.

#### Table 4.2.6 - ED drug episodes by patient demographic characteristics: Estimates for Dallas by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER	7370	000	64.0	000	720		100	0,00	, , ,		
Wale	4, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	2,303	2,179	2,900	2,057	4,054	3,3/5	3,103	44.1		
remale	2,970	018,2	79/7	3,2/4	3,518	3,174	3,397	3,362			
Unknown	``	91	29	20	29	17	24	35			
RACE/ETHNICITY <sup>2</sup>					•						
White	2,907		2,617	3,229	4,053	3,340	3,587	3,557	22.4		
Black			1,113	1,403	1,830	1,659	1,835	1,656			
Hispanic	663	612	717	791	906	992	984	855			
Race/ethnicity NTA	88		99	02	119	82	72	88			
Unknown	9/	i	:	:	290	397	309	345	353.9		
AGE											
6-17 years	739	998	832	924	965	775	840	825			
6-11 years	29	13	16	:	10	:	11	80	-72.4		
12-17 years	710	853	817	919	955	770	829	817			
18-25 years	1,312	1,356	1,198	1,593	1,797	1,531	1,735	1,622	23.6		
18-19 years	373	323	8	520	209	396	497	453			
20-25 years	939	1,033	857	1,072	1,288	1,135	1,237	1,170	24.6		
26-34 years	1,590	1,468	1,381	1,625	1,884	1,599	1,765	1,550			-12.2
26-29 years	969	634	636	711	848	718	191	629			-14.1
30-34 years	894	834	745	914	1,035	882	866	891			-10.7
35 years and older	1,494	1,533	1,552	2,045	2,544	2,338	2,446	2,477	65.8		
35-44 years	1,024	1,080	1,131	1,424	1,838	1,605	1,672	1,566	52.9		
45-54 years	335	355	326	491	261	265	209	683	103.9	15.4	12.5
55 years and older	135	66	96	130	145	141	166	228	9.69	62.4	38.0
Unknown	7	:	12	7	80	;	:	25	257.1	:	:
TOTAL DRUG ABUSE EPISODES	5,141	5,230	4,975	6,194	7,198	6,245	6,796	6,500	26.4		

1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

indicate that an estimate with an RSE greater than 50% has been suppressed. ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

. ED

#### Table 4.2.7 - ED drug episodes by patient demographic characteristics: Estimates for Denver by year

Demographic characteristics	Totai 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female Unknown.	2,417 2,389 145	2,258 2,260 87	1,632 1,745 39	2,229 2,050 53	2,223 1,821 42	2,578 2,188 48	2,567 2,327 50	2,908 2,479 81	4	12.8 13.3 68.8	13.3 6.5 62.0
RACE/ETHNICITY² White Black Hispanic Race/ethnicity NTA Unknown	2,276 551 871 90 1,164	1,555 335 558 63 2,095	1,223 269 389 26 1,510	1,777 331 614 63 1,547	1,773 427 729 68 1,089	1,909 315 650 59 1,882	1,877 237 709 33 2,087	2,101 404 817 2,100		25.7	11.9 70.5 15.2 42.4
AGE 6-17 years	614	633	516	540	445	490	634	692		41.2	1.0
12-17 years. 18-25 years. 18-19 years. 20-25 years.	1,140 281 860	617 1,036 272	499 720 192 528	53.1 89.1 256 635	436 867 223	482 1,038 285 753	625 1,038 264	683 1,248 323		41.7 20.2 13.3	20.2 20.2 22.3 25.3
26-34 years. 26-29 years. 30-34 years. 35 years and older.	1,447 610 836 1,743		923 392 531	1,181 512 669 1,716	1,004 428 576 1,767	1,152 484 668 668	1,155 497 658	1,303 562 740		13.1 16.1 10.8	12.8 13.1 12.5 5.5
35-44 years. 45-54 years. 55 years and older. Unknown.	1,266 347 130 7		867 287 97 5	1,147	1,197	1,364 610 138 22	1,289 648 173 8	1,408 636 166 17	83.3	20.3	112.5
101At Dade Abose Frisches		4,000	3,416	4,332	4,087	4,815	4,944	5,468		13.6	10.6

1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 4.2.8 - ED drug episodes by patient demographic characteristics: Estimates for Detroit by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female Unknown	10,390 7,194 69	11,173 7,387 66	12,410 8,300 86	10,464 7,094 46	10,532 6,850 95	9,417 6,598 110	9,883 6,983 177	10,662 8,503 100		28.9	21.8 -43.5
RACE/ETHNICITY² White Black	5,917	5,758	6,283	5,636 11,161	5,360	4,566 9,486	4,772	5,812 11,507		21.3	21.8
Hispanic Race/ethnicity NTA Unknown	102 48 594	83 50 659	111 41 939	85 36 687	132 52 1,655	134 40 1,899	88 34 1,590	106 49 1,791	201.5		44.1
AGE 6-17 years	1,033	1,067	1,061	806	732	734	760	985	,		29.6
0-11 years	994	1,040	1,039	785 7460	723 2375	728	747	974	4.4.4	26.9	30.4 24.6
18-19 years. 20-25 years.	2.104	2.037	632	584 1.875	1.760	522 1.512	534	1.952		29.1	26.8
26-34 years. 26-29 years. 30-34 years.	5,142 2,052 3,090	5,037 1,809 3,228	5,438 1,976 3,462	4,175 1,495 2,680	4,032 1,426 2,606	3,392 1,360 2,031	3,372 1,261 2,111	3,613 1,448 2,165			
35 years and older	8,708 6,258 1,893 556 35	9,767 6,912 2,235 620 17	11,661 8,123 2,868 669 43	10,151 6,609 2,801 742 12	10,319 6,469 3,087 763 20	9,957 5,840 3,342 775	10,818 6,083 3,817 918 18	12,081 6,206 4,674 1,201	146.9 116.0 -88.6	39.9 55.0	22.5 30.8 -77.8
TOTAL DRUG ABUSE EPISODES	17,653	18,626	20,796	17,604	17,477	16,125	17,042	19,265			

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed. ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

207

Table 4.2.9 - ED drug episodes by patient demographic characteristics: Estimates for Los Angeles by year

										i	
Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994,	% change <sup>1</sup> 1999,	% change <sup>1</sup> 2000,
									2001	2001	2001
GENDER											
Male	_	10,380	10,838	9,232	9,691	11,806	14,542	14,925	47.7	26.4	
Female	<u>∞</u>	8,604	9,239	7,823	7,266	8,713	10,294	9,442			
Unknown	291	275	197	133	146	158	450	302		91.1	
RACE/ETHNICITY <sup>2</sup>											
White	608'9	7,227	7.502	6.677	5.920	6 443	7 398	6.640			
Black			4,772	3,812	4.936	6.142	7,635	7 323			
Hispanic		5,762	6,313	5,164	4,858	5,759	7,430	7.568		31.4	
Kace/ethnicity NTA		702	724	624	510	409	623	480			-23.0
Unknown	902	857	964	910	879	1,924	2,200	2,657	194.6		
AGE			-								
6-17 years.	1.900	1.804	1.752	1.497	1 253	1 508	1 024	1 001		7 90	
6-11 years		48	50	39	27	38	4	- T		7.02	
12-17 years	1,835	1,756	1,732	1.458	1.225	1470	1 871	1 866		0 90	
18-25 years		4,135	4,545	3,655	3,134	3,810	4.745	4.928		20.3	
18-19 years		1,013	1,175	980	843	897	1.204	1.208		34.7	
20-25 years	3,215	3,122	3,370	2,675	2,291	2,914	3.541	3,720		27.7	
26-34 years.	5,604	5,292	5,683	4,685	4,367	4,595	5,765	5,501		19.7	
26-29 years	2,518	2,355	2,447	2,129	1,780	1,928	2,475	2,275			
30-34 years	3,086	2,937	3,236	2,556	2,586	2,667	3,290	3,227		210	
35 years and older	7,494	7,986	8,249	7,320	8,338	10,752	12,812	12,322	64.4	!	
35-44 years	4,884	5,158	5,192	4,517	4,896	6,013	7,063	6,754	38.3		
45-54 years	1,828	1,943	2,178	2,039	2,541	3,370	4,156	4,126	125.7	22.4	
so years and older	782	884	879	765	901	1,369	1,593	1,442	84.4	i	
Unknown	22	41	46	90	12	=	40	16	-70.4		
TOTAL DRUG ABUSE EPISODES	19,250	19,258	20,275	17,187	17,103	20,677	25,286	24,669		19.3	
		-	_	-	-		-	=		_	

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

#### Table 4.2.10 - ED drug episodes by patient demographic characteristics: Estimates for Miami by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female	3,267 2,585 56	3,552 2,812 52	3,557 2,666 60	3,674 2,562 46	3,856 2,546 24	4,418 2,683 27	5,398 3,112 49	5,627 3,220 38	72.2 24.6 -32.1	27.4	
RACE/ETHNICITY² White	2,099 2,545 1,134 27	2,225 2,768 1,341 17 66	2,319 2,477 1,305 18	2,363 2,431 1,221 28 240	2,493 2,538 1,110 17	2,728 2,924 1,148 13	3,485 3,264 1,552 22 236	3,475 3,483 1,726 193	65.6 36.9 52.2 89.2	27.4 19.1 50.3	11.2 -63.6 -18.2
AGE 6-17 years 6-11 years. 12-17 years. 18-25 years 20-25 years 26-34 years 30-34 years 35-49 years 35-49 years 35-49 years 35-49 years	425 4 4 4 21 1,077 229 849 1,866 1,741 1,795 503	457 1,221 318 903 1,942 1,942 1,59 1,927 589	490 11 478 1,099 288 288 811 1,1857 1,143 2,804 1,937 641	356 348 348 1,001 240 761 1,835 687 1,148 3,037 2,117 702	324 7 317 941 196 1737 627 1,110 3,401 864	342 336 336 205 814 1,882 673 1,209 2,505 2,505 2,505 2,505 1,049	477 477 1,400 348 1,052 2,056 7,259 4,594 2,964 1,332	463 11 452 1,434 345 1,089 2,090 823 1,266 4,866 3,112 1,433	33.1 50.7 28.3 12.0 11.1 11.1 12.5 94.0 73.7 184.9	35.4 4.00.0 34.0 68.3 33.8 2.2 2.2 36.0 36.0 36.0 36.0 37.0 36.0 36.0 36.0 36.0 36.0 36.0 36.0 36	120.0
55 yea's and older	224 21 5,908	_	226 33 6,283	219 52 6,283	263 20 6,426	301 31 7,128	2.98 33 8,560	340 15 8,886	51.8 -28.6 50.4	-51.6 24.7	-54.5

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

.. :..

### Table 4.2.11 - ED drug episodes by patient demographic characteristics: Estimates for Minneapolis by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female	1,736 2,588	1,693	1,977	2,219	1,843	1,987	2,243	2,937	69.2	47.8	30.9
Unknown	40	27	42	33	37	42	02	53			į
White	2,963	3,123	3,306	3,369	2,846	3,006	3,130	3,650			
Hispanic	કુ <u>કુ</u>	4/1 66	614 90	636 65	624	565 92	409	624			52.6
Race/ethnicity NTAUnknown	170	180	187	202	45°	178	107	170	,	1	58.9
AGE	3	3	3	3	670	200	<del>†</del>	06.	1.827	146./	35.3
	889	1,021	897	1,003	729	901	1.012	1.172	31.8	30.1	15.8
6-11 years.	-	5	17	15	:	:	4	19	72.7	;	375.0
12-17 years	878	1,011	881	987	719	887	1,008	1,153	31.3	30.0	14.4
18-19 years	417	337	382	1,259	1,015	1,116	1,433	1,716	45.3	53.8	19.7
20-25 years	764	705	<u>8</u>	825	679	811	971	1.168	52.9	44.0	20.0
26-34 years	1,042	1,023	1,137	1,042	1,004	1,013	1,022	1,331	27.7	31.4	30.2
30-34 years.	295	288	670	639	542	580	602	608	35.1	40.4	44.5 1.1
35 years and older	1,243	1,236	1,563	1,651	1,579	1,603	1,714	2,292	<b>8</b>	43.0	33.7
35-44 years	878	829	1,090	1,134	1,039	1,047	1,134	1,418	61.5	35.4	25.0
40-04 years and older	240	538	368	402	409	437	470	200	194.2	61.6	50.2
Unknown.	5	2	<u>5</u> 4	<u> </u>	132	5 5	110	891		41.2	52.7
TOTAL DRUG ABUSE EPISODES	4,364	4,325	4,828	4,957	4,328	4,643	5,197	6,521	49.4	40.4	25.5

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 4.2.12 - ED drug episodes by patient demographic characteristics: Estimates for New Orleans by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Nale	2.973	3.641	3.600	3,322	3,347	3,022	3,103	2,283	-23.2	-24.5	-26.4
Female	1,721	2,186	2,198	1,870	1,720	1,425	1,553	1,413		175.0	312.5
RACE/ETHNICITY <sup>2</sup>	100 4	100	776	000	7457	1 000	101	, ,			
White	2,822	3,403	3,346	3,048	2,834	2,446	2,642	1,780	-36.9	-27.2	-32.6
Hispanic	27	54.	99	8 1	15 £		42	S C		41.8	
Kace/eunicity N I A. Unknown.	290	, : <b>Z</b>	5.5	89	38.5	17	51	240		1,311.8	370.6
AGE				ĺ					ļ		;
6-17 years	319	398	397	286	285	185	200	135	-57.7		-32.5
6-11 years. 12-17 years.	312	38 13	397	279	784	179	: 61	-: <del>1</del> 34	-57.1	-25.1	-29.8
18-25 years.	916		1,288	1,133	1,145	1,108	1,262	966			-21.1
18-19 years	208		291	330	275	258	297	210		-18.6	-29.3
20-25 years	708		997	80.	871	820	4 6	786			-18.5
20-34 years			616	56.	556	391	528	395	-32.2		-25.2
30-34 vears	806	1,031	978	897	786	639	547	451		-29.4	-17.6
35 years and older	2,011	2,604	2,546	2,318	2,309	2,132	2,123	1,730			-18.5
35-44 years	1,402	1,741	1,732	1,594	1,583	1,412	1,322	1,002	-28.5	-29.0	-24.2
45-54 years	415	653	617	602	269	574	627	545			
55 years and older55	<u>\$</u>	210	197	123	157	146	174	183			
Unknown	0	12	18	7	_	4	፥	23		475.0	:
TOTAL DRUG ABUSE EPISODES	4,737	5,867	5,844	5,209	5,088	4,459	4,664	3,729	-21.3		-20.0

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 4.2.13 - ED drug episodes by patient demographic characteristics: Estimates for New York by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000,
GENDER Male Female	29,486 13,225 269	28,280 12,109 403	27,728 12,321 420	25,859 10,959 293	24,736 11,156 249	20,772 9,665 225	21,903 9,630 349	22,610 9,426 271			
RACE/ETHNICITY² White White Black Hispanic Race/ethnicity NTA	6,892 18,182 10,477	7,105 16,899 9,603 359	6,634 17,373 8,886 350	6,651 17,285 8,265 354	6,781 16,574 9,373 326	6,055 13,118 7,762 446		5,860 12,348 8,585 368	-32.1		, 100 100 100 100 100 100 100 100 100 10
AGE	7,162	6,826	7,226	4,556	3,086	3,280	4,709	5,146	-	56.9	
'n	1,106	1,125	1,070	1,145	832	907	892	761	-31.2		-14.7
18-25 years	4,566 603	1,093 4,470 695	1,038 4,457 868	1,116 4,131 837	814 4,030 835	889 3,721 800	3,684 839	746 3,870 847	-31.2		
26-34 years	3,963 14,973 5,453 9,520	3,775 13,420 4,890 8,531	3,589 13,184 4,709 8,474	3,293 12,184 4,340 7,844	3,195 11,513 3,749 7,763	2,921 8,773 2,671 6.103	2,845 8,154 2,497	3,023 7,858 2,438 5,420	-23.7 47.5 -55.3		
35 years and older	22,273 15,883 5,281 1,109	21,731 15,300 5,317 1,113 45	21,696 15,155 5,495 1,046	19,590 13,666 4,937 987	19,719 13,516 4,898 1,304	17,221 11,482 4,593 1,147	19,112 12,469 5,262 1,381	19,747 12,632 5,661 1,454	;	23.3	
TOTAL DRUG ABUSE EPISODES	42,980	40,792	40,468	37,111	36,141	30,662	31,882	32,307	-24.8		

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 4.2.14 - ED drug episodes by patient demographic characteristics: Estimates for Newark by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female Unknown	5,696 3,663 35	6,456 4,291 	5,794 3,943 	5,292 3,556 45	5,203 3,683 58	4,897 3,392 12	4,487 3,197 62	4,183 2,938 96	174.3	-13.4	1.8
RACE/ETHNICITY² White Black Black Hispanic Race/ethnicity NTA. Unknown.	2,661 5,251 770 30 681	2,604 5,828 954 48 1,437	2,247 5,432 875 22 1,333	1,152 4,881 1,121 1,726	1,024 4,702 957 11 2,250	1,425 4,408 930 43 1,494	1,505 3,953 958 91,323	1,622 3,402 900 7 1,286	-76.7	-22.8	-13.9
AGE 6-17 years 6-11 years 12-17 years 18-25 years		508 1,994 343 1,254	439 1,669 290 290	478 1,149 228 921	430 427 1,139 245 894	346 1,155 254 901	364 362 1,132 303	318 314 1,094 253 841	4 4 9.00		
20-25 years	3,574 1,598 1,973	1,001 4,127 1,772 2,355	3,816 1,668 2,148	2,900 1,204 1,696	2,978 1,168 1,810	2,450 857 1,593	2,066 693 1,374	602 1,234	48.7	-25.2 -29.8 -22.7	-11.3 -13.1
35 years and older		4,220 3,143 900 178 20 10,870	3,981 2,894 918 168 5 9,909	4,349 3,112 1,042 195 16 8,893	4,369 3,050 1,108 211 28 8,944	4,342 3,053 1,098 192 	4,169 2,848 1,090 230 17	3,944 2,638 1,110 195 28 7,217	81.7 57.3	-13.6	-15.2

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 4.2.15 - ED drug episodes by patient demographic characteristics: Estimates for Philadelphia by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female. Unknown.	10,131 7,378 221	12,258 8,054 189	12,538 8,907 183	13,707 9,261 256	14,876 9,860 189	14,584 9,664 164	13,780 9,289 362	15,124 10,298 368	49.3 39.6	124.4	
RACE/ETHNICITY² While While Black Hispanic Race/ethnicity NTA. Unknown.	7,951 8,371 926 108 375	9,426 9,369 1,164 103	9,903 10,206 1,086 138 295	11,432 10,009 1,355 132 297	11,068 11,923 1,484 181 268	10,857 11,673 1,509 114 260	11,657 9,400 1,530 142 702	11,641 11,116 1,665 1,707	46.4		
AGE 6-17 years 6-11 years. 12-17 years. 18-25 years. 20-25 years. 26-34 years.	1,357 1,335 3,640 2,799 5,937 2,472	1,640 1,594 1,594 4,137 3,159 6,589	1,616 39 1,577 4,121 1,012 3,109 6,788	1,945 30 1,914 4,699 1,195 3,503 6,969	1,772 28 1,744 4,688 1,227 3,461 7,310 7,310	1,662 27 1,635 4,657 1,059 3,598 6,940	1,884 38 1,845 4,976 1,175 3,801 6,087	1,863 1,827 1,328 1,328 6,449	52.6 57.9 51.0		1.6
30-34 years 35 years and older 35-44 years 45-54 years 55 years and older Unknown	3,465 6,765 4,870 1,432 464 32	4,017 8,074 5,972 1,617 485 60	4,018 9,047 6,597 1,872 577 56 56	6,910 2,044 6,910 5,561 6,064 52 52	24,924 2,410 698 24,924	24,413	23,431	2,504 3,845 11,860 7,786 3,368 707 62 25,790	75.3 135.2 93.8 45.5	33.9	14.4 24.7 30.2 48.8

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 4.2.16 - ED drug episodes by patient demographic characteristics: Estimates for Phoenix by year

Total Total Total 1994 1995 1996
3,190 3,695 3,697 3,542 4,153 3,668 75 62 65
4,757 4,632 4,086 524 1,107 1,022 1,016 1,384 1,211 80 92 63
695 913
39 874 1,833 390
2,709 2,190 112 112
6,808 7,910 7,431 7,327

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



### Table 4.2.17 - ED drug episodes by patient demographic characteristics: Estimates for St. Louis by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000,
GENDER Male Female Unknown	3,049 2,920 	2,806 2,695 	2,905 3,103 171	2,674	2,890 2,717 112	3,332	3,517 3,256 135	4,226 3,920 70		35.4	
RACE/ETHNICITY <sup>2</sup> White Black	3,024	3,013	3,567	3,435	3,188	3,675	4,219	4,896	61.9	33.2	
nispaind: Race/ethnicity NTA Unknown	. 50 :	35 304	25 108	 29 122	 51 170	15 47 160	24 92 362	94 371	450.0	193.3	83.3
AGE 6-17 years 6-11 years	781	795	853	766	618	637	625	586			
12-17 years. 18-25 years. 20-25 years. 26-34 years.	775 1,267 314 953 1922	783 1,132 276 856	843 1,245 354 890	756 1,027 290 737	1,026 318 708	1,272 1,272 350 922	616 1,435 383 1,052	1,805 1,362			
26-29 years	782 1,140 2,059 1,546	919 919 2,153 1,503	2,581 1,735	2,393 1,772	2,535 823 2,671 1,872	2,940 2,940	960 3,197 2,109	3,832 2,597	86.1 68.0		
55 years and older. Unknown. TOTAL DRUG ABUSE EPISODES	144 8 6,038	137	239 6 6,179	136 136 5,664	282 217 6 5,719	189 189 5 5 6,336	202 11 6,908	988 246 5 8,216	167.0 70.8	30.2	

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

### Table 4.2.18 - ED drug episodes by patient demographic characteristics: Estimates for San Diego by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER  Male	2,567 2,421 55	2,364 2,259 38	2,903 2,804 98	3,322 3,292 132	3,360 3,517 105	3,532 3,383 121	3,697 3,300 97	3,681 3,217 64	43.4	47.1	-2.5 -34.0
RACE/ETHNICITY² White White Black. Hispanic. Race/ethnicity NTA. Unknown.	2,760 485 899 164 735	2,683 547 778 161	3,121 675 856 197 957	3,692 723 978 301 1,052	4,589 726 968 248 450	4,576 749 1,020 283 408	4,740 709 879 216 549	4,434 648 745 213 922	60.7	-13.5 -27.0 -24.7 126.0	-6.5 -8.6 -15.2 67.9
AGE 6-17 years	514	525	899	716	695	582	688	625	21.6	7.4	-9.2
6-11 years	10 503 1,175	514 961	, 661 1,054	1,260 1,260	688 1,298	14 568 1,228	680 1,401	616 616 1,476	22.5 25.6 41.3	8.5 20.2 21.3	4.6. 4.6.
18-19 years	1,476 623	731 1,256 555	781 1,439 589 851	900 1,690 714 976	951 1,633 683	881 1,473 619 855	1,023	1,055 1,405 586 819	20.3	19.8	
35 years and older	1,348	1,901	2,636	3,071	3,342 2,024	3,745	3,617	3,449 1,790	84.6 33.2 236.1	-7.9 -17.4	10.0
45-54 years and older	156	145	202	253	329	367	11	423	171.2	15.3	45.5
TOTAL DRUG ABUSE EPISODES	5,043	4,660	5,806	6,747	6,982	7,036	7,094	6,962	38.1		-1.9

1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10. indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 4.2.19 - ED drug episodes by patient demographic characteristics: Estimates for San Francisco by year

		`   								•	
Demographic characterístics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER											
Male		6,522	6.014	6.09	5.866	5 640	4 853	5.455	0.10		,
Female	4,095	3,549	3,459	3.270	3.146	3 2 13	2,000	2,4	5 6		4.21
Unknown	118	6	29	55	29	75	109	28	-76.3	-62.7	0.0 -74.3
RACE/ETHNICITY <sup>2</sup>											<u>:</u>
White	4,966	3,947	3,521	2,387	2.083	2 2 1 9	2 107	2.360	. KO K		,
Black	2,914	2,204	1,760	884	772	911	713	2,000	26.3	300	0.75
Hispanic	1,208	893	736	475	545	441	353	319	-73.6	9	0.12-
Kace/ethnicity N.I.A	424	347	336	219	187	274	244	270	36.3		
Unknown	2,603	2,770	3,180	5,460	5,481	5,084	4,440	5.067	7.46		141
AGE			•								
6-17 years	376	347	339	346	217	324	270	101			
6-11 years	00	•	6	2 4	5	7	670		- 6	26.2	
12-17 years	368	345	336	25	802	7 7	4 1	7	-62.5	20.0	
18-25 years.	1688	1 350	1 257	200	200	0.00	0 00	402	;	26.0	
18-19 years.	323	243	946	702	100,	7,000	200	7,142	-32.3		15.6
20-25 years.	1 365	1 107	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	070	101	707	197	217	-32.8		13.6
26-34 years	3.678	006.0	2,549	2 447	245	1 000	187	676	-32.2		16.1
26-29 years	1,430	1,039	975	934	840	744	1,717	20,1	-50.2		9.9 9.0
30-34 years	2,247	1,860	1,574	1,514	1.310	1.185	1090	100	- C		D. C
35 years and older	6,352	5,545	5,371	5,410	5,528	5,579	4.747	5,181	-184		. · ·
35-44 years	4,352	3,606	3,401	3,306	3,233	3,115	2,653	2.639	-39.4	.15.3	- o
40-04 years	1,571	1,523	1,585	1,712	1,846	2,073	1,671	1,982	26.2	?	186
Jakansand older	428	416	382	391	449	391	424	559	30.6	43.0	31.8
OIINIOWIL	22	<del></del>	16	6	24	19	27	4	-36.4	-26.3	48.1
TOTAL DRUG ABUSE EPISODES	12,115	10,161	9,533	9,424	890'6	8,928	7,857	8,575	-29.2		9.1

<sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Εποτ (RSE) tables for ρ-values.

:

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 4.2.20 - ED drug episodes by patient demographic characteristics: Estimates for Seattle by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male	5,686 4,577 100	4,635 3,808 62	4,618 3,770 83	6,098 4,419 71	4,785 3,483 59	4,891 3,458 74	6,144 4,853 118	6,305 5,073 117		28.9 46.7 58.1	4.5
RACE/ETHNICITY <sup>2</sup> White	5,048 1,344	4,216 947	3,097	3,596 647	2,940	2,646	6,608	7,054	39.7	166.6 276.8	6.7
Hispanic Race/ethnicity NTA. Unknown.	227 435 3,309	185 372 2,786	119 258 4,380	102 492 5,749	115 370 4,436	163 163 5,073	350 323 2,058	391 478 1,821	72.2	407.8 193.3 -64.1	48.0
AGE 6-17 years		786	713	828	575	533	743	818	0 67 0	53.5	10.1
6-11 years	19 877 2,248	775 1,846	711	819 2,065	570 1,494	530 1,395	2,032	810 2,091		52.8 49.9 77.7	9.6
18-19 years	1,803 2,973 1,190	1,472 2,453 1,098	1,293 2,390 946	1,623 2,912 1,269	1,080 2,204 941	2,174 2,174 914	1,519 2,739 1,121	1,607 2,656 942		58.3 22.2 3.1	-16.0
30-34 years and older			1,445 3,662	1,643 4,756 3,243	1,263 4,041	1,260 4,288 2,649	1,618 5,562	1,714 5,915 3,382		36.0 37.9 27.7	6.3
33-44 years			227 227	1,268 1,268 276 27	1,157 247 13	279 279 34	372	2,048 485 16	138.1 84.4	•	13.8 30.4 -57.9
TOTAL DRUG ABUSE EPISODES	10,363	8,505	8,471	10,587	8,327	8,424	11,115	11,495		36.5	

1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

. . .

<sup>&</sup>lt;sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 4.2.21 - ED drug episodes by patient demographic characteristics: Estimates for Washington, DC by year

· Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change¹ 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Marie Female Unknown	7,280 6,815 57	6,053 5,690 87	6,083 5,570 67	5,670 5,443 80	5,887 5,586 123	5,461	5,377 4,705 221	5,687 4,723 156	-30.7		
RACE/ETHNICITY² White White Black. Hispanic. Race/ethnicity NTA. Unknown.	5,702 7,374 364 381	5,211 5,520 274 	4,728 5,575 278 	4,037 5,285 324 273	3,586 6,133 243 259	2,758 5,589 243 	3,430 5,383 259 268	4,199 4,852 364 356 795	-34.2	49.8	40.5
6-17 years	1,604	1,518	1,443	1,469	1,218	932	1,069	1,148			
0-11 years	27 1,577 2,888 697	33 1,485 2,440 673	1,427 2,144 556	20 1,449 2,183 614	1,197 1,904 1,904	14 918 1,792 548	1,061	1,127	_		
20-25 years. 26-34 years. 26-29 years. 30-34 years.	2,191 4,791 1,885 2,906	1,767 3,504 1,407 2,098	1,588 3,444 1,397 2,046	1,569 2,783 1,093 1,690	1,425 2,932 1,126 1,806	1,245 2,355 944 1,412	1,548 2,120 859 1,261	1,672	-58.6 -59.1	34.3	
35 years and older	4,800 3,636 904 260 70 14,152	4,295 3,174 874 248 73 11,830	4,643 3,350 1,057 236 47	4,741 3,296 1,157 288 18 11	5,531 3,748 1,453 330 11	5,181 3,344 1,494 343 22 10,282	3,186 1,521 3,186 315 34 10,303	3,099 1,631 347 30 30 30	80.4		
			_					_			

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (…)

indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

T-182

## Table 4.3.0 - ED drug mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun *	% change <sup>1</sup> H2 2001,	% change 1
							2007	7007	2001	7007	H1 2002	H1 2002
GENDER												<u> </u>
Male	. 241,715	257,982	256,790	266,569	269.794	282 554	286.016	300 047	300 530	207 400		
Female	224,155	228,447	230,042	238.364	230,635	263 431	250.013	256 252	281,020	264,400		
Unknown	4,216	4,980	3,524	4,515	4,366	7,317	9,975	8,907	7 803	4 813	-	0 37
RACE/ETHNICITY <sup>2</sup>										2		5.0
White												
	_	273,364	282,015	301,576	288,094	323,212	309,101	318,531	344.517	324 014		
DIRCK	_	122,041	116,914	113,630	121.112	117,194	117 890	125 742	121 485	120 122		
Hispanic	•	51,540	47,175	48.024	49,495	58 191	61 934	62,806	73.682	62,123		
Race/ethnicity NTA	4,956	5,018	4.365	3.836	5 424	4 095	4 104	2020	4,00	200		
Unknown	4	39,446	39,886	42,384	40.670	50.611	52 885	54.064	4,133	0,000		
AGE						· · · · · · · · · · · · · ·		100	2,5	05,700		
b-17 years	47,473	52,311	43,961	46,392	38.134	55.600	48 533	48 088	78 100	47.007		
6-11 years	1,340	532	547	870	679	851	00,0	000,01	70,105	700,7+		
12-17 years.	46 133	5	43 414	45 522	37 AEE	24.7	200	200	0 !	1,162		
18-25 vears			, ,	220,01	004,70	24,140	40,124	48,435	47,387	46,504		
40.40		0/7/16	196,26	97,555	100,618	110,899	110,330	109,308	119.582	117 102		
10-19 years			26,841	25,712	26,942	30,294	30.519	29.040	31 283	31 465		
zu-zo years	69,026		66,119	71,955	73,676	80,605	79,810	80 267	88 300	85,138		
26-34 years.	127,490	129,508	125,718	124,255	123.311	127,420	124 969	133 097	137 007	120,000		
Z6-29 years	52,336	54,868	50,586	52.626	47 004	50 792	51 025	55,140	20,13	20,12,	•	
30-34 years	75,154	74,639	75,132	71 629	76 307	76.628	73,020	77,140	70,720	20,967	-13.Z	
35 years and older	200,779	216 857	226 592	240 486	241 077	250,020	2,044	040,040	175,01	77,140		
35-44 vears	128 442	147.450	45,001	710,100	110,172	670,002	117,102	273,045	293,440	270,486	-7.8	
45-54 vaare	20,445	001	700,161	133,389	15/,408	169,441	164,171	170,167	184,958	165,484	-10.5	
A year or a few manners and a second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second	40,102	706,70	/cz'6c	66,117	260,99	69,321	76,096	78,809	86,057	81.057		
Jayears and Older	14,1/4	16,447	16,328	20,980	18,472	19,916	20,944	24.070	22.424	23 944		
OUKIOWII	1,358	1,464	1,124	649	755	705	962	1,667	1.040	814		
TOTAL DRUG ABUSE MENTIONS	470.085	491 409	490 355	509 449	504 705	553 202	246 004	100				
					,,,	200,000	100,010	200,100	193,261	264,196		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Attanta for the period January-June 2001. For the Attanta contribution to the national estimates, data were imputed for Attanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 4.4.0 - ED drug mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Mate Female Habrana	462,711 428,121 9.769	453,839	462,053	485,702 448,590	514,772 458,489	536,363	568,570 513,444	610,477 538,180	31.9 25.7	14.8	
Olivilowii.	, ,	9,400	3,1,6	60,0	÷	00,	767' 11	2,'0	0.00	900.4	
White	499,194	503,778	496,036	524,359	555,379	589,670	632,313	663,048	32.8		
Black	240,582	240,266	233,643	236,437	238,955	234,742	235,083	247,226 136,578		707	
Race/ethnicity NTA	9,783	8.957	10,975	9.842	9,383	9,210	8.288	8.173		- F	
Unknown	69,682	72,344	72,491	80,429	79,331	83,054	103,496	110,342	58.4	32.9	
AGE											
6-17 years.	94,230	94,674	98,088	100,800	96,272	84,526	104,133	97,091		14.9	
6-11 years	1,192	1,828	1,544	2,358	1,079	1,549	1,259	1,268			
12-17 years	93,039	92,847	96,544	98,442	95,193	82,976	102,874	95,822		15.5	
18-25 years	191,104	178,480	170,983	185,402	184,230	198,285	221,228	228,890	19.8	15.4	
18-19 years	45,336	46,855	44,792	50,058	54,565	52,654	60,813	60,323			
20-25 years	145,768	131,625	126,191	135,344	129,665	145,631	160,415	168,567			
26-34 years	269,252	259,152	255,373	252,629	255,226	247,566	252,389	270,194			
26-29 years	109,540	104,184	102,207	103,190	105,454	99,630	102,717	113,868			10.9
30-34 years	159,712	154,968	153,166	149,439	149,772	147,936	149,672	156,326			
35 years and older	340,555	365,720	380,313	400,671	443,449	482,463	519,890	566,485		17.4	0.6
35-44 years	237,001	259,207	261,888	273,712	298,465	310,796	333,612	355,125		14.3	
45-54 years	75,627	81,402	89,804	99,083	112,209	132,214	145,417	164,866	118.0	24.7	13.4
55 years and older	27,927	25,110	28,621	27,876	32,775	39,452	40,860	46,494	66.5		13.8
Unknown	;	2,261	1,609	2,879	2,587	1,404	1,666	2,707		92.8	
TOTAL DRUG ABUSE MENTIONS	899,600	900,287	906,366	942,382	981,764	1,014,243	1,099,306	1,165,367	29.5	14.9	0.9

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 4.5.0 - Alcohol-in-combination: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
	007.03		2000									
Female	33 912	35,138	36,147	092,06	57,564	59,276	61,484	62,890	66,957	59,799	-10.7	
Unknown	999		454	759	778	1,109	1,691	1,604	1,225	36,959 768	-18.4	-52.1
												į
White	44,168		49,884	57,463	49,993	54,080	55,467		62.237	53.041	-148	
***************************************	26,729		26,756	26,405	27,176	26,343	27,446		28.354	26.405	?	
Hispanic	8,522	6	9,504	9,583	9,387	10,506	11,580		13,205	9,991		
Race/ethnicity NTA	820		457	563	643	687	290		742	604		
Unknown	6,505	6,477	7,328	8,074	926'9	8,731	9,079	9,580	8,935	7,486	-16.2	-21.9
									-			
6-17 years	3,602	4,223	4,101	4,528	3.186	4.849	5.305	3.507	4 256	3.516		
6-11 years	7	:	6	9	:	9	15	10	3	) )		
12-17 years	3,596	4,219	4,092	4,522	3,140	4,843	5.290	3.501	4.181	3.511		
***************************************	14,423	14,314	14,948	18,490	15,851	17.131	19.062	17,779	20,171	17,533	-131	
18-19 years	2,786		4,331	4,266	3,930	3,836	4.321	4,045	4.596	3 957	2	
20-25 years	11,638		10,617	14,224	11,921	13,295	14,741	13,734	15,575	13,576		
26-34 years.	25,843		26,021	25,658	24,739	24,690	23,406	26,008	26.946	23,993	-11.0	
26-29 years	9,851	11,006	9,839	10,905	9,297	9,156	9,304	10,598	11,283	9.078	-19.5	
	15,992		16,183	14,753	15,442	15,534	14,102	15,410	15.663	14,915	<u>}</u>	
35 years and older	42,729		48,782	53,315	50,257	53,527	56,161	56,976	61.936	52,396	-154	
35-44 years	30,111		34,295	35,150	33,817	35,628	35,619	36,045	40.182	34 007	15.4	
45-54 years	10,338		11,894	14,474	13,288	14,833	16,621	17,283	17.725	15.215	-142	
55 years and older	2,279	2,153	2,593	3,690	3,152	3,065	3.921	3.648	4,029	3.174	į	
	146	:	75	26	100	149	229	263	164	06		
TOTAL MENTIONS	86,744	91,064	93,927	102.088	94.134	100.347	104 164	104 533	113 472	07 527	7	
							5	20,1	7,1	120,10	<u>.</u>	

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 4.6.0 - Alcohol-in-combination: ED mentions by patient demographic characteristics: Estimates for the coterminous

U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male Female	97,471 61,780 1,547	97,313 67,825 1,769	99,317 64,922 1,933	103,558 67,084 1,321	112,484 71,282 1,226	119,124 75,560 1,537	120,760 80,950 2,800	129,848 85,328 2,829	33.2 38.1 82.9	84.1	
RACE/ETHNICITY² White Black Hispanic Race/ethnicity NTA. Unknown.	81,005 52,079 14,232 1,614 11,868	86,064 53,223 13,431 1,215 12,973	83,359 51,006 17,038 1,712	88,244 53,109 16,246 1,436	97,158 53,420 19,468 1,141 13,804	107,456 53,581 18,970 1,206 15,009	109,547 53,790 22,086 1,277	116,121 56,518 25,451 1,400	43.4	34.2	
AGE 6-17 years 12-17 years 12-7 years 18-25 years 20-25 years	5,699 13 5,686 29,238 5,399 23,840	6,608 26 6,582 28,328 5,785	6,610 6,529 27,451 5,640 21,811	7,496 10 7,486 28,573 5,616 22,957	8,324 13 8,311 29,263 7,966 21,296	7,714  7,662 34,341 8,196 26,145	10,154 21 10,133 36,194 8,158 28,036	7,763 " 7,683 37,949 8,640 29,309	60.0		-23.5
26-34 years. 26-29 years. 30-34 years. 35 years and older. 35-44 years. 55 years and older. Unknown.	56,413 21,974 34,439 68,922 49,019 15,510 4,393 60,798	53,713 20,460 33,253 77,889 56,069 17,975 3,845 3,68	52,792 20,434 32,359 79,020 56,555 18,334 4,131 298	50,898 19,626 31,272 84,606 59,051 21,136 4,419 171,963	52,634 20,844 31,790 94,485 67,134 22,606 4,746 184,991	50,398 20,203 30,195 103,571 68,967 27,762 6,842 197	48,097 18,460 29,636 109,688 71,248 31,454 6,986 6,986 204,510	52,954 21,881 31,073 118,912 76,227 35,009 7,677 218,005	72.5 55.5 125.7 74.8 35.6	26.1	5.

1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 4.7.0 - Cocaine: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>†</sup> H2 2001, H1 2002	% change <sup>†</sup> H1 2001, H1 2002
GENDER Male Female	54,117 27,267 975	55,780 29,107 870	56,603 29,074 577	50,987 28,033 554	58,284 30,219 673	54,297 29,245 1,161	59,057 30,069 1,051	63,282 32,415 1,055	62,142 33,297 843	59,517 31,439 732		
RACE/ETHNICITY <sup>2</sup> White White Black. Hispanic. Race/ethnicity NTA. Unknown.	26,817 41,491 8,262 447 5,343	25,734 42,743 11,388 407 5,485	27,220 41,813 9,821 412 6,988	26,352 37,210 9,667 331 6,014	30,371 40,807 10,788 378 6,832	28,893 36,867 11,613 456 6,875	30,927 39,023 12,115 393 7,720	34,192 41,910 12,130 390 8,130	37,339 38,112 12,987 330 7,514	36,372 37,603 10,144 492 7,077		
AGE 6-17 years. 6-11 years. 12-17 years. 18-25 years. 20-25 wears.	1,550 1,547 12,875 2,256	2,289 2,235 11,885 2,803	2,074 2,073 12,622 2,282 2,482	1,525 1,441 11,797 2,301	1,773	2,379 2,375 12,586 2,451	2,023 4 2,019 13,167 2,821	1,756 4 1,752 13,808 3,113	1,758	1,255 1,255 14,896 3,156		
26-34 years. 26-39 years. 30-34 years. 30-34 years. 35 years and older. 55 years and older. Unknown.	29,400 10,492 18,909 38,299 29,477 7,855 967 82,359	29,304 11,124 11,124 118,869 41,393 31,270 8,825 1,298 197	29,015 10,332 18,632 42,337 31,770 9,270 1,297 206 86,254	26,613 10,231 16,382 39,536 28,766 9,497 1,274 103	27,445 9,673 17,772 46,337 33,789 10,805 1,739 158 89,176	24,850 8,775 16,075 44,783 32,700 10,563 1,520 165	10,346 26,157 9,389 16,318 48,574 33,605 12,988 1,981 257	27,587 9,903 17,684 53,427 38,694 12,704 2,030 174	26,107 9,997 16,110 53,383 37,73 13,487 2,162 177	11,739 25,203 8,917 16,286 50,213 34,496 13,440 2,277 120	9. 9.	

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

RIC

Table 4.8.0 - Cocaine: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male Female Unknown	96,471 45,762 1,104	89,688 44,599 1,424	100,884 50,181 1,355	106,179 53,356 1,549	112,383 58,181 1,446	109,271 58,253 1,227	113,355 59,314 2,212	125,424 65,713 1,898	30.0 43.6 71.9	14.8	10.8
RACE/ETHNICITY² White White Black Hispanic. Race/ethnicity NTA Unknown.	40,813 77,106 13,355 899 11,163	39,950 73,414 11,495 541 10,311	44,715 77,984 17,737 800 11,183	50,867 82,260 16,760 824 10,371	52,954 84,556 21,209 819 12,472	56,724 78,017 20,456 709 12,846	59,820 75,889 23,728 850 14,594	71,531 80,022 25,117 720 15,644	75.3		
AGE 6-17 years 6-11 years 12-17 years 18-25 years 20-25 years 26-34 years 26-29 years	2,078 14 2,064 25,430 3,218 22,212 26,686 24,440	2,051 2,044 21,110 3,083 18,027 54,881 21,076	2,595 13 2,581 22,060 3,393 18,667 58,729 23,529	3,642 12 3,630 25,218 4,762 20,456 57,143	4,362 4,308 24,507 5,086 19,421 59,008 21,516	3,299 3,214 25,264 4,831 20,433 54,058	4,402 4,394 25,753 5,271 20,482 51,007	3,514 3,509 28,666 5,987 22,679 53,693	86.0		
30-34 years	36,246 54,463 43,376 0 584	33,805 57,341 45,531	35,199 68,717 54,119	36,332 74,600 57,227	37,493 83,730 63,040	34,154 85,869 62,554	32,393 93,357 66,304	33,794 106,810 76,427	96.1 76.2	24.4	14.4 15.3
55 years and older. Unknown.		1,428 328 135,711	1,745 319 152,420	1,801 480 161,083	2,595 403 172,011	3,013 261 168,751	3,502 3,502 362 174,881	4,192 351 193,034	·	39.1 14.4	19.7

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 4.9.0 - Heroin: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change <sup>1</sup> H2 2001. H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER Male Female	23,365 12,133 401	25,836 11,583 439	25,630 12,052 148	25,361 11,837 208	30,200 14,216 369	32,201 14,738 696	30,518 15,408	29,604 14,046 488	32,471 15,977 478	28,911	-11.0	
RACE/ETHNICITY² White White Black Hispanic Race/ethnicity NTA Unknown	13,404 12,854 4,969 232 4,441	13,758 14,003 5,683 425 3,990	14,283 13,613 5,765 3,956	14,412 13,257 5,445 168 4,125	17,414 15,389 6,334 272 5,376	19,244 16,027 7,255 137 4,972	19,182 14,906 7,689 238 5,153	18,075 14,924 6,164 202 4,774	22,029 13,782 7,912 179 5,024	19,722 12,260 5,997 205 4,386	-24.2	-17.9
AGE 6-17 years6-11 years	840	437	461	388	288	- ; c	605	477	357	574		
12-17 years	840 4,862 751 4,111 10,159	5,361 939 4,422 11,008	460 5,890 1,202 4,687 10,067	388 7,175 1,312 5,863 8,877	287 7,726 1,407 6,319 11,276	8,203 1,408 6,795 12,034	605 9,862 8,065 11,709	477 7,449 1,829 5,620 11,116	357 10,002 2,223 7,780 11,752	574 8,552 1,434 7,118		
30-34 years. 35 years and older. 35-44 years. 45-54 years.	5,575 19,994 13,874 5,228	6,267 20,999 14,180 5,849	5,960 21,352 13,607 6,355	5,384 20,922 13,963 5,947	7,081 25,434 16,550 7,479	5,093 6,939 26,834 17,106 8,366	5,080 6,629 24,864 15,734 7,798	6,550 25,049 8,458 8,082	4,820 6,932 26,778 16,168 9,153	4,288 6,309 22,833 13,275 8,044	-14.7	-14.1
UnknownTOTAL MENTIONS	35,899	37,859	37,829	37,406	61	118 47,635	47,169	44,138	1,458 37 48,926	1,513 15 42,571	-59.5	-68.8

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 4.10.0 - Heroin: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

				-					-		
Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change' 1994, 2001	% change 1999, 2001	% change' 2000, 2001
GENDER											
Male	43,592	48,502	49,474	47,307	51,466	55,561	62,719	62,075	42.4		
Female	19,062	20,164	22,893	22,789	23,635	26,054	30,146	30,023	57.5		
Unknown	504	890	613	617	282	578	:	996			
RACE/ETHNICITY <sup>2</sup>											
White	22,516	26,113	24.696	25,895	28.041	31.827	38.426	40.104	78.1		
Biack.	25,996	27,047	28,295	26.490	27.616	28.646	30,934	28.706			
Hispanic	9,423	9,814	11,739	9,145	11,448	11,779	14,944	14,075			
Race/ethnicity NTA	285	365	469	099	637	440	376	381			
Unknown	4,938	6,217	7,781	8,522	7,946	9,501	10,125	9,798	98.4		
AGE											
6-17 years	366	398	492	1.365	898	929	1.052	834			
6-11 years.	:	:	0	0	7	_	0	0		-100.0	
12-17 years	365	396	492	1,365	896	675	1,052	834			
18-25 years	8,336	8,376	9,166	9,703	11,251	14,901	18,065	17,451	109.3		
18-19 years	1,131	981	1,436	1,554	2,141	2,719	3,205	4,052	258.3		
20-25 years	7,205	7,395	7,730	8,149	9,110	12,182	14,860	13,399	86.0		
26-34 years	21,413	22,544	21,886	20,289	21,075	20,153	23,742	22,868			
26-29 years	8,525	8,791	8,796	8,893	8,848	7,688	10,174	9,376			
30-34 years	12,888	13,754	13,090	11,396	12,227	12,465	13,568	13,492			
35 years and older	32,887	38,145	41,328	39,259	42,351	46,356	51,698	51,827	57.6	11.8	
35-44 years	24,377	27,398	27,995	27,204	27,787	30,513	32,840	31,626	29.7		
45-54 years	7,279	9,437	11,180	10,538	12,204	13,426	16,164	17,234	136.8	28.4	
55 years and older	1,231	1,309	2,153	1,517	2,361	2,417	2,694	2,967	141.0	22.8	
Unknown	157	93	108	96	113	106	247	82			
TOTAL MENTIONS	63,158	69,556	72,980	70,712	75,688	82,192	94,804	93,064	47.4		

<sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update)

# Table 4.11.0 - Marijuana: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER Male Female Unknown	21,374	24,963 12,355 544	25,812 12,928 239	28,395 14,365 334	29,648 13,843 483	31,271 17,030 177	30,350 16,304 744	36,829	34,762 20,274 311	35,405 19,752 570		
RACE/ETHNICITY² White Black Haspanic Race/ethnicity NTA Unknown.		<u>8</u> .Ω.4, ∨,	20,366 12,061 3,464 255 2,833	23,376 12,104 3,799 303 3,513	22,020 13,504 5,265 413 2,772	25,119 13,624 5,794 320 4,171	23,896 12,822 5,944 2,83	28,369 14,997 6,113 426 5,259	29,466 14,458 6,763 449	29,110 15,641 6,563 254 4,158	43.4	
AGE 6-17 years. 6-11 years. 12-17 years. 18-25 years. 20-25 years.		-	5,799 11 5,788 12,121 4,260 7,861	7,050 7,001 13,494 4,585 8,909	5,879 5,729 13,772 4,591	7,833 7,744 15,796 4,798 10,997	7,959 25 7,934 14,617 4,480	9,008 25 8,983 16,579 5,164	7,551 18 7,533 16,786 5,026	8,781 10 8,770 17,048 5,503		-60.0
26-34 years	9,255 3,836 5,419 8,348 6,714 1,378 278 37	9,620 4,182 5,438 10,063 7,578 2,152 333 45	10,140 4,908 5,232 10,727 8,121 2,360 2,450 	10,671 4,880 5,790 11,840 8,800 2,617 424 39	10,739 4,935 5,804 13,547 9,883 3,093 36	10,904 4,986 14,448 10,497 3,350 601	10,938 5,251 13,823 9,883 3,584 6,06	12,592 5,741 6,851 16,884 11,777 4,224 883	12,731 6,040 6,040 12,682 4,616 941	12,090 6,139 6,139 17,76 4,843 806 43		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 4.12.0 - Marijuana: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female Unknown.	27,901 11,764 369	31,269 13,215 775	36,635 16,697 438	43,158 21,025 537	50,776 25,283 783	58,043 28,208 817	61,621 33,334 1,471	71,591 37,781 1,139	156.6 221.2 208.7	33.9	16.2
RACE/ETHNICITY <sup>2</sup> White Black Historic	18,810	20,883	24,503	31,892	38,432	45,395 25,607	49,015	57,836 29,455	207.5		18.0
Race/ethnicity NTA	305 305 2,924	3,337	383	6,735 524 4,514	7,606 497 5,817	9,064 716 6,285	11,/39 602 8,624	12,877 875 9,470	315.4 186.9 223.9	42.1 50.7	
AGE 6-17 years 6-11 years 12-17 years 18-25 years 18-19 years	6,521 6,513 13,671 3,947	7,998 26 7,972 14,798 4,655	10,152  9,980 15,722 5,168	11,188 11,057 19,385 5,656	13,161 24 13,137 22,895 7,923	12,930  12,730 27,266 9,176	15,792  15,678 30,413 9,279	16,559 43 16,516 33,365 10,190	153.9 437.5 153.6 154.1	29.7	
26-34 years. 26-29 years. 30-34 years.	11,489 5,258 6,230	12,473 5,471 7,002	15,433 6,866 8,567	16,912 7,463 9,449	19,760 19,760 9,090 10,670	21,410 21,410 9,816 11,595	21,134 21,841 10,237 11,604	25,173 25,323 11,781 13,542	120.4 120.4 124.1 117.4		15.9
35 years and older	8,308 6,545 1,620 143 46	9,877 7,924 1,660 293	12,387 9,812 2,325 250 75	17,039 13,376 3,245 418 196	20,789 15,699 4,513 578 237	25,387 18,683 5,710 995 75	28,271 20,380 6,854 1,037 108	35,123 24,459 8,840 1,825 142	322.8 273.7 445.7 1,176.2	38.4 30.9 54.8 83.4	24.2 20.0 29.0 76.0
TOTAL MENTIONS	40,034	45,259	53,770	64,720	76,842	87,068	96,426	110,512	176.0		14.6

1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

T-193

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 4.13.0 - Amphetamines: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change¹ H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER Male Female	2,896 3,025 25	2,859 2,533	3,702 2,988 17	2,928 2,889 	3,556 2,921 	4,679 3,604 213	4,961 3,566 110	5,108 3,784 	4,604 4,858 44	5,510 4,541 28		
RACE/ETHNICITY² White	3,624 379 1,311 80 551	3,317 435 1,012 42 670	4,318 465 1,054 7.14	3,896 398 810 810	4,676 327 799 77 696	5,248 390 1,467 1,269	5,689 584 1,034 144 1,186	5,973 609 1,188 104	5,747 663 1,307 90 1,699	5,741 820 1,512 82 1,924		
AGE 6-17 years. 6-11 years. 12-17 years. 18-25 years. 20-25 years. 26-34 years. 26-29 years. 35-years and older. 35-44 years. 55 years and older.	686 4 4 1,353 1,129 1,038 1,749 1,749 463 463 463 463	856 1,386 1,523 1,523 1,706 1,706 1,312 2,844	779 724 2,116 477 1,680 1,680 757 2,074 1,482	1,028 1,011 1,011 1,022 1,622 960 960 961 1,564 3,11	658 22 23 1,692 1,756 779 977 2,461 1,621	1,450 9 1,441 2,121 661 1,460 2,081 746 1,335 2,033 2,033	1,231 1,169 2,260 643 1,617 2,516 964 1,552 1,732 1,732 673	1,400 1,368 1,368 1,898 1,510 2,351 1,510 2,676 1,768 2,035	1,203 1,192 2,689 601 2,689 1,375 1,375 2,205 2,205 2,205 2,205 2,205 2,205	1,436 1,260 3,493 1,121 2,371 2,237 1,180 1,057 1,837 1,837 1,837	86.	
UnknównTOTAL MENTIONS	5,946	5,476	6,706	5,921	7 6,575	 8,497	8,638	9,049	9)506	10,079		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>&</sup>lt;sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 4.14.0 - Amphetamines: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female Unknown	5,981	5,491 4,062 29	5,567 4,173	5,042 5,401 52	6,561 5,521 	6,484 5,809 202	9,640 7,170 324	9,712 8,642 201	62.4 125.7	49.8 48.8	
RACE/ETHNICITY² White Black.		5,963	5,720	5,928	7,635	8,572	10,936	11,720	83.8	36.7	
Hispanic Race/ethnicity NTA Unknown	2,215 182 538		2,025 136 796	2,412 168 1,129	2,066 196 1,385	1,608 171 1,419	2,502 267 2.455	2,495 194 2,874	434.2	55.2	
AGE 6-17 years. 6-11 years. 12-17 years.		913 3 911 3,375	1,741 12 1,729 2,153	1,257 11 1,246 2,720	1,635  1,515 3,502	1,686 39 1,647 2,915	2,681 2,610 4,381	2,603 43 2,560 5,302	149.1 760.0 146.2 113.4	54.4. 55.4.4.	
18-19 years. 20-25 years. 26-34 years. 26-29 years. 30-34 years.	731 1,754 3,851 1,772 2,078	829 2,546 3,219 1,212 2,007	643 1,510 2,827 978 1,849	544 2,176 3,386 1,723 1,662	956 2,546 3,203 1,448	2,141 3,378 1,739 1,638	1,304 3,077 4,596 1,710 2,887	1,315 3,986 4,820 2,215 2,605	127.3	86.2 42.7 59.0	29.5
35 years and older	2,728 2,350 260 117 10,118		3,040 2,249 553 239 11	3,069 2,219 696 154 10,496	3,780 2,794 734 252 	4,504 3,185 1,105 214 13 12,496	5,358 3,765 1,360 233 	5,819 3,973 1,500 346 12	113.3 69.1 476.9 83.4	29.2	

1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 4.15.0 - Methamphetamine: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change ' H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER  Male	6,127 2,785, 24	4,016 2,387 	2,788 2,150 15	2,741 1,928 	3,313 2,384 20	4,532 2,750 41	3,849 2,091	3,657 3,097 32	4,473 3,583 	3,552 2,561 22		
RACE/ETHNICITY² White Black Black Hispanic. Race/ethnicity NTA.	6,164 303 1,379 153 937	4,983 162 602 46 741	3,466 .:. 36 244	3,158   420	4,022 230 	4,576 440 1,424 750	4,024 397 	4,913 126 908 	6,106 243 1,060 52 677	4,121 518 645 60 792		
AGE 6-17 years. 6-11 years. 12-17 years. 18-25 years. 20-25 years. 26-34 years. 30-34 years. 35 years and older. 55 years and older.	949 2,569 819 1,750 3,137 1,664 1,473 2,275 1,861 1,861	795 1,867 1,360 1,951 1,951 1,938 1,938 1,687 1,687 1,587	 1,635 546 1,090 1,735 858 877 1,293 950	248 0 0 1,536 1,125 1,126 1,516 614 902 1,177 1,177	596  1,753 371 1,387 1,472 524 948 1,390 1,390	776 1 775 2,030 7,030 1,328 2,392 1,499 1,671 1,671 1,671	346 1,682 1,682 397 1,285 1,818 871 871 871 871 871 871 871 871 871	599  2,343 1,784 1,784 1,308 1,455	 2,307 1,825 2,663 1,673 991 2,372 	571 2,142 706 1,436 1,687 735 951 1,731 1,731 1,731	_	
UnknownTOTAL MENTIONS	 8,936	6,534	4,952	4,730	8 5,717	7,323	 6,182	6,786	8,137	6,136		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.



<sup>&</sup>lt;sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

<sup>©</sup>Table 4.16.0 - Methamphetamine: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S.

Demographic characteristics	Total . 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Famale	11,341	10,323	7,129	11,393	6,804	6,054	8,381	8,130			
Unknown	9	126	3	107	3 :	1 : 2	<u>;</u> :	3 :			
RACE/ETHNICITY <sup>2</sup> White	12,223	10,259	6,779	11,802	8,449	7,180	8,600	11,019			
Black	983	927	800	998	490		837	369			
Hispanic	2,607	2,865	1,674	2,553	: 8	1,489	2,177	1,967			
	1,612	1,473	1,428	1,680	985	985	1,573	1,414			
AGE											
6-17 years.	1,963	1,438	1,096	1,810	1,081	844	1,122	1,323			
0-11 years	1,960	1.438	1.028	1.810	1.081	::808	1.120	1.253			
18-25 years	5,432	4,787	3,728	4,718	3,482	3,289	3,711	4,651			
18-19 years	1,490	1,116	662	1,270	1,033	786	1,099	1,042			
20-25 years 26-34 vears	3,942 5,804	3,671	60. K	3,448	3,686	2,503	2,613	3,609			
26-29 years	2,967	2,075	1,347	2,993	1,637	1,138	1,764	2,406			
30-34 years	2,837	3,406	1,657	2,931	2,049	1,850	2,446	2,298			
35-44 years	3,549	3,630	2,576	3,818	2,637	2,566	3,229	2,996			
45-54 years	747	490	206	781	260	617	1,165	1,033	4 020		
Unknown	<del>-</del> = -	'	; o	: :	ဂ္ဂ ဖ	: 2	<b>7</b> 0 ::	4 :	238.1		
TOTAL MENTIONS	17,537	15,933	11,002	17,154	11,486	10,447	13,505	14,923			

. . .

<sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. 2 A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 4.17.0 - MDMA (Ecstasy): ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER	-00		300									
Male	C87	:	328	636	1,119	1,159	1,152	1,252	1,825	1,044		
remale	æ (	; "	459	311	732	096	1,051	1,107	1,224	1,255		
UNKROWN	5	2	:	0	:	9	:	:	:	:		
RACE/ETHNICITY <sup>2</sup>										-		
White	274	:	712	647	1,459	1.472	1.646	1.478	2.029	1.380		
	17	9	5	:		63	275	367	300	310		
Hispanic	4	9	8	:	51	231	170	235	255	259		
Race/ethnicity NTA	:	7	9	19	28	27	4	:	32	36		
Unknown	45	26	40	117	250	332	250	243	499	:		
AGE										<del>-</del>		
6-17 years	21	:	:	:	248	464	437	317	582	490		
6-11 years												
12-17 years	21	:	:	:	248	464	437	317	582	490		
18-25 years	243	193	457	284	1,339	1,246	1,531	1,450	1,916	1,111	-42.0	
18-19 years	47	:	305	233	44	381	757	484	597	457		
20-25 years	:	62	152	351	868	864	774	996	1,318	654	-50.4	
26-34 years	40	33	181	195	295	332	341	579	489	460		
26-29 years	29	24	20	170	260	165	<del>1</del> 8	427	381	265		
30-34 years	-	6	:	25	32	;	157	153	108	195		
35 years and older	:	5	:	:	18	:	73	81	127	235		
35-44 years	:	2	:	:	15	:	62	73	123	219		
45-54 years	0	_	0	:	7	7	9	9	7	16	700.0	166.7
55 years and older	0	7	0	0	:	0	-	7	7	0	-100.0	-100.0
Unknown	0	0	0	0	:	_	:	0	0	:		
TOTAL MENTIONS	363	351	792	947	1,903	2,125	2,385	2.427	3.115	2.303		
	_			_		-				-		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>&</sup>lt;sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 4.18.0 - MDMA (Ecstasy): ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male	207 45	259 161	199 119	413 219 5	583 554 6	1,755 1,043	2,311 2,011	3,076 2,331 	1,386.0 5,080.0	75.3 123.5	
RACE/ETHNICITY² White White Black Hispanic Race/ethnicity NTA Unknown	151 6 15 75	348 11 25 4 33	228 17 8 23 43	488 23 27 	1,013 16 30 16 67	2,106  126 47	3,118 337 402 72 582	3,507 667 490 .:.	2,222.5 11,016.7 .3,166.7	66.5 288.9 102.2	
AGE 6-17 years	- ω ω	65	: :	38	; ;	347	902	899 899	11,137.5	159.1	
18-25 years	125 24 :: 4	252	143 51 92 62	463 79 384 63	651 437 214 214	1,923 674 1,249 490	2,777 1,138 1,639 672	3,365 1,081 2,285 1,069	2,592.0 4,404.2 2,507.3	75.0 82.9 118.2	
26-29 years	30	. o	8 <del>4</del> 65	4 2	: 73	60 60	348 324	808 261	2,593.3 2,272.7	335.0	132.2
35 years and older	; <b>o</b> ;	20	4 0 0 8	111	: : -	7: :	156 143 12	209 196 8	3,166.7		34.0 37.1
55 years and olderUnknown	_	: <b>-</b>	- 2	0 -	0 0	: :	<del>-</del> ;	40		Ī	300.0
TOTAL MENTIONS	253	421	319	637	1,143	2,850	4,511	5,542	2,090.5	94.5	

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

ED = emergency department, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

# Table 4.19.0 - Ketamine: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun *	% change	% change
	1998	1998	1999	1999	2000	2000	2001	2001	2002	H2 2001, H1 2002	H1 2001, H1 2002
	35	26	193	123	74	144	422		125		
:0	0 0	_	17	:0	32	20	29	: : <sup>C</sup>	27		
	90				- u	,		•			
;0	90		<u>;</u> 4	: œ	<u> </u>	116	349	:0	119		
: : ;	:00	0 - 1		® ~ ;	<del>4</del> ; (	9 79	: 9	:0	9 :		
	7			4	71	<u> </u>	 	00	9	_	
		•	:	80	15	10	:	i	22		
			:	8	15	-01		;	22		
.: 15			: 4	:	96	: 5	227	: :	1		
			2 :	: :	36.	? :	: :	9	11		
15		4 0	<b>∞</b> υ	27	75	75	: :	<u>6</u> 1	83	73.7	
		υ ro	· :	- 6	2 22	<u> </u>	i :	- 5	4 5		
	_	ιΩ I	Φ,	13	80	5	12	12	· 80		
0 <del>C</del>		<u> </u>	<u> </u>	<del>6</del>	: e	<b>о</b> С	<u></u> Ф С	<u>5</u> c	9		
00		00	00	۰ ۳	000	<u>,</u>	100	000	; <del>o c</del>		-100.0
51		:	209	:	107	156	451	' :	152		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

<sup>&</sup>lt;sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

Table 4.20.0 - Ketamine: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female	18	15	58	124	29 ::	316	218	581	3,127.8		
Unknown	0	0	0	0	0	0	~	:			
RACE/ETHNICITY <sup>2</sup> White	7	:	26	:	185	296	201	:			
Black	1	0	4	; vc	:	7	7 0	4		-63.6	
Race/ethnicity NTA	: ° :	1 1 1	1 7	3: 6	- 6		4 7	9 တို့	i	56.0	
AGE				_			,				
6-17 years	0	~	16	÷	70	:	25	i			
12-17 years	0	_	16	i	20	÷	25	i			
18-25 years	:	12	52 5	:	: \$	:	170	:			
18-19 years	:	; «		:	7	:	133	:			
20-23 years	: <sup>1</sup> 2	7		. <del>2</del>	28	ဆ	48	: :			
26-29 years.	က	: `	9 '	<u>ω</u> ξ	17	23	<u>8</u>	·			
30-34 years	: ₹	† ;	- 9	2 ==	12	2.5	5 6	24	500.0		
35-44 years	4	:	12	9	=	16	4	20			
45-54 years	0 0	; C	; •	0 C	0	4	, r	N N		100.0	
Unknown	0	0		0	0	0	4-	0			-100.0
TOTAL MENTIONS	19	:	81	:	509	396	263	679	3,473.7		

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

January-June 2000.

288

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to

Table 4.21.0 - LSD: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

											•	
Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>†</sup> H2 2001, H1 2002	% change 1 H1 2001, H1 2002
GENDER Mala												
Female	7772	1,0/y 685	2,503	1,777	2,024	1,616	1,374	1,236	693	351		-71.6
Unknown			6			14	77#		247	ភ		-90.5
RACE/ETHNICITY <sup>2</sup>						_		_				
White	1,038		2,535	1,931	2,174	1,490	1.423	1.478	708	290	-59	708
Black	82	192	87	: 6	96	150	:	28	33	4	2	-29.3
Race/ethnicity NTA	: 4		787	135 72	165	276	112	231	: 1	47		
Unknown	307	7	295	228	239	238	212	5 96 - 6	40	7 %		-89.5 72.0
AGE									•	3		6.27
6-17 years	200	661	1,309	1.208	752	694	736	929	24.6			
6-11 years	0		:	0	0	}	30	3	2 -	<u>;</u> c		:
12-17 years	200		1,294	1,208	752	693	736	636	315	5		
18-25 years	557	781	1,463	865	1,476	1,241	918	1,005	342	:		:
18-19 years	219		269	452	801	549	554	528	:	•		:
ZU-ZD years	338		765	413	675	692	364	478	183	131		-726
26-29 years	147		264	234	288	145	136	151	179	32		-78.8
30-34 vears	37	3::	8LL	:	152	19	47	: (	:	7		
35 years and older	130	175	:	116	178	2 8	: 0	000	: 6	21		-58.0
35-44 years	111	155	:	-	5	22	8 8	6 4	701	2 4		-50.6
45-54 years	18	18	: :	: <b>6</b>	2	7 2	Σ	0 t	: 4	בי כו		-60.4
55 years and older	0	:	-	n	: 0	- ~	<u> </u>	3 6	<u>o</u>	2		42.9
Unknown	-	က	-	m	· ;	:	0 0	1	<u>:                                    </u>	<u> </u>		
TOTAL MENTIONS	1,542	1,767	3,215	2,427	2.699	2.157	1 859	1 882	030	707	7 93	1
					l l l	î		7	666	ì	.00	-/8.4

\* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, LSD = lysergic acid diethylamide, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 4.22.0 - LSD: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male Female Unknown	3,950 1,131	4,321 1,343	3,636 920 14	3,675 1,474	3,582 1,388 12	3,802 1,243	2,990 948 	1,929 820 	-51.2	49.3	-35.5
RACEJETHNICITY <sup>2</sup> White	3,970 354 250 250	3,961 269 407 76 970	3,509 216 305 49 490	3,913 162 464 35 646	3,834 279 348 17	4,105 202 300 52 52 467	2,914 254 388 10	2,186 91 382 26 136	-74.9 -74.3	-46.7 -55.0 -50.0 -70.9	160.0
AGE 6-17 years		2,142				1,960		952	•	-51.4	-100.0
12-17 years	1,933 2,240 1,091 1,149	2,136 2,817 1,494 1,323			1,954 2,244 1,082 1,162 410	1,960 2,342 1,253 1,088 522		952 1,348 687 661	9.06- -39.8 -39.8		-37.5
26-29 years. 30-34 years. 30-34 years. 35 years and older. 35-44 years. 55 years and older. Unknown.		209 268 241 184 10 10 5,682	168 168 139 26 2 2 6 6 7 7 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8	226 226 33 5,219		308 215 294 195 .: 5	157 124 139 98 35 5 8	199 139 120 122 53 12 12 12 12 12 12 12 12 12 12 12 12 12	-54.6	45.0	4.13

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, LSD = lysergic acid diethylamide, NTA = not tabulated above.

Table 4.23.0 - PCP: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

											opucho %	Topacho %
Demographic characteristics	1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	H2 2001,	, Grange H1 2001, H1 2002
GENDER											702	7007
Female	571,1 573	1,0/3	1,218	1,134	1,422	1,615	1,954	2,120	2,183	2,071		
Unknown	11		7	4	:	27	3 :	8 8	<u> </u>	<u>. 5</u>		
RACE/ETHNICITY <sup>2</sup>									-			
White.	511		611	429	695	1,034	877	992	1,031	927		
Uack. Hispanic.	263 489	3,00	623 337	328	783	928	1,240	1,124	1,454	1,257		
Race/ethnicity NTA	17		Ω.	15	9	} :	g @	B :	13 4	\$ 5		
Unknown	180		<del>2</del>	124	:	259	244	569	266	579		
AGE							_		_			
6-17 years	154	271	121	196	135	304	305	488	167	000	6	
6-11 years	0	:	_	0	:	0	-	30	2	2	50.0	
12-17 years	<del>1</del> 52	270	120	196	132	304	394	488	167	399	138.9	
10-23 years	407	208	400	473	762	808	914	1,124	1.248	1.015		
10-19 years	108	: ;	239	127	308	186	330	242	186	189		
20-20 years	300	291	470	346	454	623	284	882	1,062	826		
26-29 vears	284	517	382	444	421	556	707	558	624	647		
30-34 vears	33.5	201	940	163	202	265	333	228	336	314		
35 years and older	513	425	497	707	2733	29	374	330	288	333		
35-44 years.	369	360	408	373	2 5	3 62	200	203	486	1,189		
45-54 years.	137	9	62	15	3 5	133	323 156	107	726	9 6		
55 years and older55	7	2	9	17		3	3	25	7 6	0,00		
Unknown	:	4	:	: :	, C	<u></u>	19	0	- ro	<u> </u>		
TOTAL MENTIONS	1,760	1,725	1,711	1,607	2,057	2,607	2,798	3,074	3,028	3,257		

\* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above, PCP = phencyclidine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

29<u>1</u>

## Table 4.24.0 - PCP: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

5 <del>0</del>
2,401 2,293 1,198 1,126
1,134 1,254
•
339
380
•
259 139
3,626

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

2 A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above, PCP = phencyclidine.

#### Table 4.25.0 - Miscellaneous hallucinogens: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

	000	1	1	-							longer (	10 /0
Demographic characteristics	1997	1998	Jui-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change H2 2001, H3 2002	% change. H1 2001,
VDER Male Female	534 250 	0  669	815	373	722 236 2	620 156	768	574	932	522	7007	7007111
RACE/ETHNICITY? White	608 14 	688 16 7	840 31	393  18	713	477 24 	904 19 21	581 20 3	983	296		0.001-
E 6-17 years 6-11 years.	353	445	: ::	211	489	195	238	96 :	09 : °	: :		
12-17 years. 18-25 years. 18-19 years. 20-25 years.	353 313 174		505	211 265 58 207	489 406 223	193 399 304	238 585 413	318	413	317		
26-34 years. 26-29 years. 20-34 years. 35 years and older. 35-44 years.	:8 : :	2011	; ; <sup>k</sup> ;	\$ 55 \$ 25 \$ 26 \$ 26	20174	: :2 :	v ; <sup>co</sup> ; ;	. :	31 16 15 15 15	23 8 ::		
45-54 years	 0 845	863	986	 6 0 573	960 0 4 22	2 :: 2791	1,058	7 4 4 4 718	1,070	21 .:. 0 620	-100.0	

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 4.26.0 - Miscellaneous hallucinogens: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

Total % change % change 2001 2001 2001 2001 2001	1,506 183.3 -66.7 -94.1	1,564 3 31 5 27 7 156	2 730 8 241 6 489 2 90 2 90 7 71 7 71 1 6 65.5
Total 2000	1,389 443 17	1,381 43 196 12 217	
Total 1999	1,095 435	1,106	700 700 670 281 390 39 32 72 70 70 70 1,533
Total 1998	1,514 333	1,528 48 25 8 241	724 723 781 346 435 
Total 1997	1,204 361	1,327 26 .:. 10 124	613 613 780 373 417 131 47 47 47 47 116 629
Total 1996	1,285 308 7	1,040	801 7.7.7 7.86 5.86 7.86 7.86 7.86 7.86 7.86 7.86 7.86 7
Total 1995	1,175 284 4	935	425 425 425 862 882 282 282 282 282 25 25 25 25 45 45 45 463
Total 1994	1,395 175 6	1,213 28 210 15	593 0 0 828 828 .:: 453 124 33 22 7 7
Demographic characteristics	GENDER Male	RACE/ETHNICITY² White	6-17 years

<sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

Table 4.27.0 - Flunitrazepam (Rohypnol): ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

GENDER         Jul-Dec         Jan-Jun           GENDER         1997         1998           Male         10            Female             Unknown             White             Black             Hispanic             Hispanic             Linknown             Unknown	Jun Jul-Dec 1998	1999 	Jul-Dec 1999 0	Jan-Jun 2000 0	Jul-Dec 2000 :: :: 0	Jan-Jun 2001 144 0 0	Jul-Dec 2001 .:. 12 0	Jan-Jun * 2002 8 8 6	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
10 0 0 3 17A		::0 :::0:	; ; O ; M ; O M	::0:5	::0::	4 :0 :04		88	7007	H1 2002
0 0 0 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4		: :° : : :° :	; ; O ; n ; O n	::0 :-:	::0:5:	4 io iou		80+		
3 17A		; ; ; ° ;	, m ; O m	· : = :	· · · ·	9 6				
3		: : :° :	; m ; O m	; <del>-</del> ;	: <del>-</del> :	;0"		=	_	
;0,		;° ;	: O m	:	•	~		9 +		
D		•	<del>)</del>	: °	00	500		; 🗲		
AGE	_			V .	<b>5</b>	<del>7</del> 0		m		
6-11 years	0	:0	<u> </u>	:0	:0	~ 0	; c	m c	<u> </u>	-57.1
18-25 y gars. 4		: :	: 4	: œ	: :	· -	9 : 0	П		-57.1
<u>- ന                                   </u>	_	i i		::	: :	о <u>:</u>	; <del>1</del>	4 10	_	
0 2 6	4 (7 (	: :	ന്ന		7 +	<u>;</u> <del>-</del>	2 +		-50.0	
		: -	0 0	<del>0</del> :	<del>-</del>		<del></del>	0	-100.0	
	<del>6 0</del>	-0	N 0	7	0+	0+	000	; °		
Unknown		00	00	00	00	- 0 0	000	:00		
TOTAL MENTIONS	:	i	· ;	;	· ;	<del>-</del> ;	<del>-</del> :	o 6	<u>,                                     </u>	

\* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 4.28.0 - Flunitrazepam (Rohypnol): ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male	S	26	114	40	:	i	:	i			
FemaleUnknown	; <b>o</b>	;°	: -	: :	;°	:0	:0	; °			
RACE/ETHNICITY <sup>2</sup> White		:	99	; <del>4</del>	;0	: :	; N	:0			-100.0
Hispanic Race/ethnicity NTA. Unknown.	0 ; O	. ° 1	; † o	; ; <b>co</b>	; m O	:00	; ; 8				200.0
AGE 6-17 years		<u> </u>	; ° ;	; ° ;	; ° ;	; <sup>*</sup> ;	;0;	; 6		-100.0	
18-25 years	0000	: : <b>:</b> &	25 24 24 24 24	25 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 <del>2</del> 20 20 <del>2</del> 20 20 20 20 20 20 20 20 20 20 20 20 20	: ; N ; <del>©</del>	1111	; ; ; <b>co</b>				
26-29 years	· 	: 600		<u>u 4 u u</u>	4404	; mm	N: 00	·	-100.0	-66.7 -100.0	-100.0
45-54 years	:00	000	: vo <del>-</del>	°° ;	<del>-</del> ;0	000	:00	-00			
TOTAL MENTIONS	13	:	:	:		:		:			

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 4.29.0 - GHB: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
***************************************		195	678	267	1.402	2.030	_	1 106	900	1 202		
Female	160	192	217	622	530	772	:	22,	CEG	707,		
Unknown		0	0	:	- 1	1 :	: :	† 67 †	ο α Ο	: C	-1000	14000
RACE/ETHNICITY <sup>2</sup>									)			2.001
	206	253	899	Odd	4 500	2 405	•		į,			
Black		257	3	600	260,1	2,420	:	1,2/3	1,179	•		
Hispanic.	. o	+ +	25.	: 6	200	77	: \$	70	፥	<u></u>		-55.0
Race/ethnicity NTA.	. 67		3 5	2 5	2 6	: \$	4 5	:	: 1	; ;		
Unknown	2 :	• ;	2	208	7	282	72,		ဂ	10		;
			•	3	:	707	=	2	:	D D		-27.4
6-17 vears	4											
6-11 years.		:	:	:	:	:	:	÷	:	22		
12-17 years.	15											
18-25 years	? ;	227	::5	413	1 1 7 8	4	:	: 4	: 6	22		
18-19 years.	25	Ì	;	2 00	, 130	7,00	:	CLL,	872	:		
20-25 years.	1	8	364	37.5	202	1000	:	:	: 6	:		
	115	125	179	414	2	77.1	i	: 6	12/	:		
26-29 years	20	14	6	233	350	387	: 6	707	230	:		
30-34 years.	26	47	3	}	3	38	5	0 7	7 7 7	:		
35 years and older	22	25	4	:	133	318	: Ç	146	755	: 0		
35-44 years	21	10	22		= =	3	3 8	2 ;	3/2	9/7		
45-54 vears.	ï	9 (	1 =	: ₹	- 0	:	7 6	131	:	192		
55 years and older	7	0 0	= -	<u>+</u>	0	:	<u> </u>	<u></u>	:	:		
Unknown	- 0	<del>-</del>	: -	: 67	: *	: •	NG	7	: "	<del>o ,</del>	1	-100.0
		•	•	,	-	-	>	:	7	_	-20.0	
IOIAL MENIIONS	429	387	895	1,192	1,987	2,865	:	1,679	1,661	2.024		
								_	_	-		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (—) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, GHB = gamma hydroxy butyrate, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 4.30.0 - GHB: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female Unknown	30 21	45°C	125	530 228 5	873 409 0	1,969	3,530 1,306	2,191 1,132	7,203.3		
RACE/ETHNICITY² White Black Hispanic Race/ethnicity NTA.	47 0 3 0 6	104 8 16 17:	336 6 115 111	370 8 16 15	921 24 37 17	2,481 .:. 54 24	4,224 167 25 458	2,452	5,117.0		
AGE 6-17 years. 6-11 years. 12-17 years. 18-25 years 20-25 years	54 5 6 7 F		14 427 3337			 1,570 300 1,270	2,666 389 2,278	 1,940 202 1,738	7,361.5 4,950.0 7,456.5	-	
20-34 years	1 t t 4 c	22 28 28 28 28 28 28 28 28 28 28 28 28 2	30 30 20 30 30	109 92 58 40	157 147 65	583 446 .::	891 673 421 319	414 263 518 297			6:09-
45-54 years. 55 years and older. Unknown	99	_	638 : 8		₹	3,178	 8 1 4,969	 4 3,340	5,864.3	;	300.0

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

<sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, GHB = gamma hydroxy butyrate, NTA = not tabulated above.

## Table 4.31.0 - Inhalants: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

												ııı year
Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change¹ H2 2001, H1 2002	% change <sup>†</sup> H1 2001, H1 2002
GENDER												
Female	578			310	205	705	349	300	246	298		
Inknown		342	:	225	: `	235	224	89	: '	:		
		? -		0		n	:	0	0	:		
RACE/ETHNICITY <sup>2</sup>							_					
White		853	568	254	302	99	412	:	165	:		
Black	13		33	43	:	:	19	13	1	22	100.0	
Hispanic	291	: 5	:	:	:	:	:	25	:	33		
Kace/eunicity N.A	11	12	:	12	9	က	÷	7	0	4		100.0
CINIOWI	97	:	:	27	30	28	35	38	24	:		
AGE												
6-17 years	288	461	523	230		;	•	39	26			
6-11 years		<del>-</del>	0	4	ო	:	0	3 :	} :	: 4		
12-17 years	287	460	523	226		:	<u></u>	38	24	•		ŧ
18-25 years		266	:	22		:	20	:	i :			
18-19 years		:	:	23		:	15	: :	<b>60</b>			
20-25 years	350	195	i	35	45	:	35	:	<b>'</b>	12		
26-34 years	፥	:	: :	i		78	33	46	19	21		-54.3
30-29 years	i	: 0	21	: 4		26	<del>2</del> ;	25	6	44		
35 vears and older	171	363	114	2 - 2		: 4	100	:	<u>-</u>	7		
		3	-	5		280	236	:	:	: 4		
45-54 years.	_		. 62	<u>: "</u>	:	3 6	617	: 4	:	4		
55 years and older	4	~	? :	<u>+</u>	- 2	3 "	:	2 C	; c	: `		
Unknown	0	:	7	0	<u>i 0</u>	0	: :	0	0	<del>F</del> 0		
TOTAL MENTIONS	1,214	1,280	931	535	627	946	576	338	338	550		
								1	}	}		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the penods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

Table 4.32.0 - Inhalants: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male	999 456 	714 320 2	817 490 6	1,429 738 	1,668	817 344 1	1,054 459 8	546 130	-71.5	-100.0	-71.7 -100.0
RACE/ETHNICITY² White	1,095	647	900	1,288	1,421	556 163 368	1,077	425 24	-61.2	-85.3	-60.5
Race/ethnicity NTAUhknown	: :	± ±	47	53	: :	18 57	8 62	62		9.88-	-75.0
AGE 6-17 years	598	434	515	664	984	344	642	65	-89.1		
6-11 years	596 418	361 223	512 371	605 723	983	338 119	641	 62 225	-89.6	:	
18-19 years. 20-25 years. 26-34 years.	168 250 209	131 161	149	213 510 507	286 282	39 80 274 160	:: 17	.:. 160 38 34		-75.9	
30-29 years	172	219	148 135	287 275 206	150 477 391	424 307	389	320 ::			
45-54 years. 55 years and older	. n.	0 : 0	<u> </u>	: '	<u>ີ</u> ຕ :	0 73:	: : :	:00	-100.0	-100.0	
TOTAL MENTIONS	1,511	1,036	1,313	2,225	2,211	1,162	1,522	676	-55.3		-55.6

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

ED = emergency department, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

<sup>&</sup>lt;sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

#### Table 4.33.0 - Combinations NTA: ED mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change¹ H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
NDER Male Female Unknown		23 3	42 13	28 14 0	36 16 0	48 20 0	37 22 0	141	: 82 0	77		215.4
E/ETHNICITY² White White Black Hispanic Race/ethnicity NTA	18 17 10 0	23 27	17	40 8 0 0	13 9 9	28 17 17 19 19	250000			9 44 1 14 16	187.5 180.0	170.6
6-17 years 6-11 years 12-17 years 18-25 years 20-25 years 26-34 years 30-34 years 35 years and older 55 years and older	8 86200000000000000000000000000000000000	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	4 450 14 108640	: <u>: 7</u>	: :0 :827 c 2828 c c c c c c c c c c c c c c c c	: :5 :5250 £ <b>2</b> 0 €	: ;tr45248708	: ::::4 co 4 co 4 co 1	2 C : : : 4 4 0 6 5 0 c s	: :8 9 4 8 8 4 4 2 8 :	 157.1 350.0	157.1
TOTAL MENTIONS	75	70	55	42	25	89	- 29	156	:	118		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

<sup>&</sup>lt;sup>2</sup> A more detailed tabulation of the racial and ethnic charactenstics of DAWN cases is provided in Table 1.10.

Hereistics: Estimates for the coterminous by patient demographic characteristics: Estimates for the coterminous U.S.

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER  Male	.:. 85 0	120 41	328 54	165 36 0	87 36 3	30 0	42 0	32	-62.4		
RACE/ETHNICITY <sup>2</sup> White White Black Hispanic. Race/ethnicity NTA. Unknown.	147	61 14 14 28	225	43. 43.	84 4 60 81	¥ 8 + + 00	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	215 33 8 0 0	-63.6	83.3 -100.0 36.7	
AGE 6-17 years	4	က	10	o	ဖ	i	m	:	_		
12-17 years	4 : :	w 02 4	10: 10	0 4 6 5	36 7	:250	23.3	: : :			
20-25 years	141		1 1 1	7 : ®	32 10	5 25 6	38 2	28 	_	27.3	-40.0
30-34 years	114		107	73	23 50 43 63	13 43 36	63 4	27 <u>54</u> 8	-64.7 -52.6 -71.9	38.5	-34.1
45-54 years. 55 years and older. Unknown.	12 7		8t :: 0	29	800	0 4.7	6	0 0 0		185.7 500.0	
TOTAL MENTIONS	495	163	383	201	125	98	127	298			

This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. <sup>2</sup> A more detailed tabulation of the racial and ethnic characteristics of DAWN cases is provided in Table 1.10.

٥

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to

ED = emergency department, NTA = not tabulated above. January-June 2000.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 5.1.0 - ED drug episodes by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
DRUG CONCOMITANCE												
Single-drug episode	118,048	121,855	117,834	117,604	122,051	133,705	129,807	138,660	140.966	138.113		
Multi-drug episode			152,736	160,640	154,472	168,968	169,082	173,125	185,734	170,445	-8.2	
DRUG USE MOTIVE		_								,		
Psychic effects		47,926	49,474	48,571	56,889	60.988	57.711	62 096	66 912	60 310		
Dependence		92,669	96,422	99,613	103,079	108,042	109,080	112,045	116,949	112,667		
Suicide	91,705	98,187	91,610	91,484	83,328	98,693	94,317	94.728	99,596	89 280	401-	
Other	3,024	2,650	2,832	4,560	2,943	3,502	4,906	3,934	6.339	6.367	ò	
Unknown	30,834	30,431	30,231	34,015	30,284	31,447	32,875	38,983	36,903	39,925		
REASON FOR ED CONTACT				_								
Unexpected reaction	33,181	34,214	36,962	35,023	43,317	45,194		53.637	54 672	55 090		
Overdose	116,450	127,458	117,606	116,304	115,878	134,501		127.806	136 279	123 943	9	
Chronic effects	25,157	25,717	24,393	25,075	24,810	25,912		27.146	26.110	23.545	;	
Withdrawal	8,193	8,318	9,659	14,011	11,899	10,410		12.957	11.646	13 131		
Seeking detoxification	35,662	35,618	37,425	34,252	38,708	46,150		46.908	52.218	51,167		
Accident/injury	10,967	9,289	9,726	11,193	9,357	8,820		8.908	9.561	7 963		
Other	14,264	17,386	20,184	28,932	18,738	18,686		19.058	19,550	18 094		
Unknown	17,845	13,863	14,614	13,454	13,815	12,999	14,322	15,365	16,664	15,625		
PATIENT DISPOSITION		•									_	
Treated and released	128,706	127,225	128,557	127,266	132,085	137,193	137,621	147.312	152 52B	147 830		
Admitted to hospital	123,309	135,915	133,217	141,795	134,632	154.650	151 495	154 894	164 318	151 453	10	
Left against medical advice	5,890	4,852	5,056	5,338	5,661	6,631	5,700	5,802	6.471	780 9	0.	
Died	471	833	535	621	649	753	788	486	777	7220		
Unknown	3,343	3,037	3,205	3,224	3,496	3,446	3,286	3,292	2,610	2,257		
TOTAL DRUG ABUSE EPISODES	261,719	271,862	270,570	278,243	276,524	302,673	298,890	311.785	326.699	308 558		
										20,000		

\* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. ¹ This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



Table 5.2.0 - ED drug episodes by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode	253,061 265,820	243,927 269,592	241,746 272,187	240,881 285,937	239,689	239,655 315,112	263,513 338,050	279,626 358,858	35.0	16.7	6.1
DRUG USE MOTIVE Psychic effects	85,656 165,961	91,001	97,177	94,336	97,399	105,460 202,692	217,122	129,007	50.6 38.0	22.3	8.7
Suicide Other Unknown	199,554 5,530 62,180	4,747 52,763	53,150	5,686 5,686 56,989	5,482 60,662	7,503 64,299	8,408 64,323	10,273 75,886	85.8		
REASON FOR ED CONTACT Unexpected reaction	66,529 269,442	57,377 271,622	61,899	68,685 244,686	71,176	78,340	92,508	108,309 264,086 53,256		13.7	17.1
Chronic effects  Withdrawal Seeking detoxification Accident/injury Other Unknown	26,307 14,051 52,329 16,452 21,602 22,168	50, 166 15,127 50,482 16,184 23,904 18,657	55,365 15,011 59,922 17,992 27,282 25,726	49,27,3 15,176 67,888 20,399 28,006 32,706	17,978 73,043 19,016 37,570	25,910 72,960 20,550 47,670	22,497 22,497 90,625 16,074 36,248 27,321	24,603 24,603 99,126 18,469 38,607 32,029	75.1 89.4 78.7 44.5	35.9	
PATIENT DISPOSITION  Treated and released  Admitted to hospital  Left against medical advice  Died	243,763 258,656 9,695 978 5,789	237,712 258,311 10,771 1,359 5,366	242,661 256,033 8,940 1,122 5,177	254,099 253,861 11,244 932	255,782 269,132 9,908 1,368 6,242	259,350 276,428 10,999 1,270 6,720	274,814 306,146 12,330 1,541 6,732	299,839 319,212 12,273 1,258 5,902	23.0 23.4 26.6	15.6 15.5	<u>0</u> ,
TOTAL DRUG ABUSE EPISODES	518,880	513,519	513,933	526,818	542,432	554,767	601,563	638,484	23.1	15.1	6.1

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department.

#### Table 5.2.1 - ED drug episodes by episode characteristics: Estimates for Atlanta by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	2,703	2,252	2,079	2,089	4,076	3,552	3,114	5,208	92.7	46.6	67.2
DRUG USE MOTIVE	, ce, ,	- 0,0	1,36,7	4.0,	6,641	6,637	866'7	9,248		39.3	
Psychic effects	1,123	744	641	925	1,817	1,762	1,319	2,476	120.5	40.5	87.7
Suicide	3,648	4,019	3,093	2,435	3,156	5,044 2,626	6,534	7,115	39.5	41.1	
Other Unknown	168 622	136 389	355	99 521	1,063		62 475	11	I		11
REASON FOR ED CONTACT					_			-		-	
Unexpected reaction	4,511	3,927	2,770	2,303	3,234	3,096	4,370	1,039	-77.0	-66.4	-76.2
Overdose	2,509	2,849	2,696	2,469	2,869	2,778	2,696	3,231		16.3	19.8
Chronic effects	463	963	835	366	252	:	÷	1,930	316.8	:	· :
Viulgrawal Seeking detoxification	1 830	2 132	2 247	107	320	272	:: 5	427	310.6		
Accident/Injury	220	512	326	398	587	469	0/6,	3,440	88.3	81.8	119.4
Other	191	221	211	339	334	389	} :	2,387	1.149.7	498.2	
Unknown	533	260	221	223	:	:	:	1,166			•
PATIENT DISPOSITION	1			_							
Treated and released	4,583	5,075	3,617	3,658	5,553	5,006	6,251	8,119	77.2	62.2	29.9
Admitted to hospital	5,716	5,731	5,582	4,162	4,942	4,941	4,584	5,733			
Died	2 <del>4</del> 2	247	Z0L	4 6	84	133	135	i		1	i
Unknown	107	108	92	11,	116	124	126	284	165.4	129.0	125.4
TOTAL DRUG ABUSE EPISODES	10,660	11,063	9,400	8,003	10,717	10,189	11,112	14,456	35.6	41.9	30.1

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department.

Table 5.2.2 - ED drug episodes by episode characteristics: Estimates for Baltimore by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode	7,408 8,454	7,371	7,526	5,776 6,978	6,194 7,542	6,234 7,937	5,361 6,144	5,073 6,552	-31.5 -22.5	-18.6 -17.4	-5.4 6.6
DRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	1,181 10,838 2,037 68 1,737	1,582 10,830 2,286 48 1,220	1,659 9,231 2,189 68 2,848	1,094 6,456 2,234 82 2,889	1,487 7,150 1,961 96 3,042	1,418 8,470 1,788 72 2,423	1,464 6,910 1,297 59 1,776	1,390 6,760 1,363 84 2,027	-37.6	-20.2 -23.8 16.7	-5.2 -2.2 -5.4 -4.24 -4.44
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal Seeking detoxification Accident/injury Other Unknown	1,663 2,375 6,449 734 1,307 964 1,756	1,684 2,095 6,139 1,303 712 930 2,299 805	1,124 2,138 4,975 1,461 785 1,247 2,124	798 2,162 3,377 1,477 807 378 1,151	1,385 2,578 3,656 1,167 1,237 588 1,346 1,780	1,569 2,450 3,265 1,001 1,565 622 2,732 969	998 2,326 2,172 915 1,611 289 2,518 676	1,022 2,198 2,171 990 1,821 257 2,260	-38.5 -7.5 -66.3 34.9 39.3 -73.3	-34.9 -10.3 -33.5 -16.4 -58.7	-5.5 8.2 13.0 -11.1 34.2
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died Unknown	10,553 4,874 258 25 153 15,863	10,915 4,612 266 15 15 15,966	10,192 5,339 299 10 154	7,457 4,811 232 11 245 12,755	8,161 4,994 296 27 258 13,736	9,001 4,641 295 47 186	7,001 4,096 269 35 105	7,555 3,697 221 39 111	-28.4 -24.1 56.0 -27.5 -26.7	-16.1 -20.3 -25.1 -17.0 -40.3	7.9 -9.7 -17.8

<sup>&</sup>lt;sup>1</sup> This column denotes statistically significant ( $\rho < 0.05$ ) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for  $\rho$ -values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 5.2.3 - ED drug episodes by episode characteristics: Estimates for Boston by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	6,494	6,689	5,593	5,057	5,636	4,961	7.056	7.716		55.5	i
Multi-drug episode	8,880		7,943	7,168	8,021	6,708	7,845	9,137		36.2	16.5
DRUG USE MOTIVE											
Psychic effects	3,413		2,215	2,212	3,209	2,107	2,877	3,221			12.0
Dependence	5,475		5,243	4,537	5,548	5,536	6,946	8,501		53.6	22.4
Suicide	4,316	4,521	4,073	3,693	3,278	2,782	3,032	3,050	-29.3		i
Other	77		156	103	46	37	61	80			
Unknown	2,092	1,800	1,850	1,679	1,576	1,208	1,986	2,001			
REASON FOR ED CONTACT					-						
Unexpected reaction	2,047	1,904	1,258	950	1,460	1,232	1.535	1,523		23.6	
Overdose	966'9	6,583	5,614	5,225	4,260	3.923	4.904	5.370		2	
Chronic effects	1,167	1,134	707	664	1,522		1	)			
Withdrawal	489	496	335	334	475	545	488	534			:
Seeking detoxification	2,310	2,569	2,423	1,929	2,769	2.886	3.744	4.688	102 9	62.4	25.2
Accident/injury	640	200	653	639	670	534	679	630		-	7:07
Other	1,970	:	2,269	2,177	2,159	856	1,124	1,161		35.6	
Unknown	355	416	277	307	342	272	237	321			
PATIENT DISPOSITION											
Treated and released	7,061	7,198	5,678	5,101	6,514	5,847	7,366	9.393		909	27.5
Admitted to hospital	7,855	8,500	7,539	6,835	6,695	5,396	7.061	6.991		29.6	?
Left against medical advice	226	190	153	<del>1</del> 2	290	262	292	339		29.4	
Died	30	23	18	=	4	24	용	46		21.6	
Unknown	202	156	149	123	4	141	148	8	-58.4		43.2
TOTAL DRUG ABUSE EPISODES	15,374	16,067	13,537	12,224	13,657	11,669	14,902	16,853		4.44	13.1

 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

Table 5.2.4 - ED drug episodes by episode characteristics: Estimates for Buffalo by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	1,227	1,162	1,364	993	1,060	1,096	1,180	1,441		31.5	22.1
Multi-drug episode	1,517	1,551	2,224	1,819	1,623	1,614	1,720	1,915			
DRUG USE MOTIVE Descripto effects	403	558	810	376	221	306	503	1,176	191.8	284.3	
Dependence	1,099	1,061	1,628	1,589	1,539	1,599	1,669	1,530	39.2		
Suicide	1,075	782	735	295	200	499	395	353	-67.2	-29.3	
Other	4	4	32	7	7	19	22	41	250.0		
Unknown	165	298	383	278	417	287	313	283	71.5		
REASON FOR ED CONTACT							-				
Unexpected reaction	604	409	631	456	284	280	185	315	47.8		
Overdose	1,156	964	920	711	285	247	624	681	4.1.1	24.5	
Chronic effects	83	342	192	89	89	135	:	182		34.8	
Withdrawal	47	62	4	47	99	29	122	196	317.0	232.2	2.09
Seeking detoxification	604	289	1,271	1,082	1,156	1,279	1,282	1,587	162.7		23.8
Accident/injury	61	53	98	29	24	45	:	102		126.7	Ē
Other	98	141	317	292	455	296	186	187	117.4	-36.8	
Unknown.	105	22	9/	26	48	69	133	106		53.6	
PATIENT DISPOSITION			1								
Treated and released	1,710	1,649	2,266	1,847	1,532	1,327	1,312	1,681			
Admitted to hospital	912	942	1,140	788	865	1,133	1,287	1,386			
Left against medical advice	93	66	147	158	271	214	221	272	192.5		23.1
Died	<del>_</del>	S.	80	_	4	_	2	0	-100.0	-100.0	-100.0
Unknown	2	9	27	13	12	36	74	17			-77.0
TOTAL DRUG ABUSE EPISODES	2,745	2,714	3,587	2,812	2,683	2,711	2,899	3,356			
						1		]			

¹ This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department.

Table 5.2.5 - ED drug episodes by episode characteristics: Estimates for Chicago by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	9,999	9,852	10,053	10,204	10,341	10,718	12,508	13,833	38.3	29.1	10.6
DRUG USE MOTIVE Psychic effects	3 770	3 793	4 583	5 274	4 405	7 225		2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2	3	2	
Dependence	9,391	9,857	12,035	14,472	14,332	14,451	17,190	19,687	109.6	36.2	14.5
Other	120	90'4	97	185	165	3,849	4,208 113	4,640 162		20.6	10.3
Unknown	3,134	3,516	2,037	2,524	3,156	3,412	5,001	3,790			-24.2
REASON FOR ED CONTACT	C	1		1	1	-					
Onexpected reaction	6,597	6.127	6,933	7,028	6,810	7,674	8,659 7,568	8,901		16.0	
	843	1,949	1,401	1,293	1,667	1,876	2,141	2,627	211.6	3	
Withdrawal	1,092	914	738	696	1,406	1,310	1,378	1,712	56.8	30.7	24.2
Seeking detoxification	1,766	1,829	4,634	6,679	5,859	5,371	6,497	6,763			!
Accident/injury	1 087	1,370	1,132	1,250	1,455	1,315	1,706	1,637			
Unknown.	96.	916	1,101	1,065	099	674	1,138	1,502	-	122.8	
PATIENT DISPOSITION	,										
Treated and released	11,195	11,951	10,791	11,874	11,996	12,675	13,899	14,496	29.5	14.4	
Admitted to hospital	9,495	9,170	11,982	13,950	13,400	12,829	15,629	17,249	81.7	34.5	
Died	9.5	46	45	8	222	9.5.4 0.7.	4/0	25 C F			
Unknown	250	299	189	268	215	152	253	350		130.3	
TOTAL DRUG ABUSE EPISODES	21,484	21,883	23,522	26,875	26,206	26,154	30,327	32,647	52.0	24.8	

 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

#### Table 5.2.6 - ED drug episodes by episode characteristics: Estimates for Dallas by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	2,438 2,703	2,380	2,161	2,731	3,051	2,803 3,442	3,158 3,638	2,888 3,613	18.5 33.7		9.
DRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	890 1,258 2,410 13	1,016 1,150 2,438	960 998 2,272	1,280 1,368 2,623 45 877	1,529 1,887 2,487 49 1,246	1,591 1,605 2,083 36 931	1,738 1,778 2,435 	1,904 1,198 2,435 35 929	113.9	19.7 -25.4 16.9	-32.6
REASON FOR ED CONTACT Unexpected reaction Overdose Chronicaled	513 3,314 370 86	487 3,536 391 80	413 3,405 313	3,745 432 133	911 3,710 754 179	693 3,574 717	955 4,080 395 163	1,021 3,930 239 191	99.0 18.6 -35.4	47.3	-39.5
Seeking detoxification Accident/injury Other Unknown.	413 .:: 123	340	272	301	388 386 762 106	293 200 200 555 80	356 220 521 106	197 256 	i	-32.8	62.3
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died Unknown.	3,038 1,911 138 10 10	3,244 1,826 121 101 28	3,164 1,659 121 22	3,829 2,136 136 16	4,484 2,547 114 12 40	3,975 2,107 120 18	4,377 2,193 164 10 51	3,903 2,383 157 16 41	28.5	30.8	-10.8
TOTAL DRUG ABUSE EPISODES	5,141	5,230	4,975	6,194	7,198	6,245	6,796	6,500	26.4		

<sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

Table 5.2.7 - ED drug episodes by episode characteristics: Estimates for Denver by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	2,538	2,105	1,644	2,031	1,845	2,343	2,311	2,655		13.3 13.8	14.9
DRUG USE MOTIVE Psychic effects Dependence Suicide	1,027 585 2,009	1,141	883 539 1,549	854 887 1,649	743 862 1,463	1,222 1,189 1,620	1,308 1,221 1,749	1,048 1,548 1,824	164.6	-14:2 30:2	-19.9 26.8
Other	1,299	31 683	395	37 905	1,002	751	38 629	32 1,016			61.5
REASON FOR ED CONTACT Unexpected reactionOverdose	910	987	737	927	905	1,163	1,173	1,092			<u>φ</u>
Chronic effects	195 82	121	7 <u>9</u> 2	205 125	147	240 176	300	376	92.8	56.7 16.5	25.3
Seeking detoxilication Accident/injury Other Unknown	124	748 155	412 121	223 484 275	383 349	380 190 364 242	383 251 632 89	261 850 274	110.5	37.4 133.5	14.6 34.5 207.9
PATIENT DISPOSITION Treated and released Admitted to hospital	2,893	3,042	1,979	2,493	2,246	2,442	2,751	3,134		28.3	13.9
Left against medical advice	200	27	17	4 11 55	20 6 4	51	39 18 47	21 12	154.5	7	43.6
TOTAL DRUG ABUSE EPISODES	4,951	4,606	3,416	4,332	4,087	4,815	4,944	5,468		13.6	10.6

¹ This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.



Table 5.2.8 - ED drug episodes by episode characteristics: Estimates for Detroit by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode	7,398	7,208	7,832	6,506	6,244	5,971	5,577	6,366			
Multi-drug episode	10,254	11,418	12,963	11,098	11,233	10,154	11,465	12,899		27.0	
DRUG USE MOTIVE Peuchic effects	3.872	7.168	7.086	5.161	5.555	5,446	6.779	7.063	82.4	29.7	
Dependence	7,146	6,954	8,452	7,703	7,298	6,403	6,897	7,112			
Suicide	3,635	3,552	3,902	3,109	2,847	2,516	2,265	3,082		_	36.1
Other	138	43	28	47	47	<u>\$</u>	63	7.1		-61.4	
Unknown	2,861	806	1,298	1,584	1,730	1,575	1,038	1,936			86.5
REASON FOR ED CONTACT											
Unexpected reaction	3,789	2,512	3,716	4,346	3,897	3,295	3,900	5,051		53.3	29.5
Overdose	5,178	4,857	5,400	4,701	4,006	3,798	3,748	5,707		50.3	52.3
Chronic effects	3,358	6,760	6,726	4,231	4,351	4,249	4,986	3,906			-21.7
Withdrawal	309	411	689	616	571	295	772	775	150.8	37.9	
Seeking detoxification	1,495	1,306	1,426	1,180	1,601	830	:	471		43.3	
Accident/injury	2,022	2,046	2,168	1,883	2,052	2,031	2,031	2,249			
Other	335	221	202	355	728	840	734	772			
Unknown	1,165	513	469	293	270	519	407	335		-35.5	
PATIENT DISPOSITION											
Treated and released	9,588	9,921	13,995	11,009	10,728	10,048	11,115	11,909			
Admitted to hospital	7,594	8,125	6,234	6,179	6,300	5,619	5,393	6,921			28.3
Left against medical advice	348	414	389	308	315	325	391	334			
Died	38	26	29	32	43	38	2	53			
Unknown	82	139	110	77	6	95	8	48		49.5	40.0
TOTAL DRUG ABUSE EPISODES	17,653	18,626	20,796	17,604	17,477	16,125	17,042	19,265			

¹ This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (…) indicate that an estimate with an RSE greater than 50% has been suppressed.

### Table 5.2.9 - ED drug episodes by episode characteristics: Estimates for Los Angeles by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	10,233	10,412	11,156	9,494	8,202	9,294	10,798	10,282	59.6	10.6	
DRUG USE MOTIVE Psychic effects Dependence Suicide	4,383 6,582 5,828 159	4,390 6,686 5,696 169	4,460 7,937 5,978	4,250 6,503 4,861	3,910 7,336 4,153	5,938 8,153 4,138	7,533	7,594 10,800 3,501	64.1	32.5	-25.5
Unknown.	2,297	2,318	1,731	1,495	1,580	2,359	2,570	2,651			
Unexpected reaction Overdose Chronic effects	2,999 8,668 3,276	3,146 8,255 3,491	2,401 8,619 4,311	2,367 7,325 3,320	3,210 6,429 4,331	5,619 6,723 4,611	7,151 7,237 6,667	7,498 5,901 7,060	-31.9 115.5	53.1	-18.5
Seeking detoxification Accident/injury Other Unknown.	723 775 1,738 549	704 851 1,660	682 1,001 2,002 674	2,011 2,011	384 496 1,138	425 603 1,246 993	525 611 1,440 1,055	594 594 796 1,188			30.3 -17.5
PATIENT DISPOSITION  Treated and released  Admitted to hospital  Left against medical advice  Died	10,296 8,110 598 47	10,773 7,786 515 50	11,053 8,548 472 39	9,485 7,149 431 29	8,443 8,055 422 40	9,655 10,248 624 41	10,586 13,816 633 45	10,558 13,153 758	62.2	21.5	19.7
TOTAL DRUG ABUSE EPISODES	19,250	19,258	20,275	17,187	17,103	20,677	207 25,286	24,669	_	19.3	

¹ This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

Table 5.2.10 - ED drug episodes by episode characteristics: Estimates for Miami by year

Episode characteristics	Totai 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode	3,238 2,670	3,607	3,533	3,296 2,987	3,193	3,420 3,707	3,969 4,590	3,740 5,146	15.5 92.7	38.8	
DRUG USE MOTIVE Psychic effects Dependence Suicide	740 3,168 1,385	721 3,545 1,448	812 3,499 1,327	3,762 1,194	592 4,156 1,083	607 4,930 987	794 5,833 1,309	656 6,394 1,382	101.8	29.7	
Other	36 579		638	615	10 584	40 562	26 598	430	-33.3 -25.7		-28.1
REASON FOR ED CONTACT Unexpected reaction Overdose Chanic effects	185 2,273 2,162		201 2,274 2.035	188 1,953 2,002	253 1,815 2,155	210	239 2,094	2,102 3,215	-7.5 48.7	22.6	
Withdrawal Seeking detoxification Accident/injury	37 742 284	40 842 236	1,246 220	109 1,449 236	1,518	1,749 285	2,332 2,332 292	2,707	75.7 264.8 28.5	54.8 28.1	-19.8
OtherUnknown	196	220 220	224	320 320	274	325	396	193			-51.3
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died Unknown	3,683 2,033 155 9	4,046 2,199 147 	4,107 2,021 118 	4,308 1,857 67 1 50	2,176 2,176 62 14	4,763 2,246 76 9	5,596 2,865 53 	5,973 2,738 127 2 46	62.2 34.7 -18.1	25.4 21.9 67.1 -77.8	139.6
TOTAL DRUG ABUSE EPISODES	5,908	6,417	6,283	6,283	6,426	7,128	8,560	8,886	50.4	24.7	

¹ This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</p>
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.



### Table 5.2.11 - ED drug episodes by episode characteristics: Estimates for Minneapolis by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	1,824 2,540	1,824	2,097	2,157	1,913 2,416	1,862	2,077	2,756 3,765	51.1 48.2	48.0 35.4	32.7
DRUG USE MOTIVE Psychic effects	894	816 500	1,015	1,317	1,127	1,163 694	1,068	1,315	252.7	138.3	65.4
Suicide Other Other Unknown	2,707 72 222	2,713 61 234	2,910 50 258	2,740 69 255	2,342 59 273	2,496 72 218	2,687 88 354	2,993 142 418	88.3	19.9 97.2 91.7	61.4
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects	408 3,293 87	3,094 112	546 3,477 66	3,326	2,893	2,971	3,094 32	3,380		13.8 96.3	9.2 85.8 85.8
Withdrawal Seeking detoxification Accident/injury Other Unknown.	166 166	64 168 197 175	90 217 66 200 167	106 234 74 242 214	115 250 52 217 186	340 59 243 188	88 440 65 329 265	201 775 121 463 442	258.9 366.9 	123.3 127.9 105.1 90.5 135.1	128.4 76.1 86.2 66.8
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice	1,752 2,536	1,660 2,557 27	2,028 2,697 39	2,051 2,807 46	1,784 2,467 36	1,843 2,714 47	1,945 3,160 42	2,489 3,913 39	54.3	35.1	28.0 23.8
Died	10 37 4,364	71	4 60 4,828	 48 4,957	11 30 4,328	7 32 4,643	5,197	9 71 6,521	91.9	121.9	51.1 25.5

<sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (…) indicate that an estimate with an RSE greater than 50% has been suppressed.



Table 5.2.12 - ED drug episodes by episode characteristics: Estimates for New Orleans by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode	1,404	2,177	2,315	2,058	2,008	1,578	1,687	1,528			
Multi-drug episode	3,332	3,690	3,528	3,151	3,080	2,881	2,977	2,201	-33.9	-23.6	-26.1
DRUG USE MOTIVE Psychic effects	647	626	717	492	694	644	570	845			48.2
Dependence	2,941	3,642	3,690	3,388	3,305	2,947	3,041	1,18	-59.7	-59.8	-61.1
Suicide	896	1,353	1,203	1,078	937	715	773	629	-31.9	7 444	9 690
Other Unknown	155	212	218	229	139	141	260	975	529.0	591.5	275.0
REASON FOR ED CONTACT	601	497	444	335	476	39	474	551			
Onexpected reaction	1.457	2,001	1,918	1,696	1,690	1,499	1,604	1,373			
Chronic effects	915	1,448	1,424	1,220	1,245	1,220	1,038	164	-82.1	-86.6	-84.2
Withdrawal	9	72	<u>\$</u>	69	89	88	125	121	101.7		,
Seeking detoxification	432	249	387	405	418	386	687	327	72.0	2 62	4 6 6 7 8 7
Accident/injury	223	7.7	628	289	436	404	358	105	-73.9	-74.2	-20.7
Unknown.	328	¥	63	96	77	•	<b>1</b> 04	874		:	740.4
PATIENT DISPOSITION	3.454	4.746	4.478	3.743	3.825	3.318	3.384	2.197	-36.4	-33.8	-35.1
Admitted to hospital	1,113	1,007	1,237	1,319	1,126	988	1,113	1,338		35.4	20.2
Left against medical advice	126	82	85	118	17	120	141	124			
Died Linknown	11 32	: 58	3 2	:2	25 0	27	:23	57	78.1		147.8
TOTAL DRUG ABUSE EPISODES	4,737	5,867	5,844	5,209	5,088	4,459	4,664	3,729	-21.3		-20.0
				1							

 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

#### Table 5.2.13 - ED drug episodes by episode characteristics: Estimates for New York by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	25,403	22,542 18,250	19,751	18,391 18,720	18,191 17,950	14,834	15,249 16,634	16,426 15,881	-35.3		
DRUG USE MOTIVE Psychic effects Dependence Suicide	2,570 31,724 3,044	4,068 29,363 3,283	4,674 27,827 3,500	5,794 23,661 3,371	4,856 23,530 3,253	3,300 20,432 2,716	3,206 21,537 3,004	2,923 22,233 2,901			
Other	5,588	4,030	115 4,352	86 4,199	35 4,467	4,101	3,955	272 3,978	403.7 -28.8	140.7	50.3
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects	3,131 7,350 17,152	2,571 7,258 14,853	3,048	4,036 6,850	4,991 6,923 7,858	4,392 6,428 5,877	4,383 6,021	4,330 5,369	202		
Withdrawal Seeking detoxification Accident/injury Other	1,051	7,116	1,603 12,283 428	1,131	1,359 10,904 492	9,306	1,452 10,963 475	10,684	149.9	100.1	52.7
Unknown	2,635	2,553	2,690	3,042	2,682	2,462	2,359	3,083		25.2	30.7
Traile in Distriction Treated and released Admitted to hospital Left against medical advice Died Unknown	23,284 18,192 1,241 53 209	19,636 19,754 1,082 69 252	18,573 20,840 783 51	18,528 17,536 810 53 183	18,071 17,020 786 25 238	15,910 13,761 694 20 277	17,021 13,944 628 39 251	18,565 12,659 731 58 295	4.	190.0	
TOTAL DRUG ABUSE EPISODES	42,980	40,792	40,468	37,111	36,141	30,662	31,882	32,307	-24.8		

 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

Table 5.2.14 - ED drug episodes by episode characteristics: Estimates for Newark by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change <sup>†</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	4,193 5,201	4,695 6,175	3,988 5,921	4,206 4,686	4,085 4,859	3,950 4,351	3,734 4,013	3,354 3,863		-15.1	-10.2
PRUG USE MOTIVE Psychic effects Dependence Suicide Other	908 7,139 1,134	1,182 8,213 1,242 12	1,297 7,222 1,215 12 12	1,267 6,328 1,049 	1,006 6,768 923 	1,028 5,953 998 20 303	911 5,413 1,067 42 313	1,094 4,605 1,146 21 351	į	-22.6 14.8	-14.9
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal Seeking detoxification Accident/injury Other Unknown.	237 2,538 2,533 363 3,592 132 67	334 2,773 2,974 439 3,893 158 158	2,549 2,841 2,841 435 3,491 156 99	324 2,290 3,872 1,160 359 135	399 2,264 3,469 1,505 266 134	507 2,214 2,800 743 1,556 186 137	2,111 2,779 819 970 240 194	2,184 2,184 663 663 262 262 192	82.6 -86.2 120.7	-10.8 -68.2	-19.0 49.0
PATIENT DISPOSITION  Treated and released Admitted to hospital Left against medical advice Died Unknown.	3,388 5,714 219 22 49 9,394	4,180 6,339 293 22 22 37 10,870	4,240 5,412 196 22 29 39 9,909	5,519 3,063 227 224 60 8,893	5,536 2,927 438 11 33	4,869 2,749 600 20 63 8,301	4,988 2,142 525 13 79	4,975 1,929 222 9 82 7,217	46.8 -66.2	-29.8 -63.0 -13.1	1.72-

<sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (…) indicate that an estimate with an RSE greater than 50% has been suppressed.

### Table 5.2.15 - ED drug episodes by episode characteristics: Estimates for Philadelphia by year

	1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change 7 1994, 2001	% change 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode	8,036 9,695	9,164	9,783 11,845	9,963 13,263	10,600	10,232	9,550 13,881	10,610	32.0 56.6		11.1
DRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	2,786 6,783 4,825 98 3,238	3,193 9,021 4,928 227 3,133	2,757 9,087 5,335 256 4,194	3,655 9,556 5,537 151 4,326	3,795 11,423 5,318 60 4,328	4,297 11,305 4,331 93 4,387	3,503 12,127 4,450 117 3,233	3,546 13,114 4,695 171 4,263	93.3		
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal	4,170 6,775 1,453	4,047 6,656 2,368	4,086 7,144 2,111 650	4,514 6,754 2,783	4,309 6,686 3,484	4,123 5,557	4,428 5,794 2,884	5,635 5,860 3,722		36.7	27.3
Seeking detoxification Accident/injury Other Unknown	1,795 1,170 757 835	2,748 1,186 1,130	2,505 1,264 2,127 1,741	2,907 1,303 2,578 1,462	2,616 1,567 3,781 1,662	2,282 1,362 4,037 2,963	3,483 960 2,694 2,458	3,245 1,455 1,957 3,162	158.5 278.7		-27.4
PATIENT DISPOSITION  Treated and released  Admitted to hospital  Left against medical advice  Died  Unknown	8,942 7,804 646  282	10,327 9,188 624 68 295	11,064 9,862 483 80 140	12,057 10,356 580 53 178	12,325 11,792 538 76 193	12,898 10,647 588 58 222	11,186 11,150 728 72 295	13,935 10,774 825 92 164	55.8 38.1	40.3 58.6	24.6

 1 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

#### Table 5.2.16 - ED drug episodes by episode characteristics: Estimates for Phoenix by year

	1994	1995	1996	1997	Total 1998	l otal 1999	Total 2000	Total 2001	1994, 2001	1999, 2001	2000, 2001
DRUG CONCOMITANCE	3.467	3.881	3,617	3,421	3,353	4,394	4,714	4,915	41.8		
Multi-drug episode	3,341	4,029	3,814	3,906	3,705	3,897	4,358	5,168		32.6	18.6
DRUG USE MOTIVE	2 233	2 416	2619	2 696	2.340	2 555	2.073			-24.4	
Psychic effects	668	798	202,7	952	1,013	1,355	2,364			135.6	
Siricide	2,802	3,046	2,564	2,309	2,205	2,478	3,080		31.5	48.7	19.7
Other	40	35	1 491	1 342	21	1 880	1 469	180		682.6	109.3
Unknown	3		-	!	:		<del>}</del>				
REASON FOR ED CONTACT	,	,	2,7	000	900	4 647					
Unexpected reaction	002,1	015,1	201,1	076,1	007,1	7,0,0				0 10	400
Overdose	3,642	4,177	3,723	3,554	195,5	3,708			2.4.2	1 0	12.0
Chronic effects	099	9/3	1,266	060'L	1,2/4	45°,-				0.1.0	
Withdrawal	127	146	ষ্	82	118	174				7.68	
Seeking detoxification	8	215	222	204	132	182					
Accidentining	235	377	475	426	420	029	135	102		<del>2</del> 4 8.	
Other	712	258	253	176	231	180				83.3	40.4
Unknown	137	:	247	254	224	196				-36.2	
PATIENT DISPOSITION											
Treated and released	3,836	4,300	4,410	4,008	4,2/9				0.00	6.0.3	
Admitted to hospital	2,744	3,326	2,701	2,403	2,558						
Left against medical advice	139	<u> </u>	791	202	<u>.</u>	7/-	19	14		55.6	
Linknown	<u> </u>	32	92	45	67			_			-44.3
TOTAL DRUG ABUSE EPISODES.	6,808	7,910	7,431	7,327	7,058	8,291	9,072	10,084	48.1	21.6	
TOTAL DRUG ABUSE EPISODES	6,808	016'/	7,431	1,35,1	8cn, /	167'9	9,0,2				

¹ This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an

estimate with an RSE greater than 50% has been suppressed.

ED = emergency department.

Table 5.2.17 - ED drug episodes by episode characteristics: Estimates for St. Louis by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>†</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE											
Single-drug episode	2,653	2,477	2,847	2,463	2,350	2,718	2,750	3.172			
Multi-drug episode	3,385	3,181	3,333	3,201	3,368	3,618	4,158	5,044			
DRUG USE MOTIVE											
Psychic effects	1,084	1,017	995	913	1,005	1.073	1.042	1 224			
Dependence	1,607	1,259	1,510	1,341	1,897	2,179	2,640	3,547			
Suicide	2,695	2,677	3,081	2,572	2,014	1,950	2,144	2.437	_	25.0	
Other	42	32	31	23	26	103		71			
Unknown	610	671	295	816	747	1,031	1,030	936			
REASON FOR ED CONTACT											
Unexpected reaction	1,168	1,083	1,194	746	625	653	657	043		7 7 7	4
Overdose	3,036	2,996	3,463	3,134	2,611	2.518	2.771	2 846		Ť	4. C.
Chronic effects	221	165	165	144	102	110	95	156			
Withdrawal	113	\$	126	151	179	222	320	368	225.7	858	
Seeking detoxification	707	230	490	462	825	1,201	1.516	2.033		2	
Accident/injury	204	136	167	259	191	188	160	186			
Other	391	488	393	929	973	1,071	1.217	1.007			
Unknown	199	175	182	243	212	373	172	229			
PATIENT DISPOSITION	_				_				_		
Treated and released	2,151	2,070	2,183	1,755	1,822	2.032	2.206	2.670			
Admitted to hospital	3,760	3,441	3,834	3,774	3,803	4,114	4.482	5.336			
Left against medical advice	82	82	66	91	8	66	151	159			
Died	=	3	18	80	9	12	:		-		
Unknown	<del>-</del> -	09	45	32	स्र	79	61	47	•	40.5	
TOTAL DRUG ABUSE EPISODES	6,038	2'657	6,179	5,664	5,719	6,336	6,908	8,216			
								1			

<sup>1</sup> This column denotes statistically significant (*p* < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for *p*-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (…) indicate that an estimate with an RSE greater than 50% has been suppressed.

Table 5.2.18 - ED drug episodes by episode characteristics: Estimates for San Diego by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change ' 2000, 2001
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	2,507	2,240	2,748 3,058	3,261 3,486	3,421 3,560	3,421	3,223	3,564	42.2 33.9		-7.9 5.4
Psychic effects  Psychic effects  Dependence  Suicide  Other	842 1,416 2,023 45 717	939 925 1,750 35 1,010	1,153 1,559 2,091 27 975	1,148 2,023 2,419 34 1,123	1,245 2,175 2,381 47 1,133	1,646 1,932 2,214 65 1,178	1,277 2,595 2,213 30 978	1,833 1,915 2,200 35 978	117.7	-46.2	43.5
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal Seeking detoxification Accident/injury	1,144 2,564 667 114 114 195	1,207 2,309 525 130 128 115	1,445 2,769 628 182 182 162 162 193	1,251 3,246 1,128 210 199 332 218	1,309 1,098 1,098 2,65 2,85 2,65	1,179 2,969 1,331 240 291	1,563 2,244 2,326 234 140 93	1,609 2,298 1,868 195 160 78	40.6 180.1 71.1 60.0	36.5 -22.6 40.3 -48.7 -73.2	-19.7 -16.7 14.3
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died Unknown	103 2,896 1,944 154 12 37 3,043			3,863 2,644 161 13 66		246 4,056 2,765 122 10 83	270 4,141 2,799 76 3 74 7,094	3,916 2,904 91 6 45 6,962		25.4 -40.0 -45.8	

<sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

Table 5.2.19 - ED drug episodes by episode characteristics: Estimates for San Francisco by year

Episode characteristics	Total 1994	Total 1995	Total	Total	Total	Total	Total	Total	% change <sup>1</sup> 1994,	% change <sup>1</sup>	% change <sup>1</sup>
						222	2000	7007	2001	2001	2001
DRUG CONCOMITANCE							-				
Aingle-drug episode		6,035	5,955	6,298	6,409	6,088	4,662	4,882	-34.8	-19.8	47
winin-drug episode	4,623	4,126	3,577	3,126	2,659	2,840	3,196	3,693	-20.1	30.0	15.6
DRUG USE MOTIVE		_			-						
Psychic effects	2,266	1,473	1,494	1.111	808	026	1 017	1 137	0 07		•
Dependence	5,842	4,909	4,417	6.145	5.997	5 733	4 679	7,13,	0.00	7:71	11.8
Suicide	2,029	1,657	1,593	1,320	1,171	1,153	1.182	1 449	-286	757	9.7 9.7
Cther	35	8	39	26	27	38	68	110	214.3	180 5	27.0
Unknown	1,943	2,092	1,989	822	1,065	1,034	890	772	-603	0.601	23.0
REASON FOR ED CONTACT							_				
Unexpected reaction	1,482	1,194	1,132	1.024	1.233	1 183	1 314	1 012			ě
Overdose	4,482	3,575	3,546	2.776	2.484	2384	1,00	210,-	.1.7	_	-23.0
Chronic effects	4,345	3,725	3,355	4 233	3 975	2,627	2,00	2,0	9.70	,	14.2
Withdrawal	418	385	424	377	481	7,027	2,070	3,240	7.07-	-10.4	21.3
Seeking detoxification	199	183	229	183	148	200	5 6	7 6	ان 1.3	25.6	ω. Θ.
Accident/injury	202	ARR	9 0	2 5	1	077	107	9	23.8	35.4	
Other	320	400	001	243	193	985	255	255	-57.1	-33.9	
Inknown	300	200	203	acco	LQS :	420	639	710	8.76	0.69	
	253	<u>+</u>	7/1	223	195	266	106	119	49.4	-55.3	12.3
PATIENT DISPOSITION											
Treated and released	8,740	7,364	6,764	6.867	6.276	5 894	5 173	270	0 00		į
Admitted to hospital	3,048	2,595	2,588	2,396	2.566	2,800	2 523	2,0	0.00		ب 4 ا
Left against medical advice	204	129	128	86	154	158	105	2,5	0 00		7.62
Died	4	œ	Ξ	_	ır.	7	3 "	2 6	507-	í	38.1
Unknown	110	65	42	63	89	99	27	, G	-/0.0 47.7	0.0/-	40.0
TOTAL DRUG ABUSE EPISONES	12 115	10 161	0 533	70,70	- 000	-		3	?	_	
	2	10,101	9,000	9,424	890,8	8,928	7,857	8,575	-29.2		9.1

This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

#### Table 5.2.20 - ED drug episodes by episode characteristics: Estimates for Seattle by year

Episode characterístics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	5,204 5,159	4,508 3,997	4,643	5,234	4,351 3,976	3,904	5,644	5,732 5,763		26.8	5.3
DRUG USE MOTIVE Psychic effects	896	756	922	1,033	764 2,430	791	3,180	3,884	41.2	31.3	
Suicide Other Unknown	3,608 89 2,935	2,690	2,630	2,996 65 3,520	2,464 55 2,614	2,187 53 2,436	2,834 95 3,357	2,341 197 2,808	121.3	271.7	107.4
REASON FOR ED CONTACT Unexpected reaction	1,997	1,578	1,651	3,972	1,852	3,018	3,803	1,064		41.3 38.9 51.13	-26.0 10.2 -25.7
Chronic effects Withdrawal Seeking detoxification	263 243	153 153	334 214 256	437	247 247	397	526 502 773	558 525 525	112.2		
Accident/injury Other Unknown	225 131	120	154	221	199 233	134	685 261	1,585	1,109.9	1,082.8	131.4
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice	6,388 3,654 250	5,608 2,705 152	5,575 2,631 156	6,781 3,494 188	5,675 2,427 136	5,832 2,352 142	3,344	7,341 3,815 201		25.9 62.2 41.5	14.1
Died	4 89	36	90	121		91	138	135	98.5		
TOTAL DRUG ABUSE EPISODES	10,363	8,505	8,471	10,587	8,327	8,424	11,115	11,495		36.5	

This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 5.2.21 - ED drug episodes by episode characteristics: Estimates for Washington, DC by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994,	% change 1999,	% change 2000,
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	6,525	6,038	5,926	5,698	6,107	5,587	5,912	5,595		1002	2007
DRUG USE MOTIVE Psychic effects Dependence	1,836	1,633	1,235	1,062	1,087	1,163	1,877	1,824			
Suicide Other Unknown.	4,897	4,156	3,849	3,580	3,185	2,815	2,849 2,849 	3,198			
REASON FOR ED CONTACT Unexpected reaction	2,169	2,100	1,706	1,571	1,723	1,998	2,481	2,019		-Ze.u	
Chronic effects Withdrawal Seeking detoxification	1,147 369 1,030	4,362 1,206 327 889	3,879 1,435 427 1,068	3,863 1,177 491 918	3,955 1,587 606 1,143	3,258 1,203 579 815	3,156 1,192 582 741	3,379 886 792 976	-37.8 -22.8 114.6		-25.7 36.1 31.7
Other Unknown PATIENT DISPOSITION	1,652	1,586	1,873	1,706	1,477	1,355	1,152	1,598 348	-54.0		
Treated and released Admitted to hospital Left against medical advice Died Unknown	6,446 7,087 513 37 69	5,489 5,870 359 31	5,910 5,362 352 32 64	5,550 5,243 301 	5,900 5,317 285 21	5,472 4,521 205 18 67	5,603 4,405 214 18 65	5,530 4,603 252 23 159	-50.9		
TOTAL DRUG ABUSE EPISODES	14,152	11,830	11,720	11,193	11,596	10,282	10,303	10,566			

 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed.

#### Table 5.3.0 - ED drug mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characterístics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>†</sup> H1 2001, H1 2002
DRUG CONCOMITANCE Single-drug episode	118,048 352,037	121,855 369,554	117,834 372,521	117,604 391,845	122,051	133,705	129,807	138,660	140,966	138,113	0.5	
DRUG USE MOTIVE Psychic effects	78,115	82.788			100 618	107 097	104 363	100	9		2	
Dependence Suicide		163,238			180,882	189,746	191,664	201,740	209,401	202,060	-12.2	
Other		3,924	4,487	6,780	4,398	197,195 6,155 53,180	189,841 7,738 55,307	185,080 6,101	195,681	180,458		
REASON FOR ED CONTACT								3				
Overdose		243,240		61,555 225,572	74,272 226,130	76,802 262,618	79,999 255,107	89,323	93,777	93,137	9.7	
Chronic effects	40,399	41,908		39,982	40,023	42,041	43,228	44,821	43,274	38,510	<u>.</u>	
Seeking detoxification	69,326	67,377		65,282	71,542	15,097 87,608	17,456 82.584	19,837	17,531	19,559		
Accident/injury Other	19,782	16,573	18,141	21,449	17,754	16,080	13,078	16,301	18,173	14,872		
Unknown	30,330	23,016		22,940	24,331	21,663	25,187	26,173	28,586	26,397		
PATIENT DISPOSITION								_				
I reated and released	215,515	212,348	216,635 258,204	217,195	223,080	305,810	231,710	246,270	258,055	246,823		
Left against medical advice	10,458	8,452	8,286	9,165	9,396	10,709	9:056	10.557	11.476	10,003		
Died	597	1,636	786	1,142	1,199	1,171	1,398	778	1,610	1,356		
TOTAL DRUG ABUSE MENTIONS	470,085	491,409	490,355	509,449	504,795	553,303	546,004	566,106	599,261	3,570 564,196		40.4

 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

Table 5.4.0 - ED drug mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characterístics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	253,061 646,540	243,927 656,360	241,746 664,620	240,881 701,501	239,689 742,076	239,655 774,588	263,513 835,794	279,626 885,741	37.0	16.7	6.1
DRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	142,202 275,841 371,704 8,458 101,396	154,063 276,916 373,034 7,961 88,313	164,806 289,986 354,669 8,606 88,299	162,192 311,988 363,510 9,522 95,170	169,619 332,085 370,348 8,411	186,799 357,234 349,754 11,178	208,390 381,411 387,036 13,893	226,416 411,141 380,761 16,511	59.2 49.0 95.2	21.2	8.7
REASON FOR ED CONTACT Unexpected reaction Overdose	107,591	94,892	100,610	113,502 455,133	118,105	135,827	156,801	183,100	70.2	12.4	16.8
Chronic effects  Withdrawal Seeking detoxification Accident/injury	20,930 20,930 92,239 29,596 38,437	21,518 21,518 93,317 29,009 41,840	22,674 111,619 32,868 48,120 43,563	79,667 22,541 129,173 37,370 49,988 55,006	27,658 138,116 34,714 65,160	90,003 41,037 136,824 39,203 82,374 47,271	22,553 32,553 170,192 29,158 60,757 46,850	37,368 191,779 34,473 67,954	78.5 107.9 76.8 44.8	40.2	
PATIENT DISPOSITION  Treated and released  Admitted to hospital Left against medical advice	394,761 475,497 15,818	ω 4	402,210 478,237 14,387	424,241 484,396 20,585	428,983 521,318 16,738	440,275 541,414 18,562	461,158 601,743 20,665	504,325 625,684 22,033	27.8 31.6 39.3	14.5	9.4
Died Unknown TOTAL DRUG ABUSE MENTIONS	1,886 11,638 899,600	8	9,771 9,771 906,366	1,258 11,902 942,382	2,423 12,303 981,764	2,341 11,651 1,014,243	2,569 13,172 1,099,306	2,360 10,938 1,165,367	29.5	14.9	6.0

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



# Table 5.5.0 - Alcohol-in-combination: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

								ונפא וסו	ine colei	snoull	distribution of the constitution of the consti	alt year
Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001,	% change H1 2001,
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	N/A 86,744	N/A 91,064	N/A 93,927	N/A 102,088	N/A 94.134	N/A 100 347	N/A 104 164	N/A	N/A	A/N	7007 14	H1 2002
DRUG USE MOTIVE Psychic effects			16,020	16,897	20.013	20,329		20,40	13,472	97,52,78	-14.1	
Dependence Suicide Other	35,737 26,237 724	35,523 30,994 475	37,251 30,688	42,158 31,429	36,866	38,970	40,378	42,757 29,340	45,475 45,475 31,368	41,625 24,673	-21.3	-15.9
UnknownREASON FOR ED CONTACT	8,528	8,640	9,577	10,902	8,947	9,609	833 9,547	613 11,207	1,167	1,285 9,244		
Unexpected reaction Overdose Chronic effects	11,558 32,968 8,132	11,879 39,275 8,072	12,144 37,032 8,084	12,604 37,477 8,227	16,168 36,768 7,689	16,253 41,394 8 531	17,743 43,471 8 720	16,906	20,446,42,550	17,473	-21.6	-15.2
Withdrawal Seeking detoxification Accident/injury Other Unknown.	1,332 18,824 4,445 4,125 5,359	1,588 16,691 4,037 5,184 4,339	2,245 18,583 4,650 6,548 4,640	16,537 5,677 11,110 4,450	2,321 16,415 3,942 6,302 4,530	1,632 19,673 3,747 5,137 3,980	2,436 18,696 3,186 4,920 4,984	2,213 2,884 21,814 3,904 5,898 4,576	6,997 24,297 4,426 6,071	24,074 3,639 5,494 5,494	-23.1	-25.0
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died	41,061 42,168 2,454 29	39,886 48,364 1,700 231	41,261 49,953 1,265	44,384 54,454 1,937	42,248 48,874 1,759	41,764 55,481 1,926	45,360 54,999 2,095	46,057 54,939 2,380	47,348 62,823 2,233	41,543 53,635 1,824	-12.3	
UnknownTOTAL MENTIONS	1,031	91,064	1,258	1,069	1,168	1,069	1,359 104,164	1,106 104,533	844	430	-14.1	61.1

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. | This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, N/A = not applicable. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

## Table 5.6.0 - Alcohol-in-combination: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	N/A 160,798	N/A 166,907	N/A 166,172	N/A 171,963	N/A 184,991	N/A 196,222	N/A 204,510	N/A 218,005	35.6 35.6	Y/Z	<b>∀</b> /Z
DRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	27,343 59,447 54,261 940 18,806	29,036 61,476 59,120 1,249 16,026	32,081 63,457 54,167 1,236 15,231	31,066 68,889 55,176 1,089	31,451 72,775 61,682 866 18,217	36,910 79,024 59,211 1,228 19,849	41,501 79,349 63,174 1,330 19,156	44,355 88,231 60,708 1,780 22,930	62.2 48.4	20.2	
REASON FOR ED CONTACT Unexpected reaction	23,889	21,351	21,191	23,796	24,022	28,772	33,996	37,352	56.4	29.8	
Overdose Chronic effects	73,177 16,341 2,608	77,955 19,806 2,407	71,315 17,786 3,221	68,539 16,121 2,740	76,307 16,156 3,833	15,916	17,260 4,068	18,205 4,952			
Withdrawal	22,960	24,946	8,064	33,947 8,710	35,274 8,687	32,953 9,619	38,368 6,932	46,111 8,330 11,969	100.8		
Other	6,905	5,456	7,271	9,483	8,980	8,981	8,964	9,199			
PATIENT DISPOSITION Treated and released Admitted to hospital	74,869	76,036 85,006	76,803	79,895 85,348 4 643	81,147 98,317 2,965	86,632 103,329 3,696	87,124 110,480 4.021	93,405 117,762 4,613	24.8 47.0 49.8		
Left against medical advice	2,285	314	1,816	2,006	2,141	2,237	458	1,949			
TOTAL MENTIONS	160,798	166,907	166,172	171,963	184,991	196,222	204,510	218,005	35.6		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, N/A = not applicable. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

; , ,,

### Table 5.7.0 - Cocaine: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

										•		
Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change H2 2001,	% change <sup>1</sup> H1 2001,
DRUG CONCOMITANCE Single-drug episode	24,246 58,113	26,002 59.755	26,376	23,086	25,969	22,675	25,722	28,507	26,140	25,947	7007	H1 2002
DRUG USE MOTIVE				3	200	020,20	04,430	68,245	70,143	65,740		
Dependence		15,045 52,739	15,360 52,650	14,340 47,210	18,321	15,834	18,397	19,063	19,798	15,861	-19.9	
Suicide	7,513	7,869	7,788	7,080	8,174	7,277	8,723	8,780	8,368	9,572 9,572		
Unknown	8,791	9,774	10,218	10,714	10,399	9,725	10,971	305 14,095	487 13.250	618		102.6
REASON FOR ED CONTACT	,					_			}	2		
Overdose	16,132	17,731	17,507	15,943	21,061	20,601	23,124	24,850	24,991	24,119		
Chronic effects	12,192		12,703	11,242	12,086	12,8/1	12,921	14,337	14,355	15,065		
Withdrawal Seeking defoxification	1,843		2,011	2,951	2,471	1,551	1,669	2,771	1,790	. 1. 5. 7.		-16.0
Accident/injury	4,729		4,714	20,203	22,908	25,074	24,453	26,633	27,219	26,249		
Other	4,660	6,279	7,358	8,687	8,086	5,735	5,358	3,628	3,957	2,986	-24.5	-17.7
Olikriown	5,154	4,859	2,006	4,775	5,022	3,371	4,355	5,189	5,300	4.892		
PATIENT DISPOSITION				_								
Treated and released	44,532	46,584	46,249	41,376	48,777	42.542	44.551	49 724	46 832	- 000		!
Admitted to nospital Left against medical advice	34,043 2,552	36,330 1,828	37,200	35,627	38,891	39,499	42,756	44,025	46,622	46,387		-13.4
Died	:	118	116	179	- -	3	1,409	1,870	1,914	1,518		
Unknown	1,065	968	808	803	1,131	752	1,205	951	229	: 2		
TOTAL MENTIONS	82,359	85,757	86,254	79,575	89,176	84,704	90,178	96,752	96,282	91,687	-	
							_		_	-		

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

Table 5.8.0 - Cocaine: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	50,992 92,345	42,667 93,045	49,027 103,393	49,025 112,058	52,379 119,632	49,055 119,696	48,397 126,484	54,646 138,388	49.9	15.6	12.9
DRUG USE MOTIVE Psychic effects Dependence Suicide Other	21,498 91,430 11,699 459	23,501 86,750 12,055 13,002	28,848 95,103 13,043 680 14,746	30,609 99,154 14,449 574 16,296	30,405 105,389 15,658 567 19,992	32,661 99,250 15,254 473 21,114	34,231 103,351 15,999 604 20,696	38,861 108,887 17,148 792 27,345	80.8 46.6 72.5		13.5
	33,750 22,233 27,161 3,351 35,789	25,935 21,169 31,143 3,475	30,420 22,779 28,225 3,673 42,161	32,857 24,250 24,870 3,421 47,842	35,238 25,949 25,634 3,931 49,183	37,004 25,499 23,328 5,422 43,111	43,725 27,792 24,926 3,221 49,527	49,840 28,692 25,945 4,561 53,853		11.2	
Seeking detoxilication Accident/finjury Other Unknown	8,342 6,305 6,406	7,549 8,206 4,674	8,054 8,704 8,403	8,987 8,955 9,902	8,574 13,636 9,865	7,816 16,773 9,797	6,815 11,151 7,726	7,586 12,069 10,489	91.4		35.8
PATIENT DISPOSITION  Treated and released Admitted to hospital Left against medical advice	80,502 58,161 2,960	73,237 57,805 3,124 344	84,617 63,506 3,042 278	87,686 66,785 4,376 381	92,833 73,530 3,708 234	88,153 74,518 3,696 451	87,093 82,255 3,139	96,557 90,647 3,785 366	55.9		10.9
Unknown	1,434	1,201	976 152,420	1,855	1,706	1,934	1,957	1,680	34.7	14.4	10.4

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 5.9.0 - Heroin: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001,	% change <sup>†</sup> H1 2001,
DRUG CONCOMITANCE Single-drug episode	15,802 20,097	17,139	17,190	17,075	21,608	22,925	21,416	19,383	22,230	19,907	7007	7007
DRUG USE MOTIVE Psychic effects	2,624	2,505	2,422	2,831	2,958	3,172	2,485	3.604	3.425	3 352	2	
Suicide	1,731	30,300 1,746	31,047	30,337	36,935 1,588	39,240 1,263	40,144 1,456	36,019	40,772	35,137	-13.8	
Unknown	2,867	3,222	3,007	3,039	3,168	3,604	2,983	2,767	2,847	2,355		
REASON FOR ED CONTACT Unexpected reaction Overdose	3,338	3,864	4,034	3,908	4,758 8,585	4,585 8,032	4,166	4,660	5,130	3,953	-22.9	-15.2
Withdrawal Seeking detoxification Accident/injury	3,454 10,075 736 925	7,872 4,406 10,502 848 1,421	3,946 11,260 789 1,514	3,961 12,107 697 1,850	8,218 5,055 14,364 938 1,985	8,449 5,183 17,402 1,039 2,077	7,702 5,217 18,669 736 1,866	7,583 4,149 16,047 803 2,167	7,313 4,751 19,298 802	6,684 3,889 16,549 653	-	
PATIENT DISPOSITION Treated and released Admitted to hospital	1,675	1,314 21,333 14,863	1,134	1,053 20,088 15,203	24,484 18,185	869 25,191 20,017	1,179 24,930 20,089	1,296 24,771 17,580	1,440	1,144 23,187 17,503	-14.7	
Leit against medical advice Died Unknown.	238 435	1,210 188 265	1,658 223 269	1,657 201 256	1,674 159 284	1,832 177 419	1,564 163 423	1,224 98 466	1,518	1,448		-52.1
TOTAL MENTIONS	35,899	37,859	37,829	37,406	44,786	47,635	47,169	44,138	48,926	42,571	-13.0	

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

Table 5.10.0 - Heroin: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change ' 2000, 2001
DRUG CONCOMITANCE Single-drug episode	29,262 33,897	32,027 37,529	32,942 40,038	30,755 39,958	34,329 41,359	38,683 43,509	44,341 50,463	41,613 51,452	42.2 51.8	18.3	
PRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	4,787 50,363 1,919 126 5,964	6,288 55,120 2,198 64 5,885	6,885 57,046 2,567 83 6,400	5,257 56,499 3,104 133 5,720	4,927 61,348 3,008 176 6,229	5,789 67,272 2,750 174 6,207	5,657 79,383 2,719 457 6,588	7,029 76,791 3,432 198 5,614	46.8 52.5 78.8		
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal Seeking detoxification Accident/injury Other Unknown	6,299 13,119 16,632 6,792 14,714 1,875 1,804	6,127 15,108 17,679 8,147 16,258 1,814 2,630 1,792	6,484 14,738 17,734 7,777 19,026 2,142 2,450 2,630	6,687 14,939 15,754 6,916 19,685 1,548 2,118 3,066	7,898 14,973 15,684 8,353 21,762 1,637 2,935 2,935	8,666 15,413 15,221 9,016 26,471 1,635 1,635 1,935	8,751 15,667 16,151 10,400 36,070 1,775 3,943	9,790 15,850 14,896 8,899 35,345 1,604 3,943 2,736	31.0 140.2 118.6		-7.8
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died Unknown	37,194 22,807 2,460 154 543 63,158	40,400 25,142 2,833 2,833 762 69,556	40,753 28,935 2,316 389 588 72,980	38,592 28,267 2,750 316 786	41,738 30,137 2,868 411 533 75,688	44,572 33,388 3,332 360 540 82,192	50,121 40,106 3,396 339 843 94,804	51,944 37,277 2,742 257 844 93,064	39.7 63.4 47.4	16.5	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.



### Table 5.11.0 - Marijuana: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characterístics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
DRUG CONCOMITANCE Single-drug episode	6,918		7,416		8.655	11 390	11 290	14 511	12 540	1, 30,		
Multi-drug episode		29,293	31,563	32,822	35,319	37,638	36,099	40,653	42,798	41,433		
DRUG USE MOTIVE												
Psychic effects	_		13,067	14,578	17,148	18,017	18,953	19,072	19.621	18.544		
Dependence	_	13,079	13,683	15,029	14,731	16,280	14,481	16,870	16.947	16.237		
Suicide	<u>ო</u>		4,681	4,972	5,083	6,001	5,453	7,202	6.929	7.287		
Other		241	91	:	:	356	259	353	905	562		
Unknown	6,581	7,737	7,456	8,220	6,828	8,373	8,252	11,667	10,945	3 :		
REASON FOR ED CONTACT					_				•			
Unexpected reaction	7,332	9,132	8,872	10,668	12.471	15.105	16.113	18 555	18 071	10 650		
Overdose		7,003	7,212	7,572	9,057	9,450	9.273	11,380	11,080	11,124		
Chronic effects	2	3,457	3,212	3,405	3,484	4,308	4,312	5.038	4.796	4 671		
Withdrawal	479	405	865	:	775	648	753	869	971	579		
Seeking detoxification	5,831	5,444	6,347	5,561	6,346	7,882	6.228	6.864	7.716	7 7 14		
Accident/injury	4,175	3,603	3,531	3,635	3,351	3,137	2.495	2.905	3.226	2416		
Other	3,827	5,899	5,974	7,571	5,621	5,465	5,057	6,002	6.240	5,833		
Unknown	2,764	2,921	2,966	3,125	2,869	3,034	3,168	3,553	3,238	3,731		
PATIENT DISPOSITION												
Treated and released	19,799	22,671	22,275	24,750	24,713	26.731	25.415	29.928	29 913	28 856		
Admitted to hospital	11,487	14,092	15,275	17,010	18,033	20,766	20,949	23,594	24 012	25,628		
Left against medical advice	713	458	006	674	800	980	538	1,209	770	277		
Died	<b>о</b>	25	26	:	:	22	38	23		:		
Unknown.	322	617	203	586	373	529	459	410	: :	339		
TOTAL MENTIONS	32,331	37,863	38,979	43,094	43,974	49.028	47.398	55.164	55 347	55 727		

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.



Table 5.12.0 - Marijuana: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode	8,266 31,768	9,680 35,578	11,653	13,730 50,990	15,986 60,856	18,927 68,141	22,689	27,061 83,451	227.4 162.7	22.5	19.3 13.2
DRUG USE MOTIVE Psychic effects Dependence Suicide Other	12,987 14,996 3,914 242	15,487 18,139 4,423 155	18,405 21,022 5,518 204	21,363 23,936 6,981 242	25,516 26,762 9,040 332	31,725 29,760 10,055	36,970 30,762 11,454 615	38,694 33,817 14,130	197.9 125.5 261.0 419.8	22.0	
Unknown	7,896	7,056	8,622	12,198	15,193	15,048	16,626	22,612			
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal	11,322 7,038 4,220 610	12,012 7,738 6,445 427	14,145 9,841 5,986 682	16,165 10,961 5,594 764	18,004 14,215 6,669 1,271	23,139 16,629 6,889	31,218 18,722 8,620 1,401	36,626 22,469 9,834 1,840	223.5 219.3 133.0 201.6	35.1	1.4.
Seeking detoxilication Accident/injury Other Unknown	4,074 4,434 2,201	7,104 4,056 5,485 1,933	5,700 5,400 6,399 3,561	7,421 7,705 5,193	7,134 11,872 5,886	6,986 13,192 5,995	5,632 10,521 6,202	14,380 6,130 12,242 6,791			
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died Unknown.	23,445 15,296 592 39 39 662	27,375 16,550 844 41	32,990 19,447 714 	39,080 23,289 1,555 18	44,946 29,368 1,357 51 1,120	49,462 35,043 1,474	52,146 41,715 1,518 60 987	59,841 47,606 1,979 	155.2 211.2 234.3		14.8
TOTAL MENTIONS	40,034	45,259	53,770	64,720	76,842	87,068	96,426	110,512	176.0		14.6

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

### Table 5.13.0 - Amphetamines: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
DRUG CONCOMITANCE Single-drug episode	1,607	1,390	1,900	1,659	1,931	2,465 6,031	2,597 6,041	2,855 6,194	2,831	3,415		
DRUG USE MOTIVE Psychic effects Dependence	1,556	1,407	1,742	1,385	1,740	2,807	1,908	2,053	2,926	3,120		
Suicide Other Unknown		1,171 6 1,589	1,298	1,088	1,224	1,405	1,743 347 1,972	1,826 206 2,091	1,908 190 1,839	2,125		
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal Seeking detoxification Accident/injury Other	1,427 2,190 479 67 340 519 519	2,307 2,307 513  291 335,	1,625 2,395 452 380 360 385	1,637 1,941 536 262 334 790	1,596 2,535 562 332 410 650	1,717 2,766 715 185 453 731	1,969 3,311 858 .:. 222 414 1,316	1,920 3,283 949  581 1,084	2,543 3,516 1,079 .:. 404 335 1,060	3,257 3,687 999 72 72 557 643		
PATIENT DISPOSITION  Treated and released Admitted to hospital Left against medical advice Died Unknown	3,045 2,511 223 	2,623 2,735 40 	3,836 2,826 30 .:. 10 6,706	3,386 2,307 137 1 	3,098 3,195  29 6,575	4,964 3,342 83  40 8,497	5,182 3,269 61 14 	4,935 3,892  11 36 9,049	4,972 4,121 	5,756 4,162 140  16		-55.6

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

Table 5.14.0 - Amphetamines: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	4,035	3,541	3,358	2,841	3,290	3,591	5,062	5,686	0 777	58.3	•
Multi-drug episode	6,083	6,040	6,414	969'/	8,893	g,805	2/0,21	12,869	111.6	44.5	
DRUG USE MOTIVE	410 0	707	0 0	0		2			Î		
Psychic effects	3,115	2,497	2,0/2	2,772	3,149	3,120	4,715	4,979	73.2	59.3	
Spirite	1.462	2,073	2,308	2,668	2,469	2,00	3 148	3 735	155.5		
Other	25	:	:	36	:	219	422	396	1.484.0		
Unknown	2,640	2,489	2,145	2,569	2,675	3,027	3,782	3,930			
REASON FOR ED CONTACT											
Unexpected reaction	2,754	2,158	2,365	2,592	2,710	3,233	3,686	4,462			
Overdose	3,837	4,056	4,735	4,142	4,702	4,476	6,077	6,800		51.9	
Chronic effects	006	746	404	797	965	1,097	1,573	2,029	125.4	85.0	29.0
Withdrawal	:	:	42	101	:	196	:	360			
Seeking detoxification	351	369	292	448	671	594	675	984	180.3		
Accident/injury	541	285	292	822	694	743	1,145	833			
Other	824	932	805	756	1,490	1,440	2,682	2,143	160.1		
Unknown	402	:	572	839	709	716	1,002	943			
PATIENT DISPOSITION											
Treated and released	6,489	5,309	5,180	5,656	6,458	6,484	10,146	6,907	52.7	52.8	
Admitted to hospital	3,232	3,740	4,397	4,317	5,561	5,503	6,611	8,013	147.9	45.6	
Left against medical advice	48	÷	71	261	71	329	144	416	1991		
Died	6	9	13	œ	œ	:	;	:			
Unknown	:	:	:	:	:	:	152	:			
TOTAL MENTIONS	10,118	9,581	9,772	10,496	12,183	12,496	17,134	18,555	83.4	48.5	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

### Table 5.15.0 - Methamphetamine: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characterístics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
DRUG CONCOMITANCE Single-drug episode	4,828	3,390	2,367	2,337	2,725	4,088	3,243	3,180	3,536	2,769		
DRUG USE MOTIVE Psychic effects		1,800	1,407	1,229	1,287	1.873	1.539	1.596	2 00 2	1.573		
Dependence	4,785	3,507	2,817	2,897	3,808	4,264	3,740	3,821	3,641	2,971	_	
Other	943	629	446	301	394		009	715	716	782		
REASON FOR ED CONTACT Unexpected reaction	3,091	1,964	2,146	1,250	1,619	1,490	1,614	1.744	1,634	1 432		
Overdose	1,667	1,316 1,036	737 550	876 629	1,006	1,587	1,318	1,671	2,305	974	•	
Withdrawal Seeking detoxification	671	884	400	587	: :[	: :	: :	892	849	985		
Other Unknown	448	592	354	<del>?</del> : :	223	246	: : :	362	223	09 : :		
PATIENT DISPOSITION Treated and released	6,234	4,117	3,394	2,928	3,869	4,528	4,050	3,897	5,015	3,961		
Leff against medical advice	113	112	: - :	: :6	: - :	1::	: - :	: : :	<i>1</i> 2 ∶ ∶	; 4 0	_	
TOTAL MENTIONS	8,936	6,534	4,952	4,730	5,717	7,323	6,182	6,786	8,137	6,136		

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



Table 5.16.0 - Methamphetamine: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Totai 1997	Total 1998	Total 1999	Total 2000	Totai 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	10,097 7,440	8,948 6,985	5,021 5,981	8,956 8,199	5,757 5,729	5,118 5,329	7,331	6,715 8,208			
DRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	4,676 7,141 923 35	3,877 7,245 1,097	3,403 4,848 799	4,525 9,012 1,398 142	3,207 6,323 802 	2,516 6,705 523 7	3,412 8,004 711 1,203	3,618 7,462 1,827 		249.3	
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects	6,367 4,382 2,562	5,166 4,054 2,879	4,202 2,175 1,908	6,671 3,625 2,354	4,110 2,052 1,585	2,869 1,883 1,281	3,104 2,423 2,522	3,378 3,976 2,313		80.6	
Withdrawal Seeking detoxification Accident/injury Other Unknown	1,374 531 888 799	1,098 321 	2// 894 387 635 524		1,284 299 962 651	1,190 102 389	407	1,741	-	316.7	
PATIENT DISPOSITION  Treated and released  Admitted to hospital  Left against medical advice  Died  Unknown	12,729 3,977 266 	10,537 4,813 330 18	7,878 2,699 	11,607 4,910 357 217	7,511 3,341 249 	6,797 3,106 447 2	8,578 4,121 451 2.::	8,912 5,596 164 	i	80.2	
TOTAL MENTIONS	17,537	15,933	11,002	17,154	11,486	10,447	13,505	14,923			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

Table 5.17.0 - MDMA (Ecstasy): ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characterístics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change¹ H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
DRUG CONCOMITANCE Single-drug episode	41	33	633	189 758	447	303 1,823	616 1,770	377	422 2,693	618		
PRUG USE MOTIVE Psychic effects Dependence	 9. :	02 ::	598 135	103	1,471	1,140 466 201	1,337 505 141	1,398 647 86	1,775 801 379	1,150 569 237		
Other Unknown	38	24	45	- :	169	266	396	16 279	152	340		
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects	143	58 : .	237	414 364 21	747 698 56	572 844 63	717 897 108	810 794 145	782 956 130	766 779 92	-29.2	-36.6
Withdrawal	- <u>: 4 យ</u> ល		o	35 35	N : : : :	.:. 13 249	343 42 137	 42 113	 28  224	31 239 46		-39.5
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died Unknown	257	256  3 0	374 414 3 0	535 397  6	1,205 620 18 	1,255 776 19 9	1,630 671 	1,548 783 17 	1,800	1,313 839 		
TOTAL MENTIONS	363	351	792	947	1,903	2,125	2,385	2,427	3,115	2,303		

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, MDMA = methylenedioxymethamphetamine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 5.18.0 - MDMA (Ecstasy): ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode		259	59 260	505	950	636 2,214	918 3,592	799	2,827.8	114.2	
DRUG USE MOTIVE Psychic effects Dependence Suicide Other	127 27 9 0	240 .:: 8 0	199 59 7 3	294 194 19	899	2,101 277 164 164	2,477 971 341 	3,174 1,448 465 24 431	2,399.2 5,263.0 5,066.7	51.1	
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal Seeking detoxification Accident/injury Other		150 141 143 143 143 143 143 143 143 143 143	4 9 0 0 0 4 4 0 1 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	205 169 33 .:.	364 295  0 	1,161 1,062 77 4 4 175 128 120 170	ਦੇ ਦੇ	1,592 1,750 275 275 .:. 70 70 300	2,956 1,650 4,900	257.1	8.09
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died Unknown		287 .: 4 3	233 79 .:	429 128 	630 503 6 0 5	1,740 1,017 28 		3,348 2,003  20	1,368.4 9,438.1 1,900.0		
TOTAL MENTIONS	253	421	319	637	1,143	2,850	4,511	5,542	2,090.5	94.5	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department, MDMA = methylenedioxymethamphetamine.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



Table 5.19.0 - Ketamine: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
DRUG CONCOMITANCE Single-drug episode	10 ::	24	: :	15 194		21 86	36 120	: :	: :	31		
DRUG USE MOTIVE Psychic effects Dependence		23	: 9 :	:6		38	:: <del>1</del> 0	293	: : "			
Unknown	12		0 52	• :	0 8	23 -	25	0 =	04	0 80	-	
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal	: 8:	98 4 0	57	::	37	93 8 <del>-</del>	26 53	198	:::	22 43 13		
Seeking detoxification Accident/Injury Other Unknown	· · · · · · · · · · · · · · · · · · ·	) <u> </u>	, i <sub>0</sub> i <sub>4</sub>	- <mark>- 4 w</mark>	: : : 2	<u> </u>	- m r ; ;	9 : :2 :	, <u>0</u>	: 2000	400.0	
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died	; ; °	13	: 72	: : -	: 5 8	33.68	22 :::	: : :	111	99 : :		
UnknownTOTAL MENTIONS	:	0 7	0	00	0	- 1	2 2	: ;	0	0		
		5	:	80 <b>7</b>	;	<u> </u>		451	:	152		

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ERIC

Table 5.20.0 - Ketamine: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	2		26 55	19	: :	321	57 206	175	8,650.0		
DRUG USE MOTIVE Psychic effects Dependence	: œ	; o	36 26 4	: : :	.: 52	: :	145 45	444	:	;	206.2
Other	. 0 4	0 4	<u>. 0</u> <del>7</del> 2		22 0	0	48	<u>0 1</u>	275.0		-100.0 -68.8
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects	. ro	ro : :	11 38 3	; ; ;	45 9	107	66 93	280 123 18	2,		
Withdrawal Seeking detoxification Accident/injury Other Unknown	-0000	000 :-	o र्घ +- @ 4	: 1 2 1 :	o <u>: 0 ti r</u>	2 <sup>:</sup> 4 <del>L</del> 8	<u>८ स्ट</u> ८ : ७	. <del>1</del> 6 ± 1	100.0		
PATIENT DISPOSITION  Treated and released  Admitted to hospital  Left against medical advice	17 2 0	; ; 0	53 26	: : <sup>N</sup>	182 25 2	: : m	139	521 	2,964.7		
Unknown	19	0	81	: :	209	396	3 263	679	3,473.7		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

۲.

### Table 5.21.0 - LSD: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
DRUG CONCOMITANCE Single-drug episode	465 1,077	519 1,248	962 2,252	750 1,676	762 1,937	532 1,624	512 1,348	438 1,444	706	327	-53.7	
PRUG USE MOTIVE Psychic effects	744	948	2,336	1,484	1,508	1,066	721	1,082	303	158		ŧ
Suicide Other Unknown	<u>.</u>	⊋ 7 ÷	140	101	237	168	: 9 :	106 5 152	39	30 17		84.0 80.0 80.3
REASON FOR ED CONTACT  Unexpected reaction Overdose Chronic effects Withdrawal	482 405 68 8	492 183 156 9	1,649 842 76	754 547 132	1,105 509 117	734 659 110	582 460 110	753 440 149	196	.:: 56	.750	  -62.4
Seeking detoxification Accident/injury Other Unknown	125 19 285	403	151	480 244 180		1111	323 13 232	163	304	:0 <u>7.4</u>		-90.5 -65.9
PATIENT DISPOSITION  Treated and released  Admitted to hospital  Left against medical advice	1,124 410 3	1,073	2,115	1,353	1,794	1,212 931	1,090 748 16	1,210 650	443	195		-83.9
UnknownTOTAL MENTIONS	1,542	1,767	3,215	 2,427	2,699	2,157	0 6 1,859	0 9 1,882	939	407	-56.7	-77.8 -78.4

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, LSD = lysergic acid diethylamide.




Table 5.22.0 - LSD: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	1,835	2,264	1,855	2,070	1,481	1,513	1,044	671	-63.4 -35.3	-55.7 -40.5	
DRUG USE MOTIVE Psychic effects Dependence Suicide			2,904 766 168	2,722 1,350 335	3,284 1,098 203	2,992 1,282 414	1,787 1,169 391	1,522 839 187	45.9	49.1	
Other Unknown			15 716	13 799	379	12 425	::	188	-80.0	-55.8	
REASON FOR ED CONTACT Unexpected reaction Overdose	<del>-</del> <del>-</del> <del>-</del>	2,423 1,596 362	1,582 1,470 201	1,767	2,141 1,025 232	1,859 1,056 249	1,316	949 625 226	-55.0	40.8	44.1
Withdrawal Seeking detoxification Accident/injury Other		30 11.:. 11.	295 241	519 43 654	12 698 	946 ::45	474 .:: 431	7 615 28 321	-74.1	61.2	
UnknownPATIENT DISPOSITION			293	527	445	306	345	50	-88.4	-83.7	-85.5
Treated and released	3,279 1,686 55 	3,867 1,674  0	1,701	3,550 1,470 	3,188 1,591 	3,14/ 1,724 	2,302 1,679 24 0	1,652 1,082  0	4.	4/v	
TOTAL MENTIONS	5,158	5,682	4,569	5,219	4,982	5,126	4,016	2,821	-45.3	45.0	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department, LSD = lysergic acid diethylamide. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 5.23.0 - PCP: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change <sup>1</sup> H2 2001, H1 2002	% change¹ H1 2001, H1 2002
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	400	298 1,427	337 1,374	319 1,288	380	650 1,956	642 2,155	614	643 2,385	667		
DRUG USE MOTIVE Psychic effects Dependence Suicide	612 477 251	400 559 202	591 487 161	540 522 160	660 749	780 811 400	970 874 286	1,007 949 544	1,304	1,240 913 395	159 9	
Other	4 0 4	558	414	12 374	468	12	662	999	538	12		
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal Seeking detoxification Accidentfinjury Other Unknown	448 576 156 19 19 174 174 200 95	332 458 170 165 49 311	641 404 189 20 58 58 69 115	449 450 159 116 85 188 188	615 734 177 9 9 132 97 165	669 1,043 217 217 231 86 210 137	713 1,098 259 21 181 96 156 273	964 961 354 18 178 235 308	907 664 320 20 175 313 363	1,088 1,088 302  104 163 163		
Trailent Dispussion  Treated and released  Admitted to hospital  Left against medical advice  Died  Unknown	1,148 575 14 0 24	924 705 23 23	999 606 3 3	954 604 33 2	1,225 717 36 	1,285 1,285 22 	1,515 1,094 56 	1,682 1,282 70 0	1,651 1,198 	1,804 1,382 58 0 0	-53.6	-67.5
TOTAL MENTIONS	1,760	1,725	1,711	1,607	2,057	2,607	2,798	3,074	3,028	3,257		

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, PCP = phencyclidine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



#### Table 5.24.0 - PCP: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
DRUG CONCOMITANCE Single-drug episode	1,834	1,840 4,123	859 2,582	714	635	699 2,965	1,293	1,257 4,845	_	79.8 63.4	
DRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	1,725 2,200 458 13 1,503	2,275 1,823 411 29 1,424	1,412 1,127 285 17 599	1,404 904 538 21 759	991 1,046 363	1,200 1,271 334 16 842	1,750 1,685 686 19	2,311 1,898 696 1,104		92.6 49.3 108.4	32.1
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects	1,632 1,788 487 76	1,740 1,780 621	1,018 998 330	880 1,241 352	973 862 359	1,063 1,184 336	1,382 2,141 476 35	1,871 1,625 675	_	76.0	35.4 41.8
Windrawal Seeking detoxification Accident/injury Other Unknown	356 356 568 556 437	376 395 572 427	259 244 319 248	170 279 448 225	223 118 526 349	248 181 353 275	412 181 366 410	261 461 598 572	-26.7	154.7	154.7
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice	3,742 1,871 163 	3,869 1,793 162 6 6	2,127 1,213 71 	2,197 1,358 36 37	1,922	2,179 1,321 68 .:.	2,800 2,380 78 4	3,333 2,480 220 0 0 68		53.0 87.7 106.1	-100.0
TOTAL MENTIONS	5,899	5,963	3,441	3,626	3,436	3,663	5,404	6,102		66.6	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incompiete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, PCP = phencyclidine.

# Table 5.25.0 - Miscellaneous hallucinogens: ED mentions by episode characteristics: Estimates for the coterminous U.S. by

Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change <sup>†</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	356 489	488 375	570	233	366	210 581	276 782	433	420	242		- 1
JG USE MOTIVE Psychic effects Denendence	411	679	916	472	742	481	770	501	497	480		
Suicide Other Unknown	: : <sup>-</sup> :	;° ;		35 25	š : :&	<u> </u>	:0	17 8	रें ! !	:000		-100.0
REASON FOR ED CONTACT Unexpected reaction Overdose	468 193	362	535	245	437	447	398	325	126	232		
Curonic effects Withdrawal Seeking detoxification Accident/injury Other Unknown	2 : c : t : t : t : t : t : t : t : t : t	00 :04 :	32 6 72 0	<u>&amp; v to</u> ∶ <u>® ∞</u>	71 0 : 0 : 12	24 :: <u>10</u> 0 0 0		50 :027	<u> </u>	<u>ποκ :</u> : ω	-100.0	
PATIENT DISPOSITION Treated and released Admitted to hospital Left against medical advice Died Unknown	451 338 	355 507 1 0		316 246 9 0	177 174 13 0	560 222 7 7 0	874 	403 314 0	: : 8 - 0	55.	-100.0	-82.8
TOTAL MENTIONS	845	863	986	573	096	791	1,058	718	1,070	620		

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 5.26.0 - Miscellaneous hallucinogens: ED mentions by episode characteristics: Estimates for the coterminous U.S. by

% change 2000, 2001 ÷ % change 1999, 2001 % change 1994, 2001 853 999 139 451 Total 2001 1,251 180 223 0 195 486 845 652 52 Total 2000 682 669 30 2 21 598 935 :: 69 Total 1999 1,595 57 1,058 897 658 Total 1998 664 965 298 786 548 31 264 7 Total 1997 486 1,114 1,117 ... 272 396 37 37 ... Total 1996 487 976 1,080 129 Fotal 1995 544 805 35 683 894 394 Total 1994 Other Unknown. Dependence Suicide Suicide Episode characteristics Unexpected reaction ..... Psychic effects ..... REASON FOR ED CONTACT Mutti-drug episode ...... Single-drug episode ... DRUG CONCOMITANCE DRUG USE MOTIVE

TOTAL MENTIONS	1,577	1,463	1,600	1,629	1,849	1,533	1,849	1,788		
1 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots () indicate that an	increases a e sample of n	nd decrease on-Federal, s	s between es	timates for the spitals with 2	ne periods no 4-hour emer	oted. See R	elative Stand tments in the	ard Error (RSE coterminous L	:) tables for p-values. J.S. Dots () indicate that an	

estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to

١

-60.0

81.0

1,334

434 402 10 0 3

,087 420 21

,003 839

947 565

906 487

305

reated and released ......

PATIENT DISPOSITION Admitted to hospital

Other

Seeking detoxification .....

Chronic effects .....

Withdrawal .....

Overdose .....

Accident/injury .....

Unknown.....

,327 252 8 0 0

53.3

: 40

88.9

17

: :

: :

23

... 15 46

:: 14 22

174



T-263

Unknown

Left against medical advice ......

orduce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update) ED = emergency department.

Table 5.27.0 - Flunitrazepam (Rohypnol): ED mentions by episode characteristics: Estimates for the coterminous U.S. by half

% change 1 % change 1 H 2001, H 2002 H 2002	<u> </u>	-33.3	-100.0		100.0	-50.0	-100.0		-100.0		
Jan-Jun * 9	<u>2</u>	2 /	0 4	~	<u> </u>	<del></del>	0 ;	<u> </u>	00	o	
Jul-Dec 2001	10 ::	·	<del></del>	<u></u> თ	:00	<del>-</del> 0	<u>. 6. ←</u>	: "	<del>-</del>	0	
Jan-Jun 2001	e :	: n c					-0	:	0	0	
Jul-Dec 2000	: :		0 %		:00			: :	-	0	
Jan-Jun 2000	: :	<del>.</del>	° ;		- 4 0	0 0	8 :	: :	-	:	
Jul-Dec 1999	: :		. ~	: °	o 4 ∶	00	: :	: :	0	:	
Jan-Jun 1999	; ;	: 40 0	0 :	į	40	1 1		: :	÷	0	
Jul-Dec 1998	1 1	<u>α</u> : <del>-</del>	<del>о</del> :	:	: : :	-0	:0	; <del>4</del>	e	0	
Jan-Jun 1998	: :	111	: :	Ω.		<del>**</del> :	: :	- : :	0	0	
Jul-Dec 1997	: :	; <sup>6</sup>	- 2	2	0 0	40	: -	: :	0	0	
Episode characteristics	DRUG CONCOMITANCE Single-drug episode	DRUG USE MOTIVE Psychic effects Dependence Suicide	Other	REASON FOR ED CONTACT Unexpected reaction	Chronic effects Withdrawal	Seeking detoxification	Other Unknown	PATIENT DISPOSITION Treated and released Admitted to hospital	Left against medical advice	Unknown	TOTAL MENTIONS

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

T-264

Table 5.28.0 - Flunitrazepam (Rohypnol): ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

: :: 0
8 9 1
: :40
: : :
12
: : :
- O
:

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from ¹ This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

### Table 5.29.0 - GHB: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

PRIOR CONCOMITANCE         Jul-Dec Lan-Jun Lul-Dec Lan-Jul-Lul-Dec Lan-Jul-Dec Lan-Jul													
277         138          385         543         772         385         423           307         285         592         835         1,579         1,902          1,256           307         285         592         835         1,579         1,902          1,302           38         36         58         99         120          1,302            47         54          182         182         499         192         213           150         140          182         182         499         192         213           226         230         450         676         996         1,515         968         896           1         0          14         16         23         55         10           1         0          14         16         23         55         10           1                   0               <	ode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001,
277         249         409         807         1,443         2,043         303         1,256           38         36         592         835         1,579         1,902          1,302         1,356            12          12          12          1,302          1,356          1,356          1,356          1,356          1,356          1,356          1,356          1,356          1,356          1,133          1,133           1,133                                                    <	IITANCE Bpisode	:	138		385	543	133	100	3			7007 111	7007
307         285         592         835         1,579         1,902          1,302         99         1,202         223         186         59         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302	isode	277	249	409	807	1,443	2,093	CØ5 ::	1,256	1.214	278		
38         263         38         1579         1502         1302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302         1,302	IVE	307	300		L			_		_	:		
150         140         3         12         16         10         2         20           226         230         450         676         996         1,515         968         1,515         988         896           1         0         11         14         16         23         5         10           0         1         12         3         14         16         23         5         10           0         1         12         3         10         11         12         10           0         1         12         7         12         23         5         10           0         1         12         7         10         11         11         11           0         1         12         7         11         11         11         11           343         277         485         719         1,355         1,379         1,466         1,133         1           0         0         0         0         0         0         0         0         1         0           0         0         0         0         0         0		88	36	282	66 66	1,5/9	1,902	1	1,302	1,077	829		
150         140          340          816          632         213           150         140          340          816          632         213           1         3         450         676         996         1,515         968         896         896           1         3         13         7         24         25         24         25         24             14         16         23         5         10         12         12         12         12         12         12         12         12         12         12         12         12         12         12         12         12         12         12         13         12         13         11          19          19          10          10          10          10          10          11          10          10          1          22          10		: 8		: 67		: 4	: \$	: '	: 8	: 1	: :		
150         140          340          816          632           226         230         450         676         996         1,515         968         896           1         3         8         13         7         24         25         24             14         16         23         5         10               20          12                  10 <t< td=""><td></td><td>47</td><td></td><td>· :</td><td>182</td><td>182</td><td>499</td><td>192</td><td>213</td><td>376</td><td>187</td><td></td><td>-75.0</td></t<>		47		· :	182	182	499	192	213	376	187		-75.0
150	CONTACT									5	<u> </u>		
3         45         13         990         1,515         968         896         896         1,515         968         896         896         896         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10	Baction	2,50	2 40	: 2	340	: 6	816	: ;	632	338	622		
1         0          14         16         23         5         10           0         1         5          10          12         12           9          12         7          23          16         10            5          12           19         19         10         11         10         10         10         10         10         10         10         10         13         10         13         10         13         10         13         10         13         10         13         10         13         10         13         10         13         10         13         10         13         10         13         13         10         13         10         13         10         13         10         13         10         13         10         13         10         11         11         11         13         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1	W	1	<u> </u>	₹ *	13 6	286	1,515	896	896	1,012	: !		
20          12		-	0	· :	4	- 9	23.	<u> </u>	4 5	ล	4 0		-33.3
343 277 485 719 1,355 1,379 1,466 1,133 1,17	fication	: 0	; `	; '	: '	: '	50	· :	12	: :	-	_	
343 277 485 719 1,355 1,379 1,466 1,133 1,17		<u> </u>	=	<u>v č</u>	7 00	<del>6</del>	: 8	9	9	4	15		
343 277 485 719 1,355 1,379 1,466 1,133 1,17    "" 357 458 553 1,256 527 4    0 0 0 10 13    1 13     1,1		:	S	! ;		: :	3 :	: =	<u>ი</u>	21	<u> </u>		47.4
343     277     485     719     1,355     1,379     1,466     1,133     1,13       3     7      458     553     1,256      527     458       0     0      10      10     13         0      0      0         1     13      0         1,192     1,987     2,865      1,679     1,679	NOIL								:	:	5		
3     7     357     458     553     1,256      527     459       0     0     0      10     13         1     13      0         1     13      0         1     13      0          1     13            1     1          1     1     1	sleased	343	277	485	719	1,355	1.379	1.466	1 133	1 137	2		
0     0     0     13       0     0     0     1       0     0     0     0       0     0     0       0     0     0       1     13     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0     0     0       0<	Spital	: "	: ٢	357	458	223	1,256	:	527	449	5 :		
459 387 895 1,192 1,987 2,865 1,679 1,6		0	0	; °	2	: 0	: +	9	<u>t</u>	: 0	Ω.		
459 387 895 1,192 1,987 2,865 1,679		:	:	:	-	<u> </u>	- :	: ~	<del>-</del>	5 =	: `	1000	
	S	459	387	895	1,192	1,987	2.865		1 679	. 1881		0.00	
								:	2	3	2,02	-	

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. ED = emergency department, GHB = gamma hydroxy butyrate, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

#### Table 5.30.0 - GHB: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
19	9	47	261 376	290		928	1,157	870 2,469	4,478.9 6,573.0		
30		-	438	129	877	2,413	3,278	2,379 185	7,830.0		
:08		36		116	3 227	28 365	 12 691	 27 589	3,172.2		125.0
: 88		899		229 376	680	1,673	2,482	2, 2,	4,921.1	•	
000		0000	- 52 -			18 <u>4 t</u>			_	46.7	42.9
о <sub>і</sub>		; °			1 1	: :	i i	39 258	:		
38 4 : 0		95 48 2	485 145 0	538 156 	762 459 	2,074	2,845 1,827 	2,270 976 	5,873.7 6,871.4	-100.0	<u>-</u>
: %		1	.:. 638	 762	1,2	14 3,178	4,969	3,340	5,864.3		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000.

ED = emergency department, GHB = gamma hydroxy butyrate. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

Table 5.31.0 - Inhalants: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

Episode characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jut-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change¹ H2 2001,	% change H1 2001,
DRUG CONCOMITANCE Single-drug episode Multi-drug episode	377 837	715		255	173	4	359	153	::4	392	7007	H1 2002
DRUG USE MOTIVE Psychic effects		727	405	211	322	:	289	132	<u> </u>			
Suidde Other Unknown	588	224	25 <u>0</u> :::	: 66		: :04	1 1 17	<u> </u>	19 1	: :0	-100.0	
REASON FOR ED CONTACT Unexpected reaction	: !	248	202	:	: :	? ;	46	Ξ ;	:	: 6		
Overloose Chronic effects Withdrawal	21 1	626 24	27	224 23	17	31	181	9 9	4 ®	2 46 2	954.5 187.5	
Seeking detoxification Accident/injury Other Unknown	 7 206 174	: 42	. w :	23 2	30 12	145	: <u>0</u> 5 :	⊃ <u>† 4 6</u>	- :4 :	<u>ं 4 ं र</u> ू		
PATIENT DISPOSITION Treated and released	557	984	439	263	248		318	51	5	12		
Aumilied to nospiral Left against medical advice Died Unknown	12	0 0 0 k	· "	263	374 3 0	345	10	3 : : 0	: 400	239		
TOTAL MENTIONS.	1,214	1,280	931	535	627	946	929	338	338	559		-100.0

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

Table 5.32.0 - Inhalants: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

	•										-
Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change' 1994, 2001	% change ' 1999, 2001	% change 2000, 2001
DRUG CONCOMITANCE Single-drug episode	959 552	390 646	628 685	919	997	428 734	886 636	333 343	-65.3		
PRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	642 102 511 	544 143 282 	562 478 154	837 439 763	1,129  639 0	534 192 145	736 394 358 ::	360 73		;	
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal Seeking detoxification Accident/injury Other Unknown	227 672 38 4 4 4 271 271	224 43 43 0 0 19 19	335 335 .::	359 900 40 20 300 410	1,003 1,003 2 2 2 2 2 51 15 15 15 15 15 15 15 15 15 15 15 15	466 406 3 3 27 53 : : :	294 463 463 463 464 465 465 465 465 465 465 465 465 465	276 24 1 1 8 8	-36.8 -75.0 -70.4	-40.0 -66.7	44.2
PATIENT DISPOSITION  Treated and released Admitted to hospital Left against medical advice Died Unknown	730 651  0 	436 567 20 20  9	891 410 3 0 8 8 1,313	991 933 0 0 	1,422 709 5 	511 637 7 3	915 587 13 	340 326 6 0 0 4 4 676	-55.3		-55.6

ς - ξ<u>.</u>

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

Table 5.33.0 - Combinations NTA: ED mentions by episode characteristics: Estimates for the coterminous U.S. by half year

יייייייייייייייייייייייייייייייייייייי	Jul-Dec Jan-Jun * % change 7 % 2001 2002 H2 2001,	28 45		: 82 :80	4 w w m	23 17 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Jan-Jun 2001		_			
	Jul-Dec 2000	23			•	0000
	Jan-Jun 2000	33	3 4 8 0 0 <del>0</del> 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	23 21 0	2	2000
	Jul-Dec 1999	29	0 8 6 0 6	21 15 0		0 0
	Jan-Jun 1999	23	317	15	32 - 00	<u> </u>
	Jul-Dec 1998	27	33.72	21 1 4	000 7	00
	Jan-Jun 1998	30	7-4-6-6	4 9 5 - 5	E 8 4 7	<u> </u>
	Jul-Dec 1997	46	9 7 0	3310	0 19	2 :00
	Episode characteristics	DRUG CONCOMITANCE Single-drug episode	DRUG USE MOTIVE Psychic effects Dependence Suicide Other	REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal	Accident/injury Other Unknown.  PATIENT DISPOSITION Treated and released Admitted to be accided	Left against medical advice Died Unknown.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. 1 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 5.34.0 - Combinations NTA: ED mentions by episode characteristics: Estimates for the coterminous U.S. by year

Episode characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change¹ 2000, 2001
DRUG CONCOMITANCE Single-drug episode	261	85 78	115 268	67 134	57 68	52	56	54 244	-79.3		
PRUG USE MOTIVE Psychic effects Dependence Suicide Other Unknown	: <b>%</b> 8 0 :	88 9 0 0 22	115	 90 14 0	29 74 7	17 59 3 0 15	25 68 6 0	717 99			
REASON FOR ED CONTACT Unexpected reaction Overdose Chronic effects Withdrawal	137	32 48 63	175 175 63	16 39 45	28 27 35	3.5 3.8	28 38 1-0		-54.4		-24.4
Seeking detoxification Accident/injury Other Unknown	:£ 0 4	<del>24</del> <u> </u>	<u> </u>	o <sub>:</sub>	E 8 4		5404	<u>v 4 ú rv</u>	-73.3	1,100.0	200.0
PATIENT DISPOSITION  Treated and released  Admitted to hospital  Left against medical advice  Died  Unknown	280 203	106 48 8 0	196 184 	105 	94 27 4 0	23	88 32 7	214		500.0	
TOTAL MENTIONS	495	163	383	201	125	94	127	298			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000.

ED = emergency department, NTA = not tabulated above.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 12.1.0 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for the coterminous U.S. by half year

% change <sup>2</sup> H1 2001,	-78.7	14.0
% change <sup>2</sup> H2 2001,	-8.5 -14.1 -13.0	-12.9 -12.6 -13.3
Jan-Jun * 2002	221 388 36 77 74 74 75 76 76 76 76 76 76 76 76 76 76 76 76 76	84700044000000004+ 400 :0044000
Jul-Dec 2001	44 4 8 6 1 2 4 8 6 1 4 8 6 1 4 8 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6	0041 : 00 4440 : : 48012 c 480 0 0 4 4 8 0 0 0 4 4 8 0 0 0 8 0 0 0 4 4 8 0 0 0 0
Jan-Jun 2001	228 228 228 228 228 228 228 228 228 228	844 : 04440 :048464 - 48000449 :
Jul-Dec 2000	274 % & \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	88 1 0 0 0 4 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0
Jan-Jun 2000	25 1 2 2 2 2 3 3 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	004 tt : 0 tt 2 tt 2 tt 2 tt 2 tt 2 tt 2 tt
Jul-Dec 1999	25 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	88 CT 0 C C C C C C C C C C C C C C C C C
Jan-Jun 1999	## ## ## ## ## ## ## ## ## ## ## ## ##	844 to 0 to 4 to 0 0 : w 2 1 to 4 to 6 5 0 0 0 4 to 1 8 0
Jul-Dec 1998	258 8 5 5 6 8 4 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	88810000000 : 1040184- 889 : 0 to to to to to
Jan-Jun 1998	£888656648888888888888888888888888888888	844000848+ : : uxuvor- 8800000ee
Jul-Dec 1997	108 36 35 44 44 10 10 10 10	388 1133 177 177 179 179 179 179 179 179 179 179
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines Methamphetamine MDMA (Ecstasy) Ketamine I SD PCP Miscellaneous hallucinogens Flunitrazepam (Rohypnol) GHB Inhalants Combinations NTA	PSYCHOTHERAPEUTIC AGENTS. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Benzodiazepines. Benzodiazepines. Benzodiazepines. CNS stimulants. CNS stimulants. Analgesics. Antimigraine agents. Antimigraine agents. Cox-2 inhibitors. Narcotic analgesics/combinations. Nonsteroidal anti-inflammatory agents. Salicylates/combinations. Miscellaneous analgesics/combinations Miscellaneous analgesics/combinations Miscellaneous analgesics/combinations Miscellaneous analgesics/combinations Miscellaneous analgesics/combinations Analgesic combinations NTA.

Table 12.1.0 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

% change² H1 2001, H1 2002	166.4	50.7 142.9	65.6		-1.6
% change <sup>2</sup> H2 2001, H1 2002	294.7				-1.1
Jan-Jun * 2002	<u> </u>	8000	0- 5	200-0-	121 220 20
Jul-Dec 2001	0000 4 1 0000-0	<u> </u>	0- 0		128 234 20
Jan-Jun 2001	00004 1 01-000+6	0000	<b>ó</b>	, , , ,	124 225 20
Jul-Dec 2000	0800 80 0000	8000	0+ (	<u> </u>	120 219 19
Jan-Jun 2000	0 0 0 0 i 0 i 0 0 0 0 0 0 0 0 0 0 0 0 0	0000	0- (	00000-	124 226 19
Jul-Dec 1999	0 0 0 0   0   0 - 0 0 0 -	: NOFO	0-	<u>0000</u>	113 207 19
Jan-Jun 1999	0m000m; N=000=0	0000	0 -	<u> </u>	115 210 19
Jul-Dec 1998	000000 0-000-	: 0000	<del>- 0 0</del>	<u>6</u> 0400	112 203 19
Jan-Jun 1998	0 0 0 0 0 0 0 0 0 0 0	: 000	- 0 0	<u>000000</u> -	113 205 18
Jul-Dec 1997	000000000000000000000000000000000000000	0000	000	<u> </u>	110 197 197
Drug category¹	Anorexiants	CARDIOVASCULAR AGENTS	Calcium channel blocking agents	Altemative medicines. Anti-infectives. Gastrointestinal agents. Nutritional products. Topical agents.	TOTAL DRUG ABUSE EPISODES

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com

T-273

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 12.2.0 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for the coterminous U.S. by year

% change <sup>2</sup> 2000,	7.6	11.8			-56.7		9.0					10.0	11.3			17.6	-39.9	
% change <sup>2</sup> 1999,	11.5	42.4	86.5	59.8		8.4		-	- 22	-37.6	39.2	10.1	10.1	0	20.6	38.0	-28.3 12.2	
% change <sup>2</sup> 1994, 2001			1,889.3		5,316.4	u	9	20.1	116.3	9.68-	57.2	16.0	26.5	-37.8	15.7	102.6	-59.4	:
Total 2001	264 86 76				:-00	196	24	: <del>-</del> - rc	· α α	<del>-</del>	, K	<u> 2</u> 4	4 0	<del>- 8</del>	9 6	<u>, ⊢ &amp; a</u>	173	=
Total 2000	253 83 71				:0+0	192	24	: <u>+ r</u>	တဆ	<del>-</del>		94 8	37	- 8	89	33 0	9 8	:
Total 1999	237 81 69	8 0 v	-00	101	<del>: - 0 0</del>	180	4 °C	<u> </u>	<b>&amp;</b> 0	<del>-</del> ;	; w	<u>გ</u> რ	37	- 2	57 0		. <del>.</del> .	
Total 1998	228	32.0	0000	<del> </del>	0	180	<u>23</u>	<u>5 ro</u>	7	<b>≈</b>	010	0 4 0 4	90	7 22	- 20 0 0	11	17	
Total 1997	215 72 68				0+0	181	0 23	4	9	00	0 4 (	<del>δ</del> ω	10,	2 م	29 0	11 23 0	o € :	
Total 1996	203 71 65	25 8 4 R	000	<del></del> :	0-0	182	24 ::	<u>5 ∞</u>	ထ ဆ	<del>m 0</del>	0 4 6	<del>0</del> m	<u> </u>	7 7	57 0	1200	50 ::	
Total 1995	197 72 58 58	0 4 K	0 <sub>;</sub> 0	. + :	000	190	0 23	တထ	<u>. o or</u>	40	<u>- w f</u>	÷ e 6	<u>% ± ∠</u>	7 2	20	<u> </u>	19 ::	1
Total 1994	195 70 62 27	<u>7</u> 4 8	000	ω <del>-</del> Ο	0 - 0	195 83	0 74	o <del>L</del>	4 <del>L</del> 1	00	- v 4	<u> </u>	7 7 8	2	0 0	0 6 7 0	<u> </u>	
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin	Marijuana. Amphetamines. Methamphetamine.	MDMA (Ecstasy) Ketamine LSD	Miscellaneous hallucinogens Flunitrazepam (Rohypnol)	GHB Inhalants Combinations NTA	OTHER SUBSTANCES OF ABUSE	MAO inhibitors.	Sorti antidepressants	Antipsychotics	Psychotheracine analysis combinations.	Miscellaneous artipsychotic agents Anxiolytics, sedatives, and hyportics.	Barbiturates	Misc. anxiolytics, sedatives, and hypnotics. CNS stimulants.	CNS AGENTS	Antiprine agents.	Narcotic analgesics/combinations Nonsteroidal anti-inflammatory agents	Miscellaneous analgesics/combinationsAnalgesic combinations NTA	

Table 12.2.0 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>2</sup> 2000, 2001	16.4		56.2	312.3	49.9 3.5 4.0
% change² 1999, 2001	32.9	34.2 60.8 230.5		293.9	10.4 10.2 5.8
% change <sup>2</sup> 1994, 2001	-63.2 -42.1 -62.2 -74.6 354.1	-29.4 -86.3 -64.5	-52.6	-40.3 -63.1 -56.4 -58.5 163.2	
Total 2001	0000	<u> </u>	4	<u> </u>	9 1 252 460 40 40
Total 2000	- L C C C C C C C C C C C C C C C C C C	000000	<u> 40 0 - </u>	<u>6</u> 04-4-0	10 1 243 445 39
Total 1999	1 1 0 0 1	4-000-0	400	208-0-0	13 228 417 37
Total 1998	-00+000	\$-0-0A	400-	<u>0 0 4 0 + + 0</u>	10 1 225 408 37
Total 1997	<u> - 80 + 080</u>	₩±0 <u>+00</u>	40-	20400	11 1 221 396 38
Total 1996	-00- 100	v + + + 0 ≈ 0	4	<u>\$0489</u> <u>+ C</u>	218 385 39
Total 1995	<u>-40-00</u>	0444000	<u>0 0</u>	8 : 80 - 6	12 221 387 38
Total 1994	-4-0 <sub>000</sub>	V000	908	23 90 - 0	15 1 225 391 39
Drug category¹	Anorexiants	RESPIRATORY AGENTS	CARDIOVASCULAR AGENTS	OTHER SUBSTANCES. Alternative medicines. Anti-infectives Gastrointestinal agents. Hormones Nutritional products	TOTAL DRUG ABUSE  TOTAL DRUG ABUSE EPISODES  TOTAL ED VISITS (in 1,000s)

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique

with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate Attanta for the period January-June 2001. For the Attanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update)

Table 12.2.1 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Atlanta by year

% change <sup>2</sup> 2000,	22.1 35.3 99.1 49.6	-3.7	673.6
% change <sup>2</sup> 1999,	16.0 29.3 55.6 5.5.6 114.9 -76.6	-100.0	10.0
% change <sup>2</sup> 1994, 2001		33.0 96.2 -100.0 56.8 10.0 18.1	53.8
Total 2001	24 4 2 2 2 3 3 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	0267 084004 :: 0 0 9 9 2 8 4 5 0 0	0000000
Total 2000	221 222 221 17 17 17 17 17 17 17 17 17 17 17 17 17	86 86 86 86 86 86 86 86 86 86	37 12 20
Total 1999	200 100 100 100 100 100 100 100 100 100	203 200 100 100 100 100 100 100 100 100 100	37 37 16 31 16
Total 1998	528 170 171 171 171 171 171 171 171 171 171	200 100 100 100 100 100 100 100 100 100	0 56 1 4 61 0
Total 1997	728 173 173 173 173 173 173 173 173 173 173	754 to : 8 6 0 0 0 0 0 8 4 4 4 0 0 0 0 0 0 0 0 0 0 0	0 2 3 0 8 0
Total 1996	522 202 202 44 57 5 5 6 0 0 0	888 889 880 860 860 860 870 870 870 870 870 870 870 870 870 87	0 27 7 7 0
Total 1995	634 245 245 15 63 63 63 64 64 64 64 64 64 64 64 64 64 64 64 64	200 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	041400
Total 1994	265 235 235 177 178 198 198 198 198 198 198 198 198 198 19	66 68 66 77 75 75 75 75 75 75 75 75 75 75 75 75	0 17 0 170
Drug category¹	MAJOR SUBSTANCES OF ABUSE. Alcohol-in-combination Cocaine	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS. Antidepressants. SSR1 antidepressants. SSR2 antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antipsychotics. Phenothiazine antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbturates. Barbturates. Barbturates. CNS stimulants. CNS stimulants. Analgesics. Antimigraine agents.	Cox-2 inhibitors Narcotic analgesics/combinations Nonstroidal anti-infammatory agents Salicylates/combinations Miscellaneous analgesics/combinations Analgesic combinations NTA

Table 12.2.1 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Atlanta by year (continued)

% <b>ch</b> ange <sup>2</sup> 2000, 2001		23.5 57.0		43.9	132.1	615.6	0.0
% <b>ch</b> ange² 1999, 2001	25.8	31.3	0.3 -73.7	25.1	_		8.0 6.5 -7.3
% <b>ch</b> ange² 1994, 2001	92.8			-65.9	63.5	791.7  78.5	-2.0
Total 2001	- w <u>+ o w o</u>	<b>ω0 − 0 0</b>		<u>_</u>	N — — -	-	397 748 34
Total 2000	<u> </u>	10 O O	0 1-0 1	<u></u> 600	<u> </u>	09-	394 778 34
Total 1999	04 :-080	מבבב <sup>;</sup> מכ	- 00 - 00 <del>-</del>	15	<u>α − − −</u>	- ; 10, 17	367 702 37
Total 1998	1 1 0 2	4-0- 0	, w ; <del>- o </del> ; <del>-</del>	15	<del>4 01 ←</del> <del>-</del>	- 0 0 -	390 734 38
Total 1997	- 6 ; i 0 8 0	00000	, 00-0 <sub> </sub> -	. 19	4 0	- <u>:</u> 2-	294 595 38
Total 1996	¦4 ¦←0∞0	000 i u	4 + 0 0	. 20	<u> - 0 c</u>	206-	349 709 42
Total 1995	- 8 0 8 0	00-0-00	4 0-	. 940	<u>v − − </u>	36	416 838 42
Total 1994	¦∞ ¦+0≻0	70 : TO 8	<u> 4                                   </u>	<u>, % :</u>	4 0 <del>-</del> 1	- 0 4 0	405 791 43
Drug category¹	Anorexiants	RESPIRATORY AGENTS	Kespiratory agents N.I.A	OTHER SUBSTANCESAlternative medicines	Anti-Infectives	Nutritional products.  Topical agents.  Drug unknown.  All other substances NTA.	TOTAL DRUG ABUSE EPISODES

requirements (2002). The Multurn Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multurn.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique <sup>2</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.

with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

Table 12.2.2 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Baltimore by year

% change <sup>2</sup> 2000,		31.3	30.5 -11.3 35.2 33.2	83.1 30.9 34.0	29.7 31.5 314.0 42.0 -20.0
% change <sup>2</sup> 1999, 2004		19.6	-38.9 -100.0 -26.9 -471	33.7 17.4 -13.8	26.1 27.8 41.9 -21.0
% change <sup>2</sup> 1994, 2001		28.6 41.1 -37.8 68.0	-89.8 -100.0 -100.0	231.6 81.4 43.1 -26.8	205.7 44.1 -58.0 -34.6
Total 2001	4127 4127 4137 4130 600 600 600 600 600 600 600 600 600 6	269 157 0 0 7 7 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	10004 K	59 59 4	0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Totaí 2000	630 208 227 68 7 7 7 7 0 0 0 0 0	202 75 7 4 1 0 0 0 4 6	, o o o w &	<u>− 45</u> <u>−</u>	00 00 00 00 00 00 00 00 00 00 00 00 00
Total 1999	833 295 295 299 72 72 72 72 72 72 72 73 74 74 75 75 75 75 75 75 75 75 75 75 75 75 75	225 84 15 15 15 15 15 15 15 15 15 15 15 15 15	93 3000	5 5 1	000 000 000 000 000 000 000 000
Total 1998	2896 2896 2896 2896 2896 2896 2896 2896	222	0 0 4 &	4 8 +	<u>110</u> 0048070
Total 1997	747 147 253 256 616 616 617 617 617 617 617 617 617 61	412 83 0 V 4 4 4	-0004	080-	48 00 00 8 8 15 E
Total 1996	990 1937 376 357 53 53 60 0 0 0 0 0 0 0	205	00 m Og ·	4 6 6 2	88 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1995	1,023 212 384 42 42 0 0 0 0 0 0	86 60 70 70 70 80 80 80 80 80 80 80 80 80 80 80 80 80	000m+	7 8 <del>-</del> 7	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1994	2002 2004 337 35 2000 144 144	208 609 1 15 1 3 6 6 7	w00044	1 8 8 7	67 0 0 11 11 0 0
Drug category¹	AKJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines Methamphetamine MDMA (Ecstasy) Ketamine LSD LSD PCP Miscellaneous hallucinogens. Flunitrazepam (Rohypnol) GHB. Inhalants Combinations NTA	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS. Antidepressants. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antipsychotics.	Prenothiazine antipsychotics Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates	Benzodiazepines.  Misc. anxiolytics, sedatives, and hypnotics.  CNS stimulants.  CNS AGENTS	Analgesics. Antimigraine agents. Cox-2 inhibitors. Narcotic analgesics/combinations. Nonsteroidal anti-inflammatory agents. Salicylates/combinations. Miscellaneous analgesics/combinations. Analgesic combinations NTA.

Table 12.2.2 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Baltimore by year (continued)

% change <sup>2</sup> 2000, 2001	-35.3 -8.1 -8.1			-22.4	20.8	60.1 42.5 1 18.3 5 -34.6	6 6 6 86.4 1 -54.5	8.3 8.3 8.3
% change <sup>2</sup> 1999, 2001	-43.4 -8.7 103.6 22.2	18.5		-12.7 52.7 5.7 52.7	-35.2 -49.1 -59.3 -77.4		16.3 120.6 27.5 41.1	-16.5 -14.6 7.4
% change <sup>2</sup> 1994, 2001	-79.0 -22.8 -80.0	-100.0 -30.8	60.7 42.1 -90.4	63.8 57.3 57.3 6.18	-48.1 -70.6 -58.7 -83.9 -53.3	-78.0 -51.8 -51.8	-51.8 109.0 -43.0 -37.6	-29.3 -25.5 19.6
Total 2001	0400	0 00	0 + 0	00-0	7-000-	80	0 + 40	505 903 44
Total 2000	0400	000	e <u>+ 0</u>	00+0	0 + 0 0 0 0	80	0000	483 834 41
Total 1999	0 4 0 0	000	0 - 0	00+0	40-	242	0 0 6 -	605 1,058 41
Total 1998	1 2 0	040	e + 0	0000	M-0-0+	26	- 20 -	592 1,015 40
Total 1997	<u>⊢</u> 4 ¦⊢	000	4-0	0000	8++0++		33 0	556 962 38
Total 1996	-40-	000	4 - 0	0000	40-	00 0 1 1 1 1 3 1	52	705 1,194 38
Total 1995	-40-	000	4-0	0000	40-	£4 : 4 0 0	- 0 48 0	712 1,209 37
Total 1994	-40-	040	9	000	<b>0</b> ← ← ← ←	52 0 1 1 1 1 1 1	43	715 1,212 37
Drug category¹	Anorexiants	General anesthetics	RESPIRATORY AGENTSAntihistamines	Decongestants Expectorants Upper respiratory combinations. Resoiratory agents NTA	CARDIOVASCULAR AGENTS	OTHER SUBSTANCES	Nutritional products. Topical agents. Drug unknown. All other substances NTA.	TOTAL DRUG ABUSE EPISODES

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

365

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

Table 12.2.3 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Boston by year

% change <sup>2</sup> 2000,			122.2	-100.0	20.6	46.9			-100.0	23.4	23.3	28.1 34.9	53.3	43.1
% change <sup>2</sup> 1999, 2001	51.2 37.0 44.8 59.2	82.5 89.7 68.2	243.4		39.2			-61.2		32.1	31.1	60.3	103.8	
% change <sup>2</sup> 1994, 2001		247.5 2,679.8	-69.7 -53.4	-100.0		-51.4	-75.8	-92.9 -92.4			-55.1 -68.4		144.6 -54.0	-84.5 -34.3
Total 2001	538 163 138 122	96 1-0 4 0	<del></del>	000	152	20 =	<u>v + v</u>	<del> c</del>	000	117	95	115 106	0 8 0	<u> 460</u>
Total 2000	436 131 108 102		0-0	-00	130	<u>8 o 5</u>	400	0 <del>-</del> 0	0 1	36	6	90 ::	53	£ 90
Total 1999	356 119 95 77	<u> </u>	<del>- 0 -</del> ;	+ <sub>:</sub> 0	213	<u>60 t</u>	4 C a	20	0	<b>6</b> 6	72	72 62 0	04 -	2 6 0
Total 1998	424 139 123 74	0 + 0	000	°° ;	250 145		<u>v 6 «</u>			11.	<del>8</del> ∞ ∨	7. 7.	<u>4</u> -	174
Total 1997	350 134 91 68	æ : o o c	<del>0</del>	°° :	263 155	<u> </u>	o <u>6</u> «	<u> </u>	0 15	<u> </u>	2 1 8	62 0 0	- <del>8 -</del>	880
Total 1996	404 148 114 76	ge : ; □	700+	000	285 164	16	<u> </u>	00	20	00 0	ზ <del>გ</del> გ	.: 72	- 8 <del>-</del>	0 23 8
Total 1995	489 176 147 83	. 0 0 0	0 + 25	0 - 0	351 196 46	0 0	<u> </u>	80		<u> </u>	2 <del>4</del> 8	85	<u>8 6 6 </u>	0 25 8
Total 1994	437 167 136 72	% : ° ° :	<u>ε−</u> − 0	00 ;	365 208 54	<u> </u>	2 2 5	<b>&amp;</b> O	: 0	131	9 <del>1</del> 8	404 0 0	33.0	25 0
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination  Cocaine  Heroin  Marijigaa	Amphetamines. Methamphetamine MDMA (Ecstasy). Ketamine	LSD. PCP. Miscellaneous hallucinogens. Flunitrazepam (Rohypnol).	GHB. Inhalants. Combinations NTA.	OTHER SUBSTANCES OF ABUSE	MAO inhibitors	Miscellaneous antidepressants	Phenothiazine antipsychotics	Miscellandeus antipsychotic agents	Aukuyucs, sadauves, and nyphoucs	Misc. anxiolytics, sedatives, and hypnotics	CNS AGENTS. Analgesics. Antimigraine agents. Cox-2 inhihitors	Narcotic analgesics/combinations Nonsteroidal anti-inflammatory agents	Miscellaneous analgesics/combinations

# Table 12.2.3 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Boston by year (continued)

% change <sup>2</sup> 2000, 2001	-18.4									962 5	54.8		103.6	: 6	-/8.3	20.2	İ
% change <sup>2</sup> 1999, 2001				94.1					-85.1			,	167.1	. 6	-08.3	50.9	11.3
% change <sup>2</sup> 1994, 2001	-62.5 -40.7	i	-64.6	41.7	-89.7	-55.1	-49.7	0.09	-85.8		65.8	-33.2	230.2		/:/8-		
Total 2001	9	: : =	0 0 0	ω <del>-</del>	6 ; c	<del>- 0</del>	<u>е</u> —	-0	0+	23	<del></del>			- ; 6	5	472 835	45
Total 2000		000		4 -	0+0	0	Б.		: -	19	· - •			: : `		393	42
Total 1999	0	:00	000	2	:00	) ÷	4 -	10	0 +		:		0	: <b>60</b> 1	-	313	41
Total 1998		000		e +	:	0	С <del>С</del>	- 0	0		. 7		_	<u>.</u> 9 :	-	370	42
Total 1997	;∞	; ; <b>c</b>	000	e <del>-</del>	000	000	<b>₹</b>	2 +	: <del>-</del>	21	. m c	1	0 0	٠ ; ٠	-	335	43
Total 1996	06	0 0 0	40	9 7	0 +	; 70 ;	2 5		0+	22	. ४ •		← ⊂	4.		375	47
Total 1995	- 8	; <del>-</del> - c	000	7		- m o	7		. 7	40	4.0	<b>ν</b> ω	<del>- c</del>	78.0	7	449	45
Total 1994	10	<u> </u>	0 4 0	9 +	7 -	; ea :	2 ~	10-	0 -	40	. 4 €	3 N	← c	87	7	434	47
Drug category¹	AnorexiantsAnticonvulsants	Antiemetic/antivertigo agents	Muscle relaxants	RESPIRATORY AGENTSAuthistamines	Bronchodilators	Expected ants. Upper respiratory combinations. Respiratory agents NTA	CARDIOVASCULAR AGENTSAntiadreneralic agents centrally acting	Beta-adrenegic blocking agents. Calcium channel blocking agents.	Diuretics	OTHER SUBSTANCESAlternative medicines	Anti-infectives	Gasuolinesunal agents	Nutritional products	Drug unknown.	All other substances NIA	TOTAL DRUG ABUSE EPISODES	TOTAL ED VISITS (in 1,000s)

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique



NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

Table 12.2.4 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Buffalo by year

% change <sup>2</sup> 2000, 2001	285.1 -65.3 -100.0 -80.7	49.7 -44.7 -58.0 -52.7 -100.0 -42.2 -65.3	-22.1 -62.5 44.4
% change <sup>2</sup> 1999, 2001	-31.0 -35.1 -43.2 -56.3 -240.7 -100.0	49.3 -54.2 -73.3 -52.7 -100.0 -100.0 37.5 -57.4 50.3 55.9	88.4.6 62.5.8 62.1.1
% change <sup>2</sup> 1994, 2001	46.3 46.3 -100.0	-31.4 -73.3 -74.6 -79.5 -48.8 -81.0 -100.0 -100.0 -100.0 -100.0 -53.9 -27.3 -27.3 -27.3 -27.3	378.6 -73.6 -85.6 -36.6
Total 2001	472 145 145 145 145 145 145 145 145 145 145	25 20 20 20 20 20 20 20 20 20 20 20 20 20	00044440
Total 2000	1381 104 104 104 104 104 104 104 104 104 10	00 00 00 00 00 00 00 00 00 00 00 00 00	000400
Total 1999	355 177 177 177 177 177 177 177 177 177 1	88 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	047 4 4 20
Total 1998	775 134 148 159 160 160 160 160 160 160 160 160 160 160	£44 600 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	8 4 9 0
Total 1997	255 154 163 163 100 100 100 100 100 100 100 100 100 10	85. 85. 86. 87. 87. 87. 87. 87. 87. 87. 87. 87. 87	26 9 15 0
Total 1996	546 198 238 48 55 2 2 2 0 0 0	7.1 2.0 8 8 8 8 9 9 9 8 8 8 8 9 8 8 8 8 9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	213
Total 1995	351 124 145 411 2 2 2 2 3 3 3 0 0 0 0	188 177 177 177 188 188 198 198 198 198 198 198 198 198	0 22 0 4 4 0 0
Total 1994	35. 12.2. 2.2. 35. 4. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.	215 73 20 0 10 7 7 2 8 2 15 15 0 0 0 0 0 0 0 0 0 0 10 10 10 10 10 10 1	0 2 7 7 7 0
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Marijuana Amphetamine. Mode (Ecstasy). Ketamine. LSD PCP LSD PCP Miscellaneous hallucinogens. Flunitrazepam (Rohypnol) GHB Inhalants Combinations NTA	PSYCHOTHERAPEUTIC AGENTS. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. CNS stimulants. CNS AGENTS. Analgesics. Antimigraine agents.	Cox-2 inhibitors

Table 12.2.4 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Buffalo by year (continued)

% change <sup>2</sup> 2000, 2001	1000	-100.0	362.1 -100.0	-100.0	114.1	-65.3 -80.7	208.1	124.4 -13.3	21.5
% change <sup>2</sup> 1999, 2001	-43.2	-71.6	127.1 127.1 -100.0	43.2 -100.0 43.2 71.6	146.7	-65.9 -71.6	81.7 -77.3 297.5	171.8	9.5
% change <sup>2</sup> 1994, 2001	-46.3 -51.6 -100.0 -100.0	-74.4 -82.1 -100.0 -100.0	-64.2 -38.6 -100.0	-66.1 -100.0 -46.3 -92.3 -64.2 -51.2		-95.8 -94.3	-38.6 -82.1	37.2 -70.7	-8.0
Total 2001	0000040	0000	<u> </u>	-0000-	51	00	<del>- 0 -</del>	48	398 703 33
Total 2000	030000	0000	000	70-00-	24		000	20	297 551 27
Total 1999	0 8 0 0 0 4 0	0-000	0+0	W0+00+	21	-0	0	÷ ÷	283 514 30
Total 1998	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	-00 <u>;</u> 0	0 - 0	-00000	စ္က ၀	ю N	0	- 23	283 520 29
Total 1997	- E O O 4 O	4 - 0 - 0	000	70007	0 0	ω <del>-</del> -	0	<del>4</del> –	300 564 29
Total 1996	<del>-</del> 70 + 0 9 0	v-0-0	0 8 0	-0000-	25	2 22	0 - 0	<del>6</del> 0	387 721 32
Total 1995	- 20 + 0 50	400-	- 00	700-0-	33	4 0	0	24 0	296 531 33
Total 1994	04+20/0	V	-00	40-0	64	8 7	0 - 0	35	303 527 36
Drug category¹	Anorexiants	RESPIRATORY AGENTS	Expectorants	CARDIOVASCULAR AGENTS	OTHER SUBSTANCESAlternative medicines	Anti-infectives	Hormones	Drug unknown	TOTAL DRUG ABUSE EPISODES

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. the Census.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ERIC

Full Text Provided by ERIC

Table 12.2.5 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Chicago by year

% change <sup>2</sup> 2000, 2001		41.9 -38.0	-49.5	22.9	46.4	48.3	37.9 37.6 41.2	64.7
% change <sup>2</sup> 1999, 2001	20.7 22.9 25.6 103.8	49.2	-52.7	30.8	-39.5	40.9 49.7 42.3	33.4	22.3
% change <sup>2</sup> 1994, 2001	65.8 34.2 45.5 142.2 124.6 447.6	1,066.4	-51.8	-100.0	49.4 129.8 -81.9	 32.8 41.6	28.6 30.8	107.8 -22.6 -34.3 -23.9
Total 2001	774 176 277 203 89	- 00 <del>- 1</del>	<u> </u>	214 85 15 0	<u>: ဝကကလ</u>	: 28 8 4 28 8 4	0 0 4 0 0	65 67 77 0
Total 2000	743 169 246 206 89 6	4001	-000	174 74 13	- 0 4 4 0 0	3 7 7 42	7 2 76 68 0	39 15 15
Total 1999	641 155 225 162 77 73	94 : 4 <u>5</u>	- 10- 1	49 49 60 7	- wwn <del>-</del> ;	0 4 6 8	702 ::	
Total 1998	648 158 232 158 85 3	0 1 0 0	0	173 65 14 0	4 W 4 <u>- 0</u>	0 6 9 6 6	73 0	39 0 18 0 0
Total 1997	666 178 247 148 76 4	0 - 0 0 8	-  -00	201	<u>πω4</u> ÷	္က တို့ တစ္က ဇ	0 8 8 2 2 8	042700
Total 1996	548 139 109 61 3	0000	-00	80 87 0 0 0 0 0	00770	0 4 8 0 4 0	83 1 8 75	0 7 8 8 8 0
Total 1995	486 139 139 15 15 15	<u> </u>	-00-0	189 71 14 0	000000	0 8 0 7 7 8 0	72	02820
Total 1994	794 100 8 8 100 100	00 n 4	-00-0	0 7 4 4 0 9	007700	0 4 8 0 % 0	81 74	31 23 8 15 15 17
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines.	MDMA (Ecstasy) Ketamine LSD PCP	Miscellaneous hallucinogens	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS	Tricyclic antidepressants  Miscellaneous antidepressants  Antipsychotics  Phenothiazine antipsychotics  Psychotherapeutic combinations	Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Benzodianes.	CNS stimulants	Cox-2 Inhibitors.  Narcotic analgesics/combinations.  Nonsteroidal anti-inflammatory agents Salicy/lates/combinations. Miscellaneous analgesics/combinations.  Analgesic combinations NTA

# Table 12.2.5 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Chicago by year (continued)

% change <sup>2</sup> 2000, 2001	-37.0	33.8	175.5		92.9	-61.9	4.7 709.3		-20.4	5.6
% change <sup>2</sup> 1999, 2001			171.0	45.6	128.7	68.3	13.4 696.1	-38.1		26.9 22.8 6.3
% change² 1994, 2001	-66.5		-71.4 -54.6	41.1	-47.1	-84.3	-43.4 1,032.7 -58.2	-49.9 -60.7	-52.7 -52.7 95.0	46.5 49.7 3.6
Total 2001	04000 <u>w</u> :	<u>υ</u> ←	00000	<b>г</b> 0	00	2 0	<u> </u>		. o. v.	558 988 39
Total 2000	<del>-</del> 40000 <sup>‡</sup>	`ი ←	00000	၈၀	00	0-	80 6 6		, = -	502 917 37
Total 1999	1210070	4 +	00000	0 0	00	0-	25 0 2 1		. o ←	440 805 37
Total 1998	<del>+4+0</del> 080	4 +-	00080	e ←	<del>- 0</del>	0 -	00 6 -		4-	445 821 36
Total 1997	240+0+0	e ←	.000-	დ ←		0 -	26		17	462 867 38
Total 1996	1001:00	e ←		<b>п</b> 0		00	0000		, <del>6</del> ~	408 737 38
Total 1995	10000	9 +	0N ;	ო :		0 -	£ 0 4 t		27,	384 674 39
Total 1994	040+020	9+	<u> </u>	<b>6</b> 0	<del></del>	<b>-</b> €	31	000	<u> </u>	381 660 38
Drug category¹	Anorexiants	RESPIRATORY AGENTSAntihictamines	Brondollators. Decongestants. Expectorants. Upper respiratory combinations. Respiratory agents NTA.	CARDIOVASCULAR AGENTSAntiadrenergic agents, centrally acting	Beta-adrenergic blocking agents	Diuretics	OTHER SUBSTANCES	Hormones	Drug unknown	TOTAL DRUG ABUSE EPISODES

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

Table 12.2.6 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Dallas by year

% change <sup>2</sup> 2000, 2001	-28.9	-13.3	9.7	9.3 -1.2 5.7		-3.8 -31.2 -51.1
% change <sup>2</sup> 1999, 2001		0,0	8.0	1.6 6.9 9.5 15.0	-5.7	2.4
% change <sup>2</sup> 1994, 2001	12.5 -0.4 -7.2 -38.5 68.8 68.8 210.8 -44.8 177.3 316.0 -69.6 -69.6 -69.6 -69.6 -780.2 -780.2 -780.2 -780.2 -780.2	2.7 -0.6 -484 4111	-83.6	6.5 13.8 29.4		27.9 -39.9 -70.6
Total 2001	288744244444444444444444444444444444444	199 92 27 0 0 9 6	V-00	67 74 43 10	65	20 11 0
Total 2000	270 757 84 19 14 19 10 10 10 10 10 10 10 10 10 10 10 10 10	229 100 33 11 11 8	0 0	2 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	79	31.
Total 1999	252 868 868 72 4 + 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	211 33 40 12 12 12	V-00	04000	86 70	29 5 22
Total 1998	309 106 22 44 100 100 100 100 100 100 100 100 100	241 109 32 0 13 9 9	<b>&amp; M O O</b>	68 64 7 7	97 0 0	32 16 6 27 0
Total 1997	228 66 74 77 77 77 77 73 38 138 111 111 111 111 111 111 111 111	245 106 33 0 0 13 10 11	<b>∞</b> ო ; ○	4 0 0 6 4 E	82 0	30 17 8 27 0
Total 1996	25 25 25 25 25 25 25 25 25 25 25 25 25 2	208 92 30 0 11 13		22 32 8 8 8	886 0 0 0 0	22 16 7 25 .:
Total 1995	183 23 117 23 6 6 6 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8	224 98 29 0 0 11	ω4 <sup>; ;</sup> ί	56 3 16 37	91 75 0	: 5° 000
Total 1994	171 58 62 10 10 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0	226 90 27 10 12 5	<u> </u>	00 c 4 4 2	96	23 17 25 0
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Methamphetamine MDMA (Ecstasy) Ketamine LSD PCP LSD PCP Miscellaneous hallucinogens. Flunitrazepam (Rohypnol) GHB Inhalants.	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS Antidepressants MAO inhibitors SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants	Antipsychotics	Miscellaneous anupsychouc agents	CNS AGENTS	Narcotic analgesics/combinations

# Table 12.2.6 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Dallas by year (continued)

% change <sup>2</sup> 2000, 2001	-100.0 27.7	61.2 -61.3 -85.3			-16.5
% change² 1999, 2001	18.2	15.2		101.5	7.7-
% change <sup>2</sup> 1994, 2001	-72.8 6.9 -72.4	-76.7 -77.3	-65.7 -81.1 -72.5	 -77.4 -57.1 -56.3 39.7	4.4 -1.6 -3.7
Total 2001	+ 60 + 60	<u>800004</u>	W O O + O +	<u> </u>	210 391 34
Total 2000	1 8 0 0 0 0 0 0	<b>5</b> € 6 € 6 € 6 € 6 € 6 € 6 € 6 € 6 € 6 €	wo+ :0+	2-6000-6-	272 499 41
Total 1999		8004	00-	0-40	254 465 37
Total 1998	0 + 0 0	0 € 1 + 0 m i	40   0	20 00 00 00 00 00 00 00 00 00 00 00 00 0	295 550 37
Total 1997	w≻ ;+000	00000	40	4-1000 100	257 473 37
Total 1996	240+0	<u> </u>	4 :00	<u> </u>	208 384 35
Total 1995	0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	± 0, in i	(C) + + + (C)	00 : 80000 <del>- 4-</del>	221 407 36
Total 1994	0 0 0 0	£ 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10	N-1-01-E	2 : o w c c - c -	219 397 35
Drug category¹	Anorexiants	Antihistamines. Antihistamines. Bronchodilators. Decongestants. Expectorants. Upper respiratory combinations. Respiratory agents NTA.	CARDIOVASCULAR AGENTS. Antiadrenergic agents, centrally acting. Beta-adrenergic biocking agents. Calcium channel blocking agents. Diuretics. Cardiovascular agents NTA.	Alternative medicines Anti-infectives Anti-infectives Castrointestinal agents Hormones Nutritional products Topical agents Drug unknown All other substances NTA	TOTAL DRUG ABUSE EPISODES

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique This column denotes statistically significant (p < 0.05) Increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



Table 12.2.7 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Denver by year

% change <sup>2</sup> 2000, 2001	o. ç,	-38.7	77.5	i	5.4 4.5.4 5.5	3.2	12.5	-83.4	15.4	-5.7 -5.7	2.0 -54.6	6 4 2 6.	9.2	
% change <sup>2</sup> 1999, 2001	0.1 1.84 1.5	129.3 800.8 -59.5	8- 5.18-	:	-5.7	25.0	9	-86.4	13.6		15.9 -61.2	5.8	25.0	-100.0
% change <sup>2</sup> 1994, 2001	26.6 92.5 66.9	1,531.2		:		47 5	57.6 57.6 93.0	-98.1	-100.0 13.9	41.8	-72.0	_	64.6 41.5	-53.0
Total 2001	291 96 96 40 50 21		<u> </u>	0	193 77	000	7 /	00	0 - 1	4 8	<del>6</del> –	88	04+	- 2 <u>2</u> 0
Total 2000	326 109 83 41 51	4-40	<u> − 0 m m</u>	÷	204 79 21	<u></u> σ σ	000	- 0	0 0 0	4 K	<del>6</del> 2	104	0 8 4	25
Total 1999	312 107 87 40 43 15		<u>∶0040</u>	i	204 88 26	തെത		<del>- 0</del>	0 9 2	4 4	6 2	92	33:	25 0
Total 1998	263 98 73 31 37 7				192 87 22 0	တတ	7.5	-0	0 0 4	32 3	<del>1</del> 2	72	14 27 0	2 K O
Total 1997	275 98 69 30 32 14				207 85 28 0	2 0	ဖေ ထ	0 0	0 6 74	323	<u>£ 4</u>	96 75	0 4 9	ာ ႘ဝ
Total 1996	191 77 53 22 19 6				192 75 24 0	9 9	4 00	0 0	o æ 4	78 2	<u>ნ</u> ო_	69	0 \$ 5	0.25
Total 1995	290 107 75 33 33 18	000-	- N O O N	0	249 96 28 0	0 10	<u>е</u> Б	ო <u>:</u>	<u>o o 7</u>	4 &	<u> </u>	9000	, 8 22 o	4 % O
Total 1994	285 108 34 26 13	000+	- M O O 4	:	264 98 28 0	2 2	12	<u>:</u> ۵۰	<u>o o %</u>	က တွ	<u> </u>	88 -	25 19 19	27
סמtegory Drug category Drug	MAJOR SUBSTANCES OF ABUSE. Alcohol-in-combination Cocaine. Heroin. Marijuana. Amphetamines.	MDMA (Ecstasy) Ketamine LSD	Miscellaneous hallucinogens Flunitrazepam (Rohypnol) GHB Inhalants	Combinations N I A	OTHER SUBSTANCES OF ABUSE	SSRI antidepressantsTricyclic antidepressants	Miscellaneous antidepressants	Phenothiazine antipsychotics	I hioxanthenes	Barbiturates. Benzodiazepines	Misc. anxiolytics, sedatives, and hypnotics CNS stimulants	CNS AGENTSAnalgesicsAntimigraine agents	Cox-2 inhibitors Narcotic analgesics/combinations Nonsteroida anti-inflammatory agents	Miscellaneous analgesics/combinations

# Table 12.2.7 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Denver by year (continued)

% change <sup>2</sup> 2000, 2001	:		64.3 54.5 -75.0 -100.0	-8.5 66.4 48.8	u C P	58.1 58.1 7.0 7.0	8-8-0 6-6-6
% change <sup>2</sup> 1999, 2001	÷	37.9 15.4 54.7	-75.4 41.2		-37.1	24.5 145.7 -70.2	-7.0 -6.3 -7.0
% change <sup>2</sup> 1994, 2001	-82.7	45.2	-74.1 -61.2 -100.0	-61.2	-78.1 -70.2	74.1	8.5
Total 2001	- C 0 :: 0	r 4-	0-080	40	5-90	0000F	281 484 30
Total 2000	-6-00	0 31	00-40	40	1001	<u> </u>	306 529 33
Total 1999	-80-0	<u>80 4+</u>	<u> </u>	400	\$0 m +	0 0 0 0 0 0	302 517 33
Total 1998	0000	V 0 4 F	<u> </u>	2008	1300	.000rt	259 455 27
Total 1997	111	0 21	00	00N	<u> </u>	N + 0 9 N	278 482 28
Total 1996	0 0 0 0	0 0 0	00	<u> </u>	0 0 0	8-09-	221 383 29
Total 1995	-001	0 00	- 0 4 0	808	3 1 0 29	4400+	302 30 30
Total 1994	- 8 0 - 01	<u> </u>	<u> </u>	0 N	₹0 8 C	∞ N O ; N	328 550 28
Drug categorγ¹	Anorexiants	Muscal readelts	Bronchodiators Decongestants Expectorants Upper respiratory combinations	CARDIOVASCULAR AGENTS	OTHER SUBSTANCESAlternative medicinesAnti-infectives	Hormones.  Nutritional products.  Topical agents.  Drug unknown.  All other substances NTA.	TOTAL DRUG ABUSE EPISODES

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (ho < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of CNS = central nervous system, ED = emergency department, GHB ≃ gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

Table 12.2.8 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Detroit by year

% change <sup>2</sup> 2000, 2001	22.7	37.8 46.5 50.1 44.0 44.0 42.1 42.1 52.2 52.8 45.9 45.9 46.1 86.9
% change <sup>2</sup> 1999, 2001	24.0 31.3 51.3 187.9 -75.3	58.9 -100.0 88.9 80.9 39.9
% change² 1994, 2001	75.9 .:: -85.1	131.9 89.9 148.8 -78.9 -100.0 107.5
Total 2001	633 1 121 1 121 1 1 1 1 1 1 1 1 1 1 1 1 1 1	252 1254 262 272 273 274 275 275 275 275 275 275 275 275 275 275
Total 2000	558 1933 76 179 179 179 179 179 179 179 179 179 179	23.5 88.7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
Total 1999	512 167 178 178 95 95 95 95 97 1	88 8 8 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Total 1998	569 187 107 67 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1	428 222 0 0 0 0 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Total 1997	552 187 192 72 72 89 9 0 0 0	213 101 23 124 125 127 127 127 127 127 127 127 127 127 127
Total 1996	250 250 250 76 101 11 11 11 11 101 0	273 1193 299 200 115 115 127 128 129 129 129 129 129 129 129 129 129 129
Total 1995	283 212 212 58 60 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	247 202 203 39 99 17 27 27 27 27 27 27 27 27 27 27 27 27 27
Total 1994	523 183 203 53 7 7 0 0 0 0 0	252 99 151 144 175 190 190 190 190 190 190 190 190 190 190
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Marijuana Methamphetamine MDMA (Ecstasy) Ketamine LSD LSD LSD Riscellaneous hallucinogens Flunitrazepam (Rohypnot) GHB Inhalants	OTHER SUBSTANCES OF ABUSE  Antidepressants  MAO inhibitors.  SSRI antidepressants  Miscellaneous antidepressants  Antipsychotics. Phenothiazine antipsychotics Phenotherapeutic combinations. Thioxanthenes.  Miscellaneous antipsychotic agents.  Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. CNS stimulants.  CNS stimulants.  CNS stimulants.  Analgesics. Analgesics. Analgesics. Nonsteroidal anti-inflammatory agents. Nonsteroidal anti-inflammatory agents. Salicylates/combinations. Miscellaneous analgesics/combinations. Analgesic combinations NTA.

⊤©Table 12.2.8 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Detroit by year (continued)

Drug category¹	Total	Total	Total 1996	Total	Total	Total	Total	Total	% change <sup>2</sup> 1994,	% change <sup>2</sup> 1999,	% change <sup>2</sup> 2000,
		200		3	255	666	2000	7001	2001	2001	2001
Anticonvileants	- 0	— u	0	0 0	0	0.	0 (				141.1
Antiemetic/antivertigo agents.		? :	00	00	00	n :	۔ م	<u> </u>	191.4	76.2	
Antiparkinson agents	0	<b>←</b> c	<b>←</b> ¢	₩ (	₩ 0	+ (	0 (	0	-75.9		:
Muscle relaxants	o vo	^ 0	^	<del>-</del> 9	<b>-</b> 9	S C	O 10	^			
Miscellaneous CNS agents	0	0	0	0	0	0	· :	0			
RESPIRATORY AGENTS	9	4	Ω.	က	2	2	က	9		150.5	139.0
Antihistamines		<del>- ,</del>			-		<del></del> (	_			
Decongestants	-	- 0	- c	- 0	- c	0 0	0	<del></del>	-66.2		453.8
Expectorants	: :	<b>'</b> :	0	· :	0	<del>-</del>	: :	- 6			i
Upper respiratory combinations	<b>е</b>	00	7	_	_	<del> c</del>	- (	<u></u> е	:	472.6	142.6
agains in Comments and State of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of	5	>	÷	:	፧	5	<del>-</del>	:			:
CARDIOVASCULAR AGENTS	2	ک	2	Ω,	4	2	2	S.		101.1	106.6
Autadienergic agents, Centrally acutig Beta-adrenergic blocking agents				<del>-</del> -			<del>-</del>	<del></del>			
Calcium channel blocking agents	-	_	_	_	-	0	0	_			228.2
Ulureucs Cardiovascular agents NTA.	2 0	0 0	0 0	0 0	: -	<del>- 0</del>	<del>0 +</del>	<del></del>		1,179.4	
OTHED SIDSTANCES	י נ	1 2	1 6	1 (	- 1	- (	- !	-		1.021	
Alternative medicines	<u> </u>	מס	4, 0	20	<u>c</u>	<u> </u>	£ 0	<del>-</del>	-80.7	48.2	-20.6
Anti-infectives	2	S) C	4	: m	<u>:</u> ო	0	<del>-</del>		0 08-	46.3	
Gastrointestinal agents	2	7	8	2	_	-	_	_	3	9	
Hormones	7	- 1	7	_	-	-	_	-			
Topical agents		-			_	00	0 0	00	-64.9		40.7
Drug unknown	. 4	<u>. 6</u>	15.	<u>, 6</u>	; œ	4	5 60	5 KA	-87.8	280.4	40.5
All other substances NTA	2	_	_	_	_	-	· <del></del>	0	-75.5	2	? ?
TOTAL DRUG ABUSE EPISODES	432	451	498	417	409	374	388	463			
TOTAL DRUG ABUSE MENTIONS	775	828	933	770	763	200	746	893			
101AL ED VISITS (IN 1,0008)	es es	75		*	¥	쫑	34	38	8.2	10.9	13.3

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ERU Full text Provided to

Table 12.2.9 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Los Angeles by year

% change <sup>2</sup> 2000, 2001	-8.1 -18.6 -18.6 -43.5	-16.0 -18.8 -26.7 -26.7 -32.9
% change <sup>2</sup> 1999, 2001	47.5 45.3 66.4 172.5 249.3	-40.2 -52.7 -100.0 -27.0
% change <sup>2</sup> 1994, 2001	72.0 87.5 228.8 117.9 864.0 1,230.6 172.4	-100.0 -100.0 -100.0 -40.8 -63.0 -33.6
Total 2001	395 771 746 81 81 81 11 11 11 11	714 00 00 00 00 00 00 00 00 00 00 00 00 00
Total 2000	381 1027 1037 37 10 10 10 10 10 10 10 10 10 10 10 10 10	82.004440+ 1 148.440+ 880 1800040
Total 1999	308 24 44 10 10 10 10 10 10 10 10 10 10 10 10 10	4800488410 :8888477 084 :0074 sto
Total 1998	238 728 89 89 89 80 90 77 77	480 14884-00089498- 98 10FR4E0
Total 1997	203 56 56 75 75 75 75 75 75 75 75 75 75 75 75 75	25.0 25.0 25.0 25.0 25.0 25.0 25.0 25.0
Total 1996	239 668 868 868 87 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	\$274000000000 : : 40000 - 50000000
Total 1995	230 688 618 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	7,00 14 4,00 14 4,00 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Total 1994	230 62 62 36 7 7 7 7 7 7 7 7 0 0 0 0 0 0	0886 : 4 0 2 : 2 + 1 : 8 8 8 8 4 + 1 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Marijuana Mothetamines Mothatamphetamine MDMA (Ecstasy) Ketamine LSD LSD Riscellaneous hallucinogens Flunitrazepam (Rohypnol) GHB Inhalants	OTHER SUBSTANCES OF ABUSE Antidepressants. MAO inhibitors. SSRI antidepressants. Miscellaneous antidepressants. Tricyclic antidepressants. Miscellaneous antipsychotics. Phenothiazine antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. CNS stimulants. CNS stimulants. CNS stimulants. Cox-2 inhibitors. Narcotic analgesics/combinations. Narcotic analgesics/combinations. Norsteroidal anti-inflammatory agents. Salicylates/combinations. Miscellaneous analgesics/combinations. Miscellaneous analgesics/combinations. Miscellaneous analgesics/combinations. Miscellaneous analgesics/combinations.

── Table 12.2.9 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Los Angeles by year (continued)

% change <sup>2</sup> 2000, 2001			-38.1		-5.0
% change <sup>2</sup> 1999, 2001	-62.1		42.9	67.5	19.1 20.7 5.4
% change <sup>2</sup> 1994, 2001	-68.3	-68.0 -89.1 -62.1	-75.9 -76.2 -57.0 -75.4 -75.4		-56.6 27.9
Total 2001	000040	NO   667	-00 <u>:</u> 00	8 :004	288 522 28
Total 2000	0 m ; 0 0 m 0	N+000 <del>+</del>	<u> </u>	20 23	291 519 30
Total 1999	- m ; 00 m 0	N0000F	N0000 <del>-</del>	200 : 82	242 433 27
Total 1998	0400000	N-000-	-00000	902 10	202 352 25 25
Total 1997	0 m o ; o m o	m00-0	4000	<u> 4 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 -</u>	205 355 27
Total 1996	, i o o o o	4 <sub>:</sub> -0	WO0-	<u> </u>	245 425 28
Total 1995	- ro - o ro	<del>40</del> - ;	40	8000000 :6	235 407 27
Total 1994	-ro ;000	<u> </u>	400	802223908	237 408 29
Drug category¹	Anorexiants	RESPIRATORY AGENTS Antihistamines Bronchodilators Decongestants Expectorants Upper respiratory combinations Respiratory agents NTA	CARDIOVASCULAR AGENTS	OTHER SUBSTANCES Alternative medicines. Anti-infectives Gastrointestinal agents. Hormones. Nutritional products. Topical agents Drug unknown.	All other substances NTA

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the internet at http://www.multum.com. estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update)

379

Table 12.2.10 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Miami by year

ge <sup>2</sup> % change <sup>2</sup> 2000, 2001	25.3 29.1 9.7	68.7 8.4 39.8	178.5 70.0 189.5 65.5		-	-83.9 -74.8 39.2 -52.8	20.4	π <u>.</u>	-37.3	30.2		30.7 23.4	33.1	43.3	18.4	1,411.2	9.4	1000
% change <sup>2</sup> 1999, 2001					<u>2</u>													
% change <sup>2</sup> 1994, 2001	100.0		1 196.0 9 7,968.0	-34.8	31.5	31.5	-22.3			41.7		12.2	34.7		10 -		62.9	
Total 2001			+ <del>-</del> 10 ⊂ 0 <del>-</del> 00 ⊂										25.3			127		
Total 2000	6 571 8 162 0 225	1 ~ 63	000				-						4 64 0			0 61		
Total 1999	0 476 2 138 7 210				<del>0</del>	<del></del> -	158				00		39			0 41		
Total 1998			<u> </u>										4 4 6			0 4 7		
Total 1997	374				0+0	į	173 73						 . 88 . 5					
Total 1996			000		_	1	_						42.6			0 <del>L</del> «		
Total 1995	340 92 168					000	210 79			∞ 4	<del>۰ : ۳</del>		4 5 5	62	<b>₹</b> :	<u> </u>	0 6	30
Total 1994	298	39			000		225 83		. :		: 0 4	- CJ		63		. : 0 0 C		0
Drug category¹	MAJOR SUBSTANCES OF ABUSEAlcohol-in-combination Cocaine	Heroin	Methamphetamine	LSD	Miscellaneous hallucinogens Flunitrazepam (Rohypnol)	InhalantsCombinations NTA	OTHER SUBSTANCES OF ABUSEPSYCHOTHERAPEUTIC AGENTS	MAO inhibitors. SSRI antidepressants.	Tricyclic antidepressants	₹	Psychotherapeutic combinations	₹	Benzodiazepines. Misc. anxiolytics, sedatives, and hypnotics.	CNS AGENTS	Analgesics	Cox-2 Inhibitors	Salicy/ates/combinations. Miscellaneous analoesics/combinations	Analgesic combinations NTA

#### Table 12.2.10 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Miami by year (continued)

% change <sup>2</sup> 2000, 2001		58.4	277.8	79.5	44.0	-100.0	-27.0	104.6 114.7 -32.3 -64.2	-2.3
% change <sup>2</sup> 1999, 2001	-69.1	78.8			-69.1	-56.3 -100.0	-38.1	i i	15.7 21.5 0.6
% change <sup>2</sup> 1994, 2001	-61.0 10.0 -89.0 -73.7	40.0	-87.0 -82.5	40.5	-51.3 -62.4	-71.9	-61.1	174.0 -49.3 -66.7	31.9 47.4 7.0
Total 2001	000-000	8	:000	1+0	800	00-	37	29	430 771 37
Total 2000	04000+0	7 7	-00	: -	e :-	-0-		4 -	439 763 38
Total 1999	040-000	<del></del> c	0000	· <del>-</del> :	m o o	-0-	4001-	. + 4 £ £	372 634 37
Total 1998	101010	8.0	0000	0 + 0	<b>поо</b>	-0-	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3207	339 567 37
Total 1997	-4000-0	7 7	-000	-0	00 :	-0-	\$040+	37	335 547 36
Total 1996	<u>+4</u> ;0000	00	) <del>-</del>	-0	ж о <del>г</del>	-0-	00 00 4 4	82 - 83 -	339 535 34
Total 1995	1000010	ro c	-00	. n o	40-	004	90 90 7	. 0 0 4 0	351 550 34
Total 1994	-808080	40	<del></del>	00	m o o	-0-	2000	57	326 523 35
Drug category <sup>1</sup>	Anorexiants	RESPIRATORY AGENTS	Anunistanimes Bronchodilators Decongestants Experients	Upper respiratory combinationsRespiratory agents NTA	CARDIOVASCULAR AGENTSAntiadrenergic agents, centrally actingBeta-adrenergic blocking agents.	Calcium channel blocking agents.  Diuretics  Cardiovascular agents NTA.	OTHER SUBSTANCES. Alternative medicines. Anti-infectives. Gastrointestinal agents.	Nutritional products Topical agents Drug unknown All other substances NTA	TOTAL DRUG ABUSE EPISODES

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique



NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 12.2.11 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Minneapolis by year

% change <sup>2</sup> 2000, 2001	23.8 17.4 22.7 38.4 39.6 95.9 180.2 -69.4	6.5 14.3 9.9 10.8 65.3 65.3 431.6 12.6 22.5 35.0 35.0 37.0
% change <sup>2</sup> 1999, 2001	41.7 22.8 24.8 70.8 76.5 105.7 163.5 342.5 175.8 -72.7	25.7 19.6 22.7 22.7 21.9 2,658.4 43.1 6.9 6.9
% change <sup>2</sup> 1994, 2001	84.6 37.6 72.0 354.9 155.4 499.1 3,268.2 -81.3 162.5 5,849.0	111.5 -90.1 -100.0 -7.7.7 131.5 27.7 27.7 -76.7
Total 2001	28 4 4 4 6 5 8 8 4 6 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	254 100 100 100 100 100 100 100 100 100 10
Total 2000	777 88 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	238 8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Total 1999	250 2 4 8 8 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	228 88 36 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1998	£ 8 8 8 0 1 0 0 0 0 0 − 1 0 0 0 0	20 8 8 8 0 5 7 4 9 0 0 0 4 5 5 4 8 4 8 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1997	255 32 26 6 3 8 8 9 9 9 9 9 0 0 0 0 0 0 0	486 486 000 000 000 000 000 000 000 000 000 0
Total 1996	23 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	25. 108. 22. 22. 22. 22. 22. 22. 24. 25. 39. 90. 10. 20. 20. 20. 20. 20. 20. 20. 20. 20. 2
Total 1995	£ 6 2 2 4 2 2 4 ; 0 6 ; ; 0 0 + 0	4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1994	## ## ## ## ## ## ## ## ## ## ## ## ##	251 101 43 14 10 10 10 10 10 10 10 10 10 10 10 10 10
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines Mothamphetamine MDMA (Ecstasy) Ketamine LSD PCP Miscellaneous hallucinogens Flunitrazepam (Rohypnol) GHB Inhalants Combinations NTA	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS. Antidepressants. NAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Indicallaneous antidepressants. Niscellaneous antidepressants. Phenothiazine antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. CNS stimulants. Antinigraine agents. Cox-2 inhibitors. Narcotic analgesics/combinations. Narcotic analgesics/combinations. Narcotic analgesics/combinations. Niscellaneous analgesics/combinations. Miscellaneous analgesics/combinations. Analgesic combinations NTA.

Table 12.2.11 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Minneapolis by year (continued)

% change <sup>2</sup> 2000, 2001		76.2	33.7 187.4		i		30.7	-66.3	17.2 13.8	0.5
% change <sup>2</sup> 1999, 2001	22.8	46.3	93.6	47.9			÷		29.1	4.3
% change <sup>2</sup> 1994, 2001	-54.2	74.0	125.8	162.5		1,212.3	-46.5 -44.3 1,066.5		30.7	8.7
Total 2001	0	0 10	000	4	F :- 0 - 6	7-60	<del> 0 0</del>	_	251 473	31
Total 2000	0 w : 0 C	40	<u>8+0</u> 00	40	<u> </u>	07 + 4 0	<u> </u>	က	214	31
Total 1999	0 0 0 0	0 20	<u> </u>	mО	V001-4	<u>\$ - 2 0</u>	0 + 10	2	194	29
Total 1998	1000	40	<u> </u>	mО	0-00	7-4-	0 <del>-</del> 0 ∶	7	183	28
Total 1997	1 2 2	40	<u>0+</u> '0+	40	0.0 - 12 - 19	8 0 8 0 8	<u> </u>	2	211	29
Total 1996	i 9 i + c	40	904 : 44	4 <u>;</u>	0 : 4 <u>-</u> 00	22 0 7 0	0000	7	208	30
Total 1995	25 : - 0	40	<u>6</u> - ; 6 ;	40	8-4-02	23 : 63	ω N O 4	က	188	99
Total 1994	. 9 + + 0	40	<u>64-</u>	40	⊕ <sup>:</sup> 4 – 0 æ	22 0 6 +	0000	2	192	28
Drug category <sup>1</sup>	Andrewiants	General arrestratus	RESPIRATORY AGENTS	Upper respiratory combinationsRespiratory agents NTA	CARDIOVASCULAR AGENTS	OTHER SUBSTANCES	Hormones	All other substances NTA	TOTAL DRUG ABUSE EPISODES	TOTAL ED VISITS (In 1,000s)

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor

Table 12.2.12 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for New Orleans by year

% change <sup>2</sup> 2000, 2001		.38.3 125.9 -27.2 -56.5 -54.1 -54.1 -58.9 -44.2
% change <sup>2</sup> 1999, 2001	-26.7 -35.1 -30.0 -14.0 -29.8 -76.6 -75.0 -47.3	41.6 48.3 -100.0 47.3 .:.
% change <sup>2</sup> 1994, 2001	<u> </u>	-33.4 -41.2 -90.6 -94.5 -100.0 -85.9 -70.5 -74.2
Total 2001	366 1022 1234 1236 1200 1200 1300 1300 1300 1300 1300 1300	242 600 600 600 600 600 600 600 60
Total 2000	151 162 162 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	233 96 0 0 7 4 4 7 1 : 0 4 1 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Total 1999	861 158 863 158 863 158 158 158 158 158 158 158 158 158 158	230 80 00 00 00 4 4 + 0 : E F 8 E 8 0 0 0 0 8 4 4 ::
Total 1998	523 1 469 2 2 2 2 3 2 5 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	280 109 20 0 77 108 108 108 108 108 108 109 109 109 109 109 109 109 109 109 109
Total 1997	530 166 198 36 113 113 113 113 113 113 113 113 113	887 60 60 60 60 60 60 60 60 60 60
Total 1996	202 202 202 202 2 2 2 2 2 2 3 3 3 0 0 0 0	388 247 247 200 103 103 103 103 103 103 103 103 103 1
Total 1995	241 174 174 174 188 88 88 10 10 10 10 10 10 10 10 10 10 10 10 10	4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Total 1994	2228 1684 777 777 100 000	225 057 8 8 4 4 2 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin Manijuana Amphetamines Methamphetamine MDMA (Ecstasy) Ketamine LSD LSD LSD Rocellaneous hallucinogens FCP Miscellaneous hallucinogens Flunitrazepam (Rohypnol) GHB Inhalants	Antidepressants.  Antidepressants.  Antidepressants.  MAO inhibitors.  SSRI antidepressants.  Tricyclic antidepressants.  Antipsychotics.  Phenothiazine antipsychotics.  Phychotherapeutic combinations.  Thioxanthenes.  Miscellaneous antipsychotic agents.  Anxiolytics, sedatives, and hypnotics.  Benzodiazepines.  Misc. anxiolytics, sedatives, and hypnotics.  CNS stimulants.  Cox-2 inhibitors.  Narcotic analgesics.  Antimigraine agents.  Cox-2 inhibitors.  Narcotic analgesics.  Analgesic combinations NTA.  Miscellaneous analgesics/combinations.

#### Table 12.2.12 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for New Orleans by year (continued)

% change <sup>2</sup> 2000, 2001	-64.3 -70.4 542.6	-100.0	54.8	-100.0	-100.0	i	-100.0	-32.3			-31.1 -73.2	4.4.4	3.6
% change <sup>2</sup> 1999, 2001	-78.9 -67.4		-69.2	100.0	-100.0	:	-100.0	43.8	-82.4	-75.7	41.2	Ç	5.8 8.3
% change <sup>2</sup> 1994, 2001	-75.0 -94.6	-92.3	-83.9	-100.0	-100.0	: :	-100.0	-57.7	-88.3 -96.0	-94.7 -84.9	-88.1	-21.4	3.8
Total 2001	0	- 0 7 0	N ; €	000	- 0	: :	: : <sup>0</sup>	21	<u>; - 0</u>	000	<u> </u>	324	51
Total 2000	0 4 0	<u>+ 0 &amp; 0</u>	4 - 0	· ; <del>- ·</del>	- 0	000	0000	33	0 - 0		<u>8</u> 0	378	64
Total 1999	0	<u> </u>	υ <del>-</del> C	00-0	20	٠ : ۵	- <del> o</del> m	37	- 100		30.	367	4 84
Total 1998	040	<u> </u>	9 7 0	<u>0 + 0 (</u>	0 0	<u>ω <del>-</del> τ</u>	-00-	. 2	04-	<del> c</del>	94-	423	803 47
Total 1997	:40	4050	4	- ;00	0 0	4-0	<del>- 0 -</del>	. %	o ro ←		<u>2 € 4</u>	438	818 48
Totai 1996	16 16 0	<u>60 5</u> 0	- 0 <del>-</del>	-0-0	N :	72	- v o v	78	: ~ 0	ကက	o 12 4	497	939
Total 1995	21	<u> </u>	<del>1</del> 00	<u>√ ← □</u>	Γ	333	4 O 4 G	86	<u>o 5 5</u>	9 7 9	53	505	957
Total 1994	- 20	7000	5 6 6	o ← O (	←	<b>8</b> €€	<u> </u>	64	o <del>5</del> 4	n e	23.0	412	821 49
Drug category <sup>1</sup>	Anorexiants	Antiparkinson agents	RESPIRATORY AGENTSAntihistamines	Decongestants	Upper respiratory combinations Respiratory agents NTA	CARDIOVASCULAR AGENTSAntiadrenergic agents, centrally acting	Beta-adrenergic blocking agents	OTHER SUBSTANCES	Alternative medicines	Hormones	Topical agents  Drug unknown  All other substances NTA	TOTAL DRUG ABUSE EPISODES	TOTAL DRUG ABUSE MENTIONS

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



Table 12.2.13 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for New York by year

% change <sup>2</sup> 2000,	79.4	-16.6 -44.2 -57.6 -25.9 25.1	188.3 37.8
% change <sup>2</sup> 1999, 2001	-100.0	-37.3 -72.6 36.4 39.7	47.6
% change <sup>2</sup> 1994, 2001		-33.0 -67.1 -61.2 -61.2 -93.0 -100.0 -74.2 -74.2	58.2
Total 2001	444 444 444 444 444 444 444 444 444 44	868 887 0 4 4 - 4 0 0 0 0 0 0 4 6 7 8 8	044000
Total 2000	484 166 128 128 128 138 138 138 138 138 138 138 138 138 13	25. 27. 27. 27. 27. 20. 20. 20. 20. 20. 20. 20. 20	<u> </u>
Total 1999	674 675 675 675 675 675 675 675 675 675 675	0.00	0 8 8 8 8 0
Total 1998	283 169 173 173 173 173 173 173 173 173 173 173	4 5 8 0 4 8 - 8 - 0 : 8 8 2 7 - 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	004400
Total 1997	2447 1154 1154 100 000 000	86450004-4-00989000 0000	0 0 4 8 0 0
Total 1996	646 1986 136 44 00 00 00 00 00 00 00 10 10 10 10 10 10	23.8 8 8 : 1 4 0 4 4 0 0 € 8 2 8 2 6 0 4 2 6 0	32 211 3
Total 1995	243 1432 37 10 00 00 00 00 00 00 00 00 00 00 00 00	85. 85. 84. 84. 84. 84. 84. 96. 96. 96. 96. 96. 96. 96. 96. 96. 96	044080
Total 1994	25. 25. 25. 25. 25. 25. 25. 25. 25. 25.	87.00 : 4 2.10 0 0 2.22 0 0 6.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 5 s s o o
Drug category¹	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine	PSYCHOTHERAPEUTIC AGENTS Antidepressants Antidepressants MAO inhibitors SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants Antipsychotics Phenothiazine antipsychotics Phenothiazine antipsychotics Psychotherapeutic combinations Thioxanthenes Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics Barbiturates Barbiturates Risc. anxiolytics, sedatives, and hypnotics CNS stimulants CNS stimulants Antimigraine agents Antimigraine agents	Cox-2 inhibitors.  Narrodtc analgesics/combinations Nonsteroidal anti-inflammatory agents Salicy/ates/combinations Miscellaneous analgesics/combinations Analgesic combinations NTA

#### Table 12.2.13 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for New York by year (continued)

% change <sup>2</sup> 2000, 2001	43.6	-82.8			i	4.8
% change <sup>2</sup> 1999, 2001					406.2	10.8
% change <sup>2</sup> 1994, 2001	243.7	-59.8 -89.7 -89.7	-61.6	-69.5	2,777.1 2,777.1 -70.0	-27.9
Total 2001	-6     0		-00000	<u>8</u> 0 - 00	008-	387 623 45
Total 2000	¦0 000	5 <del>-</del> 000 <sub>1</sub> 0 <sub>1</sub>	<del>-</del> 000 ;0	37	o :&-	370 612 43
Total 1999	OR :000	<del>-0</del> ;000;	40000	37	- 300 -	362 598 40
Total 1998	90 <sub>:</sub> 50	0 -00000	700   17	84 : 00-	o :4°	431 697 41
Total 1997	000:000	0 N+0 ;000	N+000+	94 : - 0 -	004-	728 41
Total 1996	-0000	0 4-000-0	<u> 4-000</u> -	200211	55. 1	494 44
Total 1995	0m ;000	0 40-000 ;	0000	8002++	-08-	504 771 39
Total 1994	0 ; ; 707	o mo-o ;-o	m00+ ;-	11000	100	536 798 42
Drug category <sup>1</sup>	Anorexiants	Miscellaneous CNS agents  RESPIRATORY AGENTS Antihistamines Bronchodiators Decongestants Expectorants Upper respiratory combinations Respiratory agents NTA	CARDIOVASCULAR AGENTS	OTHER SUBSTANCES	Nutritional products Topical agents  Drug unknown All other substances NTA	TOTAL DRUG ABUSE EPISODES

requirements (2002). The Multurn Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multurn.com. This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

Table 12.2.14 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Newark by year

% change <sup>2</sup> 2000, 2001	-9.6 -9.6 -100.0			91.4	29.2	
% change <sup>2</sup> 1999, 2001	-11.0 -10.9 -11.4 -17.4 -27.7	145.4		102.3	38.0	49.2 483.3 48.3
% change <sup>2</sup> 1994, 2001		-69.0 104.5 		132.9 -82.5 -100.0	53.3	70.3 48.5 -74.5 -28.4
Total 2001	534 117 152 215 37 37	0   0 0	194 88 00 0	0477 :000	<u> </u>	. <u>74</u> :040040
Total 2000	537 115 147 238 29 29 		169 72 17	<u> </u>	<u>6,88 æ ←</u>	88 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1999	600 172 172 260 29 29 29	<del></del> 00	169 70 16 0	440- : :44	e 98 ±	26 0 0 5 8 8 6 0
Total 1998	681 157 208 282 30 1	<del></del>	163 65 14 0	<u> </u>	2 45 0 +	26 0 26 0 4 4 5
Total 1997	646 167 201 246 28 1	) ; 0 0 0 0 °			28 Z 12 E	50 50 10 10 10 10 10 10
Total 1996	825 225 307 36 0	FF   000	202 76 18 0	₩ 4 H O W Ø	35.2	56 50 00 00 00 00 00 00 00 00 00 00 00 00
Total 1995	879 233 227 327 43 	> m N O O O O O	232 76 18 .:.	V V 8 4 0 0 4 8	35.2	25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1994	738 187 246 262 37 37	<u> </u>	225 73 15	r 00 00 4 4	: 12 33 a	677 617 717 118
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABUSE.  Alcohol-in-combination Cocaine. Heroin. Marijuana. Amphetamines. Methamphetamine. MDMA (Ecstasy) Ketamine.	LSD	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS Antidepressants MAO inhibitors SSRI antidepressants.	Miscellaneous antidepressants Miscellaneous antidepressants Antipsychotics. Phenotylizarine antipsychotics. Psychotherapeutic combinations Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics.	Barzodiazepines	Analgesics

Table 12.2.14 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Newark by year (continued)

nge <sup>2</sup> % change <sup>2</sup> 9, 2000, 1 2001		52.5 82.6	-36.3	-34.9	123.5	-17.6 -12.3 -100.0	-55.7 -64.3 303.1 251.6 241.8 247.8	-28.7 -21.1 -64.9 -73.2	-8.6
% change <sup>2</sup> 1999, 2001			<u>m</u>			•			7
% change <sup>2</sup> 1994, 2001	119.1		. : :					-66.7 -80.1	12.7
Total 2001	- 4000	000	. : : ·	000	m + O + ; +				717 728 45
Total 2000	04 100	0 + 0	5 + 0 0	. 2 -		e :		28	419 706 41
Total 1999	<del>- 4</del> 000	-0	4 ;	0 0 ;	i00c	es 		31	457 769 40
Total 1998	0400	000	40 0	:00	w-0- ic	800	0 + + O	28	497 844 39
Total 1997	04 :+-	0+0	4-0-	:00	w- ;-0-	. 57	4 0	67	500 846 37
Total 1996	1 0 0	000	2	; n o	40	<b>- 1</b> 5 :	40	: 4 -	564 1,025 39
Total 1995	14 T	000	80	O m :	90-00-	72	4 V V + 0	62	626 1,111 40
Total 1994	1001	0 0 0	0	- 0	w+  +0+	76	200	66	547 962 40
Drug category¹	Anorexiants	General anesthetics	RESPIRATORY AGENTSAntihistamines	Expectorants Upper respiratory combinationsRespiratory agents NTA	CARDIOVASCULAR AGENTS	Cardiovascular agents N.POTHER SUBSTANCESAlternative medicines	Anti-Infectives	Topical agents	TOTAL DRUG ABUSE EPISODESTOTAL DRUG ABUSE MENTIONSTOTAL PLOISTS (In 1 000s)

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamlne, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. the Census.

Table 12.2.15 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Philadelphia by year

% change <sup>2</sup> 2000,		55.6 40.5	127.0	0.001-
% change <sup>2</sup> 1999, 2001		142.4 43.8	n G	33.1
% change <sup>2</sup> 1994, 2001		83.3		43.6 -50.1 352.6 -79.5 -100.0 43.7 63.3 147.7
Total 2001	736 205 252 252 119 129	3 : 2 5 -	-04-0	4 4 4 4 4 5 1 1 2 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1
Total 2000	216 216 96 101	<u>80005</u>	0400	294 88 4 1 6 0 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1999	675 184 260 85 85 94	<u> </u>	0-0;	279 288 287 288 288 288 288 288 288 288 288
Total 1998	666 181 275 73 112 8	- 1000	00 1-0	292 200 200 200 200 200 200 200 200 200
Total 1997	602 160 239 79 97		0 ; -0	25.00 : 4 / 7 / 5 / 4 :: 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1996	549 147 224 83 74 6	0 :08-	00+0	22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1995	536 208 84 87 67 5	: 0 to £ -	:000	122 122 127 14 15 16 16 16 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18
Total 1994	441 137 187 53 46 3	:0050	0000	259 220 23 :: 1 :: 2 :: 2 :: 2 :: 3 :: 3 :: 3 ::
Drug category¹	MAJOR SUBSTANCES OF ABUSE. Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines	MDMA (Ecstasy) Ketamine LSD PCP Miscellaneous haltucinogens.	Flunitrazepam (Rohypnol). GHB	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS Antidepressants MAO inhibitors SSRI antidepressants Tricyclic antidepressants Miscellaneous antidepressants Antipsychotics Phenothiazine antipsychotic agents Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates Barbiturates Barbiturates Barbiturates CNS stimulants CNS AGENTS Analgesics. Antimigraine agents Cox-2 inhibitors Norosteroidal anti-inflammatory agents. Norosteroidal anti-inflammatory agents. Salicyates/combinations. Miscellaneous analgesics/combinations Miscellaneous analgesics/combinations Miscellaneous analgesics/combinations Miscellaneous analgesics/combinations Miscellaneous analgesics/combinations Miscellaneous analgesics/combinations

Table 12.2.15 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Philadelphia by year (continued)

% change² 2000, 2001	4.9 6.	81.2	:	10.0
% change <sup>2</sup> 1999, 2001			568.0	9.6
% change <sup>2</sup> 1994, 2001	64.1 8.48.8 8.6.6	Č	195.2	46.4 53.0 10.0
Total 2001	10 10 10 10 10 1 10 1		160 <u>-0</u> 60	573 1,071 39
Total 2000	- HO-0100 100000 : 1	ת היד היד <sub>אלי</sub> ני		481 912 36
Total 1999	-0 1-040 RNO 1000	4 100 8 10	აღ <u>σ</u> ¦ ο <u>Φ</u> σ	510 954 36
Total 1998	-60-040 R-0-09 !	27 20 1 1 0 0 1 1 0 0 1	20-00 <u>6</u> 2	526 962 36
Total 1997	-000040 FULLOW :	29 - 10 - 13	<u> </u>	496 915 35
Total 1996	-800040 FUL-000	3 3 30 0 a	044-0 <u>5</u> 4	467 837 36
Total 1995	-0 F040	0 0 - 0 - 0 0	<u> </u>	448 807 36
Total 1994	-000000 QUUU-40	0 9 0 0 0 0 0	0 8 2 2 9	391 700 36
Drug category¹	Anorexiants Anticonvulsants Antiemeticantivertigo agents Antiemeticantivertigo agents Antiemeticantivertigo agents General anesthetics Muscle relaxants Miscellaneous CNS agents Miscellaneous CNS agents Antihistamines Bronchodilators Decongestants Expectorants Upper respiratory combinations Respiratory agents NTA	CARDIOVASCULAR AGENTS	Anti-Infectives	TOTAL DRUG ABUSE EPISODES

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. the Census.

Table 12.2.16 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Phoenix by year

% change <sup>2</sup> 2000,	-16.1 -1.2 -79.0 -66.2 -65.3	-9.7 -9.3 -14.2 3.0 -10.2 -1.9 -1.9 -1.9 -1.9 -1.9 -1.9 -1.9 -1.9	
% change <sup>2</sup> 1999, 2001	-13.2 -0.7 -9.6 23.9 28.2 247.5 -71.2 13.2 13.2	3.5. 6.1. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.1.5. 1.	
% change <sup>2</sup> 1994, 2001		7.0 -2.2 19.6 19.6 46.3 90.4 -10.7 -66.0 -7.7 -0.8 15.8 15.4 15.4 15.4 15.4 16.4 17.4 17.4 18.4	
Total 2001	288 922 272 3 3 45 1 1 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	75.5. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0
Total 2000	201 101 101 101 101 101 101 101 101 101	25. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5	0
Total 1999	332 932 174 177 177 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	84 4 : 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0
Total 1998	305 106 736 138 138 138 138 138 138 138 138 138 138	286 132 132 132 132 133 134 135 136 137 137 137 137 137 137 137 137 137 137	:
Total 1997	337 1255 66 66 72 72 74 74 75 75 75 75 75 75 75 75 75 75 75 75 75	299 138 138 138 148 158 158 158 158 158 158 158 15	o i
Total 1996	3.19 6.00 3.22 3.32 3.45 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.0	26 75 75 75 75 75 75 75 75 75 75	5
Total 1995	314 225 227 227 233 247 250 00 00 00 00 00 00 00 00 00 00 00 00 0	352 161 161 172 188 198 198 198 198 198 198 198 198 198	5
Total 1994	270 100 142 142 142 143 143 143 143 143 143 143 143 143 143	3.5 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3	,
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines Mchamphetamine MDMA (Ecstasy) Ketamine LSD LSD PCP Miscellaneous hallucinogens Flunitrazepam (Rohypnol). GHB Inhalants Combinations NTA	PSYCHOTHERAPEUTIC AGENTS.  Antidepressants.  MAO inhibitors. SSR antidepressants Tricyclic antidepressants Niscellaneous antidepressants Antipsychotics. Phenothiazine antipsychotics. Phychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents Anxiolytics, sedatives, and hypnotics. Barbiturates. Benzodiazepines Misc. anxiolytics, sedatives, and hypnotics. CNS stimulants. Analgesics. Antimigraine agents. Cox-2 inhibitors. Narcotic analgesics/combinations. Nonsteroidal anti-inflammatory agents. Salicylates/combinations. Miscellaneous analgesics/combinations. Nonsteroidal anti-inflammatory agents. Salicylates/combinations. Miscellaneous analgesics/combinations. Analgesic combinations NTA	

#### Table 12.2.16 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Phoenix by year (continued)

Total % change <sup>2</sup> % change <sup>2</sup> % change <sup>2</sup> 2001 2001 2001 2001	11 152.7 -1.4 -3.0 0 -58.7 13.8	4.1.	12 68.6 80.0 45.1 5 259.7 239.5 144.0 1 -55.6 83.9 71.6	93.6 48.7 1 60.5 280.1 286.2	9 83.6 16.5 10.1 1 42.1 26.7 2 37.5 7.7 26.7	4 202.0 62.5 19.8	39 261.0 4 49.3 5.3 3 134.4 35.7 53.3	2 2 21 2	354 1.9 -12.0 625 7.0 -8.2 -15.1
Total T 2000 2	120	<u>- 0 ữ 0</u>	<u> </u>	- 60	<u> </u>	<del>-</del> €	8 <del>- 4</del> 0 8	- 0 % 0	433
Total 1999	12	<u>0</u> 4 :	<u></u>	040	8-2-	- 2	£4 € ← ₹ € € 4	260 1	402
Total 1998	-000	<u> 10 4 0</u>	N	040	9 - 2 -	2 -	м 	- 0 6 -	346
Total 1997	<b>600</b>	2000	9 7 0 7	0 0 7	2-2-	0 +	225		363
Total 1996	0.80	0 7 0		000			35-462	- 250 -	372
Total 1995	7 0 0			0 11 0	1 2 - 2	2 - 2	22 2		400
Total 1994		20 8 0	K-10-	000	υ <del></del>	0+	£00000		348
Drug category <sup>1</sup>	Anorexiants	Antiparkinson agents	RESPIRATORY AGENTS	Expectorants Upper respiratory combinations. Respiratory agents NTA.	CARDIOVASCULAR AGENTS	Diuretics	OTHER SUBSTANCES	Nutritional products	TOTAL DRUG ABUSE EPISODES

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique



NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 12.2.17 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for St. Louis by year

% change <sup>2</sup> 2000,	:		43.2
% change <sup>2</sup> 1999, 2001	343.1	33.1 27.9 27.9 33.6 38.0 71.9 71.9 49.7 49.7 49.7	75.0
% change <sup>2</sup> 1994, 2001	231.1 155.5 347.5 123.6	-56.1 193.7 -83.3 124.2 -52.4 -52.4	166.7
Total 2001	24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	84 : 6 0 4 5 1	87400
Total 2000	888 847 878 878 878 878 878 878 878 878	201 102 103 104 100 100 100 100 100 100 100 100 100	81 0 81 0
Total 1999	08 458 758 88 84 4-08 1-000 1-1	8888 : 12 · 0 1 · - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	28 9 18 0
Total 1998	88 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	8600 4 r 0 8 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	23 10 18 0
Total 1997	222 8 4 4 4 6 6 4 4 6 6 6 6 6 6 6 6 6 6 6 6	811 8 : 1 8 8 8 8 8 9 9 9 8 9 8 9 8 9 8 9 8 9 8	26 13 23 0
Total 1996	233 886 886 237 200 000 000 000 000 000 000 000 000 00	230 24 24 25 26 27 26 27 26 27 26 27 26 27 26 27 26 27 26 27 26 27 26 26 26 26 26 26 26 26 26 26 26 26 26	19 17 26 .:
Total 1995	235 87 160 37 37 37 37 30 30 30 40 40 40 40 40 40 40 40 40 40 40 40 40	21 80 80 80 80 80 80 80 80 80 80 80 80 80	16 20 0
Total 1994	266 102 27 20 20 20 20 20 20 30 40 10 10 10 10 10 10 10 10 10 10 10 10 10	800 800 800 800 800 800 800 800 800 800	18 16 11 11
Drug category¹	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin Marijuana Methamphetamine Methamphetamine MoDMA (Ecstasy) Ketamine LSD LSD PCP Miscellaneous hallucinogens Flunitrazepam (Rohypnol) GHB Inhalants Combinations NTA	PSYCHOTHERAPEUTIC AGENTS  Antidepressants.  Antidepressants.  NAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antipsychotics. Phenothiazine antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Benzoliazepines. Misc. anxiolytics, sedatives, and hypnotics. CNS stimulants.  CNS stimulants.  CNS AGENTS. Analgesics. Antimigraine agents. CCOX-2 inhibitors.	Narcotic analgesics/combinations.  Nonsteroidal anti-inflammatory agents

Table 12.2.17 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for St. Louis by year (continued)

% change <sup>2</sup> 2000, 2001	56.2		105.8	30.9	209.7	4.7
% change <sup>2</sup> 1999, 2001	38.4	-63.0	-55.9		570.2	7.9
% change <sup>2</sup> 1994, 2001	95.8 95.8	-75.2 -78.0	105.4	-63.2 -51.7	693.3	-2.3
Total 2001	074 1070	₩-00 ; <b>%</b> 0	4 1-000	₹-00	<del>- ← w ←</del>	358 696 39
Total 2000	00++040	<u> </u>	4	1001-1	040	283 545 38
Total 1999	; w ; o o m o	<u>ν+ο+ο</u> ω ;	4000	<u> </u>	-08-	264 486 36
Total 1998	+4000 mo	4±0+ in i	400	£ <sup>;</sup> 400 4	- <u>;</u> • • •	240 450 34
Total 1997	-00-040	080; 770	2007	7097-	-00-	241 438 36
Total 1996	444040	<u>8-00</u>	<u> </u>	2 :000	-00-	266 474 38
Total 1995	+ n 0 + 0 m 0	<u> </u>	שרדר יַּמּ	0 : 0 m d	0 -	246 450 38
Total 1994	-80-080	<u> </u>	N0N	20 : L 80	2000	265 484 40
Drug category¹	Anorexiants	RESPIRATORY AGENTS. Authistamines. Bronchodilators. Decongestants. Expectorants. Upper respiratory combinations. Respiratory agents NTA.	CARDIOVASCULAR AGENTS	OTHER SUBSTANCES Alternative medicines Anti-infectives Gastrointestinal agents Hormones.	Nutritional products	TOTAL DRUG ABUSE EPISODES

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 12.2.18 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for San Diego by year

% change <sup>2</sup> 2000,	-8.6	-21.4 -31.0	12.4	;	-19.2 -55.5	44.1	-51.5 -24.7	6.7	6.1	6.7 -100.0	5.4	2.00		191.0	7.3	<u>)</u>	6.3 21.4	4. 8.	8.7 6.3	-59.6	94.0 24.9	-14.9	7.45
% change <sup>2</sup> 1999, 2001	-11.5	-27.1	14.5	98.6	-26.5	-56.6	-29.3						41.1		-30.6	8.8		4 8 8	9.3	46.9	23.2	· ·	0.02
% change <sup>2</sup> 1994, 2001			97.1 125.4		-57.3	-64.9	1,631.8 -81.8 173.4		32.5				-74.8						55.8	-54.4	198.6	8.6	
Total 2001							N00	224	103	0	<u> </u>	<u>σ</u> «	กลอ	0	67	<u> </u>	7 6 7	- 3	<u> </u>	00	25.0	<u>ज</u> र	. 60
Total 2000	266	42	37	200	- 70		m00	210	97	0	7 6	<b>o</b> o	00	10	62	9 6		- 8	78	00	4;	<u> </u>	<u>6</u> 0
Total 1999		448					m o +	225	108 28	<del>- 0 ç</del>	<u> </u>	12 0	е o	00	99	52	j 0 +	- 6	92 26	00	42.0	D (C	60
Total 1998	280	4 4 4	<del>2</del> 8 8	<del>9</del> - c	<u> </u>	0 -1	0	231	31.	0 5	9 6	<del>2                                    </del>	0 0	0 6	89	20 /	<del>-</del> -	- 6	75	<del>- c</del>	37		0 0
Total 1997	279 76	38 6	37	0	<u>ო</u> თ	-0	0	223	90 08	: ₹	12	10	40	0 10	65	47	<del>-</del> 2 °	87	7.		96.	<u>+</u> @	20 ::
Total 1996	241 76	39 41	2.7.8	- 0	4 -	-0	0 <sub>i</sub> 0	194	27.	<del></del>	. 0	-=	90	0 10	' <u>የ</u>	39 0	<u> </u>	92	62	<del></del>	26	2 ~	<u>&amp; 0</u>
Total 1995	<u>4</u> 2	7 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	30 18	00	N 60	<del>- 0</del>	-00	159	28.4	0 10	000	ဖြ	0 2	0 4	45	5 <del>8</del>	<del>6 -</del>	65	\$	- 0	20	^	0
Total 1994	204	3 8 2	71 4	00	00	<del>-</del> ;	0+0	174	2 2 4	<u></u>	. <del>0</del> .	<u>. 7</u>	<del>. o</del> .	- 4	43	29	<u> </u>	67	<b>%</b> c	00	17	6	0 0
Drug category¹	MAJOR SUBSTANCES OF ABUSEAkohol-in-combination	Heroin	Amphetamines	MDMA (Ecstasy)	PCP	Miscellaheous hallucinogens Flunitrazepam (Rohypnol)	Combinations NTA.	OTHER SUBSTANCES OF ABUSE PSYCHOTHERAPEUTIC AGENTS	Antidepressants.	SSRI antidepressants	Tricyclic antidepressants.	Antipsychotics.	Prierrouliazine anulpsychotics	Miscellaneous antipsychotic agents	Anxiolytics, sedatives, and hypnotics	Benzodiazepines	Misc. anxiolytics, sedatives, and hypnotics CNS stimulants	CNS AGENTS	Antimigraine agents	Cox-2 inhibitors	Narcotic analgesics/combinations Nonsteroidal anti-inflammatory agents	Salicy/ates/combinations	Analgesic combinations NTA

The selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated Table 12.2.18 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated

% change <sup>2</sup> 2000, 2001	-35.3	20.3			73.0	83.2 360.7 89.1	-11.3 -67.7 -39.2	-19.9	45.2	4.8	-5.3
% change <sup>2</sup> 1999, 2001	-40.3 -47.9 -57.2	19.8		20.8 -68.2	18.8 -37.7	807.2 49.0	-31.6 -84.1 -50.2	-55.7 47.6 1,045.9	-25.2 -50.3		
% change <sup>2</sup> 1994, 2001	-58.6 36.3 -67.8 -76.3	101.4	80.8	264.6	51.9	92.4 69.3	-41.5	-61.5	-54.4	25.8	9.6
Totai 2001	000-0	000	4-0-	000	4	++N	<del>2</del> 0-	- 0 - 0	9 -	276	25
Total 2000	19010	o∞ ;	4-0-	000	N	00+	<u>6</u> 00	0	<del>0</del> +	290	
Total 1999	0 0 0 0	0 80 0	4 - 0 -	000	4	-0-	17	0000	∞ ←	292	27
Total 1998	0 0 0 0 0	0 80	<b>ω</b> ← ← ←	-0 00	Ω <del></del>	-0-	<u>\$</u> 04	0 0 <del>-</del> 0	<b>~</b> +	293	
Total 1997	25-25	0 1 0	<u>rv - o -</u>	-0 110	Ω <del></del>	<del></del>	21 0 9	<u> </u>	<b>∞</b> ←	286	25
Total 1996	-40+6	900	<b>ω</b> ← ←	-0 00	<u></u> то т	00-	δοα	N0	9 -	248	25
Total 1995	T 4 0 F 6	<u> </u>	<b>ω</b> ← ← ←	000	w <del></del>	0-	<u>‡</u> ;4	- 0 - 0	<b>2</b> ←	201	22
Total 1994	- 2 - 2	0 8 0	<u>υ ← ←</u> ÷	-0 00	40+	<del>+ 0 +</del>	200 40	0++0	o +	220	23
Drug category <sup>1</sup>	Anorexiants	General anesthetics	RESPIRATORY AGENTSAnthistaminesBronchodilators	Expectorants	CARDIOVASCULAR AGENTSAntiadrenergic agents, centrally acting	Calcium channel blocking agents	OTHER SUBSTANCESAlternative medicines.	Gastrointestinal agents	Drug unknown All other substances NTA	TOTAL DRUG ABUSE EPISODES	TOTAL ED VISITS (in 1,000s)

requirements (2002). The Mutum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

Table 12.2.19 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for San Francisco by year

% change <sup>2</sup> 2000, 2001	20.4 24.4 25.8 16.9 120.6 47.9 -28.5	26.4 26.4 20.2 20.2 26.6 49.3 28.9 28.5 29.3 29.3 29.3 29.3 29.3 29.3 29.3 29.3	14.0
% change <sup>2</sup> 1999, 2001	23.6 29.4 31.3 31.3 53.7 216.9 14.1 14.1 25.5 186.7	-13.5 18.4 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 1	54.4
% change <sup>2</sup> 1994, 2001	21.8 22.8.8 25.3 25.3 36.7 36.7 36.1 36.1 36.1 43.7 129.4 129.4 142.8	-36.7 -23.8 -100.0 -73.5 106.7 -85.1 -96.3 -64.0 -49.5 -19.9 -56.5	-
Total 2001	638 158 178 178 178 178 178 178 179 179 179 179 179 179 179 179 179 179	860 101 0 8 4 8 8 1 0 0 8 0 7 7 2 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	<u></u> 0
Total 2000	530 110 126 168 38 38 7 7 7 7 7 7 7 8 9 9 9 9	4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0
Total 1999	516 106 120 190 190 34 4 4 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	273 873 77 853 61 84 84 84 84 84 84 85 86 86 86 86 86 86 86 86 86 86 86 86 86	0 2
Total 1998	456 100 116 25 2 2 3 3 3 4 4 4 4 6 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1	330 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	40
Total 1997	552 123 173 173 64 177 173 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	30 00 00 00 00 00 00 00 00 00	20
Total 1996	613 139 148 27 27 27 20 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	293 103 103 103 103 103 103 103 103 103 10	0
Total 1995	682 1672 202 33 33 42 72 72 72 72 72 72 72 72 72 72 72 72 72	25. 25. 27. 27. 27. 27. 27. 27. 27. 27. 27. 27	0
Total 1994	816 239 239 200 100 100 100 100 100 100 100 100 100	373 135 135 10 10 10 10 10 10 10 10 10 10 10 10 10	0
Drug category <sup>1</sup>	MAJOR SUBSTANCES OF ABUSE Alcohol-in-combination Cocaine Heroin Marijuana Ampidetamines Methamphetamine MDMA (Ecstasy) Ketamine LSD LSD LSD PCP Miscellaneous hallucinogens. Flunitrazepam (Rohypnol). GHB Inhalants Combinations NTA	Antidepressants. Antidepressants. Antidepressants. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotics. Psychotherapeutic sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. Barbiturates. Barbiturates. CNS stimulants. CNS stimulants. Cox-2 inhibitors. Narcotic analgesics/combinations Norsteroidal anti-inflammatory agents. Salicylates/combinations Miscellaneous analgesics/compinations	Analgesic combinations NTA.

T-312

## 🗝 Table 12.2.19 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for San Francisco by year (continued)

% change <sup>2</sup> 2000, 2001	-27.1 -34.9 86.0	25.5 116.2 87.4 -15.6	71.9 98.7 -23.7 56.2 177.6	42.0 108.2 38.8 100.8 342.4 -53.7 -26.5	13.6 17.5 12.7
% change <sup>2</sup> 1999, 2001	-60.6	90.8 130.4 84.3 258.4	34.6 309.6 220.0	.77.0 309.6 -29.4 591.2 138.9 1,640.7 -83.3	0.0
% change <sup>2</sup> 1994, 2001	-38.2 23.6 -92.8 -100.0	26.9 28.2 38.0 38.0 33.8 67.6	699 640-6 612-64	-80.9 -80.8 -20.0 -230.2 -85.3 -85.3	-31.3 -26.5 -8.4
Total 2001	0.000	000-000	R 0 - K	252 0 0 0 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	546 874 35
Total 2000		4-00000	w00-	24 0 1 1 2 2 1 2 1 2 1 2 1 1 1 1 1 1 1 1 1	480 744 31
Total 1999	0 0 + 0 0	<u> </u>	w000	107 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	555 789 35
Total 1998	0 0 0 0 0 0 0	3 4-0-000	40-0	173	569 786 32
Total 1997	000000000000000000000000000000000000000	4-0-000	N 0	127	598 856 30
Total 1996	<del>-</del> 20000	0-0-000	₩ W ~ ~ O ~	<u> </u>	611 912 32
Total 1995	0 0 0 0 0 0	V-00040	V- 01+0	107 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	659 1,007 31
Total 1994	0 4 0 C	- N0WO	W	129 7 7 2 2 115 2	794 1,189 38
Drug category¹	Anticonvulsants Anticonvulsants Anticonvulsants Antiparkinson agents General anesthetics Muscle relaxants Miscale Industrics	RESPIRATORY AGENTS	CARDIOVASCULAR AGENTS	Alternative medicines. Alternative medicines. Anti-infectives. Gastrointestinal agents. Hormones. Nutritional products. Topical agents. Drug unknown. All other substances NTA.	TOTAL DRUG ABUSE EPISODES

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).



NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor.

Table 12.2.20 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Seattle by year

% change <sup>2</sup> 2000, 2001	.28.5 4.2 -32.4 -17.0 -16.9 -46.5 -36.8 -47.2 -47.2	9.9 1.2 2.7 2.7 2.5 35.7 2.13 2.14 2.13 39.2 
% change <sup>2</sup> 1999, 2001	16.9 28.3 23.0 29.1 79.5 84.2 69.7 69.7 147.6 36.3 100.0	54.7 4.25 5.05 11.2 11.2 5.05 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3
% change <sup>2</sup> 1994, 2001	51.4 224.4 4,863.3 -74.8 452.4 223.7	-100.0 -67.2 -100.0 -100.0 -100.0 -100.0 -49.3 -49.3 -49.3 -49.3 -49.3 -49.3 -49.3 -49.3 -49.3 -49.3 -49.3 -49.3 -49.3 -49.3 -49.0
Total 2001	64 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	88 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Total 2000	612 169 126 72 27 27 6 0 0 0 1 1	248 133 140 150 150 150 150 150 150 150 15
Total 1999	465 115 130 127 18 18 18 18 18 18 18 18 18 18 18 18 18	84.88 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1998	456 125 126 126 49 44 14 14 15 15 16 16 17 16 16 16 16 16 16 16 16 16 16 16 16 16	20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1997	642 1572 1573 152 24 24 25 25 3 3 3 3 3	444 : £ £ £ £ £ £ £ 60 0 0 0 0 0 0 0 0 0 0 0
Total 1996	44 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 +	882 124 125 125 125 125 125 125 125 125 125 125
Total 1995	244 251 351 350 350 350 350 350 350 350 350 350 350	0.55 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1994	531 164 100 100 100 100 100 100 100 100 100 10	24 66 66 66 66 66 66 66 66 66 66 66 66 66
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines Methamphetamine MDMA (Ecstasy) Ketamine LSD PCP Miscellaneous hallucinogens Flunitrazepam (Rohypnol) GHB Inhalants	PSYCHOTHERAPEUTIC AGENTS. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antipsychotics. Phenothiazine antipsychotics. Phenothiazine antipsychotic agents. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. Barbiturates. CNS stimulants. CNS stimulants. Analgesics. Antigesics.

Table 12.2.20 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Seattle by year (continued)

% change <sup>2</sup> 2000, 2001	-16.9 5.8	84.7	40.2		-53.8	20.5 -38.4	17.5 -58.0	71.5 454.2	19.7	4.8	407	203.5 -0.5 -42.6	4.2
% change <sup>2</sup> 1999, 2001	104.5	142.4	65.8	84.8	-69.7	115.3	37.0 -69.7	104.5	38.3	52.2	-36.4	62.7	24.0 30.0 12.9
% change <sup>2</sup> 1994, 2001	-51.4	-46.1 -85.9		-39.3	-95.7 -52.7		-49.6 -79.4	-71.9 -71.9		37.5 374.7 -77.8	-54.9	188.3 -61.8	-13.5
Total 2001	-=	- 0 0	<u>. 6</u> 0	ത ന	0-0	240	30	<del>-                                    </del>	8	49	N N F	4 -	538 927 33
Total 2000	10	000	0 1 0	ထက	0 - 0	⊃ w ←	4	-00	_	. 20 2 C	N N +	- 0 4 2	563 961
Total 1999	0	000	000	S <del>L</del>	0 - 0	000	о <del>-</del> -	- 0 0	_	32	0 th C	204-	434 713 29
Total 1998	1 8	<del>-</del> - c	90	ჯ <del>–</del>	0+0	0 + 0	υ+ c	100	2	32 0 8	N 60 +	23:	433 723 29
Total 1997	9		000	2 7	; <del>-</del> - c	000	<b>~</b> + 0	1	2	35	0 to +	- 0 8 0	556 956 31
Total 1996	9	- 00	000	9 -	0 + 0	⊃ m ;	φ+c	1 — —	<del>-</del>	27	7 7 7	- 0 2 4	449 728 32
Total 1995	1 7	N N 0	000	2 0	<del>-</del> 0	; <del>4</del> -	8000	1	7	26 0 7	000	<u>10</u>	456 755 31
Total 1994	12	<del>-</del> ო თ	<u> </u>	<u>†</u> 4	000	000	<b>⊕</b> + 6	<del>-</del> 2 €	2	96 0 0	ω <del>4</del> υ	1 <del>- 4</del> 6	562 960 38
Drug category¹	AnorexiantsAnticonvulsants	Antiparkinson agents	Muscle relaxants	RESPIRATORY AGENTSAuthistamines.	Bronchodilators	Upper respiratory combinations	CARDIOVASCULAR AGENTSAntiadrenergic agents, centrally acting	Catcium channel blocking agents	Cardiovascular agents NTA	OTHER SUBSTANCESAlternative medicinesAnti-infectives	Gastrointestinal agents	Topical agents	TOTAL DRUG ABUSE EPISODES

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an equirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ERIC

Table 12.2.21 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Washington, DC by year

% change <sup>2</sup> 2000, 2001	13.7  47.6 56.2		54.1
% change <sup>2</sup> 1999, 2001	 -73.3 176.7	86. 80.	4. 3.
% change <sup>2</sup> 1994, 2001	.505- 47.5 32.5 .:. .:. .64.5	41.4 100.0	44.9
Total 2001	254 607 607 607 607 607 607 607 607 607 607	88 1 0 2 1 1 0 0 0 8 2 5 2 2 2 2 3	23 11 26 11 21 11 11 11 11 11 11 11 11 11 11 11
Total 2000	262 728 729 749 749 758 768 768 768 768 768 768 768 768 768 76	<u> </u>	53 17 10 20 20
Total 1999	276 717 8 8 1 1 1 6 8 1 1 1 1 1 1 1 1 1 1 1 1 1	100 8 4 8 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	23 6 73 6 74 75 75 75 75 75 75 75 75 75 75 75 75 75
Total 1998	340 855 870 870 870 870 870 870 870 870 870 870	87.2 : 0.000 : : :	679 139 258 139 139 139
Total 1997	292 88 84 88 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	808 808 808 808 808 808 808 808 808 808	20 15 20 00 00 00 00
Total 1996	80 1 4 80 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0	258 258 279 279 279 279 279 279 279 279 279 279	27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1995	33.86.27	22 0 22 0 21 0 0 21 0 0 21 0 0 21 0 0 21 0 0 21 0 0 21 0 0 21 0 0 1 0 0 1 0 0 0 0	20 0 17 17 17 17 17 17 17 17 17 17 17 17 17
Total 1994	24.1. 24.2. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4. 24.4.	266 273 273 273 66 77 77 78 88 88 72 73 73 74 75 75 75 75 75 75 75 75 75 75 75 75 75	20 0 0 0 14 14 33 34 35 36 37
Drug category¹	MAJOR SUBSTANCES OF ABUSE  Alcohol-in-combination Cocaine Heroin Marijuana Amphetamines Amphetamines Metamine MDMA (Ecstasy) Ketamine LSD LSD PCP Miscellaneous hallucinogens Fluntrazepam (Rohypnol) GHB Inhalants	PSYCHOTHERAPEUTIC AGENTS. Antidepressants. MAO inhibitors. SSRI antidepressants. Tricyclic antidepressants. Miscellaneous antidepressants. Antipsychotics. Psychotherapeutic combinations. Thioxanthenes. Miscellaneous antipsychotic agents. Anxiolytics, sedatives, and hypnotics. Barbiturates. Barbiturates. Barbiturates. CNS stimulants.	Analgesics agents. Antimigraine agents. Cox-2 inhibitors. Narcotic analgesics/combinations. Salicylates/combinations. Miscellaneous analgesics/combinations. Analgesic combinations.

Table 12.2.21 - ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population for Washington, DC by year (continued)

% change <sup>2</sup> 2000, 2001	182.9	50.1	62.4					622.9	-1.0
% change <sup>2</sup> 1999, 2001	189.9		53.6	47.1	43.8			i	3.6
% change <sup>2</sup> 1994, 2001	-65.8		0	-84.7 1,131.8	-62.3	-56.0	-40.7	-39.9	-7.2
Total 2001	<u>:</u> ω− − 0	5 0 0	- 6 ± 6	<del>)</del>		00	25 : 22	1	253 419 30
Total 2000	09 :00	000	4-0	:   7	0 ; 7 N	<del>-</del>		2007	262 413 31
Total 1999	0 0 1	000	₩ <u></u>	- ; 0 ;	w	<del>- 0</del>	27	20: 1	266 438 29
Total 1998	8 :: 0	0 00	9-01	-on <u>:</u>	4-0-	: -	0000	1021	303 497 29
Total 1997	8 1	<b>5 M O</b>	<u> </u>	-040	0 <del></del>	<del></del>	. 25 : 25	-1021	295 500 28
Total 1996	.: 6 2	240	# 00 <del>1</del>	-040	4	<del>-</del>	.: 56	1091	313 528 29
Total 1995	1 0 1	240	00-+	40	4	<del>- 0 -</del>	¥ : 0 m c	12-2-	319 536 32
Total 1994	1 0 1	0 8 0	50	40	4		240 - 20	28 1 1	386 686 33
Drug category¹	Anorexiants	General anesthetics	RESPIRATORY AGENTSAntihistaminesBronchodiators	Decorgestants	CARDIOVASCULAR AGENTS	Diuretics	OTHER SUBSTANCES	Nutritional products Topical agents. Orug unknown. All other substances NTA.	TOTAL DRUG ABUSE EPISODES

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique

CNS = central nervous system, ED = emergency department, GHB = gamma hydroxy butyrate, LSD = lysergic acid diethylamide, MAO = monoamine oxidase, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine, SSRI = selective serotonin reuptake inhibitor. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

403

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

Table 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year

% change <sup>2</sup> H1 2001, H1 2002		-100.0	0.08	-100.0		3
% change <sup>2</sup> H2 2001, H1 2002	-14.1	-100.0	:	-100.0	-13.0	-13.1
Jan-Jun * 2002	8 8 :	00 ;0 ;0	27	000 :00	0 0000017 0 : ::0	0000
Jul-Dec 2001	44 38 0	00 :000	80000 :	000	0 000000 00 000	. 0 0 6
Jan-Jun 2001	38 0	00000	000000	: ; ; 0 ; 0 0	0 0 1 1 2 0 0 0 1	9 : 00
Jut-Dec 2000	42 36 0	00 ;00 ;	78	000	0 000000 0 : 000	000 : 6
Jan-Jun 2000	35 0	00000	90 : 08 : 0	0 1000	: 000000 00 000	0 0 6
Jul-Dec 1999	39 37 0	000 :00	0 80 9	000    00	0 00 :0 :8 00 000	0000
Jan-Jun 1999	42 33 0	00 ; ;00	250000000000000000000000000000000000000	000000	o oo :oot oo ooo	0 0 0 1
Jui-Dec 1998	39	00000	27 : 0 : 0 : 0 : 0	000000	0 00 :00 00 000 0	000 9
Jan-Jun 1998	38 36	00 1000	27	:00000	0 00000 \$ 0 :000	16 0
Jul-Dec 1997	36 35 0	00000	200000000000000000000000000000000000000	;00000	: 0000 : th	0 0 £
Drug name¹	Alcohol in Combination Cocaine 8-Ball Cocaine Anhydroecgonine Methylester	Bazooka Benzoylecgonine Blow Candy. China White Cocaine.	Cocaine. Cocaine Laced Cigarette Cocaine Laced Cigarette Cocaine Metabolite Coke. Crack Joint. Crack Joint.	Dust. Ecgonine Methylester. Eight Ball. Ethylecgonine. Flake. Free Base Cocaine.	Metrylecgonine.  Moon Dust.  Norcocaethylene.  Norcocaethylene.  P-Blow. Ready Rock. Rock Cocaine. Heroin.  Acetylcodeine. Beast. Black Tar Heroin. Blue Diamond Heroin. Blue Ring. Brown Heroin. Brown Mexican Heroin. Carachi.	Crina White Heroin D-Funk Dead President. Diacetylmorphine. Floaters.

Table 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
Heroin Dope	o ;	;0	00	00	00	00	00	0	0	00	525.0	
Heroin with Scopolamine	0	0	0	0	0	0	0	0	0	0		
Iranian Heroin	00	00	00	; 0	; 0	; 0	00	00	00	00		
Mexican Mud	1	1	1		•	•	•	•	•	•		
Mixed Dope	0	0	0	0	0	0	0	0	0	8		
Mixed Junk Heroin	00	00	00	0	00	; C	0	: <sup>C</sup>	0.0	00		9
Mxd Siu Whpd Cracker	•	•	•	:		>	:	<b>5</b>	<b>5</b>	5		0.001-
P-Dope	; c		0 0	00		00	00	00	0	0	-100.0	
Persian Heroin	00	00	00	0	0	00	00	00	0	50		
Poison	00	00	00	00		0 0	00	0 0	0	00	7	
Smack	· :	0	•	0		> ;	0	0	5 6	5 6	0.001-	
Stuff	0	0	0	0		0	0	0	00	00		
Super Buick	00	00	<del></del>	00		0 0	: •	00	0	0		
White Fox Heroin	0	0	0	0	50	<del>-</del> -	5 6	5 0	: C	: c		
Marijuana	4	16	16	18		20	19	22	22	2		
11-Hydroxy-THC												
51'S.	0	0	0	0	o		-	C	C	-	-100	
Ash	0	0	0	0	0	0	0	0	0	0	2	
Bad Grass	0 0	0	0	0	0	:	0	0	0	0		
Bluet	0 0	0 0	: °		:	:	; °	0	0	0		
Bolivian Pot.	5	<b>&gt;</b>	>		:	:	5	5	5	Ö		
Buda	0	0	0	0	0	0	0	0	0	0		
Cannabinoids	0.0	က	7		7	7	7	က	က	က		
Cannabinol.	5 0	5 7	; -		<b>5</b> C	<del>-</del> -	: `	: `	0 0	: '		
Cannabis Tea.	0	- 0	0		0	0	0	- 0	<del>-</del>	5		
Charmin	0	0	0		0	0	0	0	0	. 0		
Cheba	0	0	: '		0	0	0	0	0	0		
Chronic.	: -	0 0	0 0	00	0 0	0	00	0 0	0 0	0		
Columbian Grass	•	•	•		<b>5</b>	:	>	5	5	5		
Crazy Eddie	0	0	0	0	0	0	0	:	0	0		
Delta-9-carboxy-THC	00	0 0	0	0	0	0	0	0	0	: '	,	
Double Barrell THC	0	0	; 0	; °	50	<b>&gt;</b> :	50	50	5	00	-100.0	-100.0
Flowers	(			•	•	•				)		
Grass	0 0	; °	; 0	<del></del>	0	0	0	0	0	: '		
nappy Ogarette	2	2	7	3	2	5	5	5	5	In		

Table 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

0 100 10	10 100000 10000 1000	10 100000 1000 1000 00 1000		
	20 100 1050000000000	, , , , , , , , , , , , , , , , , , , ,		,
	<u> </u>	; 000000000000000000000000000000000000	; 000000000000000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 00000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 0000 ; 00	1000000000000000000 10 10 10 10 10 10 10
0000	0000000000000		<u> </u>	<u> </u>
				Marijuana. Marijuana Cookies. Marijuana Distillate. Marijuana Distillate. Marijuana Vith Tormaldehyde. Marijuana with THC. Marijuana with THC. Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mary Anna Mar

able 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for tne coterminous U.S. by half year (continued)

9	Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
	AmphetaminesAmphetamine/thursid	2	2	8	2	3	က	8	4	4	4	<u> </u>	707
	desiccated	i	•	0	0	0	0	0	0	0	0		-100 0
	Amphetamine	2		က	7	က	က	က	ਲ	က	4		2
	Amprietamine-dextroamprietamine	o c		: C	: c	0 0	0 0	; 6	0	0 0	0		
	Bam	_	_	5 6	- C	<u>-</u>	5 6	<b>&gt;</b> C	<del>5</del> 6	<del>-</del>	5 6		
	Beans	0	0	0	0	0	0	0	0	o c	<b>5</b> C		
	Bennies	፥	0	:	0	0	0	0	· :	0	0		
	Benzphetamine	0	0	0	0	0	0	:	0	:	0		293.2
	Black Bearty	c	c		•	•	•	•					
	Black Mollies.	0	0 0	; C	<del>-</del>	5 6	5	<del>-</del>	; 6	0 0	0		
	Blue and Clears.	•	·	<del>-</del>	•	>	:	5	5	5	ò		
	Blue Crystal		_										
	Blues Amphetamine												
	Blues and Reds												
	Brown and Clears	0	0	0	:	0	0	0	0	0	Ö		
	Cat	0	0	0	0	0	0	0	-	0	0		
	Chicken Powder Amphetamine	:	0	0	0	0	0	0	0	0	ō		
	Christmas Trees Amphetamine	0	0	0	0	0	0	0	0	0	0		-100.0
	Crossroads Amphetamine	: '	5 6	0 (	0	0	0	0	0	0	0		
	d-Sacups Amprieramined-Amphatamine	50	0 0	0	<del>- 0</del>	0	0	0	0	0	0		
	Dextroamphetamine	<b>&gt;</b>	5	5 6	5	0	0 0	<del>-</del>	0	0	ō		
	Dextroamphetamine/prochlomerazine	፥	÷	>	:	:	5	:	:	i	:		
	DOM	C	C		c		c	c	•	-	-		•
	Footballs	0	•	0	<del>-</del>	<del>-</del>	<del>-</del>	<del></del>	<del>-</del>	5 6	5 6		-100.0
	Green and Clear Amphetamine	)	•	)	•	·	•	5	5	5	5		
	Hearts	0	0	0	0	0	0	0	:	0	-		
	Khat	0	0	0	0	0	0	0	0	0	0		
	Mothydoxetalline	0 0	0 0	; (	0	: '	0	: '	0	:	:		:
	Molline	5 6	5 6	5 6	5 6	<del>- 0</del>	0	0	0	<del>o</del>	0		
	Nexus	- C	5 C	5 6	5 6	5 6	5 6	<del>-</del>	0	<del>-</del>	0		
	Pep Pill.	0	o c	5 C	5 C	5 6	5 6	5 6	; °	፧	<del></del>		
	Pink Hearts Amphetamine	)	•	•	<b>)</b>	<del>-</del>	<del>-</del>	<del>-</del>	5	÷	5		
	Purple Heart Amphetamine	0	0	0	0	0	<u>-</u> 0		c	_	-		
	Red Hearts					1	)	•	·	<del>,</del>	5		
	Rockets	0	0	0	0	0	0	0	:	0	0		
	O. D. C. C. C. C. C. C. C. C. C. C. C. C. C.	0 0	0	0	0	0	0	0	0	0	0		
		5	0	0	0	0	0	0	0	0	0		
	Uppers	; 6	00	<del></del>	; '	0	0	0	0	:	:		
	West Coast Turnarounds.	>	5	5	<b>o</b>	<del>o</del>	0	0	<del>-</del>	<del>-</del>	0		
	White Cross Diet Pill.	0	-	0	0	0	C	-	c		-		
	White Crosses Amphetamine	:	0	:	0	0	0	0	0	<del>-</del>	5 6	_	
,	Whites	0	0	0	0	0	0	0	0	0	0	-100.0	

Table 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

Workstration         A vorgate         A vorgate	Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
	Yellow Mollies	4.0	n	80	0.0	8.6	က	0.0	n	e c		1	
	Su-su-su-su-su-su-su-su-su-su-su-su-su-su	000	000	000	000	00	:01	<del>5 0 (</del>	50	50	<del>5                                    </del>		
	Blue Speed	° :	0 ;	o :	o ;	<del>•</del> :	o :	o :	0 ;	o :	° ;		
	Criss Cross Speed	c	C	C	-	•	-	•	(		•		
	Crystal Methedrine	0	ີ :	0	0	00	0	50	00	00	50		
	Deb Speed												
	Hurricane												
	loe	00	0	0	00	0	00	0	0	0	0		
	Meth Crystals	00	50	0	0	0	<del></del>	0	00	00	; 0	800.0	
	Methampex								1	1			
	Methamphet Crystalline	0 0	; `	0	0	0	0 0	00	; (	0	0		
	Methamphetamine/phenobarbital/phenytoin	7	=		-	-	7	7	7	7			
	Monster	0	0	0	0	0	0	0	0	i	0		
	Mr Pep.	0	0	0	0	0	0	0	0	0	0		
	Pink Ladies Speed		c	c	c	c	c	•		c			_
	Red Devils Speed	: °	0	0	· :	0	5 0	0	; 0	<b>&gt;</b> ;	; <b>c</b>		
	Reds Speed	:	0	:	0	0	0	:	0	0	0		
	Rock Cyctal	0 0	<del>o c</del>	:	: `		00	:	0 0	0	0 0		
	Speed	<del>-</del>	0	: 0	0		5 6	; <b>c</b>	<del>-</del>	5 0	•		
	Speed Crystal	0	' i	0	0		0	0	• :	0	: :		
	Speeders Speed	•	•	•	•	•	•	(	•	(			
	White Cloud Speed	>	>	5	>	>	>	<b>&gt;</b>	5	>	:		
	Zoom Speed	0	0	0	0	0	0	0	0	C	C		
	(MDMA) Ecstasy	0	0	0	0	-	_	_	_	τ-	+		
	Ecstasy	0 0	0 0	00	0 0	- €	<del>- </del> •	- 0	<del>-</del> (	<del>-</del> (	<del>- (</del>		
	WDWA	5 6	<b>&gt;</b> C	50	<b>5</b> C	5 6	5 6	5 6	5 0	5	5 0		Ġ
	Methylenedioxymethamphetamine	· :	0	0	00	0	5 0	0	5 6	5 6	<b>5</b> C		-53.9
	Ketamine	:	0	<b>'</b>	0	' :	0	0	0	· :	0		200
	Ketamine	÷	0	:	0	0	0	0	0	:	0		
26.7	Norketamine	c	c	c	c	•	•	•	•	•			
	Special K	>	9 6	<b>5</b> C	5 6	5	<u> </u>	<b>5</b> C	5	5	; °		
	LSD	: -	<del>-</del>	<del>-</del>	<del>-</del>	<u>;</u> ~	<del>-</del>	<del>-</del>	<del>-</del>	<u>:</u> 0	0	-56.7	
	Acid	0	0	0	0	0	0	0	0	0	:		
	Acid Blotter	; C	00	o c	0 0	00	0 0	00	00	00	00		
	Acid Purple	00	00	00	0	00	0	· :	00	00	00		

Table 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
Beauty Acid Biotter Blue LSD. Blue Dot.	000	: :0	0	0	000	000	000	00	000	000		
Blue HazeBlue Heaven				•	•	)	•	:	•			
Felix ute Cat. Hallucinogenic Acid	0 0	0	0	0	; '		0	i	0	0		
Kool Aid LSD.	00	00	<b>5</b> ;	00	00		00		00	00		
LSD with Strychnine.	00	00	<del>-</del> :	<del>- 0</del>	<del>- 0</del>	-0	-0	-0	00	00	-73.6	-83.5
Micrey Mouse Micro Dots.	0	0	0	0	0	0	-	0	C	6		
Orange Barrel SunshineOrange Blossom Acid	0	0	0	0	0	0	0	' i	0	0		
Paper AcidPink Hearts I SD	00	00	<u>;</u> c	00	0.0	00	0	0	0	0		
Pink Micro Dot LSD	5	•	•	•	5	5	<b>5</b>	5	0	0		
Punk Surishine Acid	0	:	0	0	0			c		c		
Pumple Blotter LSD	0	0	0	· :'	0	0	0	0	00	00		
Snoopy.	50	<del></del>	00	00		0 0	0 0	0 0	00	00	-100.0	
Sugar	0	0	0	0		0	0	00	00	50		
VVIIILE LIGHTUING ACIG	<del></del>	<del>- 0</del>	<del>- 0</del>	<del>- 0</del>		<del>-</del>	<del>0 +</del>	0 +	0 +	0,	-50.0	-50.8
Angel Dust	- 0	0	- 0	- 0		- 0	- 0					
Animal TranquilizerBlack Dust	00	00	00	: `	; °	00	0	00	00	00		
Buzz	0	00	00	00	50	<del></del>	0	00	00	00		
Cools PCP	c	•	•	•	•	•		ı	)	,		
Dummy Dust	5	5	5	5	5	<del>-</del>	0	0	0	0	-100.0	
Energizer	00	: '	; •	0	0	0	0	:	0	0		
Green	5 0	00	5	5 6	0	:	0 0	0 0	0 0	00		-100.0
Нод	)		:	5	:	:	5	>	>	5		
Lemons.	00	0	; •	0	0	0	0	0	0	0		
Lovely	>	:	5	5	0	0	0	0	<del>-</del>	0		
Mad Dog	0	0	0	0	0	0	0	0	i	0		
Night Train.	0	0	0	0		C	-		=	-	-	
	<del>-</del> c	← c	0	₩.	- 0	<del> (</del>	<del>-</del>	<del>-</del>	<del>-</del>	<del>-</del>		
Phencyclohexyl Ethyl	0	⊃ <u>:</u>	0	50	<del></del>	00	; C	0 0	<del>-</del>	00		
Sernyl	00	00	00	00	0	0	0	0	00	00		
Suisime	3	2	2	2	ī	5	5	0	0	OII		

Table 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued) T-324

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
Super Kools. TAC. Tea PCP. Tic. Vet. Wack. Whack. Zombie. Miscellaneous hallucinogens. Angels Trumpet. Dature Stramonium. Hallucinogen Miscellaneous. Jimson Weed Tea. Liberty Cups Mushrooms. Mace. Magic Mushrooms. Macaline. Mascaline.	000000000   0     00	0000000 ;00 ;0000 ; ;	0    00000000  0  0	00000000 ;000000 ;00	;°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°	0000000 ;00 ;00000	000000000000000000000000000000000000000	000 10000000 1000 10	000 10000 1 10 1 1000 1 1	0 100 10000 1 10 1000 10		-100.0 -100.0
Mescaline Synthetic Microdot Mescaline. Morning Glory Seeds. Mushrooms. Needle Point Mescaline. Nutmeg. Peyote. Psilocyhi. Psilocyhi. Psilocyhi. Psychedelics. Shrums.	100000 1 1000	0   00   00 000	00000   0 00	00000 10 1000	000000 ; 0000	000000   0  0	000000 000	0 00 1 0 000	0 ; ; 0 0 0 0 0 0	0 000 0 0 0	-50.0	-100.0
Wild Mushrooms Flunitrazepam (Rohypnol) Flunitrazepam Rochas Rochas Roches Rohypnol Rofles Rufinal GHB Gamma Hydroxy Butyrate GBL Renewtrient. Inhalants (volatile agent).	0 100 1 10000000 10	o <sub>i i</sub> oo <sub>i</sub> ooooooooo		0 1000 1 10 1000 1000	0   00 0       0 + 0   0   0	0 1000 1000++0 10 10	0 1000 10 10 10 10 10	0 ; 000 ; 000 ; + 00 ; ; 0	o ;000 ; ;000000	00     0000000   0	.75.0	-100.0

able 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for

% change <sup>2</sup> H1 2001, H1 2002	-100.0	-100.0	-100.0
% change <sup>2</sup> H2 2001, H1 2002		-100.0	-100.0
Jan-Jun * 2002	:000		00 :0000
Jul-Dec 2001	0 :000		0000000
Jan-Jun 2001	0 ;000	000000000000 ;000000000 ;00 ; ;00 ;000	000 :0000
Jul-Dec 2000	00 :0		00 :0000
Jan-Jun 2000	0 ;00	000000   0000000000000     00       00000	0000000
Jul-Dec 1999	0000		100 10000
Jan-Jun 1999	0 :000		;000000 ;
Jul-Dec 1998	00 ;0	0   0 0   0     0 0 0 0 0 0 0 0 0 0 0	:0000000
Jan-Jun 1998	0 ; ;0 (	00000 100 10000 100000000 1 1 10 1 10 10	0000000
Jul-Dec 1997	0000	; o ; o o ; o o o o o ; o o o o o o i o ; i o o o o	0000000
Drug name¹	Aerosol air freshener Aerosol Spray. Air Deodorizer. Airplane Glue.	Alpha terpineol.  Brake Fluid  Butane. Car Cleaner. Carbon teracalloride Carburetor Cleaning Fuel Chlorothene. Coleaning Fluid Coffee Stain Remover Cologne Aerosol. Contact Cement. Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Fluid Correction Correction Fluid Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correction Correct	Lighter Fluid. Malathion Methane. Methanol. Methylchloroform. Methylcher Chloride. Moth Balls.

Table 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

00000
0000
: :
000
_
000
00
: :
0
0 ::
00

## —© ¬ able 12.3.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

% change <sup>2</sup> H1 2001, H1 2002	391.5
% change <sup>2</sup> H2 2001, H1 2002	-75.0
Jan-Jun * 2002	0   00 00 0   0   00 00 00   0000
Jul-Dec 2001	00 00 00 10 10 10 00 1 0 1000 100 1 10
Jan-Jun 2001	0; 00 0; 0000000 ;0; 00; 0; 000000
Jul-Dec 2000	00 00 00 00000 io 00 i 000000000
Jan-Jun 2000	00 00 100000 10 000 0000 1 100000
Jul-Dec 1999	00 00 ;000000 000 0000 ;00000
Jan-Jun 1999	00 00 000000 000 000000000
Jul-Dec 1998	0 ; 00 0 ; 000000 ; 0 000 ; ; 00000000
Jan-Jun 1998	:: 00 0: 000000;0 000 000000000
Jul-Dec 1997	; 0 00 ; 0 00 ; 0 0 0 0 0 0 0 0 0 0 0 0
Drug name¹	Trichlorotrifluoroethane. Inhalants (general anesthetics) Desflurane. Enflurane. Fluoromar. Halothane. Isoflurane. Nitrogen Hypoxide. Noodaling Name Hypoxide. Namijuana with Speed. Namijuana with Angel Dust. Namijuana with Cocaine. Marijuana with Cocaine. Marijuana with PCP. Marijuana with PCP. Marijuana with PCP. Marijuana with PCP. Marijuana with PCP. Namijuana with PCP. Namijuana with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP. Shermans with PCP.

<sup>&</sup>lt;sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. The Multurn Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multurn.com.

ED = emergency department, GHB = gamma hydroxy butyrate, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with Drugs are classified to the degree of specificity recorded in the DAWN case reports. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. Bureau of the Census.

Table 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year

	1994	1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	7994, 2001	% cnange 1999, 2001	% change 2000, 2001
Alcohol in Combination	02	72	7.1	72	77	81	83	98	23.1		
Cocaine 8-Ball Cocaine	62	28	65	89	<u> </u>	<u>6</u>	Ε,	92	22.3	9.7	9.7
Anhydroecgonine Methylester	:	:	:	5	5	5	5	5			
Basuco	0	0	0	0	0	0	0	0			
Bazooka	: °	<del>- 0</del>	0	0	0	0	0	0			
Blow	<b>5</b> C	<del>5 c</del>	; C	: °	0 0	0 0	0 0	<u>;</u> °			
Candy.	•	•	<del>-</del>	<del>-</del>	5	>	<del>-</del>	5			
China White Cocaine.	0	0	0	0	0	C	_	c	-100		
Cinnamoylcocaine		1	1	1	)	·	:	5	2		
Cocaine	47	43	20	51	72	53	25	22	22.3		
Cocaine Laced Cigarette	0	0	:	0	0	0	0	0			
Cocaine Metabolite	0	<del>- (</del>	0 0	0	: '	: '	0	0			
COKE	5 ;	<del>5</del> į	<del>5</del> ;	<del>o</del> (	<del>o</del> į	0	0	0			
Crack Loint	Ū.	<u> </u>	4	<u>9</u>	14	16	16	19	22.8		16.6
Crystal Cocaine	<del>-</del>	<u>:</u> c	<del>-</del> -	<del>5</del> c	5 6	5 0	; °	:			
Dust	<del>-</del>	- C	•	o c	<del>-</del> -	<del>-</del>	<del></del>	: 0			
Ecgonine Methylester	0	0	:	>	<u> </u>	<u> </u>	<del>-</del>	3 C			
Eight Ball	0	0	0	0	0	•	•	•			
Ethylecgonine	0	0	0	0	0	:	<u>:</u> C	:			
Flake	0	0	0	0	0	<u>.</u> c	<del>-</del>	<u>:</u> C			
Free Base Cocaine	0	0	0	0	0	0	<u>:</u> C	5 0	-773		
Love Drug					-	I	_				
Methylecgonine	;	:	:	•	0	0	:	0			
Moon Dust	0	0	0	0	0	0	0	0	-100.0		
Norcocaethylene	0	0	0	0	0	0	0	0			
Norcocaine	0	0	0	0	0	0	0	:			
P-Blow	0	;	0	0	:	0	0	0	-100.0	-100.0	
Keady Rock	0	0	0	0	0	0	0	:			
Rock Cocaine	:	:	0	;	0	:	0	:			
Heroin	27		31	90	33	8	38	37	33.8		
Acetylcodeine											
Beast	0 (	0 (	0	0	0	0	0	0			
plack far heroin	5	5	<del>-</del>	0	<del>-</del>	<del>-</del>	:	0		-65.1	
Blue Diamond Heroin								_			
Dine Kilig	c	-	•	-	•		•			_	
Brown Mexicon Densin	5 6	5 6	5 6	<b>5</b> (	<del>-</del>	<del>-</del>	0 0	0	-		
Carachi	<del>-</del>	5 6	<del>-</del>	<del>-</del>	5 6	5 0	5	0 (			
China Cat Heroin	•	o c	o c	<del>-</del>	5 6	5 6	<del>-</del>	5 6			
China White Heroin	<u>:</u> C	<del>-</del>	o c	<del>-</del> -	>	<del>-</del>	<del>-</del>	5			
D-Funk	0 0	<del>-</del>	<del>-</del>	o c	:	<del>-</del>	<del>-</del> -	; <b>c</b>	:		
Dead President	0	0	0	<del></del>	: 0	<del>-</del>	5 6	o c		7	
Diacetylmorphine	0	0	0	0	0	0	<b>&gt;</b> ;	)		0.00	
Floaters	:	0	0	0	0	0	0	0			
Heroin	27	30	31	<u>8</u>	31	8	38	37	34.1		

rable 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

-											
Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change² 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
		1	ľ	(		-		ſ			
Heroin Dope	0 0	0 0	5 0	5	:°	5 6	5 6	5 0			
Heroin With Dormin	5 6	0 0	5 6	:	-		o c	5 6			
Horse	o c	0 0	0	<u>;                                    </u>	0		0	0	-100.0		
Iranian Heroin	0	0	0	0			:	0		-100.0	
Mexican Heroin	0	0	0	6			0	0		-100.0	
Mexican Mud.											
Mixed Dope	0	:	0	:	0	0	0	0			
Mixed Jive Heroin			!	-		•					
Mixed Junk Heroin	;	0	0	ō	0	0	:	: '			
Monoacety/morphine	:	:	:	o T		o	:	5			
Mxd Siu Whpd Cracker	1			-(		•	•	•	6		
P-Dope	<del>-</del>	0	፥	0	5	5	5	5	<del>.</del> 		
Pakistani Heroin	(	•	•	_	•	•	•	-			
Persian Heroin	<del>-</del>	0	0	: '	5	5	5	5			
Poison	;	:	: '	0		5	<del>-</del>	5 (			
Polo	0	0	0	o ¯		0	0	0		į	
Smack	0	0	0	:	:		:			-100.0	
Stuff	0	0	0	:			0				
Super Buick	0	0	0	o				0			
Tootsie Roll Heroin	0	0	0	ō				:			
White Fox Heroin	0	0	0	0	0	0	0	0			
Marijuana	17	19	23	27				44	150.7		11.8
11-Hydroxy-THC											
11-Nor-Delta-9-THC											
51'S	:		;		0	0	0	0			
Ash	0		0			0		0			
Rad Grass	0	0	:	0		0	:	0			
Bad Weed	0		0	0				ō		-100.0	
Blint	0		0	0	0	:	:	0	77.5		
Bolivian Pot			_								
Buda	0	0	0	0	0	o	0	0			
Cannabinoids	2	2		4		4		S.	256.7		
Cannabinol	0	:	i	0	:	0	:	0			
Cannabis Sativa	0	0			<b>-</b>	·-		_	219.2		
Cannabis Tea					-	,		,			
Charmin	0	<del></del>	<del>-</del>	: '	0	0	0 0	5 0		7000	
Cheba	0	0		5	;	o (		5 (		-100.0	
Chronic	0	0		: '	ŏ	0		<del>-</del>			
Clickers Pot with Formaldehyde	0	0		0		o	:	5	0.001-		
Columbian Grass		,		(							
Crazy Eddie	:			י כ				: '			į
Delta-9-carboxy-THC	0			0			0	0			67.5
Delta-9-THC	0			0	0			o <sup>-</sup>	436.2		45.0
Double Barrell THC	0			_				•			
Flowers	-										-67.5
Grass	5 0	0	-	0		-	0	0	-100.0		•
nappy cigarene											

Table 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>2</sup> 2000, 2001	-67.5 -100.0 -100.0 -100.0	
% change <sup>2</sup> 1999, 2001	174.6	-100.0
% change <sup>2</sup> 1994, 2001		
Total 2001	100 100 100 1000000 10 +0 10 100 11000 0000 11 10 10 10	5
Total 2000	000       0 000   0000   0000   0000 0   000	:
Total 1999	0 :0 :0000000000 :000000000000000000000	<del>-</del>
Total 1998	0 1000000 2000000 1 1 0000 1000 00 1000 00000	5
Total 1997	00 10 10000 1000000 +0 100000 10 1 1 00 10 w 0 0 10 1	:
Total 1996	000 i i 0000 i 000000 to i 00000000 00 i i 0 0 0000	<del>,     </del>
Total 1995	00000004000 1000 100 10100000000 0 1001 1 0 1000	<del></del>
Total 1994	00   1000000000000000000000000000000000	<del>,</del>
Drug name¹	Hash. Hawaiian Marijuana. Hemp. Herbs. Jojuti. Joystick Marijuana. Leaf. Locoweedd. Love Leaf. Marijuana Dusted. Marijuana Distiliate. Marijuana Distiliate. Marijuana Distiliate. Marijuana Pizza. Marijuana Pizza. Marijuana With Formaldehyde. Marijuana with Formaldehyde. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana with THC. Marijuana. Mixed Jive. Marijuana. Mixed Jive. Marijuana. Mixed Jive. Marijuana. Sheefer. Seeds. Sheefer. Seeds. Shemans. Sinsemilla Marijuana. Shemans. Sinsemilla Marijuana. Shemans. Sinsemilla Marijuana. Shemans. Sinsemilla Marijuana. Shemans. Sinsemilla Marijuana. Shemans. Sinsemilla Marijuana. Shemans. Sinsemilla Marijuana. Shemans. Sinsemilla Marijuana. Shemans. Sinsemilla Marijuana. Shemans. Sinsemilla Marijuana. Shewad. Trip Weed. Trip Weed.	

able 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	1994, 2001	1999, 2001	2000, 2001
Amphetamines	4	4	4	4	2	2	2	7	66.5	42.4	
Amobarbital/dextroamphetamine/thyroid											
desiccated	0	;		: `	: '	01	01	01			
Amphetamine	4	4	4	4			7		66.3	39.3	
Amphetamine-dextroamphetamine	0	0		0 0	: '		0 0	00		177.1	
B-52 S	0	0		o (			5 (	5			
Bam	0	0	:	0			0	0			
Beans	0	:	0	0			0	0			
Bennies	0	0	0	:	:		<del>-</del>	:	:		
Benzphetamine	:	:	0	0	ō		:	:			
Black Beanies											
Black Beauty	i	0	:	0	0	0	0	:			
Black Mollies	:	0	:	0	0		:	0		-100.0	
Blue and Clears											
Blue Crystal											
Blues Amphetamine	:	0	0	0	0	0	0	0			
Blues and Reds											
Brown and Clears	0	0	<del>-</del>	0	ō			0			
Cat	0	0	0	0	ō			:			
Chicken Powder Amphetamine	:	0	:	:				0		-100.0	-100.0
Christmas Trees Amphetamine	0	0	0	0				0			
Crossroads Amphetamine	0	0	0	:	ō			<u> </u>	-100.0		
Crosstops Amphetamine	0	0	0	0	0	0	0	0	_		-100.0
d-Amphetamined-Amphetamine	፧	0	0	0	o			<u> </u>			
Dextroamphetamine	0	:	0	0	0			<u>-</u>	717.3		
Dextroamphetamine/prochlorperazine		_					(				
DOM.	0	0	0	0	0	0	0	0			
Footballs	0	0	0	0	:	0	0	o -	-100.0		
Green and Clear Amphetamine											
Hearts	0	:	0	0	0	0	0	:			
Khat	0	0		0	0		0	0		-100.0	
MDA	0	0		0	:		:		656.8		
Methylcrystalline	:	0	0	0	0		0				
Mollies											
Nexus	0	0	0	0	0		0	:			
Pep Pill	፥	:	:	0	0	0	0	:			
Pink Hearts Amphetamine	•	0		0	0		0	0	_		
Purole Heart Amphetamine	0	:	0	0	0		0	0			
Red Hearts	ı										
Rockets	0	0	0	0	0		0	:			
STP	0	0	0	•	0		0	Ö	-100.0		
Sweethearts	0	0	0	:	0	0	0	0		-100.0	
liners	C	0	;		0			-	-		
Vees	•	0	0	0	0	0		0			
West Coast Tumarounds			1	)	_						
West Coast Tamare Mile	c	C	0	į			0	0			
White Crosses Amphatamine	)	•				-	0	0	_		-100 0
			:	:			•		=		

Table 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
Yellow Mollies	80 0	7	in c	2	22	4	2	9			1007
Bathtub Speed	000	<del></del>	<del>-</del> ; 0	000	000	000	000	000	-100.0	-100.0	-100.0
Criss Cross Speed	က	: :	•	' :	:	•	<del>-</del>	<del>5 ←</del>	-76.3		
Crystal Crystal Methedrine	00	00	00	00	O :	00	00	00	-55.2	84.9	62.3
Easter Eggs Speed			_								i
Q8	0	0		:	0	0	0	-		955.0	114 A
weun Crystals	; 0	00	00	00	0	00	0	000	÷	925.6	- 5 0
Methampex	· :	0	0	00	00	50	0	5 6	-	•	
Methamphetamine	7 0	0 7	0 0	0 m	; m	0 0	<u>0 m</u>	: 4	2. 2.	a	
Metriamphetamine/phenobarbital/phenytoin Monster	ō		c		C	•	•	•	?	9	
Mr Pep	0	0	· :	0	0	0	0	; °			
PTA-Speed	0	0	_0	;							
Red Devils Speed	00	0	0	: :	0	:	00	: :			
Rock	0	00	00	: :	:0	° :	:0	00			
Rock Crystal Speed	<del>0 +</del>	0 4	0 1	0,	:	0	· :	<del>, o</del>			÷
Speed Crystal	- 0	- 0	- 0	<del>- 0</del>	-	<del>- c</del>	<del>- c</del>	=	_		
Speeders SpeedSolash	0	0	0	0	0	0	0	. 0	-100.0		
White Cloud Speed		- (		_							
(MDMA) Ecstasy.	o c	<del></del>	0 0	0 0	0 0	<del></del>	0	0	-	•	-100.0
Ecstasy	00	00	0	00	<del>5 0</del>	<del></del>	<u> </u>	<del>7</del> ~	1,889.3	86.5	
MDMA	: `	<del>-</del> -	0	0	0	0	0	0	2	9	-100.0
Methylenedioxymethamphetamine.	5 0	<del></del>	5	0	0 0	0 0	<del>-</del> -	0			
Ketamine	0	:	0	: :	0	00	0	50	3.145.4		-72.7
Nordalilile Norketamine	0	:	0	0	0	0	0	0	4,701.8		
Purple	0	:	0	0	0	0		-		_	
Special K.	<del></del>	0 6	0 0	: 0	0 0	· : '	0	· :			
Acid	<del>1</del> ←	<b>√</b>	70	<u>v</u> –	<u> </u>	77	<del>- 2</del>	<del>-</del> -	-50.3	47.2	4
Acid Blotter. Acid Blue	00	00	: 0	: 6	0	- 0	- 0	00	-100.0		<del>-5</del> 5.3
Acid Purple.	00	P ;	00	) :	0	00	<del>o</del> :	<del></del>		-100 0	
										)	

Table 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change* 1994,	% change* 1999, 2001	% change <sup>*</sup> 2000, 2001
									2001	1002	1002
Beauty Acid	0	0	0	0	:	0	0	0	,		
Blotter Blue LSD	0	:	0	0	: '	0	0	0	-100.0		
Blue Dot	0	0		0	0	0	0	:			
Blue Haze		_									
Blue Heaven		•	•	•		(	•	-	0 007		
Felix the Cat	0	0	0	0	0	0	0	Ö	-100.0		
Hallucinogenic Acid	0	0	0	0		: '	0 (	: '	:		
Hits	0	:	0	0	0	0	0	0			
Kool Aid LSD	0	:	0	0	:	0	0	0			
rsp	2	2	_	2	-	2	_	_	-50.8	45.3	
LSD with Strychnine.	0	0	0	0	:	0	0	0			
Mickey Mouse											
Micro Dots	0	0	0	0	0	0	0	0			
Oranne Barrel Sunshine	0	0	0	0	0	0	0	:			
Orange Blossom Acid											
Paner Acid	0	0	0	0	:	:		0			
Disk Doorts I SD	_	-		7		7		0			
THIS DEATH DOT TO	•	: °	· c	· c	· C	· c	· c	· 6			
PINK MIGIO DOL LOD	፥	-		•		•		•			
Pink Sunshine Acid	•			•		•	•	-			
Purple Barrel LSD	0	5	: '	5	•	5	5 (	5 6			
Purple Biotter LSD	0	0	0	5		: '	5 (	5 6			
Purple Haze	0	0	0	0		0	0	0			
Snoopy	0	<del>-</del>	0	0		0	0	5			
Sugar	0	:		0		0	0	0			
White Lightning Acid	0	0		0		0	0	0			
PCP	3	3		2		2	7	7		59.8	
Angel Dust	0	0		6	-	0	0	0			
Animal Tranouilizer	:			0		:		0			-100.0
Black Dust	:			0		0		0			
Buzz	0			0		0		0			
Cools PCP	0	0	0	0	0	0	0	0	-100.0		
Crystal PCP	0			0		0		0			
Dummy Dust											-
Fneroizer	0	0	0	0		0	0	:			
Firehall	0	0	0	0	0	0	:	0			
Green	0	0	0	0	:	:	:	0			
emons	0	0	0	ō	:	ō	0	0			
ove Boat	0	0	0	0		0	0	0	-80.9		
lovelv											
Mad Dog	;	0	0	0	0	0	0	:			
Mint I eaf	:										
Night Train	0		0			:	0	0			
PCP	2		_		-	_	2	N		58.9	_
Phencyclidine	0		0		0	0	0	<u></u>			
Phencyclohexyl Ethyl	•	0	0				0	_			
Semyl	0		0 '	ŏ	0 0	o o	0.0	-			
Cincipal	_		_				5	<u> </u>	=		

Table 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

Super Kools.         TAC.           TAC.         0           TC.         0           Vet.         0           Wack.         0           Whack.         0           Zombie.         0           Miscellaneous hallucinogens.         1           Angels Trumpet.         0           Angels Trumpet.         0           Datura Stramonium.         0           Hallucinogen Miscellaneous.         0           Jimson Weed Tea.         0           Liberty Cups Mushrooms.         0           Magic Mushrooms.         0           Mescaline.         0           Mescaline Chocolates.         0	00 10000+ 100 1 100	; 0	0							7
<del></del>	00 10000- 100 1 100	;0;	0	_		-		_		
	0  0000+  00    00	0 ;		_c	_	_	-			;
· · · · · · · · · · · · · · · · · · ·	10000- 100 1 100	-	0	<u>'</u> :	. 0	0	0			- - -
	000- 100 1 100	•	0	:	0	0	0	-100.0		
	000   100	5 6	<del>-</del> -	0 0	0	0	:			
· · · · · · · · · · · · · · · · · · ·	00   00	5	5 6	0 0	0	0 (	0	-100.0	-100.0	-100.0
· · · · · · · · · · · · · · · · · · ·	7 <del>-</del>  00    00	:	5 6	<del></del>	5 6	0 0	0		-89.3	-86.1
	100 1 100	<del>: -</del>	<del>-</del>	<del>-</del>	<del>-</del>	5 7	5 7			
	00 ; ;00	0	-	-	<del>-</del> c	- c	- 6			
	0 ; ;00	0	0	0	0 0	5	> <sup>=</sup>			
· · · · · · · · · · · · · · · · · · ·	::00	0	· :	0	•	•	: 0			
·	:00	0	0	· :	0	: C	5 6			
<del> </del>	00	-:	:	: :	-	0 0	5			
	0	0	:	0	0	<del>-</del>	<u>:</u> C			
- <del></del>		0	0	,	0	o c	0			
	0	0	0	C	•	o c	o c		_	
	:	0	0	·	: -	>	5	0.001-		
Mescaline Chocolates	0	0	0	:	0 0	: °	: `	Š		1
		_	,	=	<del>-</del> -	>	5	4.69.4		-65.2
Mescaline Synthetic	_									
Microdot Mescaline	_	_	_	-	_		_			
	<del>,</del>	· c	: C	<b>&gt;</b> c	5 6	57	0		-	
	<del>,</del>	<del>-</del>	<del>-</del>	5 6	5	5,	:			
	<del>-</del>	o c	<del>-</del>	5 6	5 6	- 7	-	_		
	,	•	0 0	<del>-</del>	<del>-</del> -	5 0	5		571.3	
		:	5	:	5	5 6	:	_		
Psilocybin	: :	: G	-	<u>:</u> C	:	5	: 6			
	0	<del>-</del>	0	<del>,</del>	<u>;</u> c	: 0	0	9.6/-		
Psychedelics0	0	0	· ;	<del>-</del>	0 0	<del>-</del>	3 6		- 1	9
Shrums	;	0		-	· c	<del>-</del>	0		<u>;</u>	-92.5
	:	0	0	•	0 0	<del>-</del>	5 0			-100.0
	0	ō	0		<del>-</del>	<del>-</del>	5 0			
	:	:	· :	: :	· ;	<del>-</del>	5			-100.0
riunitrazepam0	:	0	0	:	0	. 0	: C	1000		
	:	0	0	0	0	0	0 0	2	187 7	
<u> </u>	0	<del>-</del>	:	0	0	0	0		:	100 6
_	0	:	:	:	:	:	<u> </u>	_		0.76
Puffice.	<del>-</del>	0	<del>-</del>	0	;	0	0			
<u>.</u>	<del>-</del>	0	0	0	0	<del>-</del>	0			
_	<del></del>	0	0	:	0	0	0	•		-67.5
Gamma Hydroxy Butwate	5	0 (	0	_	<del>-</del>	7	=	5,316.4		9
•	<del>-</del>	0	0	<del>-</del>	_	7	_	5,314.8		
Renewtrient	<b>5</b> 6	<del>-</del>	<del>-</del>	0 (	0	0	0			
_	5 6	5 7	5,	<del>.</del>	:	:	0		_	
Acetone	<b>5</b> c	_	- 0	<del></del> (	0	_	0	-64.0		-59.3
Acrolics	- c	:	<del>-</del>	5 0	: '	<del>-</del>	:	:		

Table 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

Total 1994
; ; 0
00
:0
00
00
000
00
000
<del>-</del>
00
<del></del>
00
-
i i'
00
00
: 0
9 ::
0
0

Table 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>2</sup> 2000, 2001			-100.0	,	-100.0		-100.0												-100 0							6	<u> </u>			-100.0	
% change <sup>2</sup> 1999, 2001		-100.0		-100.0		7	-100.0					-100.0			_		-100.0		-100.0			_		_							
% change <sup>2</sup> 1994, 2001			_	-100.0	-100.0		-100.0		_	_			_	1000	-1000	-100.0	-100.0		_					-		_				-100.0	
Total 2001		•	000	000	000	<u>; c</u>	00	; c						<del>5 c</del>	0	0	0	5	0	0	0	:		0	0	0	· :	00	<b>&gt;</b>	0	5 6
Total 2000	0 ;;		00	• •		· : c	0	<del></del>	) ;		5 6					0		50	0	0	0 0	5		: '	0	0	0	; C	0	00	<del>5 ;</del>
Total 1999	0 :0		000		:00	•	00	-	0							00		: :		0	5	0		0	5	0	0	: 0	0	0	: :
Total 1998		-		•		Ι,			•		0					00			0	0	: <b>C</b>	•		÷	5	:	: '	<del>-</del> -	0	00	00
Total 1997	0 ; ;		000		00			: 0								00			:	<del>-</del>	; 0	0		0 0	5	0	0	÷°	0	00	· :
Total 1996		:00		•	00				•		0					00					0		_ (	0 0	•	0	0	: °	0	; C	0
Total 1995	00 :	000	o ; ē	· ¦°	00	;0	00	0	: '	00	0	0	0 0			: -						0	•	<del>-</del>	-	0	0 0	<b>→</b>	0	00	0
Total 1994	:00	:00	o : °	-	° ;	: :	-	_	0	<b>D</b>	0	0	0	0	0	0 0	0	0	: '	5 6	;	:	•	0	•	0	:	<u>:</u> 0	0	0	0
Drug name¹	Motor Oil	Paint Paint Thinner	rainivunknown composition	Petroleum hydrocarbons	Polish Remover Polyurethane	Propane Gas. Roach Poison.	Rubber CementShoe Polish	Silicone Shoe Saver.	Solvents	Starting Fluid.	Tape Recorder Cleaner	Tollione	Toluene Glue	Toluol	Trichlomothers	Trichloroethane/trichloroethylene	Tuillo	Tuleeo	Vanorizere	Volatile/unknown components.	Xylene	Inhalants (nitrites)	Butvi Nitrite	Isobutyl Nitrite	Locker Room	Poppers	Inhalants (chloro-fluoro-hydrocarbons)	Chlorinated Hydrocarbons.	Dichlorodifluoromethane	Silicone Spray.	Trichlorofluromethane

T-336

The Table 12.4.0 - ED mentions for selected major substances of abuse by drug category: Estimated rates per 100,000 in the selected major substances of abuse by drug category: Estimated rates per 100,000 in the selected major substances of abuse by drug category: Estimated rates per 100,000 in the selected major substances of abuse by drug category: Estimated rates per 100,000 in the selected major substances of abuse by drug category: Estimated rates per 100,000 in the selected major substances of abuse by drug category: Estimated rates per 100,000 in the selected major substances of abuse by drug category: Estimated rates per 100,000 in the selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of abuse and selected major substances of a

Drug name1	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change² 1999, 2001	% change² 2000, 2001
Trichlorotrifluoroethane	00	: :	0	0	: :	00	00	° :			
DesfluraneEnflurane											
Fluoromar	0	i	i	0	0	0	0	0			
soflurane	0	0	0	0	0	0	0	0		-100.0	
Methoxyflurane	0	0	0	:	0	0	0	0			
Nitrous Oxide	0	:	0	0	:	0	0	:	_		
Sevoflurane			_		_						
I richloroemylene	>	> ;	0	•	0	<u>;</u> 0	: 0	· :			
ombinations NTA.	: 0	0	0	0	0	0	0	0			
Acid with PCP.				1	1		•				
Cocaethylene	0	: '		0	0	0 0	<del>-</del>	5 6			
Cocaine with Speed	<del>-</del>	ō		5	<del>5</del>	5 0	5 0	5			
Crystal Crank with THC	: °	50	5 0	: `	; C	5 6	5 6	: C			
SO with Speed	•	•		•	)	)		)			
Marijuana with Angel Dust.	0	0	0	:		0	0	. :			
Marijuana with Cathinone	0	0	0	0	0	0 (	0	0			
Marijuana with Cocaine	:	0	0	0		0	0	5			
Marijuana with Crystal Substance	•	•	c	•			•				
Marijuana with Heroin	50	0	>	5 0	:	5 6	0 0	5 0		571.3	
Marijuana With PCP	5 0		: 0	0 0	<u>;</u>		0	•		5	
DCD with Cocaine	•	0	0	, ;			0	0			
PCP with THC	0	0	0	0			0	:			
Pot with Cocaine	0	0	0	0		:	:	:			
Pot with PCP.											
Shermans with PCP	0	0	: <	00	0 0	0 0	00	00	-84.9		
Speedball	o		5 0		<b>5</b> C	5 6	5 6	5 6			
THC with Cocaine	0		5 0		5 6	<del>-</del>	5 6	5 6	-1000		
WAC	0		2		5	,	7	7	222		

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, GHB = gamma hydroxy butyrate, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above, PCP = phencyclidine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update)

Table 12.5.0 - ED mentions for psychotherapeutic agents by drug category: Estimated rates per 100,000 population for the

% change <sup>4</sup> H1 2001, H1 2002	-100.0
% change <sup>4</sup> H2 2001, H1 2002	
Jan-Jun * 2002	700 00 100 100 100 100 100 100 10 10 10 1
Jul-Dec 2001	10 10 10 10 10 10 10 10 10 10 10 10 10 1
Jan-Jun 2001	<u>τίο                                      </u>
Juf-Dec 2000	100000 100 1000 1000 1000 1000 1000 10
Jan-Jun 2000	£ 10 1000-4 14-000 10 1 1000 1 1 1 1 1 1 1 1 1 1 1 1 1
Juf-Dec 1999	1000 1000 1 110 10 100000 14 100 11 100000 10 1
Jan-Jun 1999	£0000000 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Juf-Dec 1998	100000000 1000 1 1 1 1 1 1 1 1 1 1 1 1
Jan-Jun 1998	100000000000   muo   1000   0-40   0000   m-00   0000   1   1
Jul-Dec 1997	± 10 100000000000 10000 10000 1000 11 10
Drug name <sup>1,2,3</sup>	Antidepressants  MAO inhibitors  isocarboxazid phenelzine tranylotypromine monoamine oxidase inhibitors-NOS SSRI antidepressants citalopram fluoxetine paroxetine sertraline SSRI antidepressants-NOS Tricyclic antidepressants-NOS Tricyclic antidepressants-NOS Tricyclic antidepressants-NOS Tricyclic antidepressants-NOS Tricyclic antidepressants-NOS Inipramine clomipramine doxspine clomipramine protriptyline maprotiline maprotiline maprotiline maprotiline maprotiline maprotiline protriptyline-protriperazine prochlorperazine prochlorperazine prochlorperazine prochlorperazine prochlorperazine prochlorperazine promazine trifluoperazine promazine trifluoperazine prochlorperazine prochlorperazine promazine trifluoperazine trifluo

able 12.5.0 - ED mentions for psychotherapeutic agents by drug category: Estimated rates per 100,000 population for the oterminous U.S. by half year (continued)

255 253 258 258 259 17.00.0  100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
23 25 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1
23 25 28 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28
23 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25 28 25
. 0 000
0000
000 :

Table 12.5.0 - ED mentions for psychotherapeutic agents by drug category: Estimated rates per 100,000 population for the

% change <sup>4</sup> H1 2001, H1 2002		-100.0	 -100.0		-71.7				-100.0												-30.5
% change <sup>4</sup> H2 2001, H1 2002				-12.6	-81.6	-28.3				-	-100.0		-16.4								40.6
Jan-Jun * 2002	00 ; ; 6	00	:00	<u>1 6 r.</u>	:00	m 0	N ;	: : 07	:0	0	:0	o ;	<b>0</b> 4	0	00	8	0	:	: :	<del>-</del> 6	0+
Jul-Dec 2001	00 ::0	•	000	21.2	:00	400	700	: ~	o :	00	;°	- 0 0	<u> </u>	0	00	00	0	:	00	0	2
Jan-Jun 2001	0 ; ; ; 0		00+	20-20-02	00 :	m O 0	v <sub>;</sub> o	0 0	00	<del>0</del> ;	00	000	0 4 0	0	00	00	0	: '	00	:'	- 0
Jul-Dec 2000	00 ; ;0	0	00+	5	:00	<u>പ്</u>	v ; 0	2 0	00	00	0	<del>5 0 (</del>	4 0	0	00	00	00	· ·	00	-00	2 0
Jan-Jun 2000	00 ; ;0	0	; 0 ∓	<u>6</u> 40	000	<u>4</u> ; α	, <u>;</u> 0	. 70	00	: :'	<del></del>	- o w	0 0 0	0	00	00	00	, ,	00	00	⊃ <del>-</del>
Jul-Dec 1999	0 ::	0	:0+	₩ 4 €	000	<del>ო</del>	· ; 0	0 0 0	00	:0	: : 6	0 (	40	0	00	00	0	C	0	00	<del>-</del> −
Jan-Jun 1999	0000	0	; o <del>-</del>	<u>0</u> 40	00	400	:0	0 00	500	00	0 +	- O 10	4 :	0 (	000	00	0		00	00	<del>-</del>
Jul-Dec 1998	000 -	0 (	- 00	€ 4 :	00.	4 O W	00	0 00 0	⊃ ; c	00	: ; <b>*</b>	- O I	40	5 6	000	00	00	_ c	00	00	<del>, -</del>
Jan-Jun 1998	00 :0-0	0 0	<del>- 0 c</del>	6 4 :	00.	400	00	5 N C	000	000	0 -	04	ا س	<del>-</del>	000	00	00		0	00	2
Jul-Dec 1997	00 :000	<del>-</del>	<del>- 0 c</del>	<u> </u>	000	7 O R	:00	<u>&gt; N C</u>	000	0	0+	04	<u>000</u>	<del>-</del>	000	00	00	-0	0	0 ;	2
Drug name <sup>1,2,3</sup>	methylphenobarbital pavatrine/phenobarbital pentobarbital pentobarbital phenobarbital/henobarbital	phenytodoxamine/secobarbital	talbutal barbiturates-NOS	benzodiazepines alprazolam bromazepam	chlordiazepoxide	clorazepatediazepam	estazolamflurazepamhalzzenam	lorazepam lormetazepam	midazolam. nitrazepam.	oxazepamprazepam	quazepamtemazepam	triazolam. benzodiazepines-NOS.	Misc. anxiolytics, sedatives and hypnotics	acetylcarbromal benactyzine	bromisovalum	carbamate.	chloral hydrate	chlormetrazanone	demoxepamdexmedetomidine	dextromethorphan/doxylaminedichloralphenazone	diphenhydramine.

## able 12.5.0 - ED mentions for psychotherapeutic agents by drug category: Estimated rates per 100,000 population for the operations 11.5 by half year (continued) oterminous U.S. by half year (continued)

% change <sup>4</sup> H1 2001, H1 2002	-100.0
% change <sup>4</sup> H2 2001, H1 2002	-100.0
Jan-Jun * 2002	0 0 00 0 0000 0000000000000000000000000
Jul-Dec 2001	0 0000   0000   0000 0000
Jan-Jun 2001	0 0000 :: 0000 00000-00-0000
Jul-Dec 2000	0 1000 1 0 0000 00000 000 10
Jan-Jun 2000	0 100+0 1 0000 1 10000+00+0000 000 10
Jul-Dec 1999	0 10000 0 1000 100 100 100 100 100 10
Jan-Jun 1999	0   000   0000   00000 000   0
Jul-Dec 1998	o :000 : 0 0000 o :0000+00+0000 : 00000
Jan-Jun 1998	0 0000   0000   000   000   0
Jul-Dec 1997	0 00 100 1 0000 00000 - 0 - 1000
Drug name <sup>1,2,3</sup>	doxylamine

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002) \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

CNS = central nervous system, ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, MAO = monoamine oxidase, NOS = not otherwise specified, NTA = not tabulated above, SSRI = selective serotonin reuptake inhibitor. Bureau of the Census.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Plunitrazepam (Rohypnol) is classified under Major Substances of Abuse.

<sup>3</sup> Amphetamines are classified under Major Substances of Abuse.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with Drugs are classified to the degree of specificity recorded in the DAWN case reports. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates 4 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

Table 12.6.0 - ED mentions for psychotherapeutic agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year

% change <sup>4</sup> 2000, 2001	1007											,	-29.3									105.0																	-74.9					
% change <sup>4</sup> 1999, 2001	1007					174 E	-350	2		-				_	•	Ç	-52.3			_						•			_		27.1	-37.6					_		_					_
% change <sup>4</sup> 1994, 2001		:	:			20.1	-36.6		107.0			<del>2</del> .8			: 6			2.70-			0	782.0	116.3	5.785					063.7		-26.7	-89.6	-77.8	1.76-		i			-94.3	i	-100.0	- <del>1</del>	:	•
Total 2001	24	; c	-	; °	5 5	- ~	160	0	4	m	: '	n c	N C	5	: 0	<u> </u>	5 6	0	5 6	5	: °	70	0 0	7 0	<del>5 +</del>	-		<b>⊽</b>		10	Ø	-	0	0	0	: '	0	0	<del>-</del>	: '	0 0	5	: :	
Total 2000	24	 	· :	00			. 60	0	<del>ෆ</del>	en (	5	n c	7	; c							<del>-</del>	<del>-</del> c	0 0	N C	7			4		10	89	_	0	0	0	0	0	; '	5	0	:	:	<u>.</u> 0	-
Total 1999		00		: -		-			က					:	<u>:</u> C	7		0	5 0	5	; °	ν α	٥٥	7	: -	-	•	4	_	0	9	-	0	0	:	: 0	5 6	5 6	5 6	50	5	:	:0	:
Total 1998		00										. r		:	•			7		•	: `	7	-	•	0	-	0	4	_	0	7	7	0	5	: 0	<b>5</b> 6	5 6	5 +	- 6	5 6	5	:	: ;	
Total 1997	23	0 0	0	0 0	10	0	4	0	e c	უ c	0 6	- 4		0	0	-	-	_	•	0	<del>, -</del>	<u> </u>	<del>, -</del>		: :	0	0	4	-	0	2	7	- (	5	; <b>c</b>	5 6	>	: •	- c	5 6	<del>-</del>	0	<b>'</b> :	-
Total 1996		: :									α	9 4	•	. 0	0	=	_	_	•	0	-	9	0	· :	0	0	0	4	_	0	<b>®</b>	<del>го •</del>	- 0	5	<del></del>	- c	<del>-</del> -	7	- c	•	: 0	0	:	0
Total 1995		5 6		; °								4	•	0	0	-	<del>-</del>	_	0	0	=	5	-	:	0	0	0	4	_	0	<b>σ</b>	4 •	- 0	<del></del>	<del>-</del>		o c	<del>-</del>		5	0	0	;	5
Total 1994	24	<b>-</b>	0	: °	6	0	4	0 0	7 6	n C	. <del>L</del>	2	•	0	_	2	_	_	:	:	-	4	0	:	0	0	0	<u>ස</u>	0	0	= '	0 +		•	: -		•	: -			0	0	:	5
Drug name <sup>1,2,3</sup>	Antidepressants	isocarboxazid	pheneizine	monoamine oxidase inhibitors-NOS.	SSRI antidepressants	citalopram	fluoxethe	lluvoxamine	sertraline	SSRI antidepressants-NOS	Tricyclic antidepressants	amitriptyline	amoxapine	clomipramine	desipramine	doxepin	imipramine	nortriptyline	protriptyline	trimipramine	tricyclic antidepressants-NOS	Miscellaneous antidepressants	bupropion	maprofiline	mirtazapine	nefazodone	nomifensine maleate	trazodone	ventataxine	antidepressants-NOS	Phenothiazine anticombetica	chlomomazine	flunhenazine	mesoridazine	perphenazine	prochlorperazine	promazine	thioridazine	trifluoperazine	triflupromazine	phenothiazine antipsychotics-NOS	Psychotherapeutic combinations	amimptyline-chlordiazepoxide	annupyline-perpiteriazine

able 12.6.0 - ED mentions for psychotherapeutic agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>4</sup> 2000, 2001				10.0 30.5	-100.0	543.7		
% change <sup>4</sup> 1999, 2001	39.2		52.3	10.1	-100.0			
% change <sup>4</sup> 1994, 2001	57.2	-69.4 -48.1	524.9	16.0	-100.0	274.6		-100.0
Total 2001	0 '	000+	; 0 0 ; N N	: 0 % 4 0 0	00	0 0	000:000	000
Total 2000		0000	000-00	<u> </u>	0 ; 0	0 0	0 ; ; 0 000	0000
Total 1999	0 :::	0 ;000	0-00-0	<u> </u>	<del>-</del> - 0	0 ;	0 0 000	0000
Total 1998	000	0 ;	:   -00-0	0 0 4 1 0	000	: 0	; 000 000	00 0
Total 1997	0004	:0+0	:0-00-0	. <del> </del>	00 0	0 0	0 000 000	0000
Total 1996	0 0 4	00-00	000 10-0	<u> </u>	o ; o	0 :	0 000 000	0000
Total 1995	1 1	00-00	000	0 7 E :: C	000	0 :	0 0 000	0000
Total 1994	0 5	00-00	000 100	<u> </u>	· ; o e	0 0	; ° ; ° ; ; ;	0000
Drug name <sup>12,3</sup>	psychotherapeutic combinations-NOSThioxanthenesthiothixene	butaperazine	loxapine	ziprasidone	amobarbital amobarbital amobarbital-secobarbital aprobarbital/butabarbital/phenobarbital	barbital/butabarbital/dihydroergotamine/ phenobarbital/scopolamine barbitunc acid. belladonna/phenobarbital. butabarbital.	butabarbital/chlorpheniramine- phenylpropanolamine/theophylline butabarbital/ secobarbital. cyclobarbital. diethylbarbiturc acid. ephedrine/pentobarbital. ephedrine/pentobarbital. ephedrine/secobarbital.	heptabarbital hexobarbital hexobarbital homatropine/phenobarbital mephobarbital/phenytoin mephobarbital/phenytoin

429

Table 12.6.0 - ED mentions for psychotherapeutic agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

Drug name <sup>1,2,3</sup>	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>4</sup> 1994, 2001	% change <sup>4</sup> 1999, 2001	% change <sup>4</sup> 2000, 2001
methylphenobarbitalpavatrine/phenobarbital	0 0	0 0	00	0 0	00	00	00	0 :			-100.0
pentobarbital pentobarbital	1 1	0 0	00	00	;0	1 1	;0	: :			
pnenobaroital phenobarbital/phenytoin	- 0	1	<del>- 0</del>	<del>-</del> c	← c	← c	<del>-</del> c	0	-59.1		
phenyltoloxamine/secobarbital		•	•	5	5	5	5	:			
secoparbital. talbutal.	0 0	: -	<del></del>	00	00	: 0	0	0	9.06-		
barbiturates-NOS.	-	7	8	0 0	o m	<del>0</del> <del>0</del>	<del>- 7</del>	<u> </u>	129.6		45.0
senzodiazepines albrazolam	32	33	33	32	37	37	37	41	26.5	10.1	11.3
bromazepam	-0	0	0	0	<u> </u>	<del>∞ o</del>	တ	<u> </u>	35.6	20.1	13.1
chlordiazepoxide	_	<del>-</del> 0	₩.	0	<del>-</del>	0	_	0	-66.2		
clonazepam	: <b>'</b> C		<del>5</del> 6	0 4	0 7	0 1	1 0	: °	,		
clorazepate	0		<del>-</del>	00	-0	0	0	<del>0</del> 0	42.7		
glazepam estazolam	9 0		<del>-</del>	9	2	5	Ċ.	S	-		
flurazepam.	<b>→</b>		<del>5</del> <del>-</del>	: =	o c	; C	; °	0 0	-96.9		
halazepam	:		0	0	0	5 6	>	5	43.4		
orazepam.	S.	5	4	2	4	4	4	. v			
midazolam	5 6	: 0	0 0	<del>-</del>	<del>-</del>	0	0	0			
nitrazepam	· :		5 0	<u> </u>	; =	<del>-</del>	0 0	00			
oxazepam	0	0	0	0	0	<u>: °</u>	00	5 6			-100.0
prazepam	5	0	0	0	:	:	-	;	:		
temazepam.	; ^	: -	<del>-</del>	<del>-</del>	<del></del>	: `	; `	0		_	
triazolam	10	- 0	- 0	- 0	- 0			<del>-</del> c	70 E		
benzodiazepines-NOS	4	5	7	80	6	0	o 6	7	2011		33.4
Misc. anxiolytics, sedatives and hypnotics	<del></del>	Ξ	12	<u></u>	6	80	6	6	2		32.1
acetophenazine maleate.	; °	: :	<u>;</u> c	5 6	<del></del>	: 6	0 0	0 0			-80.5
acetylcarbromal			ī		•	•	5	5			
bromisovalum	0 0	0	:	: '	0	0	0	0	-		
buspirone	<del>-</del>	<del>-</del>	: -	5+	<del>5</del> 6	<del>-</del>	0 ,	0	_		
carbamate	0	- :	0	- 0	<del>-</del> -	- 0				41.2	45.7
chloral betaine	0	:	0	0	0	0	0	5 6			
chlormethazanone	0	0	<del>-</del>	0	0	:	0	:	:		
chlormezanone	0	0	0	0	-0		Ġ		100		
demoxepam	0	0	0	0	0	0	0	0	-90.9	-76.0	95.0
dextromethorphan/doxylamine.	0	:			_				_		
dichloralphenazone	0	0 1	0	• :	0	00	<del></del>	:0			
opriority diameter.	•	6	6	C	8	e	2	<del>ਲ</del>	-50.1		

eable 12.6.0 - ED mentions for psychotherapeutic agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>4</sup> 2000, 2001																-100.0													-75.6
% change <sup>4</sup> 1999, 2001													-100.0				60.0	50.3											
% change <sup>4</sup> 1994, 2001		-100.0		-58.0	;					000	-100.0		-100.0				7220	-	45.5	-37.8	47.6								
Total 2001	1	0	c	<del>-</del>	:		:	0	0	0 0	>	;	0				0 6		: <del>-</del>	_	_	0	0	0	,	Э <del>г</del>	- 0		
Total 2000	- 0	:	•		:		:		0				: :				° °			_	_		0			⊃ <del>-</del>			0
Total 1999	1	•			:		:			0	:		0				0 0				_		0	• 		<b>-</b>			0
Total 1998	- 0	•					:		0				: :								_		°	•			- 0	:	
Total 1997	1 0			: ~	<u> </u>		:		0				-				0 0				_		•	:		: `		0	
Total 1996		_					:		0				0				۰ °				_		0	:		<u> </u>		•	0
Total 1995	1	:	_		0				0		:		0						<del>-</del>				0			- ·			:
Total 1994		0			<u> </u>		:	_	0		<u>.                                     </u>	-	0			•	·-		. —	- 5		• 	:	:		- ·		ţ	0
Drug name <sup>1,2,3</sup>	doxylamine doxvlamine/ovridoxine	ethchlorvynol	ethinamate	hydroxyzine	meprobamate	meprobamate/pentaerythritolchloral	methylpentynol	methyprylon	paraldehyde	penfluridol	prelipiopalitate	pvílamine	salicylamide/scopolamine	sulforidazine	tricloryl	tybamate	Zalepion	zoniclone	anxiolytics, sedatives and hypnotics-NOS	CNS stimulants.	caffeing-codium honzoate	caffeine/ephedrine	caffeine/multivitamin/phenylpropanolamine	caffeine/phenylpropanolamine	dexmethylphenidate	doxaprammethytohenidate	modafinil	pemoline	CNS stimulants-NOS

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. <sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique Flunitrazepam (Rohypnol) is classified under Major Substances of Abuse.

CNS = central nervous system, ED = emergency department, MAO = monoamine oxidase, NOS = not otherwise specified, NTA = not tabulated above, SSRI = selective serotonin reuptake SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update)

<sup>&</sup>lt;sup>3</sup> Amphetamines are classified under Major Substances of Abuse.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

Table 12.7.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year T-346

% change <sup>4</sup> H1 2001, H1 2002	-100.0	14.0 14.8 14.8
% change <sup>4</sup> H2 2001, H1 2002	-100.0	-66.7
Jan-Jun * 2002	<b>9</b> : : 000 00 : : : 00 ; 0	122
Jul-Dec 2001	\$600 i000 i000 i0	130
Jan-Jun 2001	₩ 0 000 io ioooo	<u>φ</u> ξω 000 1400 1 10 0 00 000
Jul-Dec 2000	80 1 000 00 10 10000	70 000 i t 0 t 0 i i 0 0 0 0 0 0 0 0 0 0
Jan-Jun 2000	χο ο <u>:</u> ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο	707   0 0   1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
Jul-Dec 1999	0,0000000000000000000000000000000000000	το ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο
Jan-Jun 1999	0000 00 00 00 00	4 a n 00 i 0 + 0 + 0 i 0 0 0 0 i i
Jul-Dec 1998	57	£ 6 0 100 + 0 1 1 0 0 1 1 1 0 1 1 1 1 1 1 1
Jan-Jun 1998		1,00 000 to t i 0 i i 00 000
Jul-Dec 1997	%° ; ° ° ; ° ° ° ° ° ° ° ° ° ° ° ° ° ° °	± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 100 ± 10
Drug name <sup>1,2,3</sup>	Analgesics.  Antimigraine agents.  almotriptan.  APAP/dichloralphenazone/isometheptene. belladonna/caffeine/ergotamine/ pentobarbital. caffeine-ergotamine dihydroergotamine. frovatriptan. isometheptene mucate. frovatriptan. isometheptene maleate. naratriptan. sumatriptan. zolmitriptan. zolmitriptan. antimigraine agents-NOS. Cox-2 inhibitor. celecoxib. meloxicam ricecoxib.	Narcotic analgesics/combinations Narcotic analgesics/combinations. Narcotic analgesics. Narcotic analgesic combinations. alfentanil anileridine. aspirin/ethoheptazine. butrophanol. codeine/combinations codeine/combinations codeine. acetaminophen/caffeine/codeine. ASA/butabital/caffeine/codeine. ASA/butabital/caffeine/codeine. aspirin/caffeine/codeine. aspirin/caffeine/codeine/phenacetin. aspirin/caffeine/codeine/phenacetin. codeine/papaverine. codeine/phenacetin. codeine/phenacetin. codeine/phenacetin. codeine/salicylates. codeine/combination-NOS. dezocine. dihydrocodeine/combinations.



able 12.7.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

% change <sup>4</sup> H1 2001, H1 2002	-100.0 -100.0 -100.0 -100.0
% change <sup>4</sup> H2 2001, H1 2002	
Jan-Jun * 2002	000     N-400    00000000000       04 N-  00000000
Jul-Dec 2001	ioo ii 404 iiioo ioooo iuooo i io4uuooo ioo iioo o
Jan-Jun 2001	000 00 4-40 <sup> </sup> 10000000 1400 1000w4-0000 100000 0
Jul-Dec 2000	100 00 4040 10 1000000 140 10 1 104 1 10 1 10
Jan-Jun 2000	000 00 4040    0000000   1000 00    000 10
Jul-Dec 1999	000
Jan-Jun 1999	00 00   00   00   10   00   10   00   10   00   10   00   00   10   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   00   0
Jul-Dec 1998	0 10 00 W00000000000 1000000-0-00000 1 1000 0
Jan-Jun 1998	000 00 80700000000 1-0000 10000 0 10 10000 0
Jul-Dec 1997	00   00 %0000   000000   10000   10000   0   1000
Drug name <sup>1,2,3</sup>	dihydrocodeine

· ; ; ; ;

Table 12.7.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

Drug name <sup>12,3</sup>	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change <sup>4</sup> H2 2001, H1 2002	% change <sup>4</sup> H1 2001, H1 2002
propoxyphene/combinations	2	-	-	-	+	-	-	-	-			
propoxyphene	<del>0 •</del>	<del></del>	0 1	<del></del>	0,	0	0	0	0	0		
ASA/caffeine/propoxyphene	- 0	<del>-</del> :	- 0	- 0	- 0	•	<del>-</del> c		_	<del>-</del> c		
remifentanil				1		•	•	•	:	•		
sufentanii	0	0	0,	0 1	0	0	0	0	0	0		
narcotic analgesics-INOSnarcotic analgesic combinations-NOS.	4 C	4 C	4 C	Ω C	9 0	<u> </u>	<u> </u>	9	φ (			
Nonsteroidal anti-inflammatory agents.	9 69	9	מי	ט גמ	2 4	יא כ	<u> </u>	: 7	<b>&gt;</b>	: \	:	
bromfenac	0	0	0	0	0	• :	0	F 0	F 0	FC		
diclofenac	0	0	0	:	:	0	:	0	0	0		
alcrotenac-misoprostoletodolar	0	00	0	0	0	0	0	0	0	0	-	
fenoprofen.	; °	> ;	<u>:</u> -	<u>:</u> °	5 0	; =	: -	: <	: 0	; <b>c</b>		,
flurbiprofen.	0	. 0	0	0	;	•	•	<del>-</del>	<del>-</del>	5 6	0.001	0.001-
ibuprofen	4	4	4	က	က	4	· m	<del>, с</del>	<u>ਜ</u>	<u> </u>	0.00	
indomethacin	:	0	:	:	:	:	:	:	<b>:</b>	0		
Ketoproten	:	0	:	:	0	:	0	0	:	:		
Ketorolac	: '	:	:	:	÷	:	:	:	:	:		
mectorenamate	<del>-</del>	: '	: '	0	0	0	:	0	0	0		
merenamic acid	0	0	0	: '	0	0	:	0	0	0	-100.0	-100.0
napunetone	: *	5 7	0,	<del>o ,</del>	<del>o ,</del>	;	:	;	:	:		
Ovaprovin		<del>-</del> c	_	_	_	-	_	_	_	_		
phenylhitazone	5 6	<b>5</b> C	; °	•	; •	: (	: (	: '	0	0	-90.0	
piroxicam	<del>-</del>	•	o c	:	<del>5</del> 6	5 6	5 6	5 6	0	0 0		-100.0
sulindac	: :	; °	0	: C	5	5 6	<del>-</del>	5 0	:	Ö		
tolmetin.	: :	· :	•	0	:	0	<del>-</del>	>	: c	:		
nonsteroidal anti-inflammatory agents-NOS	0	:		0	: :	0	•	<u>:</u> c	0 0	; 6		
Salicylates/combinations	က	က	က	7	7	6	က	2	0 0	<u> </u>		
aspirin/combinations.	က	က	က	7	7	က	7	7	<del>-</del>	<del>-</del>		
aspinn	7	2	က	7	7	2	7	_	_	_		
Al nydroxide/ASA/Ca carbonate/Mg	(											
nydroxide	0 0	: 0	0 0	:	:	:	;	0	:	:		
ASA/butalbital/caffeine	5 6	5 6	<del>-</del>	: °	; °	; °	0	0	0	: '		
ASA/caffeine/salicylamide	· ;	•	•	0	o c	5	<del>5</del> C	5 6	:	ō		
aspirin-butalbital.	O	0	0	0	0	<u>: °</u>	5 0	<del>-</del>	: 0	; C		
aspirin-caffeine	:	0	:	0	· :	0	0	•	•	5 6		
aspirin-diphenhydramine	0	0	0	0	0	0	0	: :	<u>: °</u>	· c	_	
aspirin-phenyltoloxamine	:	:	0	0	0	Ô	0	0	•	0 0		
aspirin/salsalate	0	0	0	0	0	0	0	0	0	0		
choline salicylate	<del>- 0</del>	0	: '	0	0	0	0	0	0	0		
diffunisal	5 6	•	5	; c	0 0	0 0	0	0	0	0		
magnesium salicylate.	•	<u>:</u> C	:	o c	<del>-</del>	5	; c	5 0	5	5		
salsalate	:	· :	: :	•	•	:°	<del>-</del>	<del>-</del>	: -	:		
		-	•	i	•	<del>-</del>	5	<del>-</del>	•	:		
						1		1	1	1		ļ



able 12.7.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

% change <sup>4</sup> H1 2001, H1 2002	-18.2 -17.9	-100.0											-100.0			
% change <sup>4</sup> H2 2001, H1 2002	-13.3 -13.5	-100.0				-57.5						9	2			
Jan-Jun * 2002	0 7 7	·		0	00	000	000	· c	00		0	00	000	0	0	0 0
Jul-Dec 2001	0 8 8 9			0	00	000	:		00		0	00	· :	; <b>°</b>	0	0 0
Jan-Jun 2001	0	· 0 - 0 ; 0 c		0	0-	000	:		0		0	00	000	;	÷	o :
Jul-Dec 2000		00-00 ;		0	00	000	•		0	_	0	00	000	0	0	0
Jan-Jun 2000	0 10 9	00-000		0		000	•		0		0	00	000	•	0	0
Jul-Dec 1999	0 7 7 3	,00+0 <u>;</u> 00		0	; 0	000	· ; o		9 :		0	00	00	<b>'</b> :	0	
Jan-Jun 1999	0 8 7 7	10-0 100		0		000		ē	0		0	00	· ; c	0	0	0 0
Jul-Dec 1998	0 8 7	000-000		0	;0	000	· ; o	C	0		÷	00	00	· :	0	0 ::
Jan-Jun 1998	0 0 0 0	10-0 100		0	00	000	0 ;	ć	0		0	00	; C	· :	0	o :
Jul-Dec 1997	0 0 8 7	10-0 100		0	00	:00	· ; °	C	0		0	00	00	<b>'</b> :	0	o ;
Drug name <sup>12,3</sup>	sodium salicylate	acetaminophen-butalbital acetaminophen-caffeine	acetaminophen/ascorbic acid/chlorpheniramine/phenylephrine acetaminophen/aspirin	ephedrine APAP/AI hydroxide/ASA/caffeine/Mg	hydroxide. APAP/ASA/caffeine.	APAP/ASA/caffeine/salicylamideAPAP/butalbital/caffeineAPAP/caffeine/ovrilamine	APAP/pamabrom/pyridoxine APAP/pamabrom/pyrilamine ammonium sulfate	benoxaprofenbenzydamine HCLdibvrone.	dypyrone. glafenine	methotimeprazine morazone oxyphenbutazone.	salicylamidesuprofen	tramadolxylazine.	zomepiracanaloesics-NOS.	Analgesics combinations NTA	apriemiyu ariime-mayresum saiicylaremagnesium salicylate-phenyltoloxamine	paraminobenzoic acid/sodium salicylate prednisone/salicylamide

435

Table 12.7.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

% change <sup>4</sup> H1 2001, H1 2002	166.4		-100.0	-100.0
% change <sup>4</sup> H2 2001, H1 2002	-100.0	-100.0	-100.0	294.7
Jan-Jun *   2002		; <u>; ;</u> om 000+0	00-0 ; ; 000	00       0     00     0
Jul-Dec 2001		0 m   0 0 0 + 0	00-0     10	000 10 1 100000 0
Jan-Jun 2001	0 100 100	, ,	00-00; 00;	00000 100000 10
Jul-Dec 2000	00 ,000000		00-0 0 0 0	00000 000000
Jan-Jun 2000	, ,	0000 000-0	0 ; - 000 000	0000 ; 00 ;000 ; 0
Jul-Dec 1999		0000 000-0	0 1 - 000 100	0000   00000   0 0
Jan-Jun 1999		100 lw 0 124 l	0000 :0 000	0- 10 1 00000 10 0
Jul-Dec 1998		000% 000	00000 000	0- 100 00 100 10 0
Jan-Jun 1998	00       00   0	1000W 10 <u>++0</u>	;000 <u>;</u> 0 000	; F ; O ; OOOOO ; ; O
Jul-Dec 1997		0000 00++0	0000 ;0 000	00 100 00 1000 10
Drug name <sup>1,2,3</sup>	Anorexiants	phenylpropanolamine	felbamate	phensuximide phenytoin primidone tiagabine tiagabine topiramate trimethadione valproic acid zonisamide anticonvulsants-NOS antiemetic/antivertigo agents benzocaine-trimethobenzamide cyclizine dimenhydrinate dimenhydrinate diphenidol

able 12.7.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

% change <sup>4</sup> H1 2001, H1 2002	
% change <sup>4</sup> H2 2001, H1 2002	-100.0
Jan-Jun * 2002	000   10   0   0000   0   1   1   00 0 0 0
Jul-Dec 2001	00         000   0   00000 0 0     0   0   4000000   00
Jan-Jun 2001	000 00 0000000 10 1000 0 1000 0 0 400 100 1
Jul-Dec 2000	000   0000   0   00000     0     0 0   00   00   00
Jan-Jun 2000	io io oo i io oo oo io io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo io oo o
Jul-Dec 1999	00   00   0   00 00   00   0   0   0
Jan-Jun 1999	000 10000 1 1000000000 0 1000 0 0 000 1000 100
Jul-Dec 1998	000 10000000000000000000000000000000000
Jan-Jun 1998	00000 ;000000 ;000000 0 ;000 0 0 m00 ;0 ;00
Jul-Dec 1997	000 ;000000000 ;0 ;000 0 0000 0 0 m ;000 ; i0 000
Drug name 12.3	dolasetron dronabinol granisetron isopropamide iodide ondarizine ondarizine ondarizine ondarizine ondarizanide trinethyperazine trinethyperazine trinethyperazine trinethyperazine trinethyperazine trinethyperazine trinethyperazine trinethyperazine trinethyperazine bromocriptine bromocriptine carbidopa bromocriptine bromocriptine carbidopa pergolide procyclidine procyclidine ropinirole procyclidine ropinirole procyclidine ropinirole procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidine procyclidin

Table 12.7.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

Drug name <sup>1,2,3</sup>	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	H2 2001, H1 2002	H1 2001, H1 2002
carisoprodolchlorphenesin	-0	0 0	00	0 0	00	0 0	00	0 0	2	2		
chlorzoxazone	:	0	0	0	÷	:	:	0		:		
cyclobenzaprine	-	_	_	-	0	1	-	_	_	0	40.1	
dantrolenedoxacurium.	0	0	0	0	0	0	0	0	0	:		
mephenesin.												
metaxalone	: '	: '	:	: '	: '	0	0	0	0	:		
methocarbamol methoryethyl-1-4-	0	0	:	0	0		0	0	0	:		
benzodioxan	0	0	:	0	:	0	0	0	0	0		
metocurine												
mivacurium	0	0	0	0	0	0	0	0	0	:		
orphenadrine	:	:	:		:			0	:	:		
pancuronium	0	0	0	0	0	0	0		0			
pipecuronium	0	0	0		0				:			
rapacuronium												
rocuronium												
succinylcholine	÷	0	0	0	0	0	0	0	0	0		
tizanidine	0	0	0	:	;	:	:	:	0	;		
tubocurarine												
vecuronium	0	0	0	0	0	0	:	0	:	0		
muscle relaxants-NOS	0	:	0	:	0	0	0	•	:	ō		
Miscellaneous CNS agents	0	0	0	:	:	•	0			0		
cevimeline												
donepezil	0	0	0	•	:	:	0	:				
ergoloid mesylates	0	0	0	0	0	0	0	0		C		
galantamine	ı	1	l	i	)	)	•	)		•		
laudanosine	0	0	0	:	C		C	C	c	_		
pilocarpine			I	-	l		)	)	•	)		
rivastigmine	0	0	0	0	0	0	0	0	;	C		

<sup>1</sup> This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

CNS = central nervous system, ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NOS = not otherwise specified, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update)

Cocaine (Schedule I substance) / morphine is Brompton's mixture. All other mentions of cocaine are classified under Major Substances of Abuse.

Anesthetic gasses are classified under Inhalants.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with Drugs are classified to the degree of specificity recorded in the DAWN case reports. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates <sup>4</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

Table 12.8.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year

% change <sup>4</sup> 2000, 2001				-51.2				-51.2				,	37.6						-31.5	-33.1	į								
% change <sup>4</sup> 1999, 2001	20.6		91.8		-100.0		•		: :			ć	38.0 49.1	21.2	000	0.001-			-28.3	-34.1		- 0	0.001-		000	9			
% change <sup>4</sup> 1994, 2001	15.7		-88.3	-87.0			i					000	203.0	24.9			354.1		-64.2	9 6 9 9		9	0.001-						
Total 2001	69	0	0 (	00	:0		<u>;</u> 6	0 +	0	; =	<del>,     </del>	ć	2 <del>0</del>	4		<del>5 0</del>	0	:	<del></del>	<del></del>	:	: 0	5	0	<del>5 C</del>	0	· c	00	:
Total 2000	89	0	: '	50	00		; °	00	0	00	5	-	<u>3 <del>C</del></u>	4		; °	0	:	<b>⊘</b> ⊂	2	0	0	:	0	5 0	0	c	0	0
Total 1999	0 0	0	0	:°	00		00	÷	: :	0 0	•	oc	4 6	7	•	0	· :	:	<b>α</b> c	0	:	0 0	5	0 0	<del>5 c</del>	0	c	· :	i
Total 1998	69	0	0.0	<b>→</b> :	00		<del>-</del> -	00	0	00	•	7	7 7	77		<del>-</del> :	0	0	<del>∞ -</del>	- 2	:	0	:	: 0	<del>-</del> -	0		0	:
Total 1997	69	0	0	1 1	00		; °	00	0	00	•	22	<del>1</del> 2	12	-	0	:	: '	<del>ო</del>	<u></u> ल	÷	; c	5	0 0	>	: :		0	0
Total 1996	0 0	0	00	00	° :		:0	:0	0	00	1	- 6	3 6	9		0	0	0		- ო	÷	0 0	•	: `	0	0	:	0	0
Total 1995	59	0	; 6	<b>:</b>	: :	_	00	00	0	00	•	9	<u> </u>	9		0	0	:	4 ~	· w	0	0 0	5	; °	0	0	0	0	:
Total 1994	59 0	0	00	00	00		00	: 0	0	0 0	1	Ç	<u>.                                    </u>	7	c	0	0	0	4 -	· ന	i	0 0	•	:	<u>;                                    </u>	0	0	:	:
Drug name <sup>1,2,3</sup>	Analgesics	amourptan	pentobarbital caffeine-ergotamine.	enjuroeigodamine	Isometheptene mucate	naratriptan. rizatriptan	sumatriptan zolmitriptan	antimigraine agents-NOSCox-2 inhibitor	celecoxib	meloxicamrofecoxib.	valdecoxib	cox-2 inhibitor-NOS	Narcotic analgesics	Narcotic analgesic combinations	antenzini	aspirin/ethoheptazine	buprenorphine	butorphanol	codeine/combinationscodeine	acetaminophen-codeine.	acetaminophen/caffeine/codeineAPAP/butalbital/caffeine/codeine	ASA/butalbital/caffeine/codeine	aspirin/caffeine/codeine	aspirin/caffeine/codeine/phenacetin	aspirin/carierrie/coderrie/prierraceuri/ codeine/papaverine	codeine/phenacetin	codeine/salicylates	dezocine	dinydrocodeine/combinations

Table 12.8.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>4</sup> 2000, 2001	-100.0					-100.0	-100.0	33.8	-100.0		65.8 185.5	-70.7		-100.0	-100.0
% change <sup>4</sup> 1999, 2001		102.1	35.6	40.1				89.6	-100.0		174.6				
% change <sup>4</sup> 1994, 2001	i	2,202.8	110.1	111.9	-100.0			199.5 181.2	181.5 -100.0		310.9 7,204.6	80.1			_
Total 2001	:00	00		- <del>&amp; - C</del>	: 	•	00	•	-00	000		7000	o <u>;</u> o o	;	0
Total 2000	;00							:	-0 ;			•	1111		0
Total 1999	:00	00			•	000			-000			1000	. :	000	0
Total 1998	0 :0	00			0000			- 70	·			1000			• 
Total 1997	;0 ;	00						- 7	·			N O O O	· · ·	_	0
Total 1996	000	00							0000		•				0
Total 1995	00 :	00				·					•				0
Total 1994	;° ;	00	40			•	00	; F 0		- i i c			00 ; ;	<b>°</b> ; ;	0
Drug name <sup>1,2,3</sup>	dihydrocodeineAPAP/caffeine/dihydrocodeineASA/caffeine/dihydrocodeine	fentanyl/combinations	aropendoi-rentanyi	acetaminophen-hydrocodoneaspirin-hydrocodone	hydromorphone hydroxy-N-methylmorphinan kaolin-pectin/paregoric	levomethadyl acetate	meperidineacetaminophen/meperidine	methadone	morphine	•	A Condone Combinations.	aspirin-oxycodone	pentazocine/combinationspentazocine pentazocine	naloxone-pentazocine	aspirin/caffeine/phenacetin/ pseudoephedrine

Table 12.8.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>4</sup> 2000, 2001		. 21.1			.39.9 4.5 1.64.5	-52.3	
% change <sup>4</sup> 1999, 2001		251.7	-91.3		-68.0 -28.3 -32.6 -37.2		0.89-
% change <sup>4</sup> 1994, 2001	-59.0	252.0	-88.7 	-100.0	94.1- - 65.4- - 61.8-	-61.2	-100.0 
Total 2001	NON :	<u> </u>				100 10 10 16	<del>, 000</del>
Total 2000		, ,	; ; ° ; ° ; °			; ; <del>-</del> 0 0 0 0 0 0	·
Total 1999		0.000				; ;000 ;000	
Total 1998		7	0000 ;00			10- 10 10	
Total 1997			200000		::::::		00000
Total 1996				00000000			
Total 1995	: 	0 4 0 7 0 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		000 100
Total 1994					· · · · · · · · · · · · · · · · · · ·		
Drug name¹4.3	propoxyphene/combinations	sufentanii narcotic analgesics-NOS narcotic analgesic combinations-NOS Nonsteroidal anti-inflammatory agents	diclofenac	indomethacin. ketoprofen. ketorolac. mectofenamate. mechoramic acid nabumetone naproxen.	phenylbutazone piroxicam sulindac tolmac tolmac nonsteroidal anti-inflammatory agents-NOS sapirin/combinations aspirin.	Al hydroxide/ASA/Ca carbonate/Mg hydroxide	choline salicylate. choline salicylate-magnesium salicylate difunisal magnesium salicylate salsalate

Table 12.8.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>4</sup> 2000, 2001	- 100.0 - 100.0
% change <sup>4</sup> 1999, 2001	12.2 10.0
% change <sup>4</sup> 1994, 2001	-24.8 -81.8 -110.9
Total 2001	0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 2000	0 m t t t t t t t t t t t t t t t t t t
Total 1999	0.441 :040 :0 0 :0 0 :0 :0 :0 :0 :0 :0 :0 :0 :0 :
Total 1998	- t t t t t t t t t t t t t t t t t t t
Total 1997	- \$\pi \pi \tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\tau_{\\ \tau_{\tau_{\\tau_{\tau_{\\ \tau_{\tau_{\\ \tau_{\\ \tau_{\tau_{\\ \tau_{\\ \tau_{\\ \tau_{\\ \tau_{\\ \tau_{\\ \tau_{\\ \tau_{\\ \tau_{\\ \tau_{\\ \\ \tau_{\\ \tau_{\\ \tau_{\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\
Total 1996	-0000 in in in o o o o o o o o o o o o o o o
Total 1995	- 0 0 + 0 + 0   0 0 0 0   1   0 0 0 0   0 0 0 0 0 0
Total 1994	- \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$
Drug name <sup>12,3</sup>	sodium salicylate sodium thiosalicylate sodium thiosalicylate salicylates-NOS.  Miscellaneous analgesics/combinations acetaminophen-butalbital acetaminophen-pamabrom acetaminophen-pamabrom acetaminophen-pamabrom acetaminophen-pamabrom acetaminophen-pamabrom acetaminophen-pamabrom acetaminophen-tamadol. acetaminophen-tamadol. acetaminophen-tamadol. acetaminophen/aspirin acetaminophen/aspirin acetaminophen/aspirin acetaminophen/aspirin acetaminophen/aspirin acetaminophen/aspirin APAP/ASAcaffeine APAP/ASAcaffeine APAP/ASAcaffeine APAP/ASAcaffeine APAP/Dutalbital/caffeine APAP/pamabrom/pyridamine ammonium sulfate. benoxaprofen benoxaprofen benoxaprofen benoxaprofen benoxaprofen cyphenbutazone salicylamide suprofen tramadol. xylazine suprofen tramadol. xylazine combinations NTA diphenhydramine-magnesium salicylate paraminobenzoic acid/sodium salicylate prednissione/salicylamide

Table 12.8.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

	inzorex influramine	-000 100 10 1-004 00N-0 1	<u> </u>	-00000000-00W	-00000000v	-       00   00 00 0   0 - m 0					
1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000	mine	00 100 10 1-004 000-0 1	0 00 000-004 0 00-0	0000000+00W C	wooooooo	00   00000					
1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000	azine	100 10 1-004 000-0	00 1000+004 0 10+0		000000w	00   00000   0 <del>-</del> 00				-100.0	
	azine	00 10 1-004 000-0 1	0 1000-004 0 1u-0	0000-00W C	woooooo	00 1000000 10-00					
1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000	arzine	0 i0 i+004 000+0 i	000-004 0 10-0	0000-000	, o o o o o w	0 1000000 10+wo					
1000	anolamine	0 1-004 000-0	00-004 0 ; 0-0	00-00%	0000 W	000000 ;0-00				•	•
92.1	anolamine	:-004 0001-0	0-004 O <sup>†</sup> U-O	o + o o v c	000 K						
1	-NOS. butylbarbitunc acid. l. pine. sodium.	004 000+0	004 0 ; 0-0	0000	00 K	000 ;0-00				-80.9	-82.6
1	butylbarbituric acid	04 0001-0	04 0 <sup>;</sup> 4 + 0	ວທ c	o w	0-00					
1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000	soutylbarbitunc acid	0000-0	0 ; 0 + 0	, c	•						
	pine sodium de	000-0	0 + 0 + 0	_		;0 + m O					
	pine sodium de in.	0040	:0+0	<u>,</u>	0	0 + 8 0		0			
	sodium	N-0	N <del>-</del> 0	0	0	- m O	2				
	de in in in in in in in in in in in in in	-0 ;	- 0	N (	<del>- </del> (	n 0	7				
	in	•	•	7	7	•		າ c			
	in	:		:	:		:	•	: -		
	ų	:	<del>-</del>	0	0	0	0	0			
		0	0	0	0	0	:	:			
		i °	<del></del>	; '	0	0 (	<del>- (</del>	0.0			
	***************************************	<b>5</b> C	5 6	5 0	:	<b>5</b>					
		<del>-</del>	<del>-</del>	<del>-</del>	<u>:</u> C	; <b>c</b>					
	- Lik	•	•	•	•	•					
		:	0	0	0	0	:				
	ide	0	0	0	0	0	0			-100.0	
	pine	0	0	0	0	0	0				
	dione	•									
	eg	•	•		•		-	-			
		<del>-</del>	<del></del>	: `	<del>- ۱</del>	: '	o •	0 1			
		- (	<b>V</b> (	- 0	-	-	- (	- (			
		5 6	5	5 6	; •	: '	<b>5</b> (	0			
		5 6	5 0	<b>5</b> 6	5 6	0	o	0 (	•		
		<b>5</b>	5	5	>	:	:	0		:	
		-	c	5	c	-	-	_			
		0	0	0 0	0	0 0	· c	_	<u> </u>		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ants-NOS.	0	0	0	•	0	0	·			
	go agents	-	0	0	0	0	0	0			
tetrazol 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	-trimethobenzamide										
tetrazol 0 0 0 0 0 0 0 0 0		0	0	0	0	÷					-100.0
	nate	0	0	0	0	0					
	inate/niadin/pentylenetetrazol	•		•	•	4	,	,			

Table 12.8.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued) T-358

Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Color   Colo	Drug name <sup>1,2,3</sup>	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>4</sup> 1994, 2001	% change <sup>4</sup> 1999, 2001	% change <sup>4</sup> 2000, 2001
	dolasetron dronabinol		C	c					·			
	granisetron		· c	•	· ·	· (	: '	:	5	:		
7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652 7652	medizine	0	0	⊹°	<del></del>	50	<b>&gt;</b> :	: :	: :			
	ondansetronphosphorated carbohydrate solution	00	00	00	0	00	00	00	00		763.2	
	scopolamine	0	:	00	: :	• :	· :	50	<del>-</del>		-100.0	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	thiethylperazinetrimethohenzamide	0 0	00	0 0	00	00	0	:	: '			
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	antiemetic/antivertigo agents-NOS	· :	0	50	50	50	: :	; <b>o</b>	<del>5</del> ;			;
	Antiparkinson agents	7			<del></del>	τ- ·	₹- (	0	0			•
	biperiden	- ;	- ;	-	_		0 0	0 0	00			
	bromocriptine	: :	: :	0	. 0	0	0	· :	00			
1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000   1000	Carbidona-levodona	<del>-</del>	0	0	0 0	0	0	0	:			
-100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -1	entacapone	:	:	:	5	5	:	o <sup>-</sup>	:			
1000	levodopa	:	0	:	:	0	0	0				
1000	pergolide	•		_						-		
1000	pramipexore	0 0	0 0	0 0	o	0	0	0	0			
1	rocyclaine	>	5	5	:	5	0	0	0	-100.0	-100.0	
5 6 6 6 7 7 412 32.9  10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	selegiline		_	C								
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	tolcapone	1	)	•	:	5	:	:	5			
354.1  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	trihexyphenidyl	0	0	0	0	:	:	:	:			
25.4.1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	antiparkinson agents-NOS	0	0	0	0	0	0	0	:			
10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	General anesthetics	0	0	:	0	0	: '	:	0	354.1		
0	dioperidate	5	<del>-</del>	:	5	0	<del>-</del>	o	0			-100.0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	methohexital											
5 6 6 6 6 7 7 41.2 32.9  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	propofol	0	0	;	0	:	:	:	0	808.1	_	
5 6 6 6 7 7 41.2 32.9  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	thiamylal sodium	•										
5 6 6 6 6 7 41.2 32.9  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	unopenial	5	:	0	0	0	0	0	0	-100.0		
	Muscle relaxants.	2	9	9	·C	· C	Œ	ď		41.0	300	7 07
	acetaminophen/chlorzoxazone	· :	0	· :	· :	0	;	<del>,                                    </del>	- 0	7.14	32.3	10.4
	acetaminophen/orphenadrine	0	0	0	0	0	0	0	0		-100.0	2.00.1
	ASA/caffeine/orphenadrine	i	0	: '	0	:	:	:	0			
668	ASACansoprodol/codeine	:	:	<del>-</del>	<del>-</del>	: `	<del>-</del>	0	0	:		
	aspirin-meprobamate	<u>; 0</u>	: :	; 0	: °	<b>o</b> c	5	: -	5 6	0 08		
000	aspirin-methocarbamol	:	0	:	· :	0	0	0	<del></del>	9		
000	atracurium	_	_		•	(	•	_	1			
) · · · · · · · · · · · · · · · · · · ·	benzoctamine	: °	: °	: 0	5 0	5 6	5 6	: '	0 (			
	botulinum toxin type A.	0	5-6	5 0	0	5 6	5 6	5 0	5			-100.0
	botulinum toxin type B	ı		,	<u> </u>	•	•	<del>-</del>	:			

—© Table 12.8.0 - ED mentions for central nervous system agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>4</sup> 2000, 2001		-100.0							
% change <sup>4</sup> 1999, 2001		45.6		-100.0		÷			
% change <sup>4</sup> 1994, 2001	55.4	-100.0	-100.0 4,755.9 -51.9	-100.0		-100.0			
Total 2001	400	00	000	0	;° ;	00	°° :	:0 0	:
Total 2000	<b>4</b> 0	0 2	000	0	;00	0 0	;° ;	;° ;	0
Total 1999	4 0 	<del>-</del> 0	000	0	000	0 ::	°° :	:0 :	0
Total 1998	400	<del>-</del> 0	000	:	000	00	000	00 0	0
Total 1997	° 0	0 2	000	0	000	; °	000	00 0	0
Total 1996	e	0 0	000	0	000	00	000	00 0	0
Total 1995	000	~0	° ; °	:	000	00	000	00 0	0
Total 1994	000	~0	000	0	000	00	000	00 0	0
Drug name <sup>1,2,3</sup>	carisoprodol	cisatracurium cyclobenzaprine dantolene	mephenesin	benzodioxan metocurine	mivacurium orphenadrine pancuronium rapacuronium	rocuronium. succinylcholine. tizanidine.	vecuronium. muscle relaxants-NOS. Miscellaneous CNS agents	donepezilergoloid mesylatesgalantaminelaudanosine	plocarpine

requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique Cocaine (Schedule I substance) / morphine is Brompton's mixture. All other mentions of cocaine are classified under Major Substances of Abuse.

CNS = central nervous system, ED = emergency department, NOS = not otherwise specified, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Anesthetic gasses are classified under Inhalants.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Drugs are classified to the degree of specificity recorded in the DAWN case reports. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

Table 12.9.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year T-360

<u>n</u>	Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
	Antihistamines	1	1	-	-	-	-	1		Ī	-		
	acetaminophen/phenylpropanolamine/					•	•	•	-		-		
	phenyltoloxamine				•	•		_					
	asidiliikure	: `	; =	0 0	<del>-</del>	0 0	0 0	0	0	0 0	0		
	bromodiphenhydramine	•	•	5	i	5	5	5	0	5	<del>o</del>		
	brompheniramine	ō	:	:		0	0	0	0	:			
	carbinoxamine	0	:	0		0	0	0	· :	0	. 0		
	Chlorowamine	፧	:	0		0	:	0	0	0	:		
	chlorpheniramine	•	0	-			_				-		
	chlorphentermine	0	0	0	; O	0	,	0	<del>-</del> -	; C	5 6		
	clemastine	÷	:	0	0	0	: :	0	• :	0	0	-90.3	
	cyproneptadine	; •	<del></del>	: *	; '	: '	:	0	:	:	:		
	dexhromohonira mino	5	5	5	<del>-</del>	0	0	0	0	0	:		
	dexchlombenizamine	c	•		•	•	•	•	,				
	diphenylpyraline HCl	5	<del>-</del>	:	5	5	5	<del>-</del>	0	0	0		
	fexofenadine								•	•			
	loratadine	0	: 0	<u>;                                    </u>	0 0	<u>:</u> c	<u>;</u> c	: °	<del>-</del>	<del>-</del>	; °		
	meclozine HCI	0	0	0	0	00	5 6	0 0	5 6	5 C	<b>5</b> C		
	methapyrilene HCl	0	0	0	0	0	0	0	0	0	3 C		
	methdilazine				_		1	1	)	•	5		
	neo-antergan hydrogen meleate	0	0	0	:	0	0	0	0	0	0		
	phenindamine	•	(	-		_							
	phenicamina/abandtoloxamina/axidomina	5 6	b	<del></del>	0	0	0	:	0	:	0		-100.0
	phonical anning price in your definition by the mine in a commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the commence of the comm	<b>-</b>	: °	<del>-</del>	: `	: '	<del>-</del>	0	0	0	0		
	promethazine	0	<b>-</b>	5 6	<del>-</del>	5 6	<del>5 c</del>	0 0	: `	<del></del>	<del>-</del>		
	pyribenzamine	1	•	•	•	<del>-</del>	•	5	5	5	5		
	rotoxamine tartrate												
	terfenadine	:	0	0	:	:	:	:	:	-	-		
	rimeprazine	0	0	0	0	0	0	0	0	0	C		-100 0
	Inpelentamine	0 (	0	0	0	÷	0	0	0	0	0		?
	antihistamines-NOS	5 6	:	0 0	0 0	0	0 (	<del>-</del>	0	0	0		
	Bronchodilators	o c	; c	<del></del>	5 6	; °	<del>-</del>	<del>-</del>	: '	<del>o</del> (	: '		
Nylephrine	albuterol	· :	•	<del></del>	<del></del>	>	5	5	5 6	5	5 0		
nylephrine	albuterol-ipratropium	0	0	0	0	: 0	<u>:</u> C	: 0	•	:	5		
nylephrine	aminophylline	:	0	· :	0	0	00	0	: 0	<u>.</u> °	; C		
nylephrine	bitoiterol							ı	1	•	<del>-</del>		
nylephrine	dyphylline	0	0	0	0	0	0	0	:	0	o		
nylephrine	iontotice				_								
	isoproterenol-phenylephrine												
0 0 0 0 0	levalbuterol												
	metaproterenol	:	0	-	-	0	c		_		-	0	
	oxtriphylline			_		'	1	•	•	5	5	0.00	

<sup>2</sup>, able 12.9.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

% change <sup>2</sup> H1 2001, H1 2002	-100.0			-60.7
% change <sup>2</sup> H2 2001, H1 2002	-100.0			-70.0
Jan-Jun * 2002	00000 <u>;</u> 000000000	0-00 : 0	00 <u>1</u> 0 1	- o ; o - ·
Jul-Dec 2001	0       00   0000   000	0-00 ; 0		000
Jan-Jun 2001	10 1000 10000000	0-00 ;	00 :00	000
Jul-Dec 2000	00   0   000   00000	0+00 <sub>;</sub> 0	00 00	o : 0
Jan-Jun 2000	00000   100 100000	; <del>- 00</del> ; 0	00 00 0	O ; ;
Jul-Dec 1999	00000 100 10000	0-00 0	000	0 :0
Jan-Jun 1999	0       0   0 0 0 0 0 0 0 0	0 <del>-</del> 00 0 ;	00 0	00 ;
Jul-Dec 1998	00000 100 10000	0-00 ; ;	0 0 1 0	000
Jan-Jun 1998	000 100000	0-00 0 0	00 0	:::
Jul-Dec 1997	0000 :00000000	0-00 0 0	000	0 :0
Drug name¹	pirbuterol proxyphylline salmeterol terbutaline terbutaline theobromine magnesium oleate theobromine magnesium oleate theobromine magnesium oleate theophylline bronchodilators-NOS.  Decongestants.  Expectorants ambroxol anhytrous calcium iodide-isoproterenol chlorpheniramine/codeline/phenylaphrine gualfenesin oldide terpin hydrate.	expectorants-NOS  Upper respiratory combinations acetaminophen-chlorpheniramine acetaminophen-dextromethorphan acetaminophen-pseudoephedrine acetaminophen/dextromethorphan/ doxylamine/ephedrine acrivastine-pseudoephedrine acrivastine-pseudoephedrine acrivastine-pseudoephedrine acrivastine-pseudoephedrine acrivastine-pseudoephedrine acrivastine-pseudoephedrine ephedrine/ipecac/PE ammonium chloride/CPM/DM/	anhydrous calclum lodide-codeine  APAP/ASA/PPA  APAP/ASA/PPA  APAP/brompheniramine/pseudoephedrine  APAP/caffeine/chlorpheniramine/PPA  APAP/caffeine/CPM/hydrocodone/PE  APAP/caffeine/PPM/hydrocodone/PE  APAP/caffeine/PA/salicylamide  APAP/chlorpheniramine/codeine/phrine  APAP/chlorpheniramine/dextromethorphan/PPA  APAP/chlorpheniramine/dextromethorphan/PE  APAP/chlorpheniramine/dextromethorphan/PE  APAP/chlorpheniramine/guaifenesin/PPA  APAP/chlorpheniramine/guaifenesin/PPA  APAP/chlorpheniramine/guaifenesin/PPA  APAP/chlorpheniramine/ghynne	APAP/chlorpheniramine/phenylephrine/ dextromethorphan/guaifenesin

Table 12.9.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

% change <sup>2</sup> H1 2001,	H1 2002	-67.2																																												
% change <sup>2</sup> H2 2001,	H1 2002	-87.5	-100 0								1000	2																												_	_					
Jan-Jun * 2002		5	6	0	0	0	:		:	:			0		-		_	0	:	0		:	:	:	0	_			0	0				0	_	-	8	0	_	_		Ċ	<del>-</del>	; 6	3 6	<del></del>
Jul-Dec 2001	,	5	0	0	0	:	0		:	:	0	'	:	_				5 (	0	0		:	0	<del>-</del>	0				<del>-</del>	0			-	5	_	•	0	<del>-</del>				-	:	; c	5 6	>
Jan-Jun 2001	(	5	0	0	Ξ'	0	0		5 6	<del>-</del>	0		0	_				:	: '	5		:	0	<del>-</del>	:			-	<del>-</del>	<del>-</del>				5		_	:	:		_	_	0	,	<u>: c</u>	<b>5</b>	:
Jul-Dec 2000	1	5	0	0	0	: '	5		: °	)	0		:			-	-	<del>-</del>	: 6	5	-	5 (	0	5	:	_		- 6	5 6	5				5		•	5	:			-	0	0	, c	5	:
Jan-Jun 2000	-	5	0	0	0	; °	5	_	0	1	0		0				_	<b>5</b>	: °	5		: '	5 6	5 6	5			•	<del>-</del> -	5			_	<del>-</del>	_		5 6	<del>-</del>		_		0	:	0	•	:
Jul-Dec 1999	6	•	0	0	0 0	<del>-</del>	5		00		0		:	-				· c	5 6	>	-	; °	<del>-</del>	5	:	_			•	:			_	5		c	<del>-</del>	5			_	0	0	0	0	
Jan-Jun 1999	6	5	0	0	0 0	5 6	•	0	00		0		:	-	_		_	<del>,                                    </del>	5 6	•	c	>	: 0	<del>-</del>	5				<del>-</del>	<del>-</del>		_	-0	,	_		<del>-</del> -	<del>-</del>				:	0	<del>-</del> 0	:	
Jul-Dec 1998		,	0	0 0	5 6	0	•	0	:	_	0	•	5				0	0	<del>-</del>	5	C	<del>-</del>	<u>:</u> c	ō	•			:	:	•			0	i	_	_	0	)		_		0	:	0	0	_
Jan-Jun 1998	0		0	5 6	<del>-</del> -	5 6	•	0	0		0	•	5				0		· C	<del>-</del>	C	5	<u>:</u> C	<del>-</del>	:	•		0	0	1			0		_	0	<u> </u>		_			0	<del>-</del>	0	0	
Jul-Dec 1997	0		00	5 6	5 6	0	1	:	0	,	0		:				0	•	0	1		<u> </u>		· c	<del>-</del>		-	0	0	ı	-		0			:	•					0	:	<del>-</del>	:	
Drug name¹	APAP/CPM/phenylephrine/salicylamide	APAP/dexbrompheniramine/pseudoephednine	APAP/dextromethorphan/diphenhydramine/PSE	APAP/dextromethorphan/graifenesin/PPA	APAP/dextromethorphan/quaifenesin/PSE	APAP/dextromethorphan/phenylpropanolamine	APAP/dextromethorphan/PSE/pyrilamine	APAP/dextromethorphan/pseudoephedrine	APAP/diphenhydramine/pseudoephedrine	APAP/pseudoepnedrine/inprolidine	ASA/chlombeniramine/doctromethorphan/PPA	ASA/chloroheniramine/dextromethomban/DDA	ASA/chlorpheniramine/phenylpropanolamine	ASA/diphenhydramine/PPA.	aspinn-pseudoephedrine	atropine/CPM/hyoscyamine/PE/PPA/	scopolamine	azatadine-pseudoephedrine	bromodiphenhydramine-codeine	brompheniramine-phenylephrine	brompheniramine-phenylpropanolamine	brompheniramine-pseudoephedrine	brompheniramine/codeine/phenylpropanolamine	brompheniramine/dextromethorphan/PPA	brompheniramine/dextromethorphan/PSE	brompheniramine/DM/guaifenesin/PPA	brompheniramine/guaifenesin/phenylephrine/	РРА	brompheniramine/phenylephrine/ PPA	caffeine/pheniramine/PE/Na citrate, salicylat	carbetapentane-chlorpheniramine	carpetapentane/chlorpheniramine/phenylephrine	carbetapentane/CPM/ephedrine/phenylephrine	carbetapentane/guaifenesin/phenylephrine	carbetapentane/PE/PPA/K guaiacolsulfonate	carbinoxamine-pseudoephedrine	carbinoxamine/dextromethorphan/PSE	carbinoxamine/hydrocodone/pseudoephedrine	carpinoxamine/methscopolamine/	pseudoephedrine	ceurzine-pseudoepnedrine	Chlombonizamine-budzoodoo	chlombosin mino about the	Gilorphiemina-phenylephnne	cniorpheniramine-phenylpropanolamine	

, able 12.9.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change H2 2001, H1 2002	% cnange H1 2001, H1 2002
chlorpheniramine-pseudoephedrine	0	0	:	:	0	1	0	:	:			:
chlorpheniramine/codeine/P-E/K lodide	c		C	G			0	<del>-</del> -		0		
chlorpheniramine/codeine/pseudoepnednie chlorpheniramine/dextromethorphan/PPA	00	0	00	00	00	; O (	00	000	0	6		
chlorpheniramine/dextromethorphan/PSE	i	0	0	0	0	0	0	0	:	:		
chlorpheniramine/dinydrocodeine/PE/PPAchlorpheniramine/DM/guaifenesin/phenylephrine						_						
chlorpheniramine/DM/phenylephrine												
chlorpheniramine/guaifenesin/phenylephine		-										
chlorpheniramine/guaifenesin/pseudoephedrine	-	•		c		_	c	c				
chlorpheniramine/hydrocodone/phenylephnne	5 6	o C	:0	50	<u>: 0</u>	0	56	0	: :	. 0		
chlorpheniramine/nydiocodolie/rsc	00	0	· :	0	0	' :	0	0	: '			
chlorpheniramine/methscopolamine/PPA	0	0	0	0	0	0	0	0	0	0		
chlorpheniramine/methscopolamine/PSE	-	•		•	c			_	c			_
chlorpheniramine/PE/phenyltoloxamine	5 0	<b>&gt;</b> C	:	<b>5</b>	5 6	•	· ;	0		: 0		-100.0
chiorpheniramine/PE/PPA/phenylloloxamine	5 0		: :	; O	0	0	0		0	0		
chloroheniramine/phenyleohine/PPA	5									•		
chlorpheniramine/phenylephrine/PPA/pyrilamine	0	0	0	0	0	0	0	0 0	; •	5 6		
chlorpheniramine/phenylephrine/pyrilamine	:	0	0				5		0			-83.6
clemastine-phenylpropanolamine	; •	; °					:		: :			-100.0
codeine-guaitenesin	•		⊹ 0	<u>:                                    </u>		0	: :	·	0	•		
codeine-oseudoephedrine.	0	0					0					
codeine/guaifenesin/phenylpropanolamine	0	0	; •		00	; °	0 0	<del>-</del>		0 0	===	-1000
codeine/guaifenesin/PSE	<b>5</b> C	<b>-</b>		; 0			0		: 0		-100.0	
codeine/phenvienhine/phenyiephinie/iva duale	•	. 0				:	•					
codeine/phenylephrine/pyrilamine				1	_	•	•	•	•	,		
codeine/pseudoephedrine/triprolidine	0	0		0					•			
dexbrompheniramine-pseudoephedrine	: `	; -		; C	: C	: C	; 0	0	: 0	: :		:
dexchlorphenitamine/gualienesin/r>c	•	•		•								
dexirometropharizations/jaminetrijeenijeenimie dextrometromban-duaifenesin	:	:	0	0	0	:	0	0	0	:		
dextromethorphan-phenylpropanolamine												
dextromethorphan-potassium guaiacolsulfonate						•	_				<del>-</del>	100
dextromethorphan-promethazine	0					0			<b>-</b>		5 F	100.0
dextromethorphan-pseudoephedrine			_		5 6	; <sup>c</sup>	- C	_	:		<u> </u>	200
dextromethorphan/guarienesin/pnenyrepnine	•					0						
dextromethorphat/guaifenesin/pseudoephedrine	:°	-	•	0	0	<b>'</b>	<b>:</b>	0			<del></del>	
dextromethorphan/phenylephrine/pyrilamine												
diphenhydramine-pseudoephedrine								;		•		
ephedrine-guartenesin	:	:	:	:	:	:	:	:				

Table 12.9.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

% change <sup>2</sup> H1 2001,	7007	-100.0																																
% change <sup>2</sup> H2 2001, H1 2002																									_									
Jan-Jun * 2002	00	8	: :		: -	000	5	00	0			0	0			0		<b>5</b>	-	:	: °	0 0	5		-	8	0	0	;				5	Ô
Jul-Dec 2001	0 ::	0	⊃ <u>:</u>		0	00	5	00	:			:	:			0		:		0	: '	5 0	>			0	:	: '	5				:	0
Jan-Jun 2001	00	00	00	0	0	0	:	:	: 0			0	÷		1	<del>-</del>	c	<del>-</del>	_	0 0	5 6	5 6	<del>-</del>			0	0	:	:			c	<del>,</del> –	0
Jul-Dec 2000	00	0	: 0	0	0	: 5	•	: °	0	-		0	:		•	5		<del>-</del>	-	5 6	5 6	<del>-</del> -	<del>-</del>			0 (	<del>-</del>	<del>-</del>	<del>-</del>				•	0
Jan-Jun 2000	00	00	0	0	0	<u>;</u> c	•	00	0			:	:	_	-	5		•	•	5 6	5 C	-	•			<del></del>	5	5	:		_	-	•	0
Jul-Dec 1999	00	0	: :	0	:	00	, ,	50	0			5	:		-	5	0			5	:	<u>. 0</u>	•		•	5 6	5	<u>:</u> c	,—			-6		0
Jan-Jun 1999	00	0	: :	0	0	; <del>o</del>	•	00	0		- (	5	:			5	0			: C	-	0			•	5 6	<b>&gt;</b> C	> ;				0		0
Jul-Dec 1998	00	00	0	0	0	<del>-</del>	C	0	0	_		: =	<del>-</del>		_	:	0			: 0	· :	0			-	<del>-</del> -	<del>-</del>	· :				0	_	0
Jan-Jun 1998	00	0 ;	0	0	0	: :	-	:0	<del>-</del>			:				<del>-</del>	0	_	-	0	:	0			•	5	· c	0				0		0
Jul-Dec 1997	0	0	:	0	i	:0		00	0		-	5				•	0			0	0	0	_		<u> </u>	0	0	0				0		0
Drug name <sup>1</sup>	fexofenadine-pseudoephedrine gualfenesin-hydrocodone gualfenesin-hydromorphone	guaifenesin-phenylephineguaifenesin-phenylpropanolamine	guaifenesin-pseudoephedrineguaifenesin/hydrocodon/heniram/DDA/hydrocodon/heniram/DDA/hydrocodon/	gualfenesin/hydrocodonepheniamine/PE/PPA	guarieriesurviyu occupitelyile prientyle printine	homatropine-hydrocodone	nydrocodone-phenylephrnehydrocodone-phenyloropanolamine	hydrocodone-potassium guaiacolsulfonate	hydrocodone/pseudoepnedrine	hydrocodone/phenylephrine/pyrilamine	nydrocodone/porassium guaracolsulfonate/PSE ibuprofen-oseudoephedrine	loratadine-pseudoephedrine	methscopolamine-pseudoephedrine	naproxen-pseudoephedrine	pheniramine/PPA/phenyltotoxamine/pyrilamine	pheniramine/PPA/pyrilamine	phenylephine-promethazine	pnenyiepnnne-pyniamine pseudoephedrine-terfenadine	pseudoephedrine-triprolidine	upper respiratory combinations-NOS	Respiratory agents NTA	acetylcysteine	alpha 1-proteinase inhibitor	aminophyline/amobarbita/ephedrine	aminophylline/ephedrine/quaifenesin/PB	aminophylline/ephedrine/PB/K iodide	beclomethasone	benzonatate	beractant.	ougesonide calfactant	caramiphen-phenylpropanolamine	codeine/terpin hydrate	COILOSCETIL	GOILOINI

. able 12.9.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S.

## by half year (continued)

1998 1998 1999 2000
0 ::
0 0 0
000
00
0 0
0 0
0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0

This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NOS = not otherwise specified, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). Bureau of the Census.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with Drugs are classified to the degree of specificity recorded in the DAWN case reports. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. for Attanta for the period January-June 2001. For the Attanta contribution to the national estimates, data were imputed for Attanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates <sup>2</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

Table 12.10.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994,	% change <sup>2</sup> 1999,	% change <sup>2</sup> 2000,
Antihistamines	`								LONZ	L002	2001
acetaminonhen/nhen/dnronanolamico/	-	<b>-</b>	-	-	_	-	-	7			
phenytholoxamina											
astemizole	•										
azatadine		: 5	: 0	:	; '	0	0	0	-100.0	-100.0	
bromodiphenhydramine	· _	)		:	0	•	0	0			
brompheniramine	•	c	C	•	Ċ						
carbinoxamine	: C	0 0	<del>,</del>	5 6	>	: 0	0	0			
cetirizine	0	0	<del>-</del>	<del>-</del>	: 0	5 6		: '			
chloropyramine	<b>'</b>	ō	-	<u>:</u> C	<b>5</b> C	576		5			
chlorpheniramine	0	0	0	· c	0	5		5 0			
chlorphentermine	0	<del>-</del>	0	0	0	: -	5	<del>-</del>			
clemastine	0	0	0	•	· ;	o c	:	<u> </u>		1000	
cyproneptadine	•	0	0	•	: :	•	:	5 6	2,400.0	7.707'17	:
desionaladine							:	•			
dexprompheniramine											
dexchlorpheniramine		C	_			_	•				
diphenylpyraline HCI		)	<del>-</del>	•	:	5	5	5			
fexofenadine		_	•								
loratadine	•	0	5 6	: '	5	0	<del>-</del>	0			
meclozine HCI	: <sup>c</sup>	<del>-</del>	5 6	5 (	0	0	0	0	•	_	
methanvillene HCI	>	5	<del>5  </del>	0	0	0	0	0			
methdilazine	:	:	0	0	0	0	0	ō			
Decembers by maken malests	•	_									
no de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta de la constanta della constanta della constanta della constanta della const	5	0 (	:	0	0	:	0	0			-1000
pheniramine	5 0	5 (	0 '	<del>-</del>	0	0	0	0	-100.0		2
pheniramine/nhenythloyamine/minmin	5	5	0	0	0	0	:	:			
phenylologoping	: '	:	:	0	:	0	0	o		-100	
priority (Constitute	<del>-</del>	0	0	0	0	0	0	,		2	
Mondard American	5	0	0	0	0	_	_				
pyricenzamine					-		· -	,			
todosodise				_		_				_	
Maria and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second a second and	<del>-</del>	0	0.	0	0	0	C	_		_	
	<del>-</del>	0	0	0	0	0	0	: 0	:		
upercritical mile	0	0	0	:	0	•	0	0 0			
uipiodalile	0	0	<del>-</del>	0	:	0	0	<del>-</del>		:	
Broadstation and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second a second and cond and cond and a second and a second and	0	0	0	0	0	0	0	)			
	-	_	_	0	0	0	0	. 0	.86.3		
abuter U.	0	0	0	0	0	0	<u> </u>	<del>-</del>	-74.0	•	
	<del>-</del>	<del>-</del>	0	0	<del>-</del>	0	0	0 0			
Allimopriymme.	<del>-</del>	0	<del>-</del>	:	:	0	<del>-</del>	- C	-1000		
						_	•	•	2		
aypnylline	0	:	0	0	0	c					
FORTION OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PAR	_					,	•	:	-	-	
soetharine	:	0	0	0	0	_	-				
Isoproterenol-pnenytephrine	_		_		•	<del>,</del> –	•	5			
levalburerol				_	-						
metaproterenoi	: '	:	0	0	:	:	-			_	
	5	0	0	0	0	0	c	, c	1000		
								,	2.00.		

¹ able 12.10.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>2</sup> 2000, 2001							
% change <sup>2</sup> 1999, 2001	-93.4		508.1				205.2
% change <sup>2</sup> 1994, 2001	-98.7	-64.5 -62.5 -5	-100.0	:			
Total 2001	::00000		000-		• ; • · · · · · · · · · · · · · · · · ·	0 0	000
Total 2000		00000	0 1 00	: °		· · · · · · · · · · · · · · · · · · ·	0 : :
Total 1999		00000000		• 		· · · · · · · · · · · · · · · · · · ·	00
Total 1998	000 :00	:00000	0000	•		° :	: : :
Total 1997	000000	<u> </u>	0000	0 0	000	00	0 : :
Total 1996	000000	<del></del>	0 [ 6 ]	0 0	000	o :	000
Total 1995	0 10 1000	0000000	00 80	0 0	00 ;	00	000
Total 1994	00000	; <del></del> ; 0 ; 0 0 0	0080	0 0	.00	00	: : <sup>0</sup>
Drug name¹	pirbuterol proxyphylline	bronchodilators-NOS	potassium iodide terpin hydrate expectorants-NOS Upper respiratory combinations acetaminophen-chlorpheniramine acetaminophen-dextromethorphan	acetaminophen-pseudoephedrine	ephednne/ipecac/PE	APAP/chlorpheniramine/codeine/phenylephinie—APAP/chlorpheniramine/codeine/phenylephinie—APAP/chlorpheniramine/dextromethorphan/PPA—APAP/chlorpheniramine/dextromethorphan/PSE—APAP/chlorpheniramine/guaifenesin/PPA—APAP/chlorpheniramine/phenylephinie—	APAP/CPliopheniramine/prienylephine/ dextromethorphan/gualfenesin

Table 12.10.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>2</sup> 2000,	2001																				:										-89.2							
% change <sup>2</sup> 1999,	L007				:								-							_	•		-		-100.0		_			_		-		-				_
% change <sup>2</sup> 1994, 2001	1007									_			_			-100 0		_		_	i			-		_	_				-87.0	:						:
Total 2001	0		<del>-</del>		:		-	:		5	i				:	: °	_	-	0	<del>-</del>	:			0	5	-		0	_	-	6	:		_		5	<u>;</u> c	P :
Total 2000	0		00	0	:		:	0		•	i	-		-	5	:0		i	0	5 6	•			00	5			0			<del>-</del> -	:				<del>, -</del>	<u>:</u> C	· i
Total 1999	0	0	0	00	5		0	0	0	i	:			_	<b>O</b> C	0	_	:	: '	5	 :	-		00	5			<del>-</del>		•	5 6	5		_			0 0	0
Total 1998	0	0	_	00	5		0	:	0		0				•	0	-	0	<del>-</del> 0 0	5 6				-	i			0	_	-	5	:			-	•	0	0
Total 1997	0	0	-	0 0	5		i	0	0		:	_			;	0		0 0	5 6	· :				<del>-</del> -	·			0	_	_	:	:			0	:	0	0
Total 1996	0	0		5	:		:	:	0		i				0	0		:	; •	0			C	5	<u> </u>			5	_	_	0	•			0	;	:	0
Total 1995	0	0	00	0			÷	:	0		:			0	0	0	_	:	: c	0	_		C	<b>&gt;</b>	•	_		÷	_		0	1			0	:	:	0
Total 1994	0	0	<del>-</del> -	· :	-	-	0 0	>	0	c	•			:	:	0	-	5	: °	0			•	· :				:	_	<del>-</del> 0	0				0	:	÷	0
Drug name¹	APAP/CPM/phenylephrine/salicylamideAPAP/dexbrompheniramine/oseudoenhedrine	APAP/dextromethorphan/diphenhydramine/PSE	APAP/dextromethornhan/quaifenesin/DDA	APAP/dextromethorphan/gualfenesin/PSE	APAP/dextromethorphan/phenylpropanolamine	APAP/dextromethorphan/PSE/pyrilamine	APAP/dinhenhydramine/nseudoephedrine	APAP/pseudoephedrine/triprollidine	ASA/brompheniramine/dextromethorphan/PPA	ASA/chloroheniramine/dextromethorphan	ASA/chlorpheniramine/phenylpropanolamine	ASA/diphenhydramine/PPA	atropine/CPM/hyoscyamine/PE/PPA/	scopolamine	azatadine-pseudoephedrine	Dromodiphenhydramine-codeine	bromphenizamine-phenylmune	brompheniramine-pseudoephedrine	brompheniramine/codeine/phenylpropanolamine	brompheniramine/dextromethorphan/PPA	prompheniramine/dextromethorphan/PSE	brompheniramine/duatenesin/PPA	PPA	brompheniramine/phenylephrine/PPA	caffeine/pheniramine/PE/Na citrate, salicylat	carbetapentane-chlombonismine	carbetapentane/CPM/enhedrine/nhenylenbine	carbetapentane/quaifenesin/ohenvlenhine	carbetapentane/PE/PA/K guaiacolsulfonate	carbinoxamine-pseudoephedrine	carbinoxamine/dextromethorphan/PSE	Carbinoxamine/hydrocodone/pseudoephedrine	pseudoephedrine.	cetirizine-pseudoephedrine	chlorpheniramine-dextromethorphan	chlomboime-nydrocodone	chloribation - phenylephine	Gilor prieriiraniine-prienyipropanolamine

able 12.10.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued) ERIC

-100.0 95.0 % change 2000, 2001 -79.8 -88.0 475.4 187.7 % change 1999, 2001 -100.0 -96.3 % change <u>\$</u> 2001 Total 2001 :00 ::00 0 Total 2000 000 :::000 Total 1999 00000 0000 000 Total 1998 .0 Ö 00000 00 Total 1997 :::00000 Total 1996 : : Total 1995 00000000 000 ᇹ : : Total 1994 chlorpheniramine/guaifenesin/pseudoephedrine ... chlorpheniramine/phenylephrine/PPA/pyrilamine... dextromethorphan/guaifenesin/phenylephrine ..... dextromethorphan/guaifenesin/pseudoephedrine chlorpheniramine/DM/guaifenesin/phenylephrine.. codeine/pheniramine/phenylephrine/Na citrate .... codeine/pseudoephedrine/triprolidine ...... dextromethorphan/phenylephrine/pyrilamine...... chlorpheniramine/guaifenesin/phenylephrine ...... chlorpheniramine/methscopolamine/PSE ...... chlorpheniramine/PE/phenyltoloxamine ...... chlorpheniramine/PE/PPA/phenyltoloxamine ...... chlorpheniramine/phenylephrine/PPA ...... codeine-guaifenesin..... codeine/guaifenesin/pheny/propanolamine..... codeine/phenylephrine/promethazine ...... codeine/phenylephrine/pyrilamine ..... dextromethorphan-promethazine...... diphenhydramine-pseudoephedrine...... chlorpheniramine/phenindamine/PPA..... dextromethorphan/doxy/amine/phenylephrine.... chlorpheniramine/codeine/PE/K iodide ...... chlorpheniramine/codeine/phenylephrine/PPA .... chlorpheniramine/ephedrine/guaifenesin ...... chlorpheniramine/hydrocodone/phenylephrine .... chlorpheniramine/methscopolamine/PE..... dextromethorphan-potassium guaiacolsulfonate chlorpheniramine/DM/phenylephrine..... chlorpheniramine-pseudoephedrine ..... chlorpheniramine/dextromethorphan/PSE...... clemastine-phenylpropanolamine ...... codeine-promethazine ...... chlorpheniramine/methscopolamine/PPA ...... chlorpheniramine/phenylephrine/pyrilamine...... dexbrompheniramine-pseudoephedrine ...... dextromethorphan-guaifenesin ...... chlorpheniramine/codeine/pseudoephedrine .... dextromethorphan-pseudoephedrine ...... chlorpheniramine/dextromethorphan/PPA...... codeine-pseudoephedrine..... dextromethorphan-phenylpropanolamine ...... dextromethorphan/guaifenesin/PPA ...... chlorpheniramine/dihydrocodeine/PE/PPA .... codeine/guaifenesin/PSE..... dexchlorpheniramine/guaifenesin/PSE.. chlorpheniramine/hydrocodone/PSE Drug name ephedrine-potassium lodide ephedrine-guaifenesin...

Table 12.10.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>2</sup> 2000,																0.001-																	
% change <sup>2</sup> 1999, 2001																					230.5				-100.0								
% change <sup>2</sup> 1994, 2001		-94.9	-62.2			-93.2										_			0 00	9.26.				_		_							
Total 2001	0 :	00	0		0	0	C	5 :	:		-	:	•		Č	5	:			•	0		-		0	: 6	5	:			:		5
Total 2000	0 0	0 :	0		0	; °		: 0	0			:			_ c	•	0			0	0				0	5 6	•	:		_	0	•	5
Total 1999	00		:		:	:0		00	0			: :			c		0			. 0	0			,	0 (	5	<u>:</u> C	-		-	0	•	5
Total 1998	00	° ;	0		0	1 1		:0	0	-		<u>:</u> °					0		0	0	:			_	5 6	5 6	•	:			0	-	5
Total 1997	00	00	:		; c	00		0	0			: :	_				<del>-</del>		-0	0	0			-	5 6	0	· ;	<u> </u>			0		<del>-</del>
Total 1996	00	00	0		00	0	0	0	<del>-</del>			<u>:</u> °			0		0		0	0	0			-	5 6	0	:	!			0	c	,
Total 1995	0	• : ·	0		00	0	0	0	0		0	0			0	•	5		0	0	0				<del>-</del>	0	0			_	0		:
Total 1994	0	000	0		: 0	· :	0	0	0			. 0			0		÷		0	0	<del>-</del>			C	<del>-</del>	· :	:				0		1
Drug name <sup>1</sup>	fexofenadine-pseudoephedrine guaifenesin-hydroxodone guaifenesin-hydromorphone	guaitenesin-phenylephrine	guaireresin/pydrocodon/pheniram/PPA/pyrilamin	gualtenesin/flydrocodone/pheniramine/PE/PPA gualtenesin/flydrocodone/phenylephrine	guaifenesin/hydrocodone/pseudoephedrineguaifenesin/phenylephrine/PPA	homatropine-hydrocodone	hydrocodone-phenylephrinehydrocodone-phenylpropanolamine	hydrocodone-potassium guaiacolsulfonate	hydrocodone/pheniramine/PE/PPA/pyrilamine	hydrocodone/phenylephrine/pyrilamine	ibuprofen-pseudoephedrine	loratadine-pseudoephedrine	memscopolamine-pseudoephedrine	pheniramine/phenyltoloxamine/PSE/pyrilamine	pheniramine/PPA/phenyltoloxamine/pyrilamine	pheniramine/PPA/pyrilaminephenylephrine arrowethazine	phenylephine-pyriamine	pseudoephedrine-terfenadine	pseudoephedrine-triprolidine	upper respiratory combinations-NOS	acetylcysteine	alpha 1-proteinase inhibitor	aminophylline-guaifenesin	aminophyline/enhedrine/onaifenasin/PR	aminophylline/ephedrine/PB/K iodide	beclomethasone	benzonatate	beractant	calfactant	caramiphen-phenylpropanolamine	codeine/terpin hydrate	cromolyn	

able 12.10.0 - ED mentions for respiratory agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>2</sup> % change <sup>2</sup> 1999, 2000, 2001 2001	-100.0
% change <sup>2</sup> % 1994, 2001	-100.0
Total 2001	
Total 2000	00 0 000 10 00 0 1 1
Total 1999	0 0 0 0 0 0 0 0 0 0
Total 1998	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1997	
Total 1996	00 0 00 00 1 1
Total 1995	
Total 1994	
Drug name <sup>†</sup>	cyclopentamine/methapyrilene HCI/ pyrrobutamine dextromethorphan dornase affa dyphylline-guarienesin/PB. ephedrine/guarienesin/theophylline ephedrine/plenobarbital/theophylline ephedrine/plenobarbital/theophylline ephedrine/plenobarbital/theophylline ephedrine/plenobarbital/theophylline ephedrine/plenobarbital/theophylline ephedrine/plenobarbital/theophylline guarienesin-theophylline fluticasone-salmeterol guarienesin-theophylline hexylresorcinol. homatropine ipratropium. ketotifen fumarate montelukast. nedocromil nesirritide nikethamide poractant. zafirukast. zaleuton antiasthmatic combinations-NOS antiussives-NOS leukotriene modifiers-NOS

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an requirements (2002). The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. Drugs are classified to the degree of specificity recorded in the DAWN case reports. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department, NOS = not otherwise specified, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 12.11.0 - ED mentions for cardiovascular agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year

0. 0.	Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001,	% change <sup>2</sup> H1 2001,
	Antiadrenergic agents, centrally acting	0	0	0	0	0	0	0	0	-		Z00Z 1H	H1 2002
	guanabenz	o _	0 0	0 0	00	00	00	0	0	_	00		142.9
	guanfacine	: :	0	:	<del>-</del> :	5 6	5	5	<del>-</del>	0	0		
	metnyidopa	0	:	:	0	· ;	<u>. o</u>	: 0	:-0	; 0	: 0	1000	
	Beta-adreneralic algents, centrally acting-NOS			-					)	•	•	1000	
	acebutolol		5 6	<b>5</b> C	0 0		0	0	0	0	0		
	atenolol	0		5	<del>-</del>	5 6	; °	0 0	:	: '	:		
	betaxolol		•	•	<del>-</del>	5	>	>	0	0	0		
	Disoprolo			_									
	Carbedia			-				_					
	esmolol	5	0	0	0	0	0	0	:	0	0		
	labetalol	0	C	_		c	•		_				
	metoprolol	· :	0	<del>-</del>	<u>;</u> c	<del></del>	5	:	0 (	:	•		
	nadolol	:	<u>'</u> :	:	0	<del>-</del>	; C	: 0	0	: '	: '		
		0	0	0	0	0	0	5 C	; c	5	00	-100.0	
	Denouoloi	0	ô	0	0	0	0	0	•	; C	5 6		
	plikadiol	0	0	:	:	:	0	0	: :	0	5		
	Sotalol	5 6	0 0	<del>-</del>	0	0	0	0	0	· :	:		
	timolol	<b>-</b> C	5 6	<del>-</del>	0 0	: '	:	0	0	0	0	-	
	beta-adrenergic blocking agents-NOS	<del>-</del>	>	5 6	5	0	0	0	0	0	0		
	Calcium channel blocking agents.	0	: 0	o c	: 0	: 0	: 0	<del>-</del>	:	;	:	-	
	amlodipine	· :	ō	0	<del>, -</del>	o c	5	5 6	<u>-</u>	0	0		
	bepridil		)	,	:	5	:	5	:	<del>-</del>	0		
	diltiazem.	0	0	0	-	c		c					
	felodipine	:	0	0	0	<del>-</del>	:	<del></del>	÷	: •	: '		
	Isradipine	0	0	0	· ;	0 0	<u>:</u> C	5	: °	<del>-</del>	5		
	mibefradit				:	5	<del>-</del>	:	5	5	0	-100.0	
	incarupine	0	0	0	0	0	0	0	0			_	
	nimodinine	00	<del>-</del>	: '	0	0	:	:	:	· :	•		
	nisoidipine.	<del>-</del>	5 6	5 6	0 0	0 0	0	0	:	0	0		
	verapamil	0	<del>-</del>	<del>-</del>	5	5 0	<del>5 (</del>	<del>-</del>	0	0	0		-100.0
	calcium channel blocking agents-NOS	0	0	0	; 0	<del>-</del>	5 6	5 6	: "	0 (	<del>-</del>		
	Diuretics	0	0	0	0	<del>-</del> -	o c	5 6	5	<del>- 0</del>	: '	-	
	acetazolamide	:	0	0	0	00	<u>-</u>	<del>-</del>	5 6	5	5		
	hendroftimethisside	0	0	0	0	;	0	0	0	; c	; c	_	
	benzthiazide	-		•			-			1	<del>-</del>		
	bumetanide	5	D	<del></del>	0	0	0	0	0	:	-		
	chlorothiazide	; c	:	5 6	:	<del>-</del>	0	0	0	0	:		:
	chlorthalidone	0	<u>: °</u>	>	<u>:</u> C	5 6	; °	: '	<del>-</del>	0	0		
0 0 0	dichlorphenamide	ı	-	:	<del>-</del>	<b>5</b>	>	5	<b>D</b>	0	0		
0 0 0	etnacrynic acid	-				-				_	_		
	Infosemide	0		0	0	:	0	-			_	-	

coteningus o.o. by nan year (commecu)	Ollenaca)											•
Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change H1 2001, H1 2002
hydrochlorothiazide	0	:		:			:		:			
hydroflumethiazide	0	0	0	0	0	0	00		0			
indapamide	:	0		0		:	5	:	:	:		
mannitol	•	•	C		c		C	_	6		-100 0	-100.0
methazolamide	: -	5 6	<del>-</del>	5 0	0 0	0	0	0	0	0		
metalogounazide		•	<del>, c</del>	0	0	0	0	0	0		-100.0	
		: -		)	•	0	0	0	0			
parnablem	:	,	·	:	:	)	,					
spiropolactona			0	0	0	0	:		0		-55.0	
	0	0	0	0	0	0	0	÷	0	0		
triamterene	0		:	:	:	÷	0		0		-73.3	
trichlormethlazide	-											
urea	:							-				
9	-	:	0	:	0	፥	0	:	:	0		_
Cardiovascular agents NTA	0	-	_	_		Ψ-	<del>-</del>	-	·			9:59
adenosine												
amidenhrine	0	:	0	0	0		:		0			
amiloride-hydrochlorothiazide	0	•	0	0	0		0					
amiodarone	0	0	0	0			0	:	0			_
amlodipine-benazepril.	0	0	0	:	:	0	:		:	0		_
amyl nitrite	·	0	÷	0			0	:	o ¯			•
arbutamine							•	1				
atenolof-chiorthalidoneatenolof-chiorthalidone	<u> </u>	0	:	0	:	0	0	0	: '	•		
benazepril	:	0	፥	:	:	:	:	:	o ¯			
benazepril-hydrochiorothiazide	:		c	C	C		-	•	_	•	100	
bendroffumethiazide-nadolol	<u> </u>	5	>	5	o -		5	> ¯				
bendrottumethlazide-rauwoitia serpentina			c									
bisoproiol-hydrochioromiazide	•	•	<b>5</b> C	: °								
oretyllum			<b>S</b> C	0 0	0	0	0	0	0	•		
calludad tall	:		· ·	•								
cantobril			0	•				•				
cantonii-hvdrochlorothiazide	0	0	:	0	0	0	0	0	•	0		
chlorothlazide-methyldopa												
chlorothiazide-reserpine	-	0	0	0	0	0	0	0	0	-		
chlorthalidone-clonidine												
chlorthalidone-reservine							_	_	-			
cilostazol												
cyclandelate	0	0	0	0	0	0	0	0	0	:		
deseroidine	-											
deserpidine-hydrochlorothiazide												
deserpidine-methyclothiazide	•											
destanoside	0	•	<del>-</del>	0	0	0	5	5	<b>5</b>	_		
diazoxide	-										_	
digitoxin	-						_		_	_		
		_		_		_		_		_	-	

Table 12.11.0 - ED mentions for cardiovascular agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued) T-374

Jul-Dec 1997
i
00
0
0
0
0
.000
:00
0000
0
000 :00

ible 12.11.0 - ED mentions for cardiovascular agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

Drug name¹	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>2</sup> H2 2001, H1 2002	% change <sup>2</sup> H1 2001, H1 2002
losartan mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylamine mecamylam	0	:	:	0	0	i	i	0	:	0		424.3
mepnemermine												
methycothiazide-reserpine												
metylosine metyletine	0	0	0	0	0	0	0	0	:	0		
militione militione	00	00	00	00	00	00	00	00	00	: 0	-100.0	
moexipril.	000	000	000		000	000	000	0	· ; c	<u> </u>		
mondizine	<b>-</b>	•	<b>&gt;</b> (	•	•	•	<b>o</b> (	: (	•	<b>-</b>		
nitroglycerinnitrogramskide	÷	:	0	:	:	:	5	0	:	5		
norepinephine	00	00	00		00	00		00	00	0 :		
papacerine	000	000	000	0	00	00	00	00	00	00		
pergyinte pentaerythritol chloral	•	•	•			•	•	,				
pentaerythritol tetranitrate												
phenoxybenzamine	0	0	0		0	0	0	:	0	0		
phentolaminephentolamine one will be a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second a second and a second and a second and a second and a second a second and cond and	00	0 0	00	00	00	50	50	;°	50	50		
polythiazide-prazosin.	c		•		-	C	c		c	· c		
polymazide-reserpine prazosin	00	: :	• •	? :		•	00	00	00	•		
procalnamide	00	: `	; C		00		0	00	0 0	00	-100 0	
quinapril	00	•		.0			: :	0	· :	•		
quinidine	0	0	0		:	:	: 0	;	;	0		
ramiprii rauwolfia serpentina	o	:			:	:	>	:	:	:		
rescinnamine	(	•	•					•	c	•		
reserpinereserpine-trichlormethiazide	0	0	0	-	00	; °	:0	00	0	00		
sodium tetradecyl sulfate	c	- c	_	C	c	0	0	:	0	0	-100.0	
telmisartan	•	•	•				•	•				
terazosin	i	0 0	0 0	: °	0 0	0	00	00	00	; `		
tolazoline	i	>	<b>&gt;</b>			5	5	5	•	•		
trandolapril	0	0.0	00	-	00	0 0	00	<del></del>	00	; =	-1000	
trimethabhan camsylate	•	•					•	•	5	•		
valsartan	0	٥	0	0	0	0	0	:	<u> </u>	0		

## Table 12.11.0 - ED mentions for cardiovascular agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by half year (continued)

in Jul-Dec Jan-Jun * % change % change 2001 2002 H1 2001, H1 2001	
Jan-Jun 2001	00 00
Jul-Dec 2000	00 00
Jan-Jun 2000	
Jul-Dec 1999	,
Jan-Jun 1999	00 00 0
Jul-Dec 1998	00 00
Jan-Jun 1998	00 00 0
Jul-Dec 1997	00 00 0
Drug name¹	veratrum alkaloids.  agents for hypertensive emergencies-NOS. angiotensin converting enzyme inhibitors-NOS. angiotensin II inhibitors-NOS. antidrenergic agents, peripherally acting-NOS. antiandinal agents-NOS. antihypertensive combinations-NOS. cardiovascular agents-NOS. inotropic agents-NOS. peripheral vasodilators-NOS. vasonressors-NOS.

This classification of drugs is derived from the Multum Lexicon, Copyright © 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2002). \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. The Multum Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multum.com.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NOS = not otherwise specified, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with Drugs are classified to the degree of specificity recorded in the DAWN case reports. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce estimates 2 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. Bureau of the Census,

The stimated rates per 100,000 population for the cardiovascular agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year

Antiadrenergic agents, centrally acting  clonidine  guandacine  methyldopa  antiadrenergic agents, centrally acting-NOS  Beta-adrenergic blocking agents  acebutolol  bisoprolol  carvedilol  esmolol  metoprolol  metoprolol  carvedilol  penbutolol  propranolol  propranolol  propranolol  beta-adrenergic blocking agentsNOS  Calcium channel blocking agents  calcium channel bl	0 <sub>   </sub> -00 0 00 000-0		000 ; +00 0 00 ;00 ;00		000   0 +   0 0   000000	0 0 - 10 0 000 1 10 C	9. 8.	-65.1	56.2 51.2 51.2
· · · · · · · · · · · · · · · · · · ·	-0;; -00 0 00;000-0			-000 -00 0 00 i00 i	00 <u>10 + 1</u> 0 0 100000	-0 <u>10 - 10 0 000   100</u>	.94.8 	-65.1	58.9 -51.2
· · · · · · · · · · · · · · · · · · ·	o ; ;	_		000 -00 000 100 1	o ; o + ; o o ; o o o o o	<u> </u>	.94· 8.	-65.1	-51.2
· · · · · · · · · · · · · · · · · · ·	;;			00 -00 00 100 1	;0 + ;0 0 ;00000	10 - 10 0 000 1 100	.94.8	-65.1	-51.2
· · · · · · · · · · · · · · · · · · ·	; -00 0 00 <u>1</u> 000-0			0 00 00 100 1	<del>0                                    </del>	<del>0                                    </del>	φ. φ.	-65.1	515 -
· · · · · · · · · · · · · · · · · · ·	-00 0 00 <u>000</u> -0	·		-00 0 00 i00 i	<del>+   0                                  </del>	<del>-</del>   0 0 0 0     0 0		-65.1	
: : : : : : : : : : : : : : : : : : :	-00 0 00 <u>1</u> 000+0	·		-00 0 00 ;00 ;	- <sub> </sub> 0	<del>-</del>		-65.1	
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	0 00 1000+0	·		0 00 ;00 ;	; O O ; O O O O O	10 0 000 1 100		-65.1	
: : : : : : : : : : : : : : : : : : :	· · · · · · · · · · · · · · · · · · ·	·	·	0 00 ;00 ;	o ;00000	<u> </u>		-65.1	
: : : : : : : : : : : : : : : : : : :	0 00 ;000+0	·	·	• •• ;•• ;	o ;00000	0 000     00		-65.1	
: : : : : : : : : : : : : : : : : : :	0 00 ;000+0	·	, ,	° °° ;°°° ;	o ;00000	0 000 ; ;00		-65.1	
: : : : : : : : : : : : : : : : : : :	0 00 ;000-0	·		° °° ;°° ;	0 ;00000	0 000 ; ; 00		-65.1	
· · · · · · · · · · · · · · · · · · ·	00 000-0	·		· •• ;•• ;	,00000	· • • • • • • • • • • • • • • • • • • •		-65.1	
: ; : : : : : : : : : : : : : : : : : :	00 :000-0	·		°° ;°° ;	;00000	000 : 100		-65.1	
: : : : : : : : : : : : : : : : : : :	000-0	·		, o i o o	;00000	000 ; ;00		3	
· · · · · · · · · · · · · · · · · · ·	· ;000+0	·	•	·	0000	00    00			
: : : : : : : : : : : : : : : : : : :	:000-0			;°° ;	0000	; ; 00			
: 	00-0		·	o	000	: :00			
: 	0-0		·	· :	000	; 0 0			
: 	<del>0 - 0</del>			:	5 0	5 6			
: 	- 0			: 0					
: : : : : : : : : : : : : : : : : : : :	5			5	>	<del>-</del>	0.00		
:	_			: °	: °	<b>5</b> (			
:	<del>5 (</del>	:		5	5	5			
:: <sup>-</sup> ::::::::	5,			; `	;`	: `	1		
	_			- 0	<del>- (</del>	- 0	-52.6		
	:	: 5	5	5	0	o	1,859.0		
	•			•					
	0			0	0	0	-62.9		
	:	0	0	0	:	0	172.4		
. : : :	<del>-</del>			:	÷	0	-95.0		
	•								
: :	<del>-</del>			0	: '	0	-100.0		
	<del>-</del>			0	0	0	-74.4		
•	0	0	0	0	<del>-</del>	:			
-	0			0	0	0			
•	0			0	0	0			
:	0			<del>-</del>	0	0	-100.0	-100.0	-100.0
•	_			0	0	0			
•	0	<u>-</u>		0	÷	;			
amiloride	<del>-</del>			;	0	0			
•									
benzthiazide0	0	: 0	0	0	0	0			
:	:		:	0	0	0	-83.5		
:	÷	:		0	0	0		-100.0	-100.0
chlorthalidone0	0			0	0	0	-100.0		
dichlorphenamidedichlorphenamide				•					
ethacrynic acid									
furosemide	0	<u>-</u>	0	0	0	0			

Table 12.12.0 - ED mentions for cardiovascular agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued) T-378

Drug name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change² 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
hydrochlorothiazide hydroflumethiazide indanamide	000	000	00	0	:00	000	00	° ;			, i
mannitol			:	:	5	5	:	:			
methazolamide	00	: 0	0 0	: `	0 0	0	0	0	81.6		
metolazone	;	- 0		5 0		0 0	0	0 0			
pamabrom	0	` : 	0	0	; °	· ;	: °	00	-100.0		
polyulaziuespironolactone		C				c					
torsemide	0	0	: °	; 0	00	50	; °	: :			
triamterene	0	:	0	:	÷	:	<u> </u>	: :			
diuretics-NOS.	0	0	0	-	_ c	C					
Cardiovascular agents NTA	2	2	<del>-</del>	<del>-</del>	<del>-</del>	0	7	: -	-36.8		
adenosine						_	•				
amidephnne	0	0	0	0	0	0	:	0		-100.0	
amiionde-nydrochloromiazide	; °	0		0 0	; 6	<del>-</del>	0	:			
amlodioine-henazenril	<b>-</b>	; <sup>c</sup>		5 0	5 0	<del>-</del>	0	; '			
amyl nitrite	0	0	0	<del>-</del> -	>	; =	; c	5			
arbutamine		1		•	:	•	•	:		:	
atenolol-chlorthalidone	:	0	:	0	:	-	0				
benazepril	0	:	0	:	:	0	0	: :	_		
benazepril-hydrochlorothiazide						'					
bendroffumethiazide-nadolol.	:	0	0	0	0	0	0	0			
bendroflumethiazide-rauwolfia serpentina	,										
Disoprolutivarochioromiaziae	5 6	: '		0	0	:	:	;	•		
Candesartan	5	5 6	5 0	0 0	0 0	0 0	<del>-</del>	: 6			
candesartan-hydrochlorothiazide.	•	<del>-</del>		•	<del>-</del>	5	5	5			
captopril		ō	:	C							
captopril-hydrochlorothiazide	0	0	: :	0	: :	. 0	O	<u>.</u>	-1000		
chlorothiazide-methyldopa					_	-	'	ı			
chlorothiazide-reserpine	ō	0	0	:	0	0	0	0			
chlorusalidone-resemine											
cilostazol						_		-			
cyclandelate											
deserpidine	0	0	0	0	0	0	0	0	-100.0		
deserpidine-nydrochiororniazide							-				
deslanosidedeslanoside	c		c	_	<u> </u>		c				
diazoxide	)	•	<del>-</del>	<del>-</del>	•	•	<del>-</del>	5			
digitoxin											
digoxin	0	0	0	0	0	:	0	0	_	_	
dittazem-enalaprit			1								

able 12.12.0 - ED mentions for cardiovascular agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

Dng name¹	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>2</sup> 1994, 2001	% change <sup>2</sup> 1999, 2001	% change <sup>2</sup> 2000, 2001
disopyramide dobutamine	: :		0		0		: 0	:.0			
dofetilide		•				•	(				
dopamine	: :	0	0	:0	50	<b>&gt;</b> :	50	5	,		-100.0
edetate disodium (EDTA)						1	1				
enalapril.	0	0	0	0	0	0	0	:	:		
enalaprii-leiooipiile enalaprii-hydrochlorothiazide	0	0	0	:	:	0	:	0			
ephedrine	•	-	_	0	0	0	00	0	-66.8	-	
epinephineepinesartan	:	:	:	:	:	0	5	0		763.2	
erythrityl tetranitrate.	0	0	0	0	0	0	0	- <del>-</del>			
ethaverine	0	0	:	0	0	0	0	0			
fenoldopam											
flecainide	; c	0	0	00	: `	0 0	; °	; °			
fosinoprii-hydrochlorothiazide	>	:	•	•	>		>	5			
guanadrel											
guanethidine	0	0	0	:	0	0	0	0			
guanethidine-hydrochlorothiazide		•		c				-			
flydfalaziflehvdrochlorothiazida	; C	0	<del>-</del>	5 6	; C		; C	5			
hydralazine/hydrochlorothiazide/reserpine	0	0	_	0	0		0	:0			
hydrochlorothiazide-irbesartan	0	0	0	0	0		0	0			
hydrochlorothiazide-lisinopril	:	0	0	0	:		0	0			
hydrochlorothiazide-losartan	0	0	0	0 (	0	0	0	0			
hydrochlorothiazide-methyldopa	0	0	:	0	0		0	0			
nydrochlorothiazide-metoproiolhvdrochlorothiazide-moexipril											
hydrochlorothiazide-propranolol	0	0	0	0	0	0	0	:			
hydrochlorothiazide-quinapril											
hydrochlorothiazide-reserpine	:	0	0	0 (	0	0	0	0			
hydrochlorothiazide-spironolactone	:	:	0	0	:	0	0	:			
nydrochiotothiazide-telimisarianhvdrochlorothiazide-timoloi											
hydrochlorothiazide-triamterene.	0	0	0	:	;		:				
hydrochlorothiazide-valsartan	0	0	0	0	0	0	0	0			
hydroflumethiazide-reserpine											
ibutilide			_								
naminone	c	c	•	c	c	C	•				
isoproferenci	5 6	>		5 0	<b>-</b>	<del>-</del>	5 6	: C			
isosorbide dinitrate	0	. 0	0	0	• :		0	•			
isosorbide mononitrate	0	:					0	:			
isoxsuprine	0	0	0	0	0	: '	0	0			
IISINOPFII	2	ס					Ī	5			ŀ

Table 12.12.0 - ED mentions for cardiovascular agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued) T-380

Desartan	0 0 : 000 0 000	0 0 000 0 00 ::	0 0 1 000 1 00	0 0 0 000 0	0 0 0 000 ; 0		; 0 ; 0 ; ; 0	-100.0		
	0000000	0 0 000 0 00 ; ;	o ; 000 ; 00	0 0 000 0 000	0 0 000 1	0 0000	0 : 0 : : 0	-100.0		
	: 000 0 000	0 000 0 00 ; ;	, 000 , 00	0 000 0 000	0 000 ;	0 000 0	: 0;;			
	: 000 0 000	0 000 0 00 ; ;	: 000 ; 00	0 000 0 000	0 000 ; 0	0 000 0	: 0;:; 0			
	000 0 000	000 0 00 <sub>   </sub>	000 ; 00	000 0 000	000 ;	000 0 ;	• • • • • • • • • • • • • • • • • • •	_		
	000 0 000	000 0 00 ; ;	000 : 00	000 0 000	000 : 0	000 0 :	° ; ; ; °			
	00 0 000	00 0 00 ; ;	00 ; 00	00 0 000	00 ;	00 0 :	; ; ; °		-	
	000	0 00 ; ;		0 000	) ; c	0 0 :	: ; O			
nitroglycenn	0 000	· · · · · ·	; 00	0 000	; 0	O :			-	
nuroprusside	000	00 ; ;	00	000	c	:	0			
pagaverine pagaverine pagaverine pagaverine pagaverine pagaverine pentaerythritol chloral pentaerythritol tetranitrate pentaerythritol tetranitrate phenoxpenzamine phenoxpenzamine polythiazide-prazosin polythiazide-prazosin polythiazide-prazosin pentaerythritol pentaerythrine polythiazide-prazosin polythiazide-prazosin pentaerythrine pentaerythrine polythiazide-prazosin pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaerythrine pentaery	000	<del></del>	5 6	<del>5 0 0</del>		:	0	_		
papaverine 0 pargyline 0 pargyline 0 pentaerythritol chloral 0 pentaerythritol tetranitrate 0 phendopril 0 phenotylephrine 0 phenotylephrine 0 phenylephrine 0 pholythiazide-prazosin 0 prazosin 0 procainamide 0 propafenone 0	0	· : :		0	<del>-</del> -	2	2	_	-100.0	
pargyline		:	· :	-	0	0	0			-100.0
portate yunion crioral. peridaepythriot branitrate peridaepythriot branitrate peridaephine polythiazide-prazosin polythiazide-reserpine procariamide propafenone.	0	:	<del>-</del>	0	0	0	0			
perindopril			_							
phenoxybenzamine         0           phenticlamine         0           phenylephrine         0           polythiazide-prazosin         0           prazosin         0           prozosin         0           procainamide         0           propafenone         0           quinapril         0										
phentolamine 0 phentolamine 0 phenylephrine 0 polythiazide-prazosin 0 prazosin 0 procainamide 0 propafenone 0 quinapril 0	0	0	0	0	0	0	0			
polythiazide-prazosin	0 (	0	0	0	0	0	i			
polythiazide-reserpine 0 prazosin 0 procainamide 0 propafenone 0 quinapril 0	0	:	0	<del>-</del>	0	0	0			-100.0
prazosin 0 procainamide 0 propafenone 0 quinapril 0		0	0	-	-	c	c			
procainamide 00 propafenone 00 quinapril 00 00 00 00 00 00 00 00 00 00 00 00 00	<b>'</b> :	0	0	: :	· :	•	0	6 06-		
propatenone 0 quinapril	0	:	0	:	0	: :	0	-100.0		
dainapril	0	:	0	0	0	:	0	-69.7	-68.0	
	0	<u>:</u> c	0 0	: 0	:	:	Ö			
ramipril	:	<del>-</del>	<del>-</del>	<b>5</b>	:	:	:			
	•	•	<del>, -</del>	:	ŧ	:	:			
rescinamine	•				•	_				,
reserpine-trichlormethiazide	5 6	<del>-</del>	; =	5 6	<del></del>	; c	8 6			
sodium tetradecyl sulfate	•	<del>-</del>	<del>-</del>	•	5	>	5			
lamsulosin 0	0	0	0	0	0	0	0			
terazosin								- 000		
tocainide	:0	; O	: :	00	:0	50	50	490.3		
tolazoline		,		1		)	•			
trandolabril-verapamil	<del>-</del> -	0 0	0 0	00	0 0	0 0	00			
trimethaphan camsylate	•	<del>-</del>	•	•	5	>	5			
valsartan0	0	0	0	0	0	0	0			

Fable 12.12.0 - ED mentions for cardiovascular agents by drug category: Estimated rates per 100,000 population for the coterminous U.S. by year (continued)

% change <sup>2</sup> 2000, 2001	[
% change <sup>2</sup> 1999, 2 <b>00</b> 1	
% change² 1994, 2001	
Total 2001	0 : 0 :
Total 20 <b>00</b>	00 0
Total 1999	00 0
Total 1998	00 0
Total 1997	00 0
Total 1996	00 0
Total 1995	00 0
Total 1994	00 0
Drug name¹	agents for hypertensive emergencies-NOS anglotensin converting enzyme inhibitors-NOS anglotensin I inhibitors-NOS.  anglotensin II inhibitors-NOS.  antiadrenergic agents, peripherally acting-NOS antiarginal agents-NOS.  antiarrythmic agents-NOS.  antitypertensive combinations-NOS.  cardiovascular agents-NOS.  inotropic agents-NOS.  peripheral vasodilators-NOS.  vasodilators-NOS.

requirements (2002). The Multurn Licensing Agreement governing use of the Lexicon is provided in an appendix to this report and can be found on the Internet at http://www.multurn.com. 1 This classification of drugs is derived from the Multum Lexicon, Copyright @ 2002, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique <sup>2</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Eπor (RSE) tables for ρ-values.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department, NOS = not otherwise specified, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 13.1 - ED drug episodes: Estimated rates per 100,000 population by metropolitan area by half year

% change <sup>1</sup> H1 2001, H1 2002		I	_				-23.0												-13.1		-543	
% change <sup>1</sup> H2 2001, H1 2002					39.7		-15.7												4	-17.9	-5.	-18.0
Jan-Jun * 2002	121	178	256	235	265	236	28	153	202	131	226	128	186	180	213	303	176	213	126	228	123	101
Jul-Dec 2001																				•		124
Jan-Jun 2001	124	1	268	231	208	285	110	140	232	143	210	124	163	203	212	285	172	171	145	268	270	129
Jul-Dec 2000	120	200	240	200	151	257	132	149	191	141	225	109	191	187	202	242	221	131	139	224	271	130
Jan-Jun 2000	124																					
Jul-Dec 1999					155																	
Jan-Jun 1999	115	177	305	155	128	211	126	142	190	117	178	101	192	180	225	258	198	134	135	263	203	130
Jul-Dec 1998	112	188	314	187	148	226	146	130	210	106	171	88	193	215	240	258	161	120	142	280	192	146
Jan-Jun 1998	113	202	278	183	135	219	149	129	199	96	168	95	230	216	258	268	<b>18</b>	121	151	289	241	156
Jul-Dec 1997	110	146	267	160	132	240	136	143	195	100	162	102	219	219	266	251	177	120	155	303	287	146
Меtropolitan area	TOTAL COTERMINOUS U.S	Atlanta	Baltimore	Boston	Buffalo	Chicago	Dallas	Denver	Detroit	Los Angeles	Miami	Minneapolis.	New Orleans	New York	Newark	Philadelphia	Phoenix	St. Louis	San Diego	San Francisco	Seattle	Washington, DC

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (ho < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values.

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.2 - ED drug episodes: Estimated rates per 100,000 population by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
TOTAL COTERMINOUS U.S.	225	221	218	221	225	228	243	252	11.7	10.4	3.5
Atlanta	405	416	349	294	390	367	394	397	-2.0	8.0	9.0
Baltimore		712	705	226	592	605	483	505	-29.3	-16.5	
Boston	_	449	375	335	370	313	393	472		50.9	20.2
3uffalo	303	296	387	300	283	283	297	398			
Chicago	381	384	408	462	445	440	502	558	46.5	26.9	
Jalias	219	221	208	257	295	254	272	210	4.4		
Jenver	328	302	221	278	259	302	306	281		-7.0	-8.0
Detroit	432	451	498	417	409	374	388	463			
os Angeles	237	235	245	205	202	242	291	288		19.1	
/diami	326	351	339	335	339	372	439	430	31.9	15.7	
Minneapolis	192	188	208	211	183	194	214	251	30.7	29.1	17.2
Vew Orleans	412	202	497	438	423	367	378	324	-21.4		-14.4
Vew York	536	204	464	448	431	362	370	387	-27.9		
Vewark	547	626	264	200	497	457	419	417		-8.6	
Philadelphia	391	448	467	496	526	510	481	573	46.4		
Phoenix	348	400	372	363	346	402	433	354	1.9	-12.0	
St. Louis	265	246	566	241	240	264	283	358			
San Diego	220	201	248	286	293	292	290	276	25.8		4.8
San Francisco	794	629	611	298	269	555	480	546	-31.3		13.6
Seattle	295	456	449	556	433	434	263	538		24.0	
Washington, DC	386	319	313	295	303	266	262	253			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

### Table 13.3 - ED drug mentions: Estimated rates per 100,000 population by metropolitan area by half year

% change¹ H1 2001, H1 2002					33.8		-25.8													-19.9		
% change¹ H2 2001, H1 2002					48.4		-19.1							_								-18.2
Jan-Jun * 2002	220	344	478	420	495	418	151	256	398	242	414	242	351	281	378	562	300	393	215	346	219	171
Jul-Dec 2001	234	348	429	434	333	485	187	248	455	268	397	240	305	294	358	534	320	367	222	442	480	210
Jan-Jun 2001	225	I	473	400	370	503	204	236	438	254	374	233	305	328	369	536	304	328	246	432	447	209
Jul-Dec 2000	219	395	428	349	283	474	245	259	368	249	393	208	378	306	338	460	379	254	232	354	471	206
Jan-Jun 2000	226	383	407	333	268	443	255	271	379	271	370	208	365	306	369	452	357	291	244	390	491	206
Jul-Dec 1999	207	367	522	287	282	420	230	278	339	225	334	187	356	302	386	476	341	239	267	423	382	221
Jan-Jun 1999	210	335	536	282	232	382	235	239	361	207	300	188	378	296	383	478	340	247	233	366	331	217
Jul-Dec 1998	203	347	545	341	273	416	270	229	387	190	288	162	373	351	405	474	288	226	245	384	318	240
Jan-Jun 1998	205	387	470	332	247	405	280	225	376	163	279	180	430	346	439	489	314	224	266	402	406	257
Jul-Dec 1997	197	296	461	291	248	451	250	247	361	170	264	190	415	358	449	465	311	226	569	436	497	249
Metropolitan area	TOTAL COTERMINOUS U.S.	Atlanta	Baltimore	Boston	Buffalo	Chicago	Dallas	Denver	Detroit	Los Angeles	Miami	Minneapolis	New Orleans	New York	Newark	Philadelphia	Phoenix	St. Louis	San Diego	San Francisco	Seattle	Washington, DC

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Attanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

Table 13.4 - ED drug mentions: Estimated rates per 100,000 population by metropolitan area by year

TOTAL COTERMINOUS U.S	387 385 838 709 1,209 1,194 840 689	35 396	986	3	2000	2001	2001	2001	2000, 2001
791 1,212 802 527 660 397			408	417	445	460	17.6	10.5	3.4
1,212 802 527 660 397 550			734	702	778	748	, ru	i c	ţ
802 527 660 397 550			1,015	1,058	834	903	-25.5	-14.6	82
527 660 397 550			673	269	682	835	Ì	46.7	22.4
997 397 550			520	514	551	703		•	į
397			821	802	917	988	49.7	22.8	
220			550	465	499	391	-1.6		
			455	517	529	484		ç	κ
775			763	200	746	893		<u> </u>	9
408			352	433	519	522	27.9	20.7	
223			292	634	763	77.1	47.4	21.5	
370			342	374	416	473	27.9	26.4	13.8
821			803	734	743	611	-25.7	-16.8	-17.8
798			697	298	612	623			2
962	_		844	769	200	728			
200			962	954	912	1,071	53.0		
284			602	681	737	625	2.0	-8.2	-151
484			420	486	545	969			
378			511	200	476	467	23.7		
1,189			786	789	744	874	-26.5		17.5
096			723	713	961	927		30.0	2
. 686			497	438	413	419			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

# Table 13.5 - Alcohol-in-combination: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>†</sup> H2 2001, H1 2002	% change <sup>†</sup> H1 2001, H1 2002
TOTAL COTERMINOUS U.S.	36	38	39	42	39	41	42	42	44	38	-14.1	
Atlanta	83	92	78	81	97	110	118	i	9	87		1
Baltimore	63	26	9/	81	71	20	9	67	9	99		
Boston.	63	69	02	9	29	63	89	92	87	73		
Buffalo	65	62	72	29	89	65	78	96	87	147	68.3	53.0
Chicago	06	77	8	75	80	8	88	88	87	83		
Dallas	35	4	43	36	32	37	38	30	27	21	•	-29.4
Denver	20	47	51	22	28	25	51	4	25	51		
Detroit	92	95	92	82	82	97	96	105	114	66		
Los Angeles.	27	31	4	4	52	99	9	09	29	19		
Miami	20	22	25	4	74	78	\$	86	92	96		
Minneapolis.	8	33	9	용	36	98	37	43	43	42		
New Orleans	83	87	73	79	78	8	77	3	49	28		
New York.	06	83	98	72	74	72	73	75	29	9		
Newark	87	83	75	92	99	29	26	09	99	29		
Philadelphia	80	88	91	9	93	82	98	101	104	106		
Phoenix	64	62	45	48	45	25	28	46	46	35		-23.8
St. Louis.	43	4	4	4	4	52	47	62	92	61		
San Diego.	42	4	37	8	40	33	33	32	8	32	4.4	
San Francisco	4	25	47	51	52	99	72	65	72	45		-30.2
Seattle	82	65	51	53	61	78	83	69	78	37		-46.5
Washington, DC	43	4	41	တ္တ	35	23	9	31	35	29		
		1						7	1			

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.6 - Alcohol-in-combination: ED mentions: Estimated rates per 100,000 population by metropolitan area by

% change <sup>1</sup> 2000, 2001				24.2								17.4	•				-16.1					13.7
% change <sup>1</sup> 1999, 2001		5.8	-16.9	37.0					31.3		29.1	22.6	-35.1		-10.9		-0.7			29.4	28.3	
% change <sup>1</sup> 1994, 2001	23.1		-39.5			34.2	4.0				111.8	37.6	-55.1			50.0	-9.7			-28.8		-50.5
Total 2001	88	189	127	163	183	176	58	96	219	127	178	98	102	141	117	205	92	138	99	137	147	67
Total 2000	83	228	110	131	143	169	75	109	193	127	162	73	158	145	115	171	110	102	99	110	161	28
Total 1999	81	179	152	119	127	155	89	107	167	96	138	20	158	146	131	\$	8	82	75	106	115	7
Total 1998	11	170	133	139	134	158	83	86	187	72	112	63	160	169	157	181	106	88	79	100	115	82
Total 1997	72	173	147	134	154	178	99	86	187	26	104	72	166	177	167	160	125	8	76	123	157	82
Total 1996	71	228	193	148	198	139	28	77	218	89	91	69	209	196	225	147	130	98	76	139	114	96
Total 1995	72	294	212	176	124	139	28	107	203	89	92	62	241	167	233	150	139	87	61	167	122	8
Total 1994	20	265	209	167	123	131	28	108	183	69	\$	63	228	<u>2</u>	187	137	102	8	09	193	157	134
Metropolitan area	TOTAL COTERMINOUS U.S	Atlanta	Baltimore	Boston	Buffalo	Chicago	Dallas	Denver	Detroit	Los Angeles	Miami	Minneapolis	New Orleans	New York	Newark	Philadelphia	Phoenix	St. Louis	San Diego	San Francisco	Seattle	Washington, DC

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

### Table 13.7 - Cocaine: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>†</sup> H1 2001, H1 2002
TOTAL COTERMINOUS U.S.	35	36	36	33	37	35	36	38	38	36		
Atlanta	74	114	\$	68	9	101	120	3 1	117	110		ı
Baltimore	132	137	159	148	148	100	108	112	102	121	18.1	
Boston	46	26	29	46	49	20	28	49	74	70		
Buffalo	89	2	65	52	65	45	09	74	7.1	86		
Chicago	125	117	114	<u>5</u>	122	122	124	142	134	112		-21.4
Dallas	40	25	\$	41	4	45	43	31	26	21	-18.8	-33.3
Denver	37	32	4	4	45	42	41	33	36	47	30.1	44.3
Detroit	82	86	5	88	6	93	87	101	82	67	-21.0	-33.4
Los Angeles	29	31	37	37	42	8	51	8	62	7		į
Miami	88	93	8	86	112	110	114	107	118	120		
Minneapolis	16	17	16	17	17	17	18	18	25	26		45.0
New Orleans	9	109	8	89	87	77	85	09	63	09		
New York	120	120	114	88	87	81	82	6	76	75		
Newark	109	106	102	98	88	79	89	77	75	95		
Philadelphia	123	140	135	130	130	110	106	127	125	137		
Phoenix	33	37	36	42	49	41	44	30	31	27		
St. Louis	8	43	44	49	48	52	47	63	7.1	79		
San Diego	19	19	21	18	27	20	21	18	15	15		-12.8
San Francisco	62	22	28	48	72	99	29	78	80	61	-23.6	-22.3
Seattle	83	99	9	26	73	8	88	78	.80	28	58.5	-67.4
Washington, DC	43	20	48	38	43	35	37	35	35	25	-29.0	-29.5

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimates for Attanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

Table 13.8 - Cocaine: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
TOTAL COTERMINOUS U.S.	62	28	65	89	71	69	7.1	9/	22.3	9.7	7.6
Atlanta	235	245	202	156	218	189	221	244	3.8	29.3	10.4
Baltimore	400	384	376	273	296	292	208	214	46.5	-27.5	
Boston	136	147	114	91	123	95	108	138		44.8	27.9
Buffalo	125	145	238	163	129	117	104	145			
Chicago	190	188	220	247	232	225	246	27.7	45.5	22.9	
Dallas	62	62	28	74	106	98	87	57	-7.2	-33.3	-34.5
Denver	28	75	23	69	73	87	83	69			
Detroit	203	212	250	192	202	178	179	186			
Los Angeles	62	61	69	29	89	62	105	117	87.5	47.5	
Miami	152	168	168	174	187	210	225	225	48.1		
Minneapolis	25	20	29	31	33	34	35	43	72.0	24.8	22.7
New Orleans	<u>\$</u>	174	202	199	199	176	162	123	-24.6	-30.0	-23.8
New York	251	243	564	244	233	175	166	166	-33.8		
Newark	246	268	253	201	208	172	147	152		-11.4	
Philadelphia	187	208	224	239	275	260	216	252			
Phoenix	8	29	69	99	73	94	82	62	14.0		
St. Louis	102	8	8	64	87	97	86	134			
San Diego	29	28	33	36	41	44	41	32		-27.1	-21.4
San Francisco	211	166	148	126	116	120	126	158	-25.3	31.3	25.8
Seattle	<u>\$</u>	116	114	150	125	130	169	160		23.0	
Washington, DC	132	96	104	82	97	8	72	69	-47.5		
	1		_								

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

### Table 13.9 - Heroin: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

nge <sup>1</sup> % change <sup>1</sup> 01, H1 2001, 02 H1 2002	0	-25.1			42.4	33.4						_		-26.4		4.8		-53.6 -48.3	
% change H2 2001, H1 2002																			
Jan-Jun * 2002			60																
Jul-Dec 2001			38																
Jan-Jun 2001		_	57									•							
Jul-Dec 2000	19	105	3 54	104	0 5	38	16	39	5	41	65	113	49	20	2	18	77	22	52
Jan-Jun 2000	0,0	122	38	102	= 8	38	21	35	4	38	63	125	47	20	23	24	92	72	25
Jul-Dec 1999			<del>2</del> 8																
Jan-Jun 1999			37																
Jul-Dec 1998	91	159	33	8	<del>0</del> 4	<u>8</u>	16	21	n	24	55	138	39	8	13	21	65	29	27
Jan-Jun 1998	16	130	23	12	<u>+</u> 4	<u> </u>	14	19	4	21	52	144	34	23	3	50	83	29	77
Jul-Dec 1997	15	123	28.	80	17	8	4	17	က	17	52	140	43	50	o i	21	833	8,6	23
Metropolitan area	TOTAL COTERMINOUS U.SAtlanta	Baltimore	Buffalo	Chicago	Denver	Detroit	Los Angeles	Miami	Minneapolis	New Orleans	New York	Newark	Philadelphia	Phoenix	or Louis	San Diego	San Francisco	Woohington OC	wasimigicii, DC

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 1 This column denotes statistically significant (ho < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

### Table 13.10 - Heroin: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

% change <sup>1</sup> 2000, 2001			-14.2					-3.9	22.7		8.4		•		9.6-				-31.0		-28.5	
% change <sup>1</sup> 1999, 2001		55.6	-34.8	59.2		25.6		0.1	51.3		68.7	70.8	-14.0		-17.4				-34.2		-29.1	
% change <sup>1</sup> 1994, 2001	33.8	38.4	42.1	68.8		142.2	38.5	26.6	75.9		466.3	354.9	177.0			126.3	13.2	231.1		-25.8		32.5
Total 2001	37	23	195	122	72	203	4	40	93	34	81	13	46	127	215	119	27	57	29	178	06	45
Total 2000	38	17	227	102	2	206	19	4	92	37	74	o	8	128	238	96	4	4	42	168	126	49
Total 1999	34	15	299	77	22	162	17	40	61	34	48	80	53	110	260	85	41	35	44	190	127	46
Total 1998	31	17	289	74	25	158	21	31	67	31	40	9	42	110	282	73	43	56	41	148	126	55
Total 1997	93	4	256	89	20	148	21	30	72	30	32	9	36	115	246	79	4	19	39	173	152	45
Total 1996	31	14	357	92	48	109	4	22	92	04	21	'n	26	136	307	83	32	2	4	201	128	4
Total 1995	93	15	366	83	41	83	1	30	28	37	18	4	23	132	327	2	22	16	29	202	109	32
Total 1994	27	17	337	72	35	22	10	31	53	36	4	ო	17	139	262	53	24	17	30	239	116	34
Metropolitan area	TOTAL COTERMINOUS U.S	Atlanta	Baltimore	Boston	Buffalo	Chicago	Dallas	Denver	Detroit	Los Angeles.	Miami	Minneapolis.	New Orleans	New York	Newark	Philadelphia	Phoenix	St. Louis.	San Diego	San Francisco	Seattle	Washington, DC

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 13.11 - Marijuana: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

% change <sup>1</sup> H1 2001, H1 2002	1	49.5	-37.2	27.7		18.0 -44.9 -65.8
% change¹ H2 2001, H1 2002			-24.0			6.8 -31.5 -59.6
Jan-Jun * 2002	22 23 14	23 48	222	35 24 38	22 76 21 21 69	25 4 4 4 7 7 8
Jul-Dec 2001	22 46 36	48 22 42	29 26 26 26	2 4 35 3 4 4 8	19 23 23 52 52	2 2 2 2
Jan-Jun 2001	22 - 4	48 45 47	2 T 2 C 2	32 45 23 37	23 4 4 4 5 4 6 4	25 26 26
Jul-Dec 2000	19 41 36	04 84 84	22 52	88454	14 14 29 32	19 17 35 31
Jan-Jun 2000	20 45 33	26 26 42	25	44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	22 15 22 40 60	20 21 37 33
Jul-Dec 1999	18 48 37	27 28 38	24.23	35	20 12 23 33 35 35	20 20 34
Jan-Jun 1999	43 34 34	24 38 38	25 18 57	30 130 130 130	21 17 27 36	17 21 31
Jul-Dec 1998	16 44 34	38 26 41	34 18 53	23 10 4 10 10 10	20 15 17	22 12 32 32
Jan-Jun 1998	16 51 31	<del>3</del> 2 <del>4</del>	19 4	10 10	24 15 19 19 19	26 30 29 29
Jul-Dec 1997	14 30 31	<u>8 2 4</u>	20 19 45 45	24 13 60 13	22 15 17 18 18 18 18 18 18 18 18 18 18 18 18 18	32 4 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Metropolitan area	TOTAL COTERMINOUS U.S	Buffalo	Ualias. Denver. Detroit.	Los Angeles. Miami. Minneapolis. New Ordeans.	Newark Newark Philadelphia Phoenix St. Louis	San Luego. San Francisco. Seattle Washington, DC.

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

### Table 13.12 - Marijuana: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

% change¹ 2000, 2001	11.8	* * * *	<del>-</del>								39.6	-18.4						12.4	16.9	4.2	
% change <sup>1</sup> 1999, 2001		5.5	11 00	62.3			18.4			39.8	76.5			27.7		9.6-		14.5	53.7	79.5	
% change <sup>1</sup> 1994, 2001	150.7			,	•										•	95.8	•				
Total 2001	44	96	<del>2</del> 8	<u> </u>	8	34	20	121	67	<u>8</u>	46	71	42	37	122	45	19	4	45	75	51
Total 2000	68	98	9 6	2 (%	8	49	51	66	29	9	33	87	41	29	101	51	72	33	38	72	64
Total 1999	36	91	72	23	12	48	43	95	64	29	56	98	4	58	114	20	89	38	29	42	65
Total 1998	32	96	20 1	6/ 3	8	62	37	101	40	29	21	66	4	30	112	36	29	47	25	49	62
Total 1997	72	28	61	<u>8</u>	92	38	32	88	22	55	56	113	46	28	97	37	47	41	25	87	63
Total 1996	23	22	53	59	6.5	23	19	101	26	55	23	106	44	36	74	31	9	27	27	48	58
Total 1995	19	63	42		2 52																
Total 1994	17	29	32	25	3 5	28	56	72	20	68	18	77	32	37	46	23	39	22	33	49	74
Metropolitan area	TOTAL COTERMINOUS U.S	Atlanta	Baltimore	Boston	Buffalo	Chicago	Device	Defroit	1 oc Angelee	Mismi	Minnospolie	New Orleans	New Vork	Newark	Dhiladelphia	Dhooniv			Con Empired	South Figure 2000	Washington, DC

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.13 - Amphetamines: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

% change <sup>1</sup> H1 2001,	H1 2002	i				-24.8	54.4							45.7			28.9	-27.1	-70.4	
% change <sup>†</sup> H2 2001,	H1 2002			1	150.0	-25.1			_		_		-				11.0	-31.8	-70.6	
Jan-Jun * 2002		4 80	מו	ω τ	<del>- </del>	S	<u> </u>	n a	7	4	വ	:	:	ਲ	24	:	22	<del>2</del>	ν.	:
Jul-Dec 2001		4.4	9	<b>6</b>	<del></del>	9	27 0	σα	2 0	4	9	:	:	4	17	, e	22	56	16	:
Jan-Jun 2001		4 1	91	3.5	<u>4</u>	9	∞ ₹	† N	. 7	4	:	<del>-</del>	:	3	4	4 [	- 7	7,	2	
Jul-Dec 2000		ກທ	4 1	<u>v</u> ←	4	7	0.	<u>:</u> "	8	2	22	0	:'	<u>0 1</u>	- 6	<u>.</u>	2 (	7 [	=	:
Jan-Jun 2000	·	9	en u	0 0	121	<b>~</b> ;	2	9	7	ਲ	4	<del>-</del>	- 1	0 2	<u> </u>	<u>4</u> α	2 7	- 4	2	
Jul-Dec 1999	6	<u>, 4</u>	4 "	20	8	<b>~</b> °	2 %	O.	2	7	: (	5 4	- u	. t	2 6	2,5	70	, 5	2 :	
Jan-Jun 1999	6	100	<u> </u>	<del>, -</del>	0.0	<u>v</u> 0	7	2	*-	70	N G	5 7		1 2	<u>i 4</u>	16	2	- α	7	
Jul-Dec 1998		40	<del>7</del> m	<del>-</del>	71	~ 7	+ 4	6	7	- (	V C	7	- 4	7	2	4	2	10	<b>'</b> :	
Jan-Jun 1998	1	1 ~ 6	7 7	0	<del>-</del> r	- 4	. rc	<del>C</del>	₹ ,	- c	N C	5 6	7	- =	7	18	9	10	:	-
Jul-Dec 1997	2	Ţ <del>.</del>	- :	0	0 0	0 ~	4	Ω.	5 (	7 6	1 C	0	4	12	2	21	8	13	i	
Metropolitan area	TOTAL COTERMINOUS U.S.	AtlantaBaltimore	Boston	Buffalo	Cricago Dallas	Denver	Detroit	Los Arigeres.	Minneapolis	New Orleans	New York.	Newark	Philadelphia	Phoenix	St. Louis	San Diego	San Francisco	Seattle	Washington, DC	

estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an <sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

Table 13.14 - Amphetamines: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change 1994, 2001	% change 1999, 2001	% change 2000, 2001
TOTAL COTEDMINOLIS IIS	4	4	4	4	5	5	7	7		42.4	
	- ო	· m	. 73	6	=	:	:		293.9		
Audilia	2	2	7	4	S	9	7	11		77.8	55.0
Boston	· ;	' :	က	;	ß	9	10		:	89.7	
	-	2	7	_	-	က	က			-31.0	-21.4
Dullalo	<del></del>	· m	m	4	က	က	9			103.8	
OIICAGO	4	ý	ιά	1	4	12	14		210.8	-2.3	
O dilas	. 23	<u> </u>	9	4	7	15	21			41.5	
	_	7	7	σ	80	4	•				
	- 1		· «	<del>, o</del>	· (C	- 6	12		117.9	45.3	
_os Angeles	_	-	•	<del>, -</del>	. ~		4				
Maml	: `	: °	: °	- ເ	· c	7			400 1	105 7	
Vlinneapolis		77 -	7 (	<del>"</del>	7 '	<b>†</b> (				-	
New Orleans	7	_	7	4	Ω.	, C		<u> </u>			
New York	0	_	0	_	_	_					
Newark	_	_	0	_	_	2					
Ohiladelphia	က	2	9	6	<del>∞</del>	<u></u>					
Dhonoiv	21	23	15	20	18	52				23.9	-1.2
Ct - Onits	~	· CO	6	4	4	80					
	17	48	24	37	32	38					
Can Empired	28	21	15	17	7	16		20	76.3	216.9	120.6
Conflic	100	13	6	24	15	18	32			84.2	
		•									፥
wasnington, U.C	:	1	:	:	:	:	:				

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

# Table 13.15 - Methamphetamine: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

•	H1 2002		-						_		_	-64.3		473.5					_	-21.9	_	-49.6	118.5
H 75		ম	<u> </u>	_	<del>-</del>	_						.,				_							
Jan-Jun * 2002		•				_			r			8	_	(*)	:	0	_	Φ.	m	0	8	कर	>
Jul-Dec 2001		က	7	0	0	:	_	:	2	:	6	_	∞ ¯	: '	0	0	_	12	2	13	21	<del>-</del> -	5
Jan-Jun 2001		e e	Ι'	50	<b>D</b>	:	: '	77	က	: '	Φ,	-	4 .	_	: '	5	-	<u></u>	m_	4	18	∞ c	<del>,</del>
Jul-Dec 2000		7	77	5	; <b>°</b>	5	: '	77	n	: '	<del></del>	5	4 -	_	: `	5,	<del>-</del> ;	<u>19</u>	N :	4	07	20 0	,
Jan-Jun 2000	ľ	m (	N C	5 6	<del>-</del>	=	: °	7	4 (	5 6	ю c	5 6	7 -	- 6	5	:	: 5	2	<b>4</b> i	17,	<u>-</u> ;	2	:
Jul-Dec 1999	,	N C	V	5	<u>:</u> C	5 6	<del></del>	7 4	n	: 9	0 0	<del>-</del> c	7 7	-	:	: <b>*</b>	- 6	<del>,</del>	7 9	2 5	<u>n</u> (	<u>-</u>	_
Jan-Jun 1999	·	7 -	- c	o c	<del>-</del>	- c	<del>-</del> c	7 0	7	: u	<del>5</del>	; °	7 -	•	:	<u>:</u> C	1 0	- 0	7 7	- 4	2 0	o :	
Jul-Dec 1998	C	7 0	7 0	<del>-</del>	+		"	) r	o c	7	7	000	1 -		<del>,</del> –	: "	- 1	- 0	4 5	<u>s f</u>	2 4	70	
Jan-Jun 1998		<u>,                                    </u>	י	<u>:</u> 0	0	0	ייי	9	F C	, rc	o C	· c	<del>-</del>	•	•	<u>.</u> c	14	•	- 0	24.0	ī	00	
Jul-Dec 1997	A	r vo	0	· :	: :	0	· c	σ	) C	• cc	0 0	•	=		: :	7	17	: ^	72	33	4	: :	
Metropolitan area	TOTAL COTERMINOUS U.S.	Atlanta	Baltimore	Boston	Buffalo.	Chicago	Dallas	Denver	Detroit	Los Angeles	Miami	Minneapolis	New Orleans.	New York	Newark	Philadelphia	Phoenix	St. Louis.	San Diego.	San Francisco.	Seattle	Washington, DC	

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an † This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ERIC T-396

## Table 13.16 - Methamphetamine: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

% change <sup>1</sup> 2000, 2001	22.1 11.9 70.0 95.9 -100.0
% change <sup>1</sup> % 1999, 2001	57.8 -38.9 -35.1 178.5 163.5 10.0
% change¹ 1994, 2001	
Total 2001	82 C C C C C C C C C C C C C C C C C C C
Total 2000	24 4 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Total 1999	4600-040 :
Total 1998	0000 + + 8 8 0 0 + 0 0 0 − 1 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 1997	ト800-0トむ : む-800 : 44.4.4.4.5.5 :
Total 1996	28 28 28 28 28 28 28 28 28 28 28 28 28 2
Total 1995	r 0 0 0 − − 0 ± 0 0 4 0 0 : 0 8 € 8 5 7 4 −
Total 1994	8400-0000000000000000000000000000000000
Metropolitan area	TOTAL COTERMINOUS U.S.  Attanta. Baltimore. Baston. Buffalo. Chicago. Chicago. Dalias. Dalias. Minneapolis. Minneapolis. Minneapolis. Minneapolis. New Ordeans. New Ordeans. St. Louis. St. Louis. San Diego. San Francisco. Seattle.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

Table 13.17 - MDMA (Ecstasy): ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

										•	•	
Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001,	% change <sup>†</sup> H1 2001,
TOTAL COTEDMINOUS II S											H1 2002	H1 2002
Atlanta	0	0 (	0	0	-	-	_	_	_	-		
Baltimore	<b>-</b>	5 0	- 0	<del>-</del> (	_	=	2	ł	<u></u> 8			į
Boston.	5	5 6	5 •	0 ,	_	_	7	2	_	<del>-</del>		38.
Buffalo	; <b>c</b>	5 6	<del>-</del> c	- 1	,	_	2	2	2	_	-519	423
Chicago	0	o c	V C		- 1	<del>-</del>	_	0	0	ম	275.0	268.5
Dallas	-	5	0	- (	- (	-	7	_	-	_		-582
Denver	0 0	<u>;</u> c	5 6	5 6	-	-	7	_	_	=		
Detroit	-	o c	5 6	5 6	-	_	2	_	_	_		
Los Angeles	i	o c	5 6	5	- 1	_	:	_	_	=		
Miami.	: -	o c	5 6	5 7	0 0	<del>-</del>	_	_	_	-		
Minneapolis		<b>5</b> C	50	- (	77	<del>7</del> 7	m ·	2	4	4		-248
New Orleans.	<del>, -</del>	7	<u> С</u>	5 +	5 6	<del>-                                    </del>	7	<del>-</del>	2	N		
New York	•	- c	N C	- ,	<del>77</del>	27	2	-	_	ෆ	123.5	119.8
Newark		<del>,</del>	•	-		-	-	-	<del>-</del>	_		
Philadelphia		<u>: </u>	<u>;</u> c	: `		= 7	0	_	7	~		
Phoenix	C	· c	5 6	- 7	-	7	=	7	က	ন	-	
St. Louis.	<del>-</del>	5 6	5 6	5	- (	7	_	7	-	_		510
San Diego.	Ö	<del>5</del> c	5 6	5	0	_	=	_	7	7		?
San Francisco	+	<del>-</del>	<del>-</del>	5 7	= 7	<del>-</del> -	<del>-</del>	<del>-</del>	_	_	-37.5	45.3
Seattle	•	<del>-</del> c		-,	N -	m	m	9	4	4	!	-246
Washington, DC	: :	•	- 6		=	n	4	<del>o</del> .	7	=	-60.8	-69.3
			,	:	:	:	=	=	=	_	_	

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, MDMA = methylenedioxymethamphetamine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

## Table 13.18 - MDMA (Ecstasy): ED mentions: Estimated rates per 100,000 population by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change¹ 2000, 2001
3 II 3 I WINDERTOO 14 TOT		C	C	0	0	1	2	2	1,889.3	86.5	
IOIAL COIERMINOUS U.S	•	•	)	•	•	2	2	S		114.9	99.1
Adanta	: -	: C		C	0	_	6	n		118.1	21.3
ballinore		5 6		0	-	7	8	4	2,679.8	68.2	
DOSION	0	· c	•	0	2	7	2	_		-43.2	
Dulialo	<u> </u>	· C	C	•	0	7	4	2	1,066.4		41.9
Chicago	<del>-</del>	0 0	<del>-</del>	<del>-</del>	-	-	က	7	177.3	154.7	
Dance		ī	0	_	0	_	4	7	1,531.2	129.3	-38.7
Callval	)	0 0		· ;	0	_	_	<u></u>	:	187.9	
Detroit.	: `	0 0	<del>, -</del>	0	0	_	2	2	864.0	172.5	-18.6
Los Angeles	0		· c	•	-	· 60	Ω.	6	7,968.0	189.5	65.5
Missonolio			C		0	_	က	n	3,268.2	342.5	
Nimited Deliberton	<del>-</del>		-	-	8	4	4	ਲ	182.9	-29.8	
New Oldans	· c		0	0	0	7	2	2	2,256.5		
Nowark	0		<b>'</b> :	•	:	2	7	ന			149.7
Dhiladelphia	' :	: :	0		-	2	8	Ω.	:	142.4	55.6
Dhoody		0	•	0	0	_	4	ਲ	:	247.5	
C+ Louis		0		0	:	_	2	2			
Of. E0018		0	•	0	_	_	2	7	689.9	98.6	
Sall Diego			. ~	2	2	8	7	0	361.3	231.1	47.9
South Figure 200	10	T-		-	1	7	9	ທ	4,863.3	226.7	-17.0
Washington, DC	· :	:	:	;	-	:	2	n	:	:	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department, MDMA = methylenedioxymethamphetamine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.19 - Ketamine: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

% change   % change   H2 2001,	500.0 500.0 200.0 -78.2 -100.0 -100.0 -100.0 588.4 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0 -100.0
# 42 g	
Jan-Jun *	00000   100000   1000000
Jul-Dec 2001	1000000 100000 10 11 10000
Jan-Jun 2001	0 000 1000 10000+ 100000 1
Jul-Dec 2000	0 100000+ 10 1000 1000000
Jan-Jun 2000	000 100000000 10 1-00000
Jul-Dec 1999	10000 100 10 1000 1000000
Jan-Jun 1999	0000000 ;00000 ; ;000000
Jul-Dec 1998	10000000 10000 11 100000
Jan-Jun 1998	00000 100 100000 1 100 1000
Jul-Dec 1997	100000 10 10000 1 1 100 1000
Metropolitan area	Atlanta

estimate with an RSE greater than 50% has been suppressed. Dashes (—) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.20 - Ketamine: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

% change¹ 2000, 2001	55.3  88.9 180.2 -46.4 -79.0
% change¹ 1999, 2001	-76.6 510.8 191.1 800.8 -62.9 175.8 -76.6 181.6
% change <sup>1</sup> 1994, 2001	3,145.4
Total 2001	000000000000000000000000000000000000000
Total 2000	0   0 + 0 0 0 + 1 0 0 0 0 0 0 0 + 0 0 + 0 0
Total 1999	00000 100 10+0+0 1000+000
Total 1998	00000 1000 100000 1100000
Total 1997	1000000 100 1000 1 10 1000
Total 1996	00000000 ;0000+ ;000000
Total 1995	; 0 0 0 0 0 0 0 ; 0 0 0 0 0 0 0 0 0 0 0
Total 1994	00 ; ;00000000 ;0000000 ;
Metropolitan area	TOTAL COTERMINOUS U.S

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

Table 13.21 - LSD: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
TOTAL COTERMINOUS U.S		-	+	į.	-		-	•		1		2002
Atlanta	7	7	2	2	-		- •	•	<b>&gt; \</b>	5 6	7.95	-78.7
Baltimore	<del>-</del>	-	<del>-</del>	<del>-</del>		-	- •	I `	- (	5	-72.2	i
Boston		•				- c	- •	- •	<del></del>	0		-68.7
Buffalo	-	2			- •	<b>O</b>	- 0	-,	0	:		
Chicago	_	ı <del>-</del>	· -		- •	<del>5</del> <del>•</del>	5 •	- •	0	<del>-</del> i	75.0	
Dallas	_			- 6	- c	<del>-</del> c	- ,		5	0		-74.6
Denver	<del>-</del>	10	10	10	7	7 (	- 0	- (	<del>-</del>	ਰ	-20.0	9.68-
Detroit	_	1	<b>1</b> <del>+</del>	7 +	<del>†</del> (	7 (	7	2	=	i		:
Los Angeles.	•	: `	- •	- •	5 •	5,	:	<del>-</del>	:	0		-100.0
Miami	- ~		- 0		- 1	- 1	<del>-</del> (	_	_	_		48.3
Minneapolis	1 ←	•	7 0	- 0		_	7.	7	_	-		-36.4
New Orleans	m	- (**)	<b>1</b> 4	7.0		: *	- (	-	:	0	:	
New York.	, —	<del>,</del>	F C	N C	+ c	-	7 0	_ '	: '	0		-83.6
Newark	•	+	•	<del>-</del>	5 0	=	o '	0	0	0	-66.7	-70.2
Philadelphia	<del>.</del> <del>-</del>		: *		5 7	: `	5,	:	0	:		
Phoenix	· <del>-</del>	- 0	- (*	- 14	- c	- (	= 1	<del>-</del> ·	=	0		
St. Louis.		<del>-</del>	<del>,</del>	<del>,</del> ,	2 .	<del>7</del> (	4	2	0	0		-89.1
San Diego	<del>, -</del>	<u>: `</u>		7 7	- 7	7	=	7	:	-		-52.2
San Francisco.	- 2	+		- •	7 (	<del>- c</del>	<del>- (</del>	<del>-</del> -	<del>-</del>	0		-83.6
Seattle	4		- cr	- ~	7 6	7 6	<u> </u>	77	-	0	-63.6	-88.4
Washington, DC	7	<del>-</del>	<del>-</del>	<del>,</del>	) <del>+</del>	7 +	7	7		0	-73.7	-88.6
		•	•	-	-	=	=	-	;	0		

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, LSD = lysergic acid diethylamide. SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.22 - LSD: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

% change¹ 2000, 2001	-38.7 285.1 -38.0	-44.1 -54.8 -18.2	-69.4 -44.9	-66.2	-285 -46.5 -47.6
% change¹ 1999, 2001	2, 44 6, 44 6, 44 6, 44 7, 6, 44	-59.5	-72.7 -75.0	-71.2	-14.4 -53.4 -73.3
% change <sup>1</sup> 1994, 2001	-50.3 -73.3 -65.9 -69.7 -73.9	85.4 85.4 85.4	-69.0 -69.0	- 57.3	-69.8 -74.8 -86.9
Total 2001	-0	- NON	<del>, - 0 0</del>	100 -	- 88-
Total 2000	<u> </u>	<u> 4 – 6 (</u>	2 4 6 4 C	<u> </u>	140-
Total 1999	<u> </u>	4 <u>rv</u> ← cv c	<u>, w o ← ← c</u>	<u>,                                    </u>	7 E O C
Total 1998	<u> </u>	44-0	2000	∆ <del>1</del> 0 ← 0	ა დ <b>0</b> ←
Total 1997	<u> </u>	9 N O O	<u>, → N M W W</u>	<u> </u>	2 0 0 C
Total 1996	<u> </u>	<del>य य न</del> ्लः	<u> </u>	2001	10 10 4
Total 1995	0 0 0 0 0 0	<u> </u>		ภิติต	<b>~</b>
Total 1994	7848F	9 0 0 0	4 4 0 0 0	N N M	110
Metropolitan area	TOTAL COTERMINOUS U.S	Dallas	Miami Minneapolis. New Orleans. New York. Newark.	Philadelphia Phoenix St. Louis	San Diego

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from <sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, LSD = lysergic acid diethylamide.



Table 13.23 - PCP: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

	% change <sup>1</sup> H1 2001,	H1 2002	i	i i	273.6 96.5	-53.8	-100.0	:					48.0		73.6	-63.7 60.5
	% change <sup>1</sup> H2 2001,	H1 2002		23.5		-31.3	-100.0		-71.4				39.8		42.9	-79.3
	Jan-Jun * 2002	•	<del>-</del>	2 4	- 0	4 0	V 6	: `	00	_	<del></del>	- 77	<u>&amp;</u> +	- 7	<del>- c</del>	<u>1 ← ∞</u>
•	Jul-Dec 2001			<del>- c</del>	0	9 0	10	0	00	0	<del>-</del> 0	-	<u>o</u> +	- m	<del>- </del> €	) 4 K
	Jan-Jun 2001		<u> </u>	<u>α</u> c	0	o ←	- 0	<del>- u</del>	00	<del>- </del>	<del>-</del>	-	∞ ←	2	- ~	0101
'	Jul-Dec 2000	-	- ; ·		000	<u> </u>	0	0 4	0	0	-	<del>-</del> (	∞ ←	2	2 - 2	ເກີເກ
	Jan-Jun 2000	-	- :	0 0	<del>- 1</del>	2	0	⊃ <u>r</u> c	· ; ·	5 +	- 7	- ι	<u>o</u> ←	-	- 2	ю <b>4</b>
	Jul-Dec 1999		<del>-</del> <del>-</del> <del>-</del>	0	0	2 0	0	⊃ 4	0	==	- 2	: "	<del>0 ←</del>		- 2	2 2
	Jan-Jun 1999	-	. 0 .	- 0	0	2 0	: 0	2 4	00	<b>5</b> C	0	0 1		<del></del>	- 2	<del>- 0</del>
	Jul-Dec 1998	-		- 0	0 %		; 6	<u>₹</u>	; •	<b>5</b> C	· <del></del>	; "	<del>-</del>	<del></del>		- 8
	Jan-Jun 1998	1	<del></del>	- 0	0 6	<del>, −</del>	00	<u>ਲ</u>	00	0	2	: °	<del></del>	<del>0 +</del>	<del>-</del> ෆ	2
	Jul-Dec 1997	1	- 0	10	<del>- </del> 4	_	=	: 4	00	<del>-</del>	-	0 40	· —	<del></del>	4	5 1
	Metropolitan area	TOTAL COTERMINOUS U.S	Atlanta Baltimore	Boston	Burtato	Dallas	Detroit.	Los Angeles.	Minneapolis.	New Orleans.	New York	Philadelphia	Phoenix et louis	St. Louis	San Francisco	Washington, DC.

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, PCP = phencyclidine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.24 - PCP: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

% change <sup>1</sup> 2000, 2001			-65.3								40.5			_		56.2
% change <sup>1</sup> 1999, 2001	59.8	69.7	243.4	40.8					-47.3	L	43.8	13.2	343.1		147.6	
% change <sup>1</sup> 1994, 2001		-76.6	-53.4 -46.3	000	168.9			1E2 E	-89.2				_		452.4	
Total 2001	2	- ਲ <b>•</b>		15			12	5 <del>•</del>						<b>α</b> τ		
Total 2000	2	; m	<b></b> -	17	<b>.</b> .	-					7 2				9	
Total 1999	2	- 20		£.		: <del>-</del>	6					10		~	7 7	
Total 1998	1	: 8 :	-0	9	m с		_		<b>-</b>		- 2					
Total 1997	2	- 4		80		- 0	80		2	eo -	- 5	7	-	~ ~	о en	9
Total 1996	1	- 4	00	6	<del>-</del> -	-	6	<del>-</del> (						- ¢		
Total 1995	ε.	10	<del>7 ←</del>	15	<del>∞</del> +		15	0	: <b>9</b>	6	2 5	<u> </u>	. w	ကျ	2	
Total 1994	8	<u>4</u>	<del></del>	4	<del>-</del> -		4	0 (	9	11	<b>-</b> •	-	4	2		35
Metropolitan area	TOTAL COTERMINOUS U.S	Atlanta	Boston.	Chicago	Dallas	Derver. Detroit	Los Angeles.	Miami	Minneapolis.	New York.	Newark	Philadelphia	St. Louis.	San Diego.	San Francisco	Washington, DC

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to ¹ This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, PCP = phencyclidine.

# Table 13.25 - Miscellaneous hallucinogens: ED mentions: Estimated rates per 100,000 population by metropolitan area by half

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
TOTAL COTERMINOUS U.S	0	0	0	0	0	0	0	0	0	0		7007
Baltimore	; °	:0	00	:0	;°	; °	00	10	0	00		i
Boston Buffalo	-0	; °	00	: 0	<del>-</del> c	00	; c	00	<del>-</del> c	<del></del>	:	
Chicago	00	00	00	00	000	000	000	0	50	000		
Denver. Detroit.	-	<del>-</del>	<b>→</b> C	o <del>-</del> − c	<del>-</del>	000	<del>- c</del>		; <del>-</del> (	00	-77.8	-71.9
Los Angeles	: : °	0 0	000	9 ; 6	:01	<del>-</del>	00	⊃ <del>-</del>	00	:0		
Minneapolis. New Orleans	<del>-</del> (	<del>-</del>	<del>-</del> (	5 - 6	00	<del>-</del>	<del>- 0</del>	0 -	<del>-</del>	<u>о N</u>	75.0	-34.5
New York	0	:00	000	<del>-</del> :	:0	00	<del>-</del> :	00	00	00	-100.0	-100.0
Philadelphia Phoenix	:00	000	000	; <del>-</del> c	500	:00	00	00	1 1	00		
St Louis.	<del>- c</del>	5 ; 6	00.	70	00	N ;	0	- 0	<del>0</del> :	0		:
San Francisco	<del>-</del>	<del>-</del>		<del>-</del> 0	-0		<del></del>	2 0	<del>- 0</del>		88.9	1,572.4
Vashington, DC	00	- ;	0	- :	00	<del>-</del> ;	<del>-</del> 0	<del>-</del> :	7	0	-73.2	63.9

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

_	
<u>=</u>	
8	
ž	
Ĕ	
n S	
<u></u>	
<u> </u>	
ᅙ	
о О	
Š.	
9	
er 1	
Si	
ate	
<del>g</del>	
naț	
stir	
Ш ::	
s: ED mentions: Estimated rates per 100,000 population by metropoli	
듩	
шe	
U	
;;	
ens	
δ	
allucin	
≣	
S	
eon	
<u>lan</u>	
ce	
Mis	
9	ā
3.2	ye
<u>le</u> 1	ğ
ap	ırea
	10

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
TOTAL COTERMINOUS U.S.	1	-	1	**	-	1	1	1			
Atlanta	•	0	0	0	0	0	0	I			1
Baltimore	0	0	0	0	0	0	0	0	-39.7	-53.7	-35.3
Boston	7	-	τ-	-	0	_	<del>-</del>	-			!
Buffalo	0	-	0	_	0	0	0	0	-100.0	-100.0	-100.0
Chicago	-	~	-	<b>4</b>	0	4	<del>-</del> (	0	-51.8		49.5
Dallas	0	0	Ψ-	_	0	0	0	:'			;
Denver	ဗ	2	_	τ-	<del></del>	7	<del>,-</del> (	N			¢.//
Detroit	0	0	_	:	0	0	0	5	į		
Los Angeles	0	0	-	<del>-</del>	0	0	<del>, -</del> 1	<del>-</del> (	172.4		
Miami	0	0	0	0	0	<del>o</del> ·	0	0 (			
Minneapolis	፧	:	2	7	<del>-</del>	-	2	7	:		
New Orleans	_	:	0	0	0	:	0	5	9		
New York	1	0	<del>-</del>	0	0	: '	0	5	0.08-		
Newark	1	0	:	:	0	-	: '	:	:	: ;	
Philadelphia	0	-	<b></b>	-	0	<del>,</del> (	<del> (</del>	- 1		45.5	i c
Phoenix	0	0	_	1	0	m		-	114.9	-/4.5	50.5
St. Louis	-	:	0	Ψ.	: '	<del>-</del>	o ·	: '	Č		
San Diego	_	_	_	_	_	=	-	5	-64.9	-26.6	<del>4</del>
San Francisco	_	_	7	2	_	_	2	m	126.6	186.7	
Seattle	4	2	က	6	2	7	7	က		36.3	79.7
Washington, DC.	:	:	፥	0	-	0	:	:			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

# Table 13.27 - Flunitrazepam (Rohypnol): ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

% change H1 2001,	<u>                                     </u>	-26.2
% change <sup>1</sup> H2 2001,		200.0
Jan-Jun * 2002	000000 100 10 1000	
Jul-Dec 2001	100000 100000000	·
Jan-Jun 2001	1 0000 100 100000	00000
Jul-Dec 2000	; ;00000000 ;0000	
Jan-Jun 2000		000000
Jul-Dec 1999		000000
Jan-Jun 1999	; ; 000 ; 000 ; 000 oo	
Jul-Dec 1998	10000 100000 10000	00000
Jan-Jun 1998	100000 10000000	0000 ;0
Jul-Dec 1997	.0000000000000	00000 ;
Metropolitan area	Atlanta	Phoenix St. Louis. San Diego San Francisco Seattle Washington, DC

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

Table 13.28 - Flunitrazepam (Rohypnol): ED mentions: Estimated rates per 100,000 population by metropolitan area

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change¹ 2000, 2001
TOTAL COTERMINOUS U.S	0		: °	:	•	: 0	:	:0		-69.5	
Baltimore	00	0	0	0	. 0	0	0	0		-100.0	
Boston. Buffalo.	00	00	;0	00	00	; °	00	00			
Chicago	00	0 +	0	: ~	; C	; C	0 0	00	505 1		
Denver	000	. 0 (	0 (	0 0	000	000	00	000			
Los Angeles.	<b>&gt;</b> :	<b>&gt;</b> ;	50	0	00	<b>&gt;</b> :	<b>·</b>	э <u>:</u>			
Miami	0	0.0	m (	- 0	_	0	-	0	31.5		
Minneapolis	50	⊃ ;	50	0	; °	50	: °	50			
New York.	00	00	; C	00	00	00	00	00	-100.0		
Philadelphia	000	1	000	000	000	000	0	00			
Phoenix	50	00	00	00	00	50	:0	;·°			
San Diego	;0	00	00	00	00	00	00	00	:		-39.4
Seattle	00	00	00	0	'	0	0	0		-100.0	
Washington, DC	n	n	n		n	:	D .	5			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

### Table 13.29 - GHB: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

% change <sup>1</sup> H1 2001, H1 2002		25.2
% change <sup>1</sup> H2 2001, H1 2002	:	-55.8 -55.8 -20.0
Jan-Jun * 2002	, .	oo + i i oo + woo
Jul-Dec 2001	:00-00 ;6	
Jan-Jun 2001	- 10-0-0-0	
Jul-Dec 2000	; m o o o - m - o c	
Jan-Jun 2000		
Jul-Dec 1999	- ioo i-444	
Jan-Jun 1999	0 :000-000-0-	.000-0004-0
Jul-Dec 1998	00000-4-	
Jan-Jun 1998	0-000000000	
Jul-Dec 1997	0-000000	-00000-m00
Metropolitan area	TOTAL COTERMINOUS U.S. Atlanta. Baltimore. Boston. Buffalo. Chicago. Chicago. Dallas. Derroit. Los Angeles. Miami.	New Orleans New York Newark Philadelphia Phoenix St. Louis San Diego San Francisco Seattle Washington, DC

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, GHB = gamma hydroxy butyrate, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.30 - GHB: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
TOTAL COTERMINOUS U.S	0	0	0	0	1	1	2	1	5,316.4		
Atlanta	0	_	_	7	က	5	ις	7	5,973.0		49.6
Baltimore	0	0	0	0	0	0	0	0			141.5
Boston	0	<del></del>	0 0	0	0	<del>-</del> (		<del>- (</del>			1
Buttalo	<del>-</del>	5 0	5 7	<b>5</b>	<del>-</del>	Э C	<del>-</del> c	<u> </u>			-80.7
Circago	50	7	- m	<del>-</del> ന		9 9	7 ~	<del>1 4</del>	780 2		-7.77
Denver	0	0	0	0	_	4	က	_		-81.5	-69.0
Detroit	:	0	:	:	0	_	_	7	i		
Los Angeles	0	:	_	:	=	7	7	1	192.2		-43.5
Miami	0	0	:	0	_	7	7	ন			-32.2
Minneapolis	0	0	0	0	0	_	4	rt r	5,849.0	89.5	
New Orleans	0	0	_	7	က	9	9	9			
New York	0	0	: '	0	0	0	0	0			
Newark	0	0 0	0 0	0	0	0 ,	0 (	: '			
Philadelphia	5 6	<del>5</del> C	<b>5</b> C	: -	: =	- *-	7 -	<b>⊼</b> ∓			
St. Louis.	0	0	0	0	· :	. 0	- 0	- :		•	:
San Diego	0	-	7	_	₹-	က	က	N	1,631.8	-29.3	
San Francisco	_	_	Ω.	S	9	6	6	10	1,294.9	17.2	
Seattle	0	0	0	፥	<b>~</b>	7	က	7			-36.8
Washington, DC	0	0	0	0	0	0	_	0			
	_		_	_	,	,	,	<del>,                                    </del>			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, GHB = gamma hydroxy butyrate.



### Table 13.31 - Inhalants: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jut-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
TOTAL COTERMINOUS U.S	1	0	0	0	0	0	0	0	0	0		
Battmore	:00	<del>-</del> 0	<b>5</b> <del>-</del> (	500	o <del></del>	:0	;0	10	00	00		-60.7
Buffalo Chicago	o ← c	000	000	000	:00	000	;00	000	000	:01		
Dallas	<del>-</del> (	<del>, ,</del>	<del></del>	<del></del>	<b>→</b>	<del>-</del>	<b>⊃</b> ←	<del>-</del>	0 ~	00		-92.1
Detroit	N 0	- 0	-0	<del></del>	<del></del>	-0	00	₩0	-	N :	254.5	
Los Angeles. Miami.	00	00	<del></del>	<del>0</del> ←	<del></del>	<del>0 -</del>	<del>0 0</del>	;0	; 0	<del>6</del> 6		:
Minneapolis New Orleans	<del>- 0</del>	<del>- 0</del>	~0	<del></del>	₩ 0	00	<del></del>	· c	000	000		-60.7
New York Newark	00	· :	000	0	000	· ; c	000	000	000	<del>-</del> ; •	_	
Philadelphia	<del>, - c</del>	0	000	<del></del>	<del></del>	0	0	• :	<del>-</del> :	50		
St. Louis.	50	50	50	00	<del>- 0</del>	;0	<del>-</del> :	00	0	; c		
San Diego	00	00	<del>-</del> 0	00	00	00	00	00	00	<del>)</del> ; c	_	
Seattle	00	00	· ; c	0	<del></del>	000	00	00	000	00	-100.0	-100.0
		•	<del>,</del>	:	•	5	:	:	5	:		:

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (ho < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.32 - Inhalants: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

Total
0 -
- 0
2 -
<u>8 + 0</u>
007
- + 0
0 - 0
I = ;
0 0
:

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (ho < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

Table 13.33 - Combinations NTA: ED mentions: Estimated rates per 100,000 population by metropolitan area by half year

Metropolitan area	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
TOTAL COTERMINOUS U.S	0	ō	Õ	0	Õ	0	0	0	:	0		
Baltimore.	:00	0	000	:0	00	:0	; °	10	00			4 1 0:
Buffalo	0	; °	0	00		00		00	00	00		391.5
Unicago	00	<del>o</del> :	:0		; 0	:	0	; C	i	<del>0 +</del>		
Denver	: :	0	00				: : <sup>c</sup>	· ; c	: : <sup>c</sup>	- ; c	:	
Los Angeles	0 -	; ; c	· ; c	000		•	000	000		•		
Minneapolis	00	0	000			, i c	000	000				
New York	) ¦C	00	000		000	0	000	000			-100.0	
Philadelphia Phoenix	000	000	0	: :°	; <del>o</del>		000	90 :			275.0	126.8
St. Louis	000	-00	<del>o</del> ; o	:00	<del>- 0 0</del>	00+	<del>00-</del>	:0+	000	00+	90.0	-50.8
Seattle	;·°	00	0 :	00	.00	0	· o :	.00	<del>-</del> ;		2.00	

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 13.34 - Combinations NTA: ED mentions: Estimated rates per 100,000 population by metropolitan area by year

Metropolitan area	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
TOTAL COTERMINOUS U.S.	0	0	0	0	0	0	0	0			
Atlanta			0	: '	0	: '	: '	:			
Baltimore	0		0 0	0		0	00	0		714.4	728.1
Boston Buffalo	: -	0	0	: °	: °		0	50	-100.0		
Chicago	0	0	0	0		•	:	•			
Dallas	0	፧	0	፥		0	÷	i			
Denver	፧	0		0		: '	: '	0	:	:	:
Detroit	: '	; °	0	: '	፥	-	<del></del>	5 (			
Los Angeles		0 0	: `	0,	: `	0	0 (			249.3	6
Mignesonie	0 0	5 6			- 0	9 0	5		31.5	39.2	-52.8
New Orleans.		0	0	0	0	0	; O	<u>:</u> 0	-100.0	-100.0	-100.0
New York	-	:	1	0	0	0	0				-79.4
Newark	Õ	0	: '	0	0	:	: '		-100.0		
Philadelphia	0 0	<del></del>	o +	0 0	0 0	; •	0 0	00			127.0
St. Louis		0	- 0	0	0	•	0	•			
San Diego.	0		0	0	0	-	0	0	173.4		24.7
San Francisco			2	2	_	_	7	7	-71.5		-29.2
Seattle		:	-	0	0	0	~	<del>-</del>	72.6	36.3	-47.2
Washington, DC	0	0	0	0	:	0	:	i	÷		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, NTA = not tabulated above.



# Table 14.1.0 - ED drug episodes by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER Male Femole	116	122	120	124	124	131	128	135	136	130		
AGE	20	3	3	\$	2	2	2	-	=	2		
•	2	71	28	83	52	73	63	99	99	61		
6-11 years	125	7 2	2 4	2, 3	2 2	<u>ب</u> م	10,7	7.7	7 7	<del>ر</del> د		
18-25 years.	189	\$	8 - 2	192	196	217	203	28	197	7 <del>1</del> 2 4 5		
18-19 years	192	199	200	194	190	221	217	244	251	260		
20-25 years	188	178	184	192	198	215	206	166	183	176		
26-34 years	202	206	200	196	197	202	203	237	241	223		
26-29 years	198	204	190	194	176	195	200	291	312	271	-13.3	
35 years and older	202	/07 08	888	761	213	216	202	209	206	98	1	
35-44 years.	174	. <u>1</u>	187	8 8	192	202	2 5	2 5	213	180	1.7-	
45-54 years	79	85	91	101	102	101	110	112	123	114		
55 years and older	15	17	14	21	19	20	21	23	8	25		
TOTAL DRUG ABUSE EPISODES	110	113	112	115	113	124	120	124	128	121		

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year

Table 14.2.0 - ED drug episodes by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female	237	228	226	234 205	242	248	259	27.1	14.0 0.80	8.9	4. c.
AGE 6-17 vears		139	144	138	129	<u>+</u>	136	, C,	ļ	Ç	<u>;</u>
6-11 years.		7	2000	7	4 0	20.0	4 6	4 5		- (2	
12-17 years		375	358	381	372	388	426	379		11.2 -2.3	
18-19 years		418 360	380 351	404 373	399 362	384	438	496 349	19.6	29.1	
26-34 years	416	403	396 385	400	406 394	393 371	396	478 603			52.4
30-34 years		402	404	407	415	410	421	415	7 00		į
35-44 years.		343	340	344	368	378	397	418	28.4	10.4	5.3
45-54 years. 55 years and older.		146 29	155 32	164	176 34	203	214	235 45	65.0	15.8	10.0
TOTAL DRUG ABUSE EPISODES	225	221	218	221	225	228	243	252	11.7	10.4	3.5

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

### Table 14.2.1 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Atlanta by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1.</sup> 2000, 2001
Male	538	74.	434	354	473	436	478	489		12.1	2.2
Female	273	294	266	235	310	301	303	300	9.7	-0.2	
					•						
6-17 years	121	125	118	128	143	112	104	47			
6-11 years	:	:	-	က	-	4	•	5			
12-17 years.	241	249	238	257	289	225	209	199			
18-25 years	528	570	494	424	542	531	518	427	-191	-19 6	-17.6
18-19 years	496	200	472	476	546	531	495	492		2	- C
20-25 years	538	269	501	407	540	532	527	412	-23.4	-22.5	-218
26-34 years	772	774	604	515	829	609	586	614		0.9	4.7
26-29 years	929	029	482	448	591	284	202	691		!	•
30-34 years	882	852	869	268	748	629	651	574		-8.7	-11.8
35 years and older	338	356	313	251	352	347	412	435	28.8	25.3	!
35-44 years	643	999	220	451	615	290	695	735	14.3	24.5	ις: 80
45-54 years	231	242	233	187	292	312	384	438	7 68	404	?
55 years and older	¥	25	45	44	63	99	78	09	75.6		
TOTAL DRUG ABUSE EPISODES	405	416	349	294	330	367	394	397	-2.0	8.0	9.0

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. ED = emergency department.

Table 14.2.2 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Baltimore by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change¹ 2000, 2001
GENDER Male Female	917	909	887 531	683 431	729	736	588 375	627	-31.7	-14.8 -20.0	9.9
AGE 6-17 years	149	149	136	192	177	180	172	167	12.0		<u>ئ</u>
6-11 years		299	275	39 e	360	10 365	351	336	34.0 10.5		4 6
18-25 years	886 522	871 576	807 613	705 592	788 724	808 723	717	776 973	86.3	34.5	8.3
20-25 years	•	961	869	743	809	837	720	1 068	-27.1	-13.5	0.6
26-29 years	1,367	1,410	1,340	964	973	961	719	1,233	-9.7	28.4	. u
35 years and older. 35-44 years.	598 1,338	598 1,318	1,344	1,028	526 1.094	543	426 890	445 910	-25.6	-18.1	?
45-54 years	453	471	514	420	4 55 55	509	408	440	19.0	-13.5	8.0 38.0
TOTAL DRUG ABUSE EPISODES	715	712	705	556	293	902	483	505	-29.3	-16.5	

 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

ERIC

Table 14.2.3 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Boston by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female	482	503	412	348	421	365	459	570		56.0	24.0
AGE						1	}	-			
6-17 years.	221	246	219	202	189	136	199	179			
0-11 years		484	422	4 00	376	267	392	366	555.2		
18-25 years	605	627	548	430	545	469	594	752		60.2	26.5
18-19 years		829	285	432	634	503	599	1,047		108.4	
20-25 years		613	537	428	516	458	265	069		50.6	16.4
26-34 years.	847	828	691	222	658	220	688	880		69.3	27.8
26-29 years	778	759	572	485	518	447	009	1,099		145.7	83.1
30-34 years	901	935	783	615	774	280	200	774		33.5	1.8
35 years and older	315	334	281	284	298	269	322	404		50.3	25.3
35-44 years	685	720	298	290	627	267	299	788		39.0	18.2
45-54 years	261	294	243	270	294	262	328	447	71.4	70.2	36.4
55 years and older	ጷ	48	48	46	37	98	49	99		69.2	
TOTAL DRUG ABUSE EPISODES	434	449	375	335	370	313	393	472		50.9	20.2
		A						=			

 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

Table 14.2.4 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Buffalo by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>†</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
IDER Male	364	363	510	404	354	374	385	548	_		
Female	242	233	275	205	215	196	204	256			
6-17 years.	110	119	152	117	122	\$	89	79	-28.7	-5.7	16.6
6-11 years	-	:	4	-	7	0	2	7-			47.5
12-17 years	222	238	303	234	239	169	133	158	-28.6	-6.2	19.3
18-25 years	493	492	489	393	421	358	435	534		49.1	
18-19 years	563	401	429	371	381	357	356	594	5.5	66.3	6.99
20-25 years	472	519	509	400	435	359	463	518		44.5	
26-34 years	713	682	938	629	579	635	602	888			
26-29 years	741	289	828	200	248	591	585	1,030			
30-34 years	96 24	678	1,015	663	602	899	614	822			
35 years and older	210	209	300	245	234	247	270	382			
35-44 years	515	524	748	909	573	570	584	811			
45-54 years	207	185	272	226	211	243	331	455	•	87.5	
55 years and older	21	22	28	25	32	45	42	29	174.7		
TOTAL DRUG ABUSE EPISODES	303	296	387	300	283	283	297	398			
		_									

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of This column denotes statistically significant (ho < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values. the Census.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

T-421

### Table 14.2.5 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Chicago by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000,
GENDER Male Female	475 289	476 295	486 331	553 374	354 354	543 339	608	673	41.6	23.9	
AGE 6-17 years	144	163	164	170	157	145	CA.	46.0		3	
6-11 years.	4 00	7.00	œ ;	C)	ω,	<u> </u>	4	9	_		
18-25 years	788 646	322 628 628	324 614	339 637	312 625	230 264 264	304 692	311 565		0.3	
20-25 years	528 680	569 646	483 655	509 679	587 638	529 576	693 692	679 539	28.5	28.3	-2.1
26-34 years. 26-29 years.	770	736	804 783	882	869	812 716	873	1,027		26.4	
35 years and older	780 276 625	760 297	819 328 719	946 400	386	413	972 483	973	111.9	9.4	21.2
45-54 years 55 years and older	198	241	268	355	354	422	971 522	1,137	82.1 214.7	34.6 47.8	17.1
TOTAL DRUG ABUSE EPISODES	381	384	408	462	445	440	502	558	128.3	26.9	43.6

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This column denotes statistically significant (ho < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values. the Census.

Table 14.2.6 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Dallas by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male	189	200	187	246	307	255	277	201	8.9		
Female	247	240	526	265	281	252	265	216			
AGE											
6-17 years	159	183	173	190	196	156	167	. 129			
6-11 years	12	သ	9	:	4	;	4	ิ	-79.9		
12-17 years	317	374	353	392	403	323	343	267			
18-25 уеагъ.	447	466	415	553	617	517	571	337	-24.6		
18-19 years.	269	485	495	737	692	525	650	492			
20-25 years.	412	460	389	493	265	515	545	300	-27.0		
26-34 years	338	318	303	361	427	370	413	333			-19.4
26-29 years	341	317	318	354	425	367	401	408			1.7
30-34 years	336	318	291	368	428	373	423	293			-30.8
35 years and older	134	134	133	172	210	189	193	164	22.1		
35-44 years.	227	234	241	299	381	331	342	261	15.0		
45-54 years.	112	114	101	146	162	165	163	158	41.2	4.5	-2.7
55 years and older	37	27	56	8	88	ဗ္တ	41	48	28.3	32.4	15.1
TOTAL DRUG ABUSE EPISODES	219	221	208	257	295	254	272	210	4.4		
											-

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

Table 14.2.7 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Denver by year

change <sup>†</sup> % change <sup>†</sup> 1999, 2000, 2001 2001	<del>  ~=</del>		12 4		1.6						2.0	-7.0
% change <sup>1</sup> % ct 1994, 19 2001 20							_			20.8	1	
Total 2001	300	187	370	463	636	423	591	413	215	208	48	281
Total 2000	326	206	427	629	626	455	463	448	235	257	22	306
Total 1999	333	161	334	929	685	449	442	454	241	253	47	302
Total 1998	290	148	304	574	551	383	384	383	205	18	4	259
Total 1997	293 256	181	375	596	658	442	455	433	203	192	47	278
Total 1996	217	175	11 356	481	506	340	350	334	151	131	35	221
Total 1995	304	218	11									302
Total 1994	329	215	443	750	778	517	535	505	220 400	172	47	328
Demographic characteristics	GENDER MaleFemale	AGE 6-17 years	6-11 years	18-25 years	18-19 years 20-25 years	26-34 years.	26-29 years.	30-34 years	35-44 years.	45-54 years	55 years and older	TOTAL DRUG ABUSE EPISODES

 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</li>
 NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

Table 14.2.8 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Detroit by year

	Total Total 1994 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change 1994, 2001	% change 1999, 2001	% change 2000, 2001
534 336	568 342	623 380	519 322	517 307	457 292	472	530 396		35.3	29.9
130	132	130		87	87	88	119			33.9
10	255	5 251	187	170	171	3 173	247	-76.9		43.2
610		586		532	448	445	512		14.1	14.9
567 624	621 614	541		547	464	458	492		5.9	7.3
772	770	842		645	554	557	692			
790	839	921		735	585	609	626			
400	440	514		437	414	440	525			
847	917	1,057		819	735	759	821			
352	399	492		496	519	268	736	109.1	41.8	29.6
62	89	73		8	8	93	132	112.8		•
432	451	498	417	409	374	388	463			

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimates provided by the U.S. Bureau of estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

ED = emergency department.

Table 14.2.9 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Los Angeles by year

Nale
123
8 77
353
9 7
<u>. 0</u>
9 9
<del>2 0</del>
22
4 0
237

¹ This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.</p>
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

Table 14.2.10 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Miami by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female	380 272	409	404	412 261	428	485	582 304	570 299	50.0 9.9	17.7	
AGE 6-17 years	133	141	148	107	96	-00,	138	119	<u>,                                     </u>	19.0	9. 8.
6-11 years	261 527	269	287	206	186	196.	270	236	<u> </u>	20.6	2
16-25 years. 20-25 years.	478 556	653 601	572 550	465 523	365	371	622 692	908 100 100		62.7	
26-34 years.	653 598	646	670 588 734	671 562 750	517	715 565	790 683 877	808 956 733	23.8 59.8 5.5	69.2	
30-34 years 35 years and older		269 623 623	268 614	284	312	78	406 406	427 864		23.0	
45-54 years. 55 years and older		227 54	238 49	250 47	299	351	426 60	507 68		44.5	
TOTAL DRUG ABUSE EPISODES	326	351	339	335	339	372	439	430	31.9	15.7	

<sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an</p> estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

Table 14.2.11 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Minneapolis by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994,	% change <sup>1</sup> 1999,	% change¹ 2000,
GENDER									1007	7007	7007
Male Female	158 221	152 220	176	195	161	172	191	230	45.6	33.8	20.4
AGE					-	<u>;</u>	3	707	2.1.2	70.1	16.0
6-17 years.	205	232	201	222	159	195	216	224	9.0	14.6	er er
12-17 years.	436	4 601	7	9	: 6	: ;	7		49.5		343.8
18-25 years.	459	404	484	900	333	414	464	450	3.2	8.8	-2.9
18-19 years.	737	586	643	717	230	431	239	502	හ. ග	16.5	6.9
20-25 years	381	357	436	431	355	418	486	810	,	72.9	15.7
26-34 years	239	239	269	250	245	252	257	384	8. 0	8 6	-12.4
26-29 years	238	235	252	216	250	238	237	53.5	124 7	92.0 124.3	49.1
35 years and older	240	242	282	277	242	264	274	310	29.5	17.4	13.0
35-44 vears	80.	103	130	135	127	126	132	165	52.6	30.8	25.1
45-54 Vears	007	6 6	738	244	221	221	238	277	38.7	25.0	16.3
55 years and older	300	26 26	25.	124	2 2	128	<u>8</u> 2	179	115.6	41.6	37.5
TOTAL DBIIG ABIIEE EDISONES		1	}	i	3	- 77	47	c,		32.2	46.2
CIAL DAGG ABOSE ERISODES	192	188	208	211	183	194	214	251	30.7	29.1	17.2
							1				

<sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 14.2.12 - ED drug episodes by age and gender: Estimated rates per 100,000 population for New Orleans by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER MaleFemale	549 283	666 355	650 354	592 298	591 270	528 222	533 238	419	-23.7	-20.7	-21.4
AGE 6-17 years	130	160	157		110	71	76	25	-55.9		-24.1
6-11 years	259	312	318		223	139	147	113	-56.3	-18.9	-22.9
18-25 years	628 730	956	836 750 1		740	676	768 168	607		-10.3	-21.0 -36.6
20-23 years	26.5	910	877		762	596 548	630	637	-19.8		1.1
26-29 years 30-34 years	831	958	931 416		791	658 329	565	510	-38.6	-22.5	-9.7 -13.6
35 years and older 35-44 years.		438 438	398	727 374 50	343 343	335	350 67	497 308 74	-26.4	-21.4	-15.3
TOTAL DRUG ABUSE EPISODES	4	505	497		423	367	378	324	-21.4		-14.4

1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.</p>
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

the Census. ED = emergency department.

Table 14.2.13 - ED drug episodes by age and gender: Estimated rates per 100,000 population for New York by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000,
GENDER MaleFemale	791	752 279	728	670 248	635 249	528	547	575	000		
AGE 6-17 years	82	8	1	8	, G	· ·	3				
6-11 years12-17 vears	m (	10	ָּיָּט	14	8 0	<u>8</u> m	4	2	-38.5 -0.50		-17.6 -53.0
18-25 years	494	488	490	156 456	113 440	<u>25 8</u>	117 386	104	-34.3		
20-25 years	551	533 533	516	380 480	364 465	340	352	382	29.7		
20-34 years. 26-29 years.	1,099 922	1,003 844	998 812	935	900	700	657	676	38.5		
35 years and older	1,236	1,125	1,144 475	1,091	1,109	891 356	828 385	439	43.1		
55 vears and older	1,113 487 50	1,050	1,020 469 1	906 405	390	354	805 388	866 479		35.4	
TOTAL DRUG ABUSE EPISODES	536	504	94 494	448	431	362	370	387	-27.9	37.4	

<sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

Table 14.2.14 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Newark by year

. Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER MaleFemale	699	784	694 428	626 382	900	566 356	510 330	506 326	:	-8.4	-1.2
AGE 6-17 vears	133	168	143	154	137		113	97			
6-11 years	1 259	325	278	300	265	214	•	203			
18-25 years.	1,010	_	879	209	595			547	45.8		
18-19 years	684		633	486	501			622			
20-25 years	1,105		957	647	627			528	-52.2		ά.
26-34 years.			1,514	1.085	1,060			903		13.9	37.7
30-34 vears	Ì	•	1,401	1,139	1,249	_		828			
35 years and older			400	428	421			400			
35-44 vears			887	940	910			807		-10.7	
45-54 years			345	378	390			418	68.0		
55 years and older			42	48	20			20			φ 9:3
TOTAL DRUG ABUSE EPISODES	547	929	564	200	497	457	419	417		-8.6	

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimates provided by the U.S. Bureau of estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

Table 14.2.15 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Philadelphia by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994,	% change <sup>1</sup> 1999,	% change <sup>1</sup> 2000,
GENDER Male Female	472	566 334	571 366	617	663	643	597	707	49.7	2007	2001
AGE 6-17 years	167	199	193	230	202	193	25	5 6			
6-11 years 12-17 years	335	392	382	458	613	98.0	0 0 0	2000			
18-25 years. 18-19 years.	691 685	793	794	908	896 891	876	912	1,048	51.6		14.9
ZU-23 years	693 816 822	795 923 874	798 963	1,003	1,071	1,038	922	1,008			
30-34 years	812 274 616	957 321 740	352 352	1,053 365 827	1,1,0 0,11,0 0,13,0 0,13,0 0,0	1,110 406 606	976 372	1,527 1,076 462			24.2
45-54 years. 55 years and older.	246	267	297	312	328	361	371 45	4 8 6 4 8 6	54.8 102.5 55.4	38.0	34.3
TOTAL DRUG ABUSE EPISODES	391	448	467	496	526	510	481	573			£3.6

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

Table 14.2.16 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Phoenix by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER MaleFemale	334 353	383 410	378 359	368	362 325	420 373	440	352 349	5.4 1.2	-16.3	-14.1
AGE6-17 years	256	240	233	218	182	210	264	226		7.6	
6-11 years	519	477	463	427	328	414	532	465	-10.5	12.3	
18-25 years	747	766	695	721	646 673	752 856	818 999	528 728		-29.8 -14.9	
20-25 years	73	785	701	703	637	716	755	587		-33.3	-36.8
26-34 years	989 989	765	611	631	622	640	718	752		17.5	
30-34 years	26. 19.	263	261 565	246 527	255	326	340	291		-10.8	
35-44 years. 45-54 years. 55 vears and older	145 26	163 26 26	8 <u>8</u> 8	214 35	4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 <del>2</del> 4 4 <del>2</del> 4 4 <del>2</del> 4 4 <del>2</del> 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	333	381	341	135.9 225.3	2.4	
TOTAL DRUG ABUSE EPISODES	348	400	372	363	346	402	433	354	1.9	-12.0	

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

### Table 14.2.17 - ED drug episodes by age and gender: Estimated rates per 100,000 population for St. Louis by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>†</sup> 1999, 2004	% change <sup>1</sup> 2000,
GENDER									1007	1007	2001
Male		258	264	240	257	coc					
Female	243	222	253	227	217	20.00	25.2	382		707	
AGE					- : i	}	3	726		43.0	
6-17 years	175	475	101		-	•					
6-11 years.		<u> </u>	200	\$	131	134	130	127			
12-17 vears		ח נ	n į	4	;	2	:	4			
18.25 years		300	3/8	332	569	271	264	251			
40 40		481	532	440	434	530	582	635			
oo oo oo oo oo oo oo oo oo oo oo oo oo		464	226	460	485	520	561	705			
ZU-ZO years	533	486	515	432	415	534	591	615			
20-34 years		427	411	410	397	429	481	761			
Zo-zy years		423	392	352	372	409	457	62.0			
30-34 years.		430	424	453	417	445	498	270			
35 years and older	169	173	204	185	202	219	233	200	975 0		
35-44 years	388	370	419	422	440	480	200	200	0.0		
45-54 years.	127	160	100	170	,	9 6	0 0	0	59.4		
55 years and older	27	3 8	7 4	<u> </u>	7 6	66.	242	288	127.1	44.2	
	i	3	?	67	8°	45	32	47	71.4	40.0	
TOTAL DRUG ABUSE EPISODES	265	246	266	241	240	264	283	358			
										-	

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of <sup>1</sup> This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

ED = emergency department.

Table 14.2.18 - ED drug episodes by age and gender: Estimated rates per 100,000 population for San Diego by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female	221	203	246 242	279	280 297	291	300	296 252	33.7 18.5		4.7-
AGE 6-17 years	128	128	161	170	163	136	158	128	0.2	-5.7	-19.2
6-11 years	263	263	33 3 34	353	% 86 3	6 279	329	3 267		. <del>4</del>	-18.7
18-25 years	303	251	27.7	332	339	315	350	390	28.9	23.9	11.5
18-19 vears	400	303	347	448	415	404	435	009		48.5	37.8
20-25 Vears	280	237	258	300	318	290	327	343		18.1	
26-34 vears	385	334	387	461	455	420	400	424			
26-29 vears	434	395	417	200	483	450	453	527		17.0	
30-34 vears	356	297	369	436	436	401	367	372			1.3
35 years and older	166	166	225	257	275	303	286	261		-13.8	-8.7
35-44 vears	325	300	412	450	458	487	444	393		-19.4	-11.5
45-54 vears	142	181	235	292	329	390	372	348			
55 years and older	35	33	4	22	69	9/	98	83		8.5	
TOTAL DRUG ABUSE EPISODES	220	201	248	286	293	292	290	276	25.8		4. 8.

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

ED = emergency department. the Census.

Table 14.2.19 - ED drug episodes by age and gender: Estimated rates per 100,000 population for San Francisco by year

į	% change <sup>1</sup> 2000,	2001	16.3	11.8		<u> </u>			33.0	2.0	4 6	37.8	9: 6	5.01			2,0%		13.6
and for concern, i.e.	% change <sup>1</sup> 1999,	7001			ć	7.07	3.40	5							-19	•	47.4	:	
	% change <sup>1</sup> 1994, 2001	7007	-33.4	-26.2		255.2	7.00	-44 B	-32.2	46.8	44.3	-35.5	49.0	-20.9	-34.8	88	25.6		-31.3
	Total 2001		669	LBS	180	2	391	565	703	240	746	804	717	269	902	962	151	- (	¥ \$
	Total 2000		601	ncs	172	1 4	344	580	525	594	689	583	770	476	779	625	109	707	480
	Total 1999		710	t n	148		297	651	222	672	992	929	835	573	923	810	103	444	3
	Total 1998		746		147	80	288	643	535	672	835	748	903	277	965	746	120	560	200
	Total 1997		783	2	163	4	323	742	299	763	932	824	1,015	576	866	712	106	208	200
	Total 1996		781		161	ღ.	322	773	751	179	957	864	1,025	584	1,042	685	106	611	,
	Total 1995		858		168	7	335	823	767	837	1,075	923	1,183	615	1,12/	685	116	659	
	Total 1994		1,050		185	80	365	1,019	1,036	3,015	1,339	1,245	1,406	720	1,588	<del>8</del>	121	794	
	Demographic characteristics	GENDER	Mate Female	AGE	6-17 years	6-11 years	12-17 years	10-23 years	20.25 was	20-23 years	26-30 years	20-23 Jeans	35 years and older	35-44 years	45-54 years	AS years and older	oo jears alid older	TOTAL DRUG ABUSE EPISODES.	

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values. the Census.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 14.2.20 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Seattle by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male Female	629	508	499	652 456	507 355	513 350	634 483	595 471		15.9 34.8	-2.5
AGE 6.17 worms	284	245	219	251	172	158	218	215		36.0	-1.2
6-11 years.		7 17	463	527	362	335	460	436	-63.7		-5.3
12-17 years		924	849	1,04	748	687	975	742		7.9	
18-19 years	1,026	849 845	859 846	946 1.075	851 715	759 663	1,015	907 704	_	18.5	
26-34 years		736	727	668	469	669	890	890		27.4	•
26-29 years		889	751	976 879	695	60.	913	8 8		21.2	•
35 years and older		336	355	452	376	393	498	203		28.0	6:0 
35-44 years		287	317	455	404	459	582	593			1.9
55 years and older	_	55	62	75	65	73	95	117	59.5		••
TOTAL DRUG ABUSE EPISODES	562	456	449	556	433	434	563	538		24.0	

<sup>&</sup>lt;sup>1</sup> This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ρ-values.
NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate provided by the U.S. Bureau of estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of

the Census.

Table 14.2.21 - ED drug episodes by age and gender: Estimated rates per 100,000 population for Washington, DC by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999,	% change <sup>1</sup> 2000,
GENDER Male	412	339 296	336 287	310 278	319	293	283	282	-38.9		1007
	259	241	225	227	186	141	160	147		_	
12-17 years. 18-25 years.	_	479 545	453	455	372	283	323	30:			
18-19 years. 20-25 years.	723 616	687 505	549 463	591	443	493	452	702		4	
26-34 years. 26-29 years. 30-34 years.	693 624 747	516 475 548	514 471 547	421 367 465	452 381 511	370 325 408	337	338 400 400 700	-51.3 -35.9	O: -	
35 years and older	252 484 171	220 414 159	233 428 184	233 415 194	266 466 237	245 413 236	380	376 376	0 0		
TOTAL DRUG ABUSE EPISODES	386	39	37	295	303	266	46	253			

NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. the Census.

Table 14.3.0 - ED drug mentions by patient demographic characteristics: Estimates for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER Male	209	223	220 184	227	229	239	237	247	249	239	7.4	
AGE 6-17 years	103	4.7	90 80	6	3	,			1		•	
6-11 years		7	8 0	4	. r	<u> 4</u>	707	100	96 8	00 W		
12-17 years	203 338	330	333	198	162	236	204	201	49.	190		
18-19 years		372	351	333	347	388	386	419	445	2 4 2 8 3 4		
Z0-Z5 years		315	326	353	358	387	373	306	328	318		
26-29 years.		376	349	367	331	364	374	542	580	420 504	-13.2	
35 years and older	154	380	387	373	401	405	381	387	8 8	378		
35-44 years	321	340	347	351	359	387	370	382	410	367	-7.8	
45-54 years		30	30	189 38	186 33	191 35	203	213	225	212		
TOTAL DRUG ABUSE MENTIONS	197	205	203	210	207	226	219	225	234	220		

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

Table 14.4.0 - ED drug mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by year

je¹ % change¹ 2000, 2001	10.6	8.7	9.7		52.2	12.9 7.2	11.0	10.2
% change <sup>1</sup> 1999, 2001	-							
% change <sup>1</sup> 1994, 2001	19.0	·		28.3			70.7	17.6
Total 2001	495 413	196 5	395 683	865 635	988 1,122	404	438 81	460
Total 2000	475	220	440	774 759	765	377	394	445
Total 1999	456 373	181	360	680 711	741 698 774	358	375	417
Total 1998	443 368	207	416	723 641	749 725 766	335	329	408
Total 1997	422 365	220	435	691 669	727	309	299	396
Total 1996	406 357	217	432	634	725	299	28.7	385
Total 1995	404	212	421 645		726			387
Total 1994	416 359	215	430 684		741			391
Demographic characteristics	GENDER Male Female	AGE 6-17 years	12-17 years. 18-25 vears	18-19 years	26-34 years	35 years and older 35,444 wears	45-54 years	TOTAL DRUG ABUSE MENTIONS

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

#### Table 14.5.0 - Alcohol-in-combination: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half year

Jan-Jun * % change	7:4		<u> </u>	- T	53		200		90-19.5			75			
Jul-Dec 2001	25 25		o ·	1.	- 65	65	28	88	111	77	4	88	46	7	
Jan-Jun 2001	52			5,	2 28	28	52	98	104	9/	4	81	47	9	
Jul-Dec 2000	51														
Jan-Jun 2000	50														
Jul-Dec 1999	49														
Jan-Jun 1999	53		2 6												
Jul-Dec 1998	49	- C	n o	180	8	25	52	77	89	83	37	79	35	5	
Jan-Jun 1998	48		: מ		52			78	75	79	32	92	32	4	
Jul-Dec 1997	45	α		16	52				9			02		4	-
Demographic characteristics	GENDER MaleFemale	AGE 6-17 vears	6-11 years.	12-17 years	18-25 years	18-19 years	20-25 years	Zb-34 years	Zb-Z9 years	30-34 years	35 years and older	35-44 years	45-54 years	oo years and older	TOTAL MENTIONS

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

ERIC

#### Table 14.6.0 - Alcohol-in-combination: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER MaleFemale	88	87 56	87 53	90	97 57	101	101	105 65	20.2 26.2		
AGE 6-17 years	£1 c	15	15	16	\$5.0	16	21	16			-26.7
12-17 years	•	30,	: 82 6	± 8 €	36 105	33	43 125	32			-27.0
18-19 years		108 150	107 150	78 114 146	106 105 135	106 128 151	133 133 146	124 110	54.3		
26-29 years	148 160 56	141 157 62	140 156 62	134 156 65	143 163 71	142 158 77	155 155 8	216 153 85	50.3		62.7
35-44 years		135 59 7	134 57 8	138 8 8	155 66 9	158 79	162 85 12	93 13	41.1 76.7 57.5	18.2	
TOTAL MENTIONS	70	72	71	72	77	8	83	86	23.1		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

# Table 14.7.0 - Cocaine: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>†</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER Male		48	49	43	49	46	49	52	20	48		
Female Female	22	23	23	22	24	23	23	25	25	24		
•	e	S	4	က	4	5	4	4	4	n		
6-11 years		9:	0 0	: 9	0 80	: 6	0 6	0 ^	0 ^	<u> </u>		
18-25 years.		43	45	42	47	4	45	42	4	4		
10-15 years		8 4	5 2	47	23.33	84 49	38	45	4 1 1 1	4 4 5		
26-34 years.		86	82	62	88	92	7.0	9	8	83		
20-25 years	98	9 9	8 7	2 28	8 8	8 93	71	26 88	96 K	88 8		
35 years and older		हि	32	53	8	33	35	36	88	32		
33-44 years		<del>7</del> <del>7</del> <del>7</del> <del>7</del> <del>7</del> <del>7</del> <del>7</del> <del>7</del> <del>7</del> <del>7</del>	27	2 8	3 2	<u> </u>	35	84	ጃ ະ	77	9.6	
55 years and older		7	7	7	<u>۳</u>	<u></u> "	<u> </u>	4	3 4	3 4		
TOTAL MENTIONS	35	36	36	33	37	35	36	38	38	36		
	A		1		-			-	-	=		

estimate with an RSE greater than 50% has been suppressed. Dashes (—) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

Table 14.8.0 - Cocaine: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change¹ 1999, 2001	% change <sup>†</sup> 2000, 2001
GENDER Male Female	87 38	80	89	92	97	93	95 46	102 50	17.3 31.2	9.5	8.5
AGE	•	1	•	•	•	•	•				
6-17 years	Ω	<u>ه</u> ح	<u> </u>	<b>∞</b> с	ກ	_	o C	<u>~ c</u>			
12-17 Vears	. 0		12	<u>, 6</u>	<u>.</u> 6	<u>+</u>	<u>6</u>	<u>4</u>			
18-25 years.			80	92	88	83	88	85			
18-19 years			48	99	29	62	29	86	79.4		
20-25 vears			91	101	98	9	97	85			
26-34 years.			167	164	173	162	155	176			
26-29 years			162	142	148	139	134	196			
30-34 years.			170	181	192	179	170	167			
35 years and older			22	22	63	25	89	92	70.9	19.6	12.6
35-44 vears.			128	133	145	143	150	171	59.9	19.3	13.5
45-54 years.	33		40	47	53	58	4	02	114.0	21.0	
55 years and older	က	က	က	က	5	Ω	9	7	151.3	34.4	18.1
TOTAL MENTIONS	62	58	65	89	71	69	7	92	22.3	9.7	7.6

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department.

Table 14.9.0 - Heroin: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half

% change <sup>†</sup> % change <sup>†</sup> H2 2001, H1 2001, H1 2002	-11.0		-17.9 -15.2 -13.0
Jan-Jun * H 2002 H	23	1 0 0 2 2 2 8 4 8 3 2 4 8 3 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	16 21 3 17
Jul-Dec 2001	26 12	+ 0 + 0 5 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	19 36 3 19
Jan-Jun 2001	24	2222 2222 3725 343 343 343 343 343 343 343 343 343 34	22 35 8 8 8 8 8 8
Jul-Dec 2000	25	23 33 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	35 2 2 19
Jan-Jun 2000	27	0 2 18 33 33 34 37	23 33 4 7
Jul-Dec 1999	26	1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	19 38 3 18
Jan-Jun 1999	22	1 2 2 2 4 4 8 4 8 4 8 4 8 4 8 4 8 8 8 8 8	15 17 15
Jul-Dec 1998	22	2 2 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
Jan-Jun 1998	22	232233233	13 6 17 2 4
Jul-Dec 1997	20		32 2 2 2 3 2
Demographic characteristics	GENDER Male Female	AGE 6-17 years 6-11 years 12-17 years 18-25 years 20-25 years 26-34 years 26-29 years 30-34 years	35 years and older

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (ho < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for ho-values. estimates for Attanta for the period January-June 2001. For the Attanta contribution to the national estimates, data were imputed for Attanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

ERIC

# Table 14.10.0 - Heroin: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male	39	43	44	41	44	47	52 24	50	28.5 43.9		
AGE 6-17 years	← <u>;</u> c	٠ ; ٥	-00	<b>п</b> О 4	007	<del>,</del> 0 0	00	808		-100.0	
12-11 years	30 7 4 8	√8 <del>1</del> 8	3 2 3 v	35 21 40	28 45	33 33 59	62 41 70	52 58 50	74.3 245.4 48.4		
26-34 years. 26-29 years. 30-34 years. 35 years and older.		86 9 E	62 60 63 32	58 61 57 30	62 63 83 83	8 2 8 8	72 73 71	75 92 67 37	37.3	7.5	
35-44 years 45-54 years 55 years and older	25	31	35 4	32 83	4 % 4 4	38	4 4 4 5	71 46 5	17.7 85.4 117.2	20.4	
TOTAL MENTIONS	. 27	30	31	30	31	34	38	37	33.8		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

### Table 14.11.0 - Marijuana: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun *	% change¹ H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER Male Female	19	22 10	22	24	25	26 13	25 13	30	28 15	28 15		
E 6-17 years		<b>⊕</b> 0	270	15	<del>.</del> 5	17	- 4	\$ 0	15	\$ 0		e e e
12-17 years	34 23	32 32	43 43 56	9 48 7 9	25 49 50 50	55 S3	, <del>2</del> 5 05 0	37 50	49	3000	,	2
20-25 years 26-34 years 26-29 years	24 7 8	7 8 32 7 8 32 7 8 32 7 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8 8 8 8 8 8 8	3488	3 <del>2</del> 8 %	3 23 23	33.4.5	4 4 6	4 4 6	4 4 9		
30-34 years 35 years and older.	27.2	7 & W	22,8	<u> </u>	3598	3 = 3	3858	3 4 5 6	38 6	2 2 0		
45-54 years	<u>0</u> 4 ←	- 0 -	<u> </u>	3~-	20 -	40-	9 +	2 = 2	2 2 2	13		
TOTAL MENTIONS	41	16	16	18	18	20	19	22	22	22		

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED ≈ emergency department, H1 = first half (Jan-Jun) of year, H2 ≈ second half (Jul-Dec) of year.

ERIC

# Table 14.12.0 - Marijuana: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S.

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>†</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
NaleFemale	25	28	32	37	44 20	49	52	28	131.5 193.5	29.1	12.8
E 6-17 years.	15	18	22	24	28	78		33	125.3		
6-11 years	0 0	ဝမ္		40	0 2	: ư	:: E7	0 8	374.8		
18-25 years	<u>\$</u>	23	57	7.5	8	97		<u> </u>	103.2	7:07	
18-19 years	29	89	73	78	105	118		146	148.9		
20-25 years	46	49	25	89	74	88		87	90.5		
26-34 years	32	35	4	49	28	64		83	163.3		25.7
26-29 years	S 6		747	51	62	69		116	227.6		
35 years and older	67	က က		+ +		- 0		96	130.6	c	c
35-44 years.	16	10.	23.5	E	<u> </u>	43		55.0	239.0	27.8	18.1
45-54 years	S	S	7	<u>0</u>	13	16		23	327.3	45.2	26.3
55 years and older	<del>-</del>	_	0	_	-	2		က	1,050.0	77.2	73.7
TOTAL MENTIONS	17	19	23	27	32	36	39	4	150.7		11.8
1	-			1		_					

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

### Table 14.13.0 - Amphetamines: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half year

4 4 4 4 6 4 6 6
800
0 8 0 0 8 0
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
2004

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 14.14.0 - Amphetamines: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by year

% change¹         % change¹         % change¹           1994,         1999,         2000,           2001         2001         2001	46.5 106.2 43.4 121.0 659.6 119.4 77.7 81.4 85.9 85.9 53.4 351.7 66.5
Total %	87 807 95 5 5 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Total 2000	80 0 : T # T # T # T # T # T # T # T # T # T
Total 1999	® 10 10 10 10 10 10 10 10 10 10 10 10 10
Total 1998	04 4 : V 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Total 1997	44 E00008110180100 4
Total 1996	
Total 1995	
Total 1994	
Demographic characteristics	AGE 6-17 years. 6-17 years. 12-17 years. 12-17 years. 12-29 years. 20-25 years. 26-34 years. 26-34 years. 30-34 years. 35 years and older. 35-44 years. 55 years and older.

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

# Table 14.15.0 - Methamphetamine: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>†</sup> H2 2001, H1 2002	% change¹ H1 2001, H1 2002
GENDER MaleFemale	5	8 2	2.2	20	8 0	4 0	8 8	600	4 6	₩ N		
AGE 6-17 years	00	000	; 0		- i	0.0	-0	₹ ;	i :	<del>-</del> ;		
18-25 years	4 o <del>L</del> o	2	. 6		7 5 6 7	000	<del>- 0 Ω 0</del>	7 8 7	: ^ ^ ^	<u> </u>		
26-34 years 26-29 years 30-34 years 35 years and older.	0 1 7 2	o <u>v</u> o −	<u>~~~</u>	₩ 4 ₩ <del>←</del>	440-	7867	<u>ភ                                    </u>	6	25.79	<u> </u>		
35-44 years	4-0	4+0	ο <sub>:</sub> ο	:	<u>ω</u> − ;	4 - 0	400	۳ <sub>: :</sub>	ິ : :	· ₩ <del>-</del> 0		
TOTAL MENTIONS	4	က	2	2	7	ю	7	က	က	7		

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Waming Network, 2002 (09/2002 update).

#### Table 14.16.0 - Methamphetamine: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by year

% change <sup>1</sup> 2000, 2001	
% change <sup>1</sup> 1999, 2001	
% change <sup>1</sup> 1994, 2001	312.8
Total 2001	να ε : α44 <del>24 4 24 24 24 24 24 24 24 24 24 24 24 24</del>
Total 2000	r 4 00 n t 1 d t t t t t t t t t t t t t t t t t
Total 1999	<b>ι</b> νω ν ¦4τη ότο φού το κοι † 4
Total 1998	84 GORETTEDG800 R
Total 1997	0 4 0 8 1 1 1 1 2 2 1 1 2 1 1 2 1 1 1 1 1 1 1
Total 1996	<u>ωω ν ¦νν4τυπουφνανον <sup>;</sup> ν</u>
Total 1995	er €0 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Total 1994	ος 4 :ω <u>0 220</u> 52 52 52 54 6 8 6 8
Demographic characteristics	AGE AGE 6-17 years 6-17 years 12-17 years 12-17 years 12-19 years 20-25 years 26-34 years 26-34 years 35 years and older 35 years and older 55 years and older

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.



## Table 14.17.0 - MDMA (Ecstasy): ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change¹ H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER MaleFemale	0	: :	00	1			++					
AGE 6-17 years 6-11 years	0	ī	:	i	-	-	-	-	-	₹		
12-17 years 18-25 years 18-10 years	0-7	; <del>-</del>	: 0 3	: 010	- 60	04	<u> 20 10 </u>	<u> </u>	000	ผต	42.0	
20-25 years 26-34 years 26-29 years	- <sub>!</sub> o o o	:0000	40	20	0 4 <del>-</del> 0	0 4 <u>-</u> -	<del>5</del> 4 <u>+</u> +	≻ 4 W <u>4</u>	∞ <u>≀</u> 0 ∨ 4	<u> </u>	-50.4	
35 years and older	9 ; ; 00 0	00000	: : :000	0       0 0	0000 ; F	: : : 00 -	<u> </u>	-0000 -	-0000 <del>-</del>	-0000 -	700.0	158.3 -100.0

estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an 1 This column denotes statistically significant (ρ < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Εποτ (RSE) tables for ρ-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

Table 14.18.0 - MDMA (Ecstasy): ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male Female	00	0	00	0	1	++	2	8.8	1,240.6 4,633.5	67.2 115.4	
AGE 6-17 years	0	0	•	0	:	-	8		9,870.9	145.1	
6-11 years	00	0 +	: ~	0 0	: 0	7	4 0	4 0	9,917.5	146.0	
18-19 years 20-25 years	· • ;	: -	-0	<del>+</del> 0	9	<u>σ</u> ω	4 ®	6		41.2	
26-34 years. 26-29 years.	00	· : :'	00	00		<b>←</b> છ ÷	000	<del>4 ∞</del>	3,014.7	139.4	218.8
30-34 years	o <sub>:</sub> o	000	000	o <u>;</u> ;	: : :	P : :	N O O	-00	2,416.8	309.9	31.8 34.9
45-54 years. 55 years and older.	:0	о <u>;</u>	00	:0	00	о <u>:</u>	00	88	_	1	294.8
TOTAL MENTIONS	0	0	0	0	0	1	2	2	1,889.3	86.5	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to 1 This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, MDMA = methylenedioxymethamphetamine, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 14.19.0 - Ketamine: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change¹ H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER Male	: :	0	0 :	0	0	0	0	0		88		
AGE 6-17 years	÷	0	:	:	0	0	0	Ī	:	0		
6-11 years	i	0	:	i	0	0	0	: `	÷	0		
18-25 years	11'	000	;°	;°	: :	00	;°	<b>~</b> :	: :'	:0		
20-25 years		000	; 0 0	:00		000	:00	: :	000	:00	73.7	
30-34 years	000	000	000		000	000	000		000	000	242.9	
35-44 years. 45-54 years.	00	00	00	00		· ; °		000	000	0		
55 years and older		0	0			0	•	0		0		-100.0
TOTAL MENTIONS	i	0	:	0	:	0	0	0	:	0		

Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values.

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 14.20.0 - Ketamine: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S.

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER Male	0 ::	0 :	0	0 ::	0	0	0	0 ::	2,811.9		
6-17 years	0	0	0	i	0	i	0	:			
12-17 years	° :	00	00	: :	° :	: :	0+	: :			
18-19 years. 20-25 years. 26-34 years.	: :°	;00	000		o ; o	; ; °	0 + 0	1 1 1			
26-29 years 30-34 years 35 years and older	:	:° :	000	000	000	000	000	; ;°	422.8		
35-44 years. 45-54 years. 55 years and older.	000	: :°	0 ,0		000	000	оо <sub>:</sub>	000	353.6	93.2	
TOTAL MENTIONS	0	:	0	:	0	0	0	0	3,145.4		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 14.21.0 - LSD: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half

Jan-Jun * % change 1 % change 2002 H1 2001, H1 2001		787-   26.7
Jul-Dec Jan 2001 2	-0 -0      0  0	0
Jan-Jun 2001	-0 -0 m m m n i 0 0 0 0 0	_
Jul-Dec 2000	-0 00mmr400 ;0000	_
Jan-Jun 2000	-0 -0 m4 r m 0 - 0 0 0 0 0	_
Jul-Dec 1999	40 40 wwo week	_
Jan-Jun 1999	2- 80 0 0 0 0 1 i i 0 i 0 0	_
Jul-Dec 1998	2- 6 000 4 1 1 1 0	_
Jan-Jun 1998		_
Jul-Dec 1997	-0 0000m00 ;00000	_
Demographic characteristics	AGE  AGE  6-17 years 6-17 years 12-17 years 18-25 years 20-25 years 26-34 years 35 years and older 35-44 years 35-44 years 55 years and older	TOTAL MENTIONS

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Attanta for the period January-June 2001. For the Attanta contribution to the national estimates, data were imputed for Attanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first haff (Jan-Jun) of year, H2 = second haff (Jul-Dec) of year, LSD = lysergic acid diethylamide, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warming Network, 2002 (09/2002 update).

Table 14.22.0 - LSD: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male Female	4 ←	य र-	e ←	e +	e +	ю <del>г-</del>	ღ ←	7 -	-55.9	-51.6	-37.4
AGE 6-17 years 6-11 years	400	٠. نۍ د					<b>по</b> (	<u>N 6 4</u>		-54.0	-100.0
18-25 years	<del>-</del>		·			•-	or 4 a	1 4 <u>6 0 4</u>	49.9	n: ::	
20-34 years. 20-34 years. 30-34 years. 35 years and older. 35-44 years.	- 0 - 0 - 10	0006	0000	0-00	- 0 - 0 - 10	10-00 <sup>†</sup> C	0000	- N - 0 0 0 0	-60.5		48.3
TOTAL MENTIONS			8	8 0				<del>-</del>	-50.3	47.2	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (--) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, LSD = lysergic acid diethylamide, NTA = not tabulated above.

# Table 14.23.0 - PCP: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER MaleFemale	100	1	1	-0	-0		- 2	12	0.4	77-		:
AGE 6-17 years	00	<b>-</b> [	00	00	0 ;	-0	-0	<del>-</del> 0	00	-0	138.9	
12-17 years	<del></del> -	-0 :-	- 666	- 000	<u> </u>	<u>+ ∞ ⊘ ∞</u>	<u>∨ w 4 w</u>	N m m	-404	<u> ମ ଳ ଳ ଳ</u>	138.9	
26-34 years	0000	000	0	0		7222	000-	<u> </u>	N ⊕ ∓ −	N m N F		
55 years 55 years 55 years and older	-00 -	-00 -	-00-	-00-	0 -	NO : F	<del>-</del> 0 ; -	000	0 - 0	<del>7 6 - 7</del>		

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above, PCP = phencyclidine. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 14.24.0 - PCP: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by

year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER MaleFemale	4 2	4 4	2	1	2 -	2+	<u>ε</u> +	.e. ←		60.5 59.8	
AGE 6-17 years	-0	N :	-00	100	+00	<del>-</del> ;	+00	-00	-100.0		-100.0
12-17 years	က <b>ဖ</b> ါ	4 0	<del>ന ന</del>	N 60 (		-40	100	<u> </u>		61.8	19.0
18-19 years	တ လ လ	6 5	 		o 4 w	o 4 €	- 0 4	o 1~ 4	-39.0	87.3 50.1	28.1
26-29 years. 30-34 years.	2	. O 3	<b>е</b> е .	40,	0.00	<i>⇔ ⇔ ∗</i>	404	<u> </u>	-15.2 -51.3	115.6 17.2	
35 years and older	- 60	- <del>0</del> 4	0	- 67	- 00 0	- 67 +	- m <del>-</del>	- m <del>-</del>	100 7	84.6	
45-54 years		- 0	0	- 0	0	- 0	- :	0	48.4	80.3	
TOTAL MENTIONS	ဧ	က	1	2	1	2	2	2		59.8	:

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, NTA = not tabulated above, PCP = phencyclidine.

Table 14.25.0 - Miscellaneous hallucinogens: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half year

Jul-Dec Jan-Jun Wchange 9	7 : O : T : O : O : O : O : O : O : O : O
c Jan-Jun 2001	- : 00-40- :0 : : i0 :
Jul-Dec 2000	<u> </u>
Jan-Jun 2000	-0 -00-m 000000
Jul-Dec 1999	
Jan-Jun 1999	
Jul-Dec 1998	7 : 1: 10 : 10 : 10 · .00
Jan-Jun 1998	
Jul-Dec 1997	00 7007   7   0       0
Demographic characteristics	GENDER  Male  Male  Female  AGE  6-17 years  12-17 years  18-25 years  26-34 years  26-29 years  35 years and older  35 years and older  35 years and older  35 years and older

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

; able 14.26.0 - Miscellaneous hallucinogens: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by year

Tota Demographic characteristics 1999									-		- The - 10
	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change 1994, 2001	% change 1999, 2001	% change 2000, 2001
GENDER  Male Female Female 6-17 years 6-17 years 12-17 years 18-19 years 18-25 years 26-34 years 30-34 years 35 years and older 55 years and older	-0 -0mm   NOO   0000 -	-0 -00mm-000 ; ; ; 0 -	-0 y 14yn-0 100000 -	-0 -0 mm m d 0 0 - 1 1 0 0 -	-0 N   M M M M N   10   100 F	-0 -0wu4u00 :0000 -	-0 -00m0n0 ;  0-00 -	F : : : : : :	44.2	-61.8	

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 14.27.0 - Flunitrazepam (Rohypnol): ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half year

Demographic characteristics	Jul-Dec 1997	Jan-Jun 1998	Jul-Dec 1998	Jan-Jun 1999	Jul-Dec 1999	Jan-Jun 2000	Jul-Dec 2000	Jan-Jun 2001	Jul-Dec 2001	Jan-Jun * 2002	% change <sup>1</sup> H2 2001, H1 2002	% change <sup>1</sup> H1 2001, H1 2002
GENDER Male Female AGE	0 ::	: :	: :	: :	: :	: :	: :	0 :	:0	00		7007
6-17 years 6-11 years	;0	; 0	; 0	:0	; 0	:0	;0	00	:0	00		-57.8
18-25 years	:000	1111	1111	1111	;0;0	;° ; ;	111	0   0	; o ; o	0000		-57.9
20-34 years. 26-29 years. 30-34 years. 35 years and older.	0000	0 :00	0000	; ; ; c	0000	000	0000	10 10	0000	000	-50.0	
35-44 years 45-54 years 55 years and older	000	00 ;	000	000		:0 :0	000	000	000	¦0 ¦0		
TOTAL MENTIONS	:	:	:	i	:	i	:	:	:	0		

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce \* Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an † This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

Table 14.28.0 - Flunitrazepam (Rohypnol): ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by year

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
GENDER MaleFemale	° :	0 ;	0 ::	0 ::	I I	: :	: :	: 1			
AGE 6-17 years	;0 ;	000	·	;° ;	;° ;	;° ;	; ° ;	;0 ;		-100.0	
18-25 years	0000		0000	0000	1010	1 1 1 1	: : :°				
26-29 years. 30-34 years. 35 years and older. 35-44 years.	: 	.000			0000	::00	<del>00 ;0</del>	0 :000	-100.0	-67.9 -100.0	-100.0
45-54 years	0	00 :	0 ::	00 :	O :: :	oo <u>:</u>	;° ;	30 <sub>:</sub>			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department.

Table 14.29.0 - GHB: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half

Democratic shares desirated	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-lun		an-ha	- Pol		% change	% change
	1997	1998	1998	1999	1999	2000	2000	2001	2001	2002	H2 2001, H1 2002	H1 2001, H1 2002
GENDER Male	- 0	0	Ţ	0	-	,		•				
Female	0	0	0	00	0	<del>-</del>	: :	- 0	-	F		
Aver 6-17 years6-11 years	0	:	:	ŧ	:	÷	:	:	:	ō	-	
12-17 years18-25 years	0	; -	: 0	: *	; \	: "	:	:	: '	0		
18-19 years	0	; 6	1 ; 0	- 0 c	m 4	040	: :		N ;	: :		
26-34 years	00		1	<u> </u>	r <sub>i</sub> c	0 0 0	: :`	; <del> -</del> (	<del>v −</del>	: :		
30-34 years	000	00	- ; -	<b>N</b> ‡	v i c	2 00 0	4 ; 6	<u> </u>	<u> </u>	1 1		
35-44 years45-54 wears.	000	000	000	: : <sup>c</sup>	000	⊃ ;	00	00	<del>•</del> :	00		
55 years and older	0	0	:	<del>-</del> :	<del>-</del>	: :	00	<del></del>	1 :	; c		1000
TOTAL MENTIONS	0	0	0	0	Ψ.	-	:	-	-	-		0.00

estimate with an RSE greater than 50% has been suppressed. Dashes (—) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, GHB = gamma hydroxy butyrate, H1 = first haif (Jan-Jun) of year, H2 = second haif (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

The states are selected and gender: Estimated rates per 100,000 population for the coterminous U.S. by

Demographic characteristics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change¹ 1999, 2001	% change   2000, 2001
GENDER Male	0	0	0	0	1	- 2	დ ₹	- 2	6,488.7 4,825.8		
6-17 years. 6-11 years. 12-17 years. 18-25 years. 26-29 years. 26-29 years. 35-49 years and older. 55 years and older.	0 000000000; 0	; ;0000000000	0 00 100 000 10	0 000 1 + + + + + + + + + + + + + + + +	; ; m ; N 0 0 0 0 -		: : : : : : : : : : : : : : : : : : :	0 W F M 4 + O +     +	6,113.2 4,768.5 5,931.5 3,130.2 4,556.9 2,224.7 11,183.8 13,372.4		

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, GHB = gamma hydroxy butyrate, NTA = not tabulated above.

Table 14.31.0 - Inhalants: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by

Demographic characteristics	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Janlun	JaC-liil	* o.d.	% change	% change
	1997	1998	1998	1999	1999	2000	2000	2001	2001	2002	H2 2001,	H1 2001, H1 2002
VDER Male	<del>-</del>	*-	-	0	0	+	C					
remale	-	0	i	0	i	0	0	0	· :	<del>-</del>		
6-17 years	-	₩ 0	<b>←</b> c	00	; c	:	: 6	0	0	:		
12-17 years	+ 0	<u> 77</u>	0	o ← C	<u> </u>	::	⊃ <u>;</u>	; °	:0	<del>0</del> :		:
18-19 years	۰ ؛	- ; -	: :	000	000	: :	500	: :	; O	: :		
26-34 years	· :	- ;	: :'	<del>-</del>	⊃ <u>;</u>	: °	00	:0	<u>;</u> 0	00		3 7 3
30-34 years.	: :	; =	5	: °	:	0	00	0	0	0		\$
35 years and older	0	0	0	00	<u>:</u> °	.0	0	1 :	<del>o</del> :			
45-54 years	: : '	: :	; °	:0	i :	00	0 ;	0	: :	6		
co years all older	5	5	:	0	0	0	;	0	0	0		
IOTAL MENTIONS	<del>-</del>	_	0	0	0	0	0	0	o	0		
		-	0	0	0	0	0		0			

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update). ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year.

# Table 14.32.0 - Inhalants: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S.

Demographic characterístics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change <sup>1</sup> 1994, 2001	% change <sup>1</sup> 1999, 2001	% change¹ 2000, 2001
GENDER Male Female	-0	10	-0		1 0	1	1 0	00	-73.9		-72.3
AGE 6-17 years	<b>-</b>	-	-	Ψ-	2	<del>-</del>	<del>-</del>	0	-90.4		
6-11 years12-17 years	: m +	: 0 <del>-</del>	; 0 ←	: m m	04+	0 + 0	: ∞ -	:0+	-90.7	ŧ	
18-19 years	. A	+ 0	:			-0-	· ; ; •	: - 0		-73.6	
26-29 years	o <u>:</u> o	o <u>:</u> o	: :°	; <del>-</del> 0	; <b>~</b> 0	٠ <sub>:</sub> ٥	° ¦°	000			
35-44 years. 45-54 years. 55 years and older	000	00 :		o ; o	<b>7</b> ∺0	<del>-</del> ; 0	· : :	: :°	-100.0	-100.0	
TOTAL MENTIONS	_	0		_	-	0		0	-59.4		-56.7

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census.

ED = emergency department. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 14.33.0 - Combinations NTA: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by half year

% change   % change   H2 2001, H1 2001, H1 2002	<del> </del>	 157.1 350.0 261.7
	00	: :00000000 : 6
Jan-Jun * 2002		
Jul-Dec 2001	:0	0 0 ; ; ; 0000000
Jan-Jun 2001	00	: ::::000000;
Jul-Dec 2000	00	1000000000
Jan-Jun 2000	00	; ;0;0000000
Jul-Dec 1999	00	10 10000000
Jan-Jun 1999	00	; ;000000000
Jul-Dec 1998	00	0 000 10 100000 6
Jan-Jun 1998	00	0 0000000000
Jul-Dec 1997	0	0 0000000000
Demographic characteristics	GENDER MaleFemale	6-17 years. 6-11 years. 12-17 years. 18-25 years. 26-34 years. 26-34 years. 35 years and older. 35-44 years. 55 years and older. 55 years and older.

estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to produce Estimates for this time period are preliminary. Final estimates will be produced later and may be higher or lower than preliminary estimates due to nonresponse adjustment and other factors. NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from January-June 2000. ED rates are calculated using using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, H1 = first half (Jan-Jun) of year, H2 = second half (Jul-Dec) of year, NTA = not tabulated above. SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (09/2002 update).

# Table 14.34.0 - Combinations NTA: ED mentions by age and gender: Estimated rates per 100,000 population for the coterminous U.S. by year

Demographic characterístics	Total 1994	Total 1995	Total 1996	Total 1997	Total 1998	Total 1999	Total 2000	Total 2001	% change¹ 1994, 2001	% change <sup>1</sup> 1999, 2001	% change <sup>1</sup> 2000, 2001
VDER Male Female	:0	00	00	00	00	00	00	00	-65.6		
6-17 years	0	0	0	0	0	:	0	i			
0-11 years	° ;	000	o ; c	000	000	:00	000	: :			
18-19 years. 20-25 years. 26-34 years.	; ;°	000	P ; ;			<del>50</del> 0	300	; ; 6		39.6	!
26-29 years 30-34 years	;00	000	:00		000	000	000	000	-62.6	30.5	-17.6
35 years and older 35-44 years. 45-54 years. 55 years and older	0000	000	-	3000		0000	000	5000	-36.7	167.9 479.6	-35.2
TOTAL MENTIONS	0	0	0	0	0	0	0	0			

produce estimates for Atlanta for the period January-June 2001. For the Atlanta contribution to the national estimates, data were imputed for Atlanta nonrespondents based on actual data from NOTE: These estimates are based on a representative sample of non-Federal, short-stay hospitals with 24-hour emergency departments in the coterminous U.S. Dots (...) indicate that an estimate with an RSE greater than 50% has been suppressed. Dashes (---) indicate that an estimate has been supressed due to incomplete data. Data were not sufficiently complete to This column denotes statistically significant (p < 0.05) increases and decreases between estimates for the periods noted. See Relative Standard Error (RSE) tables for p-values. January-June 2000. ED rates are calculated using decennial census data and intercensal population estimates provided by the U.S. Bureau of the Census. ED = emergency department, NTA = not tabulated above.



# **SAMHSA** PUBLICATIONS FROM THE OFFICE OF APPLIED STUDIES (OAS)

Place an "X" next to the items you would like to receive and legibly print or type your mailing address below.
National Household Survey on Drug Abuse (NHSDA) Series - drinking, smoking, cocaine, and other illegal drug use statistics Results from the 2001 National Household Survey on Drug Abuse: Vol. I Summary of National Findings (BKD461) Results from the 2001 National Household Survey on Drug Abuse: Vol. II Technical Appendices & Selected Data Tables (BKD462) National and State Estimates of the Drug Abuse Treatment Gap: 2000 NHSDA (BKD437) State Estimates of Substance Use from the 2000 NHSDA: Vol. I. Findings (BKD458)
State Estimates of Substance Use from the 2000 NHSDA: Vol. II. Supplementary Technical Appendices (BKD459)
<ul> <li>Drug Abuse Warning Network (DAWN) Series - drug-related emergency visits to hospitals and drug-related deaths</li> <li>Emergency Department Trends From the DAWN, Preliminary Estimates January - June 2002 (BKD472)</li> <li>Emergency Department Trends From the DAWN, Final Estimates 1994-2001 (BKD432)</li> <li>Mortality Data from the Drug Abuse Warning Network, 2000 (BKD431)</li> </ul>
Drug and Alcohol Services Information System (DASIS) Series - substance abuse treatment services information  National Survey of Substance Abuse Treatment Services (N-SSATS): 2000 (BKD448)  National Directory of Drug and Alcohol Abuse Treatment Programs, 2001 (TXD01)  Treatment Episode Data Set (TEDS): 1994-1999 (BKD399)  Substance Abuse Treatment in Adult and Juvenile Correctional Facilities: Findings from the UFDS 1997 Survey of Correctional Facilities (BKD280)
Analytic Series - special topics relating to alcohol, drug abuse and mental health    Impact of September 11, 2001 Events on Substance Use and Mental Health in the New York Area (BKD457)    Substance Use by Older Adults: Estimates of Future Impact on the Treatment System (BKD404)    The ADSS Cost Study: Costs of Substance Abuse Treatment in the Specialty Sector (BKD420)    Substance Dependence, Abuse and Treatment: Findings from the 2000 NHSDA (BKD438)    Initiation of Marijuana Use: Trends, Patterns and Implications (BKD451)    Tobacco Use in America: Findings from the 1999 NHSDA (BKD400)    Youth Substance Use: State Estimates from the 1999 National Household Survey on Drug Abuse (BKD403)    Parental Influences on Adolescent Marijuana Use & the Baby Boom Generation: 1979-1996 NHSDA (BKD413)    Risk and Protective Factors for Adolescent Drug Use: Findings from the 1997 NHSDA (BKD377)    Worker Drug Use and Workplace Policies and Programs: Results from the 1994 and 1997 NHSDA (BKD276)    Substance Use and Mental Health Characteristics by Employment Status (BKD277)    The Relationship Between Mental Health and Substance Abuse Among Adolescents (BKD309)    Driving After Drug or Alcohol Use: Findings from the 1996 NHSDA (BKD274)    An Analysis of Worker Drug Use and Workplace Policies and Programs (BKD237)    Prevalence of Substance Use Among Racial and Ethnic Subgroups in the United States, 1991-1993 (BKD262)
Methodology Series - methodological issues concerning OAS data collection systems  Redesigning an Ongoing National Household Survey: Methodological Issues (BKD417)  Drug Abuse Warning Network: Development of a New Design-Methodology Report (BKD460)  Drug Abuse Warning Network Sample Design and Estimation Procedures—Technical Report (BKD249)  Development of Computer-Assisted Interviewing Procedures for the NHSDA (BKD397)  Address to mail publication(s) to: NAME:
ADDRESS:
SAMHSA's Mailing List - If you want to receive future issues of publications, add your name and address to the mailing list on the Web at <a href="http://sims.health.org">http://sims.health.org</a> . Your mailing list information can also be updated and revised at this Website. If you're unable to access the Web and want us to add your name to the mailing list, check the box below.  I am unable to access the Web and want to be added to the mailing list.

ERIC

The of Applied Studies materials also can be accessed from SAMHSA's Website at: http://www.DrugAbuseStatistics.samhsa.gov.

FOLD	
	STAMP
NATIONAL CLEARINGHOUSE FOR ALCOHOL AND DRUG INFO P. O. BOX 2345 ROCKVILLE, MD 20847-2345	ORMATION
FOLD	



# Substance Abuse and Mental Health Services Administration (SAMHSA) Office of Applied Studies Publications Series

### National Household Survey on Drug Abuse (NHSDA) Series:

Reports in the Household Survey Series present information from SAMHSA's National Household Survey on Drug Abuse. This representative survey is the primary source of information on the prevalence, patterns, and consequences of drug and alcohol use and abuse in the general U.S. civilian non-institutionalized population, age 12 and older. This survey has been conducted periodically since 1971 and annually since 1990.

### "H" Series publications currently available:

- H-1: National Household Survey on Drug Abuse: Main Findings 1995
- H-2: The Prevalence and Correlates of Treatment for Drug Problems
- H-3: Preliminary Results from the 1996 National Household Survey on Drug Abuse
- H-4: National Household Survey on Drug Abuse: Population Estimates 1996
- H-5: National Household Survey on Drug Abuse: Main Findings 1996
- H-6: Preliminary Results from the 1997 National Household Survey on Drug Abuse
- H-7: National Household Survey on Drug Abuse: Population Estimates 1997
- H-8: National Household Survey on Drug Abuse: Main Findings 1997
- H-9: National Household Survey on Drug Abuse: Population Estimates 1998
- H-10: Summary of Findings from the 1998 National Household Survey on Drug Abuse
- H-11: National Household Survey on Drug Abuse: Main Findings 1998
- H-12: Summary of Findings from the 1999 National Household Survey on Drug Abuse
- H-13: Summary of Findings from the 2000 National Household Survey on Drug Abuse
- H-14: National and State Estimates of the Drug Abuse Treatment Gap: 2000 NHSDA
- H-15: State Estimates of Substance Use from the 2000 NHSDA: Vol. I. Findings
- H-16: State Estimates of Substance Use from the 2000 NHSDA: Vol. II. Supplementary Technical Appendices
- H-17: Results from the 2001 NHSDA: Vol. I. Summary of National Findings
- H-18: Results from the 2001 NHSDA: Vol. II. Technical Appendices and Selected Data Tables

### Drug Abuse Warning Network (DAWN) Series:

Reports in the DAWN Series provide data on the number and characteristics of (1) drug abuse related visits to a national representative sample of hospital emergency departments, and (2) drug abuse related deaths from selected medical examiner offices. The medical examiner cases are not from a national representative sample. DAWN is an ongoing data system that began in the early 1970's.

### "D" Series publications currently available:

- D-1: Drug Abuse Warning Network Annual Medical Examiner Data 1995
- D-2: Mid-Year Preliminary Estimates from the 1996 Drug Abuse Warning Network
- D-3: Year-End Preliminary Estimates from the 1996 Drug Abuse Warning Network
- D-4: Drug Abuse Warning Network Annual Medical Examiner Data 1996
- D-5: Mid-Year 1997 Preliminary Emergency Department Data from the Drug Abuse Warning Network
- D-6: Year-End 1997 Emergency Department Data from the Drug Abuse Warning Network
- D-7: Annual Emergency Department Data from the Drug Abuse Warning Network, 1995
- D-8: Annual Emergency Department Data from the Drug Abuse Warning Network, 1996
- D-9: Annual Emergency Department Data from the Drug Abuse Warning Network, 1997
- D-10: Mid-Year 1998 Preliminary Emergency Department Data from the Drug Abuse Warning Network
- D-11: Year-End 1998 Emergency Department Data from the Drug Abuse Warning Network
- D-12: Drug Abuse Warning Network Annual Medical Examiner Data 1997
- D-13: Drug Abuse Warning Network Annual Medical Examiner Data 1998
- D-14: Mid-Year 1999 Preliminary Emergency Department Data from the Drug Abuse Warning Network
- D-15: Year-End 1999 Emergency Department Data from the Drug Abuse Warning Network
- D-16: Drug Abuse Warning Network Annual Medical Examiner Data 1999
- D-17: Mid-Year 2000 Preliminary Emergency Department Data from the Drug Abuse Warning Network
- D-18: Year-End 2000 Emergency Department Data from the Drug Abuse Warning Network
- D-19: Mortality Data from the Drug Abuse Warning Network, 2000
- D-20: Emergency Dept. Trends From the Drug Abuse Warning Network, Preliminary Estimates Jan.-June 2001
- D-21: Emergency Department Trends From the Drug Abuse Warning Network, Final Estimates 1994 -2001
- D-22: Emergency Dept. Trends From the Drug Abuse Warning Network, Preliminary Estimates Jan.-June 2002



(Continued on next page)

### Drug and Alcohol Services Information System (DASIS) Series:

Reports in the Services Series provide national and state level data on (1) the characteristics of specialty treatment facilities providing drug and alcohol services; (2) the number of persons in treatment; and (3) the demographic and drug use characteristics of treatment admissions. The Services Series also includes the National Directory of Drug and Alcohol Abuse Treatment Programs. The publications in this Series are based on SAMHSA's Drug and Alcohol Services Information System (DASIS).

"S" Series publications currently available:

- National Directory of Drug Abuse and Alcoholism Treatment and Prevention Programs 1996 Uniform Facility Data Set (UFDS): Data for 1995 and 1980-1995
- S-1: S-2: S-3: Uniform Facility Data Set (UFDS): Data for 1996 and 1980-1996
- S-4R:
- National Directory of Drug Abuse and Alcoholism Treatment and Prevention Programs 1997
  National Admissions to Substance Abuse Treatment Services: The Treatment Episode Data Set (TEDS) S-5: 1992-1996
- S-6: Uniform Facility Data Set (UFDS): 1997
- S-7: Treatment Episode Data Set (TEDS): 1992-1997
- S-8: National Directory of Drug Abuse and Alcoholism Treatment Programs, 1998
- S-9: Substance Abuse Treatment in Adult and Juvenile Correctional Facilities: Findings from the UFDS
- S-10:
- 1997 Survey of Correctional Facilities Uniform Facility Data Set (UFDS): 1998 Treatment Episode Data Set (TEDS): 1993-1998 S-11:
- S-12: National Directory of Drug and Alcohol Abuse Treatment Programs 2000
- S-13: S-14:
- Uniform Facility Data Set (UFDS): 1999 Treatment Episode Data Set (TEDS): 1994-1999
- S-15: National Directory of Drug and Alcohol Abuse Treatment Programs 2001
- S-16: National Survey of Substance Abuse Treatment Services (N-SSATS): 2000

### **Analytic Series:**

Reports in the Analytic Series address special topics relating to alcohol, drug abuse, and mental health. The Analytic Series generally provides data from outcome and other special studies, secondary analysis of multiple data sources, or more in-depth analysis of the data presented in the standard annual reports in the other Office of Applied Studies publication series.

"A" Series publications currently available:

- Employment Outcomes of Indigent Clients Receiving Alcohol and Drug Treatment in Washington State A-1:
- A-2: An Analysis of Worker Drug Use and Workplace Policies and Programs
- A-3: Substance Use Among Women in the United States
- A-4: Substance Abuse and Mental Health Statistics Source Book 1998
- A-5: Services Research Outcomes Study
- A-6: Prevalence of Substance Use Among Racial and Ethnic Subgroups in the U.S., 1991-1993
- A-7: Analyses of Substance Abuse and Treatment Need Issues
- A-8: Driving After Drug or Alcohol Use: Findings from the 1996 NHSDA
- A-9: The Relationship Between Mental Health and Substance Abuse Among Adolescents
- Substance Use and Mental Health Characteristics by Employment Status A-10:
- A-11: Worker Drug Use and Workplace Policies and Programs: Results from the 1994 and 1997 NHSDA
- A-12: Risk and Protective Factors for Adolescent Drug Use: Findings from the 1997 National Household Survey on Drug Abuse
- A-13: Parental Influences on Adolescent Marijuana Use and the Baby Boom Generation: Findings from the 1979-1996 NHSDA
- A-14: Youth Substance Use: State Estimates from the 1999 NHSDA
- A-15: Tobacco Use in America: Findings from the 1999 NHSDA
- A-16: Substance Dependence, Abuse and Treatment: Findings from the 2000 NHSDA
- A-17: Initiation of Marijuana Use: Trends, Patterns and Implications
- A-18: Impact of September 11, 2001 Events on Substance Use and Mental Health in the New York Area
- A-19: Risk and Protective Factors for Adolescent Drug Use: Findings from the 1999 NHSDA
- The ADSS Cost Study: Costs of Substance Abuse Treatment in the Specialty Sector A-20:
- A-21: Substance Use by Older Adults: Estimates of Future Impact on the Treatment System

### **Methodology Series:**

Reports in the Methodology Series address methodological issues concerning data collection systems conducted by SAMHSA's Office of Applied Studies. These reports include studies of new statistical techniques and theories, survey methods, sample design, survey instrument design, and objective evaluations of the reliability of collected data.

"M" Series publications currently available:

- M-1: Substance Abuse in States and Metropolitan Areas: Model Based Estimates from the 1991-1993 NHSDA--Methodology Report
- M-2: Drug Abuse Warning Network Sample Design and Estimation Procedures--Technical Report
- M-3: Development of Computer-Assisted Interviewing Procedures for the NHSDA
- M-4: Drug Abuse Warning Network: Development of a New Design--Methodology Report




## **SAMHSA**

### Substance Abuse and Mental Health Services Administration (SAMHSA) Office of Applied Studies

The Office of Applied Studies (OAS) serves as a focal point for data collection, analyses, and dissemination activities on the incidence and prevalence of substance abuse, the distribution and characteristics of substance abuse treatment facilities and services, and the costs and outcomes of substance abuse treatment programs. Both National and State-by-State data are available. Three major surveys provide information used by OAS:

- National Household Survey on Drug Abuse (NHSDA). The NHSDA provides information on the prevalence of substance use in the population, and the problems associated with use. The survey collects information on the sociodemographic characteristics of users, patterns of use, treatment, perceptions of risk, criminal behavior, and mental health. Since 1999, the NHSDA sample has been designed to provide State-level estimates, based on 70,000 respondents per year.
- Drug Abuse Warning Network (DAWN). The DAWN obtains information on drug-related admissions to emergency departments and drug-related deaths identified by medical examiners.
- Drug and Alcohol Services Information System (DASIS). The DASIS consists of three data sets (I-SATS, N-SSATS, and TEDS) developed with State governments. These data collection efforts provide National and State-level information on the substance abuse treatment system.





561

## **SAMHSA**

# Office of Applied Studies Web Site Substance Abuse and Mental Health Statistics

www.DrugAbuseStatistics.samhsa.gov


The Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies (OAS) Web site contains highlights from the latest OAS report, data on specific drugs of abuse, and publications of alcohol, tobacco, and illegal drug use. It presents both National and State-by-State data. The Web site also contains data that have not been published, such as detailed tables of data from the NHSDA and DAWN, and substance abuse treatment admissions data by State from DASIS, as well as methodological reports.

OAS Short Reports: A new feature on the Web site is a series of illustrated short reports on selected topics from OAS major data systems (NHSDA, DAWN, and DASIS). These may be accessed at the following OAS Web site: <a href="http://www.samhsa.gov/oas/facts.cfm">http://www.samhsa.gov/oas/facts.cfm</a>. Topics in this short report series include the following: club drugs, pregnancy and illicit drug use, women in treatment, marijuana use by adolescents, heroin use, heavy alcohol use, perceived availability of drugs, and beliefs about drug risks.

Substance Abuse Treatment Facility Locator: OAS's Web site also contains a searchable on-line version of the National Directory of Drug and Alcohol Abuse Treatment Programs. This Substance Abuse Treatment Facility Locator produces maps with the location of the facilities you have listed.

### Other OAS Web Site Features: You can:

- Conduct data analysis online (SAMHDA)
- Download public use files
- Submit OAS publication requests
- Join the OAS mailing list
- Find answers to frequently asked questions (FAQ) about OAS data





562



DHHS Publication No. (SMA) 03-3779
Substance Abuse and Mental Health Services Administration
Printed 2002



### U.S. Department of Education

Office of Educational Research and Improvement (OERI)


National Library of Education (NLE)

Educational Resources Information Center (ERIC)



## **NOTICE**

# **Reproduction Basis**





This document is Federally-funded, or carries its own permission to reproduce, or is otherwise in the public domain and, therefore, may be reproduced by ERIC without a signed Reproduction Release form (either "Specific Document" or "Blanket").

EFF-089 (3/2000)

